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Many risk factors for venous thromboembolism have been identified, but two particular 
exposures - the use of combined oral contraceptives and long-distance air travel -
have generated considerable concern in recent years. In contrast, a possible link 
between venous thromboembolism and a third exposure - the use of psychotropic 
drugs - was first raised in the 1950s, but has received surprisingly little attention. 
Information about all three exposures and the risk of fatal events is limited. These risks 
were examined in three inter-related national population-based studies. 
Methods 
The underlying study population included all men and women aged 15 - 59 years who 
died in New Zealand between 1990 and 2000, for whom the underlying cause of death 
was pulmonary embolism. 
The potential associations between fatal pulmonary embolism and the use of oral 
contraceptives and psychotropic drugs were explored in a general practice records-based 
case-control study. Non-users were the reference category for all analyses. 
Contraceptive supply data were used to estimate the absolute risk of death from 
pulmonary embolism in users of oral contraceptives. 
A second case-control study, in which computer-assisted telephone interviews were 
undertaken with the next of kin of cases who had been resident in New Zealand, and 
with sex and age-matched controls randomly selected from the electoral roll, 
investigated the possible association between long-distance air travel and fatal 
pulmonary embolism. 
Finally, the absolute risk of dying from pulmonary embolism following a long-distance 
flight was estimated in a descriptive study based on official migration data and deaths in 


















The adjusted odds ratio for use of any oral contraceptive in the three months before the 
index date (the onset of the fatal episode) was 13.1 (95% CI 4.4- 39.0). The odds ratio 
for formulations containing desogestrel and gestodene was about three times higher than 
the point estimate for levonorgestrel products; preparations containing cyproterone 
acetate appeared to carry the highest risk. The estimated absolute risk of fatal 
pulmonary embolism in current users of oral contraceptives was 10.5 (95% CI 6.2 -
16.6) per million woman-years. 
The adjusted odds ratio for current use of any antipsychotic was 13.3 (95% CI 2.3 -
76.3). Low-potency antipsychotics carried a 20-fold increase in risk; thioridazine was 
the main drug involved. Antidepressant use was also associated with a significantly 
increased risk (adjusted odds ratio 4.9 [95% CI 1.1 - 22.5]). 
Compared with non-travellers, people who had undertaken a flight of more than eight 
hours' duration in the preceding four weeks were eight times more likely to die from 
pulmonary embolism (odds ratio 7.9 [95% CI 1.1 - 55.1]). The absolute risk of fatal 
pulmonary embolism following air travel of more than eight hours was 1.3 (95% CI 0.4 
- 3.0) per million arrivals. 
Conclusions 
The present research was the first to have estimated the relative risks of fatal pulmonary 
embolism in relation to three exposures: oral contraceptive use in a population in which 
preparations containing desogestrel and gestodene preparations were widely used, 
conventional antipsychotics, and long-distance air travel. The findings were consistent 
with previous, and subsequent, studies of non-fatal events. Increased risks of fatal 
pulmonary embolism in users of antidepressants, and in people with an intellectual 
disability, have not been described previously and warrant further investigation. 
Referral and diagnostic biases are very unlikely in these studies of fatal events, and 
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Contemporary insight into the natural history of deep vein thrombosis and pulmonary 
embolism ( collectively referred to as venous thromboembolism) derives from 
pioneering work undertaken by the nineteenth century pathologist, Rudolf Virchow. 
From a lecture given to colleagues in 1858, it is clear that Virchow understood that deep 
vein thrombosis and pulmonary embolism were part of the same condition, a condition 
which could result in sudden death or in spontaneous recovery (Virchow 1971): 
By no means rarely do these [peripheral veins] become quite filled with masses of 
coagulum. As long however as the thrombus is confined to the branch itself, so long 
the body is not exposed to any particular danger ... Only the greater number of the 
thrombi in the small branches do not content themselves with advancing up to the 
level of the main trunk, but pretty constantly new masses of coagulum deposit 
themselves from the blood upon the end of the thrombus layer after layer, the 
thrombus is prolonged beyond the mouth of the branch into the trunk in the direction 
of the current of blood .. .It is these prolonged plugs that constitute the source of real 
danger; it is in them that ensues the crumbling away which leads to secondary 
occlusions in remote vessels ... This gives rise to the very frequent process upon 
which I have bestowed the name of Embolia ... Into the pulmonary artery the 
introduced fragments of thrombus of course penetrate to different depths according 
to their size ... In the case of very large fragments even the principal trunks of the 
pulmonary artery are blocked up and instantaneous asphyxia ensues; other fragments 
again penetrate into the most minute arteries .. .it also happens that the secondary 
disturbances, like those at the spot whence the fragments were detached, run a very 
favourable course, the embolus like the thrombus becoming converted into pigment 
and connective tissue, and at the same time growing smaller. 
Virchow also postulated that venous stasis, hypercoagulability, and damage to the 
vessel wall were predisposing factors for thrombosis (Virchow 1856). For more than a 
century these three mechanisms, referred to as "Virchow's triad", have provided a 
useful framework with which to consider the causes of venous thromboembolism. A 
limitation of this taxonomy, however, is that some risk factors fit into more than one 
category - for example, the increased risk of venous thromboembolism during 
pregnancy can be attributed both to a hormonally-induced hypercoagulable state and to 



























to classify risk factors according to whether they are inherited or acquired (Rosendaal 
1999a). 
While many acquired risk factors for venous thromboembolism have now been 
identified, two particular exposures - the use of combined oral contraceptives (that is, 
oral sex hormone preparations that contain both an oestrogen and progestogen 
component) and long-distance air travel - have generated considerable professional 
and public concern in recent years. The research which will be described in this thesis 
examined the relationships between these exposures and fatal pulmonary embolism. A 
postulated link between a third exposure - the use of psychotropic drugs - and death 
from pulmonary embolism was also explored. These risks were examined in three inter-
related national population-based studies. Specifically, the research was based on all 
men and women aged 15 - 59 years, who died in New Zealand between 1990 and 2000, 
for whom the underlying cause of death was pulmonary embolism. This group included 
both men and women who were living in New Zealand at the time of their death, as well 
as people who happened to die while visiting the country (hereafter referred to as 
overseas visitors). A case-control study, restricted to those people who were normally 
resident in New Zealand, was undertaken to investigate the potential associations 
between fatal pulmonary embolism and the use of combined oral contraceptives and 
psychotropic drugs. Sex and age-matched controls were randomly selected from the 
general practices to which the cases had belonged. Information about drug exposures 
and other risk factors for venous thromboembolism was abstracted from the records of 
general practitioners, family planning clinics, and mental health services. A second 
case-control study, in which computer-assisted telephone interviews were undertaken 
with the next of kin of cases who were resident in New Zealand and with sex and age-
matched controls randomly selected from the New Zealand electoral roll, explored the 
possible association between long-distance air travel and death from pulmonary 
embolism. A descriptive study based on official migration data and deaths in all recent 
air travellers (people resident in New Zealand and overseas visitors) was also 
undertaken to estimate the absolute risk of dying from pulmonary embolism following 
long-distance air travel. 
Throughout this and subsequent chapters, combined oral contraceptives will be referred 
























products that contain a progestogen, but no oestrogen, will be referred to as 
progestogen-only pills. 
1.2 OVERVIEW OF CHAPTERS 
The thesis is divided into four parts. Part I, entitled Overview, comprises two chapters. 
This first chapter, as well as providing an overview of the thesis, briefly describes the 
epidemiology of venous thromboembolism, including the established risk factors for the 
condition. The diagnosis and treatment of deep vein thrombosis and pulmonary 
embolism are also outlined, since an understanding of the potential pitfalls in diagnosis 
is critical for later discussions about possible biases in epidemiological studies of 
venous thromboembolism. The second chapter discusses the methods used to identify 
the cases who were eligible for inclusion in the research presented in this thesis - that 
is, men and women aged 15 - 59 years who died in New Zealand between 1990 and 
2000, for whom the underlying cause of death was pulmonary embolism. 
Part II of the thesis, entitled Fatal pulmonary embolism and the use of medicines, 
consists of four chapters. The literature about venous thromboembolism and the use of 
oral contraceptives and of psychotropic drugs is reviewed in Chapter 3. In Chapter 4, 
the objectives and methods of the case-control study which explored the associations 
between fatal pulmonary embolism and the use of oral contraceptives and psychotropic 
drugs are outlined, as are the methods used to estimate the absolute risk of death from 
pulmonary embolism in users of oral contraceptives. The results of this research are 
presented in Chapter 5 and a discussion follows in Chapter 6. 
Part III, Fatal pulmonary embolism and long-distance air travel, comprises five 
chapters. Chapter 7 reviews the evidence for an association between long-distance air 
travel and venous thromboembolism. Chapter 8 outlines the objectives and methods of 
the descriptive study of long-distance air travel and fatal pulmonary embolism. The 
results of this study are presented and discussed in Chapter 9. In Chapter 10, the 
objective and methods of the case-control study which examined the potential 
association between long-distance air travel and death from pulmonary embolism are 





Part IV, Conclusion, consists of the final chapter of the thesis in which the results of the 
research are summarised and the implications of the findings and research methods are 
discussed. 
1.3 DIAGNOSIS AND TREATMENT OF VENOUS THROMBOEMBOLISM 
1.3.1 Diagnosis 
Although venous thrombosis can occur in any vein, the vast majority of venous thrombi 
arise in the veins of the lower limb. The classical symptoms and signs of deep vein 
thrombosis are pain, tenderness, swelling, distension of superficial veins, erythema, and 
increased warmth of the affected limb (Blann and Lip 2006). For pulmonary embolism, 
the characteristic symptoms and signs include dyspnoea, tachypnoea, pleuritic chest 
pain, cough, haemoptysis, tachycardia, and circulatory collapse. However, only about a 
quarter of people with suspected deep vein thrombosis actually have the condition and, 
conversely, some episodes of venous thrombosis are asymptomatic (Kyrle and 
Eichinger 2005). The same problem is encountered with pulmonary embolism. Indeed, 
it is thought that about 50 - 80% of people with symptomatic deep vein thrombosis 
have asymptomatic pulmonary embolism (Blann and Lip 2006). Hence, the diagnosis 
of venous thromboembolism based solely on symptoms and physical examination is 
unreliable and more objective investigations are required. 
While contrast venography has been regarded as the gold standard method for the 
investigation and diagnosis of suspected deep vein thrombosis, it is an invasive 
procedure and in recent years non-invasive compression ultrasonography has become 
the preferred first-line imaging technique (Blann and Lip 2006). Ultrasonography has a 
high sensitivity and specificity for the diagnosis of proximal (above the knee) 
thrombosis, however it performs poorly in detecting deep vein thrombosis in the calves 
(Kyrle and Eichinger 2005). 
The original gold standard test for pulmonary embolism, pulmonary angiography, has 
largely been replaced by less invasive investigations (Goldhaber 2004). Initially, a 
ventilation-perfusion lung scan was the preferred alternative test and a high probability 
scan was as useful as pulmonary angiography in making a diagnosis of pulmonary 
embolism. However, because many ventilation-perfusion scans are of intermediate or 
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indeterminate probability, contrast-enhanced computed tomography (CT) is increasingly 
the investigation of choice. 
In recent years, the advent of methods for measuring the concentration of plasma D-
dimer (a cross-linked fibrin derivative produced by endogenous fibrinolysis) have 
improved the diagnostic efficiency in people with suspected venous thromboembolism 
(Goldhaber 2004; Kyrle and Eichinger 2005). Diagnostic algorithms for deep vein 
thrombosis and pulmonary embolism, which include the assignment of clinical 
probability scores (based on medical history and physical examination), have been 
developed to guide the appropriate use of investigations (Blann and Lip 2006). For 
example, in people with a low pre-test probability score for deep vein thrombosis or 
pulmonary embolism, the initial investigation of choice is a D-dimer test. In such 
persons, a normal D-dimer concentration has a high negative predictive value and no 
further tests are indicated. If, however, the D-dimer concentration is higher than 
normal, further investigations (lower limb ultrasonography, ventilation-perfusion scan, 
or contrast-enhanced CT scan) are needed to confirm, or rule out, venous 
thromboembolism. This is because elevated D-dimer levels are found not only with 
venous thromboembolism, but also with myocardial infarction, pneumonia and other 
infections, cancer, pregnancy, and following surgery (Goldhaber 2004). 
1.3.2 Treatment 
The efficacy of intravenous heparin in reducing mortality in patients with pulmonary 
embolism was first established in the late 1930s (Hume 1963). A decade later, 
following the purification of an anticoagulant substance in spoiled sweet-clover hay, the 
first oral anticoagulant, bishydroxycoumarin, was successfully used to treat patients 
with venous thromboembolism. For many years, the standard approach to the treatment 
of deep vein thrombosis and pulmonary embolism was to administer unfractionated 
heparin intravenously to achieve rapid and ongoing anticoagulation until a 
concomitantly administered oral vitamin K antagonist, such as warfarin, took effect 
(Goldhaber 2004; Kyrle and Eichinger 2005). In recent years, intravenous heparin has 
increasingly been replaced by weight-adjusted doses of low-molecular weight heparins 
administered subcutaneously. In general, oral anticoagulation therapy is given for three 
to six months following a venous thromboembolic episode (Blann and Lip 2006). For 
certain people with ongoing risk factors or recurrent events, however, therapy is 
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continued indefinitely. More intensive treatment, such as fibrinolysis and 
embolectomy, is reserved for patients with massive pulmonary embolism and 
cardiogenic shock. Similarly, the use of inferior vena cava filters is confined to people 
with pulmonary embolism in whom the risk of bleeding with anticoagulation is high and 
in those who have developed recurrent pulmonary embolism during anticoagulation 
therapy. 
1.4 DESCRIPTIVE EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM 
1.4.1 Incidence 
The annual incidence of venous thromboembolism in cohort studies in western 
countries such as the United States of America (USA) (Anderson et al. 1991; Silverstein 
et al. 1998; Tsai et al. 2002; Cushman et al. 2004), Sweden (Nordstrom et al. 1992; 
Hansson et al. 1997), France (Oger 2000), and the United Kingdom (UK) (Huerta et al. 
2007) has been estimated to be about 1 - 2 per 1,000 persons. These figures represent 
the overall incidence in the populations which were studied - in fact, the frequency of 
venous thromboembolism increased markedly with increasing age in all of the quoted 
studies. In one population-based study in the USA, for instance, the annual incidence in 
men aged 15 - 29 years, 55 - 64 years, and ~ 85 years was about 1 per 10,000, 1 per 
1,000, and 1 per 100 respectively (Silverstein et al. 1998). 
Data about the relationship between sex and the incidence of venous thromboembolism 
are conflicting. Some researchers have reported that women of child-bearing age have 
higher rates than men of the same age, a pattern which is reversed in older age groups 
(Silverstein et al. 1998; Oger 2000; Huerta et al. 2007). Conversely, other investigators 
have found that men have a slightly higher incidence at all ages (Anderson et al. 1991; 
Tsai et al. 2002; Cushman et al. 2004). Yet others have observed equal incidence in 
men and women (Nordstrom et al. 1992). The inconsistency in the results might be due 
to variations in exposure to exogenous risk factors by sex and age. In a recent meta-
analysis, the risk of recurrent episodes of venous thromboembolism following cessation 
of treatment was found to be higher in men (McRae et al. 2006). 
The incidence of venous thromboembolism has been shown to vary by ethnicity. For 














have lower rates of deep vein thrombosis and pulmonary embolism than people 
classified as white or African American (Stein et al. 2004a). Similarly, lower rates of 
venous thromboembolism have been reported for Hispanic Americans (White et al. 
1998) and Americans of Asian or Pacific Island ethnicity (White et al. 1998; Stein et al. 
2004b ). While it is possible that these findings could be an artefact of differential 
access to health care and diagnostic facilities, the reported lower incidence of venous 
thromboembolism in Indigenous, Hispanic, Asian, and Pacific Island populations in the 
USA is consistent with an observation that the prevalence of one of the inherited 
thrombophilic mutations (factor V Leiden) is much lower in these groups than in 
Caucasian Americans (Ridker et al. 1997a). Other investigators have also reported a 
low prevalence, or indeed absence, of factor V Leiden in various populations in which 
venous thromboembolism is uncommon (Rees et al. 1995; Van de Water et al. 1997). A 
similar pattern has been observed with another inherited thrombophilic abnormality, 
prothrombin G20210A (Rosendaal et al. 1998). Such findings make it more probable 
that at least part of the observed differences in incidence by ethnicity is real and not due 
to referral and diagnostic biases. 
It is likely that the published incidence figures are underestimates of the true frequency 
of venous thromboembolism in the populations which were studied. The reasons for 
this are two-fold. First, as Virchow described, episodes of deep vein thrombosis and 
pulmonary embolism may spontaneously resolve (Virchow 1971). Moreover, while 
some people with venous thromboembolism develop the classical symptoms of deep 
vein thrombosis or pulmonary embolism, many such events provoke only minor, or 
indeed, no symptoms and are therefore not identified (Goldhaber 2004; Kyrle and 
Eichinger 2005). Second, even if suspected events do come to the attention of medical 
professionals, as already noted, the diagnosis of venous thromboembolism on the basis 
of symptoms and physical examination alone is unreliable (Goldhaber 2004; Kyrle and 
Eichinger 2005). Hence, the probability that acute deep vein thrombosis or pulmonary 
embolism will be detected depends on the availability of diagnostic tests, whether the 
patient is referred for diagnostic assessment, and the sensitivity and specificity of the 
investigations which are performed. In the instance of fatal events, pulmonary 
embolism may go unrecognised if a necropsy is not performed because the death may 
be attributed to other causes of sudden death such as myocardial infarction and cardiac 
arrhythmia. Indeed, necropsy studies have suggested that the majority of pulmonary 








1.4.2 Major sequelae of venous thromboembolism 
Fatal pulmonary embolism 
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As Virchow first observed, thrombus which forms in the deep veins of the legs 
sometimes propagates proximally into larger vessels and such thrombi may embolise to 
the lungs (Virchow 1971). If sufficiently large, pulmonary emboli may completely 
occlude the main pulmonary arteries and result in sudden death. Because many 
episodes of venous thromboembolism remain undetected there is some uncertainty 
about the figures, however it is thought that up to 20 - 25% of untreated thrombi in the 
deep veins of the calf propagate proximally into the upper leg and, of these, about half 
embolise to the lungs (Dalen 2002)). 
Published estimates of the case-fatality rate for venous thromboembolism vary widely 
according to the source of the study group (population-based, hospital admissions, or 
clinical trial participants), the type of venous thromboembolic events studied (idiopathic 
or events associated with major co-morbidities), and the period of follow-up. Moreover 
in some studies, deaths from pulmonary embolism are not distinguished from mortality 
from any cause. For example, in a population-based study of 2,218 people with a first 
episode of deep vein thrombosis or pulmonary embolism in Olmsted County in the 
USA, the reported 30-day mortality rate was 28% (Heit et al. 1999). The study included 
people who developed venous thromboembolism following surgery, trauma, prolonged 
immobility, or in association with pregnancy, active cancer, and other serious illnesses. 
Hence, it is likely that some of the deaths were due to events other than pulmonary 
embolism and, moreover, that a proportion of deaths in which the mechanism of death 
was pulmonary embolism had other underlying causes. In an international study of 
2,454 consecutive cases of pulmonary embolism in seven countries in Europe and North 
America, the three-month mortality rate was 17.4% for deaths from all causes and 7 .9% 
for pulmonary embolism (Goldhaber et al. 1999). As in the previous study, many of the 
cases had major risk factors for venous thromboembolism. Similarly, 17% of 193 
consecutive patients admitted to hospital in the Netherlands with pulmonary embolism 
died during the first six months after diagnosis (van Beek et al. 1997). Of these deaths, 
5% were attributed to recurrent pulmonary embolism. A comparable in-hospital 
mortality rate (14.0%) was found in a Japanese study of 309 patients with pulmonary 
embolism, although it was not clear whether this included deaths from all causes 
(Nakamura et al. 2001). In another hospital-based study, in a defined geographical area 
:, 
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of the USA, the in-hospital case-fatality rate for 405 patients admitted with a first 
episode of deep vein thrombosis or pulmonary embolism was rather misleadingly 
quoted as 12%, however this figure included deaths from any cause (Anderson et al. 
1991). 
Lower estimates of case-fatality, ranging from 2.5 to 5.0% during the first 1 - 2 weeks 
following diagnosis, have been reported in trials of diagnostic methods (Carson et al. 
1992) and treatment of pulmonary embolism (Simonneau et al. 1997; The Columbus 
Investigators 1997). These findings are not surprising, given the selected nature of trial 
participants and the fact that the study members survived long enough to enter the trial. 
Indeed, in a meta-analysis based on 25 prospective cohort studies and randomised 
controlled trials published between 1966 and 1997, the estimated case-fatality rates 
during a three-month period of anticoagulation were 0.4% (95% CI 0.2- 0.6) for people 
initially diagnosed with deep vein thrombosis and 1.5% (95% CI 0.9 - 2.2) for those 
with pulmonary embolism (Douketis et al. 1998). However, higher rates were found for 
recurrent events; in patients who originally presented with deep vein thrombosis, 5.1 % 
died after cessation of treatment for a recurrent episode. Of the patients with pulmonary 
embolism at baseline, 26.4% died during or after treatment of a subsequent venous 
thromboembolic event. 
In a recent large population-based study of deep vein thrombosis and pulmonary 
embolism, the overall 28-day case-fatality rate was estimated to be 11 % (Cushman et al. 
2004). In an analysis stratified by patient characteristics, the case-fatality rates for 
idiopathic venous thromboembolism, events associated with major risk factors such as 
surgery and trauma (but not cancer), and cancer-related events were 5% (95% CI 1 - 9), 
7% (95% CI 2 - 13), and 25% (95% CI 15 - 36%) respectively (Cushman et al. 2004). 
Differences in case-fatality rates by age and ethnicity have also been reported (Stein et 
al. 2004). 
The most widely quoted case-fatality rate for venous thromboembolism is 1 - 2% 
(Rosendaal 1999a), although it is not entirely clear where this estimate originated. A 
figure closer to 5% for idiopathic venous thromboembolism seems more plausible based 




Chronic thromboembolic pulmonary hypertension 
In a small proportion of people who survive a pulmonary embolic event, the vascular 
obstruction persists, leading to chronic pulmonary hypertension (Fedullo et al. 2001). 
Without pulmonary thromboendarterectomy, the condition progresses to right heart 
failure and eventual death. In a recent study, 4% of people with a first episode of 
pulmonary embolism developed chronic thromboembolic pulmonary hypertension 
during the first two years of follow-up (Pengo et al. 2004 ). 
Post-thrombotic syndrome 
Between 20 and 50% of people with symptomatic deep vein thrombosis develop a 
chronic condition known as the post-thrombotic syndrome within the first two years 
following diagnosis and treatment (Kahn and Ginsberg 2004). People with this 
condition typically suffer from chronic leg swelling, pain, and venous insufficiency 
which, in severe cases, can lead to skin ulceration. Thrombus-induced damage to the 
venous valves and subsequent venous hypertension is thought to be responsible. The 
condition has been found to have a considerable impact on quality of life (Kahn et al. 
2002). 
Recurrence of venous thromboembolism 
As with case-fatality rates, the reported proportions of people with venous 
thromboembolism who suffer recurrent events varies according to the populations 
studied. In the meta-analysis referred to above, for instance, 3.8% of patients with deep 
vein thrombosis at baseline had a non-fatal recurrent episode of venous 
thromboembolism while being treated with anticoagulants (Douketis et al. 1998). 
Comparable rates of recurrence during treatment have been reported for pulmonary 
embolism (Nijkeuter et al. 2007). The annual likelihood of a recurrent episode of deep 
vein thrombosis following a first event is thought to be about 5 - 15%, with about 25% 
of patients having had a recurrence by four years (Kyrle and Eichinger 2005). In a 
recent study of people with a first episode of idiopathic pulmonary embolism, 17% 
developed a recurrent venous thromboembolic event during the first 30 months 
following cessation of anticoagulation (Eichinger et al. 2004). The risk of recurrence 
appears to be lower for people with post-operative venous thromboembolism 
(Goldhaber 2004; Kyrle and Eichinger 2005). 
.. I 
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1.5 RISK FACTORS FOR VENOUS THROMBOEMBOLISM 
Venous thromboembolism is a multi-causal disease - that is, the presence of more than 
one risk factor is usually required to trigger thrombosis (Rosendaal 1999a). Moreover, 
there is increasing recognition that inherited and acquired risk factors frequently interact 
so that the combined risks are greater than the sum of the individual risks. Thus, the 
importance of individual risk factors depends not only on their associated relative risks, 
but also on how commonly they occur, and whether they interact with other risk factors. 
As will be seen in the following sections, although venous and arterial thrombosis share 
a few risk factors in common, many of the causes of venous thromboembolism differ 
from those of arterial cardiovascular disorders such as myocardial infarction and stroke 
(Tsai et al. 2002). 
1.5.1 Inherited risk factors 
Familial thrombophilia 
In recent decades, several inherited abnormalities have been identified which increase 
the susceptibility of affected persons to venous thromboembolism. The first such 
familial thrombophilic defect to be described was a deficiency in the naturally occurring 
anticoagulant, antithrombin (Egeberg 1965). Some 20 years later, the thrombogenic 
effects of deficiencies in two other anticoagulants, protein C (Griffin et al. 1981) and 
protein S (Schwarz et al. 1984), were discovered. These deficiencies are rare, but 
strong, risk factors for venous thromboembolism (Rosendaal and Bovill 2002). Other 
rare inherited thrombophilias include dysfibrinogenaemia (Beck et al. 1965) and 
abnormal plasminogen (Aoki et al. 1978). 
During the 1990s, considerable advances were made in the understanding of the 
aetiology of venous thromboembolism and the complex interactions between inherited 
and environmental risk factors. In 1993, resistance to activated protein C was 
demonstrated in several members of a family with a strong history of venous thrombosis 
(Dahlback et al. 1993). Subsequently it was determined that a single point mutation in 
coagulation factor V, the so-called factor V Leiden mutation, caused activated protein C 
resistance (Bertina et al. 1994). Intriguingly, it later emerged that among carriers of 
factor V Leiden, the relative risk of pulmonary embolism was about half that of deep 





shown to occur in the absence of factor V Leiden and acquired resistance was 
demonstrated in users of oral contraceptives and hormone replacement therapy 
(Rosendaal 1999b). In 1996, a second variant coagulation factor, prothrombin 
G20210A, was identified (Poort et al. 1996). Carriers of this mutation were shown to 
have elevated concentrations of prothrombin and an increased risk of venous 
thromboembolism. High levels of prothrombin in people without the mutation were 
also shown to predispose to venous thrombosis. Although factor V Leiden and 
prothrombin G20210A occur reasonably commonly in populations of European 
ethnicity (Rosendaal and Bovill 2002), the majority of carriers do not develop 
thrombosis (Ridker et al. 1997b; Bank et al. 2004). 
Interactions have been demonstrated between familial thrombophilias and acquired risk 
factors. For example, the risk of venous thromboembolism during oral contraceptive 
use or pregnancy is much higher for women with deficiencies of antithrombin, protein 
C, or protein S, and for carriers of factor V Leiden or prothrombin G20210A, than it is 
for women without such abnormalities (Rosendaal 1999a; Rosendaal et al. 2003a). 
1.5.2 Acquired risk factors 
Previous venous thromboembolism 
Age 
As already discussed in an earlier section, a considerable proportion of people who have 
had one venous thromboembolic episode will subsequently develop further events. 
Damage to the venous valves and resultant stasis is thought to contribute to the 
increased risk of deep vein thrombosis in people with previous events (Rosendaal et al. 
2003a). Thrombosis and inflammation in the superficial veins of the leg, also appear to 
increase the risk of developing deep vein thrombosis (Kyrle and Eichinger 2005). 
Varicose veins are generally considered to be a risk factor for venous thromboembolism 
(Goldhaber 2004; Kyrle and Eichinger 2005), although there is some evidence to 
suggest that the risk is only increased in younger age groups (Heit 2003). 
The risk of venous thromboembolism escalates with advancing age (Goldhaber 2004; 
Kyrle and Eichinger 2005). Hence, the attributable risk of an exposure associated with, 
for example, a two-fold increased risk of venous thromboembolism will rise markedly 
















factors, the likelihood that exposure to a particular set of risk factors will trigger 
thrombosis is lower in younger people than in older people (Rosendaal 1999a). 
Malignancy 
A link between malignancy and venous thromboembolism was first described in 1865 
(Lip et al. 2002). Not only is the risk of venous thromboembolism increased in people 
with diagnosed active cancer, but apparently idiopathic venous thromboembolism is 
sometimes the presenting symptom of an occult malignancy, especially of the liver, 
pancreas, ovary, and brain (Kyrle and Eichinger 2005). Similarly, the presenting 
symptom of occult cancer may be recurrent thrombosis during anticoagulant treatment 
(Goldhaber 2004). Indeed, the risk of discovering a malignancy is increased for at least 
two years following an episode of pulmonary embolism; the prognosis of such cancers 
is generally poor . 
Acute and chronic medical conditions 
An increased risk of venous thromboembolism has been associated with current or 
repeated hospital admissions, as well as residence in chronic care facilities (Goldhaber 
2004; Kyrle and Eichinger 2005). More specifically, several acute medical conditions 
- including myocardial infarction, respiratory failure, and infection - have been 
shown to increase the risk (Kyrle and Eichinger 2005). The presence of 
antiphospholipid antibodies (lupus anticoagulant or anticardiolipin antibodies) increases 
the risk of venous thromboembolism in people with systemic lupus erythematosus and 
other autoimmune diseases, as well as people without these conditions (Goldhaber 
2004; Kyrle and Eichinger 2005). Chronic conditions associated with an elevated risk 
include limb paresis, inflammatory bowel diseases such as Crohn's disease and 
ulcerative colitis, and congestive heart failure (Goldhaber 2004; Kyrle and Eichinger 
2005). 
Other conditions which are thought by some commentators to predispose to venous 
thromboembolism include diabetes (Goldhaber 2004), nephrotic syndrome (Kyrle and 
Eichinger 2005), myeloproliferative disorders such as polycythaemia rubra vera and 
essential thrombocythaemia (Kyrle and Eichinger 2005), chronic obstructive pulmonary 
disease (Goldhaber 2004), and hypertension (Goldhaber 2004). Rarer conditions 
include thrombotic thrombocytopenic purpura (Heit 2003), thromboangiitis obliterans 









congenital venous malformations (Kyrle and Eichinger 2005), and Behcet's syndrome 
(Kyrle and Eichinger 2005). Certain behaviours, such as intravenous drug use (Kyrle 
and Eichinger 2005), increase the risk, as does invasive medical equipment such as 
central venous catheters (Goldhaber 2004), permanent pacemakers (Goldhaber 2004), 
internal cardiac defibrillators (Goldhaber 2004), and vena cava filters (Kyrle and 
Eichinger 2005). It has been suggested that dehydration increases the risk of venous 
thromboembolism (Mammen 1992), although there is a surprising lack of evidence from 
epidemiological studies to support this belief. 
Obesity is commonly accepted as a risk factor for deep vein thrombosis and pulmonary 
embolism (Goldhaber 2004; Kyrle and Eichinger 2005). A dose-response of increasing 
risk of venous thromboembolism with increasing body mass index (BMI) has been 
found in large prospective studies (Goldhaber et al. 1997; Huerta et al. 2007). 
Medicines 
Apart from oral contraceptives and psychotropic drugs, which are discussed in Chapter 
3, several medicines have been associated with an increased risk of venous 
thromboembolism. Oral hormone replacement therapy has been confirmed as a risk 
factor in randomised controlled trials (Beral et al. 2002). Elevated risks have also been 
reported for exogenous oestrogens used in other contexts, such as for the treatment of 
prostate cancer (Anderson and Spencer 2003). It seems, however, that oestrogen 
administered transdermally is not a risk factor (Scarabin et al. 2003). 
Oral and injectable progestogen-only contraceptives and combined injectable 
contraceptives do not appear to be associated with venous thromboembolism (World 
Health Organization Collaborative Study of Cardiovascular Disease and Steroid 
Hormone Contraception 1998; Heinemann et al. 1999; Vasilakis et al. 1999a). 
However, an increased risk of venous thrombosis has been observed with higher doses 
of unspecified progestogens administered orally for therapeutic indications such as the 
treatment of menorrhagia and dysfunctional vaginal bleeding (Poulter et al. 1999a; 
Vasilakis et al. 1999a). Hormones used during in-vitro fertilisation treatment and 
ovulation induction have also been implicated (Bloemenkamp 2005). 
The selective oestrogen-receptor modulator, raloxifene, and oestrogen agonist-




















shown in randomised controlled trials to increase the risk of venous thromboembolism 
(Goldhaber 2004; Kyrle and Eichinger 2005). Similarly, increased risks have been 
observed with thalidomide, various chemotherapy agents and heparin-induced 
thrombocytopenia (Kyrle and Eichinger 2005). 
Other transient or removable risk factors 
Several other transient risk factors for venous thromboembolism have been identified, 
including pregnancy and the puerperium, immobility and prolonged bed rest, and major 
trauma, especially spinal injuries and pelvic or leg fractures (Goldhaber 2004; Kyrle and 
Eichinger 2005). Major surgery, in general, also increases the risk of venous 
thromboembolism. However, the risk is particularly high for orthopaedic surgery of the 
lower limb (especially total hip and knee joint replacements and hip fracture surgery), 
abdominal and pelvic surgery, neurosurgery (especially craniotomy for brain tumours), 
and vascular surgery (Goldhaber 2004; Kyrle and Eichinger 2005). The likelihood of 
post-operative venous thromboembolism is increased by the presence of other risk 
factors, particularly cancer (Kyrle and Eichinger 2005). Evidence about smoking as a 
risk factor is equivocal; some reviewers have interpreted the data as indicating an 
increased risk (Goldhaber 2004) while others have not (Heit 2003). 
1.5.3 Risk factors which may be inherited or acquired 
Several risk factors for venous thromboembolism appear to have mixed genetic and 
environmental, or uncertain, origins. These include high concentrations of several 
clotting factors such as factors VIII (Koster et al. 1995), IX (van Hylckama Vlieg et al. 
2000), and XI (Meijers et al. 2000a), as well as high levels of thrombin activatable 
fibrinolysis inhibitor (van Tilburg et al. 2000). Homocysteinaemia, a risk factor for 
both venous and arterial thrombosis, may be due to mutations of cystathionine ~-
synthase and methylene tetrahydrofolate reductase or to an inadequate intake of folic 
acid, vitamin B6, or vitamin B12 (Rosendaal 1999a). It is uncertain whether increased 
levels of lipoprotein(a), which predispose to venous thromboembolism, are due to 















CHAPTER2 IDENTIFICATION OF MEN AND WOMEN WHO 
DIED FROM PULMONARY EMBOLISM IN NEW ZEALAND 
BETWEEN 1990 AND 2000 
2.1 INTRODUCTION 
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This chapter describes the methods used to identify eligible cases for the research that 
will be discussed in Parts II (the case-control study of oral contraceptives and 
psychotropic drugs) and III (the descriptive and case-control studies of long-distance air 
travel) of this thesis. As will be explained in later chapters, ethical approval was 
granted by the regional ethics committees to examine existing death, hospital, general 
practice, and family planning clinic records for each case. 
2.2 ASCERTAINMENT OF POTENTIAL CASES 
2.2.1 Inclusion and exclusion criteria 
The persons considered eligible for the research included all men and women aged 15 -
59 years, who died in New Zealand between January 1990 and December 2000, for 
whom the "underlying cause of death" was coded to one of the following rubrics of the 
ninth (deaths between 1990 and 1999) or tenth (deaths during 2000) revisions of the 
International Classification of Diseases: 415.1 (pulmonary embolism and infarction), 
451 (phlebitis and thrombophlebitis ), 453 ( other venous embolism and thrombosis), 
126.9 (pulmonary embolism without mention of acute cor pulmonale), 180 (phlebitis 
and thrombophlebitis), or 182 (other venous thromboembolism and thrombosis). 
As will be explained in section 2.2.2, the "underlying cause of death" is supposed to be 
the factor that begins the sequence of events that leads to death. Deaths from 
pulmonary embolism that occurred post-operatively or in people with advanced cancer, 
for example, should not (if they were coded correctly) have been identified using the 
above rubrics. Hence, such deaths were excluded from the present research. Fatal 
pulmonary embolism which occurred as a complication of pregnancy, childbirth, or the 








Potential cases were excluded if they were found to have insufficient clinical or 
pathological evidence for a diagnosis of pulmonary embolism. Thus, people for whom 
the underlying cause was coded as 451 or 453 (ninth revision) or 180 or I82 (tenth 
revision) were included in the present research only if there was clear evidence that 
distal venous thrombosis had been complicated by pulmonary embolism. 
It was originally hoped to include people who died before 1990, but a pilot study 
involving women aged 15 - 49 years showed that it was not feasible to include such 
deaths because many medical records had been destroyed or lost. For example, general 
practice records were located for just seven of the 18 women who died between 1986 
and 1989, and hospital records were found for only three of the nine women who had 
died in hospital. 
2.2.2 The management of mortality data in New Zealand 
Following most deaths in New Zealand, the doctor who attended the patient during their 
final illness completes a Medical Certificate of Causes of Death (New Zealand Health 
Information Service 2001). This certificate, which was designed in accordance with the 
International Death Certificate advocated by the World Health Organization (WHO), 
allows for the entry of the direct and antecedent causes of death, as well as other 
conditions that are considered to have contributed to the death. The direct cause of 
death is defined as the disease, injury or complication directly leading to death, while 
the antecedent causes are those morbid conditions (if any) that gave rise to the direct 
cause. The underlying condition should be recorded last in this causal sequence. 
The Coroners Act 1988 (and the subsequent Coroners Act of 2006) requires that certain 
deaths are referred to a coroner for certification of cause (New Zealand Health 
Information Service 2001). These include deaths without known cause; suicides; deaths 
resulting from unnatural or violent causes; deaths where a doctor has not issued a death 
certificate; deaths that occurred during or as a result of a medical, surgical or dental 
procedure, or an anaesthetic; and deaths of persons detained by the police or certain 
institutions. If a natural cause of death is established after preliminary investigations, 
the coroner is permitted to certify the cause of death without holding a formal inquest 
(except in certain situations, such as a death in police custody, in which an inquest is 
mandatory). To ensure that deaths are classified consistently, coroners are required to 
A 
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record the sequence of morbid events in the same manner as doctors completing the 
Medical Certificate of Causes of Death. 
For each death, a copy of the Medical Certificate of Causes of Death or the coroner's 
report is sent to the Registrar-General of Births, Deaths, and Marriages, who is 
responsible for keeping a register of the causes of death (New Zealand Health 
Information Service 2001). This information is then forwarded to the New Zealand 
Health Information Service in the Ministry of Health, where the underlying cause of 
death is classified according to the International Classification of Diseases. For some 
deaths, information from necropsy reports sent by hospitals and private pathologists is 
also used to assign the underlying cause of death. 
2.2.3 Identification of potential cases 
For the present research, the New Zealand Health Information Service was asked to 
identify all people who met the eligibility criteria and to provide the following 
information about each person: the National Health Index (NHI) number, full name, 
sex, date of birth, date of death, prioritised ethnicity (see Chapter 10), the underlying 
cause of death, other contributing causes, death registration year, death registration 
number, whether a necropsy was performed, and whether the death was certified by a 
doctor or a coroner. 
There were 149 people (53 men and 96 women) who met the eligibility criteria: 140 had 
been usually resident in New Zealand at the time of death and nine were overseas 
visitors. The underlying cause of death was certified by a coroner in 123 cases and by a 
doctor in 26. Ten of the coroner-certified deaths had been the subject of an inquest. A 
necropsy was performed on 132 (89%) of the potential cases. 
2.3 REVIEW OF EXISTING SOURCES OF INFORMATION ABOUT POTENTIAL 
CASES 
2.3.1 Phases of data collection 
The present research involved three phases of data collection. In the first, information 






















contraceptive use and fatal pulmonary embolism. Because of the delays inherent in 
coding mortality data, at the time the study was initiated it was possible to include only 
those deaths that had occurred before August 1998. 
The case-control study was later expanded in order to examine the association between 
psychotropic drugs and fatal pulmonary embolism in men and women aged 15 - 59 
years who died between January 1990 and December 1998. Hence, in the second phase 
of data collection, information was sought about men aged 15 - 59 years and women 
aged 50 - 59 years who died between January 1990 and December 1998, as well as 
women aged 15 - 49 years who died in the final months of 1998. The full methods and 
results of the case-control study of the use of oral contraceptives and psychotropic drugs 
are presented in Chapters 4 and 5. 
During the third and final phase of data collection, the case series was extended to 
include men and women aged 15 - 59 years who died in 1999 and 2000. The 
descriptive and case-control studies of long-distance air travel and fatal pulmonary 
embolism, which are discussed in Chapters 8 - 11, were based on this extended series of 
men and women aged 15 - 59 years who died between 1990 and 2000. 
2.3.2 Death records 
Coroner-certified deaths 
The Department for Courts in Wellington was the central repository in New Zealand for 
coronial files during the three phases of data collection. To view the files of the 123 
potential cases whose underlying cause of death was certified by a coroner, contact was 
made on three occasions with the Coronial Services Officer in Wellington. These 
approaches were followed by a visit by me or a research assistant to photocopy the 
records. All of the relevant files were located. Each file contained a statement by the 
coroner about the underlying cause of death, except for two deaths about which a 
coroner had yet to rule. Various other forms and reports were found in some, but not 
all, of the files. These included a Certificate as to Extinction of Life, a Statement of 
Identification form, a Notification of Death for Registration form, a report prepared by 
the Police for the coroner (the Police 47 form), a copy of the necropsy report, and 
further information from the Inquest if one had been held. 
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Unfortunately, only 56 of the 123 files contained a Police 47 form. During the study 
period, the police were required to complete this form for all deaths that were the 
subject of a coroner's inquiry. The form was used to record demographic data and next 
of kin details, as well as a description. of the circumstances of death. Hence, it was a 
particularly valuable source of information about people who had died suddenly in the 
community. In addition, it often identified the general practitioner. 
Since it was apparent that the Police 47 form was missing from the files of all the 
people who had died in one large centre, a telephone call was made to the mortuary in 
that city to ascertain whether copies of the forms were held locally. It transpired that it 
was indeed the practice in this centre, and in several others, to keep copies of the Police 
47 form in the pathology department. Therefore, for all potential cases for whom the 
Police 47 was missing, a letter was sent to the pathologist who had conducted the 
necropsy to request a copy of the form (Appendix A, letters 1 - 3). When pathologists 
were unable to provide the forms, inquest officers at the local police stations were 
telephoned. A letter was sent to a coroner who was still reviewing one woman's death 
and he provided a copy of the Police 47 (Appendix A, letter 4). As can been seen in 
Table 2.1, most of the missing Police 47 forms were obtained using these approaches. 
Necropsy reports were also missing from the files of six people and these were obtained 
from pathologists (n=3), hospital records (n=2), and the police (n=l). 
Table 2.1 Acquisition of Police 47 forms, New Zealand residents and overseas visitors 
Police 47 forms 
Obtained 
Source of Police 47 form 
Coroner's file held in the Department for Courts 
Pathologist 




Reasons why Police 47 form not obtained 
Police and pathologist's copies destroyed 
Not sought because had extensive inquest records 
Coroner did not become involved immediately after death so a Police 47 form 
was not completed 
Not sought because excluded at outset of study 
Total not obtained 






















Copies of the Medical Certificate of Causes of Death for deaths that occurred in the 
earlier years of the study period were provided by the New Zealand Health Information 
Service. Certificates for later deaths were obtained from the Registrar-General of 
Births, Deaths, and Marriages. A necropsy had been performed after 11 of the 26 
doctor-certified deaths. For six people, a copy of the necropsy report was provided 
along with the Medical Certificate of Causes of Death and for the remaining five, a copy 
was obtained from their hospital records. 
Exclusion of deaths at the outset of the research 
After examining the death records of six potential cases it was immediately apparent 
that the underlying cause of death was not pulmonary embolism. For three of these 
deaths, a necropsy revealed the underlying cause to be bilateral renal vein thrombosis in 
one, cerebral infarction in another, and pulmonary veno-occlusive disease in the third. 
A necropsy undertaken on the fourth person could find no obvious cause of death. The 
underlying causes in the remaining two persons were certified by their doctors as 
chronic renal failure and the Budd-Chiari Syndrome. These six people, who were all 
New Zealand residents, were therefore excluded. This left 143 potential cases (134 
New Zealand residents and nine overseas visitors) for whom further information was 
sought. 
2.3.3 Hospital records 
Potential cases who died in hospital were identified using the death records described 
above. Admissions at any other time during the year before death were also ascertained 
from the National Minimum Dataset. For each admission, a letter was sent to the Senior 
Medical Advisor at the relevant hospital to seek permission for me to visit and view the 
records of that patient. The names and contact details of these doctors were provided by 
the Safety and Regulation Branch of the Ministry of Health. One of two standard letters 
was sent depending on whether the potential case had died in hospital or whether they 
had simply been admitted at some other time during the year before death (Appendix A, 
letters 5 - 10): In addition to seeking permission to examine the notes, the letter 
provided information about the study and requested that a copy of the front sheet 






was sought so that any general practitioners who had not been named in death records 
could be identified before I visited the region in which the case had lived. 
About two weeks after a letter had been sent to a Senior Medical Advisor, he or she was 
contacted by telephone and arrangements were made to view the records. Protracted 
negotiations with the Chief Executive at one hospital were required before permission 
was granted to examine hospital records, while another centre would not provide copies 
of the front sheet, but would allow the records to be viewed in person. In total, 27 
hospitals around New Zealand were visited. 
Of the 134 New Zealand residents, five were pronounced dead on arrival in hospital 
emergency departments although no records about these events were found at any of the 
hospitals. As can been seen in Table 2.2, two of the five had been admitted to the same 
hospital in the year before death. Another 55 New Zealand residents died in hospital, 
31 of whom had also been admitted to the same or different hospitals at some other time 
during the year before death. The remaining 74 New Zealand residents did not die in 
hospital, although 19 were admitted to at least one hospital during the year before their 
death. The hospital records of all but three patients were examined: two had died in 
emergency departments and the records had been destroyed, and one other had 
undergone surgery in an unidentified hospital. It was concluded that this operation must 
have taken place in a private hospital as the admission was not recorded in the National 
Minimum Dataset ( during the study period, discharges from private hospitals were 
inconsistently recorded in this database). 
Of the nine overseas visitors, five died in hospital, one died on hospital premises while 
visiting a relative, and three died elsewhere (Table 2.3). The notes describing these 








Table 2.2 Admissions to New Zealand hospitals, New Zealand residents not excluded at the 
outset 
Admissions 
Dead on arrival at hospital, not noted in hospital records (n=S) 
Admitted to same hospital at least once during year before death 
Not admitted to any hospitals during year before death 
Died in hospital (n=55) 
Admitted to same hospital at least once during year before death 
Admitted to another hospital at least once during year before death 
Not admitted to any hospitals during year before death 
Did not die in hospital (n=74) 
Admitted to one hospital at least once during year before death 
Admitted to two different hospitals during year before death 
Not admitted to any hospitals during year before death 
* Records for two cases who died in the emergency department were not found. 












Number for whom the 













Table 2.3 Admissions to New Zealand hospitals, overseas visitors not excluded at the outset 
Place of death 
Died in hospital 
Died while visiting a relative in hospital 
Did not die in hospital 
























The information sought from the hospital records included the following, if available: 
the circumstances of the fatal episode, reported symptoms, and the results of any 
physical examination and diagnostic tests; the diagnosis and clinical course of any other 
events for which the person was hospitalised in the year before death; details of any 
previous illnesses ( especially venous thromboembolism, cardiovascular disease, and 
diabetes); any major injury, surgery, prolonged immobility, or pregnancies in the year 
before death; contraceptive history; other medications used in the year before death; 
parity; smoking habits; ethnicity; weight; height; and any family history of venous 
thromboembolism. All data were abstracted from the notes and recorded using a unique 
study identification number. 
2.3.4 General practice records 
During the study period, there was no requirement for people living in New Zealand to 
formally register with a general practitioner and hence there was no centralised system 
which could be used to reveal the name of a patient's doctor. This meant that several 
methods had to be employed to identify the general practitioners of the 134 potential 
cases who were New Zealand residents. For 125 people, existing documents such as 
coroners' files (n=71), the Medical Certificate of Causes of Death (n=l), hospital 
records (n=50), the Centre for Adverse Reactions Monitoring files (n=2), and family 
planning clinic records (n=l), led to the general practitioner who was likely to hold the 
records of the potential case (Table 2.4). Sometimes this doctor was identified through 
a third party. For example, for three cases, letters were sent to the locum or on-call 
general practitioner who was named in the coroner's or hospital records and this doctor 
provided the name of the usual general practitioner (Appendix A, letters 11 and 12). 
Two potential cases, for whom the course of the fatal episode was rather protracted, had 
seen new doctors after the onset of their symptoms and these doctors identified the 
general practitioners whom the cases had attended before they became unwell. Several 
practices had also been sold, sometimes more than once, since the death of the potential 
case - although fortunately most continued to operate from the same premises and a 
telephone call to the practice was all that was required to establish the name of the 
doctor who had taken over. A further two practices had closed down, but the former 
general practitioners were traced using the electoral roll. One practice had been put into 
receivership after fraud investigations were initiated and the general practitioner to 
whom the practice had been sold suddenly left the country. It was established that many 
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patients had collected their records from the receivers and had joined one or other of the 
two remaining practices in the town, although some unclaimed files were still being 
held by the receivers because the district health board and other local health services 
had declined to take responsibility for them. 
Various other methods were used to try and identify the remaining general practitioners, 
including writing to next of kin (Appendix A, letters 13 and 14) and ringing general 
practices in the towns in which the potential cases had lived. There were only two 
people for whom a general practitioner could not be identified. In addition to the above 
methods, the local police, coroners, pharmacies, private and hospital laboratories, and 
Independent Practitioner Associations were contacted. Unfortunately, because these 
two deaths occurred in 1992 and 1993, none of these organisations had reliable 










Table 2.4 Sources of information used to identify general practitioners of New Zealand 
residents not excluded at the outset 
Identification of general practitioners 
Identified using existing records (n=125) 
1. Coroners' records identified: 
General practitioner 
General practice attended by potential case 
Doctor who confirmed death, was the partner of the usual general practitioner, 
but practice had subsequently been sold 
Locum of another general practitioner in same town, that doctor identified the 
usual general practitioner 
General practitioner on index date*, but practice had subsequently been sold 
General practitioner on index date, but practice had subsequently been closed 
2. Death certificate identified: 
General practitioner who saw potential case after the index date, that doctor 
identified the general practitioner on the index date 
3. Hospital records identified: 
General practitioner 
General practitioner who saw potential case after the index date, that doctor 
identified the general practitioner on the index date 
Locum of usual general practitioner 
General practitioner on index date, but practice had subsequently been sold 
General practitioner on index date, but practice had subsequently been put into 
receivership 
4. Centre for Adverse Reactions Monitoring records 
5. Family planning clinic records 
Identified using other methods (n=7) 
1. Phoned general practices in town in which case had lived 
2. Identified incidentally when visiting general practice to view records of another case 
3. Wrote to next of kin 
General practitioner not identified (n=2) 
' The date of onset of the fatal episode was taken as the index date. 






















Once the names of the 132 identified general practitioners or their replacements had 
been confirmed, they were sent a letter which outlined the aims of the research and 
request~d permission to visit the practice to examine the records of the potential case 
(Appendix A, letters 15 - 17). As will be explained in Chapter 4, permission was also 
sought from the doctors of potential cases who died between 1990 and 1998 to view the 
records of four randomly selected controls. About a week after the letter had been sent, 
the general practitioner was telephoned to provide further information about the study 
and to arrange a suitable time for a visit. 
None of the general practitioners refused to allow me to visit their practice, although 
four said that the files of the potential case had been destroyed at an earlier date and a 
further three reported that they could not find the records. The records of an eighth 
patient could not be found by the general practitioner, but a copy of the file was 
obtained from the coroner. This person was later determined to be ineligible for 
inclusion in the study. The records of two cases who died after 1998, and who were 
therefore not included in the case-control study of oral contraceptives and psychotropic 
drugs, were couriered to the Department of Preventive and Social Medicine by their 
general practitioners, one of whom had closed her practice. Thus, 122 visits were made 
to general practices throughout New Zealand. The files of 108 patients were found 
during these visits, often after quite some effort. For example, the records of the man 
who had belonged to the practice that was put into receivership were eventually found 
inside his family file at one of the other practices in town after a morning had been 
spent in the receiver's storage shed in a city about an hour away. Table 2.5 provides 
demographic and other information about the 21 men and women for whom general 
practitioner records were not found. 
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Table 2.5 New Zealand residents not excluded at the outset for whom general practitioner records could not be found 
Year of Sex Age Confirmation Died in Other Hospital records Determined Comments 
death (years) of diagnosis hospital admission(s )* examined to be eligible 
1990 Male 19 Necropsy No No Yes General practitioner had recently retired and sold practice. 
Visited practice and searched for records at practice and in 
off-site storage facility. 
1990 Male 47 Necropsy Yes Yes Yes Yes General practitioner had destroyed records. 
1990 Male 50 Necropsy No No Yes General practitioner had destroyed records. 
1990 Male 52 Nil No No No General practitioner could not find records. 
1990 Male 53 Nil Yes Yes Yes No Visited practice, found paper records of visits up until 1987 
when switched to electronic records. Shifted premises 
several years after patient died. Computer records deleted. 
1990 Male 54 Necropsy Yes No Destroyed Yes General practitioner had retired and destroyed records. 
1990 Male 55 Necropsy Yes No Yes Yes Visited practice and searched for records. Found results of 
blood tests only. 
1990 Male 58 Nil No Yes Yes No Changed general practitioners on index date t, viewed these 
records. Visited former practice and searched for records. 
1991 Female 28 Necropsy No No Yes General practitioner who was identified in coroner's 
records did not remember case and could not find records, 
thought he must have seen her when on call. Another 
general practitioner, who was identified in hospital records 
in 1990 and had retired in 1994, he searched through the 
files stored at his home. 
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Year of Sex Age Confirmation Died in Other Hospital records Determined Comments 
death (years) of diagnosis hospital admission(s )* examined to be eligible 
1991 Female 30 Necropsy Yes Yes Yes Yes General practitioner had destroyed records. 
1991 Female 45 Necropsy Yes No Yes Yes General practitioner had sold practice. Neither he, nor new 
general practitioner, was able to find records. 
1991 Male 55 Necropsy No Yes Yes Yes Visited practice and searched for records. 
1993 Male 57 Necropsy Yes Yes Yes Yes Visited practice, found paper records of visits up until 1991, 
also electronic files archived on defunct 5Yi inch floppy 
disks. With the assistance of the doctor who developed the 
computer programme previously used by the general 
practitioner, the disks opened were by a biostatistician (Mr 
Peter Herbison) on an old computer in the Department of 
Preventive and Social Medicine. These contained records 
for 1992 only. 
1995 Female 24 Necropsy Yes Yes Yes Yes Visited practice and searched for records. 
1996 Female 35 Necropsy No No Yes Visited practice and searched for records. 
1997 Female 32 Necropsy No No Yes Visited practice and searched for records. Found a copy of 
a clinical summary which was sent to the coroner. 
1997 Female 44 Necropsy No No Yes Visited practice and searched for records. Found records of 
visits up until 1989. 
1997 Female 58 History Yes No Yes Yes General practitioner had sold practice which was 
reviewed by subsequently relocated to new premises. Visited practice 
specialists in and searched for records, general practitioner also searched 
internal 
medicine* 
through the files stored at his home. 
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Year of Sex Age Confirmation Died in Other Hospital records Determined Comments 
death (years) of diagnosis hospital admission(s)* examined to be eligible 
1998 Male 50 Nil No Yes Yes No Electronic records accidentally deleted by general 
practitioner's receptionist. Visited practice with doctor who 
developed the computer programme used by the general 
practitioner but he was unable to retrieve the records. Paper 
records also lost. 
1999 Female 30 Necropsy Yes No Yes Yes Visited practice, but general practitioner was unable to 
locate records. 
2000 Female 41 Necropsy Yes No Yes Yes Visited practice, but general practitioner was unable to 
locate records. 
* Admission to hospital at any other time in year before death. 
t The date of onset of the fatal episode was taken as the index date. 




A standardised data form was used to record medical information abstracted from the 
medical records of each of the potential cases (Appendix B). Study identification 
numbers, rather than names, were recorded on these forms. Everything within a file 
was examined, including hospital and specialist letters, laboratory and radiology reports, 
as well as old notes that had been transferred from other practices. In the practices that 
maintained a dual records system, the electronic and paper records were both examined. 
The information that was sought will be described in more detail in Chapter 4. 
2.3.5 Family planning clinic records 
One of the aims of the present research was to examine the association between the use 
of medicines and fatal pulmonary embolism. Because many women obtain oral 
contraceptives or hormone replacement therapy from family planning clinics, it was 
decided to seek permission from the New Zealand Family Planning Association to 
examine any family planning clinic records that existed for the female cases ( and their 
controls). More details will be provided in Chapter 4 about how such records were 
found, but what follows is a brief description of how the organisation came to 
participate in the study. 
First, a letter was sent to the spokesperson for the Family Planning Association and the 
manager of professional medical services in the northern region (Appendix A, letter 18). 
The matter was then discussed at a national level by the Association's regional 
directors. In one region there was concern about allowing access to clinical data 
because patients are given an undertaking that information will not be provided to third 
parties. However, because patients are informed that Government agencies may request 
statistical information, the directors felt that the Association would be able to participate 
in the research if they were to receive a request from the Ministry of Health to do so. 
One of my supervisors, Professor Charlotte Paul, therefore contacted Dr Stewart 
Jessamine (Senior Medical Advisor in the Safety and Regulation Branch of the Ministry 
of Health), who then wrote to the Executive Director of the Family Planning 
Association to ask her to allow access to any relevant data. Following this, I was 
granted permission to view any records that existed for the female cases and controls . 
All information that was abstracted from the records was recorded on a form identical to 
that used during the general practice visits. 
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In several small towns where there were no Family Planning Association clinics, 
contraceptive clinics were run by hospitals or other organisations. Permission to view 
records was sought individually from these clinics. 
2.3.6 Centre for Adverse Reactions Monitoring records 
The Centre for Adverse Reactions Monitoring, a unit within the Department of 
Preventive and Social Medicine, receives spontaneous reports of adverse reactions to 
drugs from doctors and other health professionals throughout New Zealand. During the 
study period, several deaths from pulmonary embolism in women who were taking 
combined oral contraceptives were reported to the Centre. These reports, which were 
examined with the permission of the director, will be discussed in Chapter 5. 
2.4 ELIGIBLE CASES AND EXCLUSIONS 
2.4.1 Exclusions 
Of the 149 potential cases originally identified by the New Zealand Health Information 
Service, a total of 28 were excluded for the reasons outlined in Table 2.6. Four people 
who did not have a necropsy were excluded after two specialists in internal medicine (a 
cardiologist and a respiratory physician) independently reviewed their presenting 
symptoms, signs, and the results of diagnostic tests. None of the four met standard 
diagnostic criteria for a probable or definite diagnosis of pulmonary embolism (World 
Health Organization Collaborative Study of Cardiovascular Disease and Steroid 
Hormone Contraception 1995a). 
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Table 2.6 Potential cases identified by the New Zealand Health Information Service who were excluded from the research, New Zealand residents and 
overseas visitors 
Year of Sex Age Who certified Necropsy Died in Other Hospital records GP records Underlying cause of death 
death (years) cause of death performed hospital admission(s )* examined examined 
1990 Male 52 Coroner Yes No No Lost PE found at necropsy, but underlying 
cause metastatic bowel cancer. 
1990 Male 53 Doctor No No Yes Yes Only up until 3 Metastatic bowel cancer. 
years before 
death 
1990 Male 58 Coroner Yes No Yes Yes Records after PE found at necropsy, but underlying 
index date onll cause high grade astrocytoma. 
1990 Female 59 Doctor No Yes Yes Yes Yes Discussed with two specialists in internal 
medicine, insufficient evidence for 
diagnosis of PE. 
1990 Male 59 Doctor Yes Yes Yes Yes Yes PE found at necropsy, but underlying 
cause chronic lymphocytic leukaemia. 
1991 Female 44 Doctor No Yes No Yes Yes Discussed with two specialists in internal 
medicine, insufficient evidence for 
diagnosis of PE. 
1991 Female 51 Coroner Yes No Yes Hospital not Yes PE found at necropsy, but left-sided total 
identified hip joint replacement (osteoarthritis) 14 
days before onset of symptoms. 
1991 Female 58 Coroner Yes Yes Yes Yes Yes PE found at necropsy, but hysterectomy 
(carcinoma-in-situ) and anterior repair 
(stress incontinence) day before onset of 
symptoms. 
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Year of Sex Age Who certified Necropsy Died in Other Hospital records GP records Underlying cause of death 
death (years) cause of death performed hospital admission(s)* examined examined 
1992 Female 54 Doctor No Yes Yes Yes Yes Metastatic breast cancer. 
1993 Male 58 Doctor Yes Yes Yes No, excluded at No, excluded at Pulmonary veno-occlusive disease. 
outset outset 
1994 Female 35 Coroner Yes No No No, excluded at No, excluded at Unascertained cause of death, "death by 
outset outset natural cause of obscure aetiology". 
1994 Female 58 Doctor Yes Yes Yes No, excluded at No, excluded at Bilateral renal vein thrombosis. 
outset outset 
1995 Male 45 Doctor No Yes Yes No, excluded at No, excluded at Chronic renal failure. 
outset outset 
1996 Female 38 Coroner No Yes Yes Yes Yes Discussed with two specialists in 
internal medicine, insufficient evidence 
for diagnosis of PE. 
1996 Male 55 Coroner was Yes No Yes Yes Yes PE found at necropsy, but wide excision 
yet to rule of malignant melanoma right foot and 
split skin graft 10 days before onset of 
symptoms. 
1996 Female 58 Coroner Yes Yes Yes Yes Yes PE found at necropsy, but surgical 
decompression of rotator cuff right 
shoulder one day before onset of 
symptoms. 
1997 Female 35 Coroner Yes Yes Yes No, excluded at No, excluded at Cerebral infarction. 
outset outset 
1997 Female 44 Coroner Yes Yes Yes Yes Yes PE found at necropsy, but surgery to 
place indwelling epidural pump 28 days 
before onset of symptoms. 
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Year of Sex Age Who certified Necropsy Died in Other Hospital records GP records Underlying cause of death 
death (years) cause of death performed hospital admission(s )* examined examined 
1997 Male 57 Doctor No Yes Overseas Yes Overseas visitor Discussed with two specialists in 
visitor internal medicine, insufficient evidence 
for diagnosis of PE. 
1998 Male 50 Coroner Yes No Yes Yes Computer records PE found at necropsy, but underlying 
deleted cause portal vein thrombosis. 
1998 Male 53 Coroner Yes No Yes Yes Yes PE found at necropsy, but right-sided 
total hip joint replacement 
(osteoarthritis) 7 days before onset of 
symptoms. 
1998 Female 58 Doctor No Yes Yes No, excluded at No, excluded at Budd-Chiari syndrome with secondary 
outset outset cirrhosis of the liver. 
1998 Male 59 Coroner Yes No Yes Yes Yes PE found at necropsy, but left-sided 
total hip joint replacement 
(osteoarthritis) 18 days before onset of 
symptoms. 
1999 Male 45 Coroner Yes No Yes Yes Yes PE found at necropsy, but surgical 
repair of multiple lacerations and 
application of bilateral below-knee 
plaster casts 21 days before onset of 
symptoms. 
2000 Female 44 Coroner Yes Yes Yes Examined records Yes PE found at necropsy, but laparoscopic 
from hospital in surgery left knee 14 days before onset 
which case died. of symptoms. 
Other hospital not 
identified 
2000 Female 48 Coroner Yes Dead on No No record of Yes History of recurrent DVT (no PE), 
arrival arrival at hospital ruptured liver secondary to 
anticoagulation. 
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Year of Sex Age Who certified 
death (years) cause of death 
2000 Female 54 Coroner 
2000 Female 59 Coroner 
' Admission to hospital at any other time in year before death. 




















Underlying cause of death 
Insufficient evidence for diagnosis of 
PE. 




2.4.2 Eligible cases 
Of the 121 cases who were determined to be eligible for inclusion in the present 
research, 41 were male and 80 were female. Eight were short-term overseas visitors to 
New Zealand and 113 were normally resident in New Zealand. The underlying cause of 
death in 105 cases was certified by a coroner and for 16 cases a Medical Certificate of 
Causes of Death was completed by a doctor. The diagnosis of pulmonary embolism 
was confirmed by necropsy in 113 and by ventilation-perfusion scans or pulmonary 
angiography in four. Of the remaining four cases, two had venograms that 
demonstrated venous thrombosis. The two specialists in internal medicine, using 
standard criteria (World Health Organization Collaborative Study of Cardiovascular 
Disease and Steroid Hormone Contraception 1995a), determined that these four cases 
also had sufficient evidence for a diagnosis of pulmonary embolism. 
For each eligible case, information from death and medical records was used to 
determine the date of onset of the fatal episode (the reported date on which symptoms of 
venous thromboembolism were first experienced or, if there was no recorded history of 
symptoms, the date of death). This was taken as the index or reference date. The 
numbers of deaths which occurred in each year of the study period are shown in Table 
2. 7. As can be seen, the number of cases for whom the index date fell in a particular 
year did not always correspond with the number of deaths for that year. This is because 
several cases died some days after their index date (Table 2.8). 
The age distribution of the cases by sex is shown in Table 2.9. The median ages of men 




Table 2.7 Distribution of index dates and dates of death of eligible cases, New Zealand 
residents and overseas visitors 
Year Number of cases with index date in that year Number of cases who died in that year 
(n=121) (n=121) 
1986 1 
1990 10 9 
1991 7 8 
1992 8 8 
1993 13 12 
1994 8 9 
1995 12 10 
1996 10 11 
1997 18 20 
1998 12 12 
1999 4 4 
2000 18 18 
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Table 2.8 Interval between onset of symptoms and death, New Zealand residents and 
overseas visitors 
Interval between index date and date of death 







7 -13 days 
14- 20 days 
21-27 days 
~28 days 













Table 2.9 Age on index date and date of death by sex, New Zealand residents and overseas 
visitors 
Age group Number of females in age group Number of males in age group 
(years) 
On index date On date of death On index date On date of death 
< 20 1 1 2 2 
20-24 5 5 1 1 
25-29 9 9 1 1 
30-34 12 12 3 3 
35-39 5 4 3 3 
40-44 11 11 5 5 
45-49 13 14 6 6 
50-54 11 11 11 11 
55-59 13 13 9 9 


















CHAPTER3 VENOUS THROMBOEMBOLISMAND THE USE OF 
ORAL CONTRACEPTIVES AND PSYCHOTROPIC DRUGS 
3.1 INTRODUCTION 
This chapter will discuss the relationships between venous thromboembolism and two 
groups of medicines, oral contraceptives and psychotropic drugs. The risk of venous 
thromboembolism in oral contraceptive users has been extensively studied, whereas 
there are very few studies which have examined the risk in users of psychotropic drugs 
- hence the greater part of the discussion in this chapter is devoted to oral 
contraceptives. The discussion is also confined to data that were available before the 
publication of the research outlined in Chapters 4 - 6 on fatal pulmonary embolism and 
the use of oral contraceptives (Parkin et al. 2000) and psychotropic drugs (Parkin et al. 
2003). Subsequent investigations of consequence, including two meta-analyses, are 
referred to in Chapter 6. 
The chapter takes the form of a narrative review of the evidence which links venous 
thromboembolism with the use of oral contraceptives and psychotropic drugs. In 
addition, it considers the ways in which the evolving evidence about oral contraceptives 
was disseminated and the various responses to that information. 
To identify relevant papers, several search strategies were employed. The Medline 
database was searched using the following terms: "pulmonary embolism" 
"thromboembolism", "venous thrombosis", "thrombophlebitis", "contraceptives, oral", 
"psychotropic drugs" (antidepressive agents [antidepressive agents, second-generation; 
antidepressive agents, tricyclic], tranquilizing agents [anti-anxiety agents, antimanic 
agents, antipsychotic agents]), and "hypnotics and sedatives". Terms used to search the 
Em base database included "venous thromboembolism", "thromboembolism", "vein 
thrombosis", "lung embolism", "deep vein thrombosis", "oral contraceptive agent", and 
"psychotropic agent" (psychostimulant agent [antidepressant agent], tranquilliser 
[anxiolytic agent, neuroleptic agent]). The reference lists of retrieved papers were also 
examined. 
3.2 ORAL CONTRACEPTIVES AND VENOUS THROMBOEMBOLISM 
3.2.1 Early studies and consequential action 
Early studies 
46 
In 1961, soon after the introduction of oral contraceptives, a general practitioner in the 
UK reported a case of pulmonary embolism which "had apparently been precipitated by 
drug treatment" (Jordan 1961). The medicine concerned was Enavid, an oral 
contraceptive containing 150µg mestranol and 9.85mg norethynodrel, which had been 
prescribed to a 40 year old woman to treat endometriosis. The therapy consisted of one 
tablet taken daily for two weeks, after which the dose was increased to two tablets daily. 
Uncontrolled vomiting resulted and the treatment was stopped. However, several days 
later the woman developed pleuritic chest pain and a diagnosis of pulmonary embolism 
was confirmed by chest X-ray and an electrocardiograph. The general practitioner 
proposed that dehydration, secondary to excessive vomiting, had triggered this event 
and he urged that Enavid be used with caution. 
This case report was followed by many more accounts of venous thromboembolism in 
oral contraceptive users, prompting investigations by several drug regulatory 
authorities. In 1963, an ad hoc committee in the USA estimated that the death rate 
among women taking Enovid (marketed in the UK as Enavid) was 12.1 per million 
users as compared with an age-standardised rate of 8.4 per million women in the general 
population (Ad Hoc Committee for the Evaluation of a Possible Etiologic Relation with 
Thromboembolic Conditions 1963). It concluded that no significant increase in 
mortality among Enovid users had been demonstrated, but until further data were 
available, a relationship between Enovid and venous thromboembolism "should be 
regarded as neither established nor excluded". 
In the UK, following a request to doctors to report cases of venous and arterial 
thrombosis that occurred in women taking oral contraceptives (Cahal 1965a), the 
Committee on Safety of Drugs was notified of 16 deaths from such conditions in oral 
contraceptive users in the year to August 1965 (Cahal 1965b). Using national mortality 
statistics, the Committee estimated that this was not appreciably different from what 
would have been expected among the general population of women of child-bearing 







whereas only two would have been expected. The Committee considered that "no firm 
conclusion can be drawn from the data at present available" and urged doctors to report 
all suspected adverse reactions to oral contraceptives and to ascertain whether women 
suffering thromboembolic events were pill users. 
The following year, an advisory committee of the USA Food and Drug Administration 
and a scientific group convened by WHO both concluded that the available data were 
insufficient to confirm a causal relationship between oral contraceptive use and venous 
thromboembolism (Advisory Committee on Obstetrics and Gynecology 1966; World 
Health Organization 1966). 
Meanwhile, in response to the lack of data, the Committee on Safety of Drugs in the UK 
initiated a case-control study of cardiovascular mortality in women of child-bearing age 
and sought the views of the Medical Research Council (MRC) (Inman 1970). 
Following recommendations from a subcommittee established by the Council, case-
control studies were undertaken by the MRC Statistical Research Unit and by the Royal 
College of General Practitioners to explore the possible association between oral 
contraceptives and non-fatal cardiovascular events. In May 1967, preliminary results of 
these three studies were published by the MRC subcommittee which asserted that "the 
sum of evidence .. .is so strong that there can be no reasonable doubt that some types of 
thromboembolic disorder are associated with the use of oral contraceptives" (Medical 
Research Council 1967). In the opinion of the subcommittee, the association could not 
be explained by bias or confounding, and it concluded that "the oral contraceptives are 
themselves a factor in the production of the disease". The excess of deaths from 
pulmonary embolism among oral contraceptive users was estimated to be about three 
per 100,000 women per year. The details of these and other early case-control studies 
that explored the association between oral contraceptive use and venous 
thromboembolism are shown in Table 3.1. 
In 1968, three cohort studies were set up to explore the health effects of oral 
contraceptive use: the Royal College of General Practitioners' Contraceptive Study and 
the Oxford / Family Planning Association Contraceptive Study in the UK and the 
Walnut Creek Contraceptive Drug Study in the USA. Table 3.2 provides an account of 
these studies. 
Table 3.1 Early case-control studies of oral contraceptive use and venous thromboembolism 
Reference Number of Selection of cases Selection of controls Exposure information * Results 
participants 
(Royal College Total Women aged 15-49 2 women selected Cases and controls All venous events (SVT2 DVT2 PE} 
of General 147 cases, years with a first episode from same general interviewed by their GP. 
Practitioners 294 controls of a venous or arterial practice as case. 15/87 (16.5%) cases, 12/174 (6.9%) controls current 
1967) thromboembolic disorder Current use of OC userst 
VTE between 1961 and June Matched by age Use at time of onset of 
87 cases (SVT, 1966, who attended the (within 5 years), VTE (cases) and a date in Unadjusted unmatched OR for current OC use 
DVT,orPE practices of 29 UK GPs marital status, and that same year (controls). AnyOC: 2.8t 
unrelated to who kept disease indexes parity. 
pregnancy), for the Records Unit and Reference category 
Crude incidence VTE per 100,000 woman-years 
17 4 controls Research Advisory Non-users (past and never 
OC users: 450 
Service of the Royal users combined). 
Non-users: 130 
College of General 
Practitioners. 
(Inman and Total Married women aged 20 2 - 6 married women GPs of cases and controls Idiopathic PE or PI 
Vessey 1968) 309 cases, - 44 years normally aged 20 - 44 years interviewed by medical 
998 controls resident in England, selected from the staff from Committee on 16/26 (62%) cases, 171/998 (17.1 %) controls current 
Wales, and Northern same general practice Safety of Drugs using a users. 
PE or PI Ireland who died during as each case. standardised questionnaire. 
77 cases (26 1966 from PE or Pl, Also interviewed hospital Expected number of OC users among cases, based on 
idiopathic, 51 had coronary thrombosis or and family planning clinic exposure status of controls of similar age and parity: 
predisposing MI, cerebral thrombosis Drs for cases. 4.2, p-value for difference < 0.001. 
conditions), 168 or embolism. Unadjusted OR for current OC use controls Current use of OC 
AnyOC: 7.7t 
Identified using death Using OCs at onset of 
certificates provided by terminal episode (cases), Crude mortality rate per million woman-years 
Registrar-Generals. date of interview (controls). OC users: 23t 






















Selection of cases 
Married women aged 16 
- 40 years admitted to 19 
hospitals in North-West 
Metropolitan region in 
UK between 1964 and 
1967 with DVT, PE, 
cerebral thrombosis, or 
coronary thrombosis. 
Excluded fatal events and 
women who were 
sterilised or post-
menopausal. Also those 
with any other 
predisposing chronic or 
acute conditions, 
including surgery, 
pregnancy, or trauma 
during 3 months before 
the event. 
'y 
Selection of controls Exposure information* 
For each case, 2 
married women 
admitted with an 
acute medical or 
surgical condition, or 
for elective surgery 
for a condition which 
would not have 
influenced 
contraceptive habits. 
Matched by hospital, 
date of admission 
(within 4 months), age 
(within 4 years), and 
parity. 
Other than surgery, 
same exclusion 
criteria as for cases. 
Cases and controls 
interviewed by medical 
social worker at home 
using a standardised 
questionnaire (apart from a 
few who completed a postal 
questionnaire). 
Current use of OC 
Use in month before 
admission. 
Reference category 




DVT or PE, all women 
42/84 (50%) cases and 23/168 (14%) controls current 
users. 
P-value for difference (allowing for matching)< 0.001. 
Unadjusted unmatched OR (95% CI) for current OC 
use 
Any OC: 6.3 (3.4 - 11.6). 
DVT or PE, excluding women with previous events 
30/55 (55%) cases and 20/159 (13%) controls current 
users. 
P-value for difference (allowing for matching)< 0.001. 
Unadjusted unmatched OR for current OC use 
Any OC: 3.3t 
Crude hospitalisation rate for DVT or PE per 100,000 
women per year 













145 cases (27 SVT, 
118 DVT or PE), 
145 controls 
Selection of cases 
Married women aged 15 
- 44 years admitted to 43 
hospitals in USA over 3-
year period with SVT, 
DVT, PE, or cerebral 
thrombosis or embolism. 
In one centre unmarried 
women also included. 
Excluded fatal events, 
and women who were 
sterilised, post-
menopausal, or had 
conditions considered to 
be contraindications to 
OC use or to pregnancy. 
Also those with previous 
venous or arterial 
vascular events; other 
predisposing chronic 
conditions; obesity; 
childbirth, surgery, or 
major trauma within 6 
weeks of the event; 
systemic infection within 
4 weeks; minor infection, 
trauma or inflammation 
within 2 weeks; and 
unusually strenuous 
physical activity or 
immobility within 2 
weeks. 
Selection of controls Exposure information* 
For each case, 1 
woman admitted with 
an acute medical or 
surgical condition, 
trauma, or for elective 
nose or throat surgery 
(2 controls selected 
for each case, only 1 
used). 
Matched by hospital, 
date of admission 
(within 6 months), age 
(5-year bands), parity, 
ethnicity, residence, 
payment status. Also 
by marital status. 
Other than surgery, 
same exclusion 
criteria as for cases. 
Married cases and controls 
interviewed by market 
researchers, unmarried 
women by students from a 
women's medical college. 
All participants interviewed 
at home using a 
standardised questionnaire. 
Current use of OC 
Use in month before 
admission. 
Reference category 




Matched OR for current OC use 
AnyOC: 3.ot 
DVTorPE 
Matched OR for current OC use 
AnyOC:4.2t 
29/118 (25%) cases ofDVT or PE attributable to OC 
uset 
PE only 
7/18 cases used sequential preparations. No controls 
used these products. 
50 
Reference 






30 cases, 60 controls 
Selection of cases 
Married women aged 16 
- 40 years admitted 
between 1964 and 1967 
to same 19 hospitals as in 
previous research by 
Vessey and Doll (1968 
and 1969) and to 
hospitals in Oxford 
region in UK with DVT 
or PE :S 1 month after 
acute or elective surgery 
for a condition which 
would not have 
influenced contraceptive 
habits. 
Excluded fatal events, 
and women who were 
sterilised or post-
menopausal. Also those 
with any other 
predisposing chronic or 
acute conditions, 
including pregnancy 
during 3 months before 
the event. 
Selection of controls Exposure information* 
For each case, 2 
married women who 
had undergone acute 
or elective surgery as 
for cases. 
Matched by year of 
admission, age 
(within 5 years), and 
parity. 
For cases in North-
W est Metropolitan 
region, controls 
selected from among 
168 controls included 
in previous research. 
In Oxford region, 
selected from 
hospitals in same area. 
Same exclusion 
criteria as for cases. 
Cases and controls 
interviewed by medical 
social worker at home 
using a standardised 
questionnaire ( apart from a 
few who completed a postal 
questionnaire). 
Current use of OC 
Use in month before 
surgery. 
Reference category 




12/30 (40%) cases and 9/60 (15%) controls current 
users. 
P-value for difference (allowing for matching)= 0.01. 
Unadjusted unmatched OR for current OC use 
AnyOC: 3.8 
Crude incidence per 100,000 women in month post-
appendectomy 




















Selection of cases 
Women aged 15 - 44 
years admitted between 
1964 and 1968 to selected 
hospitals in Sweden with 
a venous or arterial 
thromboembolic disorder. 
Excluded those with 
predisposing illnesses. 
Caucasian women who 
were excluded from 1969 
study by Sartwell et al 
because SVT, DVT, or 





Selection of controls Exposure information* 
Nil Cases sent a postal 
questionnaire. 
Used OC sales data for 
comparisons with cases. 
Exposure 
OC use in an unspecified 
period before admission 
(cases). 
For each case, 1 Cases and controls sent a 
Caucasian control postal questionnaire. 
selected from group 
of controls initially Completed questionnaires 
selected but not used returned by 65% cases and 
in earlier study. 63% controls. 
Current use of OC Matched by hospital, 
date of admission Use in month before 
(within 12 months), admission. 
age (within 10 years), 
Reference category ethnicity, marital 
status, and severity of Non-users (never and past 
event that precipitated users combined). 
VTE in cases. 
Results 
DVT 
55/84 (65%) cases using OCs compared with an 
average of 11 % of women in same region during same 
period. 
Number of observed cases using OCs in each year 
exceeded expected based on population sales data (p-
value < 0.001). 
All venous events (SVT, DVT, PE) 
Unadjusted matched OR for current OC use 
















Selection of cases 
Women aged 20 - 44 
years admitted to 24 
hospitals in Boston region 
during 1972 with SVT, 
DVT,orPE. 
Excluded fatal events, 
those too ill to be 
interviewed, admissions < 
72 hours, and women 
who were sterilised, post-
menopausal, or pregnant. 
Also those with any other 
predisposing chronic 
conditions and conditions 
in whichOCs 
contraindicated, and those 




Selection of controls Exposure information* 
Women aged 20 - 44 
years admitted to 
same hospitals with 
acute illness or for 
elective surgery. 
Same exclusion 
criteria as cases, plus 
women admitted with 
conditions that might 
have been related to 
OCuse. 
Cases and controls 
interviewed in hospital by 
research nurses. 
Current use of OC 
Use in 3 months before 
admission. 
Reference category 




All venous events (SVT, DVT, PE) 
31/43 (72%) cases and 170/842 (20%) controls current 
users. 
Age-adjusted OR (95% CI) for current OC use 
Any OC: 11.0 (5.2 - 25.0) 
Crude incidence VTE per 100,000 women per year 




(Stolley et al. 








88 idiopathic cases, 
335 controls with no 
predisposing factors. 
318 non-idiopathic 
cases, number of 
controls not stated. 
''"<_ 
Selection of cases 
Women aged 15 - 49 years 
admitted to 37 hospitals in 
USA between 1970 and 1973 
with venous and arterial 
thromboembolic disorders 
including, phlebitis and 
thrombophlebitis of lower 
limbs and other sites, PE, Pl, 
other venous thrombosis and 
embolism, arterial 
thrombosis and embolism 
(excluding intracranial), and 
acute MI. 
Excluded fatal events, and 
women who were sterilised, 
post-menopausal, or had 
conditions considered to be 
contraindications to OC use 
or to pregnancy. Also those 
with previous venous or 
arterial vascular events, other 
predisposing chronic 
conditions, recent surgery or 
major trauma, and pregnant 





For each case, 1 -
3 women admitted 
to same hospitals 














Cases and controls 
interviewed in hospital by 
medically-trained 
researchers. 
Current use of OC 
OC use in month before 
admission. 
Reference category 
Non-users (never and past 
users combined). 
'Including information about the use of oral contraceptives, demographic data, medical history, and other risk factors for venous thromboembolism. 
t Derived from data presented in the paper. 
* The methods and findings of the most recent paper are reported if these superseded those of the earlier publication. 
- ' 
Results 
Adjusted OR (95% CI) for current OC use 
Idiopathic SVT, DVT 
Any OC: 5.0 (2.4 - 10.3) 
Idiopathic SVT, DVT, PE 
Any OC: 4.1 (1.3 -13.1) 
Idiopathic PE 
Any OC: 6.4 (2.7 - 15.3) 
Non-idiopathic SVT, DVT 
Any OC: 1.5 (0.9 - 2.6) 
Non-idiopathic SVT, DVT, PE 
Any OC: 2.0 (1.1 - 3.8) 
Non-idiopathic PE 
Any OC: 3.4 (1.9 - 5.9) 
All ORs adjusted for age, ethnicity, weight, parity, 
marital status, centre, hospital pay status, family 
income, and whether patient or husband employed in 
medical setting. 
Abbreviations used in the table Drs: doctors, DVT: deep vein thrombosis, GP: general practitioner, MI: myocardial infarction, OC: oral contraceptive, OR: odds ratio, PE: pulmonary embolism, PI: pulmonary infarction, SVT: 
superficial venous thrombosis, VTE: venous thromboembolism. 
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Table 3.2 Early cohort studies of oral contraceptive use and venous thromboembolism 
Reference 
(Royal College of 
General Practitioners 
1974; Royal College of 
General Practitioners 
1977; Royal College of 
General Practitioners 
1978; Royal College of 
General Practitioners 
1981; Kay 1984)* 






46,000 married (or living as 
married) women of child-bearing 
age recruited by 1,400 GPs in UK 
between April 1968 and July 1969. 
OC users 
1st 2 women in calendar month for 
whom GP wrote a 1st or repeat OC 
prescription (n=23,000). 
Excluded women using OCs for 
non-contraceptive purposes. 
Women who subsequently stopped 
taking OCs classified as past users. 
If later restarted OCs, were 
censored at that time. 
Comparison group 
For each user, one woman who had 
never used OCs randomly selected 
from GP records, matched by age 
within 3 years (n=23,000). 
Never users who commenced OCs 
after recruitment were thereafter 
classified as users. An additional 
1,000 never users selected to 
replace these women. 
Exposure and outcome 
information 
Information about all 
women provided by GPs 
every 6 months, including 
contraceptive use, 
pregnancy, all new 
illnesses, and death. 
VTE classified as 
idiopathic if occurred in 
absence of previous 
history, pregnancy, other 
predisposing events such 
as surgery within 4 weeks, 
and other serious 
debilitating illness. 
Only first episodes 
counted in estimation of 
rates. 
Incidence per 100,000 woman-years 
(number of events)* 
Adjusted incidence, idiopathic events 
SVT 
OC users: 186 (67) 
Never users: 77 (36) 
DVT 
OC users: 82 (30) 
Never users: 20 (9) 
PE 
OC users: 19 (6) 
Never users: 8 (4) 
VT other sites 
OC users: 29 (12) 
Never users: 10 (4) 
Adjusted PE mortality rate per million 
woman-years 
OC users: 28 (3) 
No deaths from PE in never users 
Rates adjusted for age, parity, social class, and 
smoking. 
Relative risk* 
Adjusted RR (95% CD for 
current OC use: 
Idiopathic SVT 
Any OC: 2.4 (1.4- 2.7) 
Idiopathic DVT 
Any OC: 4.2 (2.1- 10.9) 
Idiopathic PE 
Any OC: 2.4 NS 
Idiopathic VT other sites 
Any OC: 2.9 NS 
Never users as reference. 
RRs adjusted for age, parity, social 
class, and smoking. 
Increasing SVT incidence with 
increasing oestrogen dose, DVT 
data too few to examine 
relationship with dose. 
For fixed dose of EE (50µg), 
increasing SVT incidence with 
increasing dose of norethisterone, 
DVT data too few to examine 







Unspecified number of women of 
child-bearing age selected from 
Australian general practices in 
1968. 
OC users 
Users were 181 2 women seen by GP 
in calendar month who were known 
to be taking an OC. Only those 
women who attended follow-up 
appointment 1 year after 
recruitment (n=829) were included 
in study. Of these, 541 attended 2-
year follow-up. 
Comparison group 
For each user, unsuccessfully 
attempted to select next 4 women of 
about the same age who were seen 
by GP and who were not taking an 
OC. Only those women who 
attended follow-up appointment 1 
year after recruitment (n=746) were 
included in study. Of these, 507 
attended 2-year follow-up. 
Exposure and outcome 
information 
Women followed for 2 
years, interviewed 
annually by GPs. Asked 
"have you had any trouble 
with clots in the veins in 
the past year?" Also 
questions about other 
medical conditions, blood 
pressure and weight 
measured. 
~ 
Incidence per 100,000 woman-years 
(number of events)* 
Crude incidence "spontaneous venous 
thrombosis" 
OC users: 765 (8) 
Non-users: 2314 (29) 
Events were mostly superficial thromboses in 
varicose veins. 
Relative risk* 
Unadiusted RR for OC use at 
recruitment and 1-year follow-
!!P 
Spontaneous VT 
Any OC: 0.33, p-value < 0.01 
Non-users (at recruitment and 1-




(Vessey et al. 1976; 
Vessey et al. 1977; 
Vessey 1978a; Vessey et 
al. 1981; Vessey and 
Lawless 1984; Vessey et 
al. 1986)* 





17,032 married Caucasian British 
subjects aged 25 - 39 years, 
recruited at 17 family planning 
clinics in England and Scotland 
between 1968 and 1974, who were 
users of OCs, diaphragms, or IUDs. 
OC users 
56% of participants at recruitment. 
Comparison group 
Non-users of OCs: never users 
(users of diaphragms or IUDs at 
recruitment) plus past users (OC 
users at recruitment but later 
stopped). 





admissions, and outpatient 
treatment obtained 
annually from women 
during clinic visits or by 
postal questionnaires. 
Deaths identified using 
NHS central registries. 
Only first episodes VTE 
counted in estimation of 
incidence, VTE in 
association with pregnancy 
or puerperium excluded. 
VTE incidence estimated 
for 2 groups: 
1. VTE not associated with 
surgery (n=71) 
2. VTE during 3 months 
following surgery (n=34) 
-l 
Incidence per 100,000 woman-years 
(number of events)* 
Crude incidence certain/probable DVT or 
PE unrelated to surgery 
Users of OCs with 2'._ 50µg oestrogen: 62 (20) 
Users of OCs with< 50µg oestrogen: 39 (3) 
Crude incidence possible DVT or PE 
unrelated to surgery 
Users of OCs with 2'._ 50µg oestrogen: 28 (9) 
No possible DVT or PE in women using OCs 
with < 50µg oestrogen 
Adjusted incidence, events unrelated to 
surgery 
SVT 
OC users: 21 (8) 
Non-users: 15 (17) 
Certain/probable DVT or PE 
OC users: 43 (23) 
Non-users: 6 (6) 
Possible DVT or PE 
OC users: 22 (10) 
Non-users: 7 (7) 
Rates adjusted for age, smoking, and history 
of varicose veins. 
Relative risk* 
Adjusted RR for current OC use 
SVT unrelated to surgery 
Any OC: 1.4, NS 
Certain or probable DVT or PE 
unrelated to surgery 
Any OC: 7.2, p-value < 0.001 
Possible DVT or PE unrelated to 
surgery 
Any OC: 3.1, p-value < 0.02 
Post-operative SVT, DVT, or PE 
Any OC: 1.9, NS 
Non-users as reference. 
RRs adjusted for age, smoking, 




(Ramcharan 1974; Petitti 








16,579 women aged 18 - 54 years 
who were members of the Kaiser-
Permanente Medical Care Program 
and who sought a gynaecological or 
general health check-up at the 
Walnut Creek Clinic between 1969 
and 1971. 
At recruitment women classified as 
current OC users, past OC users, 
never users, pregnant or in 
puerperium, or HRT users. 
Exposure and outcome information 
Information about contraceptive use, 
pregnancy, non-contraceptive 
oestrogen use, and hospital admissions 
obtained through baseline and annual 
examinations or postal questionnaires. 
Information also sought from inpatient 
and outpatient records at Kaiser-
Permanente Medical Center and other 
hospitals, and from death certificates. 
Nested case-control analysis 
Based on 38 cases and 8,174 controls 
matched by year of birth and calendar 
year. 17 /3 8 cases idiopathic ( no recent 
surgery, trauma, pregnancy, 
malignancy, past VTE, varicose veins, 
hypertension, or diabetes), including 2 
with retinal vein thrombosis. 
Current use of OC 
Use in month before index date ( date 
case admitted or died). 
Reference category 
Non-users (never and past users 
combined). 
' The methods and findings of the most recent paper are reported if these superseded those of the earlier publication. 
Incidence per 100,000 woman-
years (number of events}* 
Not reported. 
Relative risk* 
Unadjusted matched OR (95% 
CI) for current OC use (nested 
case-control analysis) 
All VTE events 
Any OC: 1.9 (0.9-4.1) 
Idiopathic VTE events 
Any OC: 7.6 (2.9 - 19.9) 
Non-users as reference. 
Abbreviations used in the table DVT: deep vein thrombosis, GP: general practitioner, HRT: hormone replacement therapy, IUD: intrauterine device, NHS: National Health Service, NS: not significant, OC: oral contraceptive, 




Early support for the postulated causal relationship between oral contraceptives and 
venous thromboembolism was not confined to the case-control and cohort studies just 
' 
outlined in Tables 3.1 and 3.2. Reviews of mortality trends, which demonstrated an 
increase in deaths from venous thromboembolism among women of child-bearing age 
concurrent with an increase in contraceptive sales in the UK (Vessey and Weatherall 
1968; Vessey and Inman 1973), USA (Markush and Seigel 1969; Seigel and Markush 
1969), and Canada (Anderson 1970), were also compatible with a link. In addition, an 
increased risk of venous thromboembolism was described in other situations involving 
the administration of oestrogens, such as the suppression of lactation (Daniel et al. 
1967; Jeffcoate et al. 1968) and the treatment of arterial disease (Oliver and Boyd 1961; 
The Coronary Drug Project Research Group 1970). In young women undergoing 
emergency surgery, radioactive fibrinogen uptake tests revealed that current users of 
oral contraceptives were more likely to develop post-operative deep vein thrombosis 
than non-users (Sagar et al. 1976). In other laboratory-based studies, prothrombotic 
changes were described in the blood of women taking oral contraceptives, although the 
findings were not always consistent (Poller 1978). 
Following a suggestion that sequential oral contraceptive preparations1 might carry a 
higher risk of venous thromboembolism (Sartwell et al. 1969), and the publication of a 
clinical trial in which thrombophlebitis of the leg veins occurred more often in those 
oral contraceptive users who were taking preparations with relatively high doses of 
oestrogens and low doses of progestogens (Grant 1969), a review was undertaken of 
spontaneous reports to the Committee on Safety of Drugs in the UK, the Swedish 
Adverse Drug Reaction Committee, and the Danish National Health Service's Board on 
Adverse Reactions to Drugs (Inman et al. 1970). Using oral contraceptive sales data 
and assuming that all preparations carried the same risk of venous thromboembolism, 
the number of expected events was estimated for each product and compared with the 
observed number of cases. The investigators found no evidence that sequential 
preparations carried a higher risk of venous thromboembolism than non-sequential 
1 
Preparations in which oestrogen-only tablets were taken for 14 - 16 days, followed by a five to seven 





products containing the same doses of oestrogen. However, tbey did find an excess of 
observed cases for oral contraceptives containing higher doses of oestrogen in all three 
countries. Moreover, in a pooled analysis of three case-control studies which 
individually had shown no evidence of a dose-response relationship (Inman and Vessey 
1968; Sartwell et al. 1969; Vessey and Doll 1969), oral contraceptives with higher doses 
of oestrogen were associated with a greater risk of venous thromboembolism. After 
considering several possible biases, the researchers concluded there was "no doubt" that 
the apparent dose-response relationship was real. The data about progestogens were 
less clear cut; it was thought that an observed excess of cases who were users of oral 
contraceptives containing megestrel and a deficit of cases using pills containing 
norethynodrel might indicate that the progestogen component had some influence in 
thrombogenesis, but alternative explanations for the findings could not be ruled out. 
Preliminary findings from this study prompted a decision by the Committee on Safety 
of Drugs to issue an early warning about the higher risk of venous thromboembolism 
with higher oestrogen doses and to recommend that oral contraceptives containing more 
than 50µg of oestrogen (ethinyloestradiol or mestranol) should not normally be 
prescribed (Scowen 1969a). The Committee later explained its reasoning for this 
decision, stating that it "did not feel that it could delay for months for a detailed analysis 
of the individual preparations, since during each month several women would die 
unnecessarily and many more would suffer from avoidable hazard" (Committee on 
Safety of Drugs 1970). Unfortunately, information about the impending early warning 
was leaked to the media in the UK following a confidential meeting with oral 
contraceptive manufacturers, forcing the Committee to make a public announcement in 
December 1969 before doctors had received its planned communication (Scowen 
1969b). In the wake of the media publicity, many women in the UK stopped taking oral 
contraceptives (Badaracco et al. 1973; Royal College of General Practitioners 1974), 
thousands of unintended pregnancies were thought to have occurred (Badaracco et al. 
1973), and the Committee received much criticism from the medical profession for its 
handling of the matter (Editorial 1969; Editorial 1970a). In Sweden, the source of some 
of the published data, doctors were also advised to prescribed oral contraceptives with 
the lowest possible dose of oestrogen, however there was only a slight reduction in the 
estimated proportion of women of child-bearing age who were using oral contraceptives 







In the USA, the issue received widespread coverage in the media (Phillips 1974), but 
this did not appear to result in any immediate reduction in the proportion of married 
women using oral contraceptives in the general population (Westoff 1976) or among 
those participating in the Walnut Creek cohort study (Phillips 1974). 
In New Zealand, too, the response was quite different from that of the UK. In August 
1969, the New Zealand Committee on Adverse Drug Reactions reported that it had been 
notified of several deaths and non-fatal episodes of venous thromboembolism in women 
taking oral contraceptives (New Zealand Committee on Adverse Drug Reactions 1969). 
A few months later, the New Zealand Medical Journal carried an editorial which 
outlined the results of the recently published UK study (Editorial 1970b ), as well as a 
communication from the Committee on Adverse Reactions to Drugs about a similar 
excess of venous thromboembolic events among oral contraceptive users in New 
Zealand who were taking preparations with higher doses of oestrogen (McQueen 1970). 
Subsequently, there was a notable absence of correspondence in the New Zealand 
Medical Journal about these reports and there appeared to be no evidence that a "pill 
scare" had eventuated. 
From controversy to consensus 
At first, the existence of a relationship between oral contraceptives and venous 
thromboembolism was not universally accepted. Researchers working for the 
pharmaceutical company which developed the first oral contraceptive were quick to 
dismiss the evidence for a link by citing biases in the epidemiological studies and 
presenting data from clinical trials which did not find a relationship (Drill and Calhoun 
1968; Drill and Calhoun 1969; Drill 1972a; Drill 1972b). Similarly, doctors known to 
work for two other oral contraceptive manufacturers proposed alternative explanations 
for the association, although the possibility that oral contraceptive users might have a 
slightly elevated risk of venous thromboembolism was not ruled out (Preston 1971; 
Zador 1976). Other commentators also suggested that various biases and confounding 
might have distorted the results of the published epidemiological studies (Haeger et al. 
1967; Crombie and Cross 1969; Hougie 1969; Moses 1969; Nanni 1970; Goldzieher 
and Dozier 1975). Furthermore, a randomised controlled trial which appeared to show 








(Fuertes-de la Haba et al. 1971) was taken as evidence that the findings of the 
observational studies were spurious (Hougie 1973). 
However, doubts were soon expressed about the methods of the randomised controlled 
trial and little weight was given to the results (McQueen 1971). Meanwhile, successive 
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reviews of the emerging evidence from other epid'emiological studies led researchers 
and commentators in the UK (Doll and Vessey 1970; Bradford Hill 1974; Vessey 1974; 
Vessey and Doll 1976; Vessey and Mann 1978; Vessey 1978b; Vessey 1980), USA 
(Meeker 1969; Sartwell 1972; Handin 1974; Stolley 1978; Prentice and Thomas 1987), 
and New Zealand (McQueen 1971; McQueen 1978) to conclude that the observed 
association between oral contraceptive use and venous thromboembolism was real and 
that it reflected a causal relationship. 
In 1981, a comprehensive review of the relationships between oral contraceptive use 
and venous (Stadel 1981a) and arterial (Stadel 1981b) cardiovascular disease 
summarised the current knowledge about oral contraceptive use and venous 
thromboembolism as follows. First, current use of oral contraceptives was associated 
with an increased risk of venous thromboembolism, as well as arterial cardiovascular 
diseases such as myocardial infarction and stroke. Second, the risk of venous 
thromboembolism progressively increased during the first month of use and then 
remained constant. The risk declined during the first month following discontinuation 
of oral contraceptives and then returned to the background risk found in never users. 
Third, compared with non-users, women without pre-existing risk factors who were 
current users of oral contraceptives had a 4- to 11-fold increased risk of venous 
thromboembolism. The relative risks found in cohort studies tended to be somewhat 
lower than those found in case-control studies, possibly because participation in the 
studies might have influenced doctors' prescribing habits. Fourth, the association 
between oral contraceptives and venous thromboembolism was weaker in women with 
other risk factors, although the attributable risk was higher than for idiopathic events. 
Compared with non-users, oral contraceptive users had a two-fold increased risk of 
post-operative venous thromboembolism. The association between oral contraceptive 
use and venous thromboembolism was not modified by age, parity, or socio-economic 
status. There were conflicting data about weight and smoking, but it was thought 




blood group type might modify the risk. Fifth, a dose-response relationship had been 
found for the oestrogen component of the pill. However, while a few studies had 
suggested that the progestogen component might have some role in thrombosis, no clear 
association between the progestogen content of most oral contraceptives had been 
established. Sixth, in the UK the annual incidence of symptomatic superficial or deep 
vein thrombosis for healthy women of child-bearing age was estimated to be 3 per 1,000 
in oral contraceptive users and 1 per 1,000 in non-users. Seventh, although oral 
contraceptive use increased the risk of dying from pulmonary embolism, the mortality 
rate was very low. Finally, various haematological, biochemical, and physiological 
changes in oral contraceptive users had been reported which might explain the increased 
risk of venous and arterial thrombotic events. 
Changes in prescribing practices and oral contraceptive formulations 
Following the announcement by the UK Committee on Safety of Drugs in December 
1969, prescribing practices changed rapidly and by May 1970, very few women in the 
UK were using oral contraceptives containing more than 50µg of oestrogen (Badaracco 
et al. 1973). A similar trend was observed elsewhere; by 1974 most pill users in many 
countries were taking preparations containing 50µg of oestrogen (Doll 1974). 
Emerging information about other serious adverse reactions, such as myocardial 
infarction (Inman and Vessey 1968; Mann and Inman 1975; Mann et al. 1975; Mann et 
al. 1976a; Mann et al. 1976b; Jick et al. 1978a; Jick et al. 1978b) and stroke (Inman and 
Vessey 1968; Vessey and Doll 1968; Vessey and Doll 1969; Collaborative Group for 
the Study of Stroke in Young Women 1973; Royal College of General Practitioners 
1974; Jick et al. 1978c), also served to encourage more selective prescribing of oral 
contraceptives (Sartwell and Stolley 1982). Thus, older women with other risk factors 
for cardiovascular disease were less likely to be prescribed oral contraceptives than 
previously (Thorogood and Vessey 1990). 
Major changes were also made to the formulation of oral contraceptives in an effort to 
reduce the risk of arterial and venous vascular events, as well as some of the so-called 
minor side effects associated with pill use. The dose of oestrogen was progressively 
lowered from 50µg to 30µg, and then to 20µg. New progestogens were also developed; 
levonorgestrel was introduced onto the market in the late 1960s (Newton 1995), and in 




market (Fotherby and Caldwell 1994). These latest preparations contained either 30µg 
or 20µg of ethinyloestradiol and one of two new progestogens - desogestrel and 
gestodene. One other new progestogen, norgestimate, was introduced around the same 
time. Oral contraceptives containing this progestogen have rather inconsistently been 
classified as third generation pills (because of the timing of their introduction), while at 
other times they have been grouped with levonorgestrel preparations (because 
norgestimate is reportedly metabolised to levonorgestrel) (Newton 1995). This 
highlights a confusing practice - oral contraceptives have been categorised by the date 
of introduction, the chemical structure or dose, and sometimes the rationale for a 
classification system has been unclear (Petitti 2003). 
Several reviews suggested, on the basis of haematological and biochemical studies, that 
oral contraceptives containing desogestrel and gestodene had less adverse impact on the 
coagulation system and carbohydrate metabolism than other low-dose preparations ( < 
50µg oestrogen), although it was also noted that some of the reviewed studies suffered 
from methodological problems (Speroff et al. 1993; Fotherby and Caldwell 1994; 
Newton 1995). Other metabolic studies also suggested that the new pills were less 
androgenic and, although individual progestogens appeared to have differing effects on 
various lipids, overall the effects on lipoprotein metabolism were less unfavourable than 
those seen with older products (Speroff et al. 1993; Fotherby and Caldwell 1994; 
Newton 1995). Few conclusions were drawn about the metabolic effects of 
norgestimate as the available data were limited. 
Most of the reviewers urged that these apparently beneficial metabolic effects should be 
interpreted with caution. One group stressed that the clinical relevance of the findings 
was uncertain and that epidemiological studies were required to confirm any advantages 
of the new progestogens (Speroff et al. 1993). Others pointed out that although it 
appeared that the new oral contraceptives were an improvement on the older low-dose 
pills, "this conclusion has to be viewed against the background of many years of use of 
the other low-dose COCs, which appear not to have resulted in a high incidence of 
undesirable side-effects" (Fotherby and Caldwell 1994). 
Nonetheless, the new preparations containing desogestrel and gestodene were marketed 






even suggested that the use of these preparations might tum out to be, as was 
(supposedly) the case with hormone replacement therapy, protective against arterial 
cardiovascular disease (Samsioe and Mattsson 1990). The new products were also 
advertised as causing fewer troublesome side effects such as weight gain, mood 
changes, acne, and other androgenic effects, than older preparations (Stockbridge 1998). 
Desogestrel pills were also promoted for use by peri-menopausal women (Stockbridge 
1998). The uptake of these oral contraceptives was rapid; in the four years between 
1988 and 1992 the market share in European countries increased from about 30% to 
over 60% (Fotherby and Caldwell 1994 ). 
3.2.2 The need for new studies of oral contraceptive safety 
Uncertainty about the risk of venous thromboembolism in contemporary users of new 
preparations 
In the 1980s it became clear that there was a need for new studies of oral contraceptive 
safety (Poulter et al. 1991). At the start of the decade most of the available data were 
derived from studies in which women were taking higher dose oral contraceptives and it 
was uncertain whether changes in the formulation of oral contraceptives and more 
selective prescribing practices had resulted in any reduced risk of venous 
thromboembolism in users (Stadel 1981a; Sartwell and Stolley 1982). Moreover, a few 
commentators remained doubtful about the reliability of the relative risk estimates 
obtained in the earlier research because of the small size of many of the studies, the lack 
of objective diagnostic tests, and various other biases which they suggested had inflated 
the relative risks to an unknown degree (Realini and Goldzieher 1985). 
As the decade progressed, new studies were published but much uncertainty remained. 
For example, evidence about the benefits of lower oestrogen doses was inconsistent. In 
Sweden, a comparison of official morbidity statistics in two periods (1966 to 1968 when 
oral contraceptives all contained ~ 75µg oestrogen and 1974 to 1976 when pills 
containing> 50µg oestrogen had been withdrawn from the market) showed a reduction 
in hospital admissions for idiopathic venous thromboembolic disorders among women 
of child-bearing age during the later period, although there were no differences in 
mortality (Bottiger et al. 1980). The findings of an earlier study of deaths from 





decline in mortality concurrent with the reduced use of very high-dose oral 
contraceptives (Sartwell et al. 1976). 
A review of spontaneous reports to the UK Committee on Safety of Drugs of 
cardiovascular events in users of oral contraceptives, which used similar methods to an 
earlier study (Inman et al. 1970), showed that there were fewer deaths from venous 
thromboembolism between 1974 and 1977 than expected among women using oral 
contraceptives containing 30µg oestrogen, assuming that 30µg and 50µg pills carried 
the same risk (Meade et al. 1980). However, no such difference was found for non-fatal 
events and it is difficult to know what impact under-reporting might have had on the 
results. An analysis of the role of progestogens in cardiovascular disease showed that 
for a fixed dose of oestrogen, the risk of stroke and myocardial infarction increased with 
increasing doses of norethisterone. The risk of venous thromboembolism, however, 
appeared unaffected by progestogen dose. 
Results from the Oxford / Family Planning Association Contraceptive Study also 
suggested that oral contraceptives containing< 50µg of oestrogen carried a lower risk of 
venous thromboembolism than pills containing 2::_ 50µg oestrogen, although the data 
were too few to draw a definite conclusion (Vessey et al. 1986). In the Royal College 
of General Practitioners' Study of Contraception, a dose-response was found for 
superficial venous thrombosis, but there were insufficient data to examine the 
relationship for deep venous thrombosis (Royal College of General Practitioners 1978). 
In a retrospective cohort study based on the Michigan Medicaid population, users of 
oral contraceptives containing 50µg and > 50µg oestrogen both had a higher incidence 
of venous thromboembolism than women taking pills containing < 50µg oestrogen; the 
adjusted relative risks were 1.5 (95% CI 1.0 - 2.1) and 1.7 (95% CI 0.9 - 3.0) 
respectively (Gerstman et al. 1991). An earlier analysis suggested that the relative 
oestrogen potency of oral contraceptive preparations (based on the dose of 
ethinyloestradiol or mestranol, the type and dose of progestogen, and the possible 
interactions between the two hormones) also played a role; low-oestrogen potency oral 
contraceptives carried a lower risk of venous thromboembolism than intermediate or 
high-oestrogen potency formulations (Gerstman et al. 1990). No such dose-response 
was observed in relation to progestogen potency. 
-/' 
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In laboratory-based studies, adverse changes in coagulation activity were reported to be 
less marked in women taking oral contraceptives containing 30µg of oestrogen than in 
users of 50µg pills (Bonnar 1987). In addition, for a given dose of oestrogen, the 
magnitude of coagulation changes varied with the type of progestogen. 
Conversely, other investigators reported that oral contraceptives containing different 
doses of oestrogen appeared to carry comparable risks of venous thromboembolism 
(Porter et al. 1982; Helmrich et al. 1987). Moreover, the estimates of risk in oral 
contraceptive users relative to non-users were very similar in magnitude to those found 
in the early studies. In a case-control study based on 61 cases and 1278 controls aged 
18 - 49 years, who were admitted to American and Canadian hospitals between 1976 
and 1983, the use of oral contraceptives in the month before admission was associated 
with a nine-fold increased risk of non-fatal venous thromboembolism (Helmrich et al. 
1987). It should, however, be noted that there was a wide confidence interval around this 
estimate (adjusted odds ratio 8.8 [95% CI 3.6 - 22.0]). 
Similarly in a cohort study based on women aged 20 - 44 years who were members of 
the Group Health Cooperative of Puget Sound during a three-year period between 1977 
and 1979, the incidence of idiopathic non-fatal venous thromboembolism in current 
users of oral contraceptives was reported to be about eight times that of non-users 
(Porter et al. 1982). In a later analysis involving women in the Group Health 
Cooperative who were aged 15 - 44 years between 1980 and 1982, oral contraceptive 
users were reported to have a three to five-fold increased risk (Porter et al. 1985). The 
investigators later reported that the women-years at risk for oral contraceptive users had 
been overestimated for both study periods (Porter et al. 1987); hence, it is likely that the 
relative risks were underestimated. It should also be noted, however, that the numbers 
of venous thromboembolic events during both study periods were small ( 10 and nine 
respectively). 
Uncertainty about the risk of venous thromboembolism in oral contraceptive users in other 
countries 
Almost all of the early and subsequent studies which had shown a relationship between 
oral contraceptive use and venous thromboembolism (as well as other cardiovascular 







Consequently there was some concern that this information might not be generalisable 
to populations with different background risks of venous thromboembolism, and 
different economic and environmental conditions (Poulter et al. 1991). Hence, there 
was a need for epidemiological studies in other countries - especially countries in 
which the balance of risks and benefits of oral contraceptives might differ from Western 
nations. A hospital-based case-control study undertaken in Mexico, Hong Kong, and 
the German Democratic Republic had insufficient power to examine the risk of 
cardiovascular disease by country (World Health Organization Collaborative Study 
1989). 
Other gaps in knowledge 
The early studies of oral contraceptive safety had been unable to provide certain 
important information for oral contraceptive users and prescribers. For example, there 
was very little information about the risks of venous thromboembolism in relation to the 
duration of use and the previous use of oral contraceptives (Poulter et al. 1991). In 
addition, previous studies had lacked power to determine whether the presence of other 
factors, such as smoking, modified the relationship between oral contraceptives and 
venous thromboembolism. 
3.2.3 Initiation of new research and early responses 
The new studies 
WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception 
In response to the need for more information about the safety of various contraceptive 
methods, the Special Programme of Research, Development, and Research Training in 
Human Reproduction (established by WHO) formed a Task Force on the Safety and 
Efficacy of Fertility Regulating Methods (Skegg 1999). In 1985, a steering committee 
for the Task Force identified nine priority areas for research, including cardiovascular 
disease and hormonal contraception. Subsequently, after a pilot study, the WHO 
Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception was 
initiated in 21 centres in Africa, Asia, Europe, and Latin America to determine whether 
modem oral contraceptives, as they were currently prescribed, were associated with 
increased risks of venous thromboembolism, myocardial infarction, or stroke (World 
Health Organization Collaborative Study of Cardiovascular Disease and Steroid 
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Hormone Contraception 1995a). An additional aim in each of the three hospital-based 
case-control studies was to ascertain whether any such risks differed between Europe 
and countries in three other regions (Africa, Asia, Latin America and the Caribbean). 
Secondary aims were to explore the risks in sub-groups of women (such as past users 
and those with pre-existing risk factors) and to establish whether different oral 
contraceptive preparations carried different risks of cardiovascular disease. 
Transnational study 
In 1989, the results of a German pharmacokinetic study were published which raised 
concerns about the safety of oral contraceptives containing gestodene (Jung-Hoffmann 
and Kuhl 1989). In this study, 22 volunteers were randomly assigned to take an oral 
contraceptive containing 30µg of ethinyloestradiol with either 75µg gestodene or 150µg 
desogestrel for a period of 12 months. Blood samples, which were taken on days one, 
10, and 21 during the first, third, sixth, and twelfth cycles, showed significantly higher 
levels of serum ethinyloestradiol in women taking the gestodene preparation. This 
finding prompted German regulatory authorities to issue an alert to doctors and to 
request that an epidemiological study be undertaken to investigate the cardiovascular 
safety of oral contraceptives containing this progestogen (Spitzer et al. 1996). After 
some input from investigators involved in the WHO study, the Transnational hospital-
based case-control study was initiated with funding provided by a pharmaceutical 
company. 
The UK General Practice Research Database and Leiden studies 
Early in 1995, an analysis of the WHO study unexpectedly showed a doubling of risk of 
venous thromboembolism in users of desogestrel and gestodene oral contraceptives, 
relative to users of older preparations (Farley et al. 1999). No plausible alternative 
explanations for the excess risk, which was confirmed in a more detailed analysis, were 
identified. The finding was discussed at an urgent consultation meeting in Geneva in 
July 1995, which was attended by investigators from the Transnational study, oral 
contraceptive manufacturers, and regulatory authorities. An expeditious analysis of the 
Transnational study was requested and researchers from the Boston Collaborative Drug 
Surveillance Program agreed to undertake an epidemiological study using the UK 
General Practice Research Database (GPRD) (Rawlins 1995). A reanalysis of the 





Announcement by the UK Committee on Safety of Medicines 
On 18 October 1995, on the basis of unpublished data from the WHO, GPRD, and 
Transnational studies discussed above, the Committee on Safety of Medicines (CSM) in 
the UK issued a warning that low-dose oral contraceptives containing desogestrel and 
gestodene were twice as likely to cause venous thromboembolism as other low-dose 
oral contraceptives (Committee on Safety of Medicines 1995). The CSM went on to 
recommend that desogestrel and gestodene preparations should not be prescribed to 
women with risk factors for venous thromboembolism and that current users without 
such risk factors should only continue to take the newer pills if they did not tolerate 
older preparations and they were prepared to accept the excess risk. 
Following this action by the CSM, drug regulatory authorities in Germany and Norway 
issued warnings about the excess risk and imposed prescribing restrictions (Carnall et 
al. 1995). The Federal Institute for Medical Drugs and Products in Germany ruled that 
women under the age of 30 years who were starting oral contraceptives for the first time 
were not to be prescribed contraceptives containing desogestrel or gestodene. It also 
asked manufacturers of these contraceptives to provide more detailed information about 
the risks of venous thromboembolism on the product information sheets provided to 
users. At the time, desogestrel and gestodene products were taken by about 30% of 
German oral contraceptive users. In Norway, only one product containing an implicated 
progestogen (desogestrel with 30µg ethinyloestradiol) was licensed for use and this was 
taken by about 35% of oral contraceptive users. The Norwegian Medicines Control 
Agency advised that this preparation should only be used by women who could not 
tolerate other pills and it was not to be prescribed to first-time users. 
Authorities in several other countries chose not to issue immediate advice (Carnall et al. 
1995). In the Netherlands, where about 63% of oral contraceptive users were taking 
desogestrel or gestodene pills, the Medicines Assessment College decided to await the 
publication of the relevant studies before making any decisions. A similar decision was 
made by the Canadian Federal Drugs Directorate. Gestodene preparations were not 
licensed for use in Canada and desogestrel products comprised about 12 - 15% of oral 
contraceptives used. The Food and Drug Administration in the USA concluded that the 









products to alternative preparations. Like Canada, the USA had never licensed 
gestodene products. In Australia, where about 5% of pill users took desogestrel or 
gestodene oral contraceptives, the Therapeutic Goods Administration undertook a 
review of prescribing warnings and cautions. The initial position of the European 
Union's Committee on Proprietary Medicinal Products was that until more data were 
available, it could not exclude the possibility that biases explained the apparent excess 
risk (Choo 1995). In New Zealand, where oral contraceptives containing desogestrel or 
gestodene were used by nearly 80% of pill users (Wilson 1999), the Ministry of 
Health's immediate response was to send a copy of the CSM statement to doctors and 
pharmacists and to recommend that women at high risk of venous thromboembolism 
should consider using other preparations (Paul 1996). A week later, the Ministry 
concluded that in fact no prescribing recommendations could be made until published 
data were available. 
Responses to the CSM warning 
The action taken by the CSM attracted considerable criticism, much of which echoed 
the concerns expressed following the early warning issued by the Committee on Safety 
of Drugs in December 1969. The similarity of responses was perhaps not surprising 
given that the CSM, like its predecessor, was forced to hold a press conference earlier 
than it had intended because of an unauthorised release of information to the media, and 
once again many doctors, pharmacists, and other health professionals, learned of the 
warning from the media or their patients before they received an official "Dear Doctor" 
letter (Craft 1995). Subsequently, there were anecdotal reports that doctors were 
deluged with telephone calls and visits from concerned patients (Davies et al. 1995; 
Graham et al. 1995; Hope 1995) and that some women stopped using oral 
contraceptives altogether (Armstrong et al. 1995; Ramsay 1996). Fears were also 
expressed that womens' confidence in the safety of oral contraceptives had been 
damaged by the publicity (Spitzer 1995; Allison 1996; Cramer 1996; Ketting 1996). 
Equally, other doctors reported that the "pill scare" had not caused as much trouble as 
they had anticipated - their patients had behaved with "common sense" (Seamark 
1995) and were pleased to be offered the opportunity to change to products that carried 






More systematic examinations of the effects of the CSM announcement on oral 
contraceptive use and pregnancy trends offered a slightly confused picture. A review of 
prescription trends by the UK Prescription Pricing Authority revealed that, overall, the 
total number of women taking oral contraceptives remained stable, although the 
proportion of oral contraceptive users taking desogestrel or gestodene preparations fell 
from 55% in September 1995 to 12% by February 1996 (Ferguson and Jenkins 1996). 
Similar utilisation patterns were observed for various sub-groups of women (Martin et 
al. 1997; Flett et al. 1998; Jick et al. 1998a). The pregnancy data were less consistent. 
While no increases in abortions or births were found in some groups (Flett et al. 1998; 
Jick et al. 1998a), in others the abortion rates appeared to have risen following the CSM 
announcement (Child et al. 1996; Ramsay 1996). In the UK, overall, the Office for 
National Statistics estimated that an excess 30,000 conceptions occurred between 
October 1995 and June 1996 (Wood et al. 1997). The abortion rates in Norway were 
also said to have climbed following the warning issued by the regulatory authority in 
that country (Iversen and Tore Nilsen 1996; Skjeldestad 1997). However, some of these 
accounts were criticised for failing to take longer trends in unwanted pregnancies into 
account (Vandenbroucke et al. 2000). 
In New Zealand, an examination of oral contraceptive prescription data for the period 
January 1995 to March 1998 revealed that the proportion of women of child-bearing age 
who were using oral contraceptives did not change following the CSM warning or the 
release of prescribing advice by the New Zealand Ministry of Health (Wilson 1999). It 
was also apparent that most women continued to take their usual oral contraceptive. In 
October 1995, desogestrel and gestodene contraceptives were taken by about 79% of 
pill users; this proportion dropped only slightly to 74% immediately after the CSM 
announcement and thereafter declined gradually to 62% by March 1998. Apart from a 
small increase in abortions in women aged 15 - 19 years in March 1996, there was no 
indication that the CSM or Ministry of Health advice had any impact on overall or age-
specific abortion rates in New Zealand (Wilson 1999). 
The Transnational study investigators also expressed dismay over the CSM' s actions. 
In a letter published in the BMJ on 28 October 1995, the principal investigator reported 
that once the analyses were completed his group had shared their findings with the UK 




authorities in confidence (Spitzer 1995). Without further consultation, a few days later, 
the CSM made its announcement. Such action, claimed the principal investigator, was 
hasty and not warranted by the "modest" relative risks and "very low" attributable risks. 
Moreover, he and his colleagues believed that "five unavoidable biases might be driving 
the risks up spuriously." 
The CSM also drew immediate criticism from other quarters for issuing a warning 
before the data on which it was based were published (Carnall 1995; Editorial 1995; 
Guillebaud 1995a; Simpson and Elstein 1996). It was also suggested that the CSM 
acted beyond its legal authority by issuing advice (Watt 1995a). The Chairman of the 
CSM responded by saying that much of the work of the Committee involved assessing 
data which were unpublished and, moreover, the CSM would be "failing in its duty ... .if 
it did not communicate important drug safety information promptly" (Rawlins 1995). 
Furthermore, he considered that the CSM had not acted with undue haste since it had 
been aware of the results of the WHO study since July 1995. 
Concerns were also expressed that the CSM action had compromised ongoing research 
into oral contraceptives and myocardial infarction and stroke (Davis et al. 1995; 
MacRae and Kay 1995; Spitzer 1995; Wynn et al. 1995; Simpson and Elstein 1996) and 
that the continued involvement of pharmaceutical companies in contraceptive research 
and development might have been jeopardised (Wynn et al. 1995; Cramer 1996). 
Representatives of the company which manufactured an oral contraceptive containing 
norgestimate, were quick to emphasise that their product was not implicated in the CSM 
warning (Donnelly 1995; Donnelly 1996a; Donnelly 1996b). In fact, it was not that 
norgestimate contraceptives had been shown to be safer than desogestrel and gestodene 
products - it was simply that the key studies provided insufficient data to allow an 
assessment of venous thromboembolism risk (Walker 1998). 
3.2.4 The key studies 
Two months after the CSM announcement, on 16 December 1995, the WHO, GPRD, 
and Leiden studies were published in the Lancet (Bloemenkamp et al. 1995; Jick et al. 
1995; World Health Organization Collaborative Study of Cardiovascular Disease and 






of Cardiovascular Disease and Steroid Hormone Contraception 1995c); the 
Transnational study appeared the following month in the BMJ (Spitzer et al. 1996). The 
details of these studies are shown in Table 3.3. 
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Table 3.3 Key studies which examined the association between oral contraceptive use and venous thromboembolism by progestogen type 
Reference Study design Cases Controls Exposure information Adjustment Results 
factors 
(World Health Hospital-based Ascertainment Selection Cases and controls Explored effect Europe2 adjusted 
Organization case-control Monitoring system in each centre For each case, ~ 3 interviewed in hospital using of large number matched OR (95 % CI) 
Collaborative study in 21 identified cases with DVT and/ or controls selected standardised questionnaire - of potential for current use < SOl;!g 
Study of centres in 17 PE, classified as "definite", from women demographic data, medical confounders in EEOC 
Cardiovascular countries in "probable", "possible", or "other" admitted to same and reproductive history, sequential Non-users as reference 
Disease and Africa, Asia, based on signs, symptoms, and hospital with 1 of contraceptive use, other manner, AnyOC: 
Steroid Hormone Europe, and results of investigations. 27 diagnoses medications, weight, height, retained in 4.24 (3.07 - 5.87) 
Contraception Latin America. unrelated to OC smoking status, alcohol use, model if 
1995a; World Certainty of diagnosis use, < 2 weeks family history CV A or ML resulted in~ 5% 1st generation OC: 
Health 2 groups for 58% definite, 28% probable, 7% before and < 4 Shown samples or pictures of change in OR. 3.37 (1.44 - 7.93) 
Organization analyses: possible, 8% other. months after case. locally available OCs. 2nd generation OC: 
Collaborative Europe and Only 
Study of "developing Index date Matching factors Current use of OC identifiable 
3.61 (2.53 - 5.13) 
Cardiovascular countries" Date of VTE event. Study centre, age Use at any time~ 3 months confounder in 3rd generation OC: 
Disease and (Africa, Asia, (5-year bands). before index date. Europe was 
Latin America Inclusion criteria rt generation OC: PIH. 7.36 (4.20 - 12.90) Steroid Hormone Women aged 20 - 44 years (15 - 49 
Contraception combined). Index date EE with ethynodiol diacetate, Other OC: 
1995b) 
years in 3 centres). Date of admission. lynoestrenol, norethisterone, No confounders 15.70 (3.90 - 63.15) 
Study period: 
Exclusion criteria norethisterone acetate, or 
in developing 
(WHO study) February 1989 - Inclusion/ norethynodrel. countries. Developing countries2 
January 1993. Cases classified as other; deaths < exclusion criteria 2nd generation OC: 24 hrs after admission; previous As for cases. adjusted matched OR 
history DVT, PE, CVA, MI; natural EE with norgestrel, LNG, or (95% CI) for current 
or surgical menopause; pregnancy, Total included norgestrienone. use < 501:!g EE OC 
severe trauma, surgery, or illness n= 2998 3rd generation OC: Non-users as reference 
requiring medical attention and EE with DSG, GSD, or NGM. AnyOC: 
causing prolonged bed rest < 6 OtherOC: 3.02 (2.28 - 4.00) 
weeks before index date. EE with CPA. 
Total included Reference category 




















to centres in 
which there 
were any cases 
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Cases 
Ascertainment 
Methods as above. 
Certainty of diagnosis 
42% definite, 42% probable, 9% 
possible, 7% unspecified. 
Index date 
Date of VTE event. 
Inclusion criteria 
Women aged 20-44 years (15 - 49 
years in 3 centres). 
Exclusion criteria 
As above. Also users of OCs 
containing > 35µg EE, women for 
whom OC type unknown (n=3) or 






controls as above. 
Also ::; 2 controls 
per case also 
randomly selected 
from age-sex 
register of same GP 
as case (in Oxford 
region). 
Matching factors 
Study centre, age 




Date of admission 
for hospital-based 
controls. Not 




As for cases. 
Total included 
n = 1979 (hospital) 




Cases and controls 
interviewed in hospital or at 
home (community-based 
controls) using standardised 
questionnaire as above. 
Current use of OC 
Use at any time ::; 3 months 
before index date. 
Reference categories 
1. Non-users (never and past 
users combined). 
2. Current users of OCs 
containing < 35µg EE with 
LNG (1 case and 2 controls 
who were users of NGM, 











resulted in 2': 5% 









All centres (hospital 
controls) adjusted 
matched OR (95% CI) 
for current use < 35µg 
EEOC 
Non-users as reference 
AnyOC: 
4.1 (3.2 - 5.2) 
LNGOC: 
3.4 (2.5 - 4.7) 
DSG or GSD OC: 
9.4 (5.6 - 15.6) 
CPAOC: 
14.9 (3.7 - 59.4)* 
LNG OC users as 
reference 
DSGOC: 
2.4 (1.3 - 4.6) 
GSDOC: 
3.1 (1.6 - 5.9) 
DSG or GSD OC: 
2.7 (1.6 - 4.6) 
CPAOC: 
5.1 (1.3 - 20.3)* 
Rate idiopathic VTE 
(Oxford region) per 
100,000 woman-years 
Users DSG or GSD OC: 
21.3 




Reference Study design Cases Controls Exposure Adjustment Results 
information factors 
(Jick et al. Study QOQulation Ascertainment Selection Both studies Study I Study I 
1995) Based on UK Study I Reviewed electronic records of 470 GPs to For each case Details of OC Age(< 30, 30 Adjusted RR (95% Cl} for 
GPRD. Women identify women whose cause of death was recorded in case-control exposure and - 39 years) current use < 35!:!g EE OC 
(GPRD study) aged < 40 years as PE, CV A, MI, cardiac arrest, or "sudden death". analysis of other data and calendar LNG OC users as reference 
who received :::::_ 1 Examined death certificates and necropsy reports. study 2, 4 abstracted time. DSG OC: 0.4 (0.1- 2.1) 
prescriptions for Study 2 Reviewed electronic records of 365 GPs to controls from GSD OC: 1.4 (0.5 - 4.5) 
OCs containing ~ identify women who were admitted to hospital with exposed to a electronic Study 2 Crude CV mortality rate _Qer 
35µg EE with objectively diagnosed DVT and/ or PE and study OC on records. Nested case- 1002000 woman-years 
LNG,DSG,or anticoagulated. Examined hospital referral and the index date control Users DSG OC: 1.5 (0.4 - 5.4) 
GSD between discharge letters. Classified VTE as "confirmed" or were Study 2 analysis Users GSD OC: 4.8 (2.0 - 11.1) 
January 1991 and "possible" according to results of investigations. randomly Standardised BMI, Users LNG OC: 4.3 (2.2- 8.6) 
November 1994. selected from questionnaire smoking. 
Excluded women Certainty of diagnosis the study sent to general Study 2 
with previous Study 2, cohort analysis 64% confirmed, 36% population. practitioners. Cohort (a) Nested case-control analysis 
DVT, PE, CV A, possible. analysis Adjusted matched OR (95% CI} 
MI, cancer, Matching Current use of Age(< 30, 30 for current use < 351:rn EE OC 
epilepsy, diabetes, Index date factors oc - 39 years) LNG OC users as reference 
treated Unclear whether date of admission or date of onset GP, age (2- Use on index and calendar DSG OC: 2.2 (1.1 - 4.4) 
hypertension, of symptoms. year bands, 5- date. time. GSD OC: 2.1 (1.0-4.4) 
hyperlipidaemia, Additional exclusion criteria 
year bands for 
Reference (b) Cohort analysis or cystic fibrosis. Study I Trauma or surgery < 3 months before 
15%). 
category Adjusted RR (95% CI} for 
Study I death, cerebral haemorrhage secondary to Index date Current users current use < 35!,!g EE OC 
Cohort study of congenital cerebrovascular malformation. Index date of ofOCs LNG OC users as reference 
idiopathic CV Study 2 Women not exposed to a study OC on case. containing DSG OC: 1.9 (1.1 - 3.2) 
death. index date; fatal events; pregnancy, trauma or LNG with~ GSD OC: 1.8 (1.0 - 3.2) 
surgery < 3 months before index date. Exclusion 35µgEE. Crude rate idio.Qathic VTE _Qer 
Study 2 criteria 1002000 woman-years 
Nested case- Total included As for cases in Users DSG OC: 29.3 (20.5 -41.9) 
control and cohort Study I 15 deaths study 2. Users GSD OC: 28.1 (18.5 - 42.5) 
studies of Study 2 80 non-fatal cases (cohort analysis), Users LNG OC: 16.1 (10.7 - 24.1) 
idiopathic non- 75 non-fatal cases (case-control analysis). Total included Past users: 3.8 (1.6 - 9.0) 
fatal VTE. n= 300 
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Reference Study design Cases Controls Exposure Adjustment Results 
information factors 
(Vandenbroucke et Reanalysis of Leiden Ascertainment Selection Cases and controls Undertook All women1 adjusted 
al. 1994; Thrombophilia Study, Examined files of Each case was asked both interviewed 6 - unmatched unmatched OR (95% CI} for 
Bloemenkamp et a population-based anticoagulation clinics in 3 to find a friend or 19 months after index analysis because current use OC 
al. 1995) case-control study of regions in the Netherlands to acquaintance of the date (1990 - 1993) one or other of Non-users as reference 
consecutive men and identify cases with same sex and age, about risk factors for many case-control LNG OC: 3.8 (1.7 - 8.4) 
(Leiden study) women aged < 70 objectively diagnosed DVT. who was not a DVT, including OC pairs were DSG OC: 8.7 (3.9 - 19.3) 
years with a 1st biological relative, use and a history of excluded because 
diagnosis of DVT Certainty of diagnosis had no history of VTE in ~ 1 parent or of additional LNG OC as reference 
between January 100% definite. VTE or malignancy, sibling. Physical inclusion and DSG OC: 2.2 (0.9 - 5.4) 
1988 and December 
Index date 
and did not use examination exclusion criteria 
Any study OC as reference 1992. warfarin, to serve as a undertaken and blood in reanalysis. 
DateofDVT. control. Cases who collected for DSG OC: 2.5 (1.2 - 5.2) 
Patients with known 
Inclusion criteria were unable to find a coagulation factor 
Adjusted for age 
Non-carriers of FVL malignancy excluded. 
(reanalysis) suitable control were and FVL analysis. 
as continuous 
mutation1 adjusted 
Pre-menopausal women matched with 
variable. 
unmatched OR (95% CI} for 
aged 15 - 49 years. partners of other 
Current use of OC 
current use OC Use ::; 1 month before cases. Non-users as reference 
Exclusion criteria index date. DSG OC: 9.2 (3.9 - 21.4) 
(reanalysis) Matching factors 
Age. Reference categories Pregnant < 30 days before Carriers of FVL mutation1 1. Non-users (never 
index date, use of injectable Index date and past users adjusted unmatched OR 
progestogens, malignancy. Index date of case. combined). (95% CI} for current use OC 
Also users of OCs for whom Non-users as reference 
insufficient numbers of Inclusion / exclusion 2. Current users of DSG OC: 6.0 (1.9- 19.0) 
cases and controls exposed criteria (reanalysis) OCs containing LNG 
8-fold increased risk of DVT in (including GSD, CPA OCs) As for cases. with 30µg EE. 
and women for whom OC carriers of FVL mutation, 
type unknown. Total included 3. Current users of hence risk of DVT in carriers 
(reanalysis) any study OC ( other using DSG OCs increased 
Total included (reanalysis) n = 159 than DSG with 30µg almost 50-fold compared with 
n= 126 EE). non-carrier non-users. 
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Reference Study design Cases Controls Exposure information Adjustment Results 
factors 
(Spitzer et al. Hospital-based Ascertainment Selection Interviews based on Undertook Germany and UK2 adjusted 
1993; Spitzer et case-control Monitoring system in For each case, ~ 3 controls: standardised unmatched unmatched OR {95% CI) for 
al. 1996; Lewis study in 16 each centre identified ~ 1 control from women questionnaire used in ( unexplained) current OC use 
et al. 1996a) centres in UK, cases with DVT and/ or admitted to same hospital as WHO study. Validated analyses and Non-users as reference 
Germany, PE, classified as case with diagnosis unrelated type of OCs used by adjusted for Any OC: 4.0 (3.1- 5.3) 
(Transnational Austria, France, "definite", "probable", to OC use (same as for WHO examining pill packets of study centre, 181 generation OC: 5.7 (3.4- 9.4) 
study) Switzerland. "possible", or "incorrect" study) < 2 weeks before and < sample of women. age, smoking, 2nd generation OC: 3.2 (2.3 - 4.3) 
by local committee of 4 months after case. alcohol use, 3rd generation OC: 4.8 (3.4 - 6.7) 
Primarily experts. ~ 1 control from community - Current use of OC BMI, and 
presented results same GP as case (UK) or Use at any time_:::; 3 duration of 2nd generation OC users as 
from 10 centres Certainty of diagnosis neighbourhood population months before index past OC use. reference 
in UK and Not stated. lists (Germany), interviewed< date. 3rd generation OC: 1.5 (1.1 - 2.1) 
Germany. 4 months after interview with rt generation OCs: Also DSG OC: 1.5 (1.1- 2.2) 
Index date 50µg EE with any undertook GSD OC: 1.5 (1.0 - 2.2) case. 
Study period Date of diagnosis. progestogen. matched 
UK and Matching factors 2nd generation OCs: analyses, but 5 countries combined2 adjusted 
Germany: Inclusion criteria Hospital or community _:::; 35µg EE with key results unmatched OR {95% CI) for 
August 1993 - Women aged 16-44 setting, age (5-year age progestogen other than reported were current OC use 
Oct 1995. years resident within bands). DSG or GSD (OCs with from the 2nd generation OC users as 
specified geographical NGM and CPA classified unmatched reference 
Study period areas. Index date as 2nd generation). analyses. 3rd generation OC: 1.7 (1.3 - 2.4) 
Austria, France, Date of admission (hospital- 3rd generation OCs: 
Switzerland: Exclusion criteria Germany and UK2 adjusted based) or interview _:::; 30µg EE with DSG or 
late 1994- Previous history DVT, ( community-based). matched OR {95% CI) for 
October 1995. PE,CVA,MI; 
GSD. 
current OC use 
hysterectomy; Inclusion / exclusion criteria Reference categories 2nd generation OCs as reference 
pregnancy, surgery, As for cases. 1. Non-users (never and 3rd generation OC: 1.6 (1.2 - 2.2) 
trauma requiring GA or past users combined). 
causing immobility < 6 Total included {UK, 
weeks before index date. Germany) 2. Users of 2nd generation 
n = 789 (hospital) plus 983 OCs. 
Total included (community). 
n = 471 (UK, Germany). 
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Unadjusted matched analysis. 
Abbreviations used in the table BMI: body mass index, CPA: cyproterone acetate, CV: cardiovascular, CVA: stroke, DSG: desogestrel, DVT: deep vein thrombosis, EE: ethinyloestradiol, FVL: factor V Leiden mutation, GP: 
general practice, GSD: gestodene, HRT: hormone replacement therapy, LNG: levonorgestrel, MI: myocardial infarction, NGM: norgestimate, OC: oral contraceptive, OR: odds ratio, PE: pulmonary embolism, PIH: pregnancy-






3.2.5 Doubts about the validity and importance of the findings of the key studies 
In the immediate discussions that followed the publication of the key studies, it soon 
became apparent that while some commentators felt the findings reflected a true excess 
risk of venous thromboembolism in users of desogestrel and gestodene oral 
contraceptives (Weiss 1995; McPherson 1996), others were doubtful that these 
preparations carried a higher risk than older preparations (Watt 1995b; Cramer 1996; 
Johannisson and The International Committee for Research in Reproduction 1996; 
Rosenberg et al. 1996; Lidegaard and Milsom 1996a). At issue, was the size of the 
relative risk estimates which were said to be "so small in epidemiological terms that 
modest bias could account for an effect of this size" (Rosenberg et al. 1996). 
In the months following the CSM announcement and the publication of the key studies, 
various biases were proposed that might at least partially explain the observed 
association (Watt 1995b; Guillebaud 1995b; Cramer 1996; Johannisson and The 
International Committee for Research in Reproduction 1996; Rosenberg et al. 1996; 
Westhoff 1996; Farmer and Lawrenson 1996a; Lidegaard and Milsom 1996a); many of 
these were proposed by the Transnational investigators (Davis et al. 1995; Spitzer 1995) 
and associates (MacRae and Kay 1995), representatives of pharmaceutical companies 
(Reijnen and Atsma 1995; Kaper 1996), and by participants at meetings funded by oral 
contraceptive manufacturers (Rosenberg et al. 1996; Cohen 1996a). At a press 
conference held a few days after the CSM announcement (for which he flew from 
Canada to London), the principal investigator of the Transnational study referred to at 
least three potential biases: confounding by indication, referral bias, and the switching 
of high-risk women into the pool of third generation pill users (Carnall 1995). 
For some commentators the consistency of the results of the published studies, which 
involved different methods and different study populations, was not convincing 
evidence that the difference in risk between the newer and older oral contraceptives was 
real; it was suggested that all of the studies might have been subject to the same types of 
bias (Westhoff 1996). Furthermore, it was argued that the observation that the highest 
estimates for desogestrel and cyproterone acetate products were found for the 
formulations that contained the lowest doses of oestrogen ran contrary to the generally 
accepted belief that contraceptives with higher oestrogen doses carried higher risks of 
venous thromboembolism, and hence these findings were interpreted as evidence of bias 
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(Westhoff 1996). Similarly the apparent fall in absolute risk associated with older 
preparations was also thought to reflect the influence of bias (Kaper 1996). Residual 
confounding was also raised as a possible alternative explanation for the association 
(MacRae and Kay 1995). However, the CSM reiterated that neither chance, bias, or 
confounding could explain the overall findings of the key studies (Rawlins 1995). 
Other arguments advanced against a causal relationship were that there had been no 
increase in the incidence of venous thromboembolism among women of child-bearing 
age since the introduction of desogestrel and gestodene contraceptives (Lidegaard and 
Milsom 1996a), and there was no biologically plausible explanation for a higher risk in 
users of such products - particularly since they had been shown in the laboratory to 
have less unfavourable effects on haematological and biochemical parameters than older 
preparations (Johannisson and The International Committee for Research in 
Reproduction 1996). 
It was also maintained that even if the difference in risk between desogestrel and 
gestodene preparations and older products was real, the attributable risk and public 
health impact were negligible (Spitzer 1995). In fact, one commentator (Guillebaud 
1995a) made the absolute risks appear even smaller by misrepresenting annual 
incidence (Rawlins 1995). Furthermore, it was argued that the incidence of pregnancy-
related venous thromboembolism was much higher than the risk in oral contraceptive 
users (Guillebaud 1995a). Finally, some commentators asserted that any increased risk 
of venous thromboembolism associated with desogestrel and gestodene contraceptives 
might be outweighed by other benefits conferred by these products (MacRae and Kay 
1995; Guillebaud 1995a). 
In the following sections, these issues of internal validity, biological plausibility, the 
importance of any difference in risk, and other possible benefits of desogestrel and 
gestodene contraceptives will be considered in more detail. 
3.2.6 Consideration of possible non-causal explanations for the association 
Prescription bias or confounding by indication 
Proponents of this hypothesis argued that because desogestrel and gestodene 
contraceptives were marketed as having a safer cardiovascular safety profile than older 
:_( 
83 
products, doctors preferentially prescribed these pills to women who were at higher risk 
of venous thromboembolism and hence the apparent excess risk of venous 
thromboembolic events was due to the underlying characteristics of the users rather than 
the products themselves (Johannisson and The International Committee for Research in 
Reproduction 1996; Cohen 1996a; Lidegaard and Milsom 1996a). Curiously, the 
Transnational investigators, who stated in their original publication that the "existence 
of prescribing bias is not corroborated in our data" (Spitzer et al. 1996), were also 
strong advocates of this theory (MacRae and Kay 1995; Lewis et al. 1996b; Spitzer 
1997). 
Arguments in support of this hypothesis ran as follows. During the periods under 
investigation in the WHO, GPRD, Leiden, and Transnational studies, family planning 
experts and prescriber information sources such as the British National Formulary had 
recommended that desogestrel and gestodene pills be prescribed for "high-risk" women 
(Spitzer 1997). Moreover, several surveys were said to provide evidence that selective 
prescribing had occurred (Heinemann et al. 1996; Jamin and de Mouzon 1996; van 
Lunsen 1996a; Lidegaard 1997). It was also asserted that the key studies had too few 
cases to have allowed a full exploration of the effects of a large number of potential 
confounders (Farmer and Lawrenson 1996a). A final argument related to the findings 
of inverse dose-response relationships for ethinyloestradiol in oral contraceptives 
containing desogestrel (Jick et al. 1995; World Health Organization Collaborative Study 
of Cardiovascular Disease and Steroid Hormone Contraception 1995c) and cyproterone 
acetate (World Health Organization Collaborative Study of Cardiovascular Disease and 
Steroid Hormone Contraception 1995b; World Health Organization Collaborative Study 
of Cardiovascular Disease and Steroid Hormone Contraception 1995c). Such findings 
were thought to be biologically implausible and thus were evidence of confounding by 
indication (Westhoff 1996; Lewis et al. 1996b; Lidegaard and Milsom 1996b; Spitzer 
1997; Farmer et al. 1997a; Cohen 1999). 
The question "is it the drug or the characteristics of the people who take the drug which 
is responsible for an apparent adverse reaction?" is a legitimate enquiry in studies of 
drug safety. However, in this instance, the confounding by indication hypothesis did 
not stand up to quantitative scrutiny (Farley et al. 1996; Helmerhorst et al. 1997; 








account for a doubling of risk in users of desogestrel or gestodene contraceptives, when 
compared with users of older pills, a confounding factor would have to be both an 
important risk factor for venous thromboembolism and be strongly associated with the 
decision to prescribe a third generation contraceptive (Walker 1998). It was estimated, 
for example, that if the suspected confounding factor was present in 20% of women 
using desogestrel or gestodene pills and 5% of the other users, that factor would need to 
be associated with an 11-fold increased risk of venous thromboembolism (Walker 
1999). A risk factor with such an effect was difficult to imagine. All of the key studies 
had excluded women with a previous history of venous thromboembolism and several 
other major risk factors (such as pregnancy, bed rest, surgery, or trauma), the effects of 
age were accounted for, and potential confounding by a large number of factors was 
explored (Farley et al. 1996). Risk factors such as obesity were adjusted for in the 
analyses - although, other than controlling for age, adjustment for potential 
confounders made no difference to the relative risk estimates (Walker 1998). The 
presence of inherited genetic mutations which increase the risk of venous 
thromboembolism were unlikely to have influenced prescribing decisions as they were 
not widely known about at the time of the studies and some had only recently been 
discovered (Vandenbroucke et al. 1997 a). Information about a family history of venous 
thromboembolism was not collected in the WHO, GPRD, and Transnational studies, 
and thus potential confounding by this factor could not be explored. However, a 
stratified analysis in the Leiden study showed that a two-fold difference in risk between 
users of desogestrel and levonorgestrel pills was present in women both with, and 
without, a family history (Bloemenkamp et al. 1995). Similarly, in an analysis confined 
to women without hereditary thrombophilia in a Danish case-control study, the relative 
risk estimate for users of desogestrel and gestodene preparations compared with non-
users was higher (20.9 [95% CI 3.1 - 141.3]) than the estimate for older pills (7.1 
[95%CI 2.0- 25.2]) (Andersen et al. 1998). 
In relation to other factors that might have been implicated in possible confounding by 
indication, it was pointed out that contemporary textbooks offered "very few clinical 
risk factors that predict the occurrence of a first venous thrombosis in healthy young 
persons" (Vandenbroucke et al. 1997a). Indeed, some commentators suggested that any 
differential prescribing was more likely to be related to risk factors for arterial, rather 













unlikely that factors strong enough to affect physicians' prescribing choices would fail 
uniformly to have been recognized and adjusted for in all studies based ultimately on 
medical records" (Walker 1998). 
Several concerns were also expressed about the surveys of prescribing behaviour which 
were claimed to support the confounding by indication hypothesis. In a small German 
drug utilisation study conducted in December 1995, doctors reported that they would 
choose to prescribe desogestrel and gestodene contraceptives to women with risk factors 
for venous thromboembolism (Heinemann et al. 1996). However, an examination of 
those doctors' records revealed only a small trend towards the asserted practice. 
Doctors in a UK survey also expressed a preference for prescribing desogestrel and 
gestodene contraceptives to women with venous thrombotic risk factors, however a 
review of their clinical records found no evidence of any selective prescribing (Dunn et 
al. 1998). Such findings led a commentator to warn that surveys of doctors' attitudes 
might be unreliable sources of information about actual prescribing behaviour and thus 
doubt was cast upon alleged selective prescribing practices in France, Sweden, and the 
Netherlands (Walker 1999). 
Moreover, it appeared that any selective prescribing. might have had minimal influence 
on estimates of excess risk associated with the use of desogestrel and gestodene pills. 
For example, in a Danish study that sought to quantify the possible impact of 
confounding by indication, it was reported that selective prescribing might account for 
about 15% (at most) of the excess risk (Lidegaard 1997). The information linking 
prescription choices with risk factors was obtained from the control series selected for a 
case-control study of stroke (Lidegaard and Kreiner 1998), and most of the reported 
selective prescribing of desogestrel and gestodene contraceptives was to women with a 
family history of venous thromboembolism (Lidegaard 1997). This same group of 
women was also used as the control series in a later case-control study of venous 
thromboembolism (Lidegaard et al. 1998), but as one commentator has noted, it appears 
that a family history did not act as a confounder of the association between pill type and 











Finally, it was suggested that the unexpected inverse ethinyloestradiol dose-response 
observed for oral contraceptives containing desogestrel might reflect a combination of a 
starter effect and an effect of desogestrel (Vandenbroucke et al. 1997b). 
First-time user, healthy user, attrition of susceptibles, and recency of introduction biases 
In effect, these biases all referred to the same phenomenon (V andenbroucke et al. 
1997a). Central to this hypothesis, was the suggestion that the risk of venous 
thromboembolism among oral contraceptive users is highest during the first year of use 
(Reijnen and Atsma 1995). Therefore, it was argued, duration of use must be taken into 
account when making risk comparisons between contraceptives containing desogestrel 
or gestodene and older preparations (Reijnen and Atsma 1995). This was because 
women starting on oral contraceptives for the first time were more likely to be 
prescribed the newest products on the market (MacRae and Kay 1995), and hence the 
cohort of desogestrel and gestodene contraceptive users would include a 
disproportionate number of women who were first-time and short-term users. 
Moreover, it was likely that women who had been taking oral contraceptives for some 
time would be users of older products and would comprise a cohort of "healthy users", 
since users at high risk for thrombosis would already have suffered such an event or 
been identified as carrying a substantial risk and thus would have been removed from 
the cohort (Watt 1995b). In addition, it was suggested that the cohort of users of older 
products was being "depleted of' and the cohort of third generation pill users "enhanced 
with" high-risk women (Guillebaud 1995b). The overall impact of such factors would 
be that users of desogestrel and gestodene contraceptives were, independent of pill type, 
at higher risk of venous thromboembolism than the group of women taking older pills 
- hence, the apparent excess risk of venous thromboembolism in users of desogestrel 
and gestodene pills was not due to the products themselves, but rather it was because 
dissimilar cohorts of women were being compared (MacRae and Kay 1995; Reijnen and 
Atsma 1995; Watt 1995b; Guillebaud 1995b; Cramer 1996; Johannisson and The 
International Committee for Research in Reproduction 1996; Rosenberg et al. 1996; 
Cohen 1996a; Lidegaard and Milsom 1996a; Farmer and Lawrenson 1996b; Lewis et al. 
1996b; Spitzer 1997). 
Advocates of this hypothesis pointed out that the incidence of venous thromboembolism 





products some years before - in fact, the apparent excess risk was because the 
incidence among users of older products was appreciably lower than in previous reports 
(Farmer and Lawrenson 1996a; Lidegaard and Milsom 1996a). This, they argued, was 
evidence of a cohort effect because it was implausible that the risk had actually declined 
over time. However, this argument was criticised on the basis that it was not valid to 
compare incidence rates from different periods because the age distribution of users and 
the methods used to diagnose venous thromboembolism had changed substantially 
(Farley et al. 1996; Vandenbroucke et al. 1997a). 
Other support for the hypothesis was said to be provided by four reanalyses of the 
Transnational study, as well as some new research. In the first of the Transnational 
reanalyses, the risks of venous thromboembolism for various formulations containing 
desogestrel, gestodene, and norgestimate were compared with low-dose levonorgestrel 
products (Lewis et al. 1996b). A linear trend of increasing odds ratios with decreasing 
time since the products were introduced onto the market was said to confirm the 
presence of bias. However, the investigators were criticised for restricting this analysis 
to women aged 25 - 44 years (Weiss 1997; Vandenbroucke et al. 1997c). Analyses 
including the full dataset of women aged 16 - 44 years showed no such trend (Weiss 
1997) and, in fact, an opposite trend was shown for women aged 16 - 24 years 
(Vandenbroucke et al. 1997c). Moreover, in the latter group of women, among whom 
most new users would be expected, desogestrel, gestodene, and norgestimate pills 
carried a higher risk of venous thromboembolism than levonorgestrel preparations 
(V andenbroucke et al. 1997 c). The Transnational investigators justified their sub-
analysis by claiming that it was necessary to study women who had been using oral 
contraceptives long enough for "attrition of susceptibles" to have occurred (Lewis and 
Spitzer 1997). This reasoning was later called into question by the results of the second 
reanalysis of the Transnational study (Suissa et al. 1997). In that analysis, the initial 
increase and then decline in risk in new users relative to never users was shown to 
plateau after about two years- leading one commentator to observe that if this decline 
was "attributable to depletion of susceptibles, the interval necessary to create an 
established ( depleted) user pool would be only a few years, and the critics of the 
exclusion of younger women from the reanalysis would be correct" (Walker 1998). 
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In the second reanalysis of the Transnational study, the risk of venous 
thromboembolism in never users was compared with two groups of first-time users of 
oral contraceptives: those taking desogestrel or gestodene preparations and those using 
levonorgestrel or norgestimate products (Suissa et al. 1997). Relative risks estimated 
for different durations of current use (less than one year, one to two years, three to five 
years, and more than five years), showed that for both groups of users the risk was 
greatest during the first year of use. When a quadratic spline model was used to 
compare the risks as a function of duration of use in the two groups of first-time users 
relative to never users, no difference between the two groups of products was found. 
However, the WHO investigators suggested that this was an artefact of the constraints 
placed on the model, which did not allow for a rapid increase in risk of venous 
thromboembolism following the initiation of oral contraceptive use (Farley et al. 
1998a). A reanalysis of the WHO data using an unconstrained spline model showed a 
difference between first-time users of desogestrel or gestodene preparations and first-
time users of levonorgestrel pills. 
The findings of the second Transnational reanalysis were also at variance with the 
results of a stratified analysis in the WHO study which showed an excess risk of venous 
thromboembolism in first-time users of oral contraceptives containing desogestrel and 
gestodene, when compared with first-time users of levonorgestrel (World Health 
Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone 
Contraception 1995c). Moreover an excess risk associated with desogestrel and 
gestodene pills was present regardless of duration of use (Poulter et al. 1996a). Similar 
findings were reported by the GPRD (Jick et al. 1995; Jick et al. 1996a) and Leiden 
investigators (Bloemenkamp et al. 1995; Vandenbroucke et al. 1996a) and, indeed, in 
the first report of Transnational study (Spitzer et al. 1996). A later cohort study in the 
Netherlands, which linked prescription data with hospital discharges, also showed that 
first-time users of oral contraceptives who took desogestrel and gestodene preparations 
had a higher risk of venous thromboembolism than women who used levonorgestrel 
products; the relative risk was 3.5 (95% CI 1.4- 8.8) (Herings et al. 1999). 
Undeterred by evidence to the contrary, the Transnational investigators continued to 
assert that a healthy user effect could explain the differential risk associated with 
desogestrel and gestodene oral contraceptives. Hence, they undertook a third reanalysis 
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of their data, this time using a Cox proportional hazards model to take into account the 
full duration of oral contraceptive use (Lewis et al. 1999). The excess risk associated 
with desogestrel and gestodene pills relative to low-dose pills containing other 
progestogens disappeared. But this approach, of analysing data from a case-control 
study as if they were derived from a cohort study, was severely criticised (Farley et al. 
1999). 
In a fourth reanalysis, the Transnational investigators invoked the possibility that failure 
to take patterns of oral contraceptive use fully into account had led to biased estimates 
in the previous studies (Suissa et al. 2000). Oral contraceptive users were classified as 
first-time users, repeaters (women who had had interrupted episodes of use of oral 
contraceptives from the same generation as they were currently using), or switchers 
(women who had switched to desogestrel or gestodene pills after using levonorgestrel or 
norgestimate preparations, or vice versa). In sub-analyses involving repeaters and 
switchers only, comparisons between desogestrel and gestodene preparations and those 
containing levonorgestrel and norgestimate were adjusted for duration of current use, 
length of interruption, and duration of previous use. No excess risk was found for 
desogestrel and gestodene products. 
A group of Danish investigators professed to have demonstrated that bias explained at 
least some of the apparent excess risk associated with desogestrel and gestodene 
contraceptives. In a case-control study, an elevated risk of venous thromboembolism 
associated with desogestrel and gestodene preparations compared with levonorgestrel 
and norgestimate products (odds ratio 1.70 [95% CI 1.05 - 3.06]) was attenuated after 
adjusting for duration of use (odds ratio 1.44 [95% CI 0.83 - 2.50]) (Lidegaard et al. 
1998). However, the treatment of duration of use as a confounding factor, rather than 
an exposure variable, was criticised (Walker 1998). Moreover, it was argued that it was 
not possible to reliably separate out the effects of duration of use and progestogen type 
because almost all of the short-term users were taking desogestrel or gestodene 
contraceptives. A final criticism was that the controls were originally selected as age-
matched controls for a case-control study of stroke, and the cases were required to recall 





In spite of the repeated efforts to show that the bias, variously referred to as first-time 
user, healthy user, attrition of susceptibles, and recency of introduction bias, explained 
the excess risk associated with the use of desogestrel and gestodene contraceptives, 
many commentators remained unconvinced (Farley et al. 1996; Helmerhorst et al. 1997; 
Vandenbroucke et al. 1997c; Walker 1998; Farley et al. 1999; O'Brien 1999; Walker 
1999; Hannaford 2000). In addition to the points discussed above, they offered several 
other arguments against such a hypothesis. First, a "recency of introduction" bias had 
not been found in earlier studies (Walker 1998) - in fact, new products had been found 
to carry lower risks of venous thromboembolism (Inman et al. 1970; Bottiger et al. 
1980; Meade et al. 1980; Gerstman et al. 1991). 
Second, since "established users" of older pills comprised only a small proportion of the 
user group in the Transnational study, such women would have needed to have the same 
risk of venous thromboembolism as non-users to produce a spurious doubling of risk in 
users of desogestrel and gestodene contraceptives (Walker 1998). This proposition -
that all high-risk women are eventually removed from the group of oral contraceptive 
users - was contrary to the observation that current use of any type of oral 
contraceptive conferred a higher risk of venous thromboembolism than non-use (Walker 
1998). Moreover, the attrition of susceptibles argument also required that the small 
number of women who were removed from the pool of users carried a considerably 
elevated risk of venous thromboembolism (Vandenbroucke et al. 1997a). 
Third, the suggestion that the pool of users of desogestrel and gestodene pills was 
somehow "enriched" with women at higher risk for venous thromboembolism who had 
switched from using older preparations (thus "depleting" that pool of users) was 
rejected as an explanation for the results of the key studies (Vandenbroucke et al. 
1997a). As, with the "depletion of susceptibles" proposition, the "switching" 
hypothesis also required that the women who were changing to desogestrel and 
gestodene formulations carried a much higher risk of venous thromboembolism. 
However, the main reasons given for switching from older preparations to desogestrel 
and gestodene contraceptives in one study were side effects such as poor cycle control 
and acne (Farmer et al. 1996), which are unrelated to venous thromboembolism risk. 
Moreover, the switching argument was an unlikely explanation for the findings of the 







excluded (Walker 1998). A reanalysis of data from the Leiden Thrombophilia Study 
confirmed that the risk of venous thromboembolism was highest in first-time users of 
oral contraceptives, but this effect was only partly explained by the presence of clotting 
defects such as the factor V Leiden mutation, protein C or S deficiency, antithrombin 
deficiency, and prothrombin G202IOA mutation and it did not explain the difference in 
risk between oral contraceptives containing different progestogens (Bloemenkamp et al. 
2000). 
Referral and diagnostic biases 
Some commentators suggested that women taking contraceptives containing desogestrel 
or gestodene were more likely to be referred for investigation of symptoms suggestive 
of venous thromboembolism than users of other preparations - thus, true cases with 
ambiguous symptoms would be counted if they were taking desogestrel or gestodene 
pills but not if they were taking older preparations (Rosenberg et al. 1996; Cohen 
1996a; Lidegaard and Milsom 1996a; Lewis et al. 1996b; Spitzer 1997). The 
Transnational investigators also made a rather extraordinary statement about the 
conduct of their own study: 
Bias could have arisen in the study if recruiting physicians, with the best of 
intentions, actively recruited women using the pill who developed the disease of 
interest. We believe that this might have happened in some instances, which would 
artificially inflate the risk" (Davis et al. 1995). 
Such bias, however, would not explain a differential risk between users of different 
contraceptive preparations. For referral bias to be a credible explanation for the 
observed excess risk of venous thromboembolism in users of desogestrel and gestodene 
contraceptives compared with older formulations, two conditions should have been met. 
First, doctors would have needed to believe that users of these pills had a higher risk of 
venous thromboembolism than users of older formulations (Walker 1999). Moreover, 
they would have needed to act on that belief by preferentially referring such users for 
diagnostic assessment. Second, the perception of risk would have needed to be 
independent of any known pre-existing risk factors for venous thromboembolism since, 
as discussed above, such factors were accounted for in the analyses (Walker 1998). 
In fact, there were several reasons to reject referral bias as an explanation for the excess 





been preferentially referred ran counter to the marketing messages that these pills were 
safer (Walker 1998). Second, reviews of doctors' attitudes and clinical practices gave 
no indication that such referral practices had occurred (Heinemann et al. 1996; Dunn et 
al. 1998). Third, even if such a bias was functioning, the excess risk should only have 
been apparent among women whose symptoms and signs of venous thromboembolism 
were less definite (Vandenbroucke et al. 1997a). However, analyses in which cases 
were stratified by certainty of diagnosis were undertaken in three of the studies, 
including the Transnational study, and these showed an elevated risk for both definite 
and less probable cases (Jick et al. 1995; World Health Organization Collaborative 
Study of Cardiovascular Disease and Steroid Hormone Contraception 1995b; World 
Health Organization Collaborative Study of Cardiovascular Disease and Steroid 
Hormone Contraception 1995c; Spitzer et al. 1996). Fourth, the risk estimates obtained 
from a study based on the MediPlus database in the UK, which included non-
hospitalised as well as hospitalised cases (Farmer 1996), were similar to those obtained 
in the key studies (Farley et al. 1996). Finally, the results of two later case-control 
studies suggested that it was unlikely that referral and diagnostic biases were operating 
(Realini et al. 1997; Bloemenkamp et al. 1999). In both of these studies, the study 
population consisted of women who were referred for investigation of suspected venous 
thromboembolism - those who were found to have objective evidence of thrombosis 
became cases and those who did not became controls. Among women without major 
risk factors for venous thromboembolism, the adjusted relative risk estimates obtained 
for oral contraceptive use were very similar in magnitude to those found for any pill use 
in the key studies. 
In relation to possible diagnostic bias, several commentators were concerned about the 
difficulties in reliably diagnosing venous thromboembolism (Johannisson and The 
International Committee for Research in Reproduction 1996). However it was argued 
that if any misclassification of diagnosis had occurred, then the effect would have been 
to underestimate the true relative risk (Jick et al. 1996a; Vandenbroucke et al. 1996a). 
In fact, the results of analyses stratified by certainty of diagnosis implied that such 








Although, as shown earlier, confounding by indication failed to explain the higher risk 
of venous thromboembolism observed in users of desogestrel and gestodene oral 
contraceptives, one group argued that the risk estimates in the key studies were distorted 
by residual confounding by age (Farmer et al. 1997a). These researchers undertook a 
cohort analysis based on the MediPlus database in the UK in which they adjusted for 
age in five-year bands; the relative risk of venous thromboembolism in users of 
desogestrel and gestodene pills compared with users of levonorgestrel and other 
"second generation" (undefined) products was 1.68 (95% CI 1.04 - 2.75). Next, a 
nested case-control analysis was conducted in which controls were matched with cases 
by exact year of birth; the odds ratio in this analysis was only 1.34 (95% CI 0.74 -
2.39). However, following the publication of the preliminary (Farmer 1996) and 
detailed (Farmer et al. 1997a) findings of this study the researchers were criticised for 
including non-hospitalised and unverified cases (Jick et al. 1996a; Poulter et al. 1996a; 
Jick et al. 1997; Poulter et al. 1997; V andenbroucke et al. 1997b) and for entering 
inappropriate variables into the logistic regression model (Poulter et al. 1997; 
Vandenbroucke et al. 1997b). Moreover, it was argued that finer age matching was an 
implausible explanation for the reported decrease in relative risk because adjustment for 
age in the cohort analysis had actually moved the estimate further away from the null 
value (Walker 1998). 
The authors of three of the key studies maintained that their results could not be 
explained by residual confounding by age - the odds ratios in the Leiden study had 
been adjusted by single year of age (Vandenbroucke et al. 1997b) and the excess risk for 
desogestrel and gestodene pills persisted in both the WHO (Poulter et al. 1997) and the 
GPRD (Jick et al. 1997) studies when the data were reanalysed using finer age 
matching. Similarly, adjusting for age in one-year, compared with five-year, age groups 
had little impact on the results of the Danish case-control study discussed earlier 
(Lidegaard et al. 1998). 
Nonetheless, the MediPlus investigators continued in their quest to demonstrate that the 
excess risk of venous thromboembolism in users of desogestrel and gestodene 











German MediPlus database; the unadjusted odds ratio for users of third generation 
(undefined) compared with users of second generation (undefined) pills was not 
elevated (Farmer et al. 1998a; Farmer et al. 1998b). It was not possible to explore 
potential confounding by BMI and other risk factors because of missing data. Second, 
the UK MediPlus study was reanalysed using a further 18 months' worth of data and an 
attempt was made to validate the diagnosis of venous thromboembolism in a sample of 
cases (Todd et al. 1999). However, this analysis was criticised because the investigators 
adjusted for the number of prescriptions issued for medications other than oral 
contraceptives in the six months before the index date, thereby potentially adjusting for 
early manifestations of venous thromboembolism (Farley et al. 1999). Third, the 
investigators performed a nested case-control study, based on venous thromboembolic 
events recorded in the UK GPRD between 1992 and 1997 (Farmer et al. 1999; Farmer 
et al. 2000a). Matching controls to cases by year of birth, compared with five-year age 
bands, inconsistently produced slightly lower estimates of relative risk. The 
researchers, who had earlier criticised the practice of aggregating oral contraceptives by 
progestogen component (Todd et al. 1999), estimated relative risks for individual oral 
contraceptives; products containing desogestrel and gestodene were not shown to carry 
a higher risk than other preparations. 
3.2. 7 Consideration of trends in oral contraceptive use and venous thromboembolism 
Soon after the publication of the key studies, it was claimed that the uptake of 
desogestrel and gestodene pills had not been accompanied by an increase in the 
incidence of venous thromboembolism among women of child-bearing age - an 
increase which should have been apparent, it was argued, if such oral contraceptives 
truly carried an excess risk (Lidegaard and Milsom 1996a). However, mortality trends 
among young women in England and Wales (Thomas 1996a) and the Netherlands 
(Vandenbroucke et al. 1996b) appeared to be consistent with an increased risk, and 
alternative interpretations (Farmer and Lewis 1996; van Lunsen 1996b; Cohen 1996b) 
failed to explain these trends (Thomas 1996b; Vandenbroucke et al. 1996c). 
Subsequently an attempt was made to compare mortality among users of different oral 
contraceptive preparations and non-users using sales and mortality data from seven 
European countries (Farmer et al. 1997b). However, it was not possible to standardise 
for age and, in any case, the study lacked sufficient power to detect any differences. 









thromboembolism in women aged 15 - 49 years concurrent with increased use of 
desogestrel, gestodene, and norgestimate in Denmark (Mellemkjaer et al. 1999). 
Increased admissions were also described in the Oxford region during the same period, 
however these were not confined to women or to women of child-bearing age (Goldacre 
et al. 2000). 
3.2.8 Consideration of biological plausibility 
An argument that was initially used to reject the findings of an excess risk of venous 
thromboembolism in users of desogestrel and gestodene contraceptives was that there 
was no biologically plausible explanation for such an effect (Johannisson and The 
International Committee for Research in Reproduction 1996; Westhoff 1996; Lidegaard 
and Milsom 1996a; Spitzer 1997; Winkler 1998; Speroff 1999a). One commentator 
went so far as to challenge the role of epidemiologists in researching venous 
thromboembolism and oral contraceptives, asserting that: 
It is the clinical endocrinologist, not the epidemiologist, who has the depth and 
breadth of knowledge of steroid biochemistry, molecular and cellular endocrinology, 
and endocrine physiology to scientifically design the critical experiments in this 
arena (Barbieri 1999). 
However, it was promptly argued that the lack of a biological explanation was not 
grounds to reject the observed association (Farley et al. 1996). Indeed, as one 
commentator eloquently observed: 
The lack of in vitro support for a theory that is based in real-world observation is 
seldom a crucial flaw. In drug research, it is almost tautological that serious adverse 
effects will not have a well understood physiologic basis when they are first 
observed. If the warning from preclinical studies had been in place, the drug would 
not likely have been marketed (Walker 1998). 
Moreover, a possible mechanism was subsequently reported. Compared with non-users, 
women taking oral contraceptives were shown to have a reduction in normal 
anticoagulant activity secondary to enhanced resistance to activated protein C, similar to 
that observed in carriers of the factor V Leiden mutation. This effect was more 
pronounced in women taking contraceptives containing desogestrel or gestodene than 
users of levonorgestrel or lynoestrenol preparations (Rosing et al. 1997). These findings 
were confirmed in a randomised cross-over trial of desogestrel and levonorgestrel oral 











3.2.9 Consideration of the magnitude of any difference in risk 
Some commentators asserted from early on that even if desogestrel and gestodene oral 
contraceptives really did carry a higher risk of venous thromboembolism than older 
products, the magnitude of the difference in risk in both relative and absolute terms was 
very small (Spitzer 1995; Guillebaud 1995a; Rosenberg et al. 1996). The principal 
investigator of the Transnational study later stated that "relative risks of about 2 even if 
real, are clinically unimportant and of no public health significance" (Spitzer 1997). 
However, there were several reasons to challenge this position. First, a small increase 
in risk has the potential to affect a large number of women simply because of the 
extensive use of oral contraceptives (World Health Organization 1997). Second, the 
majority of venous thromboembolic events in young women are attributable to oral 
contraceptive use (Rosendaal 1999b). Third, although the case-fatality rate is thought to 
be low, venous thromboembolism nonetheless can have substantial short and long-term 
consequences for those affected (Skegg 1997). Finally, reports that venous 
thromboembolism is rare among oral contraceptive users are unlikely to be of comfort 
to any woman who suffers a potentially avoidable event while taking a desogestrel or 
gestodene contraceptive, especially if an alternative with half the risk is available. 
3.2.10 Consideration of other benefits of desogestrel and gestodene oral contraceptives 
Immediately after the CSM warning, several commentators suggested that oral 
contraceptives containing desogestrel and gestodene might confer other benefits that 
would outweigh any excess risk of venous thromboembolism. While the contraceptive 
efficacy of the newer contraceptives appeared to be equivalent to older preparations 
(Speroff et al. 1993), it was suggested that they were associated with fewer so-called 
minor side-effects (Guillebaud 1995a) and possibly lower risks of myocardial infarction 
(Spitzer 1995) and stroke (Guillebaud 1995a). Moreover, it was argued that although 
the latter two conditions were rare in young women, they carried a higher case-fatality 
rate than venous thromboembolic events (MacRae and Kay 1995). Thus, it was 
proposed that desogestrel and gestodene contraceptives could be preferentially 











In response to anecdotal reports that desogestrel and gestodene contraceptives were 
better tolerated by women (Guillebaud 1995a), several commentators (O'Brien 1995; 
Paul 1996), including the principal investigator of the Transnational study (Spitzer 
1996), soon pointed out that there was very little evidence from well-designed studies to 
support such claims. Indeed, one pharmaceutical company was subsequently ordered 
by the Food and Drug Administration in the USA to withdraw advertising material 
which maintained that oral contraceptives containing desogestrel caused fewer minor 
side-effects than other preparations because there was no "adequate substantiation from 
well-controlled clinical trials" to support such statements (Stockbridge 1998). 
Myocardial infarction 
As discussed earlier, because they had fewer adverse effects on blood coagulation and 
lipoprotein and carbohydrate metabolism, there was an expectation that desogestrel and 
gestodene oral contraceptives would carry a lower risk of myocardial infarction than 
older products. However, it was not until immediately after the CSM warning that the 
first epidemiological data were made available (Spitzer 1995). Interim results from the 
Transnational case-control study of myocardial infarction were consistent with a lower 
risk in users of desogestrel and gestodene contraceptives, although this effect was not 
statistically significant (Lewis et al. 1996c). In later analyses, it appeared that users of 
these oral contraceptives did not have an increased risk of myocardial infarction when 
compared with non-users, whereas a significant increase was found for users of older 
preparations (Lewis et al. 1997). However this picture was not consistent. For instance, 
a significantly lower risk for desogestrel and gestodene products, compared with 
levonorgestrel, was observed in Europe, but not in the UK, and was found in women 
aged 35 - 44 years (in whom oral contraceptive use was uncommon), but not in younger 
women . 
Other studies based on events which occurred before the CSM warning did not support 
the contention that, compared with non-users, women taking older oral contraceptives 
had an increased risk of myocardial infarction whereas users of desogestrel or gestodene 
preparations did not. In the WHO case-control study of myocardial infarction, an 
increased risk in oral contraceptive users was confined to those women whose blood 









Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone 
Contraception 1997). Limited power precluded an analysis by type of progestogen. 
Similarly, in a case-control study based on the Kaiser Permanente Health Care 
Database, use of low-dose oral contraceptives was not associated with a significantly 
increased risk of myocardial infarction (Sidney et al. 1996). Moreover, a nested case-
control study undertaken by researchers at the Boston Collaborative Drug Surveillance 
Program, which was based on the UK GPRD, revealed no significant difference in 
myocardial infarction risk between current users of desogestrel and gestodene products 
compared with levonorgestrel preparations (Jick et al. 1996b), while a community-based 
case-control study in England, Scotland, and Wales showed a non-significant elevated 
point estimate for desogestrel and gestodene contraceptives compared with 
levonorgestrel and norethisterone preparations (Dunn et al. 1999). Finally, it was 
reported that trends in fatal myocardial infarction in young women in England and 
Wales (Thomas 1996a) and the Netherlands (Vandenbroucke et al. 1996b) were not 
consistent with a protective effect of desogestrel and gestodene. 
Stroke 
In two of the case-control studies of ischaemic stroke published following the CSM 
warning, current users of oral contraceptives did not have a higher risk than non-users 
(Petitti et al. 1996; Schwartz et al. 1997) whereas in three other studies, current users 
carried a higher risk (World Health Organization Collaborative Study of Cardiovascular 
Disease and Steroid Hormone Contraception 1996a; Heinemann et al. 1997; Lidegaard 
and Kreiner 1998). One group reported that the elevated risk was confined to women 
who were using oral contraceptives other than those containing desogestrel or gestodene 
(Lidegaard and Kreiner 1998). In the WHO study, when compared with non-use, 
levonorgestrel pills appeared to carry a higher risk than desogestrel or gestodene 
preparations, but the difference disappeared when blood pressure checks were taken into 
account (Poulter et al. 1999b). In the Transnational study no significant difference in 
risk by progestogen component was found among women who had their blood pressure 
monitored (Heinemann et al. 1997). 
As with ischaemic stroke, no increased risk of haemorrhagic stroke was found overall 
for users of oral contraceptives in the two case-control studies from the USA (Petitti et 










found for contraceptives containing norgestrel-type progestogens (levonorgestrel or 
norgestrel), but not norethindrone-type progestogens (norethindrone, norethindrone 
acetate, ethynodiol diacetate, or norethynodrel); no comment was made about other 
types of progestogens. In the WHO study, an increased risk of haemorrhagic stroke was 
found only in older women who were taking contraceptives (World Health Organization 
Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception 
1996b). The risk did not vary by progestogen constituent (Poulter et al. 1999b). A 
study undertaken by the Boston group, which was based on the UK GPRD, found no 
difference in risk of cerebral haemorrhage among oral contraceptive users according to 
progestogen type (Jick et al. 1999). 
Thus, in summary, there was no convincing evidence that desogestrel and gestodene 
contraceptives conferred particular benefits over older preparations. Moreover, 
arguments about whether certain oral contraceptives carried a lower risk of myocardial 
infarction or stroke were irrelevant for the majority of pill users - that is, women less 
than 30 years of age in whom such outcomes are extremely rare (Paul 1996). In fact, 
using relative risk estimates from the WHO study and incidence rates from the Oxford 
region, the WHO investigators demonstrated that the potentially avoidable excess of 
venous thromboembolic events in women who used desogestrel or gestodene 
contraceptives would represent a considerable proportion of the total cardiovascular 
morbidity in women aged less than 35 years (Farley et al. 1998b). 
3.2.11 Consideration of comparisons of risk 
A comment that was frequently heard during the debate about the safety of oral 
contraceptives containing desogestrel and gestodene was that the absolute risk of 
venous thromboembolism in users of these pills was much lower than that encountered 
during pregnancy (Farmer and Preston 1995; Guillebaud 1995a; Leader 1996; Westhoff 
1996). The implication was, therefore, that the ongoing use of such contraceptives was 
justified. However, such a line of reasoning would only be coherent if desogestrel and 
gestodene contraceptives were the sole means by which pregnancy could be prevented. 
In any case, a nested case-control study confined to women aged < 50 years in the UK 
GPRD who had been prescribed the emergency contraceptive pill at any time during an 







believed; the crude rates of idiopathic venous thromboembolism per 100,000 women-
years at risk were 15.5 (6.6 - 36.3) for pregnancy and the puerperium, 10.7 (4.9 - 23.3) 
for users of desogestrel or gestodene pills, and 5 .3 (95 % CI 1.4 - 19 .2) for users of low-
dose levonorgestrel oral contraceptives (Vasilakis et al. 1999b). 
3.2.12 Consideration of competing interests 
By the end of 1998, three independently funded analytical studies had been published 
which showed a two-fold excess risk of venous thromboembolism in users of oral 
contraceptives containing desogestrel or gestodene, when compared with users of older 
preparations (Bloemenkamp et al. 1995; Jick et al. 1995; World Health Organization 
Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception 
1995c). Conversely, three studies directly funded by the pharmaceutical industry had 
shown relative risks of 1.5 or less (Spitzer et al. 1996; Farmer et al. 1997a; Lidegaard et 
al. 1998). These findings prompted questions about the influence of competing interests 
(Vandenbroucke 1998). 
While the authors of the three key studies which were independently funded remained 
convinced that the apparent excess risk of venous thromboembolism observed in users 
of desogestrel and gestodene oral contraceptives was real (Helmerhorst et al. 1997; Jick 
et al. 1997; Vandenbroucke et al. 1997a; Vandenbroucke 1998; Farley et al. 1998c; 
Farley et al. 1999), the Transnational researchers continued to argue that the association 
was explained by bias and confounding (Spitzer 1997; Lewis 1998; Spitzer 1998a; 
Spitzer 1998b; Heinemann 1999; Spitzer 1999) and subjected their study to four 
reanalyses. 
The second group of investigators who undertook industry-funded research recycled 
accounts of their UK MediPlus study research (Farmer 1996; Farmer et al. 1997a; 
Farmer and Lawrenson 1998; Farmer et al. 1999) and later subjected the data to a 
reanalysis (Todd et al. 1999). The same researchers also published the results of their 
studies based on the German MediPlus (Farmer and Lawrenson 1998; Farmer et al. 
1998a; Farmer et al. 1998b; Farmer et al. 1999) and UK GPRD (Farmer et al. 1999; 











As well as funding reanalyses and new studies, one commentator observed that "three 
multinational companies have used enormous marketing resources to sow confusion", 
subjecting individual doctors and various organisations to an "avalanche of special 
symposia and paid supplements" (V andenbroucke et al. 2000). Indeed, a striking 
relationship can be observed between funding sources and the conclusions drawn by 
commentators about the likely explanations for the observed excess risk of venous 
thromboembolism in users of desogestrel and gestodene contraceptives. For instance, 
consensus statements and reviews by researchers who were not involved in the key 
studies, and who were known to have received funding from pharmaceutical companies 
at some point, tended to attribute at least part, if not all, of the excess risk to bias and 
confounding (Lidegaard and Milsom 1996; Rosenberg et al. 1996; Cohen 1996a; 
Lidegaard and Milsom 1996a; Carr and Ory 1997; Rosenberg et al. 1997; Chasan-Taber 
and Stampfer 1998; Ory 1998; Cohen 1999; Lidegaard et al. 1999; Speroff 1999a; 
Speroff 1999b). Conversely, reviews by several independent commentators who were 
not involved in the key studies (Paul 1996; Skegg 1997; Walker 1998; LeBlanc and 
Laws 1999; Maling 1999; McPherson 1999; O'Brien 1999; Walker 1999; Weiss 1999; 
Hannaford 2000), as well as a scientific group convened by WHO (World Health 
Organization 1997; World Health Organization 1998), all concluded that the excess risk 
could not be explained by bias or confounding . 
3.2.13 Summary 
By the end of the 1990s, the relationship between modem low-dose oral contraceptives 
and venous thromboembolism had been clarified and largely accepted. First, compared 
with non-users, current users of any oral contraceptive had a three to six-fold increased 
risk of venous thromboembolism (World Health Organization 1998). Second, this risk 
appeared to be greatest in the first year of use, although an elevated risk persisted until 
oral contraceptives were discontinued (World Health Organization 1998). Third, the 
risk declined to the same level as non-users within three months of discontinuation 
(World Health Organization 1998). Fourth, the risk in users of pills containing< 50µg 
ethinyloestradiol seemed to be unrelated to oestrogen dose (World Health Organization 
1998). Fifth, the proposed non-causal explanations for the difference in risk between 
desogestrel and gestodene contraceptives and other preparations had failed to account 
for the observed results (World Health Organization 1998). Moreover, there was 











gestodene contraceptives and an excess risk of venous thromboembolism. Compared 
with current users of levonorgestrel and norgestrel oral contraceptives, users of 
desogestrel and gestodene pills had about twice the risk of venous thromboembolism 
(summary odds ratio 1.9 [95% CI 1.5 - 2.2]) (Farley et al. 1999). Sixth, oral 
contraceptive users who were carriers of hereditary clotting defects such as factor V 
Leiden, protein C or S deficiency, and antithrombin deficiency had been shown to have 
much higher risks of venous thromboembolism than users without such abnormalities 
(World Health Organization 1998). Conversely, the relationship between oral 
contraceptives and venous thromboembolism was not modified by age, smoking, or the 
presence of varicose veins (World Health Organization 1998). The data about BMI 
were inconsistent (World Health Organization 1998). Seventh, the incidence of 
idiopathic venous thromboembolism (per 10,000 women per year) in young women was 
estimated to be about 0.5 - 1 in non-users, three to four times this baseline rate in users 
of levonorgestrel preparations, and six to eight times higher in users of desogestrel and 
gestodene contraceptives (Vandenbroucke et al. 1997a). Eighth, a biologically plausible 
explanation for the excess risk of venous thromboembolism in users of desogestrel and 
gestodene contraceptives had been identified with the discovery that women using these 
contraceptives had a greater resistance to activated protein C than users of 
levonorgestrel pills (Farley et al. 1999). Finally, suggestions that the higher risk of 
venous thromboembolism would be outweighed by other benefits of desogestrel and 
gestodene contraceptives, such as a lower incidence of myocardial infarction and stroke, 
had not been borne out (Farley et al. 1999). 
3.3 PSYCHOTROPIC DRUGS AND VENOUS THROMBOEMBOLISM 
3.3.1 Case reports and case series 
Shortly after the introduction of the first antipsychotic medications in the early 1950s, 
several reports of venous thromboembolic events among users of these drugs were 
published (Brehmer and Ruckdeschel 1953; Labhardt 1954; Maurice 1956; Mielke 
1956; Grahmann and Suchenwirth 1959). Interestingly, these and the sporadic case 
reports and case series which emerged over the next few decades (Mahmodian 1963; 
Hafner and Brehm 1965; Meier-Ewert et al. 1967; Scholz 1967; Lunel et al. 1972; 









Europe. Such reports suggested that venous thromboembolism was an important cause 
of morbidity in patients receiving psychotropic drugs; in one series of 1,590 patients 
treated with neuroleptic medication, it was the most common fatal adverse drug reaction 
(Hafner and Brehm 1965). In this study and two others, the incidence of venous 
thromboembolism in psychiatric patients who received antipsychotic drugs (Grahmann 
and Suchenwirth 1959), and those who were given either antipsychotics or tricyclic 
antidepressants (Hafner and Brehm 1965; Meier-Ewert et al. 1967), was compared with 
patients who received either very low doses of these drugs or other treatments. Venous 
thromboembolic events were significantly more common in the groups treated with 
antipsychotic and antidepressant drugs. It was thought that immobilisation, rather than 
any direct effect of the drugs on the coagulation system, was responsible. It should be 
noted, however, that these analyses were very crude and the underlying characteristics 
of the patients in the treatment and comparison groups are likely to have differed. 
More recently, reports of venous thromboembolism in users of conventional (Varia et 
al. 1983; Roche-Bayard et al. 1990; McCall et al. 1995; Kamijo et al. 2003) and atypical 
antipsychotics such as clozapine (Clardy and Gale 1995; Lacika and Cooper 1999; 
Coodin and Ballegeer 2000; Hagg et al. 2000; Knudson et al. 2000; Maynes 2000; 
Modai et al. 2000; Suttmann et al. 2000; Ihde-Scholl et al. 2001; Farah et al. 2004), 
risperidone (Kamijo et al. 2003), and zotepine (Pantel et al. 1997) have appeared in the 
English language literature. In the absence of a comparison group, however, such 
reports are only ever suggestive of a relationship. Indeed, results from a surveillance 
programme of severe adverse drug reactions in Swiss and German psychiatric inpatients 
are consistent with no association; the crude rates of venous thromboembolism were 
similar in those treated with clozapine, those given other neuroleptics, and those who 
received no such medicines (Wolstein et al. 2000). 
Several reports have described the occurrence of venous thromboembolism in patients 
taking various antidepressant regimens, including tricyclic antidepressants taken with or 
without antipsychotics (Hafner and Brehm 1965; Meier-Ewert et al. 1967; Singer et al. 
1975; Ruh-Bernhardt et al. 1976; Hagg et al. 2000), selective serotonin-reuptake 
inhibitors (SSRis) used in conjunction with antipsychotics (Pantel et al. 1997; Maynes 










2002), and the use of unspecified antidepressants and antipsychotics with lithium 
carbonate (Kallner et al. 2000). 
Other reports, while making no reference to medication, have described the occurrence 
of venous thromboembolism among psychiatric patients in general (Lal et al. 1966; 
Kendel and Fodor 1969; Ziegler 1977; Hindersin et al. 1984; Hewer et al. 1995), and 
more particularly with catatonic or depressive stupor (Sukov 1972; O'Brien 1991; 
McCall et al. 1995; Morioka et al. 1997; Arnone et al. 2002) and physical restraint 
(Hem et al. 2001; Lazarus 2001; Ramirez et al. 2001). 
3.3.2 Analytical studies 
Four decades after the first case reports, the potential association between psychotropic 
drugs and venous thromboembolism was finally explored in well-designed analytical 
studies. The first study to find an association was a case-control study of cardiovascular 
mortality in English and Welsh women of child-bearing age (Thorogood et al. 1992a). 
An incidental finding in this study, which was designed to examine the risks of fatal 
cardiovascular events associated with oral contraceptive use, was a 17-fold increased 
risk of myocardial infarction among users of psychotropic drugs, particularly tricyclic 
antidepressants and benzodiazepines. In addition, an almost three-fold increased risk of 
pulmonary embolism in current users of psychotropics was found, although no point 
estimates were reported for individual drug groups. 
Subsequently several studies were undertaken with the primary aim of examining the 
risk of venous thromboembolism in users of psychotropic drugs, in general, or 
antipsychotic medicines in particular. These studies are outlined in Tables 3.4 and 3.5. 
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Table 3.4 Case-control studies of psychotropic drug use and venous thrornboernbolisrn 
Reference Study design Cases Controls Exposure information 
(Zomberg and Nested case-control study Ascertainment Selection Details of psychotropic (antipsychotic, 
Jick 2000) of idiopathic VTE based Reviewed For each case, antidepressant) exposure and other data 
onUKGPRD. electronic GP randomly selected abstracted from electronic records. 
records to 4 controls from Most psychotropic drug prescriptions 
Study population: patients identify women study population. for 1 months' supply. 
aged < 60 years who who were 
received 2:: 1 prescriptions admitted to Matching factors Current use of 12sychotro12ic drugs 
for conventional or hospital with GP, sex, age (year Prescribed use ::; 30 days before index 
atypical antipsychotic objectively of birth), years in date. 
drugs between January diagnosed DVT GPRD. 
1990 and October 1998. and / or PE and Recent use of 12sychotro12ic drugs 
anticoagulated. Index date Prescribed use 31 - 90 days before 
Excluded all patients with Examined Index date of index date. 
previous DVT, PE, or MI; hospital case. 
those with coagulopathies discharge letters 
Non-use of 12sychotro12ic drugs 
congestive heart failure, Total included No prescribed use ::; 90 days before 
cancer, renal failure, 
and death n = 168 index date. 
certificates to 
epilepsy, diabetes, cystic verify diagnosis. Reference categories fibrosis, multiple sclerosis, 
1. Non-users. alcohol or substance abuse; Index date 2. Non-users and recent users. pregnancy, trauma or Date of 
surgery < 6 months before diagnosis. Current use of oestrogens 
index date; an acute Receipt of prescription for oral / 
psychotic episode < 2 Total included transdermal / parenteral contraception 
months before index date. n = 42 (2 fatal) or HRT < 180 days before index date. 
Also those with < 6 
months recorded clinical Recent use of oestrogens 
data before first Receipt of prescription 180- 365 days 













Adiusted matched OR (95% 
CI) for use of antipsychotic 
Non-users as reference 
Current use any antipsychotic: 
7.1 (2.3 - 21.97) 
Recent use any antipsychotic: 
2.1 (0.4 - 11.8) 
Non-users and recent users as 
reference 
Current use low potency 
anti psychotic: 
24.1 (3.3 - 172.7) 
Current use high potency 
anti psychotic: 
3.3 (0.8 - 13.2) 
Current use any antipsychotic: 
< 12 months: 
28.7 (4.9 - 169.5) 
Current use any antipsychotic: 
2:: 12 months: 
1.0 (0.1- 7.3) 
Unadiusted unmatched OR 
(95% CI) for use of 
antidepressant 
Non-users as reference 
Current use any antidepressant: 








Reanalysis of Leiden 
Thrombophilia Study, a 
population-based case-
control study of 
consecutive men and 
women aged < 70 years 
with a 1st diagnosis of 
DVT between January 
1988 and December 1992. 








clinics in 3 












Each case was 
asked to find a 
friend or 
acquaintance of 
the same sex and 
age, who was not 
a biological 
relative, had no 
history of VTE or 
malignancy, and 
did not use 
warfarin, to serve 
as a control. 
Cases who were 
unable to find a 
suitable control 
were matched 
with partners of 
other cases. 
Matching factors 
Sex and age. 
Index date 






Cases and controls both interviewed 6 
- 19 months after index date ( 1990 -
1993) about risk factors for DVT, 
including medication use and a history 
of VTE in ~ 1 parent or sibling. 
Physical examination undertaken and 
blood collected for coagulation factor 










4 cases and no controls used 
antipsychotic drugs in year 
before index date. 
Unadjusted unmatched OR 
(95% CI) 
Non-users as reference 
Use of antidepressant in year 
before index date: 
2.3 (0.6 - 10.2). 
Unadjusted unmatched OR 
(95% CI) 
Non-users as reference 
Use of benzodiazepine in year 
before index date: 
4.2 (1.8 - 11.5). 
Abbreviations used in the table BMI: body mass index, DVT: deep vein thrombosis, GP: general practice, HRT: hormone replacement therapy, MI: myocardial infarction, OR: odds ratio, PE: pulmonary embolism, VTE: venous 
thromboembolism. 
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67,072 patients aged 10 - 94 
years who were enrolled on the 
national registry of clozapine 
users (Clozaril National Registry) 
in the USA and had a record of 
receiving at least 1 weeks' supply 
of clozapine at any time between 
April 1991 and December 1993. 
Excluded patients with post codes 
from New York City, as death 
certificates not available for these 
patients. 
Key analyses confined to patients 
aged 10 - 54 years. 
Current users of clozapine 
~ 14 days since last record in 
Registry of active use. 
Recent users of clozapine 
15 to 106 days since last record in 
Registry of active use. 
Comparison group (former users) 
~ 107 days since last record in 
Registry of active use. 
Exposure and outcome 
information 
Linked data from Clozaril National 
Registry with National Death Index 
and Social Security Administration 
Death Master files using patients' 
Social Security Numbers. 
Deaths certificates examined by 
professional nosologist, coded 
underlying cause of death according 
to ICD-9. 
The Registry contained details of 
mandatory WBC counts (a pre-
treatment test, weekly tests during 
therapy, and weekly tests for 4 
weeks following discontinuation of 
medicine) for all clozapine users, as 
well as dosage information 
( clozapine supplies were dispensed 
weekly). Each WBC record 
indicated whether clozapine being 
actively received by patient, on-
hold (temporarily stopped), or 
discontinued. 
Incidence per 100,000 person-years 
(number of events) 
Adjusted mortality rates 
All causes 
Past users: 693 (111) 
Recent users: 1,174 (89) 
Current users: 322 (196) 
PE 
Past users: 6 (1) 
Recent users: 0 
Current users: 30 (18) 
Conduction disorders or sudden death 
Past users: 7 (1) 
Recent users: 28 (2) 
Current users: 15 (9) 
Respiratory diseases 
Past users: 11 (2) 
Recent users: 114 (9) 
Current users: 33 (20) 
Suicide 
Past users: 222 (33) 
Recent users: 246 (18) 
Current users: 39 (24) 




Adjusted RR (95 % CI) for use of clozapine 
Past users as reference 
All causes 
Recent use: 1.69 (1.28 - 2.25) 
Current use: 0.46 (0.37 - 0.59) 
PE 
Recent use: 0.0 
Current use: 5.2, 95% CI not computed. 
Conduction disorders or sudden death 
Recent use: 4.19, 95% CI not computed 
Current use: 2.22, 95% CI not computed. 
Respiratory diseases 
Recent use: 9.96, 95% CI not computed 
Current use: 2.92, 95% CI not computed. 
Suicide 
Recent use: 1.11 (0.62 - 1.99) 
Current use: 0.17 (0.10 - 0.30) 
Other results 
Standardised mortality ratio (95% Cl) for 
cohort ( current, recent, past users combined) 
compared with general population: 
1.73 (1.56 - 1.91). 
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131,196 patients aged 2:: 65 years 
who were enrolled with the 
Ontario Health Insurance Plan 
and were prescribed antipsychotic 
drugs (n = 22,514), 
antidepressants (n = 75,649), or 
thyroid replacement hormones (n 
= 33,033) between January 1994 
and March 2000. 
Excluded patients who had taken 
any of the study drugs in the year 
before January 1994; those who 
had not filled 2:: 2 prescriptions for 
study drug within 180 days of its 
initiation; those who concurrently 
(within 1 year) took drugs from> 
1 category; users of warfarin < 1 
year before study entry; and 
patients diagnosed with cancer or 
VTE < 3 years before study entry. 
Users of anti psychotics 
_$. 180 days since last prescription. 
Users of antidepressants 
.$. 180 days since last prescription. 
Comparison group 
Users of thyroid replacement 
therapy,.$. 180 days since last 
prescription. 
V -- ,-.; 
Exposure and outcome 
information 
To identify VTE events, new cancer 
diagnoses, and other 
hospitalisations, used patients' 
unique healthcare numbers to link 
prescription data with hospital 
discharge and outpatient databases. 
Incidence per 100,000 person-years 
(number of events) 
Crude incidence 
DVTonly 
Antipsychotic users: 1650 (307) 
Antidepressant users: 1160 (812) 
Thyroid replacement therapy users: 
1010 (593) 
DVT and/ or PE 
Antipsychotic users: 1920 (357) 
Antidepressant users: 1430 (999) 
Thyroid replacement therapy users: 
1200 (703) 




Adjusted hazard ratio (95% CI) for current 
use of psychotropic drug 
Thyroid replacement users as reference 
DVTonly 
Any antipsychotic: 1.13 (0.97 - 1.32) 
Phenothiazine: 0.86 (0.67 - 1.10) 
Dibenzothiazepine: 1.13 (0.83 - 1.55) 
Butyrophenone: 1.51 (1.23 - 1.86) 
Any antidepressant: 1.02 (0.91 - 1.13) 
SSRI: 1.00 (0.88 - 1.14) 
Tricyclic: 0.98 (0.85 - 1.13) 
Benzisoxazole: 0.73 (0.34 - 1.54) 
DVT and/ or PE 
Any antipsychotic: 1.10 (0.95 - 1.27) 
Phenothiazine: 0.83 (0.66 - 1.05) 
Dibenzothiazepine: 1.19 (0.90 - 1.58) 
Butyrophenone: 1.43 (1.18 - 1.74) 
Any antidepressant: 1.04 (0.94 - 1.15) 
SSRI: 1.04 (0.92 - 1.17) 
Tricyclic: 0.98 (0.86 - 1.11) 
Benzisoxazole: 0.70 (0.35 - 1.41) 
Hazard ratios adjusted for sex, age, currently 
residing in a long-term care facility, recent 
hospitalisation, concurrent diagnosis of cancer, 
and concurrent prescription of aspirin, 
warfarin, oestrogen, or lithium. 








As can be seen from the tables above, the first analytical study which was specifically 
designed to examine the risk of venous thromboembolism in users of antipsychotics was 
confined to an atypical preparation (Walker et al. 1997). In this cohort study, data from 
a national registry of clozapine users in the USA were linked with death registrations in 
order to explore the overall and cause-specific mortality in current and past users. 
Among patients aged 10 - 54 years, the sex, age, and ethnicity-adjusted mortality rate 
for pulmonary embolism in current users was five times that of past users. The risk of 
conduction disorders or sudden death was also elevated in current and recent users. 
Because necropsies were undertaken in only 54% of deaths (63% in current users), it is 
possible that the underlying causes of some deaths were misclassified. If, for example, 
some pulmonary embolism deaths in current users were misclassified as conduction 
disorders or sudden death, then the risk of fatal venous thromboembolism in current 
users of clozapine might have been underestimated. A second feature of the study 
which might have led to an attenuation of the relative risk was the use of past users of 
clozapine as the reference category. The major advantage of using this internal 
comparison group was that it provided some control for confounding by factors such as 
the severity of schizophrenia and the prescribing preferences of physicians. However, 
because the use of clozapine during the study period was restricted to patients with 
severe schizophrenia, it is unlikely that every past user of clozapine had discontinued 
antipsychotic use altogether. Thus, if other antipsychotics also carried an increased risk 
of venous thromboembolism, then the risk associated with current use of clozapine 
could have been underestimated. 
A nested case-control study, undertaken by researchers at the Boston Collaborative 
Drug Surveillance Program and based on the UK GPRD, explored the association 
between the outpatient use of conventional antipsychotic medication and first-time 
idiopathic venous thromboembolism (Zomberg and Jick 2000). Only two cases (one 
current and one past user) were fatal. Current use(~ 30 days before the index date) was 
associated with a seven-fold increase in risk when compared with non-use (adjusted 
odds ratio 7 .1 [95% CI 2.3 - 21.9]). The risk appeared to be highest during the first few 
months of use which led the investigators to suggest that some people might be 
predisposed to antipsychotic-induced venous thromboembolism. The odds ratios for 
current use of antipsychotics did not differ by the chemical class, nor were higher doses 
of particular drugs associated with higher risks of venous thromboembolism. However, 
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the relative risk estimates did vary by potency, that is, the dose required to achieve a 
therapeutic effect. Low potency antipsychotics. such as chlorpromazine and thioridazine 
carried a higher risk than high potency drugs such as haloperidol; the adjusted odds 
ratios for current use were 24.1 (95% CI 3.3 - 172.7) and 3.3 (95% CI 0.8 - 13.2) 
respectively. The study was confined to patients who had received at least one 
prescription for an antipsychotic drug as an outpatient at some time during a nine-year 
period; this provided some control for the underlying conditions for which patients are 
prescribed these drugs and for surveillance bias. Unlike the study of clozapine users, 
the reasons for which patients took antipsychotic drugs in this study included medical, 
as well as, psychiatric conditions. None of these diagnoses were independently 
associated with an elevated risk of venous thromboembolism, which increases the 
likelihood that the drugs themselves were responsible for the increased risk. 
The investigators also explored the risk of venous thromboembolism in current users of 
antidepressants; the unadjusted unmatched odds ratio was 1.7 (95% CI 0.8 - 3.7) 
(Zomberg and Jick 2000). This result, which was based on three exposed cases and 20 
exposed controls, should be interpreted with caution. By design, the analysis included 
only those antidepressant users who had been prescribed antipsychotic drugs during the 
study period and the underlying characteristics of such people might be different from 
other antidepressant users. 
Findings from a reanalysis of data from the Leiden Thrombophilia Study were also 
consistent with an elevated risk of venous thromboembolism in current users of 
antipsychotic drugs; four of 474 cases and none of the 474 controls used antipsychotic 
drugs in the year before the index date. Like the study based on the GPRD, people who 
received psychotropic drugs in hospital were not included in this study; an unspecified 
number of patients were excluded because they were general hospital or psychiatric 
inpatients at the time of enrolment. Moreover, 51 eligible cases declined to participate 
and another 19 were excluded because of psychiatric morbidity which was expected to 
impair involvement in the research. Hence, it is possible that the true proportion of 
antipsychotic users in the population-based sample of people with deep vein thrombosis 
was underestimated. The researchers also reviewed necropsy reports at the Leiden 






embolism occurred in psychiatric patients, five of whom were known users of 
antipsychotic drugs. 
The findings of a fourth study were less consistent. Using linked data from health care 
administrative databases, a Canadian cohort study compared the risk of venous 
thromboembolism in users of thyroid replacement hormones and users of two groups of 
psychotropic drugs: antipsychotics and antidepressants (Ray et al. 2002). In relation to 
antipsychotics, an increased risk was found for users of butyrophenones only (adjusted 
hazard ratio 1.43 [95% CI 1.18 - 1.74]). However, the study was confined to patients 
aged 65 years or more and diagnostic bias could not be ruled out since users of 
antipsychotics were older, were more likely to be living in long-term care facilities, and 
may have been more cognitively impaired than people taking thyroid replacement 
therapy. If venous thromboembolic events were less likely to have been recognised in 
such people, an increased risk in antipsychotic users might have been missed. 
Moreover, only those patients who were dispensed at least two prescriptions within 180 
days of the initiation of treatment with one of the relevant drugs were included in the 
study. The duration of prescriptions was not stated, but assuming a one-month supply, 
this had the effect of excluding patients who took a medicine for just one or two 
months. It is more likely that the excluded patients were taking antipsychotic or 
antidepressant drugs than thyroid replacement therapy, since the latter treatment is 
usually taken without interruption. If, as suggested by the nested case-control study 
discussed above (Zomberg and Jick 2000), the risk of antipsychotic-related venous 
thromboembolism is greatest during the first few months of use, the exclusion of short-
term users might have led to an underestimation of the true relative risk. No elevation 
of risk was found for antidepressant use. Two final points should be made about the 
design of this study. First, as the investigators conceded, they had very limited 
information about potential confounding factors and thus were unable to fully exclude 
confounding as an alternative explanation for their findings. Second, they 
inconsistently excluded patients who took warfarin or were diagnosed with cancer -
those in whom the events occurred before the study period were excluded, whereas 
those that occurred after entry into a cohort were not. 
Since the early years of their use through to the present day, antipsychotic drugs, 











al. 1963; Hollister and Kosek 1965; Ray et al. 2001; Hennessy et al. 2002). Similarly, 
sudden deaths in users of tricyclic antidepressants have been attributed to cardiac causes 
(Mehtonen et al. 1991). Hence, it is possible that deaths from pulmonary embolism 
could be misclassified as myocardial infarction or arrhythmia-induced (and vice versa) 
when necropsies are not performed. For instance, in a recent case-control study, 
thioridazine was identified as a risk factor for sudden unexplained death among 
psychiatric inpatients (adjusted odds ratio 5.3 [95% CI 1.7 - 16.2]) (Reilly et al. 2002). 
Drug-induced arrhythmia was thought to be the most likely cause. Since a necropsy 
was performed in only 36% of cases, the possibility that some of the remaining patients 
died from pulmonary embolism cannot be ruled out. Interestingly when the analysis 
was confined to patients who had undergone a necropsy, a significant association 
between thioridazine and sudden unexplained death was not found (adjusted odds ratio 
2.9 [95% CI 0.7 - 11.7]). 
3.3.3 Why might anti psychotic drug use increase the risk of venous thromboembolism? 
It has been suggested that the characteristics of the people who use antipsychotic 
medicines, features of the underlying condition for which they are taken, or side effects 
of the drugs such as sedation-induced immobility and obesity might be responsible for 
the observed increased risk of venous thromboembolism in users of these drugs (Tapson 
2000; Tipper et al. 2001). However, as already discussed, two of the analytical studies 
which found an elevated risk in current users took previous users as the reference group, 
which provides some evidence against the first two hypotheses (Walker et al. 1997; 
Zomberg and Jick 2000). Moreover, patients with major risk factors for venous 
thromboembolism were excluded from the nested case-control study, the relative risk 
estimates were adjusted for BMI and other potential confounding factors, and none of 
the cases were immobilised or acutely psychotic in the two months before the index date 
(Zomberg and Jick 2000). 
At the time that these studies were published, several mechanisms had been proposed to 
explain the suspected association between antipsychotic use and venous thrombosis. 
First, it appeared that platelet aggregation was enhanced during treatment with such 
medicines (Boullin et al. 1975; Orr and Boullin 1976; Ruh-Bernhardt et al. 1976), 
although the results were not consistent (Boullin et al. 1978; Orr et al. 1981). Second, 










increased risk of venous and arterial thromboembolism (Greaves 1999; Levine et al. 
2002), had been observed in patients taking antipsychotic drugs (Zarrabi et al. 1979; 
Canoso and Sise 1982; Canoso et al. 1990; Davis et al. 1994), including users who 
suffered venous or arterial events (el-Mallakh et al. 1988; Steen and Ramsey-Goldman 
1988; Roche-Bayard et al. 1990; Ducloux et al. 1999; Maynes 2000). However, these 
antiphospholipid antibodies had also been found in people with acute psychosis before 
the commencement of antipsychotic therapy (Chengappa et al. 1991; Schwartz et al. 
1998) and in healthy individuals belonging to families with several schizophrenic 
members (Firer et al. 1994). Moreover, some research had suggested that, unlike the 
antiphospholipid antibodies associated with systemic lupus erythematosus and other 
autoimmune conditions, antipsychotic-induced antibodies did not seem to carry the 
same, or any, risk of venous (Canoso and de Oliveira 1988; el-Mallakh et al. 1988) or 
arterial (Metzer et al. 1994) thromboembolism. 
Other suggested mechanisms to explain the association included the exacerbation of 
venous stasis during sedation (Zomberg and Jick 2000), increased adrenaline secretion 
during the acute psychotic phase (Hindersin et al. 1984), and the increase in 
homocysteine levels found in some schizophrenics (Susser et al. 1998). 
3.3.4 Summary 
In stark contrast to the huge volume of research on oral contraceptive safety, the risk of 
venous thromboembolism in users of antipsychotics has been poorly investigated. More 
than fifty years after the emergence of the first case reports of venous thromboembolism 
in users of antipsychotic drugs, information from analytical epidemiological studies is 
limited. Nonetheless, the data from two well-designed studies are suggestive of a causal 
relationship between antipsychotic use and venous thromboembolism (Walker et al. 
1997; Zomberg and Jick 2000); in both studies the drug exposure clearly preceded the 
thrombotic event, the relative risk estimates were high (especially for low potency 
conventional antipsychotics), the association was apparent in two different populations 
using two different study designs, an elevated risk was found for both fatal and non-
fatal events, and some biologically plausible mechanisms by which antipsychotic drugs 










While there have been case reports of venous thromboembolism in users of 







CHAPTER4 CASE-CONTROL STUDY OF THE USE OF ORAL 
CONTRACEPTIVES AND PSYCHOTROPIC DRUGS: OBJECTIVES 
AND METHODS 
4.1 INTRODUCTION 
4.1.1 Oral contraceptives and venous thromboembolism 
115 
As discussed in the previous chapter, the risk of venous thromboembolism in women 
taking oral contraceptives containing desogestrel or gestodene appears to be about 
double that of women using levonorgestrel formulations. Although the absolute risks 
are not high, the excess risk has been of particular concern in New Zealand because of 
the extensive use of these oral contraceptives. At the time of the CSM warning in 
October 1995, almost 80% of oral contraceptive users in New Zealand were taking a 
preparation containing desogestrel or gestodene (Wilson 1999), which represented the 
highest proportionate use among countries for which utilisation data were available 
(Paul 1996). Indeed, these pills had been promoted to New Zealand doctors as the 
preferred choice for women requiring oral contraceptives (Bagshaw 1992). Based on 
the number of women taking desogestrel and gestodene contraceptives in New Zealand 
in 1995, it was estimated that 20 cases of venous thromboembolism among pill users 
would be prevented each year if older preparations were used instead (Paul 1996). 
The regulatory response by the New Zealand Ministry of Health to this issue was 
described by the Chair of the New Zealand Medicines Adverse Reactions Committee as 
"muted" (Maling 1999). As outlined in the previous chapter, the Ministry's immediate 
response to the CSM announcement was to recommend that women at high risk of 
venous thromboembolism should consider using contraceptives other than desogestrel 
and gestodene preparations (Paul 1996). This advice was retracted a week later, 
pending the release and peer review of the key studies. In February 1996, following the 
publication of these studies, the Ministry sent New Zealand doctors a summary of the 
results and recommended that they "include this information on the relative risk of 
venous thromboembolism in the discussion of relative risks and benefits of 
contraceptive methods" (Medsafe 1996a). The communication concluded with the 
advice that until other potential risks and benefits of desogestrel and gestodene 











to current contraceptive practices". However, the Medicines Adverse Reactions 
Committee disagreed with this position. In March 1996, after reviewing the published 
data, the Committee urged the Ministry to recommend a change to prescribing practices 
as soon as possible (Aggett 1997). The key recommendations of the Committee, which 
were based on guidelines issued by the Faculty of Family Planning and Reproductive 
Health Care of the Royal College of Obstetricians and Gynaecologists in the UK (Mills 
et al. 1996), were that older low-dose pills should be preferentially prescribed to women 
starting on oral contraceptives, and that women with risk factors for venous 
thromboembolism who were already using desogestrel or gestodene preparations should 
be changed to other products (Aggett 1996). 
However, the new recommendations were not released until July 1996 and they were 
less directive than those originally proposed by the Medicines Adverse Reactions 
Committee (Paul 1996). In brief, doctors were advised that consideration should be 
given to prescribing oral contraceptives other than desogestrel and gestodene 
preparations when initiating oral contraceptive therapy (Medsafe 1996b ). In addition, 
various circumstances were outlined in which current users of such pills should be 
changed to another oral contraceptive preparation, or to a different method of 
contraception altogether. The tempering of the advice from the Medicines Adverse 
Reactions Committee and the delay in its release was due, in part, to pressure from the 
Royal New Zealand College of Obstetricians and Gynaecologists, the General 
Practitioners Association, and the New Zealand Family Planning Association, who were 
apparently concerned that the original advice would create a pill scare (Aggett 1997; 
Maling 1999). In addition, at least one pharmaceutical company threatened legal action 
after industry representatives were shown drafts of the proposed advice. 
Unfortunately, during the hiatus between the publication of the key studies and the 
release of the prescribing recommendations in July 1996, New Zealand doctors were 
exposed to misleading interpretations of the data by the pharmaceutical industry and the 
Family Planning Association (Paul 1996). In fact, for several years a spokeswoman for 
the latter organisation continued to cite various biases as explanations for at least some 
of the excess risk of venous thromboembolism in users of desogestrel and gestodene 
contraceptives (Roke 1997a; Roke 1997b; Roke 1998; Roke 1999; Egermayer and Roke 











Australian and New Zealand College of Obstetricians and Gynaecologists, which 
asserted in 2000 that there was no evidence that desogestrel and gestodene oral 
contraceptives carried a higher risk of venous thromboembolism than older preparations 
(New Zealand Committee RANZCOG 2000). The information on which this statement 
was based appeared to have been provided to the authors at a pharmaceutical industry-
sponsored meeting in Hong Kong, at which investigators from the Transnational and 
MediPlus studies were invited speakers (Skegg 2000a) 
These influences might partly explain why the release of the Ministry's advice in July 
1996 had a very modest impact on prescribing practices. In 1998, the proportion of oral 
contraceptive users taking desogestrel or gestodene preparations was still about 62% 
(Wilson 1999). In contrast, the proportion plummeted to around 30% in the wake of 
adverse media publicity at the beginning of 1999 about the unexpectedly high number 
of deaths from pulmonary embolism in users of desogestrel and gestodene 
contraceptives (Egermayer 1999). Based on the prevalence of use of these pills in New 
Zealand women during the mid- l 990s, and on estimates of venous thromboembolism 
incidence and case-fatality, one death from pulmonary embolism among users would 
have been expected every 1.5 to 2.5 years (Medsafe 1998). However, the Centre for 
Adverse Reactions Monitoring had received spontaneous reports of six deaths in women 
taking desogestrel or gestodene contraceptives between January 1993 and June 1998, 
four of which had occurred during the 18 months to June 1998 (Medsafe 1998). 
The present study of oral contraceptive use and fatal pulmonary embolism was 
prompted in part by this apparent excess number of deaths and in part by the lack of 
information about oral contraceptive use and the risk of fatal venous thromboembolism, 
especially within populations where desogestrel and gestodene contraceptives were 
widely used. At the time the present research was initiated only two case-control 
studies had investigated the risk of fatal pulmonary embolism in relation to oral 
contraceptive use. The first was conducted in the UK during 1966, well before the 
development of desogestrel and gestodene contraceptives (Inman and Vessey 1968). 
Using data presented in the paper, a crude odds ratio of 7.7 for current use of oral 
contraceptives can be derived. The second study examined deaths in England and 
Wales between 1986 and 1988, and it is likely to have included few users of desogestrel 









cases aged 16 - 39 years and 115 age-matched controls selected from the same general 
practices as the cases, the odds ratio for fatal pulmonary embolism among women who 
had. used oral contraceptives in the preceding month was 2.1 (95% CI 0.8 - 5.2). The 
only study to contain specific information about fatal venous thromboembolism and 
desogestrel and gestodene contraceptives was the GPRD study undertaken by the 
Boston group in which there were only six deaths from pulmonary embolism among 
oral contraceptive users (Jick et al. 1995). 
The final impetus for undertaking the present research was the potential for addressing 
some of the concerns voiced by the critics of the key studies. For example, referral and 
diagnostic biases would be highly unlikely in a study of fatal events. Moreover, in a 
relatively geographically isolated island nation such as New Zealand it would be 
possible to include all cases that occurred in the population. 
4.1.2 Psychotropic drugs and venous thromboembolism 
As outlined in the previous chapter, there is little information from analytical 
epidemiological studies about psychotropic drug use and venous thromboembolism. 
The data about fatal events are even more limited - the only study to have quantified 
the risk of fatal pulmonary embolism in users of antipsychotics was confined to an 
atypical preparation, clozapine (Walker et al. 1997). The present research was therefore 
undertaken to explore the risk of fatal pulmonary embolism in users of psychotropic 
drugs. 
4.2 OBJECTIVES 
The objectives of the study were as follows: 
1. To examine any association between the use of oral contraceptives and the risk 
of fatal pulmonary embolism 
















3. To assess the completeness of reporting of cases of fatal pulmonary embolism 
involving the use of oral contraceptives to the Centre for Adverse Reactions 
Monitoring 
4. To explore any association between the use of antipsychotic and other 
psychotropic drugs and the risk of dying from pulmonary embolism. 
4.3 DEFINITIONS 
As discussed in Chapter 2, the date of onset of the fatal episode was taken as an index 
date. Cases and controls were defined as ever users of a medicine if their medical 
records indicated that they had been given a prescription for that medicine at any time 
before the index date. Because of the way in which oral contraceptives were packaged 
during the study period, the minimum amount that could be prescribed at any one time 
was a one-month supply. Hence, the use of oral contraceptives was defined, indirectly, 
as prescribed use of at least a month's duration. For different reasons, the use of 
psychotropic drugs was also defined as prescribed use of at least a month. The rationale 
for this definition was that psychotropic drugs are sometimes prescribed in one-off 
doses or very short courses (for example, to treat conditions such as nausea and 
insomnia) and it was decided that the inclusion of such brief episodes of treatment 
might dilute any true increased risk of venous thromboembolism in users of these 
medicines. 
Current use of a medicine was defined as prescribed use at any time during the three 
months before the index date. Under this definition if a prescription was issued before 
the relevant three-month interval, but the duration of the prescribed course was such that 
it continued into that period, such use was classified as current. 
Oral contraceptives were classified according to whether they contained the so-called 
third generation progestogens ( desogestrel and gestodene ), levonorgestrel, or 
cyproterone acetate. Hormone replacement therapy was categorised as oestrogen-only, 
combined ( oestrogen and progestogen) continuous, and combined sequential. 
Psychotropic drugs were divided into three groups: antipsychotics, antidepressants, and 














carbonate, carbamazepine, sodium valproate, and zopiclone). The antipsychotic agents 
were classified according to potency, that is, the dose of the drug required to achieve a 
therapeutic effect (Zirkle and Kaiser 1974; Davis 1976; Zomberg and Jick 2000; Bourne 
and von Zastrow 2001; Potter and Hollister 2001a) 
Women aged 15 - 49 years were classified as being of child-bearing age and hence 
potential users of oral contraceptives. Women of any age were defined as post-
menopausal if there was a clear statement in the medical records that they had reached 
the menopause. If menstruation had ceased because of surgery, chemotherapy, or 
radiation, menopause was classified as artificial; otherwise it was categorised as natural. 
4.4METH0DS 
4.4.1 Overview 
This was a records-based case-control study in which the controls were randomly 
selected from the same general practices to which the cases had belonged on the index 
date. Information about medicine use and other risk factors for venous 
thromboembolism was abstracted from the records of general practitioners, family 
planning clinics, and psychiatric services, using an identical approach for cases and 
controls. The following sections provide a more detailed account of these procedures. 
4.4.2 Ascertainment of cases 
The methods used to identify all men and women aged 15 - 59 years who died in New 
Zealand between 1 January 1990 and 31 December 2000, for whom the underlying 
cause of death was pulmonary embolism, were described in Chapter 2. At the time that 
the present case-control study was initiated, mortality data were not available for deaths 
that occurred in 1999 and 2000. Hence, the study was based on people who died 
between 1 January 1990 and 31 December 1998. Only those who were normally 
resident in New Zealand on the index date were eligible for inclusion (n=92). 
Overseas visitors were excluded from the study for several reasons. First it would have 
been difficult to find an appropriate comparison group for the people who died while 














with respect to their background risks of venous thromboembolism and other factors. 
Second, the prescribing practices in the countries in which these people normally 
resided may have differed from those encountered in New Zealand. Third, it was 
unlikely that general practitioner and other medical records could be obtained for people 
who were not normally resident in New Zealand. 
To explore the association between oral contraceptives and fatal pulmonary embolism, 
the analysis was restricted to pre-menopausal women aged 15 - 49 years. In 2000, the 
results of an analysis based on deaths between January 1990 and August 1998 were 
published (Parkin et al. 2000). Subsequently, information about deaths that occurred in 
the final months of 1998 became available, and these women (n=4) were included in the 
present analysis. Another woman, who died in 1993, was also included after it was 
found that her date of birth had been incorrectly recorded in the data supplied by the 
New Zealand Health Information Service and that she was aged 49 years on the index 
date. 
4.4.3 Arranging general practice visits 
The methods used to identify the general practitioners of the cases were outlined in 
Chapter 2. For two cases (who died in 1992 and 1993), the name of the general 
practitioner was not found. Thus, for the present case-control study, the general 
practitioners of 90 of the 92 eligible cases were sent letters about the study. As 
described in Chapter 2, these letters outlined the aims of the research and requested 
permission for me to visit the practice to examine the records of the case and four 
randomly selected controls (Appendix A, letters 15 and 16). The general practitioner 
was subsequently telephoned, further information about the study was provided, and an 
appointment was made for a visit. At this time, an enquiry was also made about the 
existence of any family planning clinics in the local area. This supplemented the 
information already provided by the Family Planning Association about the clinics they 
operated. 
No doctor refused to participate in the research, although six practices were not visited 
because the records had been destroyed (four cases) or lost (two cases) (see Table 2.5). 
The records of a further nine cases were not found when their respective general 









examined. The diagnosis of pulmonary embolism was confirmed by necropsy in 69, by 
ventilation-perfusion scans or angiography in three, and by the two specialists in 
internal medicine using standard criteria (World Health Organization Collaborative 
Study of Cardiovascular Disease and Steroid Hormone Contraception 1995a) in three. 
4.4.4 Selection of controls 
Eligibility criteria 
For each eligible case four controls, matched by sex and year of birth, were selected 
from the general practice to which the case had belonged on the index date. For all but 
13 cases (who had attended practices in which there was just one doctor), controls were 
selected from the group, rather than individual, medical practice. Potential controls 
were excluded if they were not normally resident in New Zealand, or were not members 
of the group practice, on the index date. Patients were regarded as belonging to the 
practice on the index date if they had a record of at least one consultation during the two 
years before that date. Selected persons who did not meet the eligibility criteria, and 
those whose records had been lost or transferred to another practice, were replaced. 
The group, rather than the individual, general practice was chosen as a sampling frame 
to minimise any potential overmatching with respect to prescribing practices. It was 
thought that if such a phenomenon did occur, it would be most likely to arise in relation 
to the type of oral contraceptives that individual doctors chose to prescribe and would 
have the effect of biasing the odds ratio towards the null value. In any event, only six 
female cases aged 15 - 49 years belonged to sole-practitioner practices. 
Of the 300 controls who were included in the study, 14 were born in adjacent (rather 
than the same) years to their case. There were three reasons for this. First, four small 
practices (each with either one or two general practitioners) had insufficient patients 
born in the appropriate years. Second, the year of birth recorded in the general practice 
records of one woman was a year later than the date recorded in the coroner's file and 
other official death records. Unfortunately this inconsistency was not noticed at the 
time of the practice visit and hence the year of birth that was used to select the controls 
for this case was incorrect. Third, one case had been a senior army officer and his 
primary medical care was provided by the New Zealand Army. It was therefore 




that his controls should be men who had also received medical care from that service. 
However, because this man was middle-aged when he died during the early part of the 
study period, there were almost no men who were born in the appropriate year who 
were still serving in the New Zealand Army when the study was initiated. In particular, 
there were none in the military camp at which the case had been based when he died. 
Hence, to select controls, it was necessary to travel to the national facility where the 
medical records of all retired military personnel were stored. This facility contained the 
alphabetically filed records of men and women who had served in the New Zealand 
Army, Navy, or Air Force, as well as those who had undertaken compulsory military 
training. As some of the medical records dated back more than a century, it was not 
practicable to search these records to identify eligible controls. Instead, an index card 
system that contained demographic data for all military discharges after 1980 was 
examined. However, after several hours of searching, only one eligible control (a man 
who was born in the same year as the case and who was in the army on the index date) 
had been identified. Fortunately, three other men had been found who, although they 
were born in adjacent years to the case, were also in the army at the appropriate time. 
For pragmatic reasons, it was decided to include these men as controls. 
Selection of controls from general practices with age-sex registers 
For 71 cases, controls were selected from age-sex registers which were electronic in all 
but one practice. At the latter practice, the two general practitioners each had a paper-
based register that was organised by year of birth. To randomly select four controls 
from these paper registers, a numbered list was compiled of women who were born in 
the appropriate year and a random numbers table (Lindley and Muller 1971) was used to 
select four. The medical records of those selected were then examined to determine 
whether they had been members of the practice on the index date. Since one of the 
selected patients did not belong to the practice on that date, the next random number in 
the sequence was used to select a fifth patient and so on, until a fourth eligible control 
had been identified. 
At the time that the present study was initiated, most general practices were being run as 
private businesses and there was no requirement that they have electronic age-sex 
registers, let alone that they operate a particular brand of computer software. Hence, it 















practices with electronic age-sex registers. These are listed in Table 4.1. Each software 
system had a search function that enabled a list of current and past ( deceased and 
transferred) patients of the appropriate sex and year of birth to be generated. With some 
software this was a straightforward process, but with others it was not. For example, 
although a few systems allowed a direct search by year of birth (Medtech 32, Alumni, 
and two Others), most required a two-stage process of searching by age and then 
excluding those who were born in the adjacent year to the one of interest (GPDAT, 
MMAS, Medtech 16, Good Practice, Medcen, Houston, Profile for Mac, and one 
Other). When necessary, general practice and software company staff provided 
technical help with the searches. 
Once a list of patients of the correct sex and year of birth had been compiled, those 
listed were numbered from one to 'n', and the random numbers table (Lindley and 
Muller 1971) was used to randomly select four. In some practices, it was possible to 
determine the date on which selected patients had joined the practice without examining 
the clinical records. In others it was necessary to look at the records, but the only 
information sought during this process related to demographic data and the dates of 
consultations. To ensure that the exposure status of potential controls remained 
unknown, the consultations notes were not read at this time. Any patients who were 
found to be ineligible were replaced by the patient corresponding to the next random 
number in the table. 
Two doctors at different group practices (with two and six general practitioners 
respectively), would not allow their patients to be listed for potential selection. The 















Table 4.1 Software used by practices with electronic age-sex registers 
Name of software Number of practices using this software 
Alumni 6 





Medtech 16 9 
Medtech 32 22 















Selection of controls from general practices without age-sex registers 
The general practices of four cases did not have age-sex registers from which potential 
controls could easily be selected. The first of these was the "general practice" of the 
soldier for whom the methods used to select the controls are described above. At the 
second practice, the sole practitioner was asked to indicate where the records of the case 
would have been held, and a search was conducted through the adjacent records in both 
directions until four eligible controls were found. During this selection process, the 
records were examined only to obtain demographic data and the dates of consultations. 
At the third practice, a university student health service, the records of former patients 
were archived by the latest year in which they had been registered as patients. Because 
the case was only in her second year of study when she died in 1993, it was decided not 
to select all of her controls from the files of students who had left the university during 
1993 since this would have resulted in a potentially biased sample of students (those 
who had begun and completed their degrees exceptionally early, those who had left 
university without completing their course of study, and those who had died). 
Therefore, a search was made of the records of those students whose last year of 
registration was 1993, 1994, 1995, and 1996, and one eligible control was selected from 
each of these years using the method described for the solo practice above. 
The practice which had been abandoned and placed into receivership (see Chapter 2) 
was the fourth practice for which there was no age-sex register. The patient records 
from this practice were held in three different places: the two remaining general 
practices in the town and the receiver's storage shed. No eligible controls were found 
among the files held by the receiver. At one of the practices (run by a sole practitioner) 
it was possible to search for potential controls using an electronic age-sex register 
(Houston software), but none of the identified patients of the appropriate age and sex 
had been patients of the abandoned practice. The other practice in the town had a box 
of transfer forms, completed by former patients of the relevant practice, and this was 
searched to identify men who were born in the same year as the case. Exactly four were 
found and an examination of their medical files confirmed that they had all been 












In summary then, the controls were selected randomly from an age-sex register in 71 
practices ( electronic in all except one), from patient registration slips in one practice, 
and by random selection of medical records in three practices. 
4.4.5 Information obtained from general practice records 
As described in Chapter 2, information about medical histories and drug exposures 
before the index date was abstracted from the records (including any electronic records) 
of general practitioners and recorded on a standardised data form (Appendix B), using 
an identical approach for cases and controls. The assistance of general practitioners was 
sought only if required to decipher the notes. Only information that had been recorded 
before the index date was used to compare cases and controls. 
All data abstraction forms were labelled with a study identification number, rather than 
the name of the case or control, and the key which linked names with identification 
numbers was stored separately from the forms. The sex and date of birth of each person 
was recorded, as was the date on which they had joined their general practice. Because 
the records of 23 cases and 84 controls included information from practices to which 
they had previously belonged, the date of the earliest information was also noted so that 
any systematic difference in the total period of time during which information had been 
recorded for cases and controls could be identified. 
Detailed information about the use of medicines before the index date was recorded on 
the data form. For women, this included any current or past use of oral contraceptives, 
other contraceptive methods, and hormone replacement therapy. Specifically, the 
documented use (yes or no) of each of the available contraceptive methods in the year 
before the index date, and at any time before that year, were recorded. The details of 
each prescription for oral contraceptives (date, brand, duration of supply) were then 
noted, as were the details of all contraceptive methods used in the year before the index 
date (date, method, brand, duration of supply). For hormone replacement therapy, the 
date, regimen, and duration of all prescriptions were recorded. 
For both men and women, the particulars (date, medicine, dose, frequency, duration of 
supply) of all other medicines that were prescribed in the year before the index date 
were noted. The use of any psychotropic drugs before that year was also recorded. 
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In addition, the presence (including details) or absence of any documented history of the 
following were recorded: medical conditions associated with an increased risk of 
venous thromboembolism (including a history of deep vein thrombosis or pulmonary 
embolism, superficial venous thrombosis, varicose veins, known thrombophilia, 
systemic lupus erythematosus, inflammatory bowel disease, and malignancy); 
temporary risk factors for venous thromboembolism in the year before the index date 
(including major surgery, injury requiring medical attention, prolonged immobility, and 
pregnancy); other medical conditions (including ischaemic and other heart disease, 
stroke, transient ischaemic attacks, hypertension, diabetes, renal disease, and liver 
disease); intellectual disability; menopause (including the date of the last menstrual 
period and whether the menopause was natural or artificial); and a family history of 
venous thromboembolism. Details of all documented pregnancies were recorded, as 
were the most recently recorded smoking status, weight, and height (including narrative 
comments). The ethnicity of cases and controls, when documented, was also noted. 
4.4.6 Family planning clinic visits 
For the reasons outlined in Chapter 2, permission was sought and obtained to examine 
any family planning clinic records that existed for female cases and controls. Once a 
time had been made to visit the general practitioner of a female case, the local family 
planning clinics (if any) were contacted by telephone and arrangements for viewing any 
records were discussed. At this stage it was possible to supply the name and date of 
birth of the case, but obviously not those of her controls who were yet to be selected. 
On the day of the general practice visit, the family planning clinics were contacted as 
soon as four eligible controls had been identified. If records were found for any of the 
women, the clinic was then visited and information was abstracted using an identical 
data form to that employed during the general practice visit. In all, four cases and 17 
controls had family planning clinic records. 
4.4. 7 Examination of mental health records 
The general practice records of three patients ( all cases) indicated that they were being 
prescribed psychotropic drugs by a psychiatrist, but the specific details of their 
treatment were not recorded. For these patients, the psychiatric records were examined 














4.4.8 Data management 
Coding and data entry 
The information recorded on the data abstraction forms was numerically coded using a 
data dictionary (Appendix B). A simple draft version of this dictionary was developed 
before the data were collected, although decisions about how to code some of the more 
detailed information were not made until all the information had been obtained. As will 
be discussed below, some additions to the dictionary were required because of the 
incomplete nature of some information (for example, the dates on which conditions 
were diagnosed and the duration of prescriptions for contraceptives). 
The information from each data form was coded and entered into Excel spreadsheets by 
a research assistant and me, working independently of each other. If two data 
abstraction forms existed for a female case or control (because she had visited a family 
planning clinic as well as her general practitioner), the information was merged to create 
one record. The same approach was taken for the prescription data obtained from 
psychiatric services. 
Although every documented prescription for oral contraceptives was recorded on the 
data abstraction form, this information was summarised by entering it into the 
spreadsheet as episodes of continuous use. Such episodes were defined as those in 
which consecutive prescriptions for a particular preparation were issued, provided that 
any interval occurring between the date on which the supply from one prescription 
would have run out, and the start date of the next, was less than three months. This 
interval was chosen to be consistent with the assumption underlying the definition of 
current oral contraceptive use - that is, that the increase in venous thromboembolism 
risk might persist for up to three months following discontinuation of use. The start 
date of an episode of continuous use was taken as the date of the first prescription; the 
end date was calculated using the date of the final prescription and adding the number 
of months prescribed on that occasion. If the end date was less than three months 
before the index date, or the supply would have lasted beyond the index date, the 
















There were a few situations in which the information about oral contraceptive use was 
incomplete. These situations, and the rules established to deal with them in a consistent 
manner, are as follows: 
1. The medical practitioner had recorded the date on which a prescription had 
been issued, but not the amount prescribed. 
Normally, users of oral contraceptives are given a three or six-month supply, 
since one box of pills contains three one-month blister packs. Therefore, if the 
duration of a particular prescription was unknown, but there was an obvious 
precedent of prescribing a three or six-month supply, then it was assumed that 
the same amount had been prescribed on this occasion. If no obvious precedent 
existed and no subsequent prescriptions were provided, it was conservatively 
assumed that a three-month supply had been prescribed. Rarely, the provision of 
a six, rather than three, month supply would have made a difference as to 
whether or not a woman was classified as a current user ( or a user in the year 
before the index date). In these situations the uncertainty regarding the end date 
of the episode of use was flagged by coding the woman as a possible current 
user ( or a possible user in the year before the index date). 
2. A woman became pregnant while apparently taking an oral contraceptive. 
In the absence of any other information, the end date of the episode of 
contraceptive use was taken as the date of the pregnancy test. If that date was 
not recorded, the date five weeks after the last menstrual period was taken. 
3. A woman's medical records indicated that she had used oral contraceptives in 
the past, but full details were not provided. 
If the start and end dates of these episodes had been coded as unknown, then any 
information that was available about the calendar year or duration of use would 
have been lost. Two "extra data" columns were therefore created in which to 
record this information. If, for example, the medical practitioner had recorded in 
November 1997 that a woman was taking an oral contraceptive but there was no 
subsequent mention of use, "November 1997" was recorded in both of the extra 











taken the pill for six months in the past, then "six months" was recorded in the 
first extra data column and "pre-April 1992" was recorded in the second. 
For other methods of contraception, information about use during three time periods 
was coded - before the year of interest, at any time during the year before the index 
date, and during the three months before the index date. 
Hormone replacement therapy was also summarised as episodes of continuous use. 
Unlike oral contraceptives, no more than a three-month supply of hormone replacement 
therapy could be issued on one prescription during the study period. Hence, the coding 
proved relatively straightforward. 
A copy of a drug dictionary devised and used by the New Zealand Centre for Adverse 
Reactions Monitoring was used to assign numerical codes to other medicines taken in 
the year before the index date. These codes comprised a prefix and suffix, which 
together identified individual medicines. Moreover, the prefix allowed medicines to be 
identified by pharmacological group. The clinical indication for which each medicine 
was prescribed was also coded, as was the presence or absence of current use. 
Because information about the dates on which medical conditions were first diagnosed 
or treated was sometimes incomplete, the following coding conventions were 
established: 
1. If the month and year only were recorded, the date was taken as the fifteenth day 
of that month and year. 
2. If the year only was recorded, the date was taken as 1 July of that year. 
3. If the decade only was recorded, the date was taken as 1 July of the fifth year 
during that decade. 
4. If the age of a patient was recorded, rather than a date, the date of diagnosis or 
treatment was taken as the date six months after the date that the patient turned 
that age. For example, if the records stated that a patient was diagnosed with a 
condition aged 33 years, then the date on which that person had lived for 33.5 












5. Some doctors had noted that their patient had been diagnosed with a condition 
sometime in the past, but the date of diagnosis was not documented. In this 
situation, the date on which the information was recorded was entered into the 
spreadsheet and the fact that the diagnosis was made sometime before this date 
was flagged by entering the numeric value "1" in an associated date indicator 
box . 
Checking the data 
To check for coding and data entry errors, the separate spreadsheets compiled by the 
research assistant and me were compared using a computer programme written by Mr 
Peter Herbison, a biostatistician in the Department of Preventive and Social Medicine. 
Any inconsistencies between the two spreadsheets were resolved by consensus after 
referring to the original data abstraction forms. 
Preliminary analysis 
Following the steps described above, the data were imported into the SPSS statistical 
package (version 6.1.4). Several new variables were created from the coded data. For 
currently used medicines, the new variables (with their categories in parentheses) were 
as follows: the progestogen contained in oral contraceptives (levonorgestrel / 
desogestrel or gestodene / cyproterone acetate), the hormone replacement therapy 
regimen ( oestrogen-only / sequential combined / continuous combined), the type of 
psychotropic (any/ antipsychotic /antidepressant/ other), and the type of antipsychotic 
(low potency / high potency). Variables were also produced for these medicines to 
indicate ever use (use at any time before the index date), past use (use before, and 
excluding, the three months before the index date), never use, and use in the month 
before the index date. 
In addition, variables were generated to indicate a history of the following: at least one 
live birth, breast cancer, and the presence of a chronic musculoskeletal condition that 
might have affected mobility in the two months before the index date. 
Summary weight variables were created after converting imperial measurements for 
weight or height to the metric scale. In the first of these variables, three categories of 














distribution of the controls. A second weight variable, which included both comments 
and measured weight, was derived by assigning people for whom a comment about 
weight had been made to one of the above categories as appropriate. A third variable 
was created by dividing measured weight into two groups based on the median weight 
of the cases. Each of the three weight variables included a category for missing values. 
Finally, simple frequencies for all variables were produced and the following means 
were computed for cases and controls: age on the index date, number of years spent as a 
member of the general practice, number of years of years spent as a member of the 
practice by history of mental illness, number of years of recorded information, weight, 
and height. The 't-test for equality of means was used to calculate the p-value for any 
differences. The data were then transferred to STATA (version 7.0) in order to 
undertake matched analyses using conditional logistic regression. 
4.4.9 Statistical analysis 
The following logistic regression analyses were undertaken by Mr Peter Herbison, in 
collaboration with me . 
Analyses involving oral contraceptives 
To explore the association between the current use of oral contraceptives and fatal 
pulmonary embolism, the key analyses were restricted to pre-menopausal women who 
did not have a history of venous thromboembolism. Analyses were also undertaken 
from which women were excluded if they had a history of pregnancy or prolonged 
immobility during the two months before the index date. There were no women aged 
15 - 49 years who had a major injury or surgery during the same period. 
Non-users of any oral contraceptives in the three months before the index date were 
taken as the reference group. This group therefore included both never users and past 
users. The association was explored for four categories of oral contraceptives according 
to the progestogen that they contained: any, levonorgestrel, desogestrel or gestodene, 
and cyproterone acetate . 
As the study employed a matched design, a matched analysis was undertaken using 













sparse data. This problem was clearly illustrated by undertaking a stratified analysis 
using the method of Mantel and Haenszel (Mantel and Haenszel 1959): each matched 
set was treated as a separate stratum and a summary odds ratio was estimated for current 
use of any oral contraceptive. Eight of 29 strata contributed no information to this odds 
ratio because the exposure status was concordant ( the case and all four of her controls 
were exposed to an oral contraceptive [one stratum] or neither the case nor any of her 
controls were exposed [seven strata]). This loss of information was exacerbated in 
analyses which explored the association by category of oral contraceptive, and occurred 
in strata where: 
1. The case was a user of an oral contraceptive, but was not taking a 
preparation from the category of interest, and some or none of the controls 
were users of contraceptives in that category. 
2. The case was a non-user, and although some or all of the controls were users 
of an oral contraceptive, none were users of the preparations from the 
category of interest. 
The main purpose of matching is to permit the use of efficient analytical methods to 
control for confounding by the matching factors (Breslow and Day 1980). However, as 
was found in the present study, it can also result in a considerable loss of information 
that can harm efficiency (Rothman and Greenland 1998). Since matching forces the 
controls to be more similar to cases with respect to exposure than they would otherwise 
have been, a matched design requires that the matching be taken into account in the 
analysis otherwise the risk estimate will be biased towards the null value (Breslow and 
Day 1980; Rothman and Greenland 1998). It follows that an unmatched analysis can be 
undertaken provided that the matching factors are adjusted for in the analysis. Hence, in 
the present study, to explore the association between oral contraceptive use and 
pulmonary embolism an unmatched analysis was undertaken using unconditional 
logistic regression, while adjustment was made for age as a continuous variable and the 
standard error was adjusted for clustering by general practice. Adjustment was also 
made for weight category (based on measured weight and comments), but because of 
the small numbers there was limited capacity to explore potential confounding by other 













To determine the total woman-years of oral contraceptive use during the study period, 
contraceptive-supply data were obtained from the Ministry of Health. These data were 
obtained before the study was expanded to include deaths in the final quarter of 1998 
and thus relate to use between 1 January 1990 and 31 August 1998. To estimate the 
absolute risk of dying from pulmonary embolism for current users of oral 
contraceptives, the number of deaths among users between these dates was divided by 
the total woman-years of use. 
Analyses involving psychotropic drugs 
Matched analyses, using conditional logistic regression, were undertaken to examine the 
association between categories of psychotropic drugs ( antipsychotics, antidepressants 
and other) and fatal pulmonary embolism. To check the stability of the estimates thus 
produced, unconditional logistic regression analyses were also undertaken in which 
adjustment was made for the matching factors. The association between psychotropic 
drug use and fatal pulmonary embolism was examined for all subjects, although the key 
analyses were restricted to those without major risk factors for venous 
thromboembolism. The latter group is regarded as the most informative for studying 
adverse effects of medicines (Jick et al. 1998b). 
All estimates were adjusted for weight category (based on measured weight and 
comments), and oral contraceptive use and hormone replacement therapy within three 
months of the index date. In the analyses which examined the association between 
antidepressants and pulmonary embolism, two approaches were employed to deal with 
concurrent use of antipsychotics. In the first, current users of antipsychotics were 
excluded from the analyses. In the second, the odds ratios were adjusted for such use. 
4.4.10 Sample size calculations 
Sample size calculations were undertaken using PS software (Dupont and Plummer 
1998) for a matched case-control design with a case:control ratio of 1:4, alpha of 0.05, a 
correlation coefficient for failure of 0.01, and power of 80%. 
Oral contraceptive analyses 
Using the age-specific prevalence of oral contraceptive use estimated from a recent 













years (and therefore of age-matched controls), the prevalence of exposure among the 
controls was estimated to be 19%. Pulmonary embolism was the underlying cause of 
death in 40 New Zealand women aged 15 - 49 years who died during the study period 
(1 January 1990 and 31 December 1998). Hence, assuming a prevalence of exposure of 
19%, it was calculated that the study would have sufficient power to detect an odds ratio 
of 2.9 for current use of any oral contraceptive. It was anticipated, however, that 
several cases would be excluded from the key analyses because they were post-
menopausal or they had major risk factors for venous thromboembolism. Moreover, 
because of media reports of proposed litigation against doctors who had prescribed 
desogestrel or gestodene oral contraceptives to women who had subsequently developed 
venous thromboembolism (MacK.inven 1999), it was also thought that some general 
practitioners might decline to participate in the study. Therefore, the odds ratios which 











Table 4.2 Number of cases required for the oral contraceptive analyses 














* Assuming a prevalence of exposure of 19% in the control group, a case:control ratio of 1:4, a= 0.05, correlation coefficient for failure = 



















Psychotropic drug analyses 
Based on the life-time prevalence of schizophrenia (Bromet and Fennig 1999), it was 
assumed that the prevalence of antipsychotic use was 1 %. This was likely to be a 
conservative estimate because antipsychotic drugs are also used in the treatment of other 
conditions such as bipolar affective disorder. There were 92 New Zealand residents 
aged 15 - 59 years who died between 1990 and 1998 for whom the underlying cause of 
death was pulmonary embolism. Hence, assuming a prevalence of exposure of 1 %, it 
was calculated that the study would have sufficient power to detect an odds ratio of 6.2. 
However, as in the sample size calculations for the oral contraceptive analyses, it was 
expected that some cases would be excluded from the key analyses because of pre-
existing major risk factors for venous thromboembolism or the unavailability of records. 














Table 4.3 Number of cases required for antipsychotic drug analyses 













* Assuming a prevalence of exposure of 1 % in the control group, a case:control ratio of 1:4, u = 0.05, correlation coefficient for failure = 
















4.4.11 Ethical matters 
The principles of respect for autonomy and the minimisation of harm were observed in 
the design and conduct of this case-control study. Permission to examine the records of 
the cases and controls was obtained from general practitioners and family planning 
clinics, and (for mental health records) from senior medical advisors at the relevant 
hospitals. Individual patients were not approached for consent. Rule 11 of the Health 
Information Privacy Code (Privacy Commissioner 1994) and the Guidance Notes to the 
Code published by the Health Research Council of New Zealand (Health Research 
Council of New Zealand 1996) specify that disclosure of health information, without the 
authorisation of the individuals themselves, is lawful if it is either not desirable or not 
practicable to obtain this authorisation and the following two conditions are met: 
1. The information is to be used for research purposes 
2. The information will not be published in a form which could reasonably be 
expected to identify the individual concerned. 
For deceased cases it was clearly not possible to obtain authorisation. Nor was it 
practicable to obtain authorisation before examining patient records in order to identify 
eligible controls. Once the controls had been selected, it remained impracticable to 
obtain individual consent because some of those chosen might have left the practice 
after the index date. If only those patients who could be traced and gave consent were 
included, the scientific validity of the study could have been compromised and the 
ethical status of the research threatened. 
The information abstracted from the general practice, family planning, and mental 
health records was recorded without names and the data forms were stored in a locked 
filing cabinet. The key which linked the study identification numbers recorded on these 
forms with the names of the cases and controls was stored separately. 

















CHAPTER 5 CASE-CONTROL STUDY OF THE USE OF ORAL 
CONTRACEPTIVES AND PSYCHOTROPIC DRUGS: RESULTS 
5.1 SELECTION OF POTENTIAL CONTROLS AND THE AVAILABILITY OF 
THEIR GENERAL PRACTICE RECORDS 
Of the 70 general practices which had electronic age-sex registers from which controls 
were selected, 54 had an electronic register on the index date. At these practices, all 
patients who had been members of the practice on the index date were included in the 
sampling frame, as well as people who had joined the practice after that date. This 
second group of patients was included in the sampling frame simply because the various 
software packages used by the practices did not permit the quick identification and 
exclusion of such people. In order to determine whether the patients who were selected 
as potential controls were, in fact, members of the practice on the index date, it was then 
necessary to examine their individual records. As can be seen in Table 5.1, the records 
of 46 of those selected had been lost or transferred to another practice and hence it was 
not possible to establish whether they would have been eligible for inclusion. 
Sixteen general practices did not develop electronic age-sex registers until after the 
index date, as shown in Table 5.2. At some practices this meant that any potential 
controls who died or left the practice between the index date and the date on which the 
register was first compiled would not have been included in the sampling frame. At 
others, it is possible that such people could have been selected as potential controls 
because the details of all patients who had attended the practice in the past were 
retrospectively entered into the computer, although the approach to deceased patients 
varied. As shown in Table 5.3, it was not possible to examine the records of nine 
potential controls who were selected from the age-sex registers that were developed 
after the index date - although the true number of potential controls for whom records 
could not be examined is unknown for the reasons just described. Similarly, at the 
practices where controls were selected through random selection of patient records, it 














Table 5.1 General practices which had an electronic age-sex register on the index date, 
numbers of potential controls for whom medical records were missing 
Number of potential controls in practice 








' Records lost or transferred to another practice. 



























Table 5.2 Number of years after index date that other practices first compiled an electronic 
age-sex register 





















Table 5.3 General practices which did not have an electronic age-sex register on the index 
date, number of potential controls for whom medical records were missing 
Number of potential controls in practice 






' Records lost or transferred to another practice. 






















5.2 CHARACTERISTICS OF MALE AND FEMALE CASES AND CONTROLS 
AGED 15 - 59 YEARS 
The demographic characteristics of the 75 cases for whom general practitioner records 
were found, and their controls, are shown in Table 5.4. Twenty-four of the cases 
included in the present case-control study were male and 51 were female. The female 
cases were younger than the male (median ages 43.0 years and 49.5 years respectively). 
The mean times that cases and controls had been members of their general practices 
were very similar (9.9 and 8.7 years respectively), as were the mean numbers of years of 
recorded medical information (13.5 and 12.2 years). Cases and controls who had a 
history of mental illness had been members of their respective practices slightly longer 
(10.3 and 11.5 years respectively) than cases and controls without such a history (9.7 
and 8.3 years). Ethnicity was documented for only 16 (21.3%) cases and 54 (18%) 
controls. 
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Table 5.4 Demographic characteristics of cases and controls 
Cases (n=75) Controls (n=300) 
Sex (number[%]) 
Male 24 (32.0) 96 (32.0) 
'( 
Female 51 (68.0) 204 (68.0) 
( 
Age (years, median) 
All 45.0 45.0 
-( 
,t Male 49.5 49.5 
Female 43.0 43.0 
;.j._ Mean years in practice 
All 9.9 8.7 
Male 10.5 9.5 
,._ 
Female 9.6 8.3 
, 
Mean years of recorded information 
All 13.5 12.2 
Male 13.7 12.8 
,\ Female 13.4 11.9 
~ 
Recorded ethnic group (number [ % ]) 
European 15 (20.0) 30 (10.0) 
" 
;, Maori 10 (3.3) 
Pacific Islands 1 (1.3) 10 (3.3) 
Asian 4 (1.3) 
Other 
















Other characteristics of cases and controls are shown in Table 5.5. Ten cases and two 
controls had a recorded history of venous thromboembolism. Six of these cases, and 
both controls, were diagnosed with deep vein thrombosis alone and the remaining four 
cases had objective evidence of pulmonary embolism. A history of superficial venous 
thrombosis and of varicose veins was also more common among cases. Two cases, and 
no controls, had a documented family history of venous thromboembolism. Cases were 
more likely than controls to have a history of a lower limb musculoskeletal condition 
that might have affected their mobility, acutely or chronically elevated platelet counts, a 
cardiac murmur of uncertain significance, peripheral vascular disease, and chronic renal 
disease. Eight cases had a documented intellectual disability, compared with just one 
control. Pregnancy-induced hypertension was more common among cases, although 
cases and controls had similar rates of hypertension that was unrelated to pregnancy. 
Six controls had a history of cancer, but none had an advanced malignancy. There were 
no cases with advanced cancer because such people did not meet the eligibility criteria 
for the study. Nor were there any cases with a history of cancer (that had apparently 
been cured). 
Although doctors had recorded the weight of 54 (72.0%) cases and 209 (69.7%) 
controls before the index date, the files of only 28 (37.3%) cases and 59 (19.7%) 
controls contained a measurement of height. About half of the female (51.0%) and male 
(54.2%) cases belonged to the highest weight category (> 70 kg in females and 85 kg in 
males), compared with 27.0% and 17.7% of the female and male controls respectively. 
Cases were more likely to have had major risk factors for venous thromboembolism in 
the two months before the index date. Five cases (two of whom had a history of venous 
thromboembolism) were confined to bed or a chair for more than a week. Two of these 
cases had also sustained a major injury. There were no controls who had been injured 
or immobilised during the same period. No cases or controls had a history of travel 
recorded in their general practice, family planning, or mental health records. Three 
controls were pregnant during the two months before the index date and two others had 
major surgery ( one of whom had a history of venous thromboembolism). 
Of those for whom smoking status had been recorded at some time before the index 

















smokers. Although similar proportions of cases and controls were prescribed medicines 
in the year before the index date, cases (62.7%) were more likely than controls (47.3%) 
to be current users of drugs other than contraceptives and hormone replacement therapy. 
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Table 5.5 Other characteristics of cases and controls 
Characteristic Cases Controls 
(n=75) (n=300) 
Recorded history (number [ % ]) 
~~ 
Venous thromboembolism 10 (13.3) 2 (0.07) 
I Superficial venous thrombosis 16 (21.3) 7 (2.3) 
I 
7 
Varicose veins 14 (18.7) 24 (8.0) 
Inflammatory bowel disease 1 (1.3) 1 (0.03) 
Systemic lupus erythematosus 1 (1.3) 
'( 
Hypertension unrelated to pregnancy 12 (16.0) 44 (14.7) 
',;r 
Angina 2 (2.7) 14 (4.7) 
Myocardial infarction 1 (1.3) 5 (1.7) 
Congestive heart failure 2 (2.7) 1 (0.03) 
_,_ 
Stroke 1 (1.3) 
Heart valve disease 3 (1.0) 
Heart murmur, not otherwise specified 9 (12.0) 7 (2.3) 
Cardiac conduction disorders 10 (3.3) 
~ Palpitations, not otherwise specified 2 (2.7) 8 (2.7) 
Peripheral vascular disease 3 (4.0) 2 (0.07) 
Type I diabetes 1 (0.03) 
j. Type II diabetes 2 (2.7) 8 (2.7) 
Chronically elevated platelet count 4 (5.3) 1 (0.03) 
~< Acutely elevated platelet count 4 (5.3) 4 (1.3) 
_\ Antiphospholipid syndrome 1 (0.03) 
> Chronic renal disease 3 (4.0) 2 (0.07) 
Cancer 6 (2.0) 
Intellectual disability 8 (10.7) 1 (0.3) 
>-
Musculoskeletal condition of lower limbs 9 (12.0) 11 (3.7) 
0-
Risk factors in 2 months before index date (number [ % ]) 
> 
Major injury 2 (2.7) 
Prolonged immobility 5 (6.7) 
' ~ 
Surgery 2 (0.07) 
.> 
Pregnancy 3 (1.0) 
Smoking status (number [ % ]) 
Non-smoker 20 (40.8) 75 (41.7) 
-( Smoker 18 (36.7) 69 (38.3) 
-,( Ex-smoker 11 (22.4) 36 (20.0) 
















Pregnancy-induced hypertension (number[% female]) 
Weight category (number[% of sex]) 
Females Low ( < 60 kg) 
Males 
Medium (60- 70 kg) 
High (> 70 kg) 
Weight not measured 
Low(< 75 kg) 
Medium (75 - 85 kg) 
High (> 85 kg) 
Weight not measured 
Prescribed medicines, excluding contraception and HRT (number [%]) 
In year before index date 
In 3 months before index date 
Yes 
Possible 
Recorded family history of venous thromboembolism (number [ % ]) 
















t Comments in the records of three of these controls indicated that one was of average weight and two were overweight. 





























In unadjusted matched analyses (Table 5.6), significantly elevated risks of fatal 
pulmonary embolism were found for people with a history of venous thromboembolism, 
superficial venous thrombosis, varicose veins, pregnancy-induced hypertension, a 
chronic musculoskeletal condition of the lower limbs, and an intellectual disability. The 
relative risk estimates for all these factors were attenuated somewhat once people with a 
history of venous thromboembolism (and the controls of excluded cases) were excluded. 
In an analysis based on the second weight variable described in the previous chapter 
(which classified people into weight categories on the basis of measurements or 
comments), people in the highest weight category and those for whom a record of 
weight was missing had a significantly greater risk of dying from pulmonary embolism 
than those in the lowest weight category. The point estimate for the highest weight 
category increased further in the analysis confined to people without a history of venous 
thromboembolism. Further analyses were undertaken in which measured weight was 
divided into two groups based on the median weight in cases (80 kg in women and 93 
kg in men), rather than the tertiles which were based on the weight of controls. People 
whose weight was above the median, and those with missing values, had a greater risk 






























Weight category based on median 




' Based on 75 cases and 300 controls. 
t Based on 65 cases and 259 controls. 
Unadjusted matched 
odds ratios (95 % Cl), 
all subjects* 
37.6 (4.8 - 294.7) 
14.3 (4.7 - 43.1) 
2.7 (1.3 - 5.7) 
3.6 (1.0 - 12.7) 
24.0 (2.9 - 199.3) 
3.6 (1.4 - 9.2) 
1.0 
3.2 (0.8 - 12.5) 
12.8 (3.6 - 45.1) 
4.9 (1.3 - 18.0) 
1.0 
5.4 (2.7 - 10.8) 
1.7 (0.8 - 3.4) 
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Unadjusted matched odds ratios 
(95 % CI), subjects without a history 
of venous thromboembolism t 
9.3 (2.9 - 29.7) 
1.8 (0.8 - 4.3) 
2.0 (0.5 - 8.7) 
20.0 (2.3 - 171.2) 
2.9 (1.1 - 7.8) 
1.0 
3.3 (0.6-17.3) 
15.8 (3.5 - 72.4) 
6.9 (1.5 - 32.5) 
1.0 
6.6 (3.0- 14.6) 
2.1 (1.0 - 4.6) 
*Based on measured weight and comments about weight. Females with measured weight of< 60 kg, 60- 70 kg, and> 70 kg were classified 
as being of low, medium, and high weight respectively. For males the corresponding weight categories were< 75 kg, 75 - 85 kg, and> 85 
kg respectively. One control for whom weight was not measured was assigned to the medium weight category, and two cases and three 
controls were assigned to the high weight category, on the basis of comments recorded in their medical records. 
§ The control who was classified as being in the medium weight category on the basis of comments recorded in medical records is excluded 
from the second analysis because her case had a history of venous thromboembolism. 
II One case who was classified as being in the high weight category on the basis of comments recorded in medical records is excluded from 
the second analysis because she had a history of venous thromboembolism. 














5.3 ORAL CONTRACEPTIVES 
5.3.1 Characteristics of female cases and controls aged 15 - 49 years 
Thirty-three female cases were aged between 15 and 49 years on the index date; the 
median age of these cases (and their controls) was 33.0 years. The characteristics of 
this subset of cases and controls are shown in Table 5.7. Three cases had a history of 
venous thromboembolism, one of whom was also post-menopausal and had a history of 
prolonged immobility in the two months before the index date. A fourth case had spina 
bifida and was confined to a wheelchair. Three controls were pregnant in the three 
months before the index date and eight were post-menopausal. A further three controls 
may (according to the date of their last menstrual period) have been pregnant during the 
three months before the index date, but no information about the outcome of the 
pregnancy was recorded. There were no cases or controls who had suffered a major 
injury in the two months before the index date, and no controls who had been 
immobilised or undergone surgery. Fifteen (45.5%) cases either weighed more than 70 
kg (n=14) or were noted to be overweight (n=l), as compared with 30 (22.7%) controls. 
Cases (54.5%) were more likely than controls ( 42.4%) to have taken medications other 
than contraceptives and hormone replacement therapy in the three months before the 
index date. Slightly smaller proportions of cases had ever been pregnant and had had at 
least one live birth. 
Only one woman, a 48 year old control with hot flushes in whom menstruation had not 
ceased, was a current user of hormone replacement therapy ( conjugated equine 
oestrogen 0.625mg and sequential medroxyprogesterone 10mg). Four other women 
(one case and three controls) had been prescribed hormone replacement therapy in the 
past. The case was prescribed an oral contraceptive followed by a six-week course of 
hormone replacement therapy about eighteen months before the index date to treat 
menorrhagia. One control was prescribed a three-month supply of hormone 
replacement therapy following a hysterectomy and oophorectomy two years before the 
index date. She was classified as being post-menopausal and was excluded from the 
key analyses. Another control was given a three-month course one year before the 
index date by a gynaecologist to treat break-through bleeding that was attributed to oral 
contraceptive pill-induced endometrial atrophy. She subsequently restarted the oral 
contraceptive pill and was a current user. The third control was prescribed a three-
















periods. Two months before the index date it was noted that she was continuing to 
menstruate. 
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Table 5.7 Characteristics of female cases aged 15 - 49 years 
Characteristic Cases Controls 
(n=33) (n=132) 
Recorded history (number[%]) 
Venous thromboembolism 3 (9.0) 
-~ 
Superficial venous thrombosis 1 (3.0) 1 (0.8) 
~ 
Varicose veins 2 (6.1) 4 (3.0) 
Inflammatory bowel disease 
Systemic lupus erythematosus 1 (3.0) 
-< 
Hypertension unrelated to pregnancy 1 (3.0) 7 (5.3) 
V 
Pregnancy-induced hypertension 1 (3.0) 6 (4.5) 
Angina 1 (0.8) 
Myocardial infarction 1 (0.8) 
d Congestive heart failure 
,( Stroke 
Heart valve disease 1 (0.8) 
Heart murmur, not otherwise specified 4 (12.1) 5 (3.8) 
;)'. Cardiac conduction disorders 1 (3.0) 2 (1.5) 
,. Palpitations, not otherwise specified 1 (0.8) 
Peripheral vascular disease 2 (6.1) 1 (0.8) 
Type I diabetes 1 (0.8) 
Type II diabetes 1 (3.0) 1 (0.8) 
A 
Chronically elevated platelet count 3 (9.0) 
J, 
Acutely elevated platelet count 1 (3.0) 2 (1.5) 
Antiphospholipid syndrome 1 (0.8) 
Chronic renal disease 2 (6.1) 2 (1.5) 
Cancer 
t 
Intellectual disability 5 (15.2) 1 (0.8) 
D-
Risk factors in 2 months before index date (number[%]) 
Major injury 
Prolonged immobility 2 (6.1) 
Surgery ,, 
Pregnancy 3 (2.3) 
Smoking status (number[%]) 
Non-smoker 8 (24.2) 35 (26.5) 
-< Smoker 7 (21.2) 33 (25.0) 
;1 Ex-smoker 4 (12.1) 10 (7.6) 













Weight category (number[%]) 
Low(< 60kg) 
Medium (60- 70 kg) 
High (> 70 kg) 
Weight not measured 
Prescribed medicines, excluding contraception and HRT 
In year before index date 










Hysterectomy and bilateral oophorectomy 
Cyclophosphamide ( antineoplastic) 
Peri-menopausal symptoms 






























' Comments in the records of one of these cases indicated that she was overweight. She had a history of venous thromboembolism and hence 
was excluded from the key analyses. 











5.3.2 Ever and current use of contraceptive methods 
Table 5.8 provides a summary of the various methods of contraception used by cases 
and controls before the index date. Twenty-five (78.1 %) cases and 60 (48.4%) controls 
were current users of at least one method. Oral contraceptives were the most commonly 
used past and current method. Twenty-eight (84.8%) cases and 88 (66.7%) controls had 
taken the pill at some time before the index date. Among pre-menopausal women, 20 
(62.5%) cases and 26 (21.0%) controls were current users. Seven (21.2%) cases and 40 
(30.3%) controls had used the progestogen-only pill, although only 3% of the pre-
menopausal women in each group were current users. Cases were less likely than 
controls to be current users of medroxyprogesterone acetate, intrauterine devices, and 
female sterilisation. There were similar proportions of pre-menopausal cases and 
controls in the three months before the index date whose partners had had a vasectomy. 
Because these data refer to recorded contraceptive use, it is likely that the prevalence of 
condom use has been underestimated because condoms can be purchased without a 
prescription in New Zealand. It is also possible that the use of sterilisation, especially 
of male partners, has been underestimated. However, it is not expected that this would 
have differed between cases and controls. Information about the other contraceptive 












Table 5.8 Ever and current use of contraceptive methods by female cases and controls aged 
15 -49 years 
Method Ever use Current use 
(number[% of all women]) (number[% of pre-menopausal]) 
Cases Controls Cases Controls 
(n=33) (n=132) (n=32) (n=124) 
Oral contraceptives 28 (84.8) 88 (66.7) 20 (62.5) 26 (21.0) 
Progestogen-only pill 7 (21.2) 40 (30.3) 1 (3.1) 4 (3.2) 
Medroxyprogesterone acetate 5 (15.2) 16(12.1) 1 (3.1) 9 (7.3) 
Morning after pill 3 (9.1) 16 (12.1) 
Intrauterine device 4 (12.1) 15 (11.4) 3 (2.4) 
Diaphragm 1 (3.0) 3 (2.3) 
Condoms * 6 (18.2) 32 (24.2) 1 (3.1) 1 (0.8) 
Female sterilisation t 1 (3.0) 14 (10.6) 1 (3.1) 10 (8.1) 
Partner vasectomi 4 (12.1) 8 (6.1) 2 (6.3) 7 (5.6) 
Natural family planning 2 (6.1) 2 (1.5) 
Other 1 (3.0) 8 (6.1) 1 (0.8) 
' The case and control who were current users of condoms were also using oral contraceptives. 
t Four controls who had undergone female sterilisation were post-menopausal in the three months before the index date. 
1 The partner of one case had a reversal of his vasectomy, and in the three months before the index date one case and one control (whose 











5.3.3 Ever use of oral contraceptives 
Table 5.9 shows the number of different oral contraceptive preparations ever used by 
cases and controls. Formulations that contained the same progestogen but different 
doses of the progestogen and / or oestrogen components were counted as different 
preparations. The majority of both cases (67.9%) and controls (71.6%) had been 
prescribed, at most, two different preparations before the index date. If preparations 
containing the same progestogen, but different doses of oestrogen and / or progestogen, 
were counted only once, 20 (71.4%) cases and 72 (81.8%) controls had been exposed to 
a maximum of two different progestogens. 
Table 5 .10 shows the numbers of cases and controls who had been prescribed the 
various types of progestogen at any time before the index date. Eighteen (64.3%) cases 
and 40 (45.5%) controls had been prescribed an oral contraceptive containing 
desogestrel. Gestodene was less commonly prescribed for both cases (25.0%) and 
controls (27.3%). Half of the controls had been prescribed levonorgestrel-containing 
oral contraceptives as compared with only a quarter of the cases. Cases were twice as 




















Table 5.9 Number of different oral contraceptive preparations ever used by cases and controls 
aged 15 - 49 years 
Number of preparations Progestogen contained in prescribed preparation * Ever users 
prescribed (number [ % ]) 
Cases Controls 
(n=28) (n=88) 
One Desogestrel 3 11 
Gestodene 3 4 
Levonorgestrel 2 8 
Cyproterone acetate 1 1 
N orethisterone 4 
Lynoestrenol 2 
Norgestrel 1 
Preparation not specified 2 2 
Total(% ever users) 11 (39.3) 33 (37.5) 
Two Desogestrel, desogestrel 1 1 
Desogestrel, gestodene 3 3 
Desogestrel, levonorgestrel 1 3 
Desogestrel, norethisterone 3 
Desogestrel, lynoestrenol 1 
Desogestrel, preparation not specified 2 2 
Gestodene, levonorgestrel 5 
Gestodene, preparation not specified - 1 
Levonorgestrel, levonorgestrel 3 
Levonorgestrel, norethisterone 2 
Levonorgestrel, lynoestrenol 1 
Levonorgestrel, megestrol acetate 1 
Levonorgestrel, preparation not specified 4 
N orethisterone, norgestrel 1 
Total(% ever users) 8 (28.6) 30 (34.1) 
Three Desogestrel, desogestrel, gestodene 2 
Desogestrel, desogestrel, levonorgestrel 1 
Desogestrel, gestodene, levonorgestrel 1 
Desogestrel, gestodene, preparation not specified 1 
Desogestrel, levonorgestrel, levonorgestrel 1 
Desogestrel, levonorgestrel, preparation not specified 1 
Desogestrel, norethisterone, preparation not specified 1 
Desogestrel, levonorgestrel, lynoestrenol 1 
Desogestrel, lynoestrenol, lynoestrenol 1 
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Three (ctd) Gestodene. levonorgestrel. levonorgestrel 1 
Gestodene, lynoestrenol, preparation not specified 1 
Levonorgestrel, levonorgestrel, norethisterone 1 
Levonorgestrel, levonorgestrel, norgestrel 1 
Levonorgestrel, lynoestrenol, preparation not specified 1 
,_( Total{% ever users) 5 {17.9} 10 {11.4} 
Four Desogestrel, desogestrel, gestodene, levonorgestrel 2 
Desogestrel, desogestrel, levonorgestrel, norethisterone 1 
/ 
Desogestrel, levonorgestrel, levonorgestrel, 1 
levonorgestrel 
c( 
Desogestrel, levonorgestrel, levonorgestrel, - 2 
norethisterone 
Desogestrel, levonorgestrel, norethisterone, ethynodiol 1 
diacetate 
Desogestrel, cyproterone acetate, norethisterone, 1 
lynoestrenol 
y Gestodene, levonorgestrel, lynoestrenol, preparation 1 
not specified 
Levonorgestrel, levonorgestrel, levonorgestrel, 1 
ethynodiol diacetate 
Levonorgestrel, levonorgestrel, norethisterone, 1 
lynoestrenol 
i Levonorgestrel, levonorgestrel, norethisterone, 1 
preparation not specified 
Total{% ever users} 2 (7.1) 10 {11.4} 
Five Desogestrel, desogestrel, gestodene, lynoestrenol, 1 
preparation not specified 
Desogestrel, levonorgestrel, levonorestrel, 1 
.1-
norethisterone, lynoestrenol 
Desogestrel, levonorgestrel, levonorgestrel, 1 
lynoestrenol, ethynodiol diacetate 
Total(% ever users) 1 (3.6) 2 (2.3) 
Six Desogestrel, desogestrel, gestodene, cyproterone 1 
acetate, levonorgestrel, lynoestrenol 
Levonorgestrel, levonorgestrel, norethisterone, 1 
lynoestrenol, norgestrel, megestrol 
Total(% ever users} 2 {2.3) 
Seven Desogestrel, desogestrel, gestodene, norethisterone, 1 
norethisterone, lynoestrenol, norgestrel 
Desogestrel, desogestrel, levonorgestrel, 1 
:,.>-- levonorgestrel, norethisterone, lynoestrenol, ethynodiol 
diacetate 
:; Total(% ever users) 1 (3.6) 1 (1.1) 














Table 5.10 Progestogens contained in oral contraceptives ever used by cases and controls 





















* 28 cases were ever users of oral contraceptives. 
t 88 controls were ever users of oral contraceptives. 
























5.3.4 Current use of oral contraceptives 
Details of the oral contraceptive preparations that were used by cases and controls 
during the three months before the index date are shown in Table 5 .11. Seventy-five 
percent of the current pill use by cases was of oral contraceptives containing desogestrel 
or gestodene, as compared with 61.5% of the controls. 
An additional case and three controls were classified as possible users of oral 
contraceptives in the three months before the index date. A 30 year old case, the 
woman who was confined to a wheelchair because of spina bifida, had been prescribed 
a desogestrel-containing oral contraceptive for a few years in the past. She had also 
used the morning after pill. Ten weeks before the index date her general practitioner 
noted that she required contraception, but did not record whether a prescription for any 
method had been provided. 
Three weeks before the index date a gynaecologist, to whom a 20 year old control had 
been referred regarding pelvic pain, wrote to the patient's general practitioner and 
related a history of poor tolerance to oral contraceptives, of which she had tried several, 
including one containing desogestrel. This woman had only recently joined her general 
practice and there was no other documented history of oral contraceptive use. 
Four months before index date the general practitioner of a 29 year old control noted 
that she was "on the pill". Seven months earlier she had been prescribed a six-month 
supply of a pill containing desogestrel - a preparation that she had taken, with a few 
breaks, over a period of six years. 
Five months before the index date the general practitioner of a 23 year old control noted 
that she was "still taking" an oral contraceptive containing gestodene. The records 
indicated that she had been given a three-month supply of this preparation four months 
earlier when she had switched from a desogestrel-containing pill which she had taken 
since her early teens. 
Tables 5.12 and 5.13 show the duration of the current episode of use for two groups of 
cases and controls: those for whom the current episode was the first ever documented 








Table 5.12, there were only three cases and seven controls who were so-called "first-
time users". Apart from one case who had been first prescribed the pill three months 
before the index date, and two controls who had received their first prescription a few 
days before the index date, all of the women had been users for at least 15 months. 
Among current users who had had previous episodes of oral contraceptive use, four 
(23.5%) of 17 cases and four (21.0%) of 19 controls had restarted the pill in the three 







Table 5.11 Current and possible current use of oral contraceptive preparations by cases and 
controls aged 15 - 49 years by preparation 
Preparation Current use Possible current use 
(number) (number) 
Progestogen Oestrogen Cases Controls Cases Controls 
Norethisterone 500µg Ethinyloestradiol 35µg 1 
Levonorgestrel 150µg Ethinyloestradiol 30µg 2 4* 
Levonorgestrel 125µg Ethinyloestradiol 50µg 1 
Levonorgestrel 250µg Ethinyloestradiol 50µg 1 
Levonorgestrel Ethinyloestradiol 30/40/30µg 1 2 
50/75/125µg 
Desogestrel 150µg Ethinyloestradiol 20µg 6 5t 1 
Desogestrel 150µg Ethinyloestradiol 30µg 4 5 
Desogestrel 25/125µg Ethinyloestradiol 40/30µg 1* 
Gestodene 75µg Ethinyloestradiol 30µg 5 5 1 
Cyproterone acetate Ethinyloestradiol 35µg 2§ 1 
2000µg 
Unknown 1 1 
Total 20 26 1 3 
' Two of these controls were matched with a case with a history of venous thromboembolism and are therefore excluded from the matched 
analyses. 
t One of these controls conceived while apparently taking the pill and is therefore excluded from analyses from which women who were 
pregnant in the two months were excluded. 
* During the three months before the index date, this woman switched from a preparation containing gestodene 75µg and ethinyloestradiol 
30µg to the biphasic desogestrel-containing pill. 
§ During the three months before the index date, one of these cases switched from a preparation containing desogestrel 150µg and 
ethinyloestradiol 30µg to the preparation containing cyproterone acetate. 
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Table 5.12 Current users of oral contraceptives for whom this was the first episode of use 
Age (years) Preparation Duration of use 
Cases (n=3) 
19.7 Gestodene 75µg / Ethinyloestradiol 30µg 3 months 
' 
22.8 Desogestrel 150µg / Ethinyloestradiol 20µg 18 months 
·,/ 
26.7 Gestodene 75µg / Ethinyloestradiol 30µg 3 years 
( Controls (n=7) 
20.0 Gestodene 75µg / Ethinyloestradiol 30µg 21 months 
' 
20.3 Desogestrel 150µg / Ethinyloestradiol 30µg 15 months 
26.4 Levonorgestrel 150µg / Ethinyloestradiol 30µg 3.6 months 
:,-
28.8 Desogestrel 150µg / Ethinyloestradiol 30µg 2 days 
;, 29.2 Norethisterone 500µg / Ethinyloestradiol 35µg 5 years 
29.9 Cyproterone acetate 2000µg / Ethinyloestradiol 35µg 32months 












Table 5.13 Duration of current episode of use of oral contraceptives, women with previous 
episodes of use 
Duration of current episode of use Cases Controls 
< 1 month 2* 3t 
1-2 months 2 1 
3-5 months 2 2+ 
6-8 months 3§ 4 
9-11 months 3 1 
12 - 23 months 3 5 
2': 24 months 211 3'll 
Total 17 19 
' One case switched directly from another preparation to the one she was taking on the index date. 
t One control switched directly from another preparation to the one she was taking on the index date. 
* One control switched directly from another preparation to the one she was taking on the index date. 
§ One case switched directly from another preparation to the one she was taking on the index date. 
II One case switched directly from another preparation to the one she was taking on the index date. 









5.3.5 Estimated relative risk of fatal pulmonary embolism in current users of oral 
contraceptives 
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As was discussed in the previous chapter, a matched analysis produced unstable 
estimates of the risk of fatal pulmonary embolism in current users of oral 
contraceptives. Hence, unmatched analyses were undertaken, using unconditional 
logistic regression, and the matching factors (age and general practice) were accounted 
for in the analyses. Post-menopausal women and those with a history of venous 
thromboembolism were excluded from all analyses. In additional analyses, those who 
were pregnant or immobilised during the two months before the index date were also 
excluded. One case and five controls had reported peri-rnenopausal symptoms (such as 
hot flushes and changes in menstruation) before the index date. It was decided not to 
exclude these women (apart from one control who was excluded because her case had a 
history of venous thromboembolism), as low-dose oral contraceptives were sometimes 
prescribed for women with such symptoms during the study period. Similarly, the pre-
menopausal control who was a current user of hormone replacement therapy, and the 
pre-menopausal case and controls who were past users, were not excluded. 
Tables 5.14 - 5.16 show the key results. In the first of these analyses, shown in Table 
5.14, only those women who were post-menopausal or had a history of venous 
thromboembolism were excluded. Non-users (never and past users combined) were the 
reference category. The matching factors (age and general practice) were accounted for 
by adjusting the odds ratios for age as a continuous variable and adjusting the standard 
errors for clustering by practice. As expected, if these factors were ignored, the odds 
ratios were biased towards the null value. Hence, the unadjusted odds ratio for current 
use of any oral contraceptive was 7.5 (95% CI 3.1 - 18.1), whereas the estimate 
adjusted for age and clustering by practice was 10.1 (95% CI 3.7 - 27.3). Adjusting for 
the weight category had little impact (odds ratio 10.7 [95% CI 3.8 - 30.2]). Current use 
of antipsychotic drugs did not confound the association. 
When controls who were pregnant during the two months before the index date (which 
included one control who had also taken the pill during that period) were excluded 
(Table 5.15), the odds ratio (adjusted for age, weight category, and clustering by 
practice) did not change (10.7 [95% CI 3.7 - 30.5]). If the case who was confined to a 









was 13.1 (95% CI 4.4 - 39.0) (Table 5.16). Excluding the controls of the excluded 
cases had minimal impact on the odds ratio, although the precision of the estimate was 
naturally decreased (odds ratio 13.8 [95% CI 4.6 - 41.4]). 
When the possible users of oral contraceptives were recoded as current users, and four 
groups of women were excluded (those who were post-menopausal or had a history of 
venous thromboembolism, and those who were immobilised or pregnant in the two 
months before the index date), the odds ratio (adjusted for age, weight category, and 
clustered on practice) was 12.4 (95% CI 4.0 - 38.5). 
In all analyses, current users of oral contraceptives containing levonorgestrel had about 
a five-fold increased risk of dying from pulmonary embolism when compared with non-
users. As can be seen in Table 5.16, when women who were post-menopausal or had a 
history of venous thromboembolism and those who were immobilised or pregnant in the 
two months before the index date were excluded, the adjusted odds ratio was 5.9 (95% 
CI 1.4 - 25.6). Pills containing desogestrel or gestodene carried a higher risk; the 
adjusted odds ratio for these preparations was 18.8 (95% CI 4.9 - 71.3). The greatest 
risk was estimated for users of contraceptives containing cyproterone acetate; the 
adjusted odds ratio was 20.1 (95% CI 4.4- 91.4) . 
An analysis was also undertaken in which current use was re-defined as prescribed use 
during the month before the index date (Table 5.17). This analysis, in which one case 
and four controls were re-classified as non-users, produced results that were consistent 
with those obtained for use during the three months before the index date. After 
excluding women who were post-menopausal or had a history of venous 
thromboembolism and those who were immobilised or pregnant in the two months 
before the index date, the odds ratio for use of any oral contraceptive was 10.7 (95% CI 













Table 5.14 Current use of oral contraceptives and fatal pulmonary embolism, excluding 
women who were post-menopausal or had a history of venous thromboembolism 
Progestogen in Cases Controls Unadjusted odds Adjusted odds Adjusted odds 
oral contraceptive (n=30) (n=124) ratio (95 % Cl) ratio (95 % CI)* ratio (95 % CI) t 
Non-user 10 98 1.0 1.0 1.0 
Levonorgestrel 3 8 3.7 (0.8 - 16.3) 4.9 (1.3 - 18.9) 5.0 (1.2 - 21.4) 
Desogestrel or 15 16 9.3 (3.6 - 24.2) 12.6 (3.7 - 42.4) 15.2 (4.3 - 53.3) 
gestodene 
Cyproterone 2 1 19.8 (1.6 - 238.1) 26.1 ( 6.4 - 105 .9) 14.9 (3.2 - 68.8) 
acetate 
All types 20 26* 7.5 (3.1-18.1) 10.1 (3.7 - 27.3) 10.7 (3.8 - 30.2) 
' Adjusted for age as a continuous variable and clustered on general practice. 
t Adjusted for age as a continuous variable, weight (four categories, including missing values), and clustered on general practice. 














Table 5.15 Current use of oral contraceptives and fatal pulmonary embolism, excluding 
women who were post-menopausal or had a history of venous thromboembolism, and those 
who were pregnant in the two months before the index date 
Progestogen in Cases Controls Unadjusted odds Adjusted odds Adjusted odds 
oral contraceptive (n=30) (n=121) ratio (95 % Cl) ratio (95 % Cl) * ratio (95 % Cl) t 
Non-user 10 96 1.0 1.0 1.0 
Levonorgestrel 3 8 3.6 (0.8 - 15.9) 4.8 (1.2 - 18.6) 4.9 (1.1 - 20.7) 
Desogestrel or 15 15* 9.7 (3.7 - 25.5) 13.2 (3.7 - 47.2) 15.5 (4.3 - 55.7) 
gestodene 
Cyproterone 2 1 19.4 (1.6 - 233.3) 25.7 (6.3 - 104.3) 14.6 (3.1 - 67.7) 
acetate 
All types 20 25§ 7.7 (3.2 - 18.5) 10.3 (3.7 - 28.5) 10.7 (3.7 - 30.5) 
-
' Adjusted for age as a continuous variable and clustered on general practice. 
t Adjusted for age as a continuous variable, weight (four categories, including missing values), and clustered on general practice. 
* One control who was taking a desogestrel-containing oral contraceptive was also pregnant during the two months before the index date and 
was therefore excluded from these analyses. 













Table 5.16 Current use of oral contraceptives and fatal pulmonary embolism, excluding 
women who were post-menopausal or had a history of venous thromboembolism, and those 
who were immobilised or pregnant in the two months before the index date 
Progestogen in Cases Controls Unadjusted odds Adjusted odds Adjusted odds 
oral contraceptive (n=29) (n=121) ratio (95 % Cl) ratio (95 % CI)* ratio (95 % Cl) t 
Non-user 9 96 1.0 1.0 1.0 
Levonorgestrel 3 8 4.0 (0.9 - 18.0) 5.7 (1.4 - 22.6) 5.9 (1.4- 25.6) 
Desogestrel or 15 15* 10.8 (4.0 - 29.0) 15.8 (4.3 - 58.0) 18.8 (4.9 - 71.3) 
gestodene 
Cyproterone 2 1 21.6 (1.8 - 261.5) 30.5 (7.4 (125.0) 20.1 (4.4 - 91.4) 
acetate 
All types 20 25§ 8.5 (3.5 - 21.0) 12.3 (4.3 - 35.0) 13.1 (4.4- 39.0) 
-
* Adjusted for age as a continuous variable and clustered on general practice. 
t Adjusted for age as a continuous variable, weight (four categories, including missing values), and clustered on general practice. 
* One control who was taking a desogestrel-containing oral contraceptive was also pregnant during the two months before the index date and 
was therefore excluded from these analyses. 








Table 5.17 Use of oral contraceptives in the month before the index date and fatal pulmonary 
embolism, excluding women who were post-menopausal or had a history of venous 
thromboembolism, and those who were immobilised or pregnant in the two months before the 
index date 
Progestogen in Cases Controls Unadjusted odds Adjusted odds Adjusted odds 
oral contraceptive (n=29) (n=121) ratio (95 % Cl) ratio (95 % Cl)* ratio (95 % Cl) t 
Non-user 10 99 1.0 1.0 1.0 
Levonorgestrel 2 7 2.9 (0.5 - 15.6) 3.5 (0.7 -17.3) 3.0 (0.7 - 13.8) 
Desogestrel or 15 13* 11.5 (4.3 - 31.0) 14.9 (4.3 - 51.9) 17.3 (4.6- 64.6) 
gestodene 
Cyproterone 2 1 20.0 (1.7 - 240.5) 25.5 (6.2 - 104.7) 16.6 (3.7 - 74.7) 
acetate 
All types 19 22§ 8.6 (3.5 - 20.9) 10.8 (3.9 - 29.7) 10.7 (3.7 - 30.6) 
' Adjusted for age as a continuous variable and clustered on general practice. 
t Adjusted for age as a continuous variable, weight (four categories, including missing values), and clustered on general practice. 
* One control who was taking a desogestrel-containing oral contraceptive was also pregnant during the two months before the index date and 
was therefore excluded from these analyses. 
















Absolute risk of fatal pulmonary embolism in current users of oral contraceptives 
Contraceptive-supply data obtained from the Ministry of Health showed that there were 
up to 1,717,153 woman-years of use of oral contraceptives between 1 January 1990 and 
31 August 1998. During that period, 17 of the oral contraceptive users in the present 
study died from pulmonary embolism. A further death from pulmonary embolism 
(confirmed by necropsy) during the same period, of a woman taking an oral 
contraceptive containing desogestrel, was notified to the Centre for Adverse Reactions 
Monitoring. This death had been miscoded in national mortality data. Hence, the 
absolute risk of death from idiopathic pulmonary embolism in women taking oral 
contraceptives was estimated to be 10.5 (95% CI 6.2 - 16.6) per million woman-years. 
It is possible that this represents an underestimate of the true mortality, since it is not 
known whether any of the seven women aged 15 - 49 years for whom general 
practitioner records could not be located were current users of oral contraceptives. 
5.3.6 Cases reported to the Centre for Adverse Reactions Monitoring 
Only seven (35%) of the 20 deaths identified in the present study that occurred between 
1 January and 31 December 1998 among women using oral contraceptives had been 
reported to the Centre for Adverse Reactions Monitoring . 
5.4 HORMONE REPLACEMENT THERAPY 
5.4.1 Introduction 
Findings regarding hormone replacement therapy will be presented briefly, even though 
it was recognised that the study would have insufficient power to look at this issue. In 
previous surveys of hormone replacement therapy among New Zealand women during 
the study period, the highest proportions of current users were found among women 
aged 50 - 54 years and 55 - 59 years (North and Sharples 2001). For this reason, 
analyses exploring the association between hormone replacement therapy and fatal 
pulmonary embolism were confined to women aged 50 - 59 years. 
5.4.2 Characteristics off emale cases and controls aged 50 - 59 years 
Eighteen female cases were aged between 50 and 59 years on the index date; the median 










a history of venous thromboembolism. One of the two controls had also had surgery in 
the two months before the index date and, in addition, was matched to a case with a 
history of venous thromboembolism. A third control had surgery in the two months 
before the index date. These women were all excluded from the key analyses. Two 
controls who had a history of breast cancer were also excluded because the prescription 
of hormone replacement therapy was generally contraindicated for women with such 
malignancies . 
A documented history of condom use during the three months before the index date was 
found for one case and four controls. No other women were recorded as using 
contraception during that period. Sixteen (88.9%) cases and 48 (66.7%) controls were 
current users of medicines other than hormone replacement therapy during the three 
months before the index date. 
5.4.3 Ever use of hormone replacement therapy 
Ten (55.6%) cases and 40 (55.6%) controls had ever used hormone replacement therapy 
before the index date. Table 5.18 shows the various regimens that were used by these 
women. Oestrogen-only regimens were the most commonly prescribed, and had been 
used at some time before the index date by eight ( 44.4%) cases and 26 (36.1 % ) controls. 
Six cases and 15 controls had a recorded history of hysterectomy; none of these women 
had taken hormone replacement before their surgery (Table 5.19). Of the four cases and 
25 controls with no recorded history of hysterectomy, two cases and 13 controls had 














Table 5.18 Ever use of hormone replacement therapy by female cases and controls aged 50 -
59 years 
Regimens used Ever use (number [ % ]) 
Cases (n=18) Controls (n=72) 
Oestrogen-only 6 (33.3) 17 (23.6) 
Sequential combined oestrogen / progestogen 2 (11.1) 9 (12.5) 
Continuous combined oestrogen / progestogen 3 (4.2) 
Oestrogen-only and sequential combined oestrogen/ 2 (11.1) 5 (6.9) 
progestogen 
Oestrogen-only, sequential, and continuous combined 2 (2.8) 
oestrogen / progestogen 
Oestrogen-only and continuous combined oestrogen/ 2 (2.8) 
progestogen 
Sequential combined and continuous combined 1 (1.4) 
oestrogen / progestogen 
Sequential combined oestrogen / progestogen and 1 (1.4) 
testosterone 

















Table 5.19 Hormone replacement therapy regimens ever used by history of hysterectomy 
Regimens ever used Cases (n=18) Controls (n=72) 
No record of Post-hysterectomy * No record of Post-hysterectomy * 
hysterectomy hysterectomy 
Oestrogen-only 2 4 7 
Combined oestrogen / 2 12 
progestogen t 
Oestrogen-only and 2 6 
combined oestrogen / 
progestogen 
Total 4 6 25 
'No cases or controls used hormone replacement therapy before undergoing a hysterectomy. 
t Sequential or continuous combined regimens. 





















5.4.4 Current use of hormone replacement therapy 
Six cases and 15 controls were current users of hormone replacement therapy (Table 
5.20). Two of these women (one case and one control) had a history of deep vein 
thrombosis. The control had also undergone surgery in the two months before the index 
date. There were no possible users of hormone replacement therapy in the three months 


















Table 5.20 Current use of hormone replacement therapy 
Regimen Current use 
Oestrogen Progestogen Cases Controls 
(n=18) (n=72) 
Oestrogen-only 
Conjugated equine oestrogen 0.3mg 1 
Conjugated equine oestrogen 0.625mg 3* 3t 
Conjugated equine oestrogen 1.25mg 1 1 
Oestradiol, dose not specified 1 
Oestradiol TTS lOOµg - 1 
Sequential combined 
Conjugated equine oestrogen 0.625mg Medroxyprogesterone acetate 10mg 1 
Conjugated equine oestrogen 0.625mg Norgestrel 0.15mg 1 
Conjugated equine oestrogen 1.25mg Norgestrel 0.3mg 1* 
Ethinyloestradiol 0.01mg Medroxyprogesterone acetate 5mg 1 
Oestradiol TTS 25µg Medroxyprogesterone acetate 5mg 1 
Oestradiol TTS 50µg Medroxyprogesterone acetate 5mg 1§ 
Oestradiol TTS 50µg Norethisterone acetate 1mg 1 
Oestradiol valerate 3mg Norgestrel 0.5mg 1 
Continuous combined 
Conjugated equine oestrogen 0.625mg Medroxyprogesterone acetate 2.5mg 1 
Oestradiol 2mg Norethisterone acetate 1mg 1 
Total 6 15 
' One case had a history of venous thromboembolism. During the three months before the index date, the doctor of this case changed her 
regimen from 0.3mg of conjugated equine oestrogen to 0.625mg. 
t One control had a history of venous thromboembolism ( as did her case) and of surgery in the two months before the index date. 
"During the three months before the index date, the doctor of this case changed her regimen from conjugated equine oestrogen 0.625mg plus 
norgestrel 0.15mg to conjugated equine oestrogen 1.25mg plus norgestrel 0.3mg. 
§ During the three months before the index date, the doctor of this case changed her regimen from oestradiol TTS 25µg plus 
















5.4.5 Estimated relative risk of fatal pulmonary embolism in current users of hormone 
replacement therapy 
The results of matched and unmatched analyses are shown in Tables 5.21 and 5.22 
respectively. Women with a history of venous thromboembolism, breast cancer, or 
surgery in the two months before the index date were excluded and non-users were 
taken as the reference category. In the matched analysis, based on 14 cases and 52 
controls, current use of hormone replacement therapy was associated with a non-
significant three-fold increased risk of dying from pulmonary embolism. The 
unmatched analysis, which was based on 14 cases and 67 controls, produced similar 
results; the odds ratio (adjusted for age, weight category, current use of antipsychotic 
drugs, and clustered on general practice) was 3.0 and was of borderline significance 






























odds ratio (95 % CI) 
1.0 
2.3 (0.6 - 9.3) 
Adjusted matched 
odds ratio (95% CI)t 
1.0 
2.9 (0.5 - 18.0) 
Adjusted matched 
odds ratio (95 % CI)* 
1.0 
3.3 (0.5 - 21.7) 
' Excluding all women who had a history of venous thromboembolism, breast cancer, or surgery in the two months before the index date. No 
women had a major injury or prolonged immobility in the two months before the index date. 
t Adjusted for weight (four categories, including missing values). 
* Adjusted for weight (four categories, including missing values) and use of antipsychotic drugs in the three months before index date. 
§ All regimens combined. 

















Table 5.22 Current use of hormone replacement therapy and fatal pulmonary embolism, 
unmatched analysis* 
HRT Cases Controls Unadjusted odds Adjusted odds Adjusted odds Adjusted odds 
(n=14) (n=67) ratio (95 % Cl) ratio (95 % Cl) t ratio (95 % CI)* ratio (95 % Cii 
Non-user 9 53 LO 1.0 1.0 1.0 
Userll 5 14 2.1 (0.6 - 7.3) 2.1 (0.6 - 6.9) 2.8 (1.0 - 8.2) 3.0 (1.0 - 8.4) 
'Excluding all women who had a history of venous thromboembolism, breast cancer, or surgery in the two months before the index date. No 
women had a major injury or prolonged immobility in the two months before the index date. 
1 Adjusted for age as a continuous variable and clustered on general practice. 
* Adjusted for age as a continuous variable, weight (four categories, including missing values), and clustered on general practice. 
§ Adjusted for age as a continuous variable, weight (four categories, including missing values), use of antipsychotic drugs in the three months 
before index date, and clustered on general practice. 
II All regimens combined. 
















5.5 PSYCHOTROPIC DRUGS 
5.5.1 Cases and controls included in the key analyses 
The characteristics of the 75 cases and 300 controls who were considered for inclusion 
in the analyses which explored the association between psychotropic drugs and fatal 
pulmonary embolism were discussed in section 5.2. As shown in Table 5.5, 10 cases 
and two controls had a history of venous thromboembolism. During the two months 
before the index date, an additional three cases had a severe injury or prolonged 
immobility, a third control had major surgery and three controls were pregnant. These 
cases and controls were considered to have had major risk factors for venous 
thromboembolism and were therefore excluded from the main analyses. Because 
matched analyses were undertaken, the controls of excluded cases were also excluded. 
Hence, the key analyses were based on 62 cases (19 male, 43 female) and 243 controls 
(76 male, 167 female). The median ages of these cases and controls were 43.5 and 44.0 
years respectively; the median ages of the female and male cases were 42.0 and 47.0 
years respectively. The discussion in the following sections focuses on these 62 cases 
and 243 controls, although the tables also include results for all subjects. 
5.5.2 Ever and current use of psychotropic drugs 
Twenty-two (35.5%) cases and 39 (16.0%) controls had a history of being prescribed at 
least one psychotropic medicine at some time before the index date (Table 5.23). Three 
of the cases and seven of the controls were prescribed these drugs to treat non-
psychiatric conditions such as epilepsy, shingles, insomnia, myoclonus, migraine 
prophylaxis, nausea associated with inner ear disease, and behavioural problems 
associated with an intellectual disability. The remaining 19 (30.6%) cases and 32 
(13.2%) controls were treated for various mental illnesses, including depression, anxiety 
disorders, schizophrenia, and bipolar affective disorder. 
Sixteen (25.8%) cases and 15 (6.2%) controls were current users of at least one 
psychotropic drug, of whom seven cases (43.8%) and four controls (26.7%) were 
















Table 5.23 Ever and current use of psychotropic drugs by cases and controls aged 15 - 59 
years 
Type of psychotropic drug Ever use (number [ % ]) Current use (number[%]) 
Cases Controls Cases Controls 
All subjects 
(75 cases, 300 controls) 
Anti psychotic 13(17.3) 8 (2.7) 9 (12.0) 3 (1.0) 
Antidepressant 20 (26.7) 36 (12.0) 12 (16.0) 9 (3.0) 
Other* 16 (21.3) 26 (8.7) 6 (8.0) 12 (4.0) 
Any psychotropic drug t 29 (38.7) 48 (16.0) 20 (26.7) 18 (6.0) 
Subjects without major risk factors 
(62 cases, 243 controls)* 
Anti psychotic 11 (17.7) 5 (2.1) 8 (12.9) 2 (0.8) 
Antidepressant 16 (25.8) 31 (12.8) 10 (16.1) 9 (3.7) 
Other* 14 (22.6) 19 (7.8) 5 (8.1) 9 (3.7) 
Any psychotropic drug§ 22 (35.5) 39 (16.0) 16 (25.8) 15 (6.2) 
-
' This group includes benzodiazepines, zopiclone, lithium carbonate, meprobamate, sodium valproate, and carbamazepine. 
t Seven cases and five controls had used more than one type of psychotropic drug. 
* No history of venous thromboembolism, or of prolonged immobility, severe injury, major surgery, or pregnancy during the two months 
before the index date. 



















Table 5.24 Current use of psychotropic drugs 
Current use of psychotropic drugs Cases Controls 
All subjects (75 cases, 300 controls) 
Antipsychotic alone 3 1 
Antidepressant alone 7 5 
Other alone 3 7 
Antipsychotic and antidepressant 4 
Antipsychotic and other 2 1 
Antipsychotic, antidepressant, and other 1 
Antidepressant and other 1 3 
Total 20 18 
Subjects without major risk factors (62 cases, 243 controls)* 
Antipsychotic alone 2 1 
Antidepressant alone 5 5 
Other alone 2 5 
Antipsychotic and antidepressant 4 
Antipsychotic and other 2 
Antipsychotic, antidepressant, and other 1 
Antidepressant and other 1 3 
Total 16 15 
• No history of venous thromboembolism, or of prolonged immobility, severe injury, major surgery, or pregnancy during the two months 





















Use of antipsychotic drugs 
Eight cases and two controls were current users of antipsychotic drugs. The median age 
of the cases who died while taking an antipsychotic drug was 47.0 years. Thioridazine, 
a low potency antipsychotic, was used by six cases and one control (Table 5.25). High 
potency antipsychotics were used by two cases (haloperidol) and by one control 
(prochlorperazine). There were no users of atypical agents. 
All users, except for the control who was prescribed prochlorperazine for labyrinthitis 
six weeks before the index date, had received antipsychotic medication either 
continuously or intermittently over many years. Four cases and one control had a 
diagnosis of schizophrenia noted in their records, while another case had a possible 
diagnosis of schizophrenia recorded. Of the remaining cases, one had a bipolar 
affective disorder, one had an intellectual disability and was prescribed thioridazine for 
behavioural control, and one was taking thioridazine to treat insomnia. No user had an 
acute psychotic episode in the three months before the index date; one man was 













Table 5.25 Current use of antipsychotic drugs by cases and controls 
Current use of antipsychotic drugs Cases Controls 
All subjects (75 cases, 300 controls) 
Haloperidol 2 
Thioridazine 7 1 
Pimozide 1 
Prochlorperazine 1 
Total 9 3 
Subjects without major risk factors (62 cases, 243 controls)* 
Haloperidol 2 
Thioridazine 6 1 
Prochlorperazine 1 
Total 8 2 
'No history of venous thromboembolism, or of prolonged immobility, severe injury, major surgery, or pregnancy during the two months 














Risk of fatal pulmonary embolism in current users of antipsychotic drugs 
Tables 5.26 and 5.27 show the results of the matched analyses in which the risk of dying 
from pulmonary embolism was estimated for current users of antipsychotic drugs. 
Taking non-users (never and past users combined) as the reference group, the odds ratio 
(adjusted for weight category, oral contraceptive use, and hormone replacement 
therapy) for current use of any antipsychotic drug was 13.3 (95% CI 2.3 - 76.3). Low 
potency antipsychotics carried the highest risk, with an adjusted odds ratio of 20.8 (95% 
CI 1.7 - 259.0). Adding intellectual disability to the model had minimal impact to the 
estimate for use of any antipsychotic (odds ratio 12.8 [95% CI 2.1- 77.9]). 
The increased risk of pulmonary embolism in users of any antipsychotic persisted when 
women who were current users of oral contraceptives or hormone replacement therapy 
were excluded from the analysis, with an odds ratio (adjusted for weight category) of 
8.3 (95% CI 1.3 - 53.5). Past use of antipsychotics, compared with never use, was not 
associated with a significantly elevated risk of pulmonary embolism (adjusted odds ratio 
5.3 [95% CI 0.6 - 45.8]). The adjusted odds ratio for use of antipsychotic medication 
within one month of the index date was 11.2 (95% CI 1.9 - 65.4). An unmatched 
analysis (adjusted for age, sex, weight category, oral contraceptive use, hormone 
replacement therapy, and clustered on general practice) gave similar results to the 
matched analysis, with an odds ratio for antipsychotic use within three months of the 















Table 5.26 Current use of any antipsychotic drug and fatal pulmonary embolism 
Current use of any antipsychotic Cases Controls Unadjusted matched Adjusted matched 
odds ratio (95 % Cl) odds ratio (95 % CI)* 
All subjects (75 cases, 300 controls) 
Non-user 66 297 1.0 1.0 
User 9 3 12.0 (3.2 - 44.3) 9.7 (2.3 - 40.9) 
Subjects without major risk factors 
(62 cases, 243 controlsf 
Non-user 54 241 1.0 1.0 
User 8 2 16.0 (3.4 - 75.3) 13.3 (2.3 - 76.3) 
* Adjusted for weight (four categories, including missing values, for both sexes), oral contraceptive use, and hormone replacement therapy in 
the three months before the index date. 
t No history of venous thromboembolism, or of prolonged immobility, severe injury, major surgery, or pregnancy during the two months 














Table 5.27 Current use of low potency antipsychotic drugs and fatal pulmonary embolism 
Current use of low potency Cases Controls Unadjusted matched Adjusted matched 
antipsychotic odds ratio (95 % CI) odds ratio (95% CI)* 
All subjects (75 cases, 300 controls)t 
Non-user 66 297 1.0 1.0 
User 7 1 28.0 (3.4 - 227.6) 29.3 (2.8 - 308.2) 
Subjects without major risk factors 
(62 cases, 243 controls)* 
Non-user 54 241 1.0 1.0 
User 6 1 24.0 (2.9 - 199.3) 20.8 (1.7 - 259.0) 
'' Adjusted for weight (four categories, including missing values, for both sexes), oral contraceptive use, and hormone replacement therapy 
in the three months before the index date. 
t Two cases and two controls were users of high potency antipsychotics, odds ratios not shown. 
* No history of venous thromboembolism, or of prolonged immobility, severe injury, major surgery, or pregnancy during the two months 















5.5.4 Antidepressant drugs 
Use of antidepressant drugs 
Four cases and one control used both antipsychotic and antidepressant drugs in the three 
months before the index date. When current users of antipsychotics ( and their controls) 
were excluded, six cases and seven controls without major risk factors for venous 
thromboembolism were current users of antidepressants (Table 5.28). The median age 
of the cases was 53.3 years. 
Tricyclic antidepressants were used by four cases and five controls. One of the four 
cases and a fifth were taking a selective serotonin reuptake inhibitor; the sixth case was 
taking a monoamine oxidase inhibitor. Of the remaining controls, one was using a 
selective serotonin reuptake inhibitor, while the other was taking a monoamine oxidase 
inhibitor. 
None of the users had been admitted to hospital for depression during the three months 
before the index date, although two cases were diagnosed with acute depression and 
were prescribed tricyclics as outpatients about two months before the index date. Only 
one user, a control, was taking a tricyclic for a reason other than depression (migraine 
prophylaxis). Of the remaining users, one case first commenced treatment nine months 
before the index date, while all the others had been taking antidepressants intermittently 














Table 5.28 Current use of antidepressant drugs by cases and controls 
Current use of antidepressants 









Selective serotonin reuptake inhibitors 
Fluoxetine 
Paroxetine 




Subjects without major risk factors, current users of 






Selective serotonin reuptake inhibitors 
Fluoxetine 




' One case was taking desipramine and fluoxetine. 

































* No history of venous thromboembolism, or of prolonged immobility, severe injury, major surgery, or pregnancy during the two months 













Risk of fatal pulmonary embolism in current users of antidepressant drugs 
The results of the matched analysis are shown in Table 5.29. Taking non-users as the 
reference group, and excluding current users of antipsychotics, the odds ratio (adjusted 
for weight category, oral contraceptive use, and hormone replacement therapy) for 
current use of antidepressants was 4.9 (95% CI I.I - 22.5). The adjusted odds ratios for 
current and past use of antidepressants, compared to never use, were 6.3 (95% CI 1.3 -
30.8) and 2.9 (95% CI 0.7 - 11.5) respectively. 
An analysis including current users of antipsychotics, but adjusting for such use, also 
found a five-fold increased risk in current users of antidepressants (odds ratio 5.5 [95% 
CI 1.3 - 23.8]). To explore the possibility that the risk of fatal pulmonary embolism in 
current users of antidepressants was modified by the use of antipsychotics ( and vice 
versa) an interaction term was included in a conditional logistic regression model that 
included the following variables: weight category, and current use of antidepressants, 
antipsychotics, oral contraceptives, and of hormone replacement therapy. No evidence 

















Table 5.29 Current use of any antidepressant drug and fatal pulmonary embolism, excluding 
current users of antipsychotic drugs 
Current use of any antidepressant Cases Controls Unadjusted matched Adjusted matched 
odds ratio (95 % Cl) odds ratio (95 % Cl) * 
All subjects (66 cases, 261 controls) 
Non-user 58 254 1.0 1.0 
User 8 7 5.5 (1.8-17.1) 10.0 (2.4 - 41.2) 
Subjects without major risk factors 
(54 cases, 209 controls/ 
Non-user 48 202 1.0 1.0 
User 6 7 3.7 (1.1 - 12.5) 4.9 (1.1 - 22.5) 
* Adjusted for weight (four categories, including missing values, for both sexes), oral contraceptive use, and hormone replacement therapy in 
the three months before the index date. 
t No history of venous thromboembolism, or of prolonged immobility, severe injury, major surgery, or pregnancy during the two months 

















5.5.5 Other psychotropic drugs 
Use of other psychotropic drugs 
The prescribed use of other psychotropic drugs in the three months before the index date 
is shown in Table 5.30. Five cases and nine controls were current users of at least one 
psychotropic drug other than an antipsychotic or antidepressant. 
Risk of fatal pulmonary embolism in current users of other psychotropic drugs 
There appeared to be no increased risk for current or past use of other psychotropic 
drugs as a group. When users of antipsychotics or antidepressants were excluded, the 
adjusted odds ratio (adjusted for weight category, oral contraceptive use, and hormone 
replacement therapy during the three months before the index date) for current use was 
1.4 (95% CI 0.3 - 7.7). Adjusting for antipsychotic and antidepressant use produced an 



















Table 5.30 Current use of other psychotropic drugs by cases and controls 
Current use of other psychotropic drugs Cases Controls 
All subjects (75 cases, 300 controls) 
Benzodiazepines 3 8 
Lithium carbonate 2 1 
Zopiclone 1 2 
Carbamazepine 1 1 
Sodium valproate 1 2 
Meprobamate 1 
Total 5* 13t 
Subjects without major risk factors (62 cases, 243 controls)* 
Benzodiazepines 3 6 
Lithium carbonate 2 1 
Zopiclone 1 1 
Carbamazepine 1 1 
Sodium valproate 1 1 
Meprobamate 1 
Total 5§ 911 
' One case was prescribed clonazepam, lithium carbonate, and zopiclone. Another was prescribed lithium carbonate and sodium valproate. 
t One control was prescribed lithium carbonate and zopiclone. Another was prescribed carbarnazepine and sodium valproate. 
* No history of venous thromboembolism, or of prolonged immobility, severe injury, major surgery, or pregnancy during the two months 
before the index date. 
§ One case was prescribed clonazepam, lithium carbonate, and zopiclone. Another was prescribed lithium carbonate and sodium valproate. 





















CHAPTER6 CASE-CONTROL STUDY OF THE USE OF ORAL 
CONTRACEPTIVES AND PSYCHOTROPIC DRUGS: DISCUSSION 
6.1 SUMMARY OF MAIN FINDINGS 
Because fatal pulmonary embolism is a rare condition, there were only 92 deaths 
between 1 January 1990 and 31 December 1998 among people aged 15 - 59 years, who 
were normally resident in New Zealand, in which pulmonary embolism was considered 
the underlying cause. Of these, the general practitioners of two men were not identified 
and the general practice records of a further 15 people were lost. Of the remaining 7 5 
cases, 13 had major risk factors for venous thromboembolism. Hence, the key analyses 
which explored the association between psychotropic drugs and death from pulmonary 
embolism were based on 62 cases. Analyses which examined the risk in women using 
oral contraceptives were inevitably based on smaller numbers. This limited the 
precision of the estimates of relative risk, as demonstrated by the wide 95% confidence 
intervals. Nevertheless, when compared with non-use, prescribed use of any oral 
contraceptive in the three months before the index date was associated with a significant 
10-fold increased risk of fatal pulmonary embolism. The odds ratio for use of 
contraceptives containing the so-called third generation progestogens, desogestrel and 
gestodene, was about three times higher than the point estimate for levonorgestrel 
contraceptives. Oral contraceptives containing cyproterone acetate appeared to carry 
the highest risk. Compared with non-users, current users of antipsychotic drugs had a 
13-fold increased risk of fatal pulmonary embolism (odds ratio 13.3 [95% CI 2.3 -
76.3]). 
Low potency antipsychotics carried a 20-fold increase in risk (odds ratio 20.8 [95% CI 
1.7 - 259.0]), with thioridazine being the main drug involved. Antidepressant use in the 
three months before the index date was also associated with a significantly increased 
risk (odds ratio 4.9 [95% CI 1.1 - 22.5]). Because of the limited number of cases, it 
was not possible to examine the association between fatal pulmonary embolism and 


















6.2 POTENTIAL SOURCES OF BIAS TO BE CONSIDERED 
Because case-control studies are particularly vulnerable to selection and information 
biases (Hennekens and Buring 1987), it is important to consider the potential role that 
bias may have played in the present study. The following discussion examines the 
possible sources of bias and considers whether they are a likely explanation for the 
observed associations between fatal pulmonary embolism and the use of oral 
contraceptives, antipsychotics, and antidepressants. 
6.2.1 Ascertainment of cases 
Because this was a population-based study, it was possible to include all deaths that 
occurred in New Zealand during the study period for which pulmonary embolism was 
considered the underlying cause. In almost all cases, the diagnosis of pulmonary 
embolism was confirmed by necropsy or other objective investigations. It is unlikely 
that any relevant deaths were missed because legal requirements to identify the cause of 
death (New Zealand Health Information Service 2001) mean that almost all people aged 
15 - 59 years who die unexpectedly in New Zealand are referred for necropsy, generally 
at the request of a coroner. It is possible that deaths from pulmonary embolism in 
people with major health conditions (in whom death was not unexpected) might have 
gone unrecognised if a necropsy was not undertaken. However, even if detected, 
pulmonary embolism in these people should not, according to coding conventions, have 
been identified as the underlying cause of death and hence such people would not have 
been eligible for inclusion in the present study. 
The general practice records of 75 (82%) of the 92 eligible cases were examined. The 
exclusion of the 15 cases for whom records were not available might have introduced 
some bias if the loss of the files was somehow related to the use of medicines and the 
underlying risk of venous thromboembolism. However, as was shown in Table 2.5, the 
absence of records was often because of practice-related reasons (such as doctors 
moving premises, retiring, or dying) and it did not appear to be related to particular 
characteristics of cases. This was especially reassuring in relation to the oral 
contraceptive analyses because there were threats of legal action during the period of 
data collection against general practitioners who had prescribed desogestrel and 
gestodene contraceptives (MacKinven 1999) and it was initially feared that this could 

















information about any named patient or doctor would be provided to any other party 
(Appendix A, letter 15) may have helped to maximise participation. 
6.2.2 Selection of controls 
Controls were randomly selected from the same general practices as the cases and were 
required to have been normally resident in New Zealand, and to have been members of 
those same practices, on the index date. Hence, the controls were drawn from the 
populations that gave rise to the cases. Although it is probable that some potential 
controls were not included in the sampling frame (because five general practices did not 
have an electronic age-sex register when the practice was visited and a further 16 
practices had a register when visited but did not have one on the index date), the 
numbers involved are likely to have been small and hence this is unlikely to have 
created a substantial selection bias. Similarly, the refusal of two doctors in two group 
practices to allow their patients to be involved in the selection process is not expected to 
have had a meaningful impact. 
The general practice records of 55 patients who were selected as potential controls had 
either been lost or transferred to another practice. Even if all of these patients had been 
members of the practice on the index date and hence eligible for inclusion (which is 
unlikely), the proportion of eligible controls who were included in the study would still 
have been high (85% ) . 
In any event, there were no significant differences in the mean time that cases and 
controls had been members of their practices, or in the mean number of years of 
recorded medical information. Moreover, the frequency and type of contraceptives ever 
used, the prevalence of current use of oral contraceptives and hormone replacement 
therapy, and the life-time prevalence of treated mental illness observed among the 
controls was consistent with New Zealand population data from other sources (Pool et 
al. 1999; North and Sharples 2001; Oakley Browne et al. 2006), suggesting that the 
controls were indeed representative of the population from which the cases arose. 
6.2.3 Information bias 
Information about prescribed medicines and the medical history of cases and controls 























recognised, however, that the absence of a recorded history of a particular condition or 
the use of a specific medicine did not necessarily mean that a case or control had never 
experienced such an event or used that medicine. This is because many patients did not 
attend the same general practice throughout their lives and, before the advent of 
electronic records, copies of medical files were not always transferred when a patient 
shifted to a new practice. However there was no evidence of a systematic difference 
between cases and controls in this regard - the mean number of years of recorded 
information was similar for both groups. Hence, the impact of any misclassification of 
risk factor status (that is, incorrectly classifying a person as having no history of a 
particular condition or event) is likely, if anything, have been to underestimate the effect 
size associated with that risk factor. In relation to medicine use, such a phenomenon is 
unlikely to have influenced the estimates of relative risk for current use since the date of 
the first recorded information was more than three months before the index date for all 
but two cases and four controls. 
Clearly a history of being prescribed a medicine does not mean that patients actually 
delivered their prescription to a pharmacy or, indeed, that they took the medicine which 
was dispensed to them. Hence, it is possible that some cases and controls were 
classified as current users of a medicine when in fact they did not take the medicine. 
However, there was no reason to believe that cases and controls would have differed in 
such behaviours. Moreover it seems unlikely that there would be an association 
between poor adherence and an increased risk of venous thromboembolism since, unlike 
arterial thrombosis, there are no behavioural factors other than obesity that particularly 
modify the risk. Hence, any such misclassification of exposure status would have 
tended to lead to an underestimation of any association between current use of the 
medicine and fatal pulmonary embolism and thus cannot explain the increased risks 
observed in users of oral contraceptives, antipsychotics, and antidepressants. 
The date of onset of the fatal episode (rather than the date of death) was taken as the 
index date, which is important for two reasons. First, it means that the prescription of 
antipsychotic or antidepressant drugs for unrecognised early symptoms of venous 
thromboembolism is an unlikely explanation for the increased risk of fatal pulmonary 
embolism observed in current users of these drugs. In any event, most of the cases had 
















the risks associated with the use of oral contraceptives and hormone replacement 
therapy were underestimated due to the cessation of the use of these medicines by 
women who had symptoms suggestive of venous thromboembolism. 
Another source of bias to be considered is the possibility of error in the management of 
the data. The abstraction of information from medical records was all undertaken by 
me, and a systematic approach was employed to examine the medical files. Moreover, I 
had previously worked as a general practitioner, and as a medical officer in family 
planning clinics, and was familiar with how such records were compiled and the 
abbreviations commonly used. If it was not possible to decipher handwriting or 
abbreviations, assistance was sought from the relevant doctor. All data were coded and 
entered into an electronic spreadsheet by a research assistant and me. This double 
coding and data entry ensured that any errors could be identified and corrected. 
6.3 POTENTIAL CONFOUNDING 
Confounding by sex, age, weight, concomitant drug use, or underlying medical 
conditions is an unlikely explanation for the results obtained in the present study. 
People with advanced cancer, recent surgery, or pregnancy were excluded, and the key 
analyses were confined to people without a history of venous thromboembolism, recent 
injury, or prolonged immobility. Moreover, age and sex were accounted for in the 
analyses, and the risk estimates were adjusted for weight. It was not possible to adjust 
for BMI because the height of many patients was unrecorded. In the oral contraceptive 
analyses, adjustment for weight actually increased the estimated relative risks for the 
use of desogestrel and gestodene oral contraceptives and had little impact on the 
estimates for oral contraceptive use overall or for the use of levonorgestrel pills. Hence, 
if anything, residual confounding arising from adjusting for weight rather than BMI is 
likely to have produced conservative estimates. Adding weight alone to the multivariate 
models for antipsychotic and antidepressant use had minimal impact on the estimates of 
relative risk. The odds ratios for current use of psychotropic drugs were also adjusted 
for other relevant medicine use. The capacity to adjust for other potential confounders 
was inevitably limited by the small numbers, especially in the oral contraceptive 













and antidepressants all remained elevated in sensitivity analyses in which the estimates 
were additionally adjusted for a history of superficial venous thrombosis, varicose 
veins, intellectual disability, and a chronic musculoskeletal condition of the lower limbs. 
6.4 ISSUES SPECIFIC TO ORAL CONTRACEPTIVES AND VENOUS 
THROMBOEMBOLISM 
6.4.1 Consistency with other studies 
Estimates of relative risk 
The finding of a significantly increased risk of fatal pulmonary embolism in current 
users of oral contraceptives, when compared with non-users, is consistent with the 
results of the first (Inman and Vessey 1968), but not second (Thorogood et al. 1992b ), 
case-control study of fatal cardiovascular disease. The higher relative risk estimate for 
contraceptives containing desogestrel or gestodene, than for levonorgestrel preparations, 
accords with the results of the key studies of non-fatal venous thromboembolism 
outlined in Chapter 3 (Bloemenkamp et al. 1995; Jick et al. 1995; World Health 
Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone 
Contraception 1995b; World Health Organization Collaborative Study of 
Cardiovascular Disease and Steroid Hormone Contraception 1995c; Spitzer et al. 1996) 
and with several studies published both before (Andersen et al. 1998; Bennet and 
Odeberg 1998; Bloemenkamp et al. 1999; Herings et al. 1999; Vasilakis et al. 1999a; 
Vasilakis et al. 1999b) and after (Jick et al. 2000; Samuelsson and Hagg 2004; 
Hedenmalm and Samuelsson 2005; Jick et al. 2006) the present research was first 
published (Parkin et al. 2000). Because of the small number of deaths, the confidence 
intervals are wide and overlapping. However, it is worth noting that the present 
research provides additional evidence against the proposed non-causal explanations for 
the excess risk of venous thromboembolism in users of desogestrel and gestodene oral 
contraceptives that were discussed in Chapter 3. Referral and diagnostic biases are 
highly unlikely in a study of fatal events and, following on from the discussion in the 
previous section, confounding by indication and residual confounding by age seem very 
unlikely. Of the current pill users, only three of 20 (15.0%) cases and seven of 26 
(26.9%) controls were so-called "first-time users" of oral contraceptives; of these, only 










Although based on very small numbers, the present study and the WHO investigation 
(World Health Organization Collaborative Study of Cardiovascular Disease and Steroid 
Hormone Contraception 1995b; World Health Organization Collaborative Study of 
Cardiovascular Disease and Steroid Hormone Contraception 1995c) both suggested that 
oral contraceptives containing cyproterone acetate carried an even greater risk of venous 
thromboembolism than desogestrel and gestodene preparations. These findings have 
been confirmed by researchers at the Boston Collaborative Drug Surveillance Program 
in a nested case-control study based on the UK GPRD (Vasilakis-Scaramozza and Jick 
2001) and by researchers in the Netherlands in a population-based case-control study 
(Rosendaal et al. 2003a). In the former study, the adjusted odds ratio for users of 
cyproterone acetate oral contraceptives compared with levonorgestrel preparations, was 
3.9 (95% CI 1.1 - 13.4) (Vasilakis-Scaramozza and Jick 2001). In the second study, use 
of cyproterone acetate pills was associated with an 18-fold increase in risk (no 
confidence interval provided) compared with non-users (Rosendaal et al. 2003a). 
Estimates of absolute risk 
In the present study, the absolute risk of death from idiopathic pulmonary embolism in 
women taking oral contraceptives was estimated to be 10.5 (95% CI 6.2 - 16.6) per 
million woman-years. This is similar to the mortality rates from pulmonary embolism 
estimated for oral contraceptive users during the 1960s and 1970s. For instance, the 
mortality rate in users of Enovid in the USA was estimated to be 12.1 per million users 
(Ad Hoc Committee for the Evaluation of a Possible Etiologic Relation with 
Thromboembolic Conditions 1963). In the early UK study of cardiovascular mortality 
in women of child-bearing age, there were 16 deaths from pulmonary embolism among 
current users of oral contraceptives (Inman and Vessey 1968). Using the two different 
estimates of oral contraceptive utilisation data provided in the paper, the absolute risk of 
fatal pulmonary embolism in pill users can be calculated alternately as 23 or 33 per 
million woman-years. In a subsequent study by the same authors, the annual death rate 
from pulmonary embolism attributable to the use of oral contraceptives containing 50µg 
oestrogen was estimated to be 11 per million users (Vessey and Inman 1973). The 
mortality rate in the Royal College of General Practitioners' Oral Contraceptive Study, 
















The estimate in the present study was higher than expected based on the incidence of 
venous thromboembolism among users of modem oral contraceptives reported in the 
WHO study (1 - 2 per 10,000 users) and a presumed case-fatality rate of I - 2% (World 
Health Organization Collaborative Study of Cardiovascular Disease and Steroid 
Hormone Contraception 1995b; World Health Organization Collaborative Study of 
Cardiovascular Disease and Steroid Hormone Contraception 1995c). Conversely, a 
death rate of 14 per million woman-years can be derived from the GPRD study (Jick et 
al. 1995), although this is based on only six deaths. Incidentally, the present estimate is 
identical to a predicted rate in users of desogestrel and gestodene contraceptives of 10 
per million per year based on calculations undertaken by the Leiden group soon after the 
key studies were published (Vandenbroucke et al. 1996b). 
Overall, the study findings are consistent with the other epidemiological evidence. The 
estimates of venous thromboembolism mortality based on case-fatality rates are lower 
than the estimates in the present study, which suggests that the case-fatality of venous 
thromboembolism in oral contraceptive users may be higher than previously assumed. 
Certainly estimates from recent population-based studies in the USA suggest that the 
case-fatality for idiopathic venous thromboembolism is greater than 1 - 2% and may be 
about 5% (Cushman et al. 2004; Stein et al. 2004). 
6.4.2 Biological plausibility 
In recent years it has been established that oral contraceptive use is associated with 
reduced anticoagulant, enhanced procoagulant, and increased antifibrinolytic effects, 
and that these effects are more pronounced in women taking desogestrel and gestodene 
preparations (Vandenbroucke et al. 2001). For instance, the initial discovery that users 
of oral contraceptives containing desogestrel and gestodene had reduced anticoagulant 
activity secondary to enhanced resistance to activated protein C, when compared with 
users of other preparations (Rosing et al. 1997; Rosing et al. 1999), has been confirmed 
in subsequent studies (Alhenc-Gelas et al. 2004; Kemmeren et al. 2004). Moreover, in 
line with epidemiological findings, it has been shown that resistance to activated protein 
C is even more marked in users of oral contraceptives containing cyproterone acetate 
(Alhenc-Gelas et al. 2004). In other studies, additional changes leading to reduced 
anticoagulant activity, such as decreases in total and free protein S, have also been 













Mackie et al. 2001; Kemmeren et al. 2004). Enhanced procoagulant effects have been 
demonstrated in a randomised cross-over trial comparing desogestrel and levonorgestrel 
oral contraceptives; significantly increased prothrombin and factor VII concentrations 
and decreased factor V levels were observed during the use of the desogestrel 
preparation (Middeldorp et al. 2000). Finally, in a randomised cross-over trial of 
desogestrel and levonorgestrel pills, higher levels of thrombin-activatable fibrinolytic 
inhibitor were measured during use of the desogestrel product (Meijers et al. 2000b ). 
It has also been confirmed that various inherited thrombophilic abnormalities modify 
the risk of venous thromboembolism in users of oral contraceptives. For instance, the 
risk of venous thromboembolism in oral contraceptive users is substantially enhanced in 
the presence of the factor V Leiden and prothrombin G20210A mutations and with 
deficiencies of protein C, protein S, and antithrombin (Rosendaal et al. 2003a). 
Interactions between oral contraceptive use and high levels of factors II and XI 
(Rosendaal et al. 2003a) and VIII (Bloemenkamp 2005) have also been reported. 
6.4.3 Competing interests 
Despite the compelling evidence that desogestrel and gestodene pills carry a higher risk 
of venous thromboembolism than older low-dose preparations, this conclusion has not 
been universally accepted and for several years members of three groups who undertook 
earlier research directly funded by the pharmaceutical industry (as discussed in section 
3.2.12 of Chapter 3) continued to explore the possibility that the excess risk was 
explained by various biases. It is notable that this subsequent research was also funded 
directly (Heinemann et al. 2000; Heinemann et al. 2002; Lidegaard et al. 2002) or 
indirectly (Farmer et al. 2000b) by industry. 
Some of the Transnational investigators, for instance, undertook a second case-control 
study which they maintained provided "clear evidence that diagnostic suspicion and 
referral bias does play an important role in case-control studies of venous 
thromboembolism risk among oral contraceptive users" (Heinemann et al. 2000). Two 
sets of controls were used in this study: women randomly selected from the general 
population, and women who were initially suspected of having venous 
thromboembolism. The odds ratios for current use of any oral contraceptive compared 














and 2.6 (95% CI 1.75 - 3.88) when the second group of controls was used. Intriguingly, 
however, no comparisons of risk by types of oral contraceptive were reported and the 
findings, as presented, do not explain the excess risk associated with the use of 
desogestrel and gestodene contraceptives found in other studies. 
Following a re-analysis of this second case-control study, the investigators went on to 
argue that the restriction of events to hospitalised and idiopathic cases was an 
undesirable practice because it resulted in an overestimation the risks associated with 
contraceptive pills (Heinemann et al. 2002). However, this view was challenged by the 
findings of a nested case-control study based on a group of women who had been 
excluded from an earlier study undertaken by the Boston Collaborative Drug 
Surveillance Program investigators because they had acute clinical conditions such as 
surgery and lower limb fractures (Jick et al. 2000); it was shown that a failure to 
exclude such women would, in fact, obscure the true risk associated with oral 
contraceptives (Black et al. 2002). 
The second group of industry-funded investigators used data from the UK GPRD to 
compare the incidence of venous thromboembolism among pill users before and after 
the CSM warning in October 1995 (Farmer et al. 2000b). The results were said to be 
inconsistent with a two-fold excess risk for oral contraceptives containing desogestrel 
and gestodene. However, the incidence rates were not adequately adjusted for age and 
other confounders (Skegg 2000b) and the investigators were criticised for conducting a 
simple time-trend analysis when they had access to detailed data about individual 
women's exposures and other risk factors (Walker 2000). This failure to adequately 
address confounding is rather ironic considering that the same group had previously 
argued that the findings of the key studies were distorted by residual confounding 
(Farmer et al. 1997a). Moreover, a few months later, the Boston group used the same 
database to conduct cohort and nested case-control analyses and found a two-fold 
excess risk in users of desogestrel and gestodene pills relative to users of levonorgestrel 
preparations in the periods both before and after the CSM announcement (Jick et al. 
2000). In addition, it was shown that fewer events occurred after October 1995 than 
would have been expected had there been no fall in the use of desogestrel and gestodene 











(Skegg 2000b ), the editor of the BMJ took the rare action of issuing an apology for an 
inadequate review of the first study (Smith 2000). 
The third group which undertook industry-sponsored research expanded their original 
Danish case-control study (Lidegaard et al. 1998) to include both women who had 
events in the subsequent three years and additional controls selected from a population 
register (Lidegaard et al. 2002). As in the original study, the relative risk estimates were 
adjusted for duration of use; the odds ratio for desogestrel and gestodene pills compared 
with low-dose levonorgestrel, norgestimate, and norgestrel products was 1.3 (95% CI 
1.0 - 1.8). However, the criticisms of the original study (Walker 1998) still held in 
relation to the expanded study. 
The issue of competing interests attracted further attention following the disclosure that 
an industry-commissioned study based on the UK GPRD had not been published 
(Skegg 2000b). This research, which was undertaken in 1997, apparently showed that 
so-called third generation oral contraceptives carried an excess risk of venous 
thromboembolism (van Heteren 2001; Weber 2001). Representatives of the 
manufacturer defended their decision not to publish the findings, claiming that there 
were methodological problems with the study and that the results added nothing new 
(Brock 2001). A few months later it was reported that a second industry-funded study 
also remained unpublished (Sheldon 2001). 
Finally, a clear relationship between the source of funding for research and the reported 
results was highlighted in a meta-analysis based on studies in which data were collected 
before the CSM warning; the summary adjusted odds ratio of venous thromboembolism 
in users of "third generation" oral contraceptives relative to "second generation" 
preparations was 1.7 (95% CI 1.4 - 2.0) (Kemmeren et al. 2001). In an analysis 
stratified by funding source, the corresponding estimate was only 1.3 (95% CI 1.0 - 1.7) 
for studies sponsored by. the pharmaceutical industry whereas for research which 
received no such funding it was 2.3 (95% CI 1.7 - 3.2). The results of several other 
analyses also led the authors to conclude that the excess risk associated with third 
generation oral contraceptives could not be explained by various biases. First, the 
summary estimate was unchanged in an analysis restricted to cases in whom the 


















risks were found in both short and longer term users; the odds ratios for use for less than 
a year and for at least one year were 2.5 (95% CI 1.6 - 4.1) and 2.0 (95% CI 1.4 - 2.7) 
respectively. Third, the adjusted odds ratio for first-time use of third generation pills 
compared with first-time use of second generation products was 3.3 (95% CI 2.0- 5.4). 
A second meta-analysis, which included studies with data recorded after October 1995, 
produced an identical summary odds ratio to the first (1.7 [95% CI 1.3 - 2.1]) 
(Hennessy et al. 2001). This estimate was reported to be sensitive to a degree of 
unmeasured confounding, although such a conclusion seems unjustified considering the 
sensitivity analysis showed that implausibly extreme conditions (the unmeasured 
confounding factor carried a high relative risk or was very common) would have been 
required to explain the results of the key studies. Elevated risks were also demonstrated 
among first-time users in both the first, and subsequent, years of use. Similarly, the 
association persisted after controlling for duration of use. Interestingly, the authors 
received financial support from a pharmaceutical company to undertake the meta-
analysis, but did not indicate whether they had undertaken an analysis stratified by 
source of funding (Hennessy et al. 2001)]. 
6.5 ISSUES SPECIFIC TO PSYCHOTROPIC DRUGS AND VENOUS 
THROMBOEMBOLISM 
6.5.1 Consistency with other studies 
Antipsychotic drugs 
The finding of an increased risk of fatal pulmonary embolism in current users of 
conventional antipsychotics is consistent with some (Zomberg and Jick 2000; 
Thomassen et al. 2001), but not all (Ray et al. 2002), previous studies of non-fatal 
venous thromboembolism. The observation in the present study that users of low 
potency formulations carried the highest risk confirms the findings of the nested case-
control study based on the UK GPRD which was undertaken by researchers in the 
Boston Collaborative Drug Surveillance Program (Zomberg and Jick 2000). Unlike that 
study, however, most of the cases in the present research had been taking their 













Since this study was published (Parkin et al. 2003), there have been more case reports of 
venous thromboembolism in users of clozapine (Anil et al. 2003; Pan et al. 2003; Selten 
and Btiller 2003; Yang et al. 2004), olanzapine (Hagg et al. 2003; Waage and Gedde-
Dahl 2003; Toki et al. 2004; Bhanji et al. 2005), risperidone (Hamanaka et al. 2004; 
Zink et al. 2006), conventional antipsychotics (Hamanaka et al. 2004; Matsumoto et al. 
2004), and conventional preparations in combination with physical restraint (Laursen et 
al. 2005). However, it appears that only one further analytical study has directly 
examined the association between antipsychotics and venous thromboembolism 
(Liperoti et al. 2005). In this cohort study involving non-schizophrenic people aged 65 
years or more who were resident in nursing homes in five states in the USA, users of 
atypical, but not conventional, antipsychotics had an increased risk of hospital 
admission with venous thromboembolism. Compared with non-users, the adjusted 
hazard ratios for people without major risk factors for venous thromboembolism were 
4.88 (95% CI 2.03 - 11.72) for current use of clozapine or quetiapine, 2.54 (95% CI 
1.69 - 3.82) for risperidone, 1.71 (95% CI 0.96 - 3.45) for olanzapine, 0.96 (95% CI 
0.56 - 2.02) for phenothiazines, and 1.04 (95% CI 0.45 - 2.40) for other conventional 
agents. The estimate for concurrent use of more than one agent was 5.29 (95% CI 2.05 
- 13.66). The study differed from previous research in two important respects, which 
might partly explain an absence of risk for conventional antipsychotics. First, the 
period of observation was restricted to the first six months of use. Second, the 
prescribed doses of phenothiazines were said to be substantially lower than those 
previously associated with venous thromboembolism. 
The results of a Danish register-based cohort study published in the same year were also 
consistent with an increased risk of venous thromboembolism in users of psychotropic 
drugs (Strudsholm et al. 2005). People who had previously been admitted to a 
psychiatric hospital with a diagnosis of bipolar disorder, schizophrenia, or anxiety all 
had an increased risk of pulmonary embolism when compared with sex and age-
matched persons without a history of such disorders; the relative risks for the three 
conditions were 1.61 (95% CI 1.38 - 1.88), 1.78 (95% CI 1.27 - 2.51), and 1.49 (95% 
CI 1.10 - 2.02) respectively. It is possible that these estimates were distorted by 
residual confounding by age as the age bands used were extremely wide. It seems 
highly likely that most people with schizophrenia who were unwell enough to require 

















Moreover, it is probable that many patients with bipolar disorder were also prescribed 
such medicines. Curiously, however, while the investigators concluded that people with 
mental disorders have an increased risk of venous thromboembolism, they paid scant 
attention to the possible role of psychotropic drugs. 
The previous evidence of an increased risk of non-fatal venous thromboembolism in 
users of conventional antipsychotics tends to argue against differential survival as an 
alternative explanation for the results of the present investigation. Moreover, the 
absence of a significantly increased risk for past use in this study is consistent with the 
hypothesis that the drugs, rather than any underlying characteristics of the people who 
used them, were responsible for the increased risk among current users. Nevertheless, 
the point estimate for past use was elevated, with a wide confidence interval, so the 
possibility that people who are considered to need these drugs carry some increased risk 
cannot be ruled out. Earlier studies that found significantly elevated risks for current 
users of conventional and atypical antipsychotics took past users as the reference group 
(Walker et al. 1997; Zomberg and Jick 2000). This provided some control for the 
underlying condition, but it did not permit the evaluation of a possible increased 
background risk in users of antipsychotic drugs - although it should be noted that no 
psychiatric or medical conditions were independently associated with an increased risk 
of venous thromboembolism in the nested case-control study undertaken by the Boston 
group (Zomberg and Jick 2000). 
Recently, it has been proposed that antipsychotic-induced hyperprolactinaemia might be 
the mechanism by which these drugs increase the risk of venous thromboembolism. In 
a small laboratory-based study, users of antipsychotics with hyperprolactinaemia had 
significantly higher levels of platelet stimulation than non-users with normal levels of 
prolactin (Wallaschofski et al. 2003). 
Antidepressant drugs 
The observed association between current use of antidepressants and fatal pulmonary 
embolism is a new finding, although it should be noted that tricyclic drugs (which were 
most commonly used by the cases) closely resemble the phenothiazines chemically 
(Potter and Hollister 2001b). In the nested case-control study undertaken by the Boston 












current use of antidepressants (Zomberg and Jick 2000). This result was based on only 
three exposed cases and 20 exposed controls, so it was not incompatible with the 
observation in the present study. However, it should also be borne in mind that the 
antidepressant users were identified from a cohort of patients who had taken 
antipsychotic drugs at some time during the study period and such people may be 
different from other users of antidepressants. Nine cases and four controls were current 
users of antidepressants in the reanalysis of the Leiden Thrombophilia Study, giving an 
odds ratio for current use of 2.3 (95% CI 0.6 - 10.2) (Thomassen et al. 2001). 
Conversely, the adjusted relative risk for current use of antidepressants in the Canadian 
study based on administrative records was 1.04 (95% CI 0.94- 1.15) (Ray et al. 2002). 
While there have been isolated case reports of venous thromboembolic events in users 
of selective serotonin reuptake inhibitors since the present research was undertaken 
(Momen et al. 2003; Kume et al. 2004), no further analytical studies appear to have 
been published. 
Like antipsychotic users, people taking antidepressants appear to have a higher risk of 
sudden death than non-users (Mehtonen et al. 1991). Prospective cohort studies have 
also shown an association between depression and an increased risk of subsequent 
arterial thrombosis in people without cardiovascular disease at baseline (Anda et al. 
1993; Barefoot and Schroll 1996; Pratt et al. 1996; Ford et al. 1998; Ferketich et al. 
2000; Roose et al. 2001 ), and laboratory work has demonstrated enhanced platelet 
reactivity in people who are currently depressed (Nemeroff and Musselman 2000; 
Schins et al. 2003). Hence, it is possible that depression itself, rather than the drugs 
used to treat it, carries an increased risk of venous thrombosis. Indeed, the findings of 
one laboratory-based study are consistent with such an interpretation and, in addition, 
they suggest a possible alternative explanation for the preponderance of tricyclic use in 
the present research. In a randomised double-blind trial, depressed patients with 
ischaemic heart disease and haematological evidence of platelet activation were 
randomly allocated to receive a six-week course of a selective serotonin reuptake 
inhibitor (paroxetine) or tricyclic (nortriptyline) antidepressant (Pollock et al. 2000). 
The indicators of platelet activation returned to normal in the patients taking paroxetine, 














the number of participants was very small and such studies involving proxy endpoints 
should be regarded with caution. 
6.6 OTHER RISK FACTORS AND VENOUS THROMBOEMBOLISM 
In the present study, current use of hormone replacement therapy was associated with a 
borderline significant three-fold increased risk of fatal pulmonary embolism. This is 
consistent with the findings of both observational studies (Boston Collaborative Drug 
Surveillance Program 1974; Daly et al. 1996; Grodstein et al. 1996; Jick et al. 1996c; 
Perez Gutthann et al. 1997; Varas-Lorenzo et al. 1998; Scarabin et al. 2003) and recent 
randomised controlled trials of hormone replacement therapy (Hulley et al. 1998; Grady 
et al. 2000; Hoibraaten et al. 2000; Hulley et al. 2002; Writing Group for the Women's 
Health Initiative Investigators 2002) in which current users had in the order of a two to 
three-fold increased risk of venous thromboembolism when compared with non-users. 
The finding of a significantly increased risk of fatal pulmonary embolism in people with 
a past history of venous thromboembolism in the present study is compatible with 
previous research (Goldhaber 2004), as are the findings for a history of superficial 
venous thrombosis (Kyrle and Eichinger 2005), impaired mobility (Goldhaber 2004), 
and obesity (Goldhaber 2004). 
The observed association between intellectual disability and fatal pulmonary embolism 
is an interesting finding. There have been isolated case reports of venous 
thromboembolism in intellectually disabled people with co-morbid medical conditions 
(Schlichtemeier et al. 1994; Okuyama et al. 2004) or quadriplegia (Lohiya et al. 2005), 
but it appears that the potential relationship between intellectual disability and venous 
thromboembolism has not been examined in analytical studies. Indeed, it has been 
suggested that intellectually disabled people with spastic paraplegia or quadriplegia 
might be less likely to develop venous thromboembolism, even in the presence of 
additional risk factors such as fractures and orthopaedic or abdominal surgery, because 
of increased muscle tone (Rousseau and Guillote! 2001). One of the eight cases with an 
intellectual disability in the present study was confined to a wheel chair (as a result of 
















without such disabilities and this might account for the increased risk. Alternatively, it 
is also possible that the incidence of venous thromboembolism in people with 
intellectual disabilities is similar to that found in the general population, but the case-
fatality rate is higher because of difficulties in recognising and communicating 
symptoms. 
6.7 SUMMARY AND IMPLICATIONS 











































CHAPTER 7 VENOUS THROMBOEMBOLISMAND LONG-
DISTANCEAIR TRAVEL 
7.1 INTRODUCTION 
The possible link between long-distance air travel and venous thromboembolism 
received widespread media attention in late 2000 and 2001. This interest appears to 
have been generated by at least three events. The first, in October 2000, was the death 
from pulmonary embolism of a 28 year old woman shortly after disembarking from a 
flight from Australia to the UK (BBC News 2000a). Media reports of this event were 
soon followed by accounts of other people who had developed venous 
thromboembolism following long-distance air travel (Ferguson 2000; Derbyshire and 
Dutter 2001; Espiner 2001a). 
The second factor which stimulated media interest was the publication in October and 
November 2000 of the results of two studies (Bendz et al. 2000; Kraaijenhagen et al. 
2000), and the pre-publication release of the findings of another (BBC News 2000b ). In 
the first study to be published, a case-control design, travel by air and by other means of 
transport was not associated with an increased risk of deep vein thrombosis 
(Kraaijenhagen et al. 2000). In the second, an uncontrolled experiment, activation of 
the coagulation system was found in volunteers who were exposed to hypobaric hypoxic 
conditions similar to those encountered during flight (Bendz et al. 2000). Finally, in a 
randomised controlled trial of graduated compression stockings in volunteers, 10% of 
the control group were said to have had ultrasonic evidence of asymptomatic deep vein 
thrombosis following a flight of more than eight hours (Scurr et al. 2001). The media 
reports about the conflicting results of these studies (BBC News 2000b; BBC News 
2000c; BBC News 2000d) were followed by various reports of the "thousands" of 
deaths from pulmonary embolism which could be attributed to long-distance flights 
each year (BBC News 2001a) . 
The third event which attracted media attention was the release, in November 2000, of a 
report by the UK House of Lords Select Committee on Science and Technology entitled 
Air Travel and Health (House of Lords Select Committee on Science and Technology 


















the Committee had examined a broad range of issues such as cabin ventilation, air 
quality, noise, stress, deep vein thrombosis and other medical conditions, the 
management of in-flight medical emergencies, and the adequacy of information 
provided to passengers. However it was the discussion about deep vein thrombosis 
which received the most publicity (Ferriman 2000; Laurance 2000). The Committee 
concluded that the risk of developing deep vein thrombosis in relation to air travel 
appeared to be "exceedingly small" for healthy people, while for passengers with pre-
existing risk factors, it was considered that "there may be an additional risk from flying, 
but it is not currently quantifiable". Given this "paucity of data" on air travel and 
venous thromboembolism, the Committee recommended that the Department of Health 
commission a case-control study to investigate the potential link as soon as possible, 
and that in the meantime airlines and travel agents should provide prospective 
passengers with information about simple measures to minimise the risk of developing 
flight-related deep vein thrombosis. The Committee also criticised the use of the term 
"economy class syndrome" and suggested that "traveller's thrombosis" was a more 
appropriate expression. 
The ensuing months saw several developments. WHO convened a meeting in March 
2001 which was attended by several researchers with an interest in venous 
thromboembolism, as well as representatives of airline companies, the International Air 
Transport Association, the International Civil Aviation Organization, the European 
Commission, and various consumer groups (Mendis et al. 2002). The meeting 
participants concluded that there was probably a link between air travel and venous 
thromboembolism, and that it was most likely to occur in passengers with other risk 
factors for venous thromboembolism, but there were insufficient data to quantify the 
risk. In response to the need for further information, it was agreed to initiate several 
new studies under the auspices of WHO and the International Civil Aviation 
Organization. 
Advice for air passengers were subsequently issued by WHO (World Health 
Organization 2005) and by health departments in several countries, including the 
Department of Health in the UK (Department of Health 2001) and the Ministry of 
Health in New Zealand (Medsafe 2001a). In Australia the Federal Government 























were reports of proposed litigation against airlines by people who had developed venous 
thromboembolism after a long-distance flight (Espiner 2000; AAP 2001), at least one 
travel insurance company took the opportunity to attract business by assuring 
prospective customers that the costs of treating flight-related venous thromboembolism 
would be covered by their policy (Yoon 2001), the use of various devices were 
promoted as providing some protection against venous thromboembolism (Caruana et 
al. 2003), and travel medicine clinics in South Africa and the USA offered screening for 
prothrombotic genetic mutations (Bateman 2003). 
Some airlines were reportedly reluctant to acknowledge the potential association 
between air travel and venous thromboembolism (Espiner 2001b), but did provide 
advice to passengers about measures they could undertake to prevent the condition (Air 
New Zealand 2001; BBC News 2001b). The airline industry was criticised by some 
people who maintained that the risk of venous thromboembolism in air travellers had 
been recognised for decades and that the airlines had failed to do anything about it 
(BBC News 2001c). 
However, was there really sufficient evidence to conclude that air travel increased the 
risk of venous thromboembolism? The first review of the topic in 1992 concluded that 
although the published data were suggestive of a link between air travel and venous 
thromboembolism, in the absence of any analytical epidemiological studies it was 
impossible to draw any definite conclusions about the association (Milne 1992). Other 
reviews published before the media furore, also reported that the evidence for a link was 
largely circumstantial (Forbes and Johnston 1998; Giangrande 2000; Kesteven 2000). 
Since 2000, the potential association between air travel and venous thromboembolism 
has been the subject of many studies. This chapter will examine the data that were 
available before the publication of the research outlined in Chapters 8 - 11 (Parkin et al. 
2006) and will attempt to answer the following questions: 
1. Is there an association between air travel and venous thromboembolism? And if 
so, 
2. Is it likely to be causal? And if so, 




















4. What is the incidence of flight-related venous thromboembolism? 
5. What are the possible causal mechanisms? 
To identify relevant papers, the Medline database was searched using the following 
terms: "pulmonary embolism" "thromboembolism", "venous thrombosis", 
"thrombophlebitis", "travel", and "aircraft". Terms used to search the Embase database 
included "venous thromboembolism", "thromboembolism", "vein thrombosis", "lung 
embolism", "deep vein thrombosis", "travel", "aviation", "flight", and "flying". The 
reference lists of retrieved papers were also examined. 
Although several authors have described cases of arterial thrombosis following 
prolonged travel (Collins et al. 1979; Teenan and McKay 1992; Ashk:an et al. 1998), the 
discussion in this chapter will be confined to venous events. 
7.2 IS THERE AN ASSOCIATION BETWEEN AIR TRAVEL AND VENOUS 
THROMBOEMBOLISM? 
7.2.1 Case reports and case series 
The first intimation that travel might increase the risk of venous thromboembolism 
came in 1954 when a Boston surgeon described five cases of deep vein thrombosis 
which he attributed to prolonged sitting (Homans 1954 ). Four of the patients had 
recently undertaken long journeys by air (two) or car (two), and the fifth developed 
symptoms after leaving the theatre. The author proposed that people should undertake 
leg exercises when seated for long periods and advised doctors to be suspicious of calf 
pain that developed after travel and other situations involving prolonged sitting. 
Since this paper appeared, at least 45 case reports and case series have been published 
which describe almost 700 cases of venous thromboembolism among air travellers, 
some of which were fatal. In addition, several of the case series included people who 
developed venous thromboembolism following travel by car and other modes of 
transport. These accounts of venous thromboembolism following air and other travel 
are reviewed in detail in the table in Appendix C, but a few remarks will be made here 



















First, the duration of air travel undertaken by the cases ranged from less than three hours 
to more than 30 hours. Second, some of these flights were undertaken in economy class 
and some in first or business class. Ironically in one case series entitled Air travel and 
thrombotic episodes: the economy class syndrome one of the cases (also an author) 
travelled in business class (Cruickshank et al. 1988). Another report described the 
occurrence of deep vein thrombosis in a President of the USA following a long-distance 
flight on the presidential aircraft in 1974 (Barker et al. 1997). Such examples clearly 
highlight the misleading nature of the term "economy class syndrome". 
Third, while some authors confined their attention to people who developed symptoms 
during a flight or when disembarking (Beighton and Richards 1968; Thomas et al. 1981; 
Biirki 1989; Clerel and Caillard 1999; Partsch 2001; Tan et al. 2002; O'Connell et al. 
2005), others included events which occurred up to six weeks after air travel (Eklof et 
al. 1996). The immediate onset of symptoms was thought by some to provide 
compelling evidence that fresh thrombus had formed on the flight (Ledermann and 
Keshavarzian 1983). This theory was supported by the findings of a necropsy study of 
people who died following a long-distance flight - although it was also revealed that in 
a minority of cases, pulmonary emboli had been present before the index flight (Cheung 
and Duflou 2001). The latter finding was consistent with reports that some cases had 
developed symptoms after an outbound flight, but were not diagnosed until after 
subsequent flights (Kesteven and Robinson 2001). Several cases had symptoms which 
were mild and did not develop until some time after a flight, leading to delays in 
diagnosis (Voorhoeve and Bruyninckx 1990; Emonson 1997). Others had atypical 
symptoms which initially attracted alternative diagnoses (Holliday 1985; Black 1993). 
Yet others had symptoms of pulmonary embolism which at first were attributed to 
myocardial infarction (Sinzinger et al. 1999). 
Fourth, the characteristics of cases varied between reports with respect to age, the ratio 
of males to females, and the proportion of cases with pre-existing risk factors for venous 
thromboembolism. These variations may partly be explained by the methods used to 
select patients for review. Some series included consecutive patients while others did 
not, some included patients in general hospitals while others described the patients 
admitted to military hospitals, and yet others included outpatients attending specialist 

















various methods used to obtain information about air travel and other risk factors for 
venous thromboembolism. Some authors undertook retrospective reviews of medical 
records and the data obtained were therefore dependent on both the questions that the 
patients had been asked and the information they had spontaneously volunteered. Even 
data that were sought prospectively were not always comprehensive - for example, the 
use of oral contraceptives (Benoit 1992) and hormone replacement therapy (Paganin et 
al. 1996) by female passengers was not enquired about until surprisingly recently. 
Fifth, in studies of consecutive patients with venous thromboembolism varying 
proportions of patients were identified as recent air travellers. This may be due to the 
reporting and recording biases inherent in retrospective reviews of medical records, as 
well as differences in the underlying frequency of long-distance air travel in the source 
populations. 
Finally, a few studies ascertained the seating position of the cases (for example, whether 
or not they had an aisle seat) and studied their in-flight behaviour (for example, whether 
they moved about the cabin or undertook seated leg exercises, and whether they 
consumed alcohol or took sedatives during the flight) (Sinzinger et al. 1999; Parsi and 
McGrath 2000; Parsi et al. 2001). Some also ascertained whether the cases were 
passengers or crew (Parsi and McGrath 2000; Parsi et al. 2001). 
While these case reports and case series are suggestive of a link between air travel and 
venous thromboembolism, they provide only circumstantial evidence. In addition to the 
selection and information biases already discussed, one of the major limitations of these 
data, as with all case reports and case series, is the lack of a comparison group. Without 
such a group it is impossible to know whether venous thromboembolism occurs more 
often in air travellers than in non-travellers, and whether air travellers who develop the 
condition have more pre-existing risk factors than other passengers. To explore these 
questions, it is necessary to tum to analytical epidemiological studies. Unfortunately, 
however, surprisingly few such studies have explored the potential association between 
air travel and venous thromboembolism. Moreover, much of the research suffers from 
considerable methodological problems. In the following sections, therefore, these 





















7 .2.2 Case-control studies 
Only eight case-control studies had examined the association between travel by air (and 
other modes of transport) and venous thromboembolism before the publication of the 
research outlined in Chapters 8 - 11 (Parkin et al. 2006). These investigations are first 
summarised in Table 7 .1 and then discussed individually. As will be seen, the studies 
differed in their definitions of travel (travel by any mode of transport, or by air alone), 
the duration of the journey, the designated period of risk following a journey, the 
venous thromboembolic events that were included, the methods that were used to 
confirm the diagnosis, the exclusion criteria that were employed, and the approaches 
towards the selection of controls. 
""'-' -,-
y ..., <{ 




Table 7.1 Case-control studies of travel and venous thrornboernbolisrn 
Reference Number of Selection of cases Selection of Exposure information Odds ratio (95 % CI) Comments 
participants controls 
(Ferrari et al. 160 cases, All patients with VTE admitted Age-matched Interviewer-administered Unadjusted 1. Exclusion criteria inconsistently 
1999) 160 controls to the cardiology department of a consecutive questionnaire in hospital. unmatched OR applied. 
Nice hospital between July 1992 patients admitted 
Travel ex12osure Any travel > 4 hours 
2. Participation rate of controls not 
and August 1995 (except 8 to the same given. 
patients who died after cardiology Journey > 4 hours by 3.98 (1.9 - 8.4) 3. Choice of control series may have 
admission). department with aeroplane, car, train, or led to an overestimation of risk. 
a first admission boat in 4 weeks before 4. Date of admission nominated as 
Confirmation of DVT: Doppler for another admission. index date. 
US, unclear whether staff were cardiovascular 5. Cases interviewed twice, relatives 
blinded to travel history. condition. Reference category assisted. 
Confirmation of PE: not "Non-travellers" (people 6. Unmatched analysis 
specified. Unclear whether who did not undertake 7. Potential confounding was not 
individual or travel as above). explored. 
frequency 
matching. 
(Samamaand Overall Overall study population First patient after Standardised data form, Adjusted unmatched 1. 102 confirmed cases excluded 
the Sirius Study study Patients with DVT who case who unclear whether completed OR because of missing data or inadequate 
Group2000) population presented to GP centres in presented with by GPs or researchers. matching. 
636 cases, France October 1990- an influenza! or Overall study 2. Participation rates of other cases 
636 controls December 1991. rhinopharyngeal Travel ex12osure population and controls not given. 
condition. ''Long-distance travel"~ 3 Not reported. 3. Choice of control series may have 
Medical Medical study population weeks before GP visit. led to over- or underestimation of 
study Above patients excluded if Matched by GP Duration and mode of Medical study risk. 
population surgery or lower limb plaster cast centre, sex and transport not defined. population 4. Date of GP visit nominated as 
494 cases, ~ 3 weeks before admission. age (10-year age "Long-distance index date. 
494 controls bands). Reference category travel" 5. Unmatched analysis, adjusted for 2 
Confirmation ofDVT: duplex "Non-travellers" (people 2.35 (1.45 - 3.80) of the matching factors. 
US, B-mode US, venography, who did not undertake 6. Potential confounding by other 
and/ or impedance travel as above). OR adjusted for sex factors was not explored. 
plethysmography. and age. 
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Reference Number of Selection of cases Selection of Exposure information Odds ratio (95 % Cl) Comments 
participants controls 
(Kraai jenhagen FirstDVT First DVT study First DVT study First DVT study Unadjusted OR First DVT study 
et al. 2000) study Consecutive outpatients> 18 Consecutive Questionnaire before 1. Lack of power. 
(FirstDVT 186 cases, years who presented with outpatients> 18 diagnostic investigations, First DVT study 2. Researchers based in the 
study) 602 controls clinically suspected DVT years who unclear whether self or Any travel > 3 hours Netherlands and Italy, but the specific 
between April 1997 and January presented with interviewer-administered. 0.7 (0.3 - 1.4) source(s) of the cases and controls 
(ten Wolde et al. Pooled 1999, objective evidence ofDVT clinically was not given. 
2003) analysis or PE. suspected DVT Travel exposure Any travel > 5 hours 3. Participation rates of cases and 
(Pooled 244 cases ( during the same Journey> 3 hours by car, 0.4 (0.1- 1.3) controls not given. 
analysis) withDVT, Confirmation of DVT: D-dimer, period as the train, boat, or aeroplane, in Air travel > 3 hours 4. Choice of control series may have 714 controls compression US or contrast cases) who had 4 weeks before 1.0 (0.3 - 3.0) led to an underestimation of risk. 
venogram. no objective presentation. 5. Date of presentation nominated as 
233 cases evidence of index date. 
with PE, Confirmation of PE DVTorPE. 
Reference category 
756 controls (symptomatic patients only): "Non-travellers" (people Pooled analysis Pooled analysis 
D-dimer, V-Q scan or pulmonary Pooled analysis who did not undertake Any travel > 3 hours As in 2 - 5 above. 
angiogram. Consecutive travel as above). 0.9 (0.6 - 1.4) 
Investigations conducted by staff 
outpatients > 18 
years who Obtained similar 
blinded to travel history. presented with results when excluded 
Pooled analysis clinically 
those unlikely to have 
Above patients, plus patients · suspected DVT 
travelled. 
fulfilling the same criteria who or PE ( during Any travel 11 - 15 same period as presented between February 
cases) who had hours 1999 and September 2000. Also 
no objective 2.5 (1.0 - 6.2) inpatients and outpatients 
presenting with clinically evidence of Any travel > 16 hours 
suspected PE between October DVTorPE. 1.3 (0.4 - 4.3) 
1998 and September 2000, 
objective evidence of PE. Air travel > 3 hours 











Reference Number of Selection of cases Selection of Exposure information Odds ratio (95 % Cl) Comments 
participants controls 
(Dimberg et al. 81 cases, Identified from medical Randomly Travel ex11osure Adjusted OR 1. Diagnosis not confirmed by 
2001) 891 controls insurance claims for venous selected from Record of completing an reference to personal medical files. 
thrombosis by World Bank staff records of World international mission :::0: 30 Recent mission 2. May have missed some cases if 
who were employed in Bank staff with days before medical 0.89 (0.39 - 2.02) they delayed submitting claims. 
Washington and had medical medical insurance insurance claim filed. 
OR adjusted for sex insurance between 1995 and and employed in 
1998. Washington 1995 Reference category and age. 
-1998. No record of completing 
international mission :::0: 30 
days before index date. 
(Arya et al. 185 cases, Consecutive outpatients aged 16 Consecutive Interviewer-administered Unadjusted OR Original analysis 
2002) 383 controls - 93 years with clinically outpatients with questionnaire. 1. Participation rates of cases and 
(Original suspected DVT who were clinically Original analysis controls not given. 
analysis) referred by GPs and hospital suspected DVT Travel ex11osure Any travel > 3 hours 2. Choice of control series may have 
emergency department staff to who were referred Air or "surface" journey 1.4 (0.7 - 2.6) led to an underestimation of risk. 
(Arya and the DVT Clinic at King's to the DVT Clinic > 3 hours in 4 weeks 3. Date of presentation at DVT 
Cohen 2003) College Hospital in London ( during the same before presentation. Air travel > 3 hours Clinic nominated as index date. 
(Reanalysis) between February 2000 and period as the 1.2 (0.6 - 2.3) 4. Potential confounding was not 
June 2001, objective evidence of cases) who had no Reference category explored. 
"Non-travellers" (people Air travel > 8 hours DVT. objective 1.3 (0.6 - 2.8) 
evidence ofDVT. who did not undertake Reanalysis 
Confirmation of DVT: duplex travel as above). 1. As in 1 - 4 above. 
us. 2. Number of controls reported to 
Reanalysis have risk factors inexplicably 
Not stated whether staff were Any travel > 3 hours, different from original analysis. 
blinded to travel history. > 1 risk factor 
2.9 (1.1 - 7.9) 
Any travel > 3 hours, 
no risk factors 
0.7 (0.2 - 2.2) 
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Selection of cases 
Consecutive patients with 
clinically suspected DVT who 
were referred to the vascular 
laboratory at Ealing Hospital in 
London between April 2000 and 
June 2001 and were found to 
have objective evidence of 
DVT. 36 patients were excluded 
because they had no opportunity 
to travel. 
Confirmation ofDVT: duplex 
us 
Investigations conducted by 








who were referred 
to the same 
vascular 
laboratory 
between April and 
June 2001 who 















Journey > 3 hours by 
any mode of transport in 2 




who did not undertake 
travel as above). 
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Odds ratio (95 % Cl) Comments 
Unadjusted OR 
Any travel > 3 hours 
1.3 (0.6 - 2.8) 
Air travel > 3 hours 
0.8 (0.3 - 1.9) 
1. Participation rates of cases and 
controls not given. 
2. Choice of control series may have 
led to underestimate of risk. 
3. Controls selected during final 3 
months of 15-month study -
coincided with a period of intense 
media interest in the possible link 
between air travel and VTE. 
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Consecutive patients aged 20 - 70 
years referred to a thrombosis 
centre between January 1999 and 
September 2001 for thrombophilia 
screening following a first 
diagnosis of proximal DVT or PE 
at some time in the previous 24 
months. Patients with known 
malignancy were excluded. 
Confirmation of DVT: Doppler 
US or venography. 
Confirmation of PE: V-Q scan, 
computed tomography, or 
pulmonary angiography. 
Not stated whether investigations 






Matched by age 
(10-year age 
bands), sex and 
educational level, 
and selected from 




testing during the 
study period 
(friends or 
partners of all 
patients referred 
to the thrombosis 
centre). 
Potential controls 
were excluded if 













Air travel in month before 
VTE event (cases) or visit 




who did not undertake 






Odds ratio (95% Cl) Comments 
Unadjusted 
unmatched OR 
Any air travel 
2.1 (1.1 - 4.0) 
Air travel > 8 hours 
3.0 (0.9 - 9.5) 
Any air travel with 
thrombophilia 
16.1 (3.6 - 70.9) 
Any air travel with 
OCuse 
13.9 (1.7 - 117.5) 
Adjusted unmatched 
OR 
Any air travel with 
thrombophilia 
16.8 (3.8 - 74.7) 
OR adjusted for sex, 
age, and BMI. 
Any air travel with 
OCuse 
23.4 (2.6 - 211.2) 
OR adjusted for age 
and BMI. 
1. Median time of 5 months (range 1 
- 24) elapsed between VTE event 
and the date of interview for cases, 
whereas controls were asked about 
risk factors in the month leading up 
to their interview. 
2. Unmatched analysis, adjusted for 
2 of the matching factors (sex and 
age), but not the third (education). 
3. Potential confounding by other 
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Consecutive patients < 70 years 
with a first episode of VTE who 
were registered for 
anticoagulation treatment at 6 
regional anticoagulation clinics in 
the Netherlands between March 
1999 and May 2002. Excluded 
patients unable to complete 
questionnaire, those who died 
soon after VTE event, people in 
end stage of a disease. 
Case-only analysis based on 1,025 
women < 50 years. 
Reviewed diagnosis of DVT and 
PE in sample of cases, fulfilled 
criteria for Dutch diagnostic 
standard in 97% DVT and 78% 
PE cases respectively. 
Not stated whether investigations 







Spouses of 1,867 
cases, served as a 
control to their 
own husband or 
wife. 
Spouses of 229 
cases who had 
been deemed 
ineligible matched 
by sex and 5-year 
age groups to 229 
of 557 cases 
whose spouses did 
not want to 
participate. 
Same exclusion 






questionnaire, or interview 
by telephone (but did not 
ask questions about travel). 
Travel exposure 
Journey ;::: 4 consecutive 
hours by any mode of 
transport in 8 weeks before 
index date ( date of event). 
Reference category 
"Non-travellers" (people 
who did not undertake 
travel as above). 
y 
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Odds ratio (95 % Cl) Comments 
Unadjusted matched 
OR 
VTE, any travel > 4 
hours 
2.1 (1.5 - 3.0) 
VTE, any travel 
4 - 8 hours: 2.0 
8 - 12 hours: 1.8 
> 12 hours: 2.8 
VTE, air travel > 4 
hours 
1.7 (1.0- 3.1) 
DVT. any travel > 4 
hours 
1.9 (1.1 - 3.2) 
DVT, air travel> 4 
hours 
3.0 (1.3 - 7.1) 
Interactions with FVL, 
BMI > 30 kg/m2, 
height < 1.60m or > 
1.90m, OC use. 
1. Only 78% of sample of PE 
diagnoses confirmed according to 
Dutch diagnostic standards. 
2. 3,902 cases of VTE met initial 
eligibility criteria, only 1,906 
(48.8%) included in study. 
3. 190 case/control pairs excluded 
because one or both members gave 
information about travel after rather 
than before the index date. 
4. 233 cases and 182 controls had 
travelled but analyses based on 98 
cases and 47 controls because of 
concordance in positive exposure 
status in 135 case/control pairs. 
5. Possibility that relative risk 
underestimated because of 8-week 
risk period. 
6. Undertook matched analysis, but 
did not explore confounding by other 
factors. 
Abbreviations used in the table BMI: body mass index, DVT: deep vein thrombosis, FVL: factor V Leiden, GP: general practitioner, OC: oral contraceptive, OR: odds ratio, PE: pulmonary embolism, US: ultrasound, V-Q scan: 


















Ferrari et al (1999) 
This French hospital-based case-control study, which involved 160 cases and 160 
controls, was the first analytical study to examine the association between travel and 
venous thromboembolism (Ferrari et al. 1999). Travel (by air, car, train, or boat) of 
more than four hours' duration in the four weeks before admission with deep vein 
thrombosis or pulmonary embolism was associated with a significant four-fold increase 
in risk (unadjusted odds ratio 3.98 [95% CI 1.9 - 8.41). 
There were several sources of selection and information bias in this study. An age-
matched control group was reportedly selected from consecutive patients with other 
cardiovascular conditions who were admitted to the same cardiology department as the 
cases. Apparently all cases, apart from eight who died after admission, were included in 
the study. However, it is unclear whether all of the eligible controls participated. The 
events that led to the admission of the controls were chest pain (76% ), arterial 
hypertension (13% ), and syncope (11 % ). The preponderance of patients with chest pain 
resulted in a greater proportion of men in the control group (66.2% c.f. 51.8% of cases) 
and a potentially biased sample with respect to travel exposure. While only those with a 
first admission owing to a cardiovascular event were selected as controls, it is 
nevertheless possible that some of these patients experienced prodromal symptoms in 
the weeks before admission and were therefore less likely to travel than the cases . 
Hence, because the admission date of each case and control (rather than the date the 
symptoms began) was taken as the index date, any association between travel and 
venous thromboembolism might have spuriously been strengthened. Conversely, it is 
also possible that the magnitude of any travel effect was underestimated since the 
exclusion criteria seem to have been applied inconsistently in this study. Patients with 
"severe diseases that might have limited their mobility" were excluded from the control 
group, as were patients who had been treated with anticoagulant or antiplatelet drugs. 
Yet it appears that these same criteria were not applied to the cases, since 79 patients 
had known cancer or had developed thrombosis following bed rest or surgery. 
An interviewer-administered questionnaire was used to obtain information from cases 
and controls about known and suspected risk factors for venous thromboembolism, 
including travel. Cases were interviewed at their bedside within the first few days after 

















assistance of next of kin. It is not clear whether controls were also interviewed twice, 
nor is it obvious whether their relatives were involved. Any failure to follow an 
identical protocol for controls might have resulted in a less accurate ascertainment of 
travel history and could have led to a biased estimate of true risk. It is also not apparent 
whether the diagnostic investigations were undertaken before the cases were 
interviewed and whether the radiology staff were blinded to exposure status. 
Although the researchers collected extensive information about risk factors for venous 
thromboembolism (the questionnaire comprised more than 300 questions and included 
enquiries about recent surgery, bed rest, pregnancy, venous trauma, use of oral 
contraceptives or hormone treatment, known cancer, systemic disease, and known 
coagulation abnormalities), they failed to explore the possibility of confounding. This is 
surprising since they did note that cases were less likely to be male, more likely to be 
obese, and more likely to have a history of deep vein thrombosis than controls . 
Furthermore, as some commentators observed, the conditions with which the controls 
were admitted occur more often among people in lower socio-economic groups 
(MacGillavry et al. 2001). Since such people would be less likely to have travelled, it is 
possible that socio-economic status might have confounded the association between 
travel and venous thromboembolism, leading to an overestimation of the odds ratio. 
Nonetheless, the researchers simply reported a crude odds ratio. Moreover, they did not 
advise whether matching by age was undertaken at an individual level or whether 
frequency matching was employed. If the former approach was used, then age should 
have been accounted for in the analysis to avoid a conservative bias in the estimate of 
relative risk (Rothman and Greenland 1998). 
Samama and the Sirius Study Group (2000) 
In this French case-control study, which examined a number of risk factors for deep 
vein thrombosis among general practice patients, a significant two-fold increased risk of 
venous thrombosis was found for people who had undertaken long-distance travel (not 
defined) in the three weeks before diagnosis (Samama and the Sirius Study Group 
2000). In an analysis based on 494 cases and 494 controls, the sex and age-adjusted 


















Selection and information biases may have played a role in this study. Of a total of 738 
confirmed cases, 102 (13.8%) were excluded because of missing data or inadequate 
matching. Hence, a total of 636 cases were included, although the key analyses were 
based on a sub-group (referred to as the medical study population, n = 494) who had not 
undergone surgery or had a lower limb plaster cast applied in the three weeks before 
diagnosis. The overall participation rate of cases was not given. 
One control, matched by general practice, sex, and age, was selected for each case; 
general practitioners were asked to include the first patient of the appropriate sex and 
age who presented with influenza or a rhinopharyngeal condition following the 
identification of the case. Although it is unclear whether the doctors were provided 
with more detailed instructions, it is unlikely that they would have consciously 
manipulated the selection of controls according to travel exposure since the study was 
concerned with a broad range of risk factors for deep vein thrombosis. It is possible, 
however, that the general practitioners might have excluded sicker patients, who would 
have been less likely to travel, if inclusion in the study meant that controls would be 
subjected to a long interview. Any such bias would tend to lead towards an 
overestimation of the prevalence of travel in the population that gave rise to the cases 
and hence an underestimation of relative risk. Unfortunately there was no information 
provided about the participation rate of the controls . 
The selection of patients with influenza or rhinopharyngeal conditions as controls might 
have led to a biased estimate of relative risk if these complaints were associated with the 
likelihood of travel. For example, certain groups of people, such as smokers and people 
with chronic illnesses, are more at risk of respiratory infections and may also be less 
likely to travel. These people are also more likely to belong to lower socio-economic 
groups, further reducing the possibility of travel. Thus, any association between venous 
thromboembolism and air travel might have been overestimated. It is also possible that 
people who intended to travel delayed or postponed their journey following the onset of 
influenza or rhinopharyngeal symptoms. This is an issue because the date of the visit to 
the general practitioner was taken as the index date, rather than the date of onset of the 
symptoms. Conversely, if recent travellers were more likely to have contracted a 
respiratory infection than people who had not travelled, then the association between 









of a selection bias was raised by the researchers in relation to the surprising lack of an 
association between oral contraceptive use and venous thromboembolism ( odds ratio 
0.60, p = 0.08) and an apparent protective effect of smoking (odds ratio 0.66, p-value < 
0.04). They attributed these findings to the fact that smokers were more likely to 
present with respiratory conditions and thus be selected as controls, and smoking was 
strongly associated with oral contraceptive use among the female controls. 
For each case and control, a standardised form was used to record demographic data and 
information about 23 permanent ( or intrinsic) risk factors for deep vein thrombosis and 
24 triggering events in the three weeks before diagnosis. In the medical study 
population, 85.2% of cases and 53.4% of controls were reported to have one risk factor 
for deep vein thrombosis, and 56.7% and 18.4% respectively had two or more risk 
factors. It appears that an unmatched analysis was undertaken, with adjustment for two 
of the matching factors (sex and age). The researchers reported that it was not possible 
to adjust for any other potential confounders in a multivariate regression model because 
of a large number of interaction tests that were statistically significant. 
Kraaijenhagen et al (2000) 
This study, which was undertaken by researchers in the Netherlands and Italy, included 
186 cases and 602 controls (Kraaijenhagen et al. 2000). Air travel of more than three 
hours' duration in the four weeks before diagnosis was not associated with an increased 
risk of deep vein thrombosis; the unadjusted odds ratio was 1.0 (95% CI 0.3 - 3.0). The 
unadjusted estimate for travel by any form of transport (air, car, bus, train, or boat) was 
0.7 (95% CI 0.3 - 1.4). Cases were more likely than controls to have had a previous 
episode of venous thromboembolism (22% cases, 10% controls), to have a known 
malignancy (22% cases, .10% controls), and to have recently undergone surgery (26% 
cases, 13% controls), but were less likely to have suffered recent trauma (11 % cases, 
16% controls). Adjustment for these risk factors, age, and for the duration of symptoms 
reportedly had no impact on the odds ratios. The inclusion of people with such risk 
factors was criticised on the grounds that malignancy, recent surgery or trauma might 
have reduced the likelihood of travel (Ferrari and Morgan 2001), however the estimate 
for recent travel by any means did not change when such cases and controls were 
excluded (odds ratio 0.5 [95% CI 0.2 - 1.6]). Neither was an elevated risk found for 














Only four of the 186 cases (2.2% ), and an identical proportion of controls, had 
undertaken air travel and the duration of their flights were not reported. This led to 
criticisms that the study might have been underpowered to detect an elevated risk 
(Bumand et al. 2001; Reele 2001). This would be especially so if the cases undertook 
relatively short flights, since (as will be discussed later) it seems there is a dose-
response relationship between flight duration and the incidence of venous 
thromboembolism (Lapostolle et al. 2001; Perez-Rodriguez et al. 2003). In response, 
the researchers reported the. median duration of travel by any mode of transport, but did 
not provide any details about the duration of air travel (Kraaijenhagen and Bi.iller 2001). 
They also acknowledged that the upper bound of the 95% confidence interval for air 
travel (3.0) was not inconsistent with an elevated risk and indicated that they had 
extended their study to include more cases of deep vein thrombosis ( outpatients referred 
between February 1999 and September 2000) and patients with pulmonary embolism 
(outpatients and inpatients referred between October 1998 and September 2000). 
The results of the extended study were reported in 2003 (ten Wolde et al. 2003). The 
data were pooled to explore the risks associated with any travel, travel by particular 
modes of transport, and the duration of travel. In one analysis, patients who were 
unlikely to have travelled (those with a malignancy or with a history of recent surgery, 
trauma, immobilisation, or a hospital admission) were excluded. The only elevated risk 
was observed for travel by any means of 11 - 15 hours' duration (odds ratio 2.5 [95% 
CI 1.0 - 6.2]). The odds ratios for travel of more than 16 hours by any means and for 
air travel of more than 3 hours were 1.3 (95% CI 0.4 - 4.3) and 1.2 (95% CI 0.7 - 2.1) 
respectively. 
There is a strong possibility that selection biases inherent in this study led to an 
underestimate of any association between travel and deep vein thrombosis. The 
investigators reported that they tried to minimise potential referral biases by taking as 
their control group all people with clinically suspected deep vein thrombosis who were 
referred for investigation and were subsequently found to have no evidence of the 
condition. However the selection of controls from a group of patients initially suspected 
of having the disease of interest is only appropriate in situations where the exposure of 
interest does not produce similar symptoms to the outcome of interest (Rosendaal et al. 











to benign leg swelling or discomfort than non-travellers, and moreover doctors might 
have been more likely to refer patients with symptoms suggestive of deep vein 
thrombosis if they had travelled (Cates 2001; MacGillavry et al. 2001; Rosendaal et al. 
2003b ). Because patients with benign symptoms would have subsequently been 
assigned to the control group, this might have resulted in an overestimation of the 
prevalence of travel in the population that gave rise to the cases and an underestimation 
of any association between travel and deep vein thrombosis. The researchers replied 
that such a scenario was unlikely because patients were referred for investigation, on 
average, seven days after the onset of symptoms and in most patients the symptoms 
were unilateral (Kraaijenhagen and BU.Iler 2001). However, they did not indicate 
whether this was also true for the air travellers, or indeed whether there were any 
differences between cases and controls in relation to the nature of their symptoms and 
the time which had elapsed since the onset of their symptoms . 
In their later extended study, the researchers reported elevated relative risks for 
malignancy (odds ratio 2.6 [95% CI 1.8 - 3.9]) and recent surgery (odds ratio 2.4 [95% 
CI 1.6 - 3.7]) which they cited as evidence against any referral bias (ten Wolde et al. 
2003). This argument does not consider the possibility that patients with symptoms 
suggestive of deep vein thrombosis might be more likely to present themselves to their 
doctor if they had recently flown, than if they had cancer or had recently undergone 
surgery, since the public are probably more aware of the possible link between air travel 
and venous thromboembolism. 
The researchers gave no information about the participation rates of the cases and 
controls. An additional issue is that some cases might have been misclassified as controls 
if they delayed seeking attention for their symptoms and hence allowed time for a 
thrombus to spontaneously lyse (Reele 2001) - such misclassification would result in an 
underestimation of any association between air travel and venous thromboembolism. 
Since patients presented on average a week after the onset of their symptoms, this is not 
implausible. It has also been suggested that people with thrombosis in the deep veins of 
the calf might have been misclassified as controls because compression ultrasonography 
is an inaccurate technique for detecting such thromboses (Burnand et al. 2001). Finally it 
is also possible that air travel by some of the subjects was not identified because the date 
















In summary then, a lack of power, a likely selection bias, the potential misclassification of 
cases as controls, and the possibility of uncontrolled confounding would all have tended 
to bias the estimate of relative risk towards the null value and may explain the absence of 
an association in this study. 
Dimberg et al (2001) 
In this case-control study, based on the medical insurance records of World Bank staff, 
who were employed in Washington and insured between 1995 and 1998 (n= 8,189), no 
association was found between recent air travel and the risk of venous thrombosis 
(Dimberg et al. 2001). The study was prompted by an observed increase in health 
insurance claims by World Bank employees for venous thrombotic disorders in 1997. 
After adjusting for sex and age, employees who had a record of having recently 
undertaken an international mission were 0.89 times (95% CI 0.39 - 2.02) as likely to 
have filed a medical insurance claim relating to venous thrombosis as employees who 
had not recently undertaken such a mission. 
The cases were identified using medical insurance claims. Eighty one cases of 
phlebitis, thrombophlebitis or thromboembolism (ICD-9 451 or 453) were identified 
( only the first claim for each employee was included), and 30 of these had deep vein 
thrombosis (ICD-9 451.1, 451.11, 451.19, 451.2, 453.9). To identify the flight-related 
events, the researchers identified all cases who filed an insurance claim after the 
beginning and within 30 days of completion of an international mission. Eleven cases 
with superficial or deep vein thrombosis were thus identified as being flight-related. It 
is not explained why the claim date was used instead of the date of diagnosis, but the 
researchers maintained that this was a reasonable approach because recent travellers 
with venous thrombosis appeared to file claims promptly and hence potential cases 
would not have been missed. Indeed the true number of cases could, according to the 
researchers, have been overestimated because it was not possible to examine personal 
medical files to verify the diagnosis. The controls (10 per case) were randomly selected 
from the records of insured employees who had not filed a claim for venous thrombosis 
before the date the case submitted his or her claim. 
Although no association was found, the researchers rather surprisingly proposed that 











people frequently flying long distances for their work. However, it would be unwise to 
draw any conclusions from this study - the methods of case ascertainment were poor, 
the nominated index date was inappropriate, it is possible that exposure to long-distance 
air travel was incomplete (since only work-related travel was identified), and it was not 
possible to obtain information about possible confounders. 
Arya et al (2002) 
This study, which included 185 cases and 383 controls, was undertaken by researchers 
at King's College Hospital in London who concluded that travel was only associated 
with an increased risk of deep vein thrombosis in people with pre-existing risk factors 
(Arya et al. 2002). When the odds of deep vein thrombosis in travellers with at least 
one pre-existing risk factor was compared with the odds in non-travellers without risk 
factors, the unadjusted odds ratio for flights of more than eight hours in the four weeks 
before the diagnosis of deep vein thrombosis was 3.0 (95% CI 1.1 - 8.2). The 
corresponding estimate for travel of more than three hours by any mode of transport was 
2.7 (95% CI 1.2 - 6.4). Conversely, when the presence or absence of risk factors was 
not taken into account, the unadjusted odds ratios were 1.2 (95% CI 0.6 - 2.3) for air 
travel of more than three hours, 1.3 (95% CI 0.6 - 2.8) for air travel of more than eight 
hours, and 1.4 (95% CI 0.7 - 2.6) for travel of more than three hours by any means. 
However, the analysis was criticised by commentators who claimed that it was 
impossible to determine whether the elevated risk in people with pre-existing risk 
factors was attributable to travel or due to the risk factors themselves (Rosendaal et al. 
2003b ). The correct approach, they argued, was to restrict the analysis to cases and 
controls with at least one risk factor. The researchers undertook the recommended 
reanalysis and reported that the significantly elevated risk persisted for travel of more 
than three hours' duration by any form of transport (odds ratio 2.9 [95% CI 1.1 - 7.9]) 
(Arya and Cohen 2003). Among those with no additional risk factors, the odds ratio for 
any travel of more than three hours was 0.7 (95% CI 0.2 - 2.2). But inconsistencies in 
the number of controls reported to have risk factors raise questions about the reliability 
of these results. Of 31 controls who travelled, four of the 12 who were classified as 
having at least one pre-existing risk factor in the original paper were inexplicably 





















As in the studies by Kraaijenhagen and colleagues (Kraaijenhagen et al. 2000; ten 
Wolde et al. 2003), the controls were patients initially suspected of having venous 
thrombosis, thus introducing the possibility of selection bias and an underestimation of 
any elevated risk. The researchers acknowledged that the media publicity about a 
perceived association between travel and venous thromboembolism might have resulted 
in a control series that was more similar to cases with respect to travel history than the 
population that gave rise to the cases. Moreover, it is impossible to ascertain from the 
information provided whether all of the eligible cases and controls participated in the 
study. 
The researchers collected information about risk factors for venous thromboembolism 
such as a personal or family history of venous thromboembolism, obesity, hormonal 
therapies, pregnancy, immobilisation (undefined), malignancy, and surgery. It was 
found that a greater proportion of cases than controls had a personal history of venous 
thromboembolism (24.5% c.f. 15.7%) or had recently undergone surgery (12.5% c.f. 
2.1 %), and that 75.0% of the cases who travelled had at least one other risk factor for 
deep vein thrombosis, as compared with 38.7% of travelling controls. Although the 
researchers did stratify by the presence of risk factors, it is possible that the mix of those 
factors differed between cases and controls and hence residual confounding is possible. 
Moreover, neither sex nor age were accounted for in the analysis. This is relevant 
because a greater proportion of cases were male ( 49% c.f. 29% ). Moreover, the age 
range observed among the 568 case and control patients was extremely wide (16 - 93 
years). The range was not reported separately for cases and controls - instead, the 
researchers reported mean ages (cases 55 years, controls 54 years), which might have 
been skewed by extreme values. Finally, the researchers do not appear to have 
considered that some subjects, for example those who recently underwent surgery, may 
have been less likely to have travelled. 
Hosoi et al (2002) 
In this study undertaken at Ealing Hospital in London, which was based on 101 cases 
and 106 controls, the crude odds ratio for travel by air in the two weeks before the onset 
of symptoms was 0.8 (95% CI 0.3 - 1.9) (Hosoi et al. 2002). The estimate for travel by 
any mode of transport was 1.3 (95% CI 0.6 - 2.8). Unlike earlier case-control studies, 







nursing home or other chronic care facility) or surgery in two weeks before referral 
were excluded from the study as it was considered that these people would not have had 
the opportunity to undertake a recent journey. 
There were significantly more travelling cases (73%) with thrombi confined to the 
popliteal or distal veins compared with non-travelling cases (37% ), prompting the 
researchers to suggest that travel-related thrombi might have a preference for distal 
veins. However, it seems equally plausible that thrombi were simply diagnosed earlier 
in travellers, before they had time to propagate to more proximal veins. 
Participants were identified using the same approach as the studies by Kraaijenhagen, 
Arya, and their colleagues (Kraaijenhagen et al. 2000; Arya et al. 2002; ten Wolde et al. 
2003) - cases and controls were patients referred to the researchers' vascular unit with 
suspected deep vein thrombosis - and hence the study suffers from the same problems 
with potential selection bias. In fact, such bias could have been even more of an issue 
in this study because the cases were ascertained over a 15-month period between April 
2000 and June 2001, whereas the controls were not selected until the final three months 
of the study (April 2001 to June 2001). Hence, the controls were obtained immediately 
after a period of intense media interest, especially in the UK, in the possible link 
between air travel and venous thromboembolism. The fact that a rather high proportion 
(11 % ) of controls had travelled by air in the two weeks before the onset of symptoms 
(all presented with leg pain and/ or swelling) suggests that the prevalence of air travel 
in the population from which the cases was drawn may well have been overestimated. 
Ironically, the researchers themselves refer to the heightened media publicity, but do not 
appear to have considered the impact that this might have had on their study. Finally, in 
relation to the potential for selection bias, it is impossible to ascertain from the 
information provided whether all eligible cases and controls participated in the study. 
All participants were asked about their medical history using a standardised 
questionnaire. This included enquiries about a personal or family history of venous 
thromboembolism, the use of hormone replacement therapy, known malignancy, 
pregnancy or post-partum status, trauma in the two weeks before referral, and age> 60 
years. Surprisingly there is no indication that female patients were asked about oral 















presence of any chronic venous insufficiency and obesity, and most of these cases also 
underwent thrombophilia screening. Although the researchers highlighted differences 
in the age distribution and the frequency of risk factors for deep vein thrombosis among 
the cases who travelled compared with those who did not, they do not appear to have 
considered the possibility of confounding. 
Martinelli et al (2003) 
In this study, which was undertaken at the Maggiore Hospital in Milan and included 210 
cases and 210 controls, air travellers were twice as likely to develop non-fatal venous 
thromboembolism as non-travellers (Martinelli et al. 2003). The odds ratio for any air 
travel in the month before a venous thromboembolic event was 2.1 (95% CI 1.1 - 4.0); 
for flights of more than eight hours the estimate was 3.0 (95% CI 0.9 - 9.5). The 
researchers also observed an interaction between air travel and thrombophilia (factor V 
Leiden mutation, prothrombin G20210A, antithrombin deficiency, protein C or S 
deficiency, antiphospholipid antibodies, or homocysteinaemia). Compared with people 
who did not have thrombophilia and did not fly, the risk of non-fatal venous 
thromboembolism was 1.7 (95% CI 0.7 - 3.7) in air travellers without thrombophilia, 
6.3 (95% CI 3.7 - 10.5) in non-travellers with thrombophilia, and 16.1 (95% CI 3.6 -
70.9) in air travellers with thrombophilia. Oral contraceptive use also modified the 
association between air travel and non-fatal venous thromboembolism. Compared with 
non-users who did not travel, the risk was 1.4 (95% CI 0.3 - 5.6) in air travellers who 
were non-users, 3.9 (95% CI 1.9 - 8.0) in users of oral contraceptive who did not fly, 
and 13.9 (95% CI 1.7 - 117.5) in oral contraceptive users who flew. 
Cases were consecutive patients aged 20 - 70 years referred to a thrombosis centre 
between January 1999 and September 2001 for thrombophilia screening following a 
first diagnosis of proximal deep vein thrombosis or pulmonary embolism at some time 
in the previous 24 months. Patients with known malignancies were excluded from the 
study. No information was provided to allow a judgement as to whether the people with 
a recent history of venous thromboembolism who were referred to the centre had 
different characteristics from those who were not referred. For example, it has been 
suggested that this method of case ascertainment is likely to have introduced a bias 
because the cases would tend to be younger patients without other risk factors for 















such patients would be an ideal group to study because it is more likely that any 
increased risk in air travellers would be due to the travel exposure. 
Controls were selected from a group of volunteers who had undergone thrombophilia 
testing during the study period. This group comprised friends or partners of all patients 
referred to the thrombosis centre. Volunteers were eligible for inclusion in the study if 
they had no personal history of venous thrombosis ( determined using a validated 
questionnaire) or overt malignancy. One control, matched by age (IO-year age bands), 
sex, and educational level, was selected for each case. 
Participants were interviewed before their thrombophilia status was determined and 
were asked about the presence of transient risk factors for venous thromboembolism 
(including air travel, oral contraceptive use, hormone replacement therapy, pregnancy, 
surgery, trauma, and immobilisation) in the month before the index date. For cases, this 
was the date of the venous thromboembolic event, while for controls it was the date of 
their visit to the thrombosis centre. Because the cases did not visit the thrombosis 
centre immediately after the venous thromboembolic event (median 5 months, range 1 -
24 months), this raises the possibility of some differential recall about travel, oral 
contraceptive use, and the presence of potential confounders. 
Sixty of 210 cases (28.6%) could not be tested for protein S or protein C deficiency 
because they were taking oral anticoagulants. Otherwise all cases and controls were 
screened, by independent blinded technicians, for the factor V Leiden and prothrombin 
G20210A mutations; antithrombin, protein C, protein S deficiencies; the presence of 
lupus anticoagulant and anticardiolipin antibodies: and plasma homocysteine levels. At 
least one thrombophilic abnormality was found in 102 (49%) cases and 26 (12%) 
controls. The most common abnormality was factor V Leiden mutation, which was 
present in 32 (15%) cases and six (3%) controls. 
While the researchers employed individual-level matching, they appear to have 
undertaken an unmatched analysis (unexplained) in which they adjusted for only two (sex 
and age) of the three matching factors. If the level of education was associated with the 
likelihood of air travel, then the failure to adjust for this matching factor in the analysis 















thromboembolism, since the matching would have made the controls more similar to the 
cases with respect to travel history than they would otherwise have been. The 
investigators adjusted for BMI, as well as sex and age, but made no mention of whether 
they had evaluated confounding by other factors. For example, several cases, but none of 
the controls, had transient risk factors for venous thromboembolism (such as surgery, 
trauma, immobilisation, pregnancy, and recently having given birth) which could also 
have reduced the likelihood of air travel. Failure to consider these factors in the analysis 
might have led to a further underestimation of the association between air travel and 
venous thromboembolism . 
Cannegieter et al (2006) 
In an ongoing population-based case-control study in the Netherlands, the Multiple 
Environmental and Genetic Assessment (MEGA) study, travel of more than four hours 
by any mode of transport in the two months before the index date carried a two-fold 
increase in risk (odds ratio 2.1 [95% CI 1.5 - 3.0]) (Cannegieter et al. 2006). No dose-
response was found for duration of travel. The individual point estimates for travel by 
air (1.7 [95% CI 1.0 - 3.1]), car (2.2 [95% CI 1.3 - 3.7]), bus (2.2 [95% CI 0.8 - 6.3]), 
and train (3.5 [95% CI 0.8 - 16.8]) were all very similar. Because a review of the 
discharge letters and diagnostic reports of 742 cases revealed that the diagnosis of 
pulmonary embolism complied with the Dutch diagnostic standard in only 78% of 
patients, as compared with 97% of those with deep vein thrombosis, the researchers also 
undertook analyses confined to cases with deep vein thrombosis (and their controls). 
The odds ratio for air travel was larger (3.0 [95% CI 1.3 - 7.1]) than that found for 
travel by car, bus, or train (1.9 [95% CI 1.1 - 3.2]). Incidentally, these estimates are 
lower than those found in an earlier analysis (based on 829 cases and 829 controls) in 
which the investigators reported that travel by air was associated with six-fold increased 
risk of venous thromboembolism (odds ratio 5.8 [95% CI 2.0 - 16.6]), while those who 
travelled by other modes of transport had twice the risk of non-travellers (odds ratio 2.2 
[95% CI 1.9 - 4.3]) (Rosendaal 2002). 
In the later analysis, carriers of factor V Leiden who travelled by car, bus, or train had a 
six-fold increased risk of deep vein thrombosis when compared with non-travellers 
without the mutation (odds ratio 6.2 [95% CI 1.7 - 22.3]) (Cannegieter et al. 2006). For 









CI 3.8 - 344.1]). Conversely, there appeared to be no interaction between air travel and 
prothrombin G20210A. Multiplicative increases in risk were also observed for air 
travellers with a BMI > 30 kg/m2 (odds ratio 7.1 [95% CI 2.0 - 24.9]) and height< 1.60 
metres (odds ratio 6.8 [95% CI 1.1 - 43.5]) or> 1.90 metres (odds ratio 9.4 [95% CI 0.9 
- 97.1]) when compared with non-travellers with a BMI < 25 kg/m2 and a height 
between 1.60 and 1.90 metres respectively. Using a case-only approach (Khoury and 
Flanders 1996) to explore the possibility of an interaction between air travel and oral 
contraceptive use, it was estimated that women taking oral contraceptives who travelled 
by any means had a 15-fold increased risk of deep vein thrombosis when compared with 
non-users who did not travel. The corresponding increase for women who flew was 27-
fold. 
Cases were consecutive patients aged < 70 years who were referred to six regional 
anticoagulation clinics with a first episode of deep vein thrombosis or pulmonary 
embolism between March 1999 and May 2002. Patients who were unable to complete 
the questionnaire, those who died soon after the venous thromboembolic event, and 
persons in the terminal stages of a disease were excluded. Of the remaining 3,902 cases, 
656 declined to participate or could not be traced and 135 were excluded because they 
were interviewed by telephone and no questions were asked about travel. Because the 
investigators chose to use the cases' spouses as their controls, this led to the exclusion of 
687 cases because they were not married and another 557 because their spouse declined to 
participate - although 229 of the latter group were matched with the spouses of cases who 
were subsequently found to be ineligible. A further 190 cases were excluded because one 
or both members of the case/control pair gave information about travel after the index 
date. Hence, only 1,906 of 3,902 (48.8%) cases were included in the study . 
For each case, their opposite sex spouse served as their control, except for the "spare" 
controls who were matched by sex and age to 229 of the 557 cases whose spouses did 
not want to participate. Thus, some case/control sets were opposite-sex pairs and others 
were same-sex. The investigators maintained that an advantage of choosing spouses as 
controls was that it provided some control for factors such as socio-economic status. 
Conversely, since spouses often travelled together, 135 case/controls pairs did not 
contribute to the matched analysis because their positive exposure status was concordant. 






















The researchers reported that the risk of venous thromboembolism was greatest during the 
first week after a journey, however the only odds ratios which were provided related to an 
eight-week period following travel. It is likely, therefore, that these published odds ratios 
underestimated the true relative risks. 
Both cases and controls completed a detailed questionnaire about risk factors for venous 
thromboembolism and were tested for factor V Leiden and prothrombin G202IOA 
mutations. Although the researchers reported effect modification by factors such as 
factor V Leiden, BMI, and height, they didn't explore the possible role of confounding 
by other risk factors. 
7 .2.3 Case-crossover studies 
A potential association between an exposure and outcome can be studied using a case-
crossover design in situations where the exposure status changes over a short period of 
time, the outcome has a reasonably sudden onset with a short latency period, and the 
induction period is short (Maclure 1991). There are advantages to using such an 
approach to examine the potential association between air travel and venous 
thromboembolism - because each case serves as his or her own control and the 
required study period is short, confounding by inherent characteristics (for example, 
thrombophilia) and characteristics that are generally stable over short periods (for 
example, BMI) can be avoided. Moreover, characteristics that may change relatively 
quickly (for example, exposure to surgery, injury, immobility, pregnancy, and the use of 
oral contraceptives or hormone replacement therapy) can be adjusted for in the analysis 
if necessary. One disadvantage of the case-crossover approach is that any flight-related 
risk of venous thromboembolism might be modified by risk factors such as 
thrombophilia and hence it has been suggested that relative risks obtained from case-
crossover studies should be generalised with caution (van der Born 2003). Table 7.2 
provides details of the case-crossover studies which have considered the risk of venous 
thromboembolism in travellers, following which each study is discussed in more depth. 
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Table 7.2 Case-crossover studies of travel and venous thromboembolism 
Reference 
(Eekhoff et al. 
2000) 
Methods 
Extension of Leiden Thrombophilia Study 
(LETS), but based solely on patients from 
Leiden (original study included 474 
consecutive patients from anticoagulant 
clinics in Leiden, Amsterdam, and 
Rotterdam who had a first episode of 
objectively confirmed DVT and no known 
malignancy) because information about 
presence of minor risk factors before the 
onset of DVT had been recorded for these 
patients. Of 271 Leiden patients, 84 
excluded because they had major acquired 
risk factors before onset of their DVT, 
hence 187 eligible patients. 
Follow-up questionnaire sent to 187 
patients 4 years after inclusion in LETS 
study, enquired about the occurrence of 
minor events in the 2 weeks before receipt 
of questionnaire. Minor events defined as 
bed rest of> 12 hours a day for;::::_ 2 
consecutive days, heavy physical exertion, 
minor trauma, minor surgery, or prolonged 
(not defined) travel by car, bus or 
aeroplane. Further details of any events 
were obtained by telephone interview. 
59/187 (31.6%) patients were excluded for 
various reasons (major medical events, 
pregnancy, declined to participate, could 
not be traced). 
Results 
3-fold increased risk of DVT in people who had experienced minor events in 
preceding 2 weeks (RR 2.9 [95% CI 1.5 - 5.41). 
Similar relative risk (2.4) when people with FVL mutation excluded. 
Estimated 17-fold increase in risk in people with minor events and FVL 
mutation compared with those without mutation and no minor events. 
Only 2/128 patients (1.6%) had travelled in the 2 weeks before the onset of 
their DVT compared with 5/128 (3.9%) in the later 2-week period. 
,,> 
Comments 
The incidence of minor events 
(including travel) in the 2 weeks 
before the DVT might have been 
underestimated for two reasons: 
(i) The LETS questionnaire did not 
include specific questions about 
minor events. Instead this 
information was spontaneously 
recorded by the investigators. 
(ii) The subjects who could be 
traced and were willing to 
complete the follow-up 
questionnaire might have been 
more likely to travel than those 




(Kelman et al. 
2003) (Original 
analysis) 








Identified all admissions (16,205 
admissions, 13,184 patients) to Western 
Australian hospitals between 1981 and 
1999 for which the principal discharge 
diagnosis was DVT or PE. Estimated sex 
and age-specific incidence rates for first 
episode of VTE. 
Australian migration data linked to 
hospital records to identify all individuals 
of any age who had undertaken at least one 
international flight and been admitted to a 
Western Australian hospital with VTE 
between 1981 and 1999 (2,279 Australian 
and 3,129 non-Australian citizens). 
Identified subset admitted .'.S. 100 days of 
arrival (153 Australian and 438 non-
Australian citizens) and estimated 
expected number of events within defined 
periods following international flight 
(assuming a uniform distribution during 
100 days following flight). 
Compared incidence rate of VTE for 
Australian citizens within defined time 
periods following international flight with 
background risk (.'.S. 100 days after flight). 
Reanalysis 
Allowed for ageing during study period, 
excluded time spent outside Australia, 





Observed number of cases in 14 days after international flight was greater 
than expected, assuming uniform distribution of cases during 100 days 
following flight ( 46 c.f. 22.1 for Australian citizens and 200 c.f. 63.2 for non-
Australians ). 
"Healthy traveller" effect for Australian citizens, observed number of cases 
less than expected based on estimated population sex and age-specific rates 
(46 c.f. 102.7). Opposite true for non-Australians (200 c.f. 105.3). 
Risk of VTE admission following international flight compared with baseline: 
4.17 (95% CI 2.94- 5.40) in first 2 weeks 
5.61 (95% CI 3.94 - 7.97) in first week 
2.63 (95% CI 1.55 - 4.45) in second week 
No increased risk in third week. 
Absolute risk of VTE in Australian citizens who undertook international flight 
lower than risk in non-Australians (9.6 c.f. 43.5 per million arrivals). 
Risks attributable to international flights: 7.3 and 33 per million arrivals for 
Australian and non-Australian citizens respectively. 
Estimated rate of death from flight-related VTE: 0.5 per million arrivals. 
Reanalysis 
Relative risk of VTE following an international flight same in Australian and 
non-Australian citizens. 
Relative risk of VTE being triggered following international flight compared 
with baseline: 
29.8 (95% CI 22.4 - 37.3) on day of flight 
3.84 and 1.94 (95% Cis not given) for first and second weeks respectively. 
Abbreviations used in the table DVT: deep vein thrombosis, FVL: factor V Leiden, PE: pulmonary embolism, RR: relative risk, VTE: venous thromboembolism. 
Comments 
Original analysis 
1. Expected number of admissions 
of non-Australian citizens in the 2 
weeks following a flight probably: 
(i) Underestimated when based on 
number of admissions during 100 
days following flight. 
(ii) Probably overestimated when 
based on Australian population sex 
and age-specific rates. 
2. Non-Australian citizens 
excluded from analyses to 
calculate relative risk. 
3. Assumed that time spent away 
from Western Australia was 
negligible. 
4. Not possible to examine effect 
of flight duration. 
5. Did not allow for ageing over 
study period. 
6. Possible that some patients were 
included in the denominator but 
not numerator, for example: deaths 
outside hospital, international 
arrivals whose intended destination 
was Wes tern Australia but 
admitted to hospital immediately 
on arrival at an international 
airport in another state, and DVT 

















Eekhoff et al (2000) 
This extension of the Leiden Thrombophilia Study employed a case-cross over analysis 
to explore the association between minor events and deep vein thrombosis (Eekhoff et al. 
2000). The proportion of cases who suffered from minor events was compared during 
two periods: the two weeks before the onset of the first episode of deep vein thrombosis 
and the two weeks preceding the receipt of a follow-up questionnaire which was sent to 
the participants four years later. The occurrence of minor events was associated with a 
three-fold increased risk of a first episode of deep vein thrombosis (odds ratio 2.9 
[95%CI 1.5 - 5.4]). Only 2/128 patients (1.6%) had a recorded history of travel in the 
two weeks before the onset of their deep vein thrombosis, compared with 5/128 (3.9%) 
who reported travel in the later two-week period, but it is possible that the incidence of 
travel in the initial period was underestimated because the information was not obtained 
systematically. It is also possible that the people who agreed to complete the follow-up 
questionnaire were different with respect to the likelihood of travel during the later 
period than those who did not wish to participate or could not be traced ( one third of the 
eligible group). 
Kelman et al 2003 
In this study, which linked national immigration data with Western Australian hospital 
admissions data, the incidence rate of venous thromboembolism in Australian citizens in 
the first week following an international flight was almost six times the baseline rate 
(relative risk 5.61 [95% CI 3.94 - 7.97]) (Kelman et al. 2003). The relative risk was 
2.63 (95% CI 1.55 - 4.45) in the second week after an international flight and was not 
significantly elevated in the third week. The overall risk of venous thromboembolism in 
the first two weeks after a long-distance flight was 4.17 (95% CI 2.94-5.40). Sex and 
age did not modify the risk. Because of uncertainties about the size of the denominator 
with increasing time since arrival, cases who were not Australian citizens were not 
included in these analyses. 
In the first 14 days after an international flight, the number of observed cases exceeded 
the number expected for both Australian (46 c.f. 22.1) and non-Australian citizens (200 
c.f. 63.2). The expected number of cases was obtained by counting the number of cases 
which occurred within 100 days following an international flight and then calculating 













distribution throughout the 100-day period. However, the researchers cautioned that the 
expected number of non-Australian cases was probably underestimated because many 
visitors remained in Wes tern Australia for less than 100 days and therefore some cases 
of venous thromboembolism would have been missed. 
A "healthy traveller" effect was observed among the Australian citizens; the observed 
number of cases in the two weeks following a flight (n=46) was substantially lower 
than the number expected (n=102.7) based on Western Australian population rates. The 
opposite was found for non-Australian citizens, although it was thought that the 
expected number of cases had been overestimated because this figure was obtained by 
applying the sex and age-specific rates of venous thromboembolism to the number of 
arrivals by non-Australian citizens and assuming that such visitors remained in Western 
Australia for 100 days . 
The estimated absolute risks also differed between Australian and non-Australian 
citizens; the overall rates were 9.6 and 43.5 cases per million arrivals respectively and 
the cases attributable to an international flight were 7 .3 and 33 per million arrivals. The 
researchers found that the higher risk in non-Australians was not due to differences in 
the sex and age distribution, and suggested that it might be due to differences in flight 
duration, differences in underlying risk, or different thresholds for hospital admission 
when compared with Australian citizens. Unfortunately it was not possible to examine 
the effect of flight duration using the existing data. 
It was estimated that the annual risk of venous thromboembolism would be increased by 
12% in persons undertaking one international flight per year. Based on five inpatient 
deaths and 9.4 million arrivals of all ages during the study period, the estimated absolute 
risk of fatal events was 0.5 deaths per million arrivals. This is likely to be an 
underestimate of the total population rate, since deaths which did not occur in hospital 
were excluded. Moreover it should be remembered that discharge diagnoses are coded 
differently from causes of death - discharges are coded to the principal reason for 
admission, while deaths are coded to the underlying cause. Hence, patients who had 
recently undergone surgery or who had disseminated cancer, for example, would have 
















other hand, they should have been excluded if they died in hospital from pulmonary 
embolism. 
In a later analysis, the researchers removed person-years not spent in Australia and 
accounted for ageing over the study period (Becker et al. 2006). The relative risks of 
flight-related venous thromboembolism in Australian citizens and the non-Australian 
citizens were not significantly different in this analysis. Moreover, since many of the 
non-Australian citizens were found to be long-term residents of Australia, their 
exclusion from the original analysis was judged to have been unnecessary. This 
allowed the pooling of data from both groups (and a consequent increase in power) to 
estimate the risk of venous thromboembolism following an international flight relative 
to the baseline risk. The risk for all ages of a venous thromboembolic event being 
triggered on a day on which an international flight was undertaken was 30 times higher 
than the risk on a non-flying day (relative risk 29.8 [95% CI 22.4 - 37.3]). Although 
this is a large relative risk, the researchers stressed that for most people the baseline 
probability that a venous thromboembolic event would be triggered on a single day was 
very small and hence the absolute risk of a venous thromboembolic event being 
precipitated on the day of a flight was also small. When slightly longer periods were 
considered, it was found that the relative risks of being admitted to hospital with venous 
thromboembolism in the first and second weeks following an international flight were 
3.84 and 1.94 respectively (95% CI not provided). These estimates were said to be 
lower than those obtained in the earlier analysis because ageing during the study period 
was now accounted for and person-years spent away from Australia were now excluded 
rather than ignored. Sex did not modify the risk, but the researchers pointed to weak 
evidence that the relative risk increased slightly with age. 
7 .2.4 Cohort studies 
Only one cohort study has estimated the relative risk of venous thromboembolism 









Table 7.3 Cohort study of travel and venous thromboembolism 
Reference Exposed Unexposed Information sought Outcomes Relative risk Comments 
(95% CI) 
(Schwarz Emolled 1081 persons who Emolled 1230 persons who At baseline Risk factors Isolated calf Unadjusted RR 1. Clinical relevance of 
et al. intended to undertake long- did not intend to undertake for VTE, coagulation and muscle venous events unclear. 
2003) distance air travel (non-stop long-distance air travel thrombophilia screening, thrombosis Flight > 8 hours, 2. Shorter mean follow-up 
outbound and return flights 2': 8 within 3 months of entry D-dimer, compression and 20/964 exposed, isolated calf muscle time for unexposed, 
hours). Recruited through into study. Recruited using Doppler US (1 week 10/1213 venous thrombosis possible underestimation 
advertisements in travel same methods as for before outbound flight for unexposed. 2.52 (1.20 - 5.26) of incidence (cumulative) 
agencies, local newspapers, and exposed group. exposed group). 
Flight > 8 hours, 
in unexposed. 
on radio and television. DVT 3. Biases towards 
Exclusion criteria: as for Standardised US grotocol 7 /964 exposed, DVT overestimation of 
Exclusion criteria: < 18 years, exposed, although unclear Each examination 2/1213 4.40 (1.04 - 18.62) incidence of venous 
life expectancy < 3 months, whether users of undertaken independently unexposed. 
Flight > 8 hours, thrombosis in air travellers venous thrombosis on baseline compression by 2 physicians blinded to 
venous thrombosis (because volunteers) and US, any use of compression stockings/bandages also exposure status. Symgtomatic underestimation because: 
stockings/bandages or excluded. PE (isolated calf muscle (i) Excluded users of 
anticoagulants. Confirmation of PE 1/964 exposed and DVT combined) compression stockings, 
1 had thrombosis at V-Q scan. (passenger with 2.83 (1.46 - 5.49) bandages, and 
4 had thrombosis at baseline and baseline and 16/1229 US evidence of 
113/1077 (10.5%) excluded from (1.3%) excluded from final Follow-u12 DVT) 
anticoagulants possibly at 
final analysis (22 [2.0%] analysis (9 [0.7%] declined Any new risk factors for 
higher background risk. 
declined follow-up examination, follow-up examination, 7 VTE, any symptoms, D- No deaths. 
(ii) Other in-flight 
87 [8.1 % ] used compression [0.6%] treated with dimer, US (48 hours after 
preventive measures. 
stockings/bandages or anticoagulants for reasons return flight in exposed, All events 
(iii) Extension of isolated 
anticoagulants in association other than venous mean of 25 days after 
diagnosed at 1st calf muscle venous 
with air travel, 4 [0.4%] treated thrombosis). baseline visit in follow-up visit. 
thrombosis to DVT 
with anticoagulants for reasons unexposed). Repeat US All participants 
possibly prevented by 
other than venous thrombosis). 1213 included in final and telephone interview 4 
attended for 2nd treatment with heparin. 
analyses. weeks after 1st follow-up follow-up, no 4. Did not address 
964 included in final analyses. visit ( exposed and further events. potential confounding. 
unexposed). 









Schwarz et al. 2003 
In this study, based on 964 passengers who departed from and returned to Germany on 
flights of at least eight hours' duration and a concurrent comparison group of 1213 non-
travellers, the crude relative risks of deep vein thrombosis and of isolated calf muscle 
(soleus or gastrocnemius) venous thrombosis were 4.4 (95% CI 1.04 - 18.62) and 2.52 
(95% CI 1.20 - 5.26) respectively. The relative risk for both types of event combined 
was 2.83 (95% CI 1.46 - 5.49). 
A major limitation of this study is that the clinical relevance of the venous thrombotic 
endpoints is uncertain. First, most events were asymptomatic and were diagnosed by 
compression ultrasound, which was undertaken on each participant both before and after 
the exposure period by two physicians who were blinded to exposure status. Of the 
participants diagnosed with deep vein thrombosis, 5/7 air travellers and 1/2 non-
travellers had no symptoms. Of those with isolated calf muscle venous thrombosis, 
19/20 air travellers and 10/10 non-travellers were asymptomatic. Second, elevated D-
dimer levels were found in only 4/7 air travellers and 1/2 non-travellers diagnosed with 
deep vein thrombosis and 7 /20 air travellers and 2/10 non-travellers with isolated calf 
muscle venous thrombosis. As discussed in Chapter 1, normal D-dimer levels in the 
context of a low pre-test probability have a high negative predictive value (Blann and 
Lip 2006). Third, although the researchers conceded that little is known about the 
natural history of isolated calf muscle venous thrombosis, this was the primary outcome 
that the study was powered to detect. Information from a pilot study was used to 
calculate the required sample size (Schwarz et al. 2002). In justifying their choice of 
primary outcome, the researchers referred to a study which suggested that isolated 
thrombosis in the veins of the soleus and gastrocnemius muscles was "the first step 
toward DVT" (Masuda et al. 1998). The researchers then went on to conclude that the 
incidence of isolated calf muscle venous thrombosis "may be used as a surrogate marker 
of DVT associated with air travel". This conclusion was criticised by a member of 
another research group which had followed 135 patients who were initially suspected of 
having deep vein thrombosis, but were found on ultrasound to have isolated calf muscle 
vein thrombosis (Kahn 2004). All of the 135 patients had symptoms, but only 3% had 
ultrasonic evidence that the thrombus had extended to the popliteal vein during the 


















A second concern is that the mean follow-up period for non-travellers was significantly 
shorter than that for air travellers. Hence, it is possible that the cumulative incidence of 
venous thrombotic events in non-travellers was underestimated and the relative risk 
overestimated. 
A third limitation of the study is that it was based on volunteers who are likely to have 
had a particular interest in taking part in the study and may have had a higher baseline 
risk than the general population. Hence, it is possible that the cumulative incidence of 
venous thrombosis in air travellers was overestimated. However the inclusion of people 
at higher baseline risk is unlikely to have over-inflated the relative risk because most 
pre-existing risk factors for venous thromboembolism were equally distributed between 
air travellers and non-travellers . 
It is possible, however, that the relative risk was biased downwards because 87 (8.1 % ) 
air travellers initially enrolled in the study were excluded from the final analysis 
because they used prophylactic heparin or compression stockings. If these people were 
at higher baseline risk than the other air travellers, then their exclusion could have 
deflated the true relative risk. The researchers identified two other factors which could 
have led to an under-estimation of the relative risk. First, the air travellers were 
encouraged to drink plenty of non-alcoholic fluids, perform stretching exercises, and to 
walk about the cabin during their flights - although it is not known whether the 
participants complied with these suggestions, or indeed, whether these measures reduce 
the risk of venous thromboembolism. Second, participants with isolated calf muscle 
vein thrombosis were all diagnosed 48 hours after their flight and were given a 10-day 
course of low-molecular weight heparin. According to an earlier study by the 
researchers, such a regimen prevents thrombus progression (Schwarz et al. 2001). 
Finally, the researchers made no mention of exploring possible confounding despite 
acknowledging that there were more women, and more people with varicose veins and 
venous insufficiency, in the non-travelling group. Moreover, among those who 






















7 .2.5 Intervention studies 
It is not surprising that no prospective studies have explored the association between air 
travel and symptomatic, clinically relevant, venous thromboembolism. One 
commentator has estimated that, assuming a background incidence of venous 
thromboembolism of two cases per 1,000 person-years, 80% power, and alpha of 0.05, a 
sample size of 100,000 exposed and 100,000 unexposed would be required to detect a 
four-fold increase in risk in the two weeks following a long-distance flight 
(MacGillavry et al. 2001). Such a study would clearly be expensive and logistically 
difficult. Moreover, the practical and ethical constraints of randomly allocating people 
to undertake long-distance flights mean that it is highly unlikely that an intervention 
study will ever be undertaken to examine the association between air travel and venous 
thromboembolism. There have, however, been several randomised controlled trials of 
interventions designed to prevent flight-related venous thromboembolism. These studies 
will be discussed briefly later in the chapter. 
7 .2.6 Discussion 
To return to the question posed at the beginning of this chapter, overall, the evidence 
from epidemiological studies is consistent with an association between air travel and 
venous thromboembolism, although that risk is poorly defined. Eleven analytical 
epidemiological studies have examined the potential association between travel and 
venous thromboembolism: eight case-control studies, two case-crossover analyses, and 
one cohort study. However, as has been shown in the preceding sections, the quality of 
most of these studies is poor and thus no attempt has been made in this chapter to 
perform a meta-analysis. The most reliable relative risk estimates suggest that 
compared with non-travellers, air travellers have in the order of a four-fold increased 
risk of developing non-fatal venous thromboembolism in the week following a long-
distance flight. On the day of a flight, the risk that a venous thromboembolic event will 
be triggered increases by about 30-fold relative to the background incidence. The 
relative risk of fatal events has not been examined. 
At this point it is useful to reflect on Bradford Hill's suggested criteria for assessing the 
likelihood of a causal relationship (Bradford Hill 1965): the strength of the association 
is not inconsequential; the association has been observed in different populations and in 
















timing of the pathological onset of venous thromboembolism, it appears that the travel 
exposure preceded the onset of symptoms; as already mentioned, there is evidence of a 
dose-response relationship between the duration of air travel and the incidence of 
pulmonary embolism; and, as will be discussed in a later section, it is biologically 
plausible that remaining seated for prolonged periods in cramped conditions might lead 
to venous thrombosis. In light of these considerations, there appears to be sufficient 
grounds for accepting that the relationship between long-distance air travel and venous 
thromboembolism is likely to be causal. Hence, it is appropriate to proceed to a 
consideration of the subsidiary questions posed in the introduction to this chapter. 
7.3 DO OTHER RISK FACTORS MODIFY THE RISK OF FLIGHT-RELATED 
VENOUS THROMBOEMBOLISM? 
As discussed earlier, several researchers have reported an interaction between air travel 
and oral contraceptive use (Martinelli et al. 2003; Cannegieter et al. 2006), 
thrombophilia (Martinelli et al. 2003; Cannegieter et al. 2006), BMI > 30 kg/m2 
(Cannegieter et al. 2006), height < 1.60 metres (Cannegieter et al. 2006), height > 
1.90m (Cannegieter et al. 2006), and other risk factors for venous thromboembolism 
(Arya and Cohen 2003). An interaction between temporary risk factors for deep vein 
thrombosis, including travel, and the factor V Leiden mutation has also been reported 
(Eekhoff et al. 2000). 
Two other studies have been undertaken with the express purpose of determining 
whether certain groups of air travellers are more likely to develop venous 
thromboembolism than others (Jacobson et al. 2003; Paganin et al. 2003). Details of 
these studies can be found in Table 7.4 and this is followed by a discussion . 
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Table 7.4 Additional studies which attempted to identify whether certain groups of air travellers are at particular risk of venous thromboembolism 
Reference Study design Participants Information sought Results Comments 
(Jacobson Cohort "Low and intermediate risk" passengers on D-dimer at check-in. On arrival 1. Participation rates for each 
et al. 2003) 11-hour flights between London and 0/434 had DVT on US, 74/899 had class of travel not stated. 
Johannesburg. Exclusion criteria: previous D-dimer, thrombophilia raised D-dimer levels. 2. Insufficient power to 
VTE, anticoagulant use, pregnancy, recent screening, duplex US on compare incidence by class of 
surgery, intention to use compression arrival in Johannesburg. OR (95% CI) for raised D-dimer travel. 
stockings on flight, raised D-dimer levels levels after flight 3. Batch of pre-flight D-
before flight (9/491 assayed). Telephone enquiry after FVL 3.36 (1.17 - 9.63) dimer results available for 
6 months about any Aspirin use 2.04 (1.04 - 3.99) only 54% of passengers. 
180 recruited in business class (33.9% female, symptoms or diagnoses HRT 2.15 (0.91- 5.10) 4. Incomplete follow-up. 
median age 47 years [range 28 - 78]) and 719 ofVTE. oc 1.23 (0.42 - 3.62) 5. Potential confounding not 
in economy class (48.8% female, median age 
After 6 months 
explored. 
43 years [range 18 - 81]). 
0/505 had been diagnosed with VTE. 
(Paganin et Case-control Cases: 46 people diagnosed with DVT (US) or Cases and controls OR (95% CI) for VTE 1. Did not include cases who 
al. 2003) PE (spiral CT scan, angiography, or V-Q scan) completed questionnaire Past VTE 63.3 (3.6-1098) died before reaching hospital. 
during 1997 who had undertaken 11-hour which enquired about Obesity 9.6 (2.9 - 31.5) 2. Participation rates of 
flight from Paris to Reunion Island < 15 days class of travel, aisle or Varicose veins 10.0 (3.7 - 27.0) eligible cases and controls not 
before onset of symptoms. Ascertained non-aisle seat, in-flight Cardiac disease 8.9 (1.0 - 82.0) stated. 
through all 750 doctors on Island "who might behaviour (alcohol, Recent injury 13.6 (1.5 - 117) 3. Not stated whether controls 
be expected to treat VTE." hypnotics, number of Failure to leave seat 9.3 (2.5 - 35.0) randomly selected. 
times that left seat), 4. Possible recall bias. 
Controls: On 4 days during 1997, medication to prevent No significant risk was found for 5. Potential confounding not 
questionnaire provided to 25 passengers thrombosis, pre-existing "oestrogen treatment", travel in explored. 
disembarking from a flight from Paris. 92 risk factors for VTE. economy class, non-aisle seat, 
passengers who remained symptom-free 15 alcohol consumption in-flight, or the 
days after flight were included. use of hypnotics. 
Abbreviations used in the table CT: computed tomography, DVT: deep vein thrombosis, FVL: factor V Leiden, HRT: hormone replacement therapy, OC: oral contraceptive use, OR: odds ratio, US: ultrasound, V-Q scan: ventilation-






















Jacobson et al (2003) 
One of the aims of this cohort study was to compare the incidence of venous 
thromboembolism in business class passengers who undertook an 11-hour non-stop 
flight from London to Johannesburg with the incidence in those who travelled in 
economy class (Jacobson et al. 2003). Unfortunately, insufficient volunteers were 
recruited in the former group to allow this comparison. In fact it is unclear how many 
potential participants, who were approached as they checked in for their flights on a 
South African airline, agreed to take part in the study. Moreover, while all 899 
participants had a D-dimer test directly after their flight, only 434 agreed to undergo an 
ultrasound examination at the Johannesburg International Airport (n=328) or at a local 
hospital within one week of landing (n=47). Seventy-four passengers had raised D-
dimer levels after their flight, but only 38 of these had an ultrasound. None of these 38 
passengers, or any of the other travellers who were examined ultrasonically, had 
ultrasonic evidence of venous thrombosis. Telephone contact was made with 505 
participants (including 64/74 passengers with elevated D-dimers) six months later and 
none reported signs or symptoms of venous thromboembolism following the index 
flight. One man did, however, develop symptomatic deep vein thrombosis after his 
sixth subsequent long-distance flight. It should be noted that, due to a technical 
problem, the results of pre-flight D-dimer assays were available for only 482 of the 899 
participants. Hence, it is possible that some of the passengers with positive tests on 
arrival might also have had raised levels before they flew. 
Further aims of the study were to explore the risk of venous thromboembolism in 
travellers with pre-existing risk factors and to evaluate in-flight behaviours. In 
unadjusted analyses, the researchers reported a positive association between the factor V 
Leiden mutation and raised D-dimer levels (odds ratio 3.36 [95% CI 1.17 - 9.63]) and a 
borderline significant result for aspirin use (odds ratio 2.04 [95% CI 1.04 - 3.99]). 
Possible explanations suggested for the latter result were that aspirin was taken by 
people at higher risk of venous thromboembolism or alternatively aspirin users had 
developed gastritis and hence had falsely raised D-dimer levels. No significant 
associations were noted for other thrombophilic mutations, smoking, weight, height, 
age, sex, or the use of other non-steroidal anti-inflammatory drugs, hypnotics, oral 
contraceptives, or hormone replacement therapy. Interestingly, despite participating in 
a study of flight-related venous thromboembolism, there was no evidence that 


















alcohol, or performed the exercises recommended in the in-flight magazine. Indeed 
only 6% of all passengers in both classes exercised during their flight. 
Paganin et al (2003) 
This population-based case-control study was undertaken by researchers on Reunion 
Island, in the Indian Ocean, to ascertain risk factors for developing venous 
thromboembolism among people who had been on an 11-hour flight from Paris 
(Paganin et al. 2003). Passengers were more likely to develop venous 
thromboembolism if they had a history of previous events (odds ratio 63.3 [95% CI 3.6 
- 1098]), were obese (odds ratio 9.6 [95% CI 2.9 - 31.5]), had varicose veins (odds ratio 
10.0 [95% CI 3.7 - 27.0]), had cardiac disease (odds ratio 8.9 [95% CI 1.0 - 82.0]), had 
suffered a recent injury (odds ratio 13.6 [95% CI 1.5 - 117]), or if they had not left their 
seat during the flight (odds ratio 9.3 (95% CI 2.5 - 35.0). All odds ratios appear to have 
been unadjusted. No significant risk was found for "oestrogen treatment", travel in 
economy class, sitting in a non-aisle seat, consumption of alcohol, or the use of 
hypnotics. 
The methods of this study were not clearly described, but it is possible that not all cases 
were ascertained - the investigators stated that they had no way of determining the true 
number of cases because venous thromboembolic events were not notifiable to health 
authorities. Moreover, pathologists were not included on the list of medical staff that 
the investigators approached to identify cases, so presumably cases who died suddenly 
in the community were excluded. Indeed, at least two such potential cases were 
excluded - these passengers, who died on arrival, were said to have symptoms highly 
suggestive of pulmonary embolism, but no definitive diagnosis was available. 
On four occasions during the study period, 25 passengers arriving from Paris were 
selected as controls and were given the same questionnaire as the cases. The 
researchers did not explain how these people were chosen, and given that the exposures 
of interest in this study were risk factors for venous thromboembolism and in-flight 
behaviours, any failure to obtain a random sample could have resulted in a bias. For 
example, if the first 25 passengers to disembark were selected, it is likely that they were 
generally healthier and more mobile than those who disembarked later and hence the 
risk associated with particular characteristics could have been overestimated. Ninety-

















the questionnaire was accepted by all of the potential controls who were approached. It 
is also unclear when exactly the controls completed the questionnaire - although they 
received the questionnaire on arrival, it appears that they were required to wait for two 
weeks before returning it to ensure that they had not developed symptoms of venous 
thromboembolism. However this would not have prevented them from answering the 
questions about in-flight behaviour immediately, introducing the possibility of a recall 
bias since cases were asked the same questions up to 15 days later. It is likely that 
factors such as the number of times an individual left their seat during the flight would 
be recalled more accurately immediately after the flight. Interestingly, the only 
behaviours that differed between cases and controls were the average number of times 
they left their seats and the proportions in each group who did not leave their seats at all 
during the flight. 
The final limitation of the study is that the researchers gave no indication that they had 
explored potential confounding. 
7.4 WHAT IS THE ABSOLUTE RISK OF VENOUS THROMBOEMBOLISM IN 
LONG-DISTANCE AIR TRAVELLERS? 
7.4.1 Incidence studies 
Incidence studies of symptomatic venous thromboembolism have nearly all involved 
non-fatal events in passengers requiring medical care on arrival at international airports 
as shown in Table 7.5. A dose-response relationship between flight duration and the 
absolute risk of pulmonary embolism was observed in two of these studies (Lapostolle 
et al. 2001; Perez-Rodriguez et al. 2003). Rates per million arrivals at Charles de 
Gaulle Airport were 0.11 (95% CI 0.01 - 0.71), 0.40 (95% CI 0.19 - 0.79), 2.66 (95% 
CI 1.83 - 3.79), 4.77 (95% CI 2.66 - 8.41) for flights of 3 - 5 hours, 6 - 8 hours, 9 - 11 
hours, and 12 or more hours respectively (Lapostolle et al. 2001). Rates of similar 
magnitude were observed among arrivals at Charles de Gaulle and Orly (Clerel and 
Caillard 1999), Madrid-Barajas (Perez-Rodriguez et al. 2003) and Sydney (Hertzberg et 
al. 2003) airports. These studies are likely to have underestimated the true incidence of 
venous thromboembolism among air travellers, since those who died from pulmonary 
embolism during a flight or on arrival were excluded, as were those who developed deep 
















Two of the studies outlined in Table 7 .5 did include people who developed symptoms of 
venous thromboembolism, including deep vein thrombosis, after leaving the airport 
(Kelman et al. 2003; Paganin et al. 2003). In the Western Australian record-linkage case-
crossover study, the incidence of venous thromboembolism in the two weeks following an 
international flight was 9.6 per million arrivals for Australian citizens (Kelman et al. 
2003). Conversely, the absolute risk in the two weeks following an 11-hour flight to 
Reunion Island was an order of magnitude higher (116 cases per million arrivals) 
(Paganin et al. 2003). It is unclear why the latter figure is so much higher than the first 
since it was reportedly based on objectively confirmed deep vein thrombosis and 
pulmonary embolism. Moreover, many passengers arriving in Western Australia would 
have undertaken equally long journeys. 
There is very little information about pulmonary embolism mortality in air travellers. In 
one study, the rate was reported to be less than one per million arrivals, although it was 
not possible to calculate a precise incidence from the available data (Kline et al. 2002). A 
rate of 7.6 deaths per million arrivals on flights of 11 hours can be derived from data 
presented by the Reunion Island researchers (Paganin et al. 2003), although this estimate 
excludes people who died from pulmonary embolism before reaching hospital. The only 
study to explicitly estimate the incidence of fatal events was the Western Australian study 
which also excluded people who died in the community (Kelman et al. 2003). The risk 
of dying from pulmonary embolism following an international flight was estimated to 
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Table 7.5 Incidence of symptomatic venous thromboembolism in air travellers 
Reference Observation period VTE events in arriving passengers Number of arrivals Absolute risk per million arrivals 
(millions) (95% Cl) 
(Clerel and Caillard 1998 15 cases of PE seen at the medical department at Aeroports 3 Risk of PE 
1999) de Paris on arrival at Charles de Gaulle or Orly airports, 0.5 
Paris. Median duration of travel 12 hours (range 3 - 15). 
(Lapostolle et al. Nov 1993 -Dec 2000 56 cases of confirmed PE who required medical care and By duration of air travel Risk of PE by duration of air travel 
2001) transfer to hospital on arrival at Charles de Gaulle Airport, < 3 hours: 88.49 < 3 hours: 0 (0.0 - 0.04) 
Paris, after flights of 3 - 5 hours (1), 6 - 8 hours (9), 9 - 11 3 - 5 hours: 9.18 3 - 5 hours: 0.11 (0.01 - 0.71) 
hours (33), ~ 12 hours (13). 6 - 8 hours: 22.53 6 - 8 hours: 0.40 (0.19 - 0.79) 
9 - 11 hours: 12.37 9 - 11 hours: 2.66 (1.83 - 3.79) 
~ 12 hours: 2.72 ~ 12 hours: 4.77 (2.66 - 8.41) 
Total arrivals: 135.29 Overall risk: 0.4 
(Kline et al. 2002) Jan 1992 - June 2001 No deaths from PE in passengers who required medical care Trans-Atlantic flights Risk of fatal PE immediately after 
and transfer to hospital on arrival at Charlotte-Douglas 1.1 trans-Atlantic flight 
Airport, North Carolina, after a trans-Atlantic flight. Also no < 1.0 
flight-related deaths found in review of records of people who 
died from PE in the community. 
(Hertzberg et al. Jan 1998 - Jan 2001 17 cases of confirmed PE who required medical care and Air travel > 9 hours Risk of PE with air travel > 9 hours 
2003) transfer to hospital on arrival at Sydney Airport. All had 6.58 2.57 
flown~ 9 hours. 
(Kelman et al. 2003) 1981 - 1999 46 Australian citizens with confirmed DVT or PE who were International flight RiskofVTE 







(Paganin et al. 2003) 
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Observation period VTE events in arriving passengers 
Jan 1995 -Dec 2000 16 cases of confirmed PE who required medical care and 
transfer to hospital on arrival at Madrid-Barajas Airport after 
flights of 6 - 8 hours (1), > 8 hours (15). 
1997 46 cases of confirmed VTE (33 DVT only, 13 PE) who 
received medical care within 2 weeks of 11-hour flight. 
Abbreviations used in the table DVT: deep vein thrombosis, PE: pulmonary embolism, VTE: venous thromboembolism. 
:.:; 
,; 
Number of arrivals 
(millions) 
-( 
By duration of air travel 
< 6 hours: 28.0 
6 - 8 hours: 3.9 
> 8 hours: 9.1 
Total arrivals: 41.0 
Air travel 11 hours 
0.4 
·, ~ .J 
Absolute risk per million arrivals 
(95% Cl) 
Risk of PE by duration of air travel 
6 - 8 hours: 0.25 (0.0 - 0 .75) 
> 8 hours: 1.65 (0.81 - 2.49) 
Overall risk: 0.39 (0.20 - 0.58) 
Overall risk of DVT and PE with air 
travel 11 hours 
116 























7.4.2 Other sources of information about absolute risk 
High rates of asymptomatic and symptomatic venous thrombosis have been reported in 
studies of volunteers who undertook long-distance air travel (Table 7.6). As discussed 
in the introduction to this chapter, the finding that 10% of controls in a randomised 
controlled trial of graduated compression stockings had ultrasonic evidence of 
asymptomatic distal deep vein thrombosis following a long-distance flight received 
extensive media coverage (Scurr et al. 2001). However the validity and clinical 
relevance of this finding was questioned in an accompanying editorial (Hirsh and 
O'Donnell 2001). The commentators' concerns were that the interpretation of calf vein 
ultrasonography is a subjective process and that there was no assurance that the 
technicians had remained blinded to treatment group. In addition, none of the controls 
who were diagnosed with thrombosis had symptoms and only half had elevated D-dimer 
levels. This suggested, according to the commentators, that either the thrombi were very 
small or the ultrasound results were falsely positive. The other studies in which 
asymptomatic venous thrombosis wa$ detected had similar limitations (Arfvidsson et al. 
1999; Belcaro et al. 2001; Belcaro et al. 2002; Cesarone et al. 2002; Belcaro et al. 2003; 
Jacobson et al. 2003; Schwarz et al. 2003; Cesarone et al. 2003a; Cesarone et al. 2003b; 
Cesarone et al. 2003c; Cesarone et al. 2003d; Belcaro et al. 2004). 
In only one of the studies involving volunteers were most cases symptomatic (Hughes et 
al. 2003). In this uncontrolled cohort study, 1.0% (95% CI 0.5 - 1.9) of participants had 
radiological evidence of venous thromboembolism in the three months following 
outbound and return flights of at least four hours' duration, although the exact timing of 
the diagnoses is not stated. Interestingly, almost identical proportions of volunteers had 
raised D-dimer levels before travel (these were excluded from the study) and within 72 
hours of their return; the proportions were 8.3% (83/1,000) and 8.7% (76/878) 
respectively. The numbers of cases of venous thromboembolism within each of these 
groups were not stated, however if similar proportions had radiological signs of venous 
thromboembolism this would raise questions about the validity of attributing the events 
in the returning passengers to their air travel. Surprisingly high proportions of 
participants, in whom there was no objective evidence of venous thromboembolism, 
reported symptoms consistent with deep vein thrombosis (283/869) and pulmonary 
embolism (87 /869). Because it seems unlikely that a control group who had not flown 














hypothesis that the prevalence of air travel in the population that gave rise to the cases 
could have been overestimated in the case-control studies in which people with 
clinically suspected, but unconfirmed, venous thromboembolism became controls. 
Ultimately it is difficult to draw any firm conclusions about the incidence of flight-related 
venous thromboembolism from these prospective studies of volunteers. First, volunteers 
are not a representative sample of air travellers and they are likely to have different 
background risks for venous thromboembolism. Second, the study populations were not 
comparable and varying proportions of participants were lost to follow-up. Third, the 
duration of flights differed between studies, as did the number of flights undertaken, the 
preventive measures that were employed by the participants, and the length of follow-up. 
Fourth, the type of venous thromboembolic events that were included varied, different 
approaches were used to diagnose venous thromboembolism, and the potential for 
diagnostic bias sometimes existed. Finally, pre-existing venous thromboembolism was 
ruled out before air travel in only some of the studies. 
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Table 7.6 Incidence of venous thromboembolism in prospective studies of volunteers 
Reference Inclusion Exclusion Participants Air travel Preventive Exclusion of VTE Diagnosis of Proportion who 
criteria criteria measures before travel VTE developed VTE 
(Arfvidsson et Delegates who Local delegates. 83 symposium Flights to and from 31% wore Duplex US before Duplex US~ 0/83 DVT after 
al. 1999) had flown to delegates with interest Hawaii (unspecified compression departure from 1 week after arrival in Hawaii. 
Pacific Vascular in flight-related VTE, origin and stockings. Hawaii. arrival in 
Symposium on 49 followed up. destination). Hawaii (83) 1/49 DVT after 
Venous Disease and~ 4 weeks departure, 
in Hawaii. after departure asymptomatic. 
(49). 
(Scurr et al. > 50 years. VTE in past or at Control group in RCT Outbound and return Nil Duplex US and D- Duplex US Quoted 
2001) baseline, of compression non-stop flights 2: 8 dimer before andD-dimer proportion 12/116 
anticoagulant stockings. 116 in hours within 6 outbound flight. ~ 48 hours (10% [95% CI 
use, regular use control group, 100 weeks. after return 4.8 - 16.0]) DVT 
of compression followed up. flight. No calf veins, 
stockings, Median flight time further asymptomatic, 
cardiorespiratory 24 hours. follow-up. D-dimer raised in 
disease, cancer, only 6/12. 
and other serious 
illness. 
(Belcaro et al. High-risk group Low-risk Low-risk group One economy class Nil Nil Sonosite US ~ Low-risk group 
2001) inclusions: Past exclusions: 379 enrolled, 355 flight within 24 hours after 0/355 DVT 
(LONFLIT1, VTE, High-risk followed up. Northern flight. No 
incidence coagulation conditions plus Hemisphere, no further High-risk group 
study) disorders, recent surgery, High-risk group other flights > 2 follow-up. 11/389 (2.8%) 
cancer, large travelling with 399 enrolled, 389 hours in preceding 2 DVT, not stated 
varicose veins, children< 2 followed up. weeks. whether 
severe obesity, years, chronic symptomatic. 
and limited renal, hepatic, or Mean flight time 
mobility. cardiovascular 12.4 hours (range 10 
disease. -15). 
262 
,._ \/ v '( \> 'i(" 'I y "' ~( -< 
Reference Inclusion Exclusion Participants Air travel Preventive Exclusion of VTE Diagnosis of Proportion who 
criteria criteria measures before travel VTE developed VTE 
(Belcaro et al. "High-risk" VTE at baseline. Control group in RCT As in LONFLITl. Instructions Sonosite US ~ 48 Sonosite US ~ 19/422 (4.5%) 
2001) passengers as of stockings. Unclear re exercise, hours before flight. 24 hours after DVT, not stated 
(LONFLIT2) defined in how many randomised Mean flight time fluid intake, flight. No whether 
LONFLITl. to control group, 422 12.5 hours (range 10 food, and further symptomatic. 
followed up. -15). clothing. follow-up. 
(Cesarone et "High-risk" VTE at baseline. Control group in RCT No details provided. Asin Sonosite US Sonosite US 4/82 (4.8%) 
al. 2002) passengers as of aspirin and LMWH. LONFLIT2. unspecified time unspecified DVT, unclear 
(LONFLIT3) defined in Some inclusion 100 in control group, before flight. time after whether 
LONFLITl. criteria listed as 82 followed up. flight. No symptomatic. 
exclusion further 
criteria. follow-up. 
(Belcaro et al. "Low-medium High-risk Control groups in 2 J81RCT Asin Sonosite US Sonosite US 7 - 8 hour flights: 
2002) risk" passengers as RCTs of stockings. One non-stop flight LONFLIT2. unspecified time unspecified 4/179 (2.2%) 
(LONFLIT4 passengers. defined in of7 - 8 hours in before flight. time after DVT. 
Concorde LONFLITl, also l
81 RCT economy class. flight. No 11-12 hour 
Edema-SSL those with other 188 in control group, further flights: 
Study) treated medical 179 followed up. 2ndRCT follow-up. 3/143 (2.1%) 
conditions, > 1.9 
2nd RCT 
One non-stop flight DVT. 
metres tall, of 11 - 12 hours in Not stated 
weight > 90 kg, 143 in control group, economy class. whetherDVT 
VTE at baseline. 135 followed up. symptomatic. 
(Cesarone et "Low-medium Asin Control groups in 2 1st RCT Asin Sonosite US Sonosite US 7 - 8 hour flights: 
al. 2003a) risk" LONFLIT4 RCTs of stockings. One non-stop LONFLIT2. unspecified time unspecified 0/98 DVT. 
(LONFLIT4 passengers. Concorde flight of 7 - 8 hours before flight. time after 
EcoTraS Edema-SSL I'' RCT in economy class. flight. No 11-12 hour 
Study) Study. 108 in control group, further flights: 
98 followed up. 2nd RCT follow-up. 0/71 DVT. 
2nd RCT 
One non-stop 
flight of 11 - 12 
82 in control group, hours in economy 
71 followed up. class. 
263 
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Reference Inclusion Exclusion Participants Air travel Preventive Exclusion of VTE Diagnosis of Proportion who 
criteria criteria measures before travel VTE developed VTE 
--
(Cesarone et "Low-medium Asin Control (placebo) One non-stop flight As in Sonosite US Sonosite US 0/70DVT. 
al. 2003b) risk" passengers LONFLIT4 group in RCT of of7 - 8 hours in LONFLIT2. unspecified time unspecified 
(LONFLIT4- with Concorde hydroxyethyl economy class. before flight. time after 
Venoruton uncomplicated Edema-SSL rutosides. flight. No 
Study) varicose veins. Study. 81 in control group, further 
70 followed up. follow-up. 
(Cesarone et "Low-medium As in Control groups in 2 J81 RCT As in Sonosite US Sonosite US 7 - 8 hour flights: 
al. 2003c) risk" LONFLIT4 RCTs of stockings. One non-stop flight LONFLIT2 unspecified time unspecified 0/72DVT. 
(LONFLIT4- passengers. Concorde of7 - 8 hours in before flight. time after 
Concorde Edema-SSL J8
1 RCT economy class. flight. 11-12 hour 
Deep Venous Study. 76 in control group, flights: 
Thrombosis 72 followed up. 2nd RCT No further 2/66 (3.0%) 
and Edema 
2nd RCT 
One non-stop flight follow-up. DVT, not stated 
Study) of 11 - 12 hours in whether 
68 in control group, economy class. symptomatic. 
66 followed up. 
(Cesarone et "High-risk" Anticoagulant or Control (placebo) One non-stop flight Shown Sonosite US ~ 90 Sonosite US ~ 5/92 (5.4%) 
al. 2003d) passengers as anti thrombotic group in RCT of of7 - 8 hours in video re minutes before 90 minutes DVT, not stated 
(LONFLIT- defined in use, VTEor pinokinase. economy class. exercise, flight. after flight. whether 
FLITE Trial) LONFLITl. raised D-dimer at 103 in control group, fluid intake, symptomatic. 
baseline. 92 followed up. food, D-dimer, D-dimer, 
Some inclusion clothing, fibrinogen ~ 12 fibrinogen ~ 4 0/5 had raised D-
criteria listed as and stowing before flight. days after dimer or 
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Reference Inclusion Exclusion Participants Air travel Preventive Exclusion of VTE Diagnosis of Proportion who 
criteria criteria measures before travel VTE developed VTE 
(Belcaro et al. "High-risk" > 1.9 metres tall, Control group in RCT One non-stop flight Video as in Sonosite US s 90 Sonosite US s 6/102 (5.9%) 
2003) passengers as weight > 90 kg, of stockings .. of 11.5 - 12 hours in LONFLIT- minutes before 90 minutes DVT, not stated 
(LONFLIT5 defined in VTE at baseline. 114 in control group, economy class. FLITE trial. flight. after flight. whether 
JAP study) LONFLITl. Some inclusion 102 followed up. symptomatic. 
criteria listed as D-dimer, D-dimer, 
exclusion fibrinogen s 12 fibrinogen s 4 0/6 had raised D-
criteria. before flight. hours after dimer or 
flight. fibrinogen levels. 
(Jacobson et See Table 7.4. See Table 7.4. Uncontrolled cohort One non-stop flight Nil. D-dimer. D-dimer, 74/899 had raised 
al. 2003) study of passengers on of 11 hours in duplex US. D-dimer levels, 
flights between business or economy but 0/434 had 
London and class. DVTon US. 
Johannesburg. 
(Schwarz et al. See Table 7.3. See Table 7.3. Air travellers in Outbound and return Encouraged D-dimer and US D-dimer and 7/964 (0.7%) 
2003) controlled cohort non-stop flights 2: 8 to exercise 1 week before US at48 DVT, 5/7 
study. 1077 in control hours during and drink outbound flight. hours and 4 asymptomatic. 
group, 964 followed unspecified period. plenty of weeks after 
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Reference Inclusion Exclusion Participants Air travel Preventive Exclusion of VTE Diagnosis of Proportion who 
criteria criteria measures before travel VTE developed VTE 
(Hughes et al. 18 - 70 yrs, PastVTE, 1000 recruited, 83 had Outbound and return 146 (16.6%) D-dimer ::; 1 week D-dimer::; 72 9/878 (1 % [95% 
2003) "low to anticoagulant raised D-dimer at non-stop flights 2'. 4 wore before outbound hours and 2 CI 0.5 - 1.9]) had 
(NZATT moderate risk" use, pregnancy, baseline. Hence 917 hours within 6-week compression flight. weeks after radiological 
Study) passengers. contraindications eligible, 878 followed period. stockings. return flight. evidence of DVT 
to intravenous up. or PE in 3 months 
contrast, active Mean duration of Compression following flight, 
cancer, recent return flight 18.1 US andCTPA all had raised D-
major surgery or hours (SD 5.9). (or V-Q scan dimer levels. 
trauma. for all with 
raised D- 5/9 had 
Raised D-dimer dimer levels symptoms of 
at baseline. or high DVT, 3/8 
clinical symptoms of PE, 
probability but total number 
symptoms in of people with 
3 months after symptoms not 
travel stated. 
(n=ll2). 
9/9 had total 
Follow-up flight time > 24 
telephone call hours. 
to 845/878 
(96%) at 3 
months. 
(Belcaro et al. "High-risk" Asin Control (placebo) One non-stop flight Video as in Sonosite US ::; 90 Sonosite US ::; 1/97 (1.0%) 
2004) passengers as LONFLIT5 JAP group in RCT of of7 - 12 hours in LONFLIT- minutes before 2 hours after DVT, 
defined in study pycnogenol. economy class. FLITE trial. flight. flight. asymptomatic. 
LONFLIT1. 105 in control group, 
97 followed up. 4/97 (4.1%) SVT, 
symptomatic. 
Abbreviations used in the table CTPA: computed tomography pulmonary angiography, DVT: deep vein thrombosis, LMWH: low-molecular weight heparin, PE: pulmonary embolism, RCT: randomised controlled trial, SD: standard 















7 .4.3 Discussion 
In absolute terms, the risk of clinically important venous thromboembolic events 
following long-distance air travel is uncertain. Surprisingly high rates of asymptomatic 
venous thrombosis have been reported in volunteers, while studies of symptomatic 
venous thromboembolism have nearly all involved non-fatal events in passengers 
requiring medical care on arrival at international airports and so are likely to have 
underestimated the true incidence. A dose-response relationship has been observed in 
studies of symptomatic events. The only study to estimate the incidence of fatal events is 
likely to have provided an underestimate of risk, as it excluded people who died in the 
community. 
7.5 WHAT ARE THE POSSIBLE CAUSAL MECHANISMS OF FLIGHT-RELATED 
VENOUS THROMBOEMBOLISM? 
Research into the possible causal mechanisms of flight-related venous 
thromboembolism has focused on three main factors: venous stasis, dehydration, and 
exposure to hypobaric hypoxic conditions. Each of these factors is considered below. 
7.5.1 Venous stasis 
Venous stasis in air travellers is said to arise from prolonged sitting in cramped 
conditions, with a consequent reduced function of the calf muscle pump and the 
possible compression of the popliteal vein against the edge of the seat (Chee and 
Watson 2005). There is both observational and experimental evidence to support the 
view that sitting, in general, promotes venous stasis and venous thromboembolism. In 
1940, a London forensic pathologist suggested that prolonged sitting was a risk factor 
for venous thromboembolism after observing a six-fold increase in the number of deaths 
from pulmonary embolism during the London Blitz (Simpson 1940). Most of the 
deaths had occurred while sitting in cramped conditions in an air raid shelter, or soon 
after leaving one. It was concluded that while these people had pre-existing risk factors 
for venous thromboembolism, the precipitating factor was the prolonged period of 
immobility in a deck chair or a similar seat - a hypothesis supported by the 
observation that the number of deaths from pulmonary embolism declined concurrently 
















Venous thromboembolism has also been reported in people who had undertaken long 
journeys by car, bus, truck, train, or ship (Tardy et al. 1993; Eschwege and Robert 1996; 
Bertos-Polo et al. 2003; Lapostolle et al. 2004; Hitosugi et al. 2005) (and see Appendix 
C and Table 7 .2). In addition, the condition has been described following long periods 
spent watching television (de Zwaan et al. 1984; Walsh et al. 1986) or sitting at a 
computer (Beasley et al. 2003; Ng et al. 2003; Beasley et al. 2005). It has also been 
observed that the appearance of illustrations and accounts of unilateral swelling of the 
lower limb coincided with the widespread adoption of the chair and a more sedentary 
lifestyle (Dexter 1973). 
Several experiments have recorded a reduction in venous flow in the legs of seated 
volunteers (Wright and Osborn 1952; Delis et al. 2004). One research group has shown 
that folds and rings appear in the wall of the popliteal vein when the knee is flexed and 
these can cause a temporary impairment of venous flow (Schmitt and Mihatsch 1992). 
Moreover, in recent air and bus travellers with venous thromboembolism, the thrombi 
appeared to have originated at such folds and rings. It has been suggested that raised 
intra-abdominal pressure in seated obese passengers might further impede venous return 
(Arfvidsson et al. 1999). Leg oedema, a sign of venous stasis, has been observed in 
persons sitting for prolonged periods in normobaric conditions in mock aircraft cabins 
(Landgraf et al. 1994), office settings (Noddeland and Winkel 1988), lecture theatres 
(Hollingsworth et al. 2001), and while travelling by bus (Schobersberger et al. 2004). 
Oedema has also been reported in those travelling by air (Marshall and Dormandy 1987; 
Loew et al. 1998; Cesarone et al. 2001; Belcaro et al. 2002; Mittermayr et al. 2003; 
Cesarone et al. 2003a; Cesarone et al. 2003b; Cesarone et al. 2003c; Cesarone et al. 
2003d) and the shift of fluid into the interstitial space has been found to continue for up 
to 24 hours following a flight (Mittermayr et al. 2003). In air travellers, however, it is 
not possible to disentangle the effects of sitting from the other conditions inherent in 
flying such as hypobaric hypoxia and possible dehydration. 
Venous stasis has been reported to cause endothelial damage (Wu and Mansfield 1980) 
and has also been associated with increased coagulability, although the results are not 
consistent. An increase in the viscosity of venous blood has been observed in people 
who have sat for prolonged periods in normobaric conditions, with some researchers 
















Hitosugi et al. 2000; Iwama et al. 2002) and others noting signs of systemic 
haemoconcentration (Hodkinson et al. 2003). A few investigators have drawn blood 
solely from antecubital veins and have found little or no change in viscosity (Landgraf 
et al. 1994; Hollingsworth et al. 2001; Stricker et al. 2003; Schobersberger et al. 2004). 
These inconsistent findings may be due to the small numbers of volunteers involved in 
the studies, as well as differing methods - for example viscosity has been shown to 
vary by time of day (Landgraf et al. 1994), the site and method of blood sampling 
(Moyses et al. 1987; Hamada et al. 2002), and the ambient temperature (Noddeland et 
al. 1981). 
Several investigators have also found signs of increased coagulability in people sitting 
in normobaric conditions (Iwama et al. 2002; Schobersberger et al. 2004), while others 
have found no such changes (Tardy et al. 1996) or have measured a reduction in the 
markers of thrombin generation (Hodkinson et al. 2003; Stricker et al. 2003; Colucci et 
al. 2004). Increases in platelet packing and in total numbers of platelets have also been 
described in such conditions (Makris et al. 1986; Hollingsworth et al. 2001). 
One group, which observed an increased concentration of lactate in the venous blood of 
the leg, has proposed that arterial compression and subsequent ischaemia in the seated 
position also plays a role in the aetiology of flight-related thrombosis (Iwama et al. 
2002). 
7 .5.2 Dehydration 
It has been suggested that the relatively low humidity (8 - 12%) encountered on aircraft 
results in greater insensible and ventilatory fluid losses than occur at higher humidity 
(Eklof et al. 1996). In addition, an insufficient fluid intake and the diuretic effects of 
coffee and alcohol can further predispose air passengers to dehydration and a 
consequent hypercoagulable state. However, as discussed in Chapter 1, the evidence 
linking dehydration with venous thromboembolism is surprisingly scanty. Moreover, 
the data regarding dehydration and air travel are inconsistent, with some researchers 
recording physiological changes consistent with dehydration during real or simulated 
flight conditions (Carruthers et al. 1976; Simons and Krol 1996) and others finding no 
such changes (Jacobson et al. 2002; Schobersberger et al. 2002; Mittermayr et al. 2003; 





















humidity encountered while flying leads to a subjective, but incorrect, impression of 
dehydration because of the drying of mucous membranes, conjunctivae, and the skin 
(Bagshaw 1996). 
7.5.3 Hypobaric hypoxia 
At usual cruising altitudes, the air pressure in the cabins of modern aircraft is equivalent 
to that found at altitudes between 1500 and 2400 metres above sea level (Chee and 
Watson 2005). One consequence of this is that the oxygen saturation of arterial blood 
decreases during air travel. For example, in a recent study the mean peripheral oxygen 
saturation in 45 of 84 healthy air travellers dropped to 94% or less at cruising altitude -
levels which, according to the researchers, would have prompted the administration of 
supplemental oxygen in hospitalised patients (Humphreys et al. 2005). Moreover it 
appears that drowsiness may exacerbate this phenomenon because it impairs the normal 
increased ventilatory response to hypoxia. In one study, the arterial oxygen saturation 
of volunteers seated in a hypobaric chamber fell to 80% among those who dozed off and 
increased again when they were prompted to breathe properly (Simons and Krol 1996). 
In the introduction to this chapter, it was revealed that the reported activation of 
coagulation in hypobaric hypoxic conditions in an uncontrolled experiment (Bendz et al. 
2000) received widespread media coverage. However, the findings of that study were 
questioned because inexplicably high levels of markers of activated coagulation were 
found before the exposure and, moreover, it is possible that the further increases in these 
markers during the experiment were artefactual (Bartsch et al. 2001). The lack of a 
control group invariably precluded the exploration of these issues. 
Two further uncontrolled studies have examined the coagulability of venous blood 
during air travel, but the results are conflicting. One research group reported an 
increase in the markers of coagulation activation and a suppression of fibrinolysis 
during and after an eight-hour flight (Schobersberger et al. 2002). However, since the 
researchers later observed that coagulation was also activated in bus passengers 
(Schobersberger et al. 2004), they concluded that stasis, rather than hypoxia, was 
responsible for the changes in air travellers. Conversely fibrinolysis, which was 
suppressed in air travellers, was not inhibited in the bus passengers, suggesting that 


















activated coagulation, instead observing a reduction in markers of thrombin generation 
in air travellers (Boccalon et al. 2005). As discussed earlier, such a change had also 
been observed in seated volunteers in normobaric conditions (Hodkinson et al. 2003; 
Stricker et al. 2003; Colucci et al. 2004). 
Several researchers have conducted small cross-over trials, in which volunteers were 
exposed alternately to normobaric hypoxic and non-hypoxic conditions, and have 
concluded that hypoxia does not stimulate activation of coagulation (Crosby et al. 2003; 
Hodkinson et al. 2003; Dick et al. 2004). One group found no significant change in the 
markers of coagulation in either exposure situation (Crosby et al. 2003), another found 
an increase in markers in both situations but no significant differences between hypoxic 
and control conditions (Hodkinson et al. 2003), and the third simply reported that there 
were no differences between the two exposures (Dick et al. 2004). In a fourth trial, 
there were no signs that hypobaric hypoxic conditions stimulated platelet activation or 
reactivity (Jones et al. 2004). 
Research into the possible effects of hypoxia on coagulation has also focused on 
mountaineers and others exposed to high altitudes, but the results are inconsistent. 
Signs of increased thrombin generation and inhibition of fibrinolysis at high altitude 
were described in one recent study (Mannucci et al. 2002), while another found no such 
changes (Bartsch et al. 2001). 
Other possible effects of hypobaric hypoxia have also been discussed. In one review it 
was suggested that in-flight hypoxia and the subsequent re-oxygenation might cause 
endothelial damage (Keynan et al. 2006). It has also been suggested that in air 
travellers with pre-existing small pulmonary emboli, hypoxia-induced pulmonary 
vasoconstriction around the embolism might trigger a fatal event (Cheung and Duflou 
2001). 
7.5.4 Is venous stasis or hypobaric hypoxia to blame? 
Two recent cross-over trials, conducted under the auspices of the WHO Research Into 
Global Hazards of Travel (WRIGHT) initiative, have attempted to disentangle the 
potential effects of hypobaric hypoxia and immobility on the coagulability of blood 














coagulation and fibrinolysis were measured before, during, and after eight-hour 
exposures of the 71 participants to air travel (immobility in hypobaric hypoxia), a movie 
marathon (immobility in normobaric conditions), and usual daily activities (Schreijer et 
al. 2006). The experiments were separated by two-week intervals and occurred at the 
same time of day to control for circadian rhythm. Air travel, but not the two normobaric 
exposures, was associated with an increase in the median concentrations of one of the 
two measured markers of activated coagulation (thrombin-antithrombin complex). This 
increase was particularly evident in oral contraceptive users who were carriers of the 
factor V Leiden mutation. Consistent with previous studies (Hodkinson et al. 2003; 
Stricker et al. 2003; Colucci et al. 2004; Boccalon et al. 2005), the median value of the 
another marker of activated coagulation (prothrombin fragment 1 and 2) decreased after 
both flying and sitting in the cinema and this exceeded the small decrease observed after 
daily activities whi.ch was probably due to circadian changes. It has been suggested that 
such a change might inhibit the activation of protein C, an important inhibitor of 
coagulation (Stricker 2006). A few volunteers had very large increases in the two 
markers of coagulation and the marker of fibrinolysis (D-dimer). The researchers 
concluded that flying led to an activation of coagulation and fibrinolysis in some 
susceptible individuals (such as oral contraceptive users with the factor V Leiden 
mutation) due to some mechanism over and above the effect of immobilisation. 
The second cross-over trial produced conflicting results (Toff et al. 2006). In this study, 
73 healthy volunteers sat for eight hours in a hypobaric chamber on two occasions at 
least a week apart. On one of those occasions, the chamber was depressurised to 
hypobaric hypoxic conditions. Overall, no differences between the hypoxic and the 
control conditions were found in measures of coagulation, fibrinolysis, platelet function, 
or markers of endothelial activation. The investigators reported that although there 
were some changes in a few clotting parameters in both groups, some of which were 
attributable to normal circadian changes and others to prolonged sitting, there was no 
significant change in the endogenous thrombin potential, a global marker of 
coagulation. The researchers thus concluded that there was no support for the 


















An editorial, which discussed both cross-over trials, concluded that mild hypoxia 
combined with prolonged sitting does not produce a hypercoagulable state in healthy air 
travellers, although there does appear to be an interaction between these factors and oral 
contraceptive use and the factor V Leiden mutation (Bartsch 2006). 
7 .5.5 Discussion 
Several possible causal mechanisms have been proposed to explain the increased risk of 
venous thromboembolism in air travellers, such as venous stasis, dehydration, and 
exposure to hypobaric hypoxic conditions. Experimental studies, involving volunteers 
exposed to real or simulated aeroplane cabin conditions, have confirmed the role of 
venous stasis but have provided mixed results regarding the role of dehydration and the 
possible activation of coagulation in hypobaric hypoxic conditions. These inconsistent 
results may be due to the small numbers of volunteers involved in the studies and 
differences in methods. However, there is also evidence to suggest that activation of 
coagulation in response to hypoxia may only occur in some people - for example, oral 
contraceptive users and carriers of the factor V Leiden mutation. 
7.6 CAN FLIGHT-RELATED VENOUS THROMBOEMBOLISM BE PREVENTED? 
Much of the early information about how to avoid flight-related venous 
thromboembolism appears to have been derived from assumptions about the causal 
mechanisms and the extrapolation of data from other settings, rather than being based 
on any firm evidence. The authors of the initial case reports and case series stressed the 
importance of leg exercises (Homans 1954), moving about the cabin (Beighton and 
Richards 1968), adequate fluid intake (Symington and Stack 1977), and the avoidance 
of alcohol (Holliday 1985) when flying. Aspirin was recommended for high-risk 
passengers (Holliday 1985), as were compression stockings and subcutaneous heparin 
(Bounameaux 1988). The use of devices which exercised the lower legs were also 
promoted (Coller 1988). 
Since these early reports, reviewers have continued to advocate general preventive 
measures to avoid venous stasis and dehydration such as walking about the aircraft 




















alcohol, and ensuring a generous intake of other fluids (Bartsch 2006; Stricker 2006). 
However the evidence for such measures remains limited and not all are without risk -
for example, unexpected turbulence may be encountered while moving about the cabin 
(Gallus and Baker 2001). Some researchers have found that regularly exercising the 
calves when seated reduces oedema (Noddeland and Winkel 1988), while others have 
not (Landgraf et al. 1994). A substantial increase in venous return has been measured in 
persons using a bipedal device to alternately plantar flex and dorsi flex the feet (Caruana 
et al. 2003). It has also been suggested that compliance with recommended leg 
exercises could be enhanced by the use of accelerometers to monitor calf muscle pump 
activity (O'Donovan et al. 2005). Intermittent pneumatic compression of the lower 
limbs has been shown to suppress procoagulant activity and enhance global fibrinolytic 
potential in seated volunteers and hence may have some implications for the prevention 
of flight-related venous thromboembolism (Giddings et al. 2004). 
As discussed earlier, it is unclear whether dehydration occurs during long-distance air 
travel. However, in one randomised controlled trial conducted in simulated flight 
conditions, the consumption an electrolyte-carbohydrate drink was associated with a 
more favourable net fluid balance than drinking plain water (Hamada et al. 2002). 
Moreover, the viscosity of venous blood in the legs remained normal in the intervention 
group whereas it increased in the plain water group. 
Passengers with pre-existing risk factors for venous thromboembolism have usually 
been advised to see their doctor to determine the need for additional preventive 
measures (Chee and Watson 2005). Several randomised controlled trials have shown 
that below-knee compression stockings help to prevent ultrasound-detected 
asymptomatic deep vein thrombosis in air travellers (Belcaro et al. 2001; Scurr et al. 
2001; Belcaro et al. 2002; Belcaro et al. 2003; Cesarone et al. 2003c), although the 
clinical relevance of such thrombi is unknown. Compression stockings have also been 
shown to reduce oedema during long-distance flights (Loew et al. 1998; Belcaro et al. 
2002; Cesarone et al. 2003a; Cesarone et al. 2003c) and prolonged sitting in normobaric 
conditions (Hollingsworth et al. 2001; Iwama et al. 2002). In one trial, in which 
participants wore a stocking on just one leg, increases in viscosity and lactate, and a 
decrease in coagulation time, were observed solely in the leg without a stocking (Iwama 

















In a recent Cochrane systematic review of the above trials, it was estimated that the use 
of compression stockings reduced the odds of developing asymptomatic deep vein 
thrombosis by about 90% and decreased the incidence of such events from 10 - 30 per 
1,000 to 1 - 3 per 1,000 passengers on flights of more than four hours (Clarke et al. 
2006). The reviewers concluded that stockings also helped to prevent superficial 
venous thrombosis, although an increased incidence of thrombophlebitis was reported in 
one study (Scurr et al. 2001). However, it was not possible to determine whether 
stockings reduced the occurrence of more clinically relevant symptomatic deep vein 
thrombosis, non-fatal pulmonary embolism, or death because none of the trial 
participants had suffered these outcomes. 
Opinion about the prophylactic role of aspirin has been divided. Some commentators 
have supported its use in air travellers (Kesteven 2000; Bagshaw 2001; Geroulakos 
2001; British Thoracic Society Standards of Care Committee 2002), while others have 
maintained that it should not be promoted because of a lack of efficacy and the risk of 
adverse reactions such as gastrointestinal discomfort, bleeding complications, and 
hypersensitivity (Gallus and Baker 2001; MacGillavry et al. 2001; Giangrande 2002; 
Makris 2002; Possick and Barry 2004; Chee and Watson 2005; Stricker 2006). For 
example, one randomised controlled trial not only failed to show that aspirin was 
beneficial in preventing asymptomatic deep vein thrombosis in air travellers, but 13% of 
treated participants suffered from mild gastrointestinal discomfort (Cesarone et al. 
2002). In a second randomised controlled trial conducted in normobaric conditions, the 
total platelet count was reduced in participants who had taken aspirin one hour earlier, 
however no measurements were made before the aspirin was dispensed (Hollingsworth 
et al. 2001). Despite a lack of information about its effectiveness, the "number needed 
to treat" has been estimated for the prophylactic use of aspirin in air travellers (Loke 
and Derry 2002). Assuming an incidence of flight-related deep vein thrombosis of 20 
per 100,000 passengers, and that the beneficial effect of aspirin observed in patients 
with hip fractures would also apply for air travellers, 17,000 passengers would need to 
be treated with a single dose of aspirin to prevent one case. 
The use of prophylactic low-molecular weight heparin for air travellers with a high 
background risk of venous thromboembolism has been more widely accepted (Forbes 















2001; British Thoracic Society Standards of Care Committee 2002; Giangrande 2002; 
Makris 2002; Possick and Barry 2004; Chee and Watson 2005; Bartsch 2006; Stricker 
2006), although some commentators have expressed concern regarding the lack of 
information about its effectiveness and safety in air travellers (MacGillavry et al. 2001). 
One randomised controlled trial of a single dose of low-molecular weight heparin before 
a long-distance flight showed a reduced risk of asymptomatic deep vein thrombosis 
(Cesarone et al. 2002). In another trial, of volunteers confined to a hypobaric hypoxic 
environment, low-molecular weight heparin reportedly prevented the activation of 
coagulation in the participants (Bendz et al. 2001) - although the trial did not include a 
control group, so it is impossible to know whether coagulation was indeed prevented or 
whether hypobaric hypoxic conditions simply do not provoke changes in coagulability. 
Several small randomised controlled trials have also examined the prophylactic 
potential of various herbal preparations. For instance, a decreased incidence of 
asymptomatic deep vein thrombosis or superficial venous thrombosis was reported in 
air travellers treated with pinokinase (Cesarone et al. 2003d) and pycnogenol (Belcaro 
et al. 2004). Similarly, oedema was apparently reduced in passengers who received an 
extract of horse chestnut seed (Marshall and Dormandy 1987), a Centella asiatica 
preparation (Cesarone et al. 2001), hydroxyethyl rutosides (Cesarone et al. 2003b), and 
pinokinase (Cesarone et al. 2003d), while a dried extract of vine leaves had no 
observable effect on oedema (Loew et al. 1998). 
Finally, secondary prevention obviously has an important role in the prevention of fatal 
venous thromboembolic events following long-distance air travel. As such, medical 
staff at airports need to be aware of the possible significance of symptoms such as leg 
pain or swelling, transient shortness of breath, chest pain, and syncope in recent arrivals. 
Moreover, because symptoms may not develop immediately after disembarking from 















CHAPTERS DESCRIPTIVE STUDY OF LONG-DISTANCE AIR 
TRAVEL: OBJECTIVES AND METHODS 
8.1 INTRODUCTION 
The possible relationship between air travel and venous thromboembolism is of 
particular relevance to New Zealand because of its relative geographical isolation, 
because most people travel to and from the country by air, and because increasing 
numbers of New Zealand residents and overseas visitors are undertaking such journeys. 
According to the national statistics office, Statistics New Zealand, by 1970 about 90% of 
travellers arrived in New Zealand by air (Statistics New Zealand 2001a). In 2000 












Table 8.1 Arrivals in New Zealand in the year to May 2000 by mode of travel* 
Mode of Short-term migrants Permanent and long-term migrants§ 
travel (number[%]) (number [%]) 
New Zealand residentst Overseas visitors* 
Air 1,223,711 (98.5) 1,633,854 (97.2) 60,082 (97.7) 
Sea 1,421 (0.1) 12,530 (0.8) 239 (0.4) 
Unspecified 17,820 (1.4) 34,203 (2.0) 1,196 (1.9) 
Total 1,242,952 1,680,587 61,517 
' Data provided by Statistics New Zealand. 
1 Defined by Statistics New Zealand as New Zealand residents who arrived from overseas after an absence of less than 12 months. 
* Defined by Statistics New Zealand as overseas visitors who intended to stay in New Zealand for less than 12 months. 
278 
§ Defined by Statistics New Zealand as overseas migrants who intended to stay in New Zealand for 12 months or more (including 















With the exception of flights from neighbouring Pacific Island nations and the east coast 
of Australia (three to four hour flights), and from other parts of Australia (five to eight 
hour flights), air passengers who arrive in New Zealand have all undertaken journeys 
with total flight times of more than eight hours, and in many cases more than 24 hours. 
In the year to May 2000 for example, data obtained from Statistics New Zealand show 
that at least 994,508 (34.1 % ) of the 2,917,647 passengers who arrived in New Zealand 
by air had flown for more than eight hours (Table 8.2). This is likely to be a 
conservative estimate for two reasons. First, the port of embarkation refers to the 
airport where the passenger first boarded the aircraft on which they arrived in New 
Zealand and this is not necessarily the airport from which they began their journey. For 
example, a passenger travelling from the UK to New Zealand who changed aircraft at 
one of the main transfer ports (in Los Angeles, Singapore, or Sydney) would record that 
airport as their port of embarkation (Statistics New Zealand 2001a). Second, the 
estimated flight times in Table 8.2 represent the shortest journeys from the ports of 
embarkation to New Zealand. These flight times were obtained by searching the 
schedules of two major networks of international airlines2 to find the most direct flights 
to Auckland International Airport - the airport at which 71 % of international travellers 
arrived in 2000 (Statistics New Zealand 2001a). 














Table 8.2 Arrivals in New Zealand by air in the year to May 2000, by port of embarkation* 
Estimated flight time t and 
port of embarkation* 
















Other South Pacific airports 
Total (number[%]) 



























































































































Estimated flight time t and Short-term migrants Permanent and long-
port of embarkation* term migrants'll 
New Zealand residents§ Overseas visitors II 
Flight time 12 - 15 hours 
Bangkok 11,362 12,716 640 
Beijing 39 30 
Buenos Aires 4,579 9,941 292 
Fukuoka - 4,076 
Los Angeles 90,781 150,880 6,467 
Seoul 13,022 51,627 2,875 
Shanghai 199 24 
Vancouver 280 781 6 
Total (number[%]) 120,024 (9.8) 230,259 (14.1) 10,334 (17.2) 
Flight time::: 16 hours 
Chicago 187 173 5 
Frankfurt tt 449 4016 62 
Heathrowtt 10,334 17276 1,549 
Gatwicktt 157 1,426 178 
Total (number[%]) 11,127 (0.9) 22,891 (1.4) 1,794 (3.0) 
Total arrivals by air 1,223,711 1,633,854 60,082 
' Data provided by Statistics New Zealand. 
t Shortest flight time between port of embarkation and Auckland International Airport. 
* Defined by Statistics New Zealand as the airport or country in which the migrant first boarded the aircraft on which they arrived in New 
Zealand. 
§ Defined by Statistics New Zealand as New Zealand residents who arrived from overseas after an absence of less than 12 months. 
II Defined by Statistics New Zealand as overseas visitors who intended to stay in New Zealand for less than 12 months. 
1 Defined by Statistics New Zealand as overseas migrants who intended to stay in New Zealand for 12 months or more (including 
permanently) and New Zealand residents who returned after an absence of 12 months or more. 
"Shortest flight time less than 12 hours, but some flight times?. 12 hours. 















Travel to and from New Zealand not only involves long flights, but increasing numbers 
of such journeys are being undertaken by New Zealanders of all ages. Statistics New 
Zealand migration data reveal that in the year to May 1990, 726,163 New Zealand 
residents (21.5% of the estimated resident population of 3,379,2503) arrived back in the 
country by air after an absence of less than twelve months, as compared with 1,268,388 
residents (33.1 % of the estimated resident population of 3,832,9304) in 2000 (Table 
8.3). These figures may reflect a greater number of New Zealanders travelling overseas, 
or an increase in the number of overseas trips undertaken by certain individuals, or both. 
The annual number of arrivals by short-term overseas visitors also increased 
substantially between 1990 and 2000, from 964,690 to 1,775,530 (Table 8.4). In 
contrast to the New Zealand residents who travelled internationally, many of whom 
visited Australia or neighbouring Pacific Islands, overseas visitors tended to have 
undertaken longer flights. In the year to May 2000, at least 40% of short-term overseas 
visitors arrived in New Zealand after flights of more than eight hours, as compared with 
at least 26% of the New Zealand resident short-term arrivals (Table 8.2). 
3 Estimated population on 31 December 1990, derived from census data and obtained from Statistics New 
Zealand 


















Table 8.3 Arrivals of New Zealand residents by air, after an absence of less than 12 months, 
in the years to May 1990 and May 2000 * 
Age (years) 1990 2000 
Under 5 18,521 35,340 
5-9 19,565 40,988 
10-14 25,634 46,181 
15 -19 40,048 53,389 
20-24 57,679 74,377 
25-29 66,668 105,275 
30-34 66,646 122,995 
35-39 69,665 138,318 
40-44 78,596 131,375 
45-49 69,286 133,664 
50-54 56,647 130,245 
55-59 46,685 92,707 
60-64 44,248 62,949 
65-69 32,079 43,556 
70-74 18,747 29,950 
75-79 10,954 18,249 
80-84 3,383 6,565 
85-89 923 1,807 
90-94 142 432 
95 Years and Over 47 26 
Total 726,163 1,268,388 
* Data provided by Statistics New Zealand. 
284 
Table 8.4 Arrivals of overseas visitors by air, who intended to stay for less than 12 months, in 
the years to May 1990 and May 2000 * 
---r Age (years) 1990 2000 
0-14 75,130 145,713 
15-19 42,442 81,265 
·1 
20-24 91,731 132,447 
"' 25-29 130,162 201,463 
4 30-34 101,351 185,341 
35-39 88,839 163,212 
40-44 91,092 150,743 
({ 
45-49 76,936 154,092 
(>- 50-54 65,306 158,599 
55-59 56,687 133,937 
~ 
60 and over 145,014 268718 
-
Total 964,690 1,775,530 
?" 
























In July 2000, it was decided to undertake a population-based study in New Zealand to 
explore the potential association between long-distance air travel and venous 
thromboembolism. As described in Chapter 7, at that time the evidence for a link was 
purely circumstantial; the published data comprised case reports, case series, and one 
poorly designed case-control study in which a four-fold significant risk of venous 
thromboembolism was found for travel by any mode of transport. The decision to 
undertake a study was prompted by this lack of information and the particular relevance 
of any association between air travel and venous thromboembolism both for individual 
travellers and for the providers of medical services in New Zealand. Since venous 
thromboembolism is a relatively rare event and the population of New Zealand is small, 
a case-control study was considered the most appropriate analytical study design to 
explore the possible association. 
Initially descriptive and case-control studies involving people admitted to hospital with 
deep vein thrombosis or pulmonary embolism were planned. However, as was 
discussed at the beginning of Chapter 7, the possible link between long-distance air 
travel and venous thromboembolism received widespread media attention in late 2000 
and early 2001. In light of the subsequent public and professional concern about the 
potential association, the proposed hospital-based prospective research was no longer 
feasible because of the potential for referral and diagnostic biases. While a study 
confined to severe cases might have avoided these problems, such an investigation 
would have taken many years to complete given the relative rarity of such events and 
the size of the New Zealand population. On the other hand, a study of people who had 
already died from pulmonary embolism was feasible. Moreover, while concerns were 
expressed in the media and elsewhere about deaths in air travellers, none of the 
published epidemiological studies had explored the relative or absolute risks of dying 
from pulmonary embolism following a long-distance flight. Hence, a study involving 
fatal cases of pulmonary embolism (initiated at the end of 2002) was undertaken to 
examine these risks. 
There were two components to the research: a descriptive study of men and women aged 
15 - 59 years who died from pulmonary embolism in New Zealand between 1 January 
1990 and 31 December 2000, and a national case-control study which was based on a 


















people aged 15 - 59 years because the majority (77%) of people who arrived in New 
Zealand on international flights during the study period were within this age range ( data 
provided by Statistics New Zealand). The methods of the descriptive study are outlined 
in this chapter, and the results are presented and discussed in the next chapter. The 
methods of the case-control study are explained in Chapter 10, and the results and 
discussion follow in Chapter 11. 
8.2 DEFINITION OF LONG-DISTANCE AIR TRAVEL 
In both the descriptive and the case-control studies, long-distance air travel was defined 
as a flight of at least three consecutive hours. If a journey consisted of more than one 
flight, the total flight time for the journey was calculated by adding together the 
duration of each flight (but at least one flight had to be three or more consecutive 
hours). A minimum flight time of three hours was chosen for several reasons. First, it 
allowed comparisons with the studies published at the time the present research was 
initiated, which had all examined the risk of venous thromboembolism following 
journeys of at least three or four hours' duration (Ferrari et al. 1999; Kraaijenhagen et 
al. 2000; Arya et al. 2002). Second, since domestic air travel within New Zealand 
involves flight times of less than three hours, while international flights to and from 
New Zealand involve journeys of at least three consecutive hours, such a definition 
simply required study participants to recall international travel during the relevant 
period. This had several potential advantages. It would be unlikely that cases and 
controls who had never left New Zealand would be incorrectly classified as having 
undertaken a long-distance flight. Next of kin would be likely to remember an 
international flight undertaken by their relative in the weeks before they became unwell, 
and controls who travelled very rarely would also be likely to recall such an event. For 
similar reasons, it is likely that any domestic flights within countries other than New 
Zealand that had involved flight times of more than three hours would be identified. 
While controls who travelled frequently might have difficulties recalling details of flights, 
such travel could often be verified by reference to passports and other personal records. 
Finally, a three-hour definition was appropriate because the absolute risk of dying from 
pulmonary embolism following a long-distance flight was to be estimated using data 





the total duration of travel undertaken by arriving passengers cannot be accurately 
established using these data, it is clear that people arriving on international flights must 
have flown for at least three hours. As discussed in Chapter 2, the date of onset of the 
fatal episode was taken as an index date. 
8.3 OBJECTIVES 
The objectives of the descriptive study were as follows: 
1. To determine the proportion of individuals who died from pulmonary embolism in 















during the four weeks before the onset of the fatal episode. 
To estimate the absolute risk of dying from pulmonary embolism following a 
long-distance flight. 
To compare the sex and age-adjusted mortality rate from pulmonary embolism in 
a population in which almost all people had recently undertaken long-distance 
air travel (overseas visitors to New Zealand) with the rate in a population where 
few would recently have travelled (the resident population of New Zealand). 
To examine the possibility that the overall health status of overseas visitors 
differed from that of New Zealand residents by comparing mortality from all 
causes in the overseas visitor population with the rate in the resident population of 
New Zealand. 
The four-week period was chosen to allow comparisons with the analytic studies that 
had been published at the time the research was initiated (Ferrari et al. 1999; 















8.4.1 Case ascertainment 
As discussed in Chapter 2, there were 41 men and 80 women aged 15 - 59 years who 
died in New Zealand between January 1990 and December 2000 for whom pulmonary 
embolism was considered the underlying cause of death. Of these 121 cases, eight were 
short-term overseas visitors to New Zealand and 113 were normally resident in New 
Zealand on the index date. According to existing records and information from next of 
kin, none of the 113 "normally resident" cases were recent "permanent or long-term 
migrants" (as defined by Statistics New Zealand). All of the 121 cases were included in 
the case series. 
8.4.2 Sources of information about long-distance air travel 
Information about long-distance air travel in the four weeks before the index date was 
sought from the next of kin of cases, as well as from existing records. The latter 
included coroners' and police records, death certificates, and hospital, general 
practitioner, mental health, and family planning clinic records as described in Chapter 2. 
The details of journeys of at least four hours' duration by other means of transport in the 
four weeks before the index date were also obtained from existing records and from 
next of kin. 
8.4.3 Identifying next of kin 
Table 8.5 shows the sources of information that were used to identify next of kin. As 
outlined in Chapter 2, the underlying cause of death in 105 of the 121 cases was 
certified by a coroner and for 16 cases a death certificate was completed by a doctor. 
For 102 of the 105 coroner-certified deaths, the Police 47 or Statement of Identification 
forms provided the name, relationship, address, and phone number of at least one next 
of kin. Of the remaining three coroners' cases, no relatives were identified in the 
coroner's records of the first case, a homeless alcoholic man. During a brief hospital 
admission a few weeks before his death, he told hospital staff that he had no relatives or 
friends that could serve as next of kin. The coroner's and hospital records also failed to 
identify the next of kin of the second case, a Swiss tourist. Attempts to obtain this 
information from the police and the Swiss Embassy in Wellington were unsuccessful 



















record of his death. The name and contact details of a sibling were eventually obtained 
by Swiss medical contacts. The coroner's records of the third case identified a mental 
health worker, but no next of kin. This information was found in hospital records. For 
12 of the 16 doctor-certified deaths, a Notification of Death for Registration form was 
appended to the Medical Certificate of Causes of Death. This form contained the names 
and occupations of the parents of the case, the names and ages of any former or current 
spouses, and the sex and age of any offspring. For the remaining four cases, next of kin 
details were obtained from hospital records. Hence, the next of kin of all but two cases 


















Table 8.5 Sources of information used to identify the next of kin of New Zealand residents 
and overseas visitors 
Source of information New Zealand residents Overseas visitors Total 
Coroners' records 96 6 102 
Notification of Death for 12 12 
Registration forms 
Hospital records 4 1 5 
Other 1 1 
No next of kin identified 1 1 


















8.4.4 Obtaining the current contact details for next of kin of New Zealand residents 
Although the existing records generally contained the contact details of next of kin, this 
information was compiled up to 13 years before the study was initiated. In order to 
obtain the current contact details of the relatives of New Zealand cases, an electronic 
copy of the current New Zealand Parliamentary Electoral Roll ("the electoral roll") and 
the on-line national telephone directory were searched. Unfortunately, it was not 
possible to obtain a telephone number for all the next of kin for several reasons. First, 
people can choose not to have their home address and telephone number listed in the 
telephone directory. Second, even if a household number is listed, the entry usually just 
includes the name(s) of the account holder(s), rather than the names of all the people 
living in the household. Finally, many mobile telephone numbers are not listed in the 
directory. 
Before describing the search of the electoral roll in more detail, it is necessary to 
provide some background information about the roll. By law, all New Zealand citizens 
and permanent residents aged 18 years and over who have lived in New Zealand 
continuously for at least one year are required to enrol to be registered on the electoral 
roll (Elections New Zealand 2005a). People who are concerned that their life could be 
in danger if their details appeared on the publicly available roll and have supporting 
documents such as a protection order, can apply to be enrolled on a confidential 
unpublished roll (Elections New Zealand 2005a). A Registrar of Electors within each 
electorate is responsible for maintaining and updating the electoral roll on a daily basis, 
and for conducting enrolment update campaigns before major elections (Elections New 
Zealand 2005b). The Registrars receive change of address information from electors 
(directly or through change of address forms submitted to New Zealand Post), and 
information about name changes and deaths from the office of Births, Deaths, and 
Marriages (Elections New Zealand 2005a). At any one time, only a very small 
proportion of the eligible population will not be registered on the electoral roll. As of 
17 June 2005, for example, about 8% of eligible citizens and residents (estimated from 
census data) were not enrolled (Elections New Zealand 2005c). 
An annually updated paper copy of the electoral roll is available for public inspection at 
local Registrars' offices, and copies of the current and previous rolls are held by the 





















to obtain an electronic copy of the electoral roll at any time from the Electoral 
Enrolment Centre in Wellington (Elections New Zealand 2005b). Unlike paper versions 
of the roll, the age of each elector is included in the electronic version. Moreover, it is 
possible to search the electronic roll using any of the following fields: name, age in 
individual years, sex, occupation, residential and postal addresses, and electorate. 
For the present research, it was possible to refer to electronic copies of the electoral roll 
(General and Maori5 combined) for the years 1993, 1996, 1998, 2000, 2002, and 2003. 
To find the current addresses of the next of kin of the New Zealand cases, the 2002 and 
2003 (when it became available) electronic rolls were searched by name. Spouses, 
partners, or other adult family members with whom the case had lived on the index date 
were considered the most appropriate next of kin to approach. For cases who did not 
live with a family member, contact details of the closest named relative were sought. If 
the next of kin who were being sought were not found on the latest electoral roll or in 
the telephone directory, electoral rolls from earlier years were searched to determine the 
year in which they were last enrolled. Enquiries were then made with Births, Deaths, 
and Marriages to ascertain whether the person had died or changed their name after this 
date. In situations where the next of kin had died or there was no record of a name 
change, and other methods had failed to locate them, the contact details of the next 
named relative were sought. If there were no other named next of kin, the electoral roll 
was searched by address to identify others living at the same address as the case ( or the 
named next of kin) before or on the index date. Official birth records held by the 
Hocken Library were also examined to identify the children of female cases. 
Of the 112 New Zealand cases for whom next of kin were identified, the postal address 
of at least one next of kin was found on the electoral roll for 107 of the cases. The wife 
of a further case was located by searching the telephone directory. The wives of another 
three cases were subsequently found to have remarried and changed their surnames. 
One marriage was identified by the office of Births, Deaths, and Marriages and the next 
5 
Maori can choose to be enrolled on either the General Parliamentary Electoral Roll or the Maori 























of kin's new surname and address was recorded on the marriage certificate. The second 
woman, who remarried overseas, was found with the assistance of her deceased 
husband's general practitioner who obtained her new contact details from her son. The 
third woman had previously been contacted during the case-control study of 
psychotropic drugs, but a letter sent to her previous address was returned marked "gone, 
address unknown". Her new address was obtained, with her permission, from the real 
estate agent who had sold her house. The husband of the remaining case was located 
with the assistance of his general practitioner, who forwarded the invitation letter to him 
and provided his telephone number. 
8.4.5 Obtaining the current contact details for next of kin of overseas visitors 
Several methods were used to locate the next of kin of the cases who died while visiting 
New Zealand. The father of one woman was found on the Australian electoral roll and 
the on-line Australian telephone directory. The Taiwanese, Swiss, and UK on-line 
telephone directories provided the addresses and telephone numbers of the cousin and 
brothers of three further cases. The hospital records of a man who lived in Australia 
contained the address of relatives who lived in New Zealand. By searching for this 
address on past electoral rolls, the names of these relatives were found, as was their new 
address. A letter addressed to the wife of the case was then sent to their residence. The 
hospital records of a Tongan woman contained both the name and address of a New 
Zealand relative. As this relative was not found on later electoral rolls, earlier rolls 
were searched by address to identify others who had lived in the household. The new 
address of one relative, a sister-in-law, was found on the 2003 electoral roll. 
Attempts to trace the husbands of the two remaining overseas cases were unsuccessful. 
These attempts included engaging the assistance of research colleagues in the UK, and 
contacting the Japanese Consulate-General and a former travel agent who was listed as 
the New Zealand contact of one of the women. Thus, for three cases (including the 
New Zealand case with no identified next of kin), no next of kin were traced. 
8.4.6 Contacting next of kin 
A letter was sent to the next of kin in New Zealand and overseas, inviting them to take 
























next of kin specific questions about the circumstances of their relative's death because 
such information was already available from existing records and hence not subject to 
recall bias. Moreover it was felt that some next of kin might be reluctant to participate 
if they thought that they would be asked to recount such a distressing event to a 
stranger. The letter of invitation, therefore, indicated that the interview would involve 
questions about the life of their relative before they became unwell. 
One of two standard letters was sent to the next of kin of the New Zealand residents, 
according to whether contact had previously been made to enquire about the name of 
their relative's general practitioner during the case-control study described in Chapters 4 
- 6 (Appendix A, letters 19 and 20). For the next of kin of the overseas visitors, one of 
two standard letters were also sent, depending on whether it was thought likely that they 
spoke English fluently (Appendix A, letters 21 and 22). The second of the letters asked 
the recipient to indicate in which language they would prefer to conduct any telephone 
conversations. One letter was translated into Taiwanese at the outset by a final-year 
medical student, who advised that it was unlikely that the next of kin would understand 
the letter of invitation if it was written in English. 
All next of kin were asked to return, in a reply-paid envelope, a form recording their 
contact details and suitable times to be contacted by telephone. Those who returned the 
form were telephoned by me at the designated time to discuss the study and oral consent 
was sought for a telephone interview (Appendix D, form 1). On the other hand, if no 
reply was received after two weeks, next of kin were contacted by telephone (Appendix 
D, form 2). Those who did not have a traceable telephone number were sent up to two 
further letters (Appendix A, letter 23). Since it was impossible to know whether a lack 
of response was due to an unwillingness to participate or simply that the next of kin had 
changed address, a letter was sent to a relative at another address if no reply was 
received after a maximum of three letters. For next of kin who agreed to participate in 
the study, a time of their choosing was made for a telephone interview. 
The initial and subsequent letters, reply-paid forms, and oral consent forms were 
adapted from those employed in two previous case-control studies in which response 





















8.4.7 Telephone interviews with next of kin 
Computer-assisted telephone interviews were undertaken using a standardised 
questionnaire, as will be described in detail in Chapter 10. Briefly, the questionnaire 
included questions about any international flights undertaken in the four weeks before 
the index date and domestic flights undertaken in countries other than New Zealand 
during the same period. Demographic data and information about other risk factors for 
venous thromboembolism were also sought. In addition, next of kin were asked about 
journeys of at least four hours' duration undertaken by their relative using other means 
of transport during the four weeks before the index date. While next of kin were not 
asked specific questions about the course of their relative's fatal condition, many 
volunteered this information. 
All of the interviews were undertaken by a registered nurse (Ms Sue McAllister) or me, 
except for interviews with the next of kin of two overseas visitors. One of these 
interviews was conducted in Swiss German by a Specialist Physician, while the other 
was undertaken in Taiwanese by the final-year medical student who had translated the 
letter of invitation. Translated paper versions of the questionnaire were used for these 
interviews and the responses of next of kin were entered into the computer later. 
8.4.8 Estimation of the absolute risk of fatal pulmonary embolism following long-
distance air travel 
As already discussed, the cases who had undertaken long-distance air travel in the four 
weeks before the index date were identified through interviews with next of kin and by 
examining existing records. Statistics New Zealand provided records of the numbers of 
short-term arrivals on international flights by New Zealand residents and overseas 
visitors, by sex and five-year age groups, in the years 1990 to 2000. These data, derived 
from analyses of the arrival cards which all travellers arriving in New Zealand are 
required to complete, were used to calculate the number of arrivals on flights of at least 
three hours' duration. Because travellers are asked to record only the airport from which 
their last flight departed, these data provided insufficient information about the total 
duration of air travel undertaken by arriving passengers. Therefore, information from the 
control series in the case-control study was used to estimate the number of arrivals by 















period. The proportion of controls who arrived on a flight of more than eight hours in the 
four weeks before the index date was multiplied by 13 (to estimate the proportion over 
one year) and the product multiplied by the annual estimates of the New Zealand 
population aged 15 - 59 years to estimate the number of arrivals by New Zealand 
residents on flights of more than eight hours in the years 1990 to 2000. To assess the 
validity of this approach, the number of arrivals on international flights of any duration 
was estimated and compared with the arrivals data provided by Statistics New Zealand. 
The absolute risks of dying from pulmonary embolism after a long-distance flight were 
estimated by dividing the number of cases who undertook a long-distance flight in the 
four weeks before the index date by the number of passengers aged 15 - 59 years who 
arrived in New Zealand between 1990 and 2000. For New Zealand residents and 
overseas visitors, the absolute risks of dying from pulmonary embolism following a 
flight of at least three hours' duration were calculated using the arrivals data supplied by 
Statistics New Zealand. For New Zealand residents only, the risks after a flight of at 
least three hours' duration and a flight of more than eight hours were calculated using 
the estimated numbers of arrivals derived from the control series. The Poisson 
distribution was used to compute 95% confidence intervals for the estimates of absolute 
risk. 
8.4.9 Comparison of mortality rates in overseas visitors and New Zealand residents 
Numbers of deaths from pulmonary embolism and from all causes 
As already explained in Chapter 2, the New Zealand Health Information Service 
provided the details of 121 people aged 15 - 59 years who died from pulmonary 
embolism between 1990 and 2000. The numbers of deaths from all causes in New 
Zealand residents and overseas visitors by sex and five-year age groups for the years 
1990 - 1998 were also obtained from the New Zealand Health Information Service. 
Data for 1999 and 2000 were not available for all-cause deaths because the country of 
usual residence was not coded in these years. Existing records were used to determine 
whether people who died from pulmonary embolism in 1999 and 2000 had been 


















Sources of population data for New Zealand residents and overseas visitors 
The estimated mean New Zealand resident population by sex and five-year age groups 
on 31 December in the years 1990 to 2000 was obtained from Statistics New Zealand. 
These estimates were based on the national Census of Population and Dwellings that is 
conducted by Statistics New Zealand quinquennially in the month of March. In census 
years the resident population is estimated by adding the number of residents who were 
present in New Zealand and counted on the census date to the number of residents who 
were temporarily overseas on that date, and then adjusting this figure for a net census 
undercount (Statistics New Zealand 2002). In non-census years, birth, death, and net 
migration data are used to update the estimates. 
Census date counts of the overseas visitor population by sex and five-year age groups 
for the years 1986, 1991, 1996, and 2001 were also obtained from Statistics New 
Zealand. Sex and age-specific estimates for intervening years were derived by linear 
interpolation. For example, the difference between the March 1996 and 1991 census 
counts was multiplied by 0.2, 0.4, 0.6, and 0.8, and then added to the 1991 count to 
estimate the overseas visitor populations in March 1992, 1993, 1994, and 1995 
respectively. 
Because seasonal trends were evident in the monthly sex- and age-specific estimates of 
short-term overseas visitor arrivals between 1990 and 2000, the visitor census counts 
and estimated population in non-census years were seasonally adjusted. In brief, for 
each sex and five-year age stratum, the total number of arrivals in each year was divided 
by 12 to obtain the mean monthly arrivals for that year. To calculate the seasonal 
adjustment factor for each stratum for that year, the estimated visitor population for the 
month of March was divided by the mean monthly arrivals. The March population 
count or estimate was then divided by the correction factor to derive the seasonally-
adjusted estimate. 
Person-years of observation 
Sex and age-specific population data for New Zealand residents and for overseas 
visitors were added together to calculate the person-years of observation in residents 
and visitors for the relevant periods. For the comparison of pulmonary embolism 

















for the period 1990 to 2000 were calculated. For deaths from all causes, the relevant 
period was 1990 to 1998. 
Calculation of adjusted rate ratios and standardised mortality ratios 
Direct and indirect methods of sex and age standardisation were used to compare 
mortality rates for pulmonary embolism and all causes in the overseas visitor population 
with the rates in the New Zealand resident population (Hennekens and Buring 1987). 
Both methods were used because of the potential for unstable estimates with small 
numbers. The Poisson distribution was used to compute 95% confidence intervals for the 
adjusted rate ratios and standardised mortality ratios. 
8.4.10 Estimation of attributable proportion 
To estimate the attributable proportion, it was assumed that the mortality rate from 
pulmonary embolism in the overseas visitor population approximated the rate in recent 
long-distance air travellers (mortality rate in the exposed) and the rate in the New 
Zealand resident population was similar to the rate in non-travellers (mortality rate in 
the unexposed). To calculate the proportion (percent) of deaths from pulmonary 
embolism among people who had recently undertaken a long-distance flight, which 
could be attributed to the flight itself, the mortality rate in the unexposed was subtracted 
from the mortality rate in the exposed, divided by the mortality rate in the exposed, and 
multiplied by 100 (Hennekens and Buring 1987). The first calculations were based on 
the mortality rate for overseas visitors which had been standardised to the sex and age 
distribution of the New Zealand resident population. However, because the sex and age 
distribution of the New Zealand residents who undertook long-distance air travel 
differed slightly from that of the general population, the attributable fraction was also 
calculated after standardising the mortality rates of both the overseas visitors and the 
resident population to the sex and age distribution of the New Zealand air travellers 
(using the arrivals data provided by Statistics New Zealand). 
8.4.11 Ethical matters 
Ethical approval for the research was granted by each of the 12 regional ethics 














discussion of ethical matters relating to both the descriptive study and the case-control 
















CHAPTER9 DESCRIPTIVE STUDY OF LONG-DISTANCE AIR 
TRAVEL: RESULTS AND DISCUSSION 
9.1 RESULTS 
9.1.1 Participation of next of kin 
As described in the previous chapter, one of the cases who was a New Zealand resident 
had no identified next of kin and the husbands of two overseas cases were not traced. 
Hence, there were 118 cases for whom the contact details of next of kin were available. 
Figure 9.1 shows the responses of these next of kin to the letters that invited them to 
take part in the study. For 103 of the 118 cases, letters were sent to just one relative. 
For the remaining 15 cases it was necessary to write to more than one relative because 
the letters sent to the first next of kin were either returned by the postal service ("gone, 
no forwarding address"), or no response was received and the next of kin did not have a 
traceable telephone number; for eight cases a second next of kin was sent at least one 
letter, for six cases three next of kin were sent letters, and for one case letters were sent 
to a total of six next of kin. 
The next of kin of 103 (85.1 % ) of the 121 cases eligible for inclusion in the descriptive 
study were interviewed. Only eight (6.6%) next of kin directly declined to participate 
(five husbands, one wife, and two mothers). The sons of two women consented to an 
interview, but both subsequently proved to be impossible to contact. The other next of 
kin of these two cases (the husband and a son of one, and the husband and four 
daughters of the other) did not reply to letters of invitation. For five cases, none of the 
identified next of kin had traceable telephone numbers, and despite sending several 




















121 eligible cases 
Letters sent to first next of kin (n=l 18) 
5 declined 
51 did not reply to first 
letter, no other next of kin 
approached 
44 telephoned 
Letters sent to second next of kin because 
first did not reply or letters returned and 
no traceable telephone number (n=l5) 
6 did not reply to first letter, 
no other next of kin 
approached 
4 telephoned 
Letters sent to third next of kin because 
first two did not reply or letters returned 
and no traceable telephone number (n=7) 
1 declined 
4 did not reply to first letter, 
no other next of kin 
approached 
2 telephoned 
Letters sent to sixth next of kin because 
first five did not reply or letters returned 
and no traceable telephone number (n=l) 
1 did not reply to first letter 
1 telephoned 
Figure 9.1 Participation of next of kin 
301 
3 no letters sent to next of kin, because no 
relatives identified (n=l} or not traced (n=2) 
52 replied to first letter 
2 declined 
7 no traceable 
telephone number 
2 no reply to further 
letters, no other next 
of kin traced 
2 replied to first letter 
2 no traceable 
telephone number 
1 no reply to further 
letters, no other next 
of kin traced 
2 replied to first letter 
1 consented, but then 
not contactable 
2 no traceable 
telephone number 
2 no reply to further 
letters, no other next 
of kin traced 
50 interviewed 











1 consented, but then not contactable, 

















Fifty-four of the 103 next of kin interviews were conducted with the spouse, de-facto 
partner, or adult family member with whom the case had lived on the index date (Table 
9.1). Another 17 cases were known to have lived with a spouse, partner, or family 
member on the index date, but a different relative was interviewed (Table 9.2). The 
reasons for this were varied: the husbands of three cases had died, six spouses and two 
adult children were not traced, one spouse and two partners did not respond to the letters 
of invitation, one partner's name was unknown, one case lived with an uncle but it was 
felt more appropriate to interview his father, and the husband of one case declined to 
participate but her father volunteered when he was being interviewed about his wife 
who was also a case. 
Of the remammg 32 cases, existing records indicated that four lived with young 
children, three with flatmates or boarders, two lived in psychiatric half-way houses, six 
were intellectually disabled and lived in supported accommodation, 12 lived alone, and 
the living circumstances of five were not documented (Table 9.1). For each of these 
cases, the closest named relative was interviewed. 
303 
Table 9.1 Next of kin who were interviewed and their relationship to the case 
Persons with whom the case had Next of kin interviewed New Zealand Overseas visitors 
lived on the index date* (n=103) residents 
Husband/ male partner (n=37) Husband / male partner 24 
Husband and daughter 1 
( 
Husband and brother-in-law 1 
't Mother 2 
Father and uncle 1 
Father 1 
( Daughter or son 6 
Sister-in-law - 1 
" Wife / female partner (n=22) Wife / female partner 18 1 




H Both parents (n=3) Mother 3 
Mother (n=5) Mother 4 
Mother and aunt 1 
I>--
Sister (n=l) Sister 1 
Adult son (n=l) Another son 1 
~ 
Adult daughter (n=l) Sister 1 
Uncle (n=l) Father and sister 1 
Young children only (n=4) Mother 3 
Ex-husband 1 
,{ Flatmates or boarder (n=3) Mother 1 
Ex-husband 1 
Sister-in-law 1 
Psychiatric half-way house (n=2) Brother 1 
Son 1 
J- Intellectually disabled care (n=6) Mother 2 
Sister or brother 4 
> Lived alone (n=l2) Mother 2 
Sister 3 






Unknown (n=5) Parents 1 
Mother 1 
" Sister or brother 2 
"' Brother and friends 1 
Total 98 5 


















Table 9.2 Reasons why next of kin other than those with whom the cases had lived were 
interviewed 
Next of kin with whom the case Reason why next of kin with whom the case Next of kin who 
had lived on index date* had lived was not interviewed was interviewed 
Husband/ male partner (n=l 1) Husband died after index date Son 
Husband died after index date Daughter 
Husband died after index date Sister-in-law 
Name of partner unknown Mother 
Husband not traced Mother 
Husband not traced Father 
Husband not traced Son 
Husband not traced Daughter 
Husband declined, father volunteered when he Father and uncle 
was contacted about his wife who was also a case 
Husband did not reply to letters of invitation Son 
Partner did not reply to letters of invitation Son 
Wife/ female partner (n=3) Wife not traced Mother and brother 
Wife not traced Cousin 
Partner did not reply to letters of invitation Brother 
Son (n=l) Two sons did not reply to letters of invitation Another son 
Daughter (n=l) Daughter not traced Sister 
Uncle (n=l) Father thought to be more appropriate Father and sister 
















9.1.2 Long-distance air travel 
The next of kin of nine cases reported that their relative had undertaken at least one 
international flight in the four weeks before the index date. These flights were all 
confirmed by medical and death records. Of the 18 cases for whom next of kin 
interviews were not undertaken, two were identified as international air travellers -
long-distance flights to New Zealand were documented in the coroner's records of one 
of these women and the hospital records of the other (a doctor-certified death). Both 
were overseas visitors whose husbands were not traced. The existing records of the 
remaining 16 cases (15 residents and one overseas visitor who was known to have been 
in New Zealand for more than a month), contained no references to long-distance air 

















Table 9.3 Existing records examined for cases whose next of kin were not interviewed in 
which there was no mention of long-distance air travel 
Existing records examined 
General practitioners', hospital, and coroners' records 
General practitioners' and coroners' records 
General practitioner's, coroner's, and family planning records 
General practitioner's, coroner's, and mental health records 
General practitioners' and hospital records 
Hospital and coroner's records (overseas visitor) 
Hospital, coroner's and mental health records 
Coroner's records 
Total 


























Although a further two cases were found to have undertaken return three to four hour 
flights to the east coast of Australia about two and three weeks before they died (the 
next of kin of one was interviewed, the other was identified using existing records), 
these journeys were undertaken after the index date: a 33 year old woman was being 
treated for deep vein thrombosis and a 58 year old man had already developed 
symptoms of pulmonary embolism and at necropsy was found to have pulmonary 
emboli of varying ages. 
There were no additional subjects who had undertaken domestic flights within a country 
other than New Zealand during the relevant period. Thus, 11 (9.1 %) of the 121 cases 
(five New Zealand residents and six overseas visitors) were determined to have 
undertaken long-distance air travel in the four weeks before the index date. The 
characteristics of these people are shown in Table 9.4. Seven were female and four 
were male. The median age was 47.9 years. Several of these cases had other risk 
factors for venous thromboembolism. Two people had a personal, as well as a family, 
history of deep vein thrombosis. One developed deep vein thrombosis during her sixth 
and final full-term pregnancy, 13 years before the onset of the fatal episode. She 
subsequently suffered from post-thrombotic syndrome, but her symptoms were relieved 
by surgery to her varicose veins six years before her death. An uncle and three of her 
cousins had been diagnosed with deep vein thrombosis. Following her death, three of 
her six children were found to have protein S deficiency. The other case developed 
deep vein thrombosis following a bicycling accident ten months before the index date 
and was treated with a six-month course of warfarin. One of his aunts also had a history 
of deep vein thrombosis. Another two cases had taken medications which are 
associated with an increased risk of venous thromboembolism: one was receiving 
hormone replacement therapy and the other had taken norethisterone, 
medroxyprogesterone acetate, and tranexamic acid to treat menorrhagia. A fifth case 
had become paraplegic following a fall 33 years earlier and was using continuous 
ambulatory peritoneal dialysis for chronic renal failure. He and four other cases had a 












Table 9.4 Characteristics of cases who undertook long-distance air travel in the four weeks before the index date 
Case * Sex Age Past venous BMI Other risk factors for venous thromboembolism* 
(years) thromboembolism (kg/m2) t 
1 Female 47 No 34.9 N orethisterone 
Medroxyprogesterone acetate 
Tranexamic acid 
2 Female 51 Pregnancy-related "tall, rather obese" History of varicose veins 
deep vein thrombosis ("average") 
3 Female 58 No 21.6 History of varicose veins 
Hormone replacement therapy 
4 Male 36 No 31.2 Nil 
5 Male 49 No 34.3 Paraplegia 33 years 
6 Female 42 No "well-built" Nil 
(26.1) 
7 Female 47 No 43.6 Nil 
8 Female 54 Unknown Unknown Unknown 
9 Female 57 Unknown 30.4 Nil reported to airport medics 
10 Male 32 Injury-related deep "well-nourished" Nil 
vein thrombosis (28.9) 
11 Male 39 No 24.2 Nil 
-~ 
,.; 
Family history of venous 
thromboembolism 
No 










'Cases 1 - 5 were usually resident in New Zealand on the index date, cases 6 - 11 were overseas visitors. Information about cases 8 and 9 was obtained from coroners' and hospital records only, as next of kin were not 
traced. 
t Pathologists' comments and BMI calculated from weight and height at necropsy. Next of kin comments and BMI calculated from reported weight and height are shown in parentheses. 
1 Information was sought about major risk factors for venous thromboembolism in the three months before the index date (including surgery, major injury, prolonged immobility, pregnancy, hospital admissions for 
other reasons, hormone replacement therapy, and the use of oral contraceptives, psychotropic drugs and other medications), varicose veins, known thrombophilia, systemic lupus erythematosus, inflammatory bowel 



















Table 9.5 shows the details of the long-distance flights undertaken by the 11 cases in the 
four weeks before the index date. One case had undertaken three long-distance journeys 
during the relevant period, and two had flown on two separate occasions. The 
remaining cases flew only once in the four weeks before the index date, although two 
women each undertook a further flight after the onset of their fatal episode. 
One of these women (Case 2) developed severe right sided chest and upper abdominal 
pain seven days after flying from Christchurch to Western Australia (total flight time of 
eight hours five minutes). At this time she consulted a general practitioner who 
attributed her symptoms to "a viral infection" and prescribed an analgesic. Following 
her return to New Zealand seven days later, she experienced intermittent chest pain 
from the evening of her arrival until two days later when she collapsed and died at 
home. Necropsy findings included fresh embolus completely occluding the left and 
right main pulmonary arteries, older emboli in the peripheral vessels, small fresh ( one to 
two days' old) infarcts in both lungs, and an older (one to two weeks' old) infarct in the 
right lower lobe. 
The second woman (Case 3) complained of unilateral calf pain and shortness of breath 
on arrival at Singapore, following a flight from London (non-stop flight of 12 hours 45 
minutes). An airport medical practitioner suspected pulmonary embolism and sent her 
by ambulance to a local hospital, where she spent several hours. No apparent cause was 
found for her symptoms and she spent the next three days resting at a hotel before flying 
from Singapore to Auckland. She required oxygen during this flight. On arrival in New 
Zealand she undertook a short domestic flight without difficulty. The following 
morning she collapsed and was transported to the local hospital's emergency 
department where she died. At necropsy, the main pulmonary arteries were completely 
occluded by fresh embolus and thrombi were found in the deep veins of the right calf. 
No older pulmonary emboli or infarcts were seen. 
Nine (five New Zealand residents and four overseas visitors) of the 11 air travellers had 
journeys of at least eight hours. Seven travelled in economy class, one had undertaken 
two flights in economy class and one in business class, and for three cases the class of 
travel was not determined. None were reported to have taken hypnotic drugs 



















directly before a flight and one man undertook several bus trips during the four-week 
period. 
For nine people (five New Zealand residents and four overseas visitors), the symptoms 
of venous thromboembolism developed within eight days of a flight. Four cases, 
including Case 3 who has already been discussed, developed symptoms during or 
immediately after a long-distance flight. Case 1 became dizzy and short of breath on a 
flight from Bangkok to Auckland (total flight time of 11 hours 45 minutes). On arrival 
at Auckland International Airport she had an episode of vomiting and diarrhoea, and 
collapsed. She was reportedly assessed by airport staff and sent home. A few hours 
later she was admitted to hospital with increasing shortness of breath, but collapsed and 
died. Emboli were found throughout the major and minor pulmonary arteries. Case 8 
complained of abdominal pain and distension one hour before landing at Auckland after 
a flight from Japan (total flight time of 11 hours). She collapsed soon after 
disembarking but was resuscitated and transferred to the nearest hospital's intensive 
care unit. A computerised tomography pulmonary angiogram confirmed the presence of 
multiple large pulmonary emboli. She was given thrombolytic therapy and supportive 
care, but was later pronounced brain dead. Case 9 complained of feeling hot and unwell 
on the first leg of her journey from London to Auckland (total flight time of 22 hours 50 
minutes), but there was no record of her having sought medical attention during a two 
hour wait at Singapore Airport. She collapsed and died at Auckland International 
Airport. Fresh emboli were found throughout the pulmonary vasculature at necropsy. 
Only two of the air travellers were admitted and died in hospital, two others died on 
arrival at hospital emergency departments, one died while visiting a relative in hospital, 
and six died at home or elsewhere in the community. 
).-




.. 1 "' ~ <1 <[ 
Table 9.5 Long-distance air travel undertaken by cases in the four weeks before the index date 
Case * Next of kin Number oflong- Total duration of Number of Class of Aisle seat Hypnotic Interval Journeys of at 
interviewed distance journeys long-distance journey stops during travel use between flight least four hours 
undertaken by air (duration of each leg) journey and onset of by other modes 
(duration) symptoms of transport 
1 Daughter 2 13 h, 25 m 1 (unknown) Economy Unknown No 14 days 5-hour bus trip 
(11 h 5 m, 2 h 20 m) before 2nd 
journey 
11 h, 45 m 1 (1 h) Economy Unknown No During flight 
(8 h 50 m, 2 h 55 m) 
2 Husband 1 8h,5m 1 (1- 2 h) 
(3 h 15 m, 4 h 50 mt) 
Economy Unknown No 7 days Unknown 
3 Husband 1 12h, 45 m 0 Economy Yes No On No 
disembarking 
4 Brother 3 9h, 20m 0 Economy Unknown Unknown 24 days No 
10 h, 30m 0 Economy Unknown Unknown 9 days 
9h, 20m 0 Business Unknown Unknown 4 days 
5 Wife 2 12h, Om 0 Economy Yes No 7 days No 
12h, Om 0 Economy Yes No 2 days 
6 Father 1 3 h, 30m 0 Economy Unknown Unknown 8 days Possibly 
311 
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Case * Next of kin Number of long- Total duration of Number Class of Aisle seat Hypnotic Interval Journeys of at 
interviewed distance journeys long-distance journey (duration) of travel use between flight least four hours 
undertaken by air ( duration of each leg) stops during and onset of by other modes of 
journey symptoms transport 
7 Sister-in-law 1 3h,Om 0 Unknown Unknown Unknown 24 days No 
8 Not traced 1 11 h, Om 0 Unknown Unknown Unknown During flight Unknown 
9 Not traced 1 22h, 50m 1 (2 h) Unknown Unknown No During first Unknown 
(12h45m, 10h5m) leg of journey 
10 Brother 1 4h, 15 m 0 Economy Unknown No 25 days Probably 
11 Cousin 1 11 h, Om 0 Economy Unknown No 2 days No 
'Cases 1 - 5 were usually resident in New Zealand on the index date, cases 6 - 11 were overseas visitors. 
t Domestic flight within a country other than New Zealand. 






















9.1.3 Long-distance travel by other modes of transport 
A further 11 cases, who had not undertaken long-distance air travel, undertook at least 
one car journey of more than four hours' duration in the four weeks before the index 
date and one made several trips in a small boat (Table 9.6). It was not possible to 
estimate the absolute risks of fatal pulmonary embolism for these modes of transport 



















Table 9.6 Long-distance travel by other modes of transport in the four weeks before the index 
date by cases who did not undertake long-distance air travel 
Sex Age Mode of Total duration of Interval between 
(years) transport journey(s) journey(s) and onset of 
symptoms 
Female 26 Car 6h50m 2 days 
Female 29 Car* 14h0m Immediate onset 
Female 34 Car 5h50m Unknown 
Car 5h50m Unknown 
Female 45 Car 5h0m Immediate onset 
Female 53 Car 4h20m 23 days 
Car 4h20m 21 days 
Female 58 Car 4h30m Unknown 
Male 43 Car 4h 15m 21 days 
Male 52 Bus driver 8h0m 6-28 days 
Car 7h40m 5 days 
Male 55 Car 4h50m 12 days 
Car 5h 10m 10 days 
Car 5h 10m 4 days 
Car 4h50m 3 days 
Male 55 Small boat 6-8h Unknown ( 4 or 5 trips 
during 4 weeks before 
index date) 
Male 56 Taxi driver 12h0m 1-28 days 
Male 58 Car 6h5m 26 days 
Car 6h5m 15 days 





















9.1.4 Absolute risk of fatal pulmonary embolism following a long-distance flight 
The risks of developing fatal pulmonary embolism in the four weeks following a long-
distance flight are shown in Table 9.7. Using Statistics New Zealand migration data as 
the denominator, the risks following a flight of at least three hours' duration were 0.5 
(95% CI 0.2 - 1.2) and 0.6 (95% CI 0.2 - 1.4) per million arrivals for overseas visitors 
and New Zealand residents respectively. Using arrival estimates based on exposure 
data from controls in the case-control study as the denominator, the risk in residents 
following a flight of more than eight hours' duration was 1.3 (95% CI 0.4 - 3.0) per 
million arrivals, while the risk following a flight of at least three hours' duration was 


















Table 9.7 Absolute risk of dying from pulmonary embolism following long-distance air travel 
Overseas visitors, 
air travel 2': 3 hours' duration 
New Zealand residents, 
air travel 2': 3 hours' duration 
New Zealand residents, 
air travel 2': 3 hours' duration 
New Zealand residents, 
air travel> 8 hours' duration 
Number of deaths 
among international 
arrivals aged 15 - 59 





'Number of arrivals provided by Statistics New Zealand. 
t Estimated number of arrivals based on data from the case-control study. 
Number of 
international arrivals 






Absolute risk per 
million international 
arrivals (95% Cl) 
0.5 (0.2 - 1.2) 
0.6 (0.2 - 1.4) 
0.6 (0.2 - 1.3) 
















9.1.5 Pulmonary embolism and all-cause mortality rates 
The mortality rate from pulmonary embolism in the overseas visitor population was 
higher than the rate in the New Zealand resident population (Table 9.8); the sex and 
age-adjusted rate per million person-years in the overseas visitor population was 19.70 
compared with 4.56 in the New Zealand resident population. The adjusted mortality 
rate ratio was thus 4.3 (95% CI 3.9 - 4.7); the standardised mortality ratio was 3.8 (95% 
CI 1.6 - 7.4). This is consistent with an increased risk of pulmonary embolism in air 
travellers, since almost all overseas visitors arrive by air and about 90% of visitors 
remain in New Zealand for less than 30 days (Statistics New Zealand 2001a), while 
only a small proportion of the resident population undertakes international air travel 
during a four-week period . 
These results are particularly striking, given that there appears to be a "healthy 
traveller" effect. During the period 1 January 1990 to 31 December 1998 there were a 
total of 40,471 deaths from all causes in New Zealand residents and 533 in overseas 
visitors aged 15 - 59 years. The sex and age-adjusted mortality rates for all causes per 
million person-years were 1465.83 and 2022.42 in the overseas visitor and New Zealand 
resident populations respectively (Table 9.8). Hence, the adjusted mortality rate ratio 
















Table 9.8 Mortality from pulmonary embolism and all causes in the overseas visitor and New 
Zealand resident populations 
Cause of death Mortality rate in overseas Mortality rate in New Adjusted rate ratio 
visitor population* Zealand resident (95% Cl) 
(per million person-years) population 
(per million person-years) 
Pulmonary embolism 19.70 4.56 4.32 (3.94 - 4.72) 
All causes 1465.83 2022.42 0.72 (0.71 - 0.73) 



















9.1.6 Attributable proportion 
Based on the assumptions that the mortality rate from pulmonary embolism in the 
overseas visitor population approximates the rate in recent air travellers, and that the 
rate in the New Zealand resident population is similar to the rate in non-travellers, the 
proportion of deaths from pulmonary embolism in people who had recently undertaken 
long-distance air travel which could be attributed to the flight itself was estimated using 
the following formula (Hennekens and Buring 1987): 
Attributable proportion = le-Io xlOO 
le 
Where le = sex and age-adjusted mortality rate from pulmonary embolism in 
overseas visitors 
and I0 = mortality rate from pulmonary embolism in New Zealand residents 
Thus, it was estimated that 76.8% of deaths from pulmonary embolism in people who 
had recently undertaken a long-distance flight could be attributed to the flight itself. In 
this estimation, the mortality rate for overseas visitors was standardised to the sex and 
age distribution of the New Zealand population aged 15 - 59 years. However the age 
distribution of New Zealand men aged 15 - 59 years who undertook long-distance air 
travel between 1990 and 2000 differed from those who did not - about 34% of the air 
travellers were aged between 35 - 59 years as compared with 25% of the total 
population of New Zealand. No such difference was observed for women. Because the 
age structure of male travellers differed from the general population, the attributable 
fraction was recalculated after standardising the mortality rates for the overseas visitor 
and New Zealand resident populations to the sex and age distribution of the New 
Zealand air travellers (using arrivals data provided by Statistics New Zealand). While 
the mortality rates in overseas visitors and New Zealand residents increased slightly (to 
22.72 and 5.18 per million person-years respectively), the attributable fraction barely 
changed (77.2%). 
9.2 DISCUSSION 
In this study of 121 men and women aged 15 - 59 years who died from pulmonary 










undertaken long-distance air travel in the four weeks before the onset of the fatal 
episode. Long-distance air travellers appeared to have a higher risk of fatal pulmonary 
embolism than non-travellers; the mortality rate from pulmonary embolism in the 
overseas visitor population (most of whom would recently have undertaken long-
distance flights) was about four times higher than the rate in the resident population of 
New Zealand. Conversely, the mortality rate from all causes in overseas visitors was 
about 30% lower than the rate in New Zealand residents. Allowing for this "healthy 
traveller" effect, air travel may carry as much as a six-fold increase in risk. In absolute 
terms, however, the risk of dying from pulmonary embolism after a long-distance flight 
appears to be very low. The absolute risks in people aged 15 - 59 years following a 
flight of at least three hours' duration were 0.5 (95% CI 0.2- 1.2) and 0.6 (95% CI 0.2 -
1.4) per million arrivals for overseas visitors and New Zealand residents respectively. 
The risk in New Zealand residents following a flight of more than eight hours was 1.3 
(95% CI 0.4 - 3.0) per million arrivals . 
9.2.1 Strengths and limitations of the research 
~· One of the strengths of this population-based research, as outlined in the discussion in 
Chapter 6, is that the ascertainment of eligible cases who died in New Zealand during 











en-route to New Zealand would also have been identified in this study, except in rare 
situations where the aircraft did not proceed as intended. 
As the study included deaths that occurred between 1990 and 2000, some next of kin 
were required to recall whether their relative had undertaken a long-distance flight 
during a four-week period more than 10 years earlier. Wherever possible, the next of 
kin with whom the cases had lived on the index date were interviewed. These people 
appeared to be a reliable source of information, as all long-distance flights reported by 
next of kin were confirmed by medical and death records. Similarly, existing records 
did not identify any flights that were not also reported by next of kin. It was not 
possible to interview all next of kin, but existing records identified only two further air 
travellers, both of whom were overseas visitors whose next of kin were not traced. 
The estimates of absolute risk in this study are based on a group of 15 - 59 year old men 

















considered to be the underlying cause of death. It was not possible to exclude people 
with these conditions from the arrivals data, but it is unlikely that there would have been 
sufficient numbers to have substantially biased the estimates of absolute risk. Moreover 
any such bias would be in a conservative direction and result in an underestimate of the 
mortality rate. 
Because of the way in which mortality data were recorded during the study period, it 
was not possible to identify all people for whom pulmonary embolism was the 
mechanism, but not the underlying cause, of death. Hence, it was not possible to 
estimate flight-related mortality rates in groups with predisposing conditions, in whom 
the absolute risk of fatal pulmonary embolism following a long-distance flight is likely 
to be greater. Nevertheless, the cases studied were not an entirely idiopathic group, 
since people with a personal history of venous thromboembolism, recent hospital 
admission, major injury, prolonged immobilisation, and obesity, as well as users of oral 
contraceptives, hormone replacement therapy, and antipsychotics, were included. 
It was not possible to ascertain the duration of air travel from the migration data 
provided by Statistics New Zealand, but the use of information from the control series 
(in the accompanying case-control study) to estimate the risk of fatal pulmonary 
embolism in people who undertook air travel of more than eight hours' duration appears 
to have been a reasonable approach - identical estimates of risk were obtained for 
flights of at least three hours' duration using information from the control series and the 
official migration data. Because deaths in which fatal pulmonary embolism is the 
underlying cause are rare, a more detailed exploration of risk by duration of travel was 
not possible owing to the inevitably small number of flight-related deaths. 
Denominator data for long-distance flights within countries other than New Zealand were 
not available. However the only case who undertook domestic flights within a country 
other than New Zealand, undertook these flights immediately after and before her 
international flights from and to New Zealand. Hence, these domestic flights were 














9.2.2 Consistency with previous research 
Nine percent of cases in the present study had undertaken long-distance air travel in the 
four weeks before the onset of the fatal episode. This accords with the results of a later 
New Zealand records-based study, in which 10.4% of patients who were admitted to 
four hospitals with confirmed venous thromboembolism had a documented history of 
air travel within 28 days of admission (Hughes et al. 2006). The only other studies to 
have determined the proportion of air travellers among a series of cases with venous 
thromboembolism were based on non-fatal events and the results are inconsistent. In a 
study of 182 consecutive patients admitted to hospitals in Glasgow with pulmonary 
embolism over a three-year period, only three (1.6%) were reported to have undertaken 
long-distance air travel shortly before the onset of symptoms (Symington and Stack 
1977). It is not clear, however, whether all the patients were questioned about travel, so 
this could represent an underestimate. Similarly a review of medical records in a 
Western Australian hospital found that, of 250 patients admitted with venous 
thromboembolism during a three-year period, only eight (3.2%) had a documented 
history of "recent" (not defined) long-distance flights (O'Donnell 1988). In a 
population-based study undertaken in the north of England, 1,250 consecutive patients 
admitted to hospital over a two-year period with objective evidence of venous 
thromboembolism were asked about risk factors using an interviewer-administered 
questionnaire (Kesteven and Robinson 2002). Twenty-eight (2.2%) reported 
undertaking a flight (unspecified) in the four weeks before diagnosis. By contrast, in 
two Hawaiian case series based on retrospective review of hospital records, 17% (Eklof 
et al. 1996) and 25% (Mercer and Brown 1998) of the cases had undertaken flights of at 
least five hours up to six weeks before the onset of symptoms. In a subsequent 
Hawaiian study, 25 of 109 patients (23%) admitted between July 1995 and October 
1998 with objective evidence of venous thromboembolism gave a history of recent air 
travel when interviewed in hospital (Arfvidsson et al. 1999). 
It is not possible to make meaningful comparisons between these studies and the present 
research for several reasons. In the absence of control groups it is impossible to know 
whether the underlying frequency of long-distance air travel in the source population 
differed between studies and, indeed, whether the proportion of cases exposed to recent 
air travel was any higher than would be expected in the source population. If crude 














annually between 1988 and 1993 (Eklof et al. 1996), than there were in New Zealand in 
1990 (six million c.f. 1.7 million). 
The Hawaiian studies also included people over the age of 59 years and a substantial 
proportion of the cases had malignancies or had recently undergone surgery (as well as 
having other risk factors for venous thromboembolism). Given the multi-causal nature 
of venous thromboembolism, a long-distance flight in people who had several pre-
existing risk factors might have been enough to trigger a thromboembolic event. Hence, 
it is perhaps not surprising that higher proportions of air travellers were found in the 
studies which included people with multiple risk factors for venous thromboembolism. 
The observation that several other cases in the present study had undertaken long 
journeys by car and other modes of transport is consistent with previous case reports 
(Homans 1954; Symington and Stack 1977; Voorhoeve and Bruyninckx 1990; Benoit 
1992; Schmitt and Mihatsch 1992; Tardy et al. 1993; Eschwege and Robert 1996; 
Nissen 1997; Parsi and McGrath 2000; Parsi et al. 2001; Partsch 2001; Kesteven and 
Robinson 2002; Tan et al. 2002; Bertos-Polo et al. 2003; McQuillan et al. 2003; 
Lapostolle et al. 2004; Hitosugi et al. 2005). 
The finding in the present study that long-distance air travellers had a higher risk of 
fatal pulmonary embolism than non-travellers is consistent with some (Ferrari et al. 
1999; Arya and Cohen 2003; Martinelli et al. 2003; Schwarz et al. 2003; Becker et al. 
2006; Cannegieter et al. 2006), but not all (Kraaijenhagen et al. 2000; Hosoi et al. 2002; 
ten Wolde et al. 2003), previous analytical studies of non-fatal events. This will be 
discussed in greater detail in Chapter 11. 
Assuming a case-fatality rate of 2 - 5% (Cushman et al. 2004; Goldhaber 2004), the 
estimates of pulmonary embolism mortality in the present study are higher than would 
be expected based on studies of non-fatal cases referred to hospitals located near 
airports (Clerel and Caillard 1999; Lapostolle et al. 2001; Hertzberg et al. 2003; Perez-
Rodriguez et al. 2003), presumably because it was possible to include all cases that 
occurred in New Zealand in the days following a long-distance flight. In contrast, the 
present estimates are much lower than would be expected from studies of volunteers 













Belcaro et al. 2001; Scurr et al. 2001; Belcaro et al. 2002; Cesarone et al. 2002; Belcaro 
et al. 2003; Schwarz et al. 2003; Cesarone et al. 2003c; Cesarone et al. 2003d) and from 
a study in which 1 % of volunteers developed symptomatic non-fatal venous 
thromboembolism after a flight of at least 10 hours (Hughes et al. 2003). The clinical 
relevance of asymptomatic venous thromboembolism is unclear, and the latter study 
included subjects up to the age of 70 years and may have included a non-representative 
group of air travellers. For example, the mean age of the participants was 49 years and 
51 % were female, whereas in migration data provided by Statistics New Zealand the 
median age of New Zealand residents arriving back in the country between 1990 and 
2000 after an absence of less than one year lay in the 40 - 44 year age group and 48 % 
were female. Moreover venous thromboembolic events which occurred up to three 
months following a long-distance flight were defined as flight-related in the that study. 
The estimates of pulmonary embolism mortality in New Zealand residents and in 
overseas visitors following air travel of at least three hours' duration are consistent with 
the estimate of 0.5 deaths per million arrivals reported in the Western Australian record 
linkage study (Kelman et al. 2003), although the study groups were not strictly 
comparable. Indeed some features would have decreased their calculated risk and other 
features increased it, compared with the study described here. 
The finding in this study that the rate of fatal pulmonary embolism was higher for 
flights of more than eight hours' duration, than for flights of three or more hours, is 
suggestive of a dose-response relationship - although it should be emphasised that 
these categories are overlapping. A dose-response relationship between duration of 
travel and risk of venous thromboembolism has been reported in previous studies 
(Lapostolle et al. 2001; Hertzberg et al. 2003). 
9.3 SUMMARY AND IMPLICATIONS 













CHAPTER IO CASE-CONTROL STUDY OF LONG-DISTANCE AIR 
TRAVEL: OBJECTIVE AND METHODS 
10.1 OBJECTIVE 
The objective of this case-control study was to examine any association between long-
distance air travel in the four weeks before the index date and the risk of dying from 
pulmonary embolism. As outlined in Chapter 8, long-distance air travel was defined as 
a flight of at least three hours' duration and the date of onset of the fatal episode was 
taken as an index date. The four-week period was chosen to allow comparisons with the 
analytical studies that had been published at the time the study was initiated (Ferrari et al. 
1999; Kraaijenhagen et al. 2000; Samama and the Sirius Study Group 2000; Arya et al. 
2002; Martinelli et al. 2003). 
10.2 METHODS 
10.2.1 Ascertainment of cases 
The methods used to identify all men and women aged 15 - 59 years who died in New 
Zealand between 1 January 1990 and 31 December 2000, for whom the underlying 
cause of death was pulmonary embolism, were described in Chapter 2. This case-
control study was based on a subset of the 121 cases thus identified. The eight overseas 
visitors were excluded, as it was not possible to identify and contact members of an 
appropriate comparison group. Because controls were to be selected from the electoral 
roll, 14 cases who were New Zealand residents but were not registered on the electoral 
roll on the index date were also excluded. Thus, 99 cases were considered eligible for 
inclusion in the case-control study. The diagnosis of pulmonary embolism was 
confirmed by necropsy in 92, by pulmonary angiography or .ventilation-perfusion scans 
in three, and by two physicians using standard criteria (World Health Organization 
Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception 







10.2.2 Selection of controls 
For each eligible case, four controls matched by sex, individual year of age, and 
electorate were selected randomly from electronic copies of the electoral roll. During 
the planning phase of the study, consideration was given as to whether the most recent 
electoral roll, or rolls from earlier years, should be used to select the controls. The 
advantage of using the most recent roll was that it would have been relatively simple to 
trace those who were selected. On the other hand, this approach would have precluded 
the selection of some potentially eligible controls such as those who had died after the 
index date and those who were not enrolled for some other reason. Hence, it was 
decided to use the electronic rolls from earlier years to select the controls. For cases 
whose index dates occurred between 1 January 1990 and 13 October 1994 (the date on 
which the 1994 paper electoral roll was compiled), the 1993 electronic roll was used to 
select potential controls; for index dates between 13 October 1994 and 31 December 1997 
(no paper electoral roll was compiled in 1997), the 1996 electronic roll was used; for 
index dates between 1 January 1998 (the date on which the 1998 electronic roll was 
compiled) and 26 October 1999 (the date on which the 1999 paper roll was compiled), the 
1998 electronic roll was used; and for index dates between 27 October 1999 and 31 
December 2000, the 2000 electronic roll was used. For each case whose index date did 
not occur in 1993, 1996, 1998, or 2000, a paper copy of the roll from the index year was 
then examined to establish whether the people selected as potential controls for that case 
were enrolled in the appropriate electorate on the index date. Those who were not 
enrolled were excluded from the study . 
Controls were matched to cases by electorate because regional differences in exposure 
to international travel have been observed in New Zealand (data provided by the New 
Zealand Blood Service). This process was complicated by the fact that population 
growth and electoral reform had led to changes in the number of electorates ( and their 
boundaries) during the 11-year study period. Electoral boundaries are reviewed 
regularly in light of population estimates derived from the quinquennial Census of 
Population and Dwellings, with any changes coming into effect at the end of the three-
year parliamentary term in which the changes were finalised (Statistics New Zealand 
1998). These changes meant that for several of the cases ( a subset of those whose index 
dates did not occur in the years in which the electronic rolls were compiled) the 













by the time the relevant electronic roll was compiled. For these cases, potential controls 
were selected from the electorate to which the case would have belonged on the date 
that the electronic roll was compiled. 
To be eligible for inclusion in the study, selected persons had to be the same sex as the 
case, to have been born in the same year as the case, to have been normally resident in 
New Zealand on the index date, and to have been registered on the electoral roll in the 
same electorate as the case on the index date. People who did not meet the eligibility 
criteria, could not be traced, or did not consent to be interviewed were replaced. 
Potential controls who did not wish to participate were asked if they were willing to 
answer two questions to establish eligibility. Those who agreed were asked for their 
date of birth and whether they were usually resident in New Zealand on the index date. 
Eligible participants and non-participants were also asked whether they were in New 
Zealand or overseas on the date of death of their case. This information was important 
to obtain because the exposure of interest, international travel, was clearly related to 
whether a potential control belonged to the population that gave rise to the case. In 
theory this population comprised otherwise eligible people who were in New Zealand 
on the date the case died, since to become a case, a person had to have died in New 
Zealand. However some cases died on their index date, while others did not. Thus, if 
potential controls who were not in New Zealand on the date of death of their case were 
excluded, some people who were overseas on the index date might also have been 
excluded. This, in turn, could have resulted in the overestimation of the risk of 
pulmonary embolism in long-distance air travellers. Hence, it was decided at the outset 
to seek information about a potential control's whereabouts on the date of death of the 
case so that analyses could be undertaken both including, and then excluding, any 
persons who were not in New Zealand on the date that their case died. 
In the course of the study a total of 462 potential controls were selected from the 
electoral rolls (a further 79 were initially sent letters but had to be discarded because of 


























10.2.3 Decision to interview controls rather than their next of kin 
The study was reliant on interviews to obtain information about long-distance air travel 
because such information is not routinely recorded in medical records and at the time 
the study was initiated it was not possible to obtain migration data relating to 
individuals. The decision to interview controls themselves, rather than their next of kin, 
was made after weighing up the advantages and disadvantages of both approaches. This 
process involved a trade-off of potential biases. The main argument in favour of 
interviewing the relatives of controls was that information about cases and controls 
should be sought in an identical manner to minimise the potential for information bias 
(Hennekens and Buring 1987). This condition is relatively easy to meet when it is 
possible to interview both cases and controls. In a study of fatal events, however, it is 
obviously necessary to interview proxy respondents. It would therefore follow that 
proxy respondents should also be used for controls. However it was felt that such an 
approach could, in fact, increase the possibility of bias. The reasons for this were two-
fold. First, it was possible that the next of kin of controls would be less motivated to 
participate than the next of kin of cases, thus introducing a selection bias. Second, the 
next of kin of cases would clearly have reason to remember a flight undertaken by their 
relative in the four weeks before the onset of the fatal event. The next of kin of 
controls, on the other hand, would have no such memory prompt and, in addition, might 
be less likely than the next of kin of cases to have access to the passport and other 
records belonging to their relative. It is therefore conceivable that some controls might 
be misclassified as non-travellers and hence the risk of fatal pulmonary embolism in 
long-distance air travellers would be overestimated. It is also possible that the next of 
kin of controls would have less complete knowledge or recall about whether their 
relative had other risk factors for venous thromboembolism before the index date than 
the next of kin of cases (who again would have reason to have obtained and recalled 
such information). Potentially this would hinder the identification of those with major 
risk factors and consequently limit the evaluation of potential confounding. 
For these reasons it seemed preferable to interview the controls themselves, as they 
would be expected to report their travel and medical histories more accurately than their 
relatives. It was also recognised, however, that such an approach might not entirely 
minimise the potential for recall bias in relation to some risk factors for venous 

















respondents has been shown to be dependent on the relationship of the respondent to the 
case and the nature of the information being sought (Poulter et al. 1996b). In the 
present study, for example, it is possible that the husbands of older cases would have 
less knowledge about the use of hormone replacement therapy by their wives than the 
female controls would have about themselves. On the other hand, younger men might 
report the use of oral contraceptives by their partners just as accurately as the controls 
reported their own use. It is also possible that the next of kin of cases would report the 
presence of temporary risk factors for venous thromboembolism in the three months 
before the index date (for example, injury) more accurately than the controls who might 
have no reason to locate specific events in time . 
After consideration of all these issues it was decided to interview the controls 
themselves, rather than their next of kin, since this approach gave the best possible 
chance of obtaining information of comparable quality for cases and controls about 
long-distance flights and other key exposures. As with next of kin, controls were 
interviewed by telephone. 
10.2.4 Obtaining current contact details for controls 
The methods that were used to search for the contact details of the 462 potential 
controls who were selected from the 1993, 1996, 1998 and 2000 electronic electoral 
rolls are shown in Figure 10.1. The names and addresses of 400 were found on the 
2003 electoral roll and a further two were found in the electronic telephone directory. 
Two main methods were employed to search for the remaining 60 potential controls. 
The first involved a search, by residential address, of electronic electoral rolls from past 
years to obtain the names of any adults with whom the potential controls had lived 
before or after the index date. The 2003 roll was then searched to find the current 
contact details of these household members. Invitation letters were subsequently sent to 
25 potential controls via the addresses of past household members, since the surnames 
and ages of these people suggested that they were relatives. Second, the office of 
Births, Deaths, and Marriages was approached to ascertain whether any of the untraced 
potential controls had died or changed their names. Because a fee was payable for 
record searches, the enquiries were initially confined to older people who had been 
consistently enrolled in the past before disappearing from the roll sometime after the 


















10.1), three of whom were determined to be ineligible because of their dates of birth. 
No attempt was made to contact the next of kin of the 14 potentially eligible deceased 
controls because it was thought that it would be unreasonable to ask them to participate 
in a study of a condition other than the one from which their relative had died. It was 
expected that such people would have been less likely to have travelled and hence any 
bias introduced by the exclusion of these potential controls would be conservative. The 
initial search of Births, Deaths, and Marriages records also identified the new surnames 
of three women. The married names of two other women were found when searching 
for household members, and one person was traced using an alumni database. 
Thus, in summary, 17 of 462 of the potential controls who were selected died after the 
index date and before the 2003 electoral roll was compiled, 433 were sent letters at their 
own (n=408) or a relative's address (n=25), and for 12 a personal or relative's postal 
address could not be found. 
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Table 10.1 Deaths of potential controls identified by a search of Births, Deaths, and 
1\llarriagesrecords 
Sex Age at death Interval between Causes of death Eligible date 
(years) index date and (intervals between onset and death)* of birth 
date of death 
Male 
52 1 month Acute congestive heart failure Yes 
Hypertensive heart disease 
(intervals not recorded) 
56 8 years, 8 months Hypercalcaemia (1 month) Yes 
Metastatic lung cancer (2 years) 
Heavy smoker (years) 
Ex-alcoholic (years) 
Hypertension (years) 
58 10 years, 8 months Myocardial infarction (1 day) Yes 
2 earlier infarcts 
Mild emphysema (interval not 
recorded) 
61 2 years, 10 months Gastrointestinal haemorrhage (days) Yes 
Alcoholic liver failure (weeks) 
Chronic alcoholism (years) 
61 5 years, 5 months Ischaemic bowel Yes 
Mesenteric vessel occlusion 
Large neglected inguinoscrotal hernia 
(intervals not recorded) 
61 11 years, 0 months Cardiac arrest (3 minutes) Yes 
Myocardial infarction (3 minutes) 
Hypertension (14 years) 
Diabetes ( 14 years) 
Peripheral vascular disease (1 year) 
63 8 years, 11 months Congestive heart failure (5 months) Yes 
Coronary heart disease (5 years) 
Type 1 diabetes(> 10 years) 
Diabetic retinopathy, blind (3 years) 
Cerebrovascular accident (3 years) 
64 5 years, 9 months Metastatic renal carcinoma (18 months) Yes 
Renal carcinoma (2 years) 
Cerebral thrombosis (6 years) 
64 13 years Subject to coroner's finding No 
67 12 years, 6 months Bronchopneumonia (1 week) Yes 
Emphysema (10 years) 
Ischaemic heart disease (7 years) 
333 
Sex Age at death Interval between Causes of death Eligible date 
(years) index date and (intervals between onset and death)* of birth 
date of death 
Female 
57 7 years 11 months Metastatic ovarian cancer (28 months) Yes . ., 
., 
58 4 years, 7months Metastatic lung cancer (months) No 
59 1 year, 2 months Pneumonia (interval not recorded) Yes 
'7' 
61 1 year, 3 months Metastatic adenocarcinoma, probable Yes 
f large bowel primary (2 months) 
62 3 years, 10 months Renal failure Yes 
Metastatic breast cancer 
(intervals not recorded) 
~ 
62 3 years, 8 months Chronic renal failure Yes 
•"f' Type 2 diabetes 
Peripheral vascular disease 
(intervals not recorded) 
65 5 years, 5 months Metastatic bowel cancer (18 months) No 
> 
lo' 






















10.2.5 Contacting next of kin and controls 
The methods used to contact next of kin were described in Chapter 8. Potential controls 
were sent a letter which invited them to take part in a study of "an important health 
condition that affects many New Zealanders" (Appendix A, letter 24). They were not 
told that the condition was venous thromboembolism, since this might have introduced 
a selection bias, with those who had a personal or family history of the condition being 
more inclined to participate. Similarly, neither the next of kin nor the controls were 
informed of the study hypothesis until their interview was completed. As with next of 
kin, potential controls were sent a letter about the study which asked them to return, in a 
reply-paid envelope, a form confirming their contact details and suitable times to be 
contacted by telephone. Those who replied were called at the appropriate time to discuss 
the study and oral consent was sought for a telephone interview at a later time (Appendix 
D, form 3). Occasionally, at the request of a potential participant, an interview was 
conducted during that first telephone contact. Potential controls who had not responded 
after two weeks were contacted by telephone (Appendix D, form 4) or, if they did not 
have a traceable telephone number, were sent up to two further letters (Appendix A, letter 
25). To ensure that information about the study was given in a consistent manner, these 
initial telephone calls to next of kin and potential controls were all made by me. All 
attempts to contact participants by telephone were recorded on the oral consent form. As 
with next of kin, the initial and subsequent letters sent to controls, the reply-paid forms, 
and the oral consent forms were adapted from those used in two previous case-control 
studies (Paul et al. 1989; Cox et al. 2002). 
10.2.6 Telephone interviews with next of kin and controls 
Development of a draft questionnaire 
A standardised questionnaire was developed for use during the telephone interviews 
with next of kin and controls. The questionnaire was designed to obtain details of any 
long-distance air travel in the four weeks before the index date, as well as demographic 
data, information about hereditary and acquired risk factors for venous 
thromboembolism, the presence of other medical conditions, and the use of medicines. 
The development of the questionnaire involved several stages. First, interviewer-
administered questionnaires used by colleagues in previous case-control studies were 














had involved telephone interviews of the cases and controls (Paul et al. 1989; Cox et al. 
2002), while the third had been used in face-to-face interviews of the parents of the 
cases and controls (Dockerty et al. 1998). A few introductory statements from these 
questionnaires were modified for use in the present study. 
Second, the Individual Form used in the 2001 New Zealand Census of Population and 
Dwellings was examined (Statistics New Zealand 2001b), with particular attention 
directed towards the wording of questions about ethnicity, educational attainment, and 
employment. For the purposes of this study it was important to obtain information 
about both "ethnic group" (self-identified cultural affiliation) and "ethnic origin" 
(biological ancestry). Self-identified ethnicity is associated with socio-economic status 
(Reid et al. 2000), and hence the opportunity to undertake international air travel, while 
some thrombophilic mutations are found more frequently among New Zealanders of 
European descent than among Maori and those of Pacific Island ancestry (Van de Water 
et al. 1997). The Census question about ethnic group was included verbatim in the 
study questionnaire. This asked participants to indicate which ethnic group or groups 
the case, or they (if controls), belonged to. Since people with both non-European and 
European ancestors sometimes self-identify as belonging solely to one of the non-
European ethnic groups (for example, Maori), a second Census-derived question was 
included for cases and controls who were reported to belong exclusively to one of the 
non-European ethnic groups. This enquired whether they had any European ancestors. 
The remainder of the draft questionnaire was composed by me with reference to 
principles of good questionnaire design (Bennett and Ritchie 1975; Foddy 1993). The 
questionnaire opened with a paragraph that introduced the interviewer and her 
affiliation with the Otago Medical School, and thanked the next of kin or control for 
agreeing to participate in the study. An assurance of confidentiality was also given. 
The purpose of the study was explained in general terms, namely that it was a study of 
health problems before a particular date. The questionnaire was then divided into 
sections of related questions, starting with some general questions about health and 
concluding with enquiries about more sensitive subjects such as educational attainment, 
employment, marital status, and ethnicity. Each new section began with a statement 
that introduced the broad subject area of the subsequent questions. The questions 



















Hence, sentences were kept as short, grammatically simple, and unambiguous as 
possible. Although medical terms were included in the questionnaire, explanations 
were also given in lay language. Negative and leading questions were avoided. Since 
open-ended questions about the health of the case or control before the index date would 
have required active recall, respondents were initially asked closed questions about 
medical conditions and exposures. If the answer to certain questions was "Yes", they 
were then asked some supplementary open-ended questions. Additional space was also 
allowed at the end of the questionnaire for extra comments. Statements were included 
throughout the questionnaire which reminded respondents of the time periods of 
interest. These statements were made as specific as possible. For example, when 
enquiries were made as to whether the case or control had ever been treated for a 
particular medical condition before the index date, it was stressed that the time period of 
interest was from the time they were born right through until the specified date. 
Similarly questions about exposures in the three months or four weeks before the index 
date stressed the exact dates involved. As will be discussed later, respondents were also 
asked to mark these dates on a customised calendar. 
Finally, the draft questionnaire was discussed with two Maori and two Samoan hospital 
and community-based health workers, as well as two Maori health researchers. This 
was to help ensure that the content and wording of questions was not culturally 
inappropriate for Maori or Samoan people, as it was already known that some of the 
cases and their next of kin belonged to these ethnic groups. Moreover it was clear that 
some Maori would be selected as controls since some of the Maori cases had been 
enrolled on the Maori Electoral Roll and thus their controls would be selected from a 
Maori electorate. 
Piloting the draft questionnaire 
The draft questionnaire was piloted over the telephone with volunteers from a variety of 
community groups including the Medical Auxillary (a group of older people in Dunedin 
who voluntarily participate in medical research), Toastmasters, and an outdoor 
recreational club, as well as people contacted by Maori health workers. The volunteers 
were each allocated an index date and were sent a life-events calendar for the 13 months 
leading up to this date. Local and national public holidays and school terms were 
















volunteers were asked at the beginning of the interview to circle the index date on the 
calendar, as well as dates three months, and four weeks, before the index date. They 
were also asked to recall any significant events that occurred around that time. The 
calendar was referred to throughout the interview. 
In total 18 women and 13 men of varying ages (range 22 - 83 years, median 69 years), 
educational levels, socio-economic status, and ethnicity were interviewed during this 
pilot phase. A deliberate effort was made to interview older people because they were 
likely to have experienced more health problems and this provided a greater opportunity 
to test the questions about past medical conditions . 
Ten of the volunteers were interviewed about their spouse (designated as a "case") and 
their spouse was interviewed about himself or herself. Couples were asked not to sit in 
the same room during the interview and the first spouse to be interviewed was asked to 
refrain from telling their partner about the interview. Five men were interviewed about 
their wife (and the wife about herself), and five women were interviewed about their 
husband (and the husband about himself). Although the "case" hadn't died, and as such 
there was no particular reason to remember a four-week period up to 13 years earlier, 
seven of ten couples were in agreement that the "case" had not undertaken international 
air travel in the four weeks before the index date. Two women reported that they hadn't 
undertaken an international flight during the relevant period, although the husband of 
one thought that she had undertaken a three to four hour flight, while the other man 
thought it "possible" that his wife had undertaken an international flight. One woman 
thought her husband might have flown internationally, while he reported that he didn't. 
Although they were not asked to do so, the volunteers spontaneously reported that they 
would have been willing to check their passports to ensure that they gave accurate 
information. Thus, it was decided to ask participants in the descriptive and case-control 
studies to check passports and other records if necessary before answering any questions 
about international air travel. In addition, people were to be offered the choice of 
checking their records while the interviewer waited on the telephone, or of making a 
time to be contacted later. 
In relation to questions about medical history, medications, the use of oral 












good agreement between the information provided by both members of a couple. While 
some partners thought that the "case" was heavier or lighter, or taller or shorter than the 
"case" reported himself or herself to be on the index date, this had no impact on which 
BMI category seven of the ten "cases" were classified as belonging to(< 20, 20 - 24.9, 
25 - 29.9, 2 30 kg/m2). One man had no idea what his wife had weighed, and in the 
remaining two couples the difference in estimated BMI was not great (18.8 c.f. 20.9 and 
23.3 c.f. 26.1 30 kg/m2), although it did mean that there was disagreement about the 
category to which the "case" belonged. Consequently a question was added to the final 
questionnaire which enquired whether, in relation to height, the case or control was "of 
normal weight", "overweight", or "underweight". 
Ongoing feedback about the draft questionnaire was sought from the registered nurse 
who conducted some of the pilot interviews and from all of the volunteers. In 
particular, the nurse interviewer was asked the following questions (Foddy 1993): 
Did any of the questions seem to make respondents uncomfortable? 
Did you have to repeat any questions? 
Did the respondents misinterpret any questions? 
Which questions were the most difficult or awkward to read? 
Have you come to dislike any specific questions? Why? 
Did any sections seem to drag? 
Were there any sections in which you felt that the respondents would have 
liked the opportunity to say more? 
In response to the feedback, further modifications were made to the draft questionnaire, 
which was then tested with subsequent volunteers. Most of the modifications involved 
the insertion of additional introductory statements at the beginning of sections or before 
certain questions. These statements were of two main types: statements which 
acknowledged potentially difficult tasks and those which explained why certain 
questions were being asked. Other minor amendments included altering the sequence of 
some questions and modifying the enquiries about superficial and deep vein thrombosis. 
The latter change was made because several of the volunteers reported that their partner 
had been treated for a blood clot in the legs, but they were unable to say whether it had 














one so that respondents were first asked whether their relative (or they themselves, if 
they were a control) had been treated for a blood clot in a leg vein before the index date, 
before being asked further questions such as about its location. 
With the exception of one volunteer, who said that she generally declined to answer 
questions about qualifications and employment because they highlighted gender 
inequalities, the volunteers had no objections to the content of any of the questions. Of 
particular note, they all indicated that had they been genuine participants in the study 
they would have given their permission for the dates of their hospital admissions (if 
any) to be checked. 
The final version of the questionnaire 
A copy of the final version of the interviewer-administered questionnaire can be found 
in Appendix E. Briefly, the questionnaire included enquiries about the following before 
the index date: international air travel, domestic air travel in countries other than New 
Zealand, medical conditions associated with an increased risk of venous 
thromboembolism (including a history of venous thrombosis or pulmonary embolism, 
varicose veins, known thrombophilia, systemic lupus erythematosus, inflammatory 
bowel disease, and malignancy), acquired risk factors for venous thromboembolism in 
the three months before the index date (including major surgery, major injury, 
pregnancy, hospital admissions for other reasons, and being confined to bed or a 
wheelchair for more than one week), other medical conditions (including ischaemic and 
other heart disease, stroke, hypertension, diabetes, renal disease, and liver disease), 
medication use in the three months before the index date (including oral contraceptives 
and hormone replacement therapy), parity, past exposure to female hormones, smoking 
habits, estimated weight and height on the index date, post-secondary school 
educational attainment, occupation, ethnicity, and a family history of venous 
thromboembolism. For subjects who lived with a spouse, partner, or parents, information 
was also sought about their occupation on the index date. 
For those who had undertaken long-distance air travel, participants were asked to name 
the airports at which the journey began and ended (the final destination), and the dates 
of departure and arrival. In addition, they were asked to name any airports at which the 


















these airports. If participants were unable to give an exact answer to the latter question, 
they were asked to choose between several time categories ("< 2 hours", "2 to < 5 
hours", "5 to< 9 hours", "9 to< 12 hours", "12 hours or more", or "Don't know"). For 
each leg of the journey, participants were asked about the duration of the flight, the 
class of travel, whether the traveller had sat in an aisle seat, and whether they had taken 
a hypnotic drug immediately before, or during, the journey. Participants who were 
unsure about the duration of a flight, were asked to select a time category ("< 4 hours", 
"4 to< 9 hours", "9 to< 12 hours", "12 hours or more", or "Don't know"). Details of 
any domestic flights undertaken immediately before or after international flights were 
also obtained. Otherwise no information about domestic flights within New Zealand 
was sought, because of the short travelling times involved and the possibility of recall 
bias. 
As discussed in Chapter 8, the next of kin were also asked whether the cases had 
undertaken journeys of more than four hours' duration by other means of transport in the 
four weeks before the index date. This information was not sought from controls because 
it was considered unlikely that they would remember such episodes. Hence, the data 
regarding cases were included in the descriptive study only . 
Permission was sought from controls to check the dates of any hospital admissions before 
the index date. This information was already available for cases. 
Computer-assisted telephone interviews 
Computer-assisted telephone interviews, as the name suggests, are telephone interviews 
in which the interviewer asks the relevant questions as they are displayed on the 
computer screen and then records the participants' responses directly into the computer. 
In the present study it was decided to undertake such interviews for several reasons. 
First, the wording of the interview questions varied slightly according to whether the 
respondent was a next of kin or a control, whether the case or control was male or 
female, and the relationship of the case to the next of kin. In addition, each case and 
their controls had a unique set of relevant dates. Thus, it was necessary to customise the 
questionnaire for each interview. Moreover, the paper-based version of the 
questionnaire proved rather cumbersome to administer because of the number of 
















if the answer to a preceding question was "No". In these situations it was sometimes 
necessary to flick through several pages to find the next relevant question. Such pauses 
interrupted the flow of the interview and were particularly awkward because the 
respondent was unable to see what the interviewer was doing. 
Various options for undertaking computer-assisted telephone interviews were therefore 
explored and it was decided to accept an opportunity to pilot some newly-developed 
software (Abbey CATI software®), which was developed by Mr Charlie Blakey from 
the Life in New Zealand (LINZ) Activity and Health Research Unit at the University of 
Otago (Blakey 2003). All of the problems outlined above were easily addressed using 
this software. While setting up the computer-based questionnaire, I was able to create 
links between the questions and a list of variables. which included the subject's status 
( case or control), sex, and date of birth, as well as the date of death of the case, the 
index date, the dates three months and four weeks before the index date, and a variable 
to indicate whether the date of death was the same as the index date. A variable was 
also included to record the relationship of the case to the next of kin. Then, as 
participants were enrolled in the study, the values of the variables for each subject were 
entered into the system. Consequently the appropriate pronouns, relationships, and 
dates were automatically displayed on the interviewer's computer screen during each 
interview. Moreover it was possible to insert certain commands before or after 
particular questions to ensure that only the relevant questions were displayed. For 
example, "pre-logic" statements that were placed before the questions about pregnancy, 
oral contraceptives, and hormone replacement therapy ensured that these questions were 
only shown if the case or control was female. Likewise, "response logic" statements 
that were placed at the end of some questions ensured that if a respondent answered 
"Yes" to a particular question, then supplementary questions about that subject would 
be displayed. Conversely, if the respondent answered "No", the supplementary 
questions would remain hidden and the next major question would be shown. 
Additionally, for some questions, a "Don't know" response would prompt another set of 
questions. 
A further advantage of undertaking computer-assisted interviews using the Abbey 
system was that responses to questions were entered directly into the computer during 




















checking that would have been necessary, had the responses been recorded on a paper-
based questionnaire and later entered into a computer database. Moreover the Abbey 
software allowed me to specify, for each question, which type of response was required. 
Possibilities included numeric responses, single or multiple choices from lists of 
specified responses, and single or multiple line narrative comments. For all but the 
narrative comments, this facilitated the simultaneous entry and coding of responses and 
minimised the amount of coding that was required following the interview. For 
example, if the possible answers to a particular question were "Yes", "No", or "Don't 
know", these options were all listed on the screen with corresponding check boxes. If 
the respondent's answer was "Yes", the interviewer simply needed to click on the "Yes" 
check box to both record and code the response in the underlying data file. For 
questions to which there were a large number of possible responses (for example those 
about medicine use, qualifications, occupation, and detailed enquiries about conditions 
such as cancer) various options for coding these data during the interview were 
considered. However it was felt that these would be difficult to carry out in the context 
of an interview and hence would be vulnerable to coding errors. Thus, it was decided 
that narrative responses to these questions would be recorded during the interview and 
that I would code these responses when all the interviews were completed. 
The use of logic statements also facilitated checks for internal consistency, thus 
removing the need to rely solely on the interviewer's memory to identify contradictory 
responses. For example, in the first section of the questionnaire respondents were asked 
whether the case or control had ever been treated for specific medical conditions; later 
they were asked about the indication for any medication taken in the three months 
before the index date. If a respondent initially stated that they ( or their relative) had 
never been treated for high blood pressure, but later reported that they were taking 
medication to treat this condition in the three months before the index date, a question 
about this inconsistency was displayed on the interviewer's computer screen. Similarly 
questions were asked about the birth of any children, the use of oral contraceptives, and 
hormone replacement therapy at any time before the index date; while in a later section 
















Measures to detect data entry errors were also established. As already discussed, if a 
respondent replied "Yes" to certain questions, then other related questions would be 
displayed. Hence, if a respondent's affirmative response was incorrectly entered as 
"No", the interviewer was alerted to the error when the supplementary questions failed 
to appear on the computer screen. Questions to which supplementary enquiries were 
not attached were grouped together at the beginning of the questionnaire, following 
which respondents were asked to confirm that the answers the interviewer had recorded 
were correct. To help prevent the entry of improbable values for questions that required 
numeric responses, the permissible number of digits was specified. 
Finally, once the computer-based questionnaire had been set up, the system was tested 
by conducting telephone interviews with colleagues who deliberately gave contradictory 
answers and provided improbable values . 
Training and supervising the nurse interviewer 
The nurse interviewer undertook supervised practice interviews with colleagues and 
then with volunteers. The importance of adhering to the exact wording of the 
questionnaire was emphasised, as well as the need to adopt a standard tone and manner 
when asking the questions. Oral and written guidance was given about how to interpret 
and record responses. Difficulties that might be encountered during the interviews were 
also discussed and instructions for dealing with these were recorded in writing. The 
training initially involved a paper-based version of the questionnaire, but once the 
computer-based version was set up, the necessary skills for undertaking computer-
assisted interviews were taught and practised. The importance of keeping paper copies 
of the questionnaire on hand in case of computer problems or power failures was also 
stressed. 
The nurse interviewer observed the interviews I undertook with study participants at the 
beginning of the study and, in tum, I observed the first 25 interviews undertaken by the 
nurse and independently recorded the responses of the participants. There were no 
discrepancies between these data and those recorded by the nurse interviewer. 
Subsequent interviews were periodically observed to confirm that they continued to be 
conducted in a standardised manner. The nurse interviewer was also urged to seek 














The interviews were all undertaken by the nurse interviewer or me using the 
standardised questionnaire. To assist recall about events before the index date, the life-
events calendar was used as described for the pilot study. If participants had mislaid 
their calendar, the interview was postponed and a replacement calendar was emailed, 
faxed, or posted. People who did not wish to have their interview rescheduled were 
asked to write the relevant dates on a piece of paper and this was referred to during the 
interview. 
The case-control study was based solely on data obtained from the telephone interviews 
and the confirmation of hospital admission dates. No information about cases derived 
from other sources was used for comparisons between cases and controls. 
Post-interview data management 
Once the interviews were completed, the data were imported into the SPSS statistical 
package (version 13.0). Data coded during the interview were checked for improbable 
values, and post-interview coding was all undertaken and double-checked by me. 
The duration of each long-distance flight undertaken by subjects in the four weeks 
before the index date was confirmed by reference to flight schedules on the web sites of 
the Star and Oneworld alliances. These schedules were also used to assign more exact 
flight times for subjects for whom categories of flight duration were reported. In 
situations where there was some variation in the flight durations recorded in the 
schedules, the convention was to assign the shortest travel time. 
As anticipated, while some participants who responded affirmatively to the question 
about treated venous thrombosis were able to indicate whether the clot was superficial 
or deep, others could not. Information was sought about the type of treatment given, but 
this did not always help to determine the type of thrombosis. Because of this, and 
because it is possible that superficial and deep vein thrombosis are part of the same 
process, it was decided to classify all those who had a history of treatment for 
superficial, deep, or unspecified venous thrombosis ( or pulmonary embolism) as having 













Narrative comments regarding malignancy, non-ischaemic cardiac disease, and renal 
and hepatic conditions were coded to ICD-9 rubrics, while the drug dictionary obtained 
from the Centre for Adverse Reactions Monitoring ( discussed in Chapter 4) was used to 
assign numerical codes to medicines taken in the three months before the index date. 
The highest qualification that a subject obtained after leaving school was assigned a 
numerical code corresponding to one of the following categories: Trade certificate or 
diploma, nursing certificate or diploma, New Zealand certificate or diploma, technical 
certificate or diploma, teaching certificate or diploma, university certificate or diploma, 
Bachelor's degree, post-graduate certificate or diploma, post-graduate degree, other 
certificates or diplomas from polytechnics and other institutions, and other 
qualifications. 
The occupations of cases and controls on the index date ( or their last job before this 
date) were assigned a numerical score according to the New Zealand Socio-Economic 
Index 1996 (NZSEI-96) (Galbraith et al. 2003). The occupations of spouses, and of co-
habiting partners or parents of subjects, were also coded. The NZSEI-96 is an 
occupationally-based measure of socio-economic status based on the New Zealand 
Standard Classification of Occupations (Statistics New Zealand 2001c) and census data. 
Occupations are assigned scores ranging from 10 (lowest end of the socio-economic 
scale) to 90 (highest end). These scores may be used as continuous variables or, with 
recommended cut-off points, be used to assign subjects to one of six socio-economic 
categories. The latter approach was used in the present study. 
10.2.7 Statistical analysis 
The data were transferred from SPSS into version 8 of the SAS statistical software by a 
biostatistician in the Department of Preventive and Social Medicine, Dr Melanie Bell, 
who then undertook the statistical analyses in collaboration with me. 
Cases and controls were classified as belonging to one of six socio-economic categories 
on the basis of their NZSEI-96 score. For subjects living with a partner or parents, 
socio-economic status was classified using the highest score in the household. The 
ethnicity of cases and controls who were reported to belong to more than one ethnic 













subjects who were identified as belonging to both Maori and other ethnic groups were 
classified as Maori. Cases and controls who belonged to both a Pacific Island ethnic 
group, and other non- Maori groups, were classified as Pacific. 
Estimates of weight and height on the index date that had been reported in imperial 
measures were converted to metric measures. BMI was then calculated and classified as 
underweight ( < 20.0 kg/m2), normal weight (20.0 - 24.9 kg/m2), overweight (25 - 29.9 
kg/m2), and obese (2: 30.0 kg/m2). The normal weight category was taken as the 
reference category for BMI. Three controls and the next of kin of 24 cases provided 
estimates of height, but not weight, on the index date and the next of kin of two cases 
provided neither weight nor height. A further three controls were unable to supply an 
estimate of height on the index date, but did provide an estimate of weight. For these 
six controls and 26 cases, the BMI category was assigned using answers to the question 
about weight in relation to height. There were three possible responses to this question: 
"about right", "overweight", or "underweight". However because some respondents 
made additional comments which indicated that the subject was actually obese, some 
"overweight" subjects were reclassified as "obese". Only one participant (the relative 
of a case) declined to answer questions about weight, although she did provide 
information about height. 
In addition, as an alternative to treating BMI as a categorical variable, the missing BMI 
values were estimated using the median BMI measure for each BMI category ( cases and 
controls combined) as shown in Table 10.2. In brief, the data of persons for whom both 
estimates of weight and height, and narrative comments about weight in relation to 
height, had been provided were used to calculate the median BMI for each BMI 
category. The median BMI for a particular BMI category was then assigned to those 
persons in that category for whom weight and height estimates were missing. 
347 
Table 10.2 Median BMI measure for each BMI category 
BMI category Median BMI for category (kg/m2) 
·, Underweight' 19.0 
Normal weightt 22.8 
·}' 
·( Overweight* 27.1 
Obese§ 33.2 
"' 
* BMI < 20.0 kg/m2 
, .. tBMI 20.0- 24.9 kg/m2 
t BMI 25.0- 29.9 kg/m2 

























Odds ratios and 95% confidence intervals were calculated using conditional logistic 
regression (using the statistical software SAS, version 8). Exposures of any long-
distance flight and flights greater than eight hours' duration were modelled separately. 
The key analyses were restricted to subjects who did not have disseminated or recently 
diagnosed (less than five years before the index date) cancer (excluding localised 
malignant melanoma), were not pregnant, and had not undergone major surgery in the 
three months before the index date (since the ascertainment of cases excluded patients 
with these conditions). As matched analyses were performed, the controls of excluded 
cases were also excluded. Subjects who had not undertaken an international flight in 
the four weeks before the index date were taken as the reference category. Those who 
undertook flights of eight hours or less were excluded from the analyses that examined 
flights of more than eight hours. 
Unadjusted and adjusted odds ratios were estimated. Confounders were identified using 
both backwards deletion and forward selection strategies (Rothman and Greenland 
1998) and were confirmed in univariate analyses. The following potential confounders 
were examined: a history of venous thromboembolism; a history of varicose veins; BMI 
(both as a categorical variable and then as a continuous variable); socio-economic 
status; the use of oral contraceptives, hormone replacement therapy, aspirin, and 
antipsychotic drugs in the three months before the index date; and major injury 
including a fracture, prolonged immobility, and a hospital admission owing to a medical 
condition in the three months before the index date. Only those variables which 
resulted in a greater than 5% change in the odds ratios were included in the final 
models. 
In secondary analyses, additional exclusion criteria were applied so that subjects with a 
history of venous thromboembolism were excluded, as well as those with a history in 
the three months before the index date of major fracture, other major injury, a hospital 
admission owing to a medical condition (an admission for reasons other than surgery, 
fracture, other injury, or pregnancy), or of prolonged immobility (confined to bed or a 
chair for more than a week). Controls who were not in New Zealand on the date of 














10.2.8 Sample size calculations 
Sample size calculations were undertaken using PS software (Dupont and Plummer 
1998) for a matched case-control design with a case:control ratio of 1 :4, alpha of 0.05, a 
correlation coefficient for failure of 0.01, and power of 80%. Because the proportion of 
New Zealand residents who undertook international air travel increased during the study 
period, sample size calculations were undertaken using three different estimates of 
exposure (that is, the proportion of the resident population aged 15 - 59 years who 
undertook long-distance air travel during a four-week period). Exposure estimates were 
obtained for the years 1990, 1995, and 2000 by dividing the total number of short-term 
arrivals by New Zealand residents aged 15 - 59 years in the appropriate year by the 
estimated resident population aged 15 - 59 years for that year (all data provided by 
Statistics New Zealand), and then dividing the quotient by 13. The prevalence of 
exposure in the years 1990, 1995, and 2000 was thus estimated to be 2.0%, 2.4%, and 
3.2% respectively. Table 10.3 shows the number of cases required to detect given odds 
ratios for each of these levels of exposure. At the time the study was planned, it was 
known that pulmonary embolism was the underlying cause of death in 103 New 
Zealand residents aged 15 - 59 years who died between 1990 and 2000. Hence, 
assuming a prevalence of exposure of 2.4%, a case:control ratio of 1 :4, alpha of 0.05, 
and a correlation coefficient for failure of 0.01, it was calculated that the study would 









Table 10.3 Number of cases required according to odds ratios and the proportion of exposed 
controls 
Odds ratio Number of cases required* 
2.0% of controls exposedt 2.4% of controls exposed* 3.2% of controls exposed§ 
3.5 149 126 97 
3.6 140 118 92 
3.9 132 112 86 
3.8 125 106 82 
3.9 118 100 77 
4.0 112 95 74 
4.1 106 90 70 
4.2 101 86 67 
4.3 97 82 64 
4.4 92 78 61 
4.5 88 75 58 
'With a case:control ratio of 1:4, u = 0.05, correlation coefficient for failure= 0.01, and power= 80%. 
t Exposure estimate based on 1990 data obtained from Statistics New Zealand (short-term arrivals data and population estimates for New 
Zealand residents aged 15 - 59 years). 
" Exposure estimate based on 1995 data obtained from Statistics New Zealand (short-term arrivals data and population estimates for New 
Zealand residents aged 15 - 59 years). 
§ Exposure estimate based on 2000 data obtained from Statistics New Zealand (short-term arrivals data and population estimates for New 















10.2.9 Ethical matters 
The principles of respect for autonomy and the minimisation of harm were observed in 
the design and conduct of the both the descriptive and case-control studies. The letters 
of invitation to both next of kin and controls outlined why (in general terms) the study 
was being undertaken, the potential benefits of the research, and what was involved for 
participants; emphasised that participation was voluntary, that participants could chose 
not to answer particular questions or could withdraw from the study at any time if they 
wished; gave an assurance of confidentiality; provided the contact details of the local 
Health and Disability Services Consumer Advocate; and contained an invitation to 
make a reverse charges telephone call to me should they wish. Potential participants 
were not informed of the study hypothesis, since this might have affected their decision 
to participate and therefore have introduced bias. For similar reasons, controls were not 
told that pulmonary embolism was the condition under investigation. This information 
was, however, provided at the end of the interview to all those who were interested. 
Various measures were taken to minimise potential harm to participants. The research 
was confined to cases who had died at least three years earlier, and therefore no next of 
kin who were very recently bereaved were approached. Nevertheless, receiving the 
letter of invitation and answering questions about their partner or relative had the 
potential to cause psychological distress for the next of kin. Hence, it was decided not 
to enquire about the particular circumstances of death, and an experienced nurse 
interviewer, who was accustomed to dealing with sensitive issues, was employed to 
conduct the interviews along with me. Next of kin were also able to have other family 
members or friends with them during the interview, and it was again stressed that (as 
with controls) they could choose not to answer particular questions and could withdraw 
from the research at any stage if they wished. 
Following positive responses to letters previously sent to a few next of kin in order to 
identify the general practitioners of the cases, it was surmised that the next of kin might 
derive some benefit from knowing that the death of their relative was regarded as 
sufficiently important to be investigated further - and that the information obtained 

















Written consent was not sought from participants because it was thought preferable that 
people had the opportunity to seek more information before making a commitment to 
take part in the research. Hence, all potential participants with traceable telephone 
numbers were telephoned by me to discuss the research and to answer any questions. 
Those wishing to take part gave oral consent, which was recorded in writing. At the end 
of the interview, oral consent was also sought from controls to collect information on 
the dates of any hospital admissions before the index date and this was also recorded in 
writing. No-one refused. All participants were asked whether they wished to receive a 
summary of the results of the study when it was completed. 
Passwords were used to restrict access to the raw interview data. The passwords were 
known only to the nurse-interviewer, me, and the researcher from the Life in New 
Zealand (LINZ) Activity and Health Research Unit who had designed the computer-
assisted telephone interview software and who provided ongoing technical support and 
back-up of the data. Files in which the names and contact details of potential 
participants were recorded, and the forms completed by such people, were stored in a 
locked filing cabinet. Neither the nurse-interviewer nor the researcher from LINZ had 
access to any information about cases that had been obtained from medical and death 
records. 



















CHAPTERll CASE-CONTROL STUDY OF LONG-DISTANCE AIR 
TRAVEL STUDY: RESULTS AND DISCUSSION 
11.1 RESULTS 
11.1.1 Participation of next of kin and controls 
Responses of next of kin and controls to letters of invitation 
The responses of the next of kin of 99 cases who were initially considered eligible for 
inclusion in the case-control study are shown in Figure 11.1. For 87 of the 99 cases, 
letters of invitation were sent to just one relative. For the remaining cases, letters were 
sent in turn to two (seven cases), three (four cases), and six different relatives (one 
case). 
The responses of the 433 potential controls who were sent letters of invitation are shown 
in Figures 11.2 - 11.5. Of the 408 potential controls to whom letters were sent directly, 
only 161 (39.5%) replied to the first letter (Figure 11.2), a second letter was sent to 64 
who did not have traceable telephone numbers (Figure 11.3), and 37 were sent a third 
letter (Figure 11.4). Six (24%) of the 25 potential controls to whom letters were sent via 
former household members replied to the first letter, five were sent a second letter, and 
three were sent a third letter (Figure 11.5). It transpired that eight of these 25 potential 
controls had changed their surnames and all were subsequently located on the 2003 
electoral roll under their new names. It was also ascertained that five of the 62 people 













Letters sent to first next of kin of 
eligible cases (n=99) 
5 declined 
43 did not reply to first letter 
no other next of kin 
approached 
38 telephoned 
Letters sent to second next of kin because 
first did not reply or letters returned and 
no traceable telephone number (n=l2) 
5 did not reply to first letter, 
no other next of kin 
approached 
4 telephoned 
Letters sent to third next of kin because 
first two did not reply or letters returned 
and no traceable telephone number (n=S) 
1 declined 
3 did not reply to first letter, 
no other next of kin 
approached 
2 telephoned, no 
other next of kin 
approached 
Letters sent to sixth next of kin because 
first five did not reply or letters returned 
and no traceable telephone number (n= l) 
l did not reply to first letter 
l telephoned 
Figure 11.1 Responses of next of kin 
44 replied to first letter 
2 declined 
5 no traceable 
telephone number 
2 replied to first letter 
l no traceable 
telephone number 
l replied to first letter 
l no traceable 
telephone number 
1 no reply to 
further letters, no 
other next of kin 
42 interviewed 











1 consented, but then not contactable, 
















First letters sent to the 
addresses of 408 
potential controls 
161 replied to first letter (6 had 
shifted, but letters forwarded) 
6 not eligible: wrong 
sex (2) or age ( 4) 




10 letters returned 7 searched past electoral 
rolls to identify others at 
same address as potential 
control in the past 
4 letters sent via former 
household members 
3 fonner household 
members in telephone 
directory 
2 potential controls 
not located, 
eligibility 
unknown (1 letter 
returned, 1 no 
reply) 
1 declined, did not 
answer eligibility 
questions 
1 potential control 
not located, eligibility 
unknown 
(whereabouts not 
known to former 
household member) 
2 new addresses obtained 
from former household 
members, letters sent 
2 letters sent via others: Nursing 
Council (1), apartment manager (1) 
2 replied 
1 new address found in 
telephone directory 
1 replied 
237 did not reply 
to first letter 
175 telephoned 
(9 letters lost in 
post) 
62 no traceable 
telephone number 
1 no further 
letters because 





64 sent a second letter 




8 had shifted, letters 
forwarded, new telephone 
number obtained from 
others at old address 
2 overseas: contact details 
from voice mail (1), 
housesitter (1) 
2 replied 
6 not eligible 
because 
wrong sex (2) 










1 did not reply 
1 telephone number 





















64 sent a second letter 12 replied to second letter, 12 eligible 11 interviewed 
3 had shifted: Jetter forwarded (2), 
new address from neighbours (1) 
3 letters returned 2 searched past electoral rolls to 
identify others at same address as 
potential control in the past 
1 letters sent via 2 
former household 
members, returned (1), 
no reply (1) 
1 potential control 
not located, eligibility 
unknown 
1 had shifted, found new 
address in telephone directory 
1 fonner household member in 
telephone directory, provided 
contact details of potential control 
I replied 
1 replied 
1 declined (initially consented but 
wife died after interview booked) 
1 eligible 1 interviewed 
1 eligible 1 interviewed 
49 did not reply to second Jetter 1 no further letters sent, end of study, eligibility unknown 
5 telephone number traced after second letter sent 
1 had shifted, found new 
address in telephone directory 
1 replied 
4 searched 2003 electoral roll to identify others at same address 
4 other household members in telephone 
directory, potential controls telephoned 
1 not eligible because not living 
in New Zealand on index date 
1 telephone number obtained from daughter 
37 a sent third letter 
5 eligible 5 interviewed 
1 eligible 1 interviewed 
3 eligible 3 interviewed 
1 eligible 1 interviewed 
Figure 11.3 Responses of 64 potential controls to whom a second letter was sent 
37 sent a third letter 
'T 
1 letter returned 
,, 
f 30 did not reply to third letter 
.. 
6 replied to third letter 
1 searched past electoral rolls to 
identify others at same address as 
potential control in the past, no-
one located 
6 eligible 2 interviewed 
4 declined 
1 potential control not 
located, eligibility unknown 
25 searched 2003 electoral roll to identify others at same address 
357 
1 rechecked 
electoral roll, not 
eligible because 
\ I I I wrong sex 
6 no others at same address, 
no other contact people 
identified, eligibility of 

















9 no others at same address (1) or 
other household members not in 
telephone directory (8). 
Telephone numbers obtained from 
relatives (8) or neighbours (1) who 
were found in telephone directory. 
3 had shifted, found new 
address in telephone directory 
1 had changed telephone number, found 
new number in telephone directory 
3 replied 
6 other household members not 
in telephone directory, no other 
contact people identified, 







2 not interviewed: unwell in hospital (1), husband 
was to translate for potential control but was 
unexpectedly away from home for several months (1) 
3 eligible 3 interviewed 
1 eligible 1 interviewed 

















First letters to 25 potential 
controls sent via former household 
members 
3 letters returned 
1 no record of 
death or name 
change, but not 
eligible because of 
date of birth 
6 replied to first letter 
2 not eligible because not living 
in New Zealand on index date 
1 letter sent via a second 
household member, returned 





found on 2003 
electoral roll 
1 potential control 
not located, eligibility 
unknown 
1 did not reply 1 telephone number 
obtained from mother 
16 did not reply 
to first letter 
10 telephoned fonner 
household member 
6 telephone numbers obtained 
from household members, 2 
provided new surname, both 
found on 2003 electoral roll 
1 not eligible because not living 
in New Zealand on index date 
2 provided new surname, 
found on 2003 electoral 
roll, letters sent 
1 potential control still 
at that address 1 replied 
1 declined 1 telephoned 
6 no traceable 
telephone number 
1 no further letters sent because 
end of study, potential control 
not located, eligibility unknown 
5 sent a second letter 1 replied to second letter 
I letter returned, potential control 
not located, eligibility unknown 
3 did not reply to second letter, sent a third letter 
3 did not reply to third letter, potential 



























Next of kin and controls who were interviewed 
The eligibility and participation of the next of kin of cases and of the controls is 
summarised in Figure 11.6. The next of kin of 89 cases (89.9%) were interviewed, 
eight declined to participate, one initially consented but then could not be contacted, and 
for one case no replies were received from any of the three next of kin to whom letters 
were sent. Of the 462 potential controls selected from past electoral rolls, 21 were not 
eligible for inclusion in the study: 12 were the wrong age (three of whom died after the 
index date), five were the wrong sex, and four were not living in New Zealand on the 
index date. The eligibility status of 55 potential controls was not established: 15 died 
after the index date (including one man who died soon after a letter was sent to him) and 
were of an eligible age but it was not known whether they were living in New Zealand 
on the index date, 14 did not respond to letters of invitation, three declined to participate 
and to answer eligibility questions, and a total of 23 were not traced. Of the latter 
group, no postal address was found for 12, letters to six were returned ("gone, no 
forwarding address"), and no reply was received from five to whom letters were sent via 
former household members. A search of Births, Deaths, and Marriages records found 
no evidence that any of these 23 people had changed their names or died in New 
Zealand. The remaining 386 potential controls were eligible to be interviewed, but 28 
did not wish to participate ( one man initially consented, but cancelled the interview 
following the sudden death of his wife), one person was in hospital and too ill to be 
interviewed, and one woman agreed to be interviewed if her husband was able to act as 
her translator but he was subsequently away from home for several months. Hence, the 
response rate of potential controls lay between 80.7% (356 of 441) and 92.2% (356 of 
386), since it is unlikely that everyone for whom eligibility status was not determined 













Potentially eligible cases (n= 121) 
8 overseas visitors 
14 New Zealand residents not registered on electoral roll 
99 eligible for interview of next of kin*, diagnosis confirmed by: 
- 92 necropsy 
- 3 pulmonary angiography or ventilation-perfusion scans 
- 4 by 2 physicians using standard criteria and blinded to 
exposure status 
* Case lived in New Zealand and was registered on the electoral roll 
on the index date 
..Ir 
Participation of next of kin 
99 eligible for interview: 
- 8 did not wish to participate 
- 1 initially consented, subsequently not contactable 
- 1 no response from any next of kin 
- 89 interviewed 
89 interviewed: 
- 1 reported by next of kin to have undergone surgery 
- 88 included in key analyses 
360 
Potential controls selected from electoral roll (n=462) 
21 not eligible for interview: 
- 5 wrong sex 
- 12 wrong age (3 died after index date) 
- 4 not living in New Zealand on index date 
55 eligibility status unknown: 
- 15 died after index date 
- 14 no response to letters 
- 23 not traced 
- 3 declined to participate and did not answer 
eligibility questions 
386 eligible for interview* 
* Same age and sex as their case, lived in New Zealand and 
registered on the electoral roll on the index date 
..Ir 
Participation of controls 
386 eligible for interview: 
- 28 did not wish to participate 
- 1 too ill to be interviewed 
- 1 appropriate translator not available 
- 356 interviewed 
356 interviewed: 
- 4 were controls of excluded case 
- 3 had advanced or recently diagnosed cancer 
- 13 were pregnant in 3 months before index date 
- 2 had surgery in 3 months before index date 
- 3 34 included in key analyses. 
















Cases and controls included in the key analyses 
One case was reported by relatives to have undergone surgery following major injury in 
the three months before the index date. Although the reported surgery was not 
confirmed by his hospital or necropsy records (the injury was), this man was excluded 
from the key analyses because comparable sources of information were not available for 
the controls who stated that they had undergone surgery. Of the 356 controls who were 
interviewed, four were excluded from the key analyses because they were matched to 
the excluded case. A further 18 were excluded because they had conditions for which 
cases had been excluded: 13 were pregnant and two underwent surgery in the three 
months before the index date, while three had disseminated cancer or had been 
diagnosed with a malignancy (other than localised malignant melanoma) in the five 
years before the index date. Several other subjects who had reportedly been treated for 
cancer before the index date were not excluded from the key analyses as their disease 
appeared to have been cured. These cancers included localised malignant melanoma 
(one case, five controls), cervical cancer (two controls, both treated 10 years earlier -
one with cone biopsy, the other with hysterectomy), ovarian cancer (one control, 
oophorectomy 40 years earlier when 12 years old), leukaemia (one control, treated 23 
years earlier), and a malignant polyp of the colon (one case, excised seven years 
earlier). Hence, the key analyses were based on 88 cases and 334 controls . 
11.1.2 Characteristics of cases and controls 
The demographic characteristics of cases and controls are shown in Table 11.1. Of the 
88 cases, 30 were male and 58 were female. The female cases were younger than the 
male (median ages 50.8 years and 42.6 years respectively). Cases spent fewer years at 
secondary school than controls and were less likely to have obtained a qualification 
after leaving school. Seven cases, but no controls, had attended special classes for 
people with intellectual disabilities. Cases were more likely than controls to belong to 
the lowest socio-economic group, although in univariate matched analyses people in the 
lowest socio-economic category did not have a significantly elevated risk of fatal 
pulmonary embolism when compared with those in the highest category (1.3 [95% CI 
0.4 - 3.9]). The prioritised ethnic group of subjects did not differ appreciably between 
the case and control groups. Nine cases and 28 controls were identified as belonging to 
the Maori ethnic group. Of these, six cases and nine controls were also reported to 





















11.3). Of the three cases and 19 controls who were identified as belonging solely to the 
Maori ethnic group, all three cases and 16 of the controls were reported to have some 
European ancestry. 
363 
Table 11.1 Demographic characteristics of cases and controls 
Characteristic Cases (n=88) Controls (n=334)* 
Sex (number[%]) 
Male 30 (34.1) 120 (35.9) 
-;, Female 58 (65.9) 214 (64.1) 
Age (years, median) 
1 All 45.5 47.1 
Male 50.8 50.4 
"" Female 42.6 43.0 
Years of secondary schooling 
r None 3 (3.4) 8 (2.4) 
1-2 18 (20.5) 57 (17.1) 
.. 3-4 43 (48.9) 202 (60.5) 
2::_5 13 (14.8) 67(20.1) 
/ 
Attended special education classes because of intellectual disability 7 (8.0) 
Unknown 3 (3.4) 
Did not answer question 1 (1.1) 
Highest qualification obtained after leaving school 
None 53 (60.2) 154 (46.1) 
Trade or technical certificate or diploma 16 (18.2) 83 (24.9) 
J_ 
Nursing certificate or diploma 4 (4.5) 18 (5.4) 
Teaching certificate or diploma 4 (4.5) 12 (3.6) 
.. 
University certificate or diploma 5 (1.5) 
Bachelors degree 6 (6.8) 30 (9.0) 
,. 
Post-graduate certificate or diploma 11 (3.3) 
)" Post-graduate degree 1 (1.1) 6 (1.8) 
. Other 4 (4.5) 15 (4.5) 
Socio-economic group (number [ % ]) 
'r 1 (highest) 5 (5.7) 18 (5.4) 
2 8 (9.1) 32 (9.6) 
,. 3 27 (30.7) 119 (35.6) 
4 18 (20.5) 82 (24.6) 
5 9 (10.2) 43 (12.9) 
6 19 (21.6) 39 (11.7) 


















































Table 11.2 Reported ancestry of cases who were reported to belong to the Maori ethnic group 
Reported ancestry Reported ethnic group 
Maori only Maori and European 
Maori only 
Maori and European 3 6 
Table 11.3 Reported ancestry of controls who were reported to belong to the Maori ethnic 
group 
Reported ancestry Reported ethnic group 
Maori only Maori and European 
Maori only 3 













Other characteristics of cases and controls are shown in Table 11.4. Cases were more 
likely than controls to have a history of venous thromboembolism, to be obese, and to 
be nulliparous. In the three months before the index date, cases were also more likely 
than controls to have been immobilised for a prolonged period ( confined to bed or a 
wheelchair for more than a week), to have been admitted to hospital owing to a medical 
condition, and to have taken oral contraceptives or antipsychotic drugs. Five of the 
cases and one of the controls who were admitted to hospital were also immobilised for a 
prolonged period . 
Cases and controls had similar rates of smoking, of regular aspirin use, and of hormone 
replacement therapy during the same period. One case, and no controls, had systemic 
lupus erythematosus. Three cases, but no controls, had been told that they had a blood 
disorder which increased their chances of developing venous thromboembolism. Only 
one subject (a case) was reported to be taking an anticoagulant (warfarin). Comparable 
proportions of cases and controls had a history of varicose veins and a family history of 
venous thromboembolism. None of the cases or controls had been diagnosed with 
inflammatory bowel disease. Although female cases were more likely than controls to 
have taken oral contraceptives in the three months before the index date, the proportion 
of cases who had ever used this method of contraception before the index date was 
smaller that the proportion of controls who were ever users. Similarly, cases were less 
likely to have ever taken hormone replacement therapy and to have been diagnosed with 
hypertension during pregnancy. 
In univariate matched analyses, statistically significant elevated risks of fatal pulmonary 
embolism were found for a history of venous thromboembolism (odds ratio 9.2 [95% CI 
3.6- 23.8]), BMI ~ 30 kg/rn2 compared with BMI 20- 24.9 kg/m2 (odds ratio 2.9 [95% 
CI 1.5 - 5.5]), prolonged immobility (odds ratio 9.5 [95% CI 2.5 - 36.3]), a hospital 
admission owing to a medical condition (odds ratio 7.9 [95% CI 2.4 - 26.1]), and 
current use of oral contraceptives (odds ratio 4.9 [95% CI 2.0 - 12.0]) and antipsychotic 
drugs (odds ratio 7.8 [95% CI 1.9 - 31.1]). These variables were all included in the 
final multivariate models. 
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Table 11.4 Other characteristics of cases and controls 
Characteristic Cases Controls Matched 
(n=88) (n=334)* unadjusted odds 
ratio (95 % Cl) 
Reported history (number [ % ]) 
Venous thromboembolism 16 (18.2) 9 (2.7) 9.2 (3.6 - 23.8) 
';Y 
Varicose veins 23 (26.1) 80 (24.0) 1.2 (0.7 - 2.1) 
Clotting disorder 3 (3.4) 
( Systemic lupus erythematosus 1 (1.1) 
Hypertension unrelated to pregnancy 9 (10.2) 32 (9.6) 
,., Angina 3 (3.4) 8 (2.4) 
Myocardial infarction 1 (0.3) 
Stroke 1 (1.1) 4 (1.2) ,. 
Heart valve disease 4 (1.2) 
Cardiac conduction disorders 1 (1.1) 2 (0.6) 
J. 
Type I diabetes 1 (1.1) 1 (0.3) 
Type II diabetes 1 (1.1) 5 (1.5) 
' Gestational diabetes only 1 (1.1) 1 (0.3) 
Chronic renal failure 2 (2.3) 1 (0.3) 
,. BMI (kg/m2, number [%]f 
< 20 7 (8.0) 26 (7.8) 1.2 (0.5 - 3.1) 
20-24.9 31 (35.2) 153 (45.8) 1.0 
25 -29.9 21 (23.9) 104 (31.1) 1.0 (0.5 - 1.9) 
2"._30 28 (31.8) 51 (15.3) 2.9 (1.5 - 5.5) 
Did not answer question 1 (1.1) 
Ir Risk factors in 3 months before index date (number [% ]) 
Major fracture 3 (0.9) 
\> Major injury 1 (1.1) 1 (0.3) 
Prolonged immobility* 8 (9.1) 3 (0.9) 9.5 (2.5 - 36.3) 
Hospital admission owing to a medical condition 9 (10.2) 4 (1.2) 7.9 (2.4- 26.1) 
Smoking status in 3 months before index date (number 
r%n 
Never smoked 47 (53.4) 157 (47.0) 1.0 
Smoker 27 (30.7) 97 (29.0) 1.1 (0.6 - 1.8) 
Ex-smoker 14 (15.9) 80 (24.0) 0.6 (0.3 - 1.1) 
Medication use in 3 months before index date 
Antipsychotic (number [% total]) 6 (6.8) 3 (0.9) 7.8 (1.9 - 31.1) 
\ Antidepressant (number[% total]) 1 (1.1) 8 (2.4) 
Aspirin (number[% total]) 3 (3.4) 7 (2.1) 
1 Oral contraceptives (number[% female]) 22 (37.9) 41 (19.2) 4.9 (2.0 - 12.0) 















Characteristic Cases Controls Matched 
(n=88) (n=334)* unadjusted odds 
ratio (95 % Cl) 
Ever use of medications before index date (number[% 
female]) 
Oral contraceptives 41 (70.7) 179 (83.6) 
Hormone replacement therapy 5 (8.6) 30 (14.0) 
Number of births (number[% female]) 
0 22 (37.9) 47 (22.0) 
1-2 20 (34.5) 82 (38.3) 
3-4 11 (19.0) 69 (32.2) 
5-6 2 (3.4) 10 (4.7) 
>6 3 (5.2) 6 (2.8) 
Hypertension in pregnancy (number[% female]) 3 (8.3) 23 (13.8) 
Reported family history of venous thromboembolism 10 (11.4) 38 (11.4) 
(number [%]) 
* 18 controls are excluded: three had a history of cancer, two had surgery, and 13 were pregnant in the three months before the index date. 
t Based on weight and height measurements when provided, otherwise the BMI category was assigned using narrative comments about 
weight in relation to height. 


















11.1.3 Cases and controls who undertook long-distance air travel 
Five cases and nine controls had undertaken at least one long-distance flight in the four 
weeks before the index date. The median ages of these cases and controls were 49 years 
and 52.5 years respectively. Table 11.5 shows the characteristics of the cases, as 
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Table 11.5 Characteristics of cases who undertook long-distance air travel in the four weeks before the index date* 
Case Sex Age History of venous BMI Other risk factors for venous Family history of venous 
(years) thromboembolism (kg/m2)t thromboembolism thromboembolism 
1 Female 47 No 35.5 N orethisterone No 
Medroxyprogesterone acetate 
Tranexamic acid 
2 Female 51 Pregnancy-related DVT "Average weight in History of vein surgery, but husband did 1 cousin with deep vein thrombosis 
relation to height" not think that she had varicose veins 
3 Female 58 No 21.2 History of varicose veins No 
4 Male 36 No "Slightly Nil No 
overweight in 
relation to height" 
5 Male 49 No 30.7 Paraplegia 33 years No 
* Information obtained from next of kin interviews only. 
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Table 11.6 Characteristics of controls who undertook long-distance air travel in the four weeks before the index date 
Control Sex Age History of venous BMI Other risk factors for venous Family history of venous 
(years) thromboembolism (kg/m2)* thromboembolism thromboembolism 
1 Female 25 No 19.4 Oral contraceptive use No 
2 Female 32 No 32.7 Nil 2 sisters with deep vein thrombosis 
3 Female 48 No 19.7 Hormone replacement therapy No 
4 Female 52 No 21.7 No No 
5 Female 57 No 30.8 No No 
6 Female 59 No 24.1 Hormone replacement therapy No 
Varicose veins 
7 Male 19 No 26.3 No No 
8 Male 54 No 25.0 No No 
9 Male 58 No 28.1 No No 



















11.1.4 Long-distance air travel undertaken by cases and controls 
Information about the long-distance air travel undertaken by the five cases (cases 1 - 5) 
was shown in Table 9.5 in Chapter 9. As this information was obtained from next of 
kin it can be included in the case-control study. Corresponding information about 
controls is shown in Table 11.7. Four of the nine controls had journeys of at least eight 
hours. One control was an international flight attendant and had at least 18 long-
distance flights during the relevant four-week period. She routinely lay down for two or 
three hours on each flight of more than 10 hours' duration. Another control undertook 
four long-distance flights, all in business class. Only one other control travelled in 
business class. Five of the six remaining controls travelled twice in the four weeks . 
None of the controls reported taking hypnotic drugs immediately before or during the 
flight, and there were no additional controls who had undertaken domestic flights within 
a country other than New Zealand during the relevant period. 
Hence, in summary, five cases and nine controls undertook at least one flight of more 
than three hours' duration in the four weeks before the index date. All five cases and 
four of the controls had journeys of more than eight hours' duration. 
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undertaken by air 
18-26 
2 
Total duration of 
long-distance journey 
(duration of each leg) 
11 h, 55 m, twice 
10 h, 35 m, twice 
11 h, 20 m, twice 
12 h, 45 m, twice 
10 h, 45 m, once 
11 h, 0 m, once 
7 h, 35 m, twice 
6 h, 25 m, twice 
3 h, 30 m, 2 - 6 times 
3h,Om,2-6times 
3 h, 30m 
3h,Om 
Number (duration) 
of stops during 
journey 
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International flight attendant. 
During each flight of more 
than 10 hours had a 2 - 3 
hour rest period during which 





.... .. ,.. ,. "i ''( "" '-; " ~ 
Control Number of long- Total duration of Number (duration) Class of Aisle Hypnotic Interval between Other comments 
distance journeys long-distance journey of stops during travel seat use end of flight and 
undertaken by air ( duration of each leg) journey index date 
3 4 11 h, 55 m 0 Business Yes No 26 days The control's case had a 
5h,5m • 0 Business No No 21 days history of venous 
thromboembolism 
6h,5m * 0 Business No No 14 days 
12h, 30 m 0 Business Yes No 4 days 
4 1 3 h,45 m 0 Business No No 2 days The control's case had a 
history of venous 
thromboembolism 
5 2 4h,Om 0 Economy No No 17 days Not in New Zealand on the 
3 h, 30m 0 Economy No No 11 days 
index date / date of death of 
case 
6 2 11 h, 40 m 0 Economy No No 17 days 
11 h, 0 m 0 Economy No No 11 days 
7 2 3h,Om 0 Economy No No 21 days 
3h,Om 0 Economy No No 12 days 
8 2 14h, 25 m 1 (2 h) Economy Not No 25 days 
(3 h 30 m, 10 h 55 m) recalled 
12h, 15 m 1 (4 h) Economy Not No 15 days 
(9 h 20 m, 2 h 55 m) recalled 
9 1 3 h, 45 m 0 Economy Yes No 23 days Not in New Zealand on the 
index date, but returned 
before the date the case died 
* Domestic flights within a country other than New Zealand. 

















11.1.5 Estimated relative risk of fatal pulmonary embolism in long-distance air 
travellers 
375 
The results of the key analyses are shown in Table 11.8. Taking those who had not 
flown as the reference group, the odds ratio (adjusted for a history of venous 
thromboembolism, for the BMI category, and for prolonged immobility, any hospital 
admission owing to a medical condition, oral contraceptive, or antipsychotic use in the 
three months before the index date) for a flight of at least three hours' duration was 1.8 
(95% CI 0.5 - 7.1). For flight times of more than eight hours, the adjusted odds ratio 
was 7.9 (95% CI 1.1 - 55.1). Socio-economic status did not confound the association. 
When BMI as a continuous variable was entered into the multivariate model the 
adjusted odds ratio for a flight of more than eight hours' duration was 7.6 (95% CI 1.2 -
48.1). 
Excluding controls who were not in New Zealand on the date of death of their case 
(n=2) had minimal impact on the results. The odds ratios (adjusted for a history of 
venous thromboembolism, for the BMI category, and for prolonged immobility, any 
hospital admission owing to a medical condition, oral contraceptive, or antipsychotic 
use in the three months before the index date) for air travel of at least three hours' and 
more than eight hours' duration were 1.9 (95% CI 0.5 - 7.5) and 7.9 (95% CI 1.1 -
55.1) respectively. 
Similar point estimates were obtained when people with a history of venous 
thromboembolism, or of major injury or prolonged immobility in the three months 
before the index date were excluded from the analysis (Table 11.9). The odds ratio 
(adjusted for the BMI category and for any hospital admission owing to a medical 
condition, oral contraceptive, or antipsychotic use in the three months before the index 
















Table 11.8 Long-distance air travel and fatal pulmonary embolism 
Flight details Cases Controls Matched unadjusted Matched adjusted Matched adjusted 
odds ratio (95 % CI) odds ratio odds ratio 
(95% CI)* (95% Cif 
No long-distance 83 325 1.0 1.0 
flight 
Air travel ~ 3 hours 5 9 2.2 (0.7 - 6.8) 1.8 (0.5 - 7.1) 
No long-distance 83 325 1.0 1.0 1.0 
flight 
Air travel > 8 5 4 6.0 (1.4 - 25.4) 7.9 (1.1 - 55.1) 7.6 (1.2 - 48.1) 
hours* 
'Adjusted for a history of venous thromboembolism, for the BMI category, and for prolonged immobility, any hospital admission owing to a 
medical condition, oral contraceptive, or antipsychotic use in the three months before the index date. 
t Adjusted for a history of venous thromboembolism, for BMI as a continuous variable (using imputed values for missing data), and for 
prolonged immobility, any hospital admission owing to a medical condition, oral contraceptive, or antipsychotic use in the three months 
before the index date. 













Table 11.9 Long-distance air travel and fatal pulmonary embolism, excluding people with a 
history of venous thromboembolism or of major injury or prolonged immobility in the three 
months before the index date 
Flight details Cases Controls Matched unadjusted Matched adjusted 
odds ratio (95 % Cl) odds ratio (95 % CI)* 
No long-distance flight 62 230 1.0 1.0 
Air travel ~ 3 hours 3 7 1.6 (0.4 - 6.5) 1.1 (0.2 - 5.4) 
No long-distance flight 62 230 1.0 1.0 
Air travel > 8 hourst 3 3 5.0 (0.8 - 31.0) 7.1 (0.8 - 64.1) 
* Adjusted for the BMI category, and for any hospital admission owing to a medical condition, oral contraceptive, or antipsychotic use in the three months 
before the index date. 

















11.1.6 Other risk factors for fatal pulmonary embolism 
The estimated relative risks of fatal pulmonary embolism associated with other risk 
factors are shown in Table 11.10. People with a history of venous thromboembolism 
had a 10-fold increased risk of dying from pulmonary embolism when compared with 
people without such a history; the odds ratio (adjusted for air travel of more than eight 
hours, for the BMI category, and for prolonged immobility, any hospital admission 
owing to a medical condition, oral contraceptive, or antipsychotic use in the three 
months before the index date) was 10.6 (95% CI 3.7 - 31.0). People who were obese 
were more likely to die from pulmonary embolism than those with a normal BMI; the 
adjusted odds ratio for a BMI ;::: 30 kg/m2, compared with a BMI of 20 - 24.9 kg/m2, 
was 2.8 (95% CI 1.3 - 5.8). The adjusted odds ratios for prolonged immobility and for 
any admission to hospital owing to a medical condition in the three months before the 
index date were 2.4 (95% CI 0.4 - 14.6) and 11.5 (1.5 - 88.6) respectively. When 
compared with non-users, users of oral contraceptives in the three months before the 
index date had an increased risk of fatal pulmonary embolism; the adjusted odds ratio 
was 7.1 (95% CI 2.7 - 18.8). Antipsychotic use was also associated with an increased 
risk; the adjusted odds ratio was 8.4 (95% CI 1.7 - 42.0). No increased risks were 
observed for a reported history of varicose veins, a family history of venous 
thromboembolism, or for smoking or hormone replacement therapy in the three months 
before the index date. Very similar results were obtained when the odds ratios were 
















Table 11.10 Other risk factors and fatal pulmonary embolism 
Risk factor Cases Controls Matched Matched 
(n=88) (n=334) adjusted odds adjusted odds 
ratio (95 % CI)* ratio (95% Cl)t 
Reported history 
VTE 16 9 10.6 (3.7 - 31.0) 8.8 (3.1 - 25.4) 
Risk factors in 3 months before index date 
Prolonged immobility 8 3 2.4 (0.4 - 14.6) 2.4 (0.4 - 14.2) 
Hospital admission owing to a medical 9 4 11.5 (1.5 - 88.6) 11.2 (1.6 - 78.1) 
condition 
Medication use in 3 months before index 
date 
Anti psychotic 6 3 8.4 (1.7 - 42.0) 7.4 (1.6 - 34.6) 
Oral contraceptives 22 41 7.1 (2.7 - 18.8) 5.9 (2.2 - 15.4) 
BMI as a categorical variable 
<20 7 26 0.7 (0.2 - 2.2) 
20-24.9 31 153 1.0 
25 -29.9 21 104 1.0 (0.5 - 2.0) 
~30 28 51 2.8 (1.3 - 5.8) 
Did not answer question 1 0 
BMI as a continuous variable* 88 334 1.08 (1.02 - 1.14) 
' Variables included in the model were long-distance air travel of more than eight hours, a history of venous thromboembolism, the BMI 
category (four categories), and prolonged immobility, any hospital admission owing to a medical condition, oral contraceptive, and 
antipsychotic use in the three months before the index date. 
t Variables included in the model were long-distance air travel of more than eight hours, a history of venous thromboembolism, BMI as a 
continuous variable, and prolonged immobility, any hospital admission owing to a medical condition, oral contraceptive, and antipsychotic 
use in the three months before the index date. 





















As discussed earlier, the number of cases of fatal pulmonary embolism was inevitably 
restricted by the relative rarity of the condition and the size of the New Zealand 
population. Hence, there were only 121 deaths over an 11-year period among people 
aged 15 - 59 years in which pulmonary embolism was considered the underlying cause. 
Of these, 98 were identified as being eligible for inclusion in the case-control study and 
the next of kin of 88 were interviewed. The precision of the estimates of relative risk 
was accordingly restricted, as shown by the wide 95% confidence intervals. 
Nevertheless, people who had undertaken air travel of more than eight hours' duration 
had a significant eight-fold increased risk of fatal pulmonary embolism in the 
subsequent four weeks when compared with people who had not undertaken any long-
distance flights. This is consistent with the findings of the descriptive study from 
which, allowing for a "healthy traveller" effect, a six-fold increase in risk can be 
estimated. The relative risk estimate for flights of at least three hours' duration, 
although not significant, was also elevated. 
11.2.1 Potential sources of bias to be considered 
Ascertainment of cases 
As has already been discussed in previous chapters, in this population-based research it 
was possible to identify all deaths that occurred in New Zealand during the study period 
for which pulmonary embolism was considered the underlying cause. Because fatal 
events were studied, and because the deaths occurred before widespread media publicity 
about a possible link between long-distance flights and venous thromboembolism, 
diagnostic and referral biases are very unlikely in this study. Moreover, even if a 
referral bias had occurred, with individuals who developed symptoms of venous 
thromboembolism following a flight being more likely to be referred promptly for 
investigation and treatment (possibly preventing some deaths), this should have led to 
an underestimate of the association between air travel and fatal pulmonary embolism. 
The response rate of next of kin was high (89.9% ). However, to explore the possible 
impact that the omission of the 10 eligible cases might have had on the estimates of 
relative risk, a sensitivity analysis was undertaken. It was assumed that none of the 10 
















and that one of their 40 controls had undertaken a flight of at least three hours' duration, 
but none had flown for more than eight hours (based on the observed proportions of 
controls exposed to flights of these durations). In this matched analysis, based on 98 
cases and 374 controls, the unadjusted odds ratios for a flight of at least three hours' 
duration and air travel of more than eight hours were 2.0 (95%CI 0.6 - 5.9) and 4.5 
(95 % CI 1.2 - 17 .1) respectively. Hence, the failure to include all eligible cases could 
not fully explain the observed association between air travel of more than eight hours' 
duration and fatal pulmonary embolism. 
Selection of controls 
Controls were selected using the same criteria as the cases, namely that they had to have 
been living in New Zealand, and registered on the electoral roll, on the index date. 
Moreover, electoral rolls from the index ( or adjacent) years, rather than the most recent 
roll, were used to select potential controls, thus ensuring that the controls did indeed 
come from the population that gave rise to the cases. The response rate of potential 
controls was similar to that of cases and lay between 80.7% and 92.2%, since it is 
unlikely that everyone for whom eligibility status was not determined would have been 
eligible. 
It is possible that potential controls who died after the index date, or could not be traced 
or contacted, were less likely to have undertaken long-distance air travel because of 
illness or because they belonged to a lower socio-economic group. For instance, it is 
clear that some of the potential participants who died after the index date were suffering 
from serious medical conditions that were present before the index date (see Table 10.1 
in the previous chapter). The effect of any selection bias arising from the exclusion of 
such people, and the failure to trace other potential controls, should have been to 
weaken the association between air travel and pulmonary embolism. It appears, 
however, that the control group gave a reliable estimate of exposure in the population 
that gave rise to the cases, since the estimated number of arrivals based on the 
proportion of exposed controls was similar to the number of arrivals identified in 

















A potential source of bias in the present study is the use of proxy respondents for cases, 
but not for controls. The reasons for interviewing the controls, rather than their next of 
kin, were reviewed in the previous chapter. Several measures were employed to 
minimise any differential recall or knowledge between controls and the next of kin of 
cases. First, a life events calendar was sent to each participant and used during the 
interview to locate events in time as described in the previous chapter. Second, next of 
kin and controls were asked to check passports and other records before they answered 
questions about international air travel. Many cases and controls had never left New 
Zealand and hence there was no need to refer to records. It was also interesting to 
observe that for those who had undertaken one "trip of a life-time" or a "big overseas 
experience", and for those who had travelled rarely, the next of kin and controls 
appeared to have no difficulty in correctly recalling whether long-distance air travel had 
been undertaken during the relevant four-week period. Similarly, accurate recall did not 
appear to be difficult in situations where cases and controls undertook at least one 
international trip annually for work or family-related reasons, because travel was often 
undertaken at the same time each year. These people also appeared to habitually travel 
in the same class, request certain seating positions, and to use or not use hypnotics. The 
third measure to minimise differences in the information obtained for cases and controls 
was that the dates of hospital admissions were verified for both groups. Hence, it was 
possible to confirm admissions for surgery, major injury, pregnancy, and medical 
conditions during the three months before the index date. Finally, wherever possible, the 
next of kin with whom the cases had lived were interviewed and the reliability of the 
information provided by these relatives was tested by comparing it with data from other 
sources. 
Comparison of information obtained from next of kin with data from other sources 
All long-distance flights reported by next of kin were confirmed by medical and death 
records and existing records did not identify any flights that were not also reported by 
next of kin. The dependability of information provided by next of kin about other risk 
factors for venous thromboembolism was also examined by comparing it with 
information from existing records (Tables 11.11 - 11.15). From Table 11.11 it appears 
that the next of kin were a reliable source of information about the use of oral 




















Further support for this view is provided by the adjusted odds ratios for these risk 
factors ( as reported in Table 11.10) which are remarkably consistent with the findings of 
the case-control study described in Chapters 4 - 6 and with the results of other research 
(Walker et al. 1997; Zomberg and Jick 2000; Vandenbroucke et al. 2001). In contrast, 
it appears that the next of kin were not a good source of information about hormone 
replacement therapy and that some users were misclassified as non-users. This might be 
one explanation for the absence of an association between hormone replacement therapy 
and fatal pulmonary embolism where one would be expected. Alternatively, the 
observed socio-economic and educational differences between cases and controls (more 
cases in the lower socio-economic groups and fewer with tertiary education) may also 
have played a part - since hormone replacement therapy was used more often in the 
1990s by New Zealand women with higher levels of education and income (North and 
Sharples 2001). It is also possible that while the medical records indicated that 
hormone replacement therapy was prescribed, the next of kin knew that the prescription 
was not taken to the pharmacy, or that the dispensed medication was not taken. 
Next of kin identified more cases who had been immobilised for a prolonged period in 
the three months before the index date than did existing records. This is not surprising 
since it is possible to be confined to bed or a chair for more than a week without such 















Table 11.11 Presence of risk factors for venous thromboembolism in the three months before 
the index date, comparison of information obtained from existing records and from next of kin 
Information from existing records Information from next of kin 
Yes No Don't know Other 
Taking oral contraceptive (n=58)* 
Yes 17 2 1 1 ("minipill") 
No 29 3 
Possibly 1 
Progestogen-only pill 2 
Depo medroxyprogesterone acetate 1 
General practice records lost, no reference to 1 
contraceptive methods in hospital records 
Taking hormone replacement therapy (n=58) t 
Yes 4 4 1 
No 48 1 
Taking antipsychotic medication (n=88)* 




Prolonged immobility (n=88) 
Yes 3 
No 1 80 
Record of hospital admission and reduced 4 
mobility 
* This information was obtained in response to a specific question about the use of oral contraceptives in the three months before the index 
date. 
t This information was obtained in response to a specific question about hormone replacement therapy in the three months before the index 
date. 
* This information was obtained in response to questions about the use of medications ( other than oral contraceptives and hormone 
















Table 11.12 compares the data obtained from existing records with the information 
provided by next of kin about previous venous thromboembolism events. As was 
explained in the previous chapter, all those who had a history of treatment for 
superficial, deep, or unspecified venous thrombosis, or for pulmonary embolism, were 
classified as having a history of venous thromboembolism. Using this approach, only 
two cases who had a recorded history of deep vein thrombosis or pulmonary embolism 
were not identified by next of kin as having a history of venous thromboembolism. 
Perhaps not surprisingly, since it is a less serious event, only seven of the 17 cases with 
a recorded history of superficial venous thrombosis were reported by next of kin to have 
had a blood clot in the legs. The effect of classifying some cases of superficial venous 
thrombosis as having a history of venous thromboembolism appears to have had little 
impact on the estimates of relative risk of fatal pulmonary embolism in people with a 
history of venous thromboembolism; the adjusted odds ratios for a history of venous 
thromboembolism in the present study were consistent with previous research (Samama 
and the Sirius Study Group 2000). This classification did, however, contribute to a loss 
of power in analyses from which people with a history of venous thromboembolism 
were excluded . 
Table 11.13 compares the data obtained from existing records with the information 
provided by next of kin about a family history of venous thromboembolism. The next 
of kin identified more cases with a family history of venous thromboembolism than did 
existing records. This is not unexpected since family members are likely to possess 
more complete information. It is surprising however, that the adjusted odds ratio for a 
family history of venous thromboembolism was not elevated. 
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Table 11.12 History of venous thromboembolism event, comparison of information obtained from existing records and from next of kin 
Information from existing records 
History of venous thromboembolism 
event 
Superficial venous thrombosis only 
Deep vein thrombosis, no pulmonary 
embolism 
Pulmonary embolism, with or without 
venous thrombosis 
No venous thrombosis or pulmonary 
embolism 
Blood clot in leg, 
not known whether 




Blood clot in leg, 





* These cases were classified as having a history of venous thromboembolism in the case-control study. 
Information from next of kin 
Blood clot in leg, 





embolism, with or 
without venous 
thrombosis 
Don't know whether had 





























Table 11.13 Family history of venous thromboembolism, comparison of information obtained 
from existing records and from next of kin 
Information from existing records Information from next of kin 
Family history of venous thromboembolism Yes No 
Yes 3 2 





















In Tables 11.14 and 11.15, the information obtained from necropsy reports ( or other 
records in the absence of such information) about BMI is compared with information 
provided by next of kin. Table 11.14 compares information about the 61 cases for 
whom weight and height estimates were provided by next of kin, while Table 11.15 
compares information about the 26 cases for whom the BMI category was assigned 
using the narrative comments made by next of kin about weight in relation to height. 
The case whose relative did not wish to provide weight information was observed at 
necropsy to be a "normal weight". As can be seen in the tables, some pathologists did 
not measure the weight and height of cases and instead simply made comments, some of 
which were not particularly informative about body size. For example, some of the 
cases who were described by pathologists as being "well-nourished" were reported by 
their relative to be underweight, while others were reported to be a normal weight, 

























Table 11.14 BMI calculated from weight and height reported by next of kin of 61 cases, 
compared with information obtained from existing records 
BMI category based on information BMI category calculated from weight and height reported by 
from existing records next of kin 
Underweight Normal weight Overweight Obese 
(n=3) (n=22) (n=13) (n=23) 
BMI calculated from weight and height 
measured at necropsy (n=35) 
Normal weight 3 8 
Overweight 4 1 2 
Obese 3 5 9 
Comments at necropsy (n=21) 
"Diminutive" 1 
"Lean" 1 
"Medium build" 1 
"Well-nourished" 1 1 1 
"Solid build" 1 
"Very heavily built" 1 
"Overweight" 1 
"Slightly obese" 1 
"Moderate central obesity" 1 
"Moderate obesity" 2 2 
"Obese" 1 1 2 
"Hugely or markedly obese" 2 
No information from necropsy, but 
information from other records (n=l) 
Obese 1 
No information from necropsy, or from 1 1 
other records (n=2) 
No necropsy, but information frQm other 
records (n=2) 
Obese 1 1 
























Table 11.15 BMI category reported by next of kin of 26 cases, compared with information 
obtained from existing records 
BMI category based on Next of kin reported that for height case was: 
information from existing Underweight About right Overweight (n=13) 
records (n=4) weight (n=9) 
No additional Additional comments 
comments indicated was obese 
(n=8) (n=5) 
BMI calculated from weight 
and height at necro12sy (n=lO} 
Normal weight 1 
Overweight 1 1 
Obese 1 3 3 
BMI category assigned from 
weight at necro12sy (n=l} 
Obese 1 
Comments at necro12sy (n=lO} 
"Average build" 1 
"Well-nourished" 1 1 
"Moderately heavily built" 1 
"Moderately overweight" 1 
"Tall, rather obese" 1 
"Obese" 1 1 
"Grossly obese" 1 1 
No information from 
necro12sy, but information 
from other records (n=2} 
Underweight 1 
Overweight 1 
No necronsy, but information 
from other records (n=2} 
Overweight 1 1 
No necronsy, and no 1 
information from other 
records (n=l} 
























To obtain an estimate of BMI for cases whose weight or height was not measured at 
necropsy, as well as those who did not have a necropsy, other records were searched to 
find the most recent weight and height measurements. If a measurement was found for 
only one of these variables, then sex and age-specific data from the 1997 New Zealand 
National Nutrition Survey (Russell et al. 1999) were used to replace the missing 
variable. For instance, if there was a record of weight, but not height, for a 21 year old 
female case, then the mean height of women aged 19 - 24 years in the National 
Nutrition Survey was used to estimate BMI. If there was some indication in the records 
that the woman was short or tall, then the lower and upper quartile values respectively 
were used instead of the mean. 
This investigation revealed that there were 40 cases for whom the BMI category derived 
from next of kin information differed from that derived from existing records; the BMI 
of 37 of these cases was underestimated by their relatives (Table 11.16). Some of this 
apparent misclassification can be attributed to the fact that next of kin were only 
presented with three possible narrative responses ("about right", "overweight", or 
"underweight") to the question about weight in relation to height ( although they were 
given the opportunity to make additional comments). Moreover, several cases only just 
scraped into a BMI higher category. These issues aside, it appears that many next of kin 
simply misjudged the weight and height measurements of their relative such that the 
BMI was underestimated. This would be a problem if controls had accurately reported 
their weight and height. However systematic underestimation of self-reported weight 
has been observed (Spencer et al. 2002), and hence it is possible that the BMis of the 
controls were also underestimated. 
Nonetheless, it was decided to re-examine the association between long-distance air 
travel and fatal pulmonary embolism using a conservative scenario in which the BMI 
category of the above 40 cases was reclassified based on information from existing 
records, as shown in Table 11.16. In addition, the case whose next of kin did not 
answer the weight questions was classified as "normal weight" on the basis of existing 
data. In this analysis, the BMI categories of the remaining 47 cases and those of the 
controls remained unchanged. Following the reclassification, only one case was left in 






















combined to form the reference category for BMI. The odds ratio (adjusted for a history 
of venous thromboembolism, for the BMI category ["underweight / normal", 
"overweight", "obese"], and for prolonged immobility, any hospital admission owing to 
a medical condition, oral contraceptive, or antipsychotic use in the three months before 
the index date) for a flight of at least three hours' duration was 1.1 (95% CI 0.2 - 5.0) 
compared with the original estimate of 1.8 (95% CI 0.5 - 7.1). For flight times of more 
than eight hours, the adjusted odds ratio was 5.5 (95% CI 0.6- 50.8) as compared with 
7.9 (95% CI 1.1 - 55.1) in the original analysis. A second sensitivity analysis was 
undertaken in which BMI was treated as a continuous variable. After correcting for the 
misclassification discussed above, the odds ratio (adjusted for a history of venous 
thromboembolism, for BMI as a continuous variable, and for prolonged immobility, any 
hospital admission owing to a medical condition, oral contraceptive, or antipsychotic 
use in the three months before the index date) for air travel of more than eight hours was 
6.1 (95% 0.9 -42.5). Thus, the misclassification of BMI among the cases (assuming no 
misclassification among controls) did not have an appreciable impact on the estimated 




















Table 11.16 Reassignment of BMI category for sensitivity analysis 
BMI category based on information 
from next of kin* 
Reassigned BMI category based on Number of cases (n=41) 





















* The BMI was calculated from weight and height estimates if provided, otherwise the BMI category was assigned based on the response to 
the question about weight in relation to height. 
t Necropsy, hospital, general practice, family planning, and mental health records. 
* BMI < 20.0 kg/m2 
§ BMI 20.0 - 24.9 kg/m2 
II BMI 25.0- 29.9 kg/m2 



















In summary then, recall bias seems an unlikely explanation for the observed association 
between long-distance air travel and the risk of fatal pulmonary embolism for several 
reasons. First, the use of passports and other records to confirm travel details helped to 
ensure that accurate information about air travel by cases and controls as far back as 
1990 was obtained. Second, since hospital admissions were verified, it was possible to 
confirm the presence of several major risk factors for venous thromboembolism in the 
three months before the index date for both cases and controls. Third, next of kin 
appeared to be a reliable source of information about most other risk factors for venous 
thromboembolism. Fourth, although next of kin tended to underestimate the body size of 
their relative, sensitivity analyses showed that this had only a small effect on the observed 
association betweenJong-distance air travel and fatal pulmonary embolism. Finally, the 
relative risk estimates for most established risk factors for venous thromboembolism in 
the present study were in keeping with the results of earlier research (Rosendaal 1999a; 
Goldhaber 2004), which would tend to suggest that recall bias did not play a meaningful 
role. 
Interviewer bias 
Obviously the nurse interviewer and I always knew whether we were interviewing a 
next of kin or a control, however the administration of a standardised computer-assisted 
telephone interview and ongoing supervision of the nurse interviewer minimised any 
potential for interviewer bias. We both undertook interviews with similar proportions 
of next of kin and of controls. Next of kin and controls were not informed of the study 
hypothesis, nor were the controls told about the condition being studied until their 
interview was completed. The enquiries about air travel were made following questions 
about medical conditions and medicine use, so it is unlikely that participants would have 
identified this as the primary exposure of interest and modified their responses. 
11.2.2 Potential confounding 
Controls were matched to cases by sex, individual year of age, and electorate, and a 
matched analysis was undertaken. Hence, the observed association between air travel of 
more than eight hours' duration is not due to confounding by sex, age, or proximity to 
an international airport. Although there were temporal changes in travel patterns during 
the study period, such changes cannot explain the association because controls were 



















Concomitant drug use is also an unlikely explanation as the relative risk estimates were 
adjusted for the use of oral contraceptives and antipsychotic drugs in the three months 
before the index date. Since the use of aspirin did not differ between cases and controls, 
it was not included in the final model. Hormone replacement therapy was also excluded 
from the final model as its use by cases (as reported by next of kin) did not differ from 
controls. The use of anticoagulant drugs was not of concern as only one subject was 
taking one of these drugs. 
The relative risk estimates were also adjusted for BMI. As discussed above, it appears 
that the BMI category of a substantial proportion of the cases was misclassified. While 
the significant association between air travel and fatal pulmonary embolism remained 
when the BMI of the cases was reclassified correctly, it is not possible to rule out some 
residual confounding by BMI since it is not known to what degree the BMI of the 
controls was also misclassified. 
Confounding by an underlying medical condition is unlikely since individuals with 
cancer or a history of surgery or pregnancy in the three months before the index date 
were excluded, and the relative risk estimates were adjusted for a history of venous 
thromboembolism, and for prolonged immobility, and any hospital admissions owing to 
a medical condition in the three months before the index date. It was decided to adjust 
for a history of venous thromboembolism, a hospital admission, and prolonged 
immobility rather than excluding subjects with these risk factors, to avoid the loss of 
power inherent in excluding subjects. Because the study was confined to cases that 
occurred before widespread publicity about a possible link between air travel and 
venous thromboembolism, there was no reason to suppose that people with a history of 
venous thromboembolism would have been less likely to undertake long-distance air 
travel than those without such a history. Hence, the inclusion of these people should not 
have introduced a bias. While it is conceivable that people who had been unwell in the 
three months before the index date might have been less likely to travel during the four 
weeks leading up to the index date, the point estimate that was obtained when such 
people (and those with a history of venous thromboembolism) were excluded was 















11.2.3 Consistency with other studies 
The finding in the present study that long-distance flight is associated with a increased 
risk of fatal pulmonary embolism is consistent with most previous analytical studies of 
non-fatal events (Ferrari et al. 1999; Arya and Cohen 2003; Martinelli et al. 2003; 
Schwarz et al. 2003; Becker et al. 2006; Cannegieter et al. 2006), although a few 
studies found no such increase (Kraaijenhagen et al. 2000; Hosoi et al. 2002; ten Wolde 
et al. 2003). 
Sensitivity analyses suggested that the omission of 10 eligible cases and the 
misclassification of BMI, might have led to a slight overestimation of the true risk of 
fatal pulmonary embolism in recent air travellers. Conversely, other factors may have 
operated to produce a conservative estimate of risk Nonetheless, the magnitude of the 
increased risk in the present research is similar to that initially reported in a population-
based case-control study in the Netherlands and a record-linkage case-crossover study 
in Western Australia (Rosendaal 2002; Kelman et al. 2003). In the first MEGA study 
analysis, based on 829 cases and 829 controls, air travel in the two months before the 
index date was associated with a six-fold increased risk of non-fatal venous 
thromboembolism (odds ratio 5.8 [95% CI 2.0 - 16.6]) (Rosendaal 2002). This risk was 
attenuated in a later analysis based on 1,906 cases and 1,906 controls (odds ratio 3.0 
[95% CI 1.3 - 7.1]) (Cannegieter et al. 2006), although confounding by factors such as 
BMI and the factor V Leiden mutation was not accounted for in this estimate. Moreover, 
although the researchers reported that the risk of venous thromboembolism was greatest 
during the first week after a flight, they only reported odds ratios for an eight-week period 
following travel. It is possible, therefore, that the true relative risk of flight-related 
venous thromboembolism was underestimated. The Western Australian investigators 
also reported a declining risk with increasing time since travel. In their first analysis, 
the relative risks of venous thromboembolism in the first and second weeks after flying 
were 5.61 (95% CI 3.94- 7.97) and 2.63 (95% CI 1.55 -4.45) respectively, and the risk 
was not elevated after a 14-day period. In their later analysis, which included both 
Australian and non-Australian citizens and accounted for ageing over the study period 
and time spent outside Australia, there was a 30-fold increased risk that a venous 
thromboembolic event would be triggered on the day of an international flight (relative 
risk 29.8 [95% CI 22.4 - 37.3]). This risk decreased quite rapidly with time so that the 

















and second weeks following an international flight were 3.84 and 1.94 respectively. All 
of the flight-related cases in the present study developed symptoms of venous 
thromboembolism within eight days of a journey of more than eight hours' duration. 
Sensitivity analyses, which explored the potential impact of the omission of 10 eligible 
cases and the misclassification of BMI, suggested that the true risk of fatal pulmonary 
embolism in recent air travellers might have been marginally lower than estimated. 
There is evidence to suggest that flight-related venous thromobembolism is more likely 
to occur in passengers with other risk factors such as thrombophilic mutations 
(Martinelli et al. 2003; Cannegieter et al. 2006), a history of venous thromboembolism 
(Paganin et al. 2003) or cardiac disease (Paganin et al. 2003), varicose veins (Paganin et 
al. 2003), obesity (Paganin et al. 2003; Cannegieter et al. 2006), being very short or very 
tall (Cannegieter et al. 2006), a history of recent injury (Paganin et al. 2003), and the use 
of oral contraceptives (Martinelli et al. 2003; Cannegieter et al. 2006). 
In the present research it was initially planned, and ethical approval was obtained, to 
determine whether the cases on whom necropsies had been performed had the factor V 
Leiden mutation and other prothrombotic mutations by obtaining pathological 
specimens (small paraffin-imbedded tissue blocks or slides) from the pathologist 
responsible for the necropsy. This work, which was to have been undertaken in the 
laboratory of Professor Robin Olds in the Department of Pathology at the University of 
Otago, proved to be feasible at a practical level but was abandoned for funding reasons. 
Similarly it would have been feasible to send buccal smears kits to the controls so that 
their thrombophilia status could also be determined. We were unable to examine the 
relative risk of fatal pulmonary embolism associated with air travel in other sub-groups, 
such as oral contraceptive users, since the number of cases was inevitably restricted by 
the size of the New Zealand population. 
11.3 SUMMARY AND IMPLICATONS 
These are presented in the next chapter. 
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CHAPTER12 SUMMARY AND IMPLICATIONS 
12.1 SUMMARY 
The research presented in this thesis explored the associations between fatal pulmonary 
embolism and three particular exposures: oral contraceptives, psychotropic drugs, and 
long-distance air travel. Mortality rates in users of oral contraceptives and in long-
distance air travellers were also estimated. These risks were examined in three inter-
related national population-based studies: a case-control study of the use of oral 
contraceptives and psychotropic drugs, a descriptive study of long-distance air travel, 
and a case-control study of long-distance air travel. The underlying study population 
for this research included all men and women aged 15 - 59 years, who died in New 
Zealand between 1990 and 2000, for whom the underlying cause of death was 
pulmonary embolism. 
12.1.1 Oral contraceptives and fatal pulmonary embolism 
The present research was the first to have examined the association between oral 
contraceptives and fatal pulmonary embolism in a population in which preparations 
containing the progestogens desogestrel and gestodene were widely used. Compared 
with non-users, in several analyses women prescribed oral contraceptives in the three 
months before the index date had a 10-fold increased risk of fatal pulmonary embolism. 
In an analysis which excluded women who were post-menopausal or had a history of 
venous thromboembolism, as well as those who were immobilised or pregnant in the 
two months before the index date, the adjusted odds ratio was 13.1 (95% CI 4.4 - 39.0). 
In accordance with previous studies of non-fatal events, formulations containing 
desogestrel and gestodene carried a higher risk than levonorgestrel products; the 
adjusted odds ratios were 18.8 (95% CI 4.9 - 71.3) and 5.9 (95% CI 1.4 - 25.6) 
respectively. Moreover, pills containing cyproterone acetate were associated with a 
higher risk again; the adjusted odds ratio was 20.1 (95% CI 4.4 - 91.4). The absolute 
risk of death from idiopathic pulmonary embolism in oral contraceptive users was 















12.1.2 Psychotropic drugs and fatal pulmonary embolism 
Earlier studies had found associations between current use of conventional 
antipsychotics and non-fatal venous thromboembolism and current use of an atypical 
agent (clozapine) and fatal events. The present research, however, was the first to have 
estimated the relative risk of fatal pulmonary embolism in current users of conventional 
antipsychotics. Taking non-users as the reference category, people prescribed 
antipsychotic drugs in the three months before the index date had a 13-fold increased 
risk of fatal pulmonary embolism (adjusted odds ratio 13.3 [95% CI 2.3 - 76.3]). Low-
potency antipsychotics carried a 20-fold increase in risk (adjusted odds ratio 20.8 [95% 
CI 1.7 - 259.0]), with thioridazine being the main drug involved. Antidepressant use 
was also associated with a significantly increased risk (adjusted odds ratio 4.9 [95% CI 
1.1 - 22.5]). 
12.1.3 Long-distance air travel and fatal pulmonary embolism 
Previous studies which examined the association between air travel and venous 
thromboembolism were all confined to non-fatal events. Hence, this was the first study 
to estimate the relative risk of dying from pulmonary embolism following a long-
distance flight and the estimates were of the same order of magnitude as previously 
reported for non-fatal venous thromboembolism. People who had undertaken a flight of 
more than eight hours' duration were eight times more likely to suffer a fatal-pulmonary 
embolic event than non-travellers; the adjusted odds ratio was 7.9 (95% CI 1.1 - 55.1). 
The odds ratio for a flight of at least three hours' duration was 1.8 (95% CI 0.5 - 7.1). 
These results were consistent with the findings of the descriptive study of long-distance 
air travel in which, allowing for a "healthy traveller effect", the sex and age-adjusted 
mortality rate from pulmonary embolism was about six times higher for overseas 
visitors to New Zealand (most of whom would recently have undertaken long-distance 
flights) than the rate in the resident population of New Zealand (very few of whom 
would recently have flown long-distance). 
In absolute terms, the risk of dying from pulmonary embolism after a long-distance 
flight appears to be very low. The absolute risks in people aged 15 - 59 years following 
a flight of at least three hours' duration were 0.5 (95% CI 0.2 - 1.2) and 0.6 (95% CI 0.2 


















The risk in New Zealand residents following a flight of more than eight hours was 1.3 
(95% CI 0.4 - 3.0) per million arrivals. 
12.1.4 Other risk factors and fatal pulmonary embolism 
In the case-control studies, a previous history of venous thromboembolism, superficial 
venous thrombosis, obesity, a chronic musculoskeletal condition of the lower limbs, 
prolonged immobility, a hospital admission owing to a medical condition, hormone 
replacement therapy, and an intellectual disability were associated with an increased 
risk of fatal pulmonary embolism. 
12.2 IMPLICATIONS 
12.2.1 The methods 
There were both advantages and challenges to undertaking the present population-based 
research in New Zealand. Some of these factors, which will be discussed below, have 
implications for the conduct of any epidemiological research in this country, while 
others are more related to the specific associations which were investigated . 
The main challenge to undertaking epidemiological research in New Zealand is the size 
of the population - at the end of the study period there were just under four million 
people living in the country. This inevitably requires a careful consideration of the 
outcomes and exposures which can feasibly be studied here and of the appropriate study 
design for the research question. With regards to venous thromboembolism and oral 
contraceptives containing desogestrel and gestodene, New Zealand had the highest 
proportionate use of these preparations in the world and, as such, this provided both an 
opportunity and a responsibility to undertake the research described in Part II of this 
thesis. Nevertheless, the small sample size meant that there was limited power for 
comparing the risks associated with different oral contraceptive formulations. 
New Zealand is an island nation which is relatively geographically isolated. This had 
two main advantages with regards to the research described in this thesis. First, the 
population was well-defined, which is a fundamental requirement for undertaking any 



















people arriving in New Zealand do so by air provided a unique opportunity to explore 
the potential association between long-distance air travel and fatal pulmonary 
embolism. Moreover, all persons entering and leaving the country are required to 
complete reasonably detailed arrival and departure cards, and thus reliable denominator 
data were available for the estimation of absolute risks of fatal pulmonary embolism in 
long-distance air travellers. In relation to future population-based studies, the well-
defined nature of the New Zealand resident population is unlikely to change - indeed, 
recent international security concerns have ensured that strict immigration checks and 
border controls will probably continue. 
The topography of New Zealand also presented some challenges. Because the 
population is scattered over two main islands, the hospitals, general practices, and 
family planning clinics which the cases attended were also widely dispersed. This, 
combined with poor air and road links to some areas, inevitably meant that a lot of time 
(and money) was spent travelling to undertake the research. For example, a full day of 
combined air and car travel was required to reach the general practices of several cases. 
Incidentally, the visits to these general practices were especially interesting from the 
perspective of health services provision and, possibly because of their isolation, the 
general practitioners appeared particularly willing to participate in the research. 
In the future, it is possible that advances in information technology and the increasing 
use of computers to record clinical information will mean that it is not always necessary 
to physically visit general practices in order to examine records and, for instance, to 
select controls. A promising precedent in this regard is the safety monitoring 
undertaken by the New Zealand Pharmacovigilance Centre of a new meningococcal B 
vaccine, in which an automated system abstracted data from the electronic records of 
children attending practices that were using MedTech32 practice management software . 
Indeed, an exciting possibility exists to establish a similar system to the UK GPRD in 
New Zealand, both to monitor drug safety and to undertake other public health research. 
Certainly the current population size of New Zealand is very similar to the number of 
patients enrolled in the UK database. 
Nonetheless, there may well be future research projects which still require general 
















information directly into an electronic questionnaire rather than transcribing it onto 
paper data abstraction forms, since the latter are not only cumbersome to transport, but 
they also require a second stage of data entry. The Abbey CA TI® software could easily 
be employed for such a task. 
Apart from geographical barriers to obtaining information, there were a number of other 
factors which either aided or impeded access to the required data. Ethical approval for 
the research was sought on two occasions - first for the case-control study of the use of 
oral contraceptives and psychotropic drugs and then for the descriptive and case-control 
studies of long-distance air travel. When these studies were initiated, it was necessary 
to obtain ethical approval from 12 regional ethics committees in order to undertake a 
national study. This was inevitably time consuming and, at times, frustrating - for 
example, when different committees proposed conflicting conditions for ethical 
approval. Moreover, it appeared from some of the comments which were received, that 
the committees in some areas had no members who were familiar with observational 
epidemiological research. Fortunately, however, this situation has now changed with 
the advent of a multi-region ethics committee which considers all proposals for national 
studies. In addition, the National Ethics Advisory Committee, which was established 
under the New Zealand Public Health and Disability Act 2000, has recently published 
guidelines for the conduct of observational studies (National Ethics Advisory 
Committee 2006) . 
Once ethical approval was obtained, the official mortality data were very promptly 
provided by the New Zealand Health Information Service. However, because of 
considerable delays in the provision of information by coroners, the most recent data 
that could be obtained related to deaths three years earlier. This situation should 
hopefully be improved with the recent passing of the Coroners Act 2006, under which a 
new position of Chief Coroner has been established and up to 20 full-time coroners will 
replace the 55 mostly part-time coroners who were working previously (Coronial 
Services of New Zealand 2007). 
During the 1990s, and subsequently, the New Zealand health system underwent an 
unprecedented number of structural and philosophical reforms, several of which had an 












the traditional model of having medical superintendents and nursing matrons towards a 
more corporate style of management. Consequently, although all letters which sought 
permission to view the hospital records of cases were sent to Senior Medical Advisors, 
and in spite of the fact that all regional ethics committees had given ethical approval for 
hospital records to be examined, managers at several hospitals required that various 
committees and legal advisors of their own considered the research (at length) before 
allowing access to the records. This was particularly noticeable in the larger centres. 
By contrast, in smaller hospitals in which clinicians were still involved in management, 
there were fewer delays in granting permission. 
There were also changes in primary care which had an impact on the research. For 
instance, in the 1990s there was a move away from the traditional small-business model 
of general practice towards other models such as fund-holding practices, union health 
centres, Maori-led services, nurse and midwife-run family planning clinics, and 24-hour 
primary care emergency and accident centres. In addition, increasing numbers of 
doctors left general practice and decreasing numbers of New Zealand-trained doctors 
entered - as a result, a few of the practices which were visited had been staffed by a 
succession of overseas-trained long-term locums. Some of these new providers 
appeared unfamiliar with the system of ethical review and the legitimacy of research 
based in general practice, and were thus initially uncertain about allowing access to 
medical records. Furthermore, several general practitioners complained that they felt 
overwhelmed by increasing amounts of paperwork which was unrelated to patient care. 
Until they were reassured that they would not be required to abstract any data 
themselves, these doctors were reluctant to participate in the research. This underlines 
the importance of continuing to develop research methods, such as automated data 
abstraction, which do not require any effort on the part of general practitioners. 
A more recent development in general practice which has positive implications for 
future research is the establishment of Primary Health Organisations as part of the 
Primary Health Care Strategy (Ministry of Health 2007). These organisations are 
funded to provide primary health care for enrolled populations and their existence will 
hopefully make it easier to identify the general practitioners of potential cases in future 
studies. Moreover, it is possible that they might prove to be an efficient means of 











hoped that the requirement to obtain basic demographic data about enrolled patients will 
ensure that accurate ethnicity data is recorded in medical records and hence the dismal 
lack of ethnicity information encountered in this research will not be an issue in the 
future. 
Several problems relating to the storage of medical records were encountered during the 
course of the research. Some of the larger hospitals sent old files to off-site storage 
facilities and it proved time-consuming to obtain these records. On the other hand, the 
storage of records on hospital premises was no guarantee that records would be easily 
accessible - in several hospitals the filing systems appeared quite disorganised. Also 
of concern was the fact that while several hospitals kept inpatient records for at least 10 
years, they destroyed emergency department records much earlier. It is to be hoped that 
the increasing use of electronic records in hospitals, especially in emergency 
departments, will prevent this loss of information in the future . 
In general practice, it was surprising to find that some doctors had no idea about how 
long they were legally required to keep records. Moreover, the approaches to archiving 
records varied considerably. In some practices, for example, the records of patients who 
had died or left the practice were filed systematically by name or year of death, whereas 
in others they were placed in boxes in no particular order or simply tied up with string 
and then left in ceiling spaces, basements, or even garden sheds. The worst example of 
this was a practice which had locked the old records in a shed and subsequently lost the 
key. A locksmith was called to open the shed, whereupon it was found that not only 
had a hive of bees established itself in the wall, but many records had been partially 
eaten by rats. It was also worrying that in the instance of the abandoned practice there 
was no health service or agency which was prepared to take responsibility for storing 
the records. While developments in information technology may mean that such issues 
are less likely to be encountered in future studies, the problems met in the present 
research (the deletion of some electronic files, outdated customised computer software, 
and the use of now defunct 5Y2 inch floppy disks) should also sound a note of caution 
about the need for considerable thought regarding the most appropriate way to save 
electronic records. Moreover, in the absence of any appropriate repository external to 














lost even more easily than paper files when practices upgrade their computer systems or 
a practice closes down. 
The descriptive and case-control studies of long-distance air travel, and other case-
control studies previously undertaken in the Department of Preventive and Social 
Medicine, show that it is possible to attain very high response rates when such 
investigations are undertaken in New Zealand. Of particular note in the current work, 
was the positive response of the next of kin. Several people explicitly stated at the 
outset that they were pleased the research was being undertaken and most next of kin 
wished to receive a summary of the results. At the conclusion of the study, several 
relatives also wrote to thank us for carrying out the investigation. Given that some of 
the regional committees which gave approval for the present research were initially very 
concerned about the proposal to interview next of kin, it might be helpful to describe 
this positive experience when applying for ethical approval of any future study which 
requires contact with relatives. 
A high response rate was also achieved among potential controls, with only about 7% 
directly declining to take part in the study. Moreover, 92% of those included in the final 
analyses wanted to be sent a summary of the findings . 
Unfortunately, there are several potential threats to achieving such high participation 
rates in future studies. First, there is no population register which includes all children 
and adults living in New Zealand. The most complete source of information about the 
population aged 18 years and over is the electoral roll. However, because the New 
Zealand population is increasingly mobile, any copies of the roll which are obtained 
from the Electoral Enrolment Centre rapidly become out of date. For example, before 
sending out a summary of the research findings (Appendix A, letters 26 and 27), the 
contact details of study participants were updated using a recent version of the roll. 
Nonetheless, a surprising number of letters were returned because people had already 
shifted from their listed addresses. Given that there is a considerable fee attached to 
obtaining electronic copies of the electoral roll, it is not practicable to receive regular 
updates. Second, the low response rate to the letters which were sent during the present 
research highlights the importance of being able to contact potential study participants 












numbers, this is likely to become more difficult in the future. Third, the increasing 
trend towards telemarketing also poses a threat - indeed, one or two of the people who 
declined to take part in the research expressed annoyance at being bothered by 
unsolicited telephone calls. In this context, it will be even more important than ever to 
send letters to potential participants before attempting to telephone them. Fourth, in the 
present research, considerable use was made of the Births, Deaths, and Marriages 
Registry records - for example, to identify additional next of kin of cases and to 
establish whether people who could not be traced had died or changed their names. 
There is currently a bill before a Parliamentary Select Committee, the Births, Deaths, 
Marriages, and Relationships Registration Amendment Bill, which, among other 
changes, proposes to restrict public access to registered information about other 
individuals. At present, the proposed amendments would allow access to such records 
for health research provided that the Registrar-General is "satisfied that benefit to the 
public of allowing the information to be obtained outweighs the effect on individual 
privacy" (Births, Deaths, Marriages, and Relationships Registration Amendment Bill 
2006). If the amendment is passed, it is to be hoped that this statement will be 
interpreted in such a way as to permit continued access to information for 
epidemiological studies which have ethical approval. 
12.2.2 The results 
Oral contraceptives and venous thromboembolism 
The voluntary system for reporting adverse drug reactions in New Zealand fulfilled its 
primary role by providing an early warning of an excess number of deaths from 
pulmonary embolism among women taking oral contraceptives containing desogestrel 
and gestodene. However, the finding that only about a third of the total number of 
pulmonary embolism deaths among oral contraceptive users were reported to the Centre 
for Adverse Reactions Monitoring highlights the major limitation of such spontaneous 
reporting systems and reinforces the need to follow up so-called "safety signals" with 
systematic ascertainment of adverse reactions in users of medicines. 
Following the publication of the analysis of oral contraceptive use and fatal pulmonary 
embolism (Parkin et al. 2000), the Ministry of Health held a press conference to 
















about the use of oral contraceptives containing desogestrel and gestodene. The Ministry 
also sent this information to doctors, midwives, and pharmacists along with copies of 
up-dated patient information leaflets which included a toll-free telephone number that 
women could ring for further information (Medsafe 2000). The letter to the health 
professionals also criticised two publications mentioned in Chapter 4 for being 
"misleading and inaccurate" - these included an article by the spokeswoman for the 
Family Planning Association and a colleague (Egermayer and Roke 2000), reprints of 
which had been widely distributed to New Zealand doctors by a pharmaceutical 
company, and the letter from the New Zealand branch of the Australian and New 
Zealand College of Obstetricians and Gynaecologists to the New Zealand Medical 
Journal (New Zealand Committee RANZCOG 2000). 
Specific recommendations about oral contraceptives containing cyproterone acetate 
were made by the Ministry of Health after the publication of the Boston group's study 
based on the UK GPRD (Vasilakis-Scaramozza and Jick 2001). Prescribers were 
informed that these pills carried a similar, if not higher, risk of venous 
thromboembolism than formulations containing desogestrel and gestodene and were 
reminded that cyproterone acetate preparations were only indicated for use in New 
Zealand by women with androgen-dependent conditions and polycystic ovary 
syndrome, and for oral contraception in such women (Medsafe 2002). This advice was 
important, because although the market share of these pills was not high, it was 
increasing. Indeed, at that time cyproterone acetate preparations were being heavily 
promoted, almost as cosmetics, in magazines read primarily by young women. 
Psychotropic drugs and venous thromboembolism 
In 2001, restrictions were placed on the prescription of thioridiazine, the antipsychotic 
which was primarily implicated in the present research (Medsafe 2001b). Because of 
concerns about the increased risk of fatal arrhythmias, the initiation of thioridazine 
therapy was restricted to psychiatrists and the drug was to be used as third-line therapy 
only. Later, in July 2005, supplies of thioridazine were discontinued by one of the two 
pharmaceutical companies which supplied the drug in New Zealand (Medsafe 2005). 
With regards to the excess risk of venous thromboembolism in current users of other 


















with psychotic disorders. For example, total mortality from all causes has been shown 
to be lower in schizophrenics who are current users of clozapine than in former users, 
mostly due to a striking reduction in deaths from suicide (Walker et al. 1997). In 
patients aged 10 - 54 years, the standardised mortality rate for suicide among past users 
of clozapine was 222 per 100,000 person-years, whereas the rate of fatal pulmonary 
embolism in current users was only 30 per 100,000 person-years. Thus, for most people 
with psychotic illnesses (even those with major risk factors for venous 
thromboembolism) it is clearly inappropriate to place restrictions on the prescription of 
antipsychotic medicines in the hope of preventing venous thromboembolism. Instead, 
attention should be focussed on other primary and secondary preventive measures such 
as minimising immobilisation and avoiding delays in the diagnosis of venous 
thromboembolism. Because physical illness often goes unrecognised in people with 
psychiatric disorders (Licht et al. 1993; Hewer et al. 1995), it is important that 
prescribers and carers of people taking antipsychotics are especially vigilant with 
regards to possible signs and symptoms of venous thromboembolism. It is also vital 
that sudden deaths in users of antipsychotics are thoroughly investigated. 
One final comment can be made about the use of antipsychotic drugs - it would seem 
prudent to avoid prescribing antipsychotic medicines in situations in which they are not 
strictly indicated. One of the cases in the present research, for example, had been 
prescribed an antipsychotic drug for the treatment of simple insomnia. 
An association between antidepressant drugs and venous thromboembolism has not 
been described previously. If the association between these medicines and fatal 
pulmonary embolism is real, it needs to be established whether the drugs increase the 
risk of venous thromboembolism, or whether people with depression who develop the 
condition are simply more likely to die. Antidepressants are widely used, and further 
studies are required to clarify the association between these drugs and venous 
thromboembolism. To this end, I have initiated a record-linkage study, based on 
prescription and hospital discharge data, to further investigate the potential association. 
This method of studying medicine safety has not been explored in New Zealand and if the 
approach proves feasible, this will allow the investigation of potential adverse reactions 














Long-distance air travel and venous thromboembolism 
While this study confirmed that long-distance air travellers have a greater risk of dying 
from pulmonary embolism than non-travellers, it was reassuring to find that fatal events 
were rare in relatively healthy persons aged 15 - 59 years. Risks of the order of one in a 
million are much lower than recent publicity about the "economy class syndrome" has 
implied. 
Other risk factors and venous thromboembolism 
Finally, the observed association between intellectual disability and fatal pulmonary 
embolism warrants further investigation. It may be that people with such disabilities do 
indeed have a greater risk of venous thromboembolism, or conversely that such events 
are more likely to prove fatal because of delays in diagnosis and the initiation of 
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Letter 1: Sent to pathologists to request copies of Police 47 forms for women aged 15 - 49 
years who died from pulmonary embolism between January 1990 and August 1998 
Dear Dr ___ _ 
We have been contracted by the Ministry of Health to carry out a confidential study of deaths 
from pulmonary embolism in New Zealand women of child-bearing age. The aim of the 
study is to identify risk factors and possible means of preventing such deaths in the future. 
We are interested in documenting the clinical course of the fatal episode for each woman, 
including any symptoms of venous thromboembolism that she may have reported in the days 
and hours before death. In many cases we have found the narrative section of the Police 47 
form to be a valuable source of this information. In order to carry out the study, we also need 
to contact the usual general practitioner of each woman. 
We understand that an autopsy was performed at the request of the Coroner in ( name of 
mortuary) on the woman named on the enclosed sheet. You will see that we have indicated 
on the sheet what information we are seeking about this patient. We would be extremely 
grateful if you were able to send us this information in the enclosed reply-paid envelope. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. We will be taking particular care to safeguard confidentiality. 
We would greatly appreciate your help in this study, which could be important for the health 









Letter 2: Sent to pathologists to request copies of Police 47 forms for women aged 50 - 59 
years and men aged 15 - 59 years who died from pulmonary embolism between January 1990 
and December 1998, as well as women aged 15 -49 years who died between September and 
December 1998 
Dear Dr ___ _ 
Recently we conducted a confidential study of deaths from pulmonary embolism in New 
Zealand women of child-bearing age. A copy of our report is enclosed. This study has now 
been expanded to include men and women up to the age of 59 years. The aim of the study, 
which is supported by the Ministry of Health, is to identify risk factors and possible means of 
preventing such deaths in the future. 
We are interested in documenting the clinical course of the fatal episode for each patient, 
including any symptoms of venous thromboembolism that he or she may have reported in the 
days and hours before death. In many cases we have found the narrative section of the Police 
47 form to be a valuable source of this information. In order to carry out the study, we also 
need to contact the usual general practitioner of each patient. 
We understand that a necropsy was performed at the request of the Coroner in the ( name of 
mortuary) on the (man/woman) named on the enclosed sheet. You will see that we have 
indicated on the sheet what information we are seeking about this patient. We would be 
extremely grateful if you were able to send us this information in the enclosed reply-paid 
envelope. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. We will be taking particular care to safeguard confidentiality. 
We would greatly appreciate your help in this study, which could be important for the health 










Letter 3: Sent to pathologists to request copies of Police 47 forms for men and women aged 
15 -59 years who died from pulmonary embolism between January 1999 and December 2000 
Dear Dr ___ _ 
Recently we conducted a confidential study of deaths from pulmonary embolism in New 
Zealand men and women aged 15 -59 years, who died between 1990 and 1998. A copy of 
our report is enclosed. We have now expanded this study to include people who died in 1999 
and 2000. The aim of the study, which is supported by the Ministry of Health, is to identify 
risk factors and possible means of preventing such deaths in the future. 
We are interested in documenting the clinical course of the fatal episode for each patient, 
including any symptoms of venous thromboembolism that he or she may have reported in the 
days and hours before death. In many cases we have found the narrative section of the Police 
4 7 form to be a valuable source of such information. In order to carry out the study, we also 
need to contact the usual general practitioner of each patient. 
We understand that a necropsy was performed at the request of the Coroner in the ( name of 
mortuary) on the (man/woman) named on the enclosed sheet. You will see that we have 
indicated on the sheet what information we are seeking about this patient. We would be 
extremely grateful if you were able to send us this information in the enclosed reply-paid 
envelope. 
This study has received approval from all regional Ethics Committees, and meets the 
requirements of the Health Information Privacy Code. We will be taking particular care to 
safeguard confidentiality. 
We would greatly appreciate your help in this study, which could be important for the health 










Letter 4: Sent to a coroner to request a copy of a Police 47 form 
Dear ___ _ 
As discussed with you today, we have been contracted by the Ministry of Health to carry out a 
confidential study of deaths from pulmonary embolism in New Zealand women of child-
bearing age. The aim of the study is to identify risk factors and possible means of preventing 
such deaths in the future. 
We are interested in documenting the clinical course of the fatal episode for each woman, 
including any symptoms of venous thromboembolism that she may have reported in the days 
and hours before death. In many cases we have found the narrative section of the Police 47 
form to be a valuable source of this information. 
As I mentioned, we would be extremely grateful if you were able to send us a copy of the 
Police 47 form for (name of woman). 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. We will be taking particular care to safeguard confidentiality. 
We would greatly appreciate your help in this study, which could be important for the health 














Letter 5: Sent to senior medical advisors about women aged 15 -49 years who died from 
pulmonary embolism in hospital between January 1990 and August 1998 
Dear Dr ___ _ 
We have been contracted by the Ministry of Health to carry out a confidential study of deaths 
from pulmonary embolism in New Zealand women of child-bearing age. The aim of the 
study is to identify risk factors and possible means of preventing such deaths in the future. 
We understand that the patient listed on the enclosed sheet died from pulmonary embolism in 
(name of hospital) on (date). We would be extremely grateful for your help in obtaining the 
information we require. Initially we are seeking a copy of the front sheet from the medical 
records of this patient. We would also like to arrange for one of us (Dr Lianne Parkin) to visit 
your Hospital and examine the complete records at a later date. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. We will be taking particular care to safeguard confidentiality. 
We would greatly appreciate your help in this study, which could be important for the health 
of New Zealand women. Please could you initially send us a photocopy of the front sheet 
of this patient's case notes? We will then contact you by telephone to ask about a suitable 












Letter 6: Sent to senior medical advisors about women aged 15 -49 years who died from 
pulmonary embolism between January 1990 and August 1998, and who were admitted to 
hospital in the year before their death 
Dear Dr ___ _ 
We have been contracted by the Ministry of Health to carry out a confidential study of deaths 
from pulmonary embolism in New Zealand women of child-bearing age. The aim of the 
study is to identify risk factors and possible means of preventing such deaths in the future. 
We understand that the patient listed on the enclosed sheet was admitted to (name of hospital) 
in the year prior to her death from pulmonary embolism on (date). We would be extreme I y 
grateful for your help in obtaining the information we require. Initially we are seeking a copy 
of the front sheet of the medical records that relates to the last admission of this patient. We 
would also like to arrange for one of us (Dr Lianne Parkin) to visit your Hospital and examine 
the complete records at a later date. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. We will be taking particular care to safeguard confidentiality. 
We would greatly appreciate your help in this study, which could be important for the health 
of New Zealand women. Please could you initially send us a photocopy of the front sheet 
of this patient's case notes? We will then contact you by telephone to ask about a suitable 













Letter 7: Sent to senior medical advisors about women aged 50 - 59 years and men aged 15 -
59 years who died from pulmonary embolism in hospital between January 1990 and 
December 1998, as well as women aged 15 - 49 years who died in hospital between 
September and December 1998 
Dear Dr ___ _ 
Recently we conducted a confidential study of deaths from pulmonary embolism in New 
Zealand women of child-bearing age. A copy of our report is enclosed. This study has now 
been expanded to include men and women up to the age of 59 years. The aim of the study, 
which is supported by the Ministry of Health, is to identify risk factors and possible means of 
preventing such deaths in the future. 
We understand that the patient listed on the enclosed sheet died from pulmonary embolism in 
(name of hospital) on (date). We would be extremely grateful for your help in obtaining the 
information we require. Initially we are seeking a copy of the front sheet from the medical 
records of this patient. This is so that we can identify the patient's general practitioner. We 
would also like to arrange for one of us (Dr Lianne Parkin) to visit your Hospital and examine 
the complete records at a later date. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. We will be taking particular care to safeguard confidentiality. 
We would greatly appreciate your help in this study, which could be important for the health 
of New Zealanders. Please could you initially send us a photocopy of the front sheet of 
this patient's case notes in the enclosed reply-paid envelope? We will then contact you by 










Letter 8: Sent to senior medical advisors about women aged 50 - 59 years and men aged 15 -
59 years who died from pulmonary embolism between January 1990 and December 1998, as 
well as women aged 15 -49 years who died between September and December 1998, and 
who were admitted to hospital in the year before their death 
Dear Dr ___ _ 
Recently we conducted a confidential study of deaths from pulmonary embolism in New 
Zealand women of child-bearing age. A copy of our report is enclosed. This study has now 
been expanded to include men and women up to the age of 59 years. The aim of the study, 
which is supported by the Ministry of Health, is to identify risk factors and possible means of 
preventing such deaths in the future. 
We understand that the patient listed on the enclosed sheet was admitted to ( name of hospital) 
in the year before (his I her) death from pulmonary embolism on (date). We would be 
extremely grateful for your help in obtaining the information we require. Initially we are 
seeking a copy of the front sheet of the medical records that relates to the last admission of 
this patient. This is so that we can identify the patient's general practitioner. We would also 
like to arrange for one of us (Dr Lianne Parkin) to visit your Hospital and examine the 
complete records at a later date. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. We will be taking particular care to safeguard confidentiality. 
We would greatly appreciate your help in this study, which could be important for the health 
of New Zealanders. Please could you initially send us a photocopy of the front sheet of 
this patient's case notes in the enclosed reply-paid envelope? We will then contact you by 















Letter 9: Sent to senior medical advisors about men and women aged 15 - 59 years who died 
from pulmonary embolism in hospital between January 1999 and December 2000 
Dear Dr ___ _ 
You may remember that recently we conducted a confidential study of deaths from pulmonary 
embolism in New Zealand men and women aged 15 -59 years, who died between 1990 and 
1998. A copy of our report is enclosed. We have now expanded this study to include people 
who died in 1999 and 2000. The aim of the study, which is supported by the Ministry of 
Health, is to identify risk factors and possible means of preventing such deaths in the future. 
We understand that the patient listed on the enclosed sheet died from pulmonary embolism in 
(name of hospital) on (date). We would be extremely grateful for your help in obtaining the 
information we require. Initially we are seeking a copy of the front sheet from the medical 
records of this patient. This is so that we can identify the patient's general practitioner. We 
would also like to arrange for one of us (Dr Lianne Parkin) to visit your hospital and examine 
the complete records at a later date. 
This study has received approval from all regional Ethics Committees, and meets the 
requirements of the Health Information Privacy Code. We will be taking particular care to 
safeguard confidentiality. 
We would greatly appreciate your help in this study, which could be important for the health 
of New Zealanders. Please could you initially send us a photocopy of the front sheet of 
this patient's case notes in the enclosed reply-paid envelope? We will then contact you by 

















Letter 10: Sent to senior medical advisors about men and women aged 15 - 59 years who 
died from pulmonary embolism between January 1999 and December 2000, and who were 
admitted to hospital in the year before their death 
Dear Dr ___ _ 
You may remember that recently we conducted a confidential study of deaths from pulmonary 
embolism in New Zealand men and women aged 15 - 59 years, who died between 1990 and 
1998. A copy of our report is enclosed. We have now expanded this study to include people 
who died in 1999 and 2000. The aim of the study, which is supported by the Ministry of 
Health, is to identify risk factors and possible means of preventing such deaths in the future. 
We understand that the patient listed on the enclosed sheet was admitted to (name of hospital) 
in the year before (his I her) death from pulmonary embolism on (date). We would be 
extremely grateful for your help in obtaining the information we require. Initially we are 
seeking a copy of the front sheet of the medical records that relate to the last admission of this 
patient. This is so that we can identify the patient's general practitioner. We would also like 
to arrange for one of us (Dr Lianne Parkin) to visit your hospital and examine the complete 
records at a later date. 
This study has received approval from all regional Ethics Committees, and meets the 
requirements of the Health Information Privacy Code. We will be taking particular care to 
safeguard confidentiality. 
We would greatly appreciate your help in this study, which could be important for the health 
of New Zealanders. Please could you initially send us a photocopy of the front sheet of 
this patient's case notes in the enclosed reply-paid envelope? We will then contact you by 








Letter 11 Sent to locmns to enquire about the names of the general practitioners of women 
aged 15 -49 years who died from pulmonary embolism between January 1990 and August 
1998 
Dear Dr ----
We have been contracted by the Ministry of Health to carry out a confidential study of deaths 
from pulmonary embolism in New Zealand women of child-bearing age. The aim of the 
study is to identify risk factors and possible means of preventing such deaths in the future. 
We understand that on (date) whilst working in / for ( name of town I name of general 
practice), you attended the patient listed on the enclosed sheet who died from pulmonary 
embolism at (place of death). In order to carry out the study, we need to contact the usual 
general practitioner of this woman. We would be very grateful if you were able to write the 
name and address of this doctor on the attached sheet, and return this in the reply-paid 
envelope. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. We have a professional obligation of confidentiality as medical 
practitioners ourselves, and we give an undertaking that no information about any named 
patient or doctor will be provided to any other party. 
We would greatly appreciate your help in this study, which could be important for the health 



















Letter 12 Sent to locums to enquire about the names of the general practitioners of women 
aged 50 - 59 years and men aged 15 - 59 years who died from pulmonary embolism between 
January 1990 and December 1998, and of women aged 15 - 49 years who died between 
September and December 1998 
Dear Dr ___ _ 
Recently we conducted a confidential study of deaths from pulmonary embolism in New 
Zealand women of child-bearing age. A copy of our report is enclosed. This study has now 
been expanded to include men and women up to the age of 59 years. The aim of the study is 
to identify risk factors and possible means of preventing such deaths in the future. 
We understand that on (date) whilst working in / for ( name of town I name of general 
practice), you attended the patient listed on the enclosed sheet who died from pulmonary 
embolism at (place of death). In order to carry out the study, we need to contact the usual 
general practitioner of this patient. We would be very grateful if you were able to write the 
name and address of this doctor on the attached sheet, and return this in the reply-paid 
envelope. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. We have a professional obligation of confidentiality as medical 
practitioners ourselves, and we give an undertaking that no information about any named 
patient or doctor will be provided to any other party. 
We would greatly appreciate your help in this study, which could be important for the health 









Letter 13 Sent to next of kin to enquire about name of their relative' s general practitioner 
Dear ___ _ 
I was very sorry to learn that your (husband I wife I partner) died from pulmonary embolism 
in (year). My colleagues and I have been asked by the Ministry of Health to conduct a study 
into the causes of this condition. Our aim is to identify factors that could help in preventing 
such cases in the future. 
In order to carry out the study, we need to contact the main general practitioner used by your 
(husband I wife I partner) in recent years. Please would you be kind enough to write the name 
and address of this doctor on the attached sheet, and return this in the reply-paid envelope? 
You will see that we are also asking whether you would like to receive information about the 
findings of our survey when it is completed. 
Thank you very much indeed for your help. If you would like to discuss any aspects of this 
study, please don't hesitate to call me collect on (03) 479 7205. 
Yours sincerely 
David Skegg 





Letter 14 Thank you letter sent to the next of kin who provided the name of their relative' s 
general practitioner 
])ear~~~-
Thank you very much for returning our form detailing the name and address of your (wife's I 
husband's I partner's) general practitioner. Your help is most appreciated. 
We will send you information about the findings of the pulmonary embolism study when it is 
completed. 
With many thanks once again, 
Yours sincerely 
])avid Skegg 







Letter 15 Sent to general practitioners about women aged 15 - 49 years who died from 
pulmonary embolism between January 1990 and August 1998 
Dear Dr ___ _ 
475 
We have been contracted by the Ministry of Health to carry out a confidential study of deaths 
from pulmonary embolism in New Zealand women of child-bearing age. The aim of the 
study is to identify risk factors and possible means of preventing such deaths in the future. 
We understand that the patient listed on the enclosed sheet was a member of your practice. 
We would be extremely grateful for your help in obtaining the required information. This 
would involve a brief visit from one of us (Dr Lianne Parkin), to examine the medical records 
of this patient and of four randomly selected controls. Although it would be valuable if you 
could help to interpret the notes, we believe that this visit should cause you minimal 
inconvenience. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. None of the information recorded will be linked with the names of 
individual patients or of the particular practice. We have a professional obligation of 
confidentiality as medical practitioners ourselves, and we give an undertaking that no 
information about any named patient or doctor will be provided to any other party. 
We would greatly appreciate your help in this study, which could be important for the health 
of New Zealand women. One of us will contact you by telephone to ask about a suitable date 












Letter 16 Sent to general practitioners about women aged 50- 59 years and men aged 15 -
59 years who died from pulmonary embolism between January 1990 and December 1998, as 
well as women aged 15 -49 years who died between September and December 1998 
Dear Dr ___ _ 
Recently we conducted a confidential study of deaths from pulmonary embolism in New 
Zealand women of child-bearing age. A copy of our report is enclosed. This study has now 
been expanded to include men and women up to the age of 59 years. The aim of the study is 
to identify risk factors and possible means of preventing such deaths in the future. 
We understand that the patient listed on the enclosed sheet was a member of your practice. 
We would be extremely grateful for your help in obtaining the required information. This 
would involve a brief visit from one of us (Dr Lianne Parkin) to examine the medical records 
of this patient and of four randomly selected controls. Although it would be valuable if you 
could help to interpret the notes, we believe that this visit should cause you minimal 
inconvenience. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. None of the information recorded will be linked with the names of 
individual patients or of the particular practice. We have a professional obligation of 
confidentiality as medical practitioners ourselves, and we give an undertaking that no 
information about any named patient or doctor will be provided to any other party. 
We would greatly appreciate your help in this study, which could be important for the health 
of New Zealanders. One of us will contact you by telephone to ask about a suitable date for a 































Letter 17 Sent to general practitioners about men and women aged 15 - 59 years who died 
from pulmonary embolism between January 1999 and December 2000 
Dear Dr ___ _ 
Recently we conducted a confidential study of deaths from pulmonary embolism in New 
Zealand men and women aged 15 -59 years, who died between 1990 and 1998. A copy of 
our report is enclosed, along with a report from an earlier study in women of child-bearing 
age. We have now expanded the study to include people who died in 1999 and 2000. The 
aim of the study is to identify risk factors and possible means of preventing such deaths in the 
future . 
We understand that the patient listed on the enclosed sheet was a member of your practice. 
We would be extremely grateful for your help in obtaining the required information. This 
would involve a brief visit from one of us (Dr Lianne Parkin) to examine the medical records 
of this patient. Although it would be valuable if you could help to interpret the notes, we 
believe that this visit should cause you minimal inconvenience. 
This study has received approval from all regional Ethics Committees, and meets the 
requirements of the Health Information Privacy Code. None of the information recorded will 
be linked with the name of the individual patient or of the particular practice. We have a 
professional obligation of confidentiality as medical practitioners ourselves, and we give an 
undertaking that no information about any named patient or doctor will be provided to any 
other party. 
We would greatly appreciate your help in this study, which could be important for the health 
of New Zealanders. One of us will contact you by telephone to ask about a suitable date for a 










Letter 18 Sent to the New Zealand Family Planning Association about the case-control study 
of oral contraceptive use and fatal pulmonary embolism 
Dear Dr ___ _ 
We have been contracted by the Ministry of Health to carry out a confidential study of deaths 
from pulmonary embolism in New Zealand women of child-bearing age. The aim of the 
study is to identify risk factors and possible means of preventing such deaths in the future. 
As well as a descriptive element, the study has a case-control component in which the use of 
oral contraceptives will be compared in women who died from pulmonary embolism and an 
appropriate comparison group . 
Although the main source of information for cases and controls will be general practitioner 
records, we are aware that many women attend Family Planning Clinics to obtain oral 
contraceptives, and we are therefore writing to seek the assistance of the New Zealand Family 
Planning Association in obtaining the information we require. This would involve a visit by 
one of us (Dr Lianne Parkin) to various NZFP A clinics to examine any records that exist for 
the deceased women and control women. 
This study has received ethical approval, and meets the requirements of the Health 
Information Privacy Code. None of the information recorded will be linked with the names of 
individual women, particular NZFP A clinics, or staff. We have a professional obligation of 
confidentiality as medical practitioners ourselves, and we give an undertaking that no 
information about any named women, NZFP A clinics, or staff will be provided to any other 
party. 
We would greatly appreciate your help in this study, which could be important for the health 
of New Zealand women. We have enclosed a confidential copy of the study protocol, but 




















Letter 19 Sent to next of kin of New Zealand men and women aged 15 - 59 years who died 
from pulmonary embolism between January 1990 and December 2000 (next of kin who had 
not previously been contacted), descriptive and case-control studies of long-distance air travel 
Dear ___ _ 
We were very sorry to learn that your (husband/wife /partner) died from pulmonary 
embolism in (year). The Department of Preventive Medicine at the Otago Medical School is 
conducting a study into the causes of this condition, with patients being identified from 
national mortality records. Our aim is to look for factors that could help in preventing deaths 
in the future. The study has received ethical approval from the Otago Ethics Committee on 
behalf of all regional ethics committees. 
We would be extremely grateful if you would agree to take part in this study. We would like 
to interview you by telephone about aspects of your (husband's !wife's /partner's) life before 
(he I she) developed pulmonary embolism. The interview will take about 20 minutes of your 
time; the interviewer will be . If you agree to take part, all the information you give 
us will be recorded without names and will be kept strictly confidential. You do not need to 
answer all the questions, and you may stop the interview at any time. 
One of us will contact you by telephone during the next two weeks to request your permission 
for the interview. In the meantime, we would be most grateful if you could correct your 
address and telephone number on the attached form if necessary, and mark the most 
convenient time for us to telephone. Please could you return this form in the reply-paid 
envelope? 
If you would like advice as to your rights as a participant in this study, you may wish to 
contact a Health and Disability Services Consumer Advocate, telephone (relevant phone 
number). 
We do very much hope that you will agree to take part in this study. We believe that the 
results of the study could be important to the health of New Zealanders. 
If you would like to discuss any aspects of this study, please don't hesitate to contact me by 
mail or by telephoning collect. 
Yours sincerely 
Dr Lianne Parkin 
Ph (03) 479 8425 









Please would you complete or correct this form and return it in the reply-paid envelope 
provided. 
Full name ( of next of kin) 
Address (of next of kin) 
Telephone number 
Mobile number (if you don't have a home phone number) 
Which days and/ or times in the next month would be convenient for us to phone you? 
(please give as many choices as possible) 









Letter 20 Sent to next of kin of New Zealand men and women aged 15 - 59 years who died 
from pulmonary embolism between January 1990 and December 2000 (next of kin who had 
previously been contacted), descriptive and case-control studies of long-distance air travel 
Dear ___ _ 
(Last year I In 1999) we wrote to you about a study we are conducting into the causes of 
pulmonary embolism and we asked you for the name of your (husband's /wife's I partner's) 
general practitioner. The aim of our study is to identify factors that could help in preventing 
cases of pulmonary embolism in the future. The study has received ethical approval from the 
Otago Ethics Committee on behalf of all regional ethics committees. 
We would be extremely grateful if you would agree to take part in the final phase of our 
study. We would like to interview you by telephone about aspects of your (husband's /wife's 
I partner's) life before (he I she) developed pulmonary embolism. The interview will take 
about 20 minutes of your time; the interviewer will be . If you agree to take part, 
all the information you give us will be recorded without names and will be kept strictly 
confidential. You do not need to answer all the questions, and you may stop the interview at 
any time. 
One of us will contact you by telephone during the next two weeks to request your permission 
for the interview. In the meantime, we would be most grateful if you could correct your 
address and telephone number on the attached form if necessary, and mark the most 
convenient time for us to telephone. Please could you return this form in the reply-paid 
envelope? 
If you would like advice as to your rights as a participant in this study, you may wish to 
contact a Health and Disability Services Consumer Advocate, telephone ( relevant phone 
number). 
We do very much hope that you will agree to take part in this study. We believe that the 
results of the study could be important to the health of New Zealanders. 
If you would like to discuss any aspects of this study, please don't hesitate to contact one of 
us by mail or by telephoning collect. 
Yours sincerely 
Dr Lianne Parkin 
Ph (03) 479 8425 
Professor David Skegg 
Ph (03) 479 7205 
P.S. A calendar is also enclosed. We will refer to this during the interview. 
Please would you complete or correct this form and return it in the reply-paid envelope 
provided. 
Full name (of next of kin) 
Address (of next of kin) 
Telephone number 
Mobile number (if you don't have a home phone number) 
Which days and/ or times in the next month would be convenient for us to phone you? 
(please give as many choices as possible) 





Letter 21: Sent to next of kin of overseas visitors aged 15 - 59 years who died from 
pulmonary embolism in New Zealand between January 1990 and December 2000 (presumed 
English speakers), descriptive and case-control studies of long-distance air travel 
Dear ----
We were very sorry to learn that your ( husband I wife I partner) died from pulmonary 
embolism in New Zealand. The Department of Preventive Medicine at the Otago Medical 
School in New Zealand is conducting a study into the causes of this condition, with patients 
being identified from New Zealand mortality records. Our aim is to look for factors that 
could help in preventing deaths in the future. The study has received ethical approval from all 
the New Zealand Health and Disability Ethics Committees. 
We would be extremely grateful if you would agree to take part in this study. We would like 
to interview you by telephone about aspects of your (husband's /wife's /partner's) life before 
(he I she) developed pulmonary embolism. The interview will take about 20 minutes of your 
time; the interviewer will be . If you agree to take part, all the information you 
give us will be recorded without names and will be kept strictly confidential. You do not 
need to answer all the questions, and you may stop the interview at any time. 
One of us will contact you by telephone during the next four weeks to request your 
permission for the interview. In the meantime, we would be most grateful if you could 
correct your address and telephone number on the attached form if necessary, and mark the 
most convenient time for us to telephone. Please could you return this form in the enclosed 
envelope? 
We do very much hope that you will agree to take part in this study. If you would like to 
discuss any aspects of the study, please don't hesitate to contact us by mail or by telephoning 
collect. 
Yours sincerely 
Dr Lianne Parkin 
Tel 64 3 479 8425 
Professor David Skegg 
P.S. A calendar is also enclosed. We will refer to this during the interview. 
I 
I ~ 
Please would you complete or correct this form and return it in the reply-paid envelope 
provided. 
Full name ( of next of kin) 
Address (of next of kin) 
Telephone number 
Mobile number (if you don't have a home phone number) 
Which days and/ or times in the next month would be convenient for us to phone you? 
(please give as many choices as possible) 
Thank you for your help. 
484 
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Letter 22: Sent to next of kin of overseas visitors aged 15 - 59 years who died from 
pulmonary embolism in New Zealand between January 1990 and December 2000 (possible 
non-fluent speakers of English), descriptive and case-control studies of long-distance air 
travel 
Dear ___ _ 
We were very sorry to learn that your (husband I wife I partner) died from pulmonary 
embolism in New Zealand. The Department of Preventive Medicine at the Otago Medical 
School in New Zealand is conducting a study into the causes of this condition, with patients 
being identified from New Zealand mortality records. Our aim is to look for factors that 
could help in preventing deaths in the future. The study has received ethical approval from all 
the New Zealand Health and Disability Ethics Committees. 
We would be extremely grateful if you would agree to take part in this study. We would like 
to interview you by telephone about aspects of your (husband's /wife's I partner's) life before 
(he I she) developed pulmonary embolism. The interview will take about 20 minutes of your 
time; the interviewer will be . We are happy to provide a medical translator if 
you would prefer not to be interviewed in English. If you agree to take part, all the 
information you give us will be recorded without names and will be kept strictly confidential. 
You do not need to answer all the questions, and you may stop the interview at any time. 
One of us will contact you by telephone during the next four weeks to request your 
permission for the interview. In the meantime, we would be most grateful if you could 
correct your address and telephone number on the attached form if necessary, and mark the 
most convenient time for us to telephone. Please could you return this form in the enclosed 
envelope? 
We do very much hope that you will agree to take part in this study. If you would like to 
discuss any aspects of the study, please don't hesitate to contact us by mail or by telephoning 
collect. 
Yours sincerely 
Dr Lianne Parkin 
Tel 64 3 479 8425 
Professor David Skegg 
P.S. A calendar is also enclosed. We will refer to this during the interview. 
Please would you complete or correct this form and return it in the reply-paid envelope 
provided. 
Full name (of next of kin) 
Address (of next of kin) 
Telephone number 
Preferred language for interview 
Which days and/ or times in the next month would be convenient for us to phone you? 
(please give as many choices as possible) 





Letter 23: Sent to next of kin ( of New Zealand residents or overseas visitors) without a 
traceable telephone number who did not reply to the letter inviting them to take part in the 
study (descriptive and case-control studies of long-distance air travel and fatal pulmonary 
embolism) 
Dear ___ _ 
I hope that you will excuse my writing to you again, but I cannot trace a reply to my previous 
letter. As my letter (or your reply) may have gone astray in the post, I am enclosing a further 
copy. If you have replied already, please accept my apologies for putting you to this further 
trouble, but I am anxious to make this study as complete as possible. 
Yours sincerely 
Dr Lianne Parkin 
Research Fellow 




Letter 24: Sent to potential controls, case-control study of long-distance air travel 
Dear ___ _ 
A major study is being carried out by the Department of Preventive Medicine at the Otago 
Medical School on the causes of a condition that affects many New Zealanders every year. 
Our aim is to identify factors that could help in preventing deaths from this condition in the 
future. The study involves interviewing a large number of men and women all over New 
Zealand, and has received ethical approval from the Otago Ethics Committee on behalf of all 
regional ethics committees. 
We would very much appreciate your help in this study. Your name was chosen at random 
from the electoral roll. We would be extremely grateful if you would agree to take part by 
answering several questions by telephone about aspects of your life and health. The interview 
will take about 20 minutes of your time; the interviewer will be . If you agree to 
take part, all the information you give us will be recorded without your name and will be kept 
strictly confidential. You do not need to answer all the questions, and you may stop the 
interview at any time . 
One of us will contact you by telephone during the next two weeks to request your permission 
for the interview. In the meantime, we would be most grateful if you could correct your 
address and telephone number on the attached form if necessary, and mark the most 
convenient time for us to telephone. Please could you return this form in the reply-paid 
envelope? 
If you would like advice as to your rights as a participant in this study, you may wish to 
contact a Health and Disability Services Consumer Advocate, telephone ( relevant phone 
number). 
We do very much hope that you will agree to take part in this study. We believe that the 
results of the study could be important to the health of New Zealanders. 
If you would like to discuss any aspects of this study, please don't hesitate to contact me by 
mail or by telephoning collect. 
Yours sincerely 
Dr Lianne Parkin 
Ph (03) 479 8425 
P.S. A calendar is also enclosed. We will refer to this during the interview. 
/ , I 






Mobile number (if you don't have a home phone number) 
Date of birth 
Which days and/ or times in the next month would be convenient for us to phone you? 
(please give as many choices as possible) 




Letter 25: Sent to potential controls without a traceable telephone number who did not reply 
to the letter inviting them to take part in the study (case-control study of long-distance air 
travel and fatal pulmonary embolism) 
I hope that you will excuse my writing to you again, but I cannot trace a reply to my previous 
letter. As my letter (or your reply) may have gone astray in the post, I am enclosing a further 
copy. If you have replied already, please accept my apologies for putting you to this further 
trouble, but I am anxious to make this study as complete as possible. 
Yours sincerely 
Dr Lianne Parkin 
Research Fellow 
Ph (03) 479 8425 
'I 
Letter 26: Letter sent to next of kin who participated in the descriptive and case-control 
studies of long-distance air travel and fatal pulmonary embolism 
Dear ----
491 
Thank you very much for helping with our research into risk factors for pulmonary embolism. 
I apologise for taking so long to write to you, but it took us longer than expected to complete 
the study. 
The final results of the study are to be published this month in an international medical 
journal, Thrombosis and Haemostasis. I am very happy to send you a copy of this article and 
two previous ones if you would like to read them, but in the meantime I thought I would send 
you a summary of the results. 
Long-distance air travel 
We found that long-distance air travel increased the risk of dying from pulmonary embolism. 
People who flew more than eight hours had about eight times the risk of dying from 
pulmonary embolism than non-travellers. However because fatal pulmonary embolism is 
actually a very rare occurrence, the number of people who developed pulmonary embolism 
after a flight was very small. For example, we found that for every million people aged 
between 15 - 59 years who flew for more than eight hours, one passenger died from 
pulmonary embolism. 
Other risk factors 
Other factors which increased the risk of dying from pulmonary embolism included previous 
episodes of deep vein thrombosis (blood clots in the legs) and pulmonary embolism, certain 
medicines (the combined oral contraceptive pill, hormone replacement therapy, and 
antipsychotic drugs), obesity, prolonged immobility, and a recent hospital admission. 
Once again, I'd like to thank you very much for taking the time to help us with this study. We 
believe that the results of the study are of importance to the health of New Zealanders. If you 
would like to receive a copy of the journal articles or discuss any aspects of the study, please 
don't hesitate to contact me by mail or by telephoning collect. 
Yours sincerely 
Dr Lianne Parkin 
Ph (03) 479 8425 
".) 
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Letter 27: Letter sent to controls who participated in the case-control study of long-distance 
air travel and fatal pulmonary embolism 
Dear ___ _ 
Thank you very much for helping with our study of risk factors for pulmonary embolism 
(blood clots in the lungs). I apologise for taking so long to write to you, but it took us longer 
than expected to complete the study. 
The results of the study are to be published this month in an international medical journal, 
Thrombosis and Haemostasis. I am very happy to send you a copy of the article if you would 
like to read it, but in the meantime I thought I would send you a summary of the results. 
We found that long-distance air travel increased the risk of dying from pulmonary embolism. 
People who flew more than eight hours had about eight times the risk of dying from 
pulmonary embolism than non-travellers. However because fatal pulmonary embolism is 
actually a very rare occurrence, the number of people who developed pulmonary embolism 
after a flight was very small. For example, we found that for every million people aged 
between 15 - 59 years who flew for more than eight hours, one passenger died from 
pulmonary embolism. This is a much lower risk than media publicity about "economy-class 
syndrome" has led many people to believe. 
Once again, I'd like to thank you very much for taking the time to help us with this study. If 
you would like to receive a copy of the article, please don't hesitate to contact me. 
Yours sincerely 
Dr Lianne Parkin 
Ph (03) 479 8425 
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APPENDIX B: DATA ABSTRACTION FORM AND DATA DICTIONARY 





Data abstraction form 
1. Study ID Number: 
2. Practice ID Number: 
3. Sex: 
4. Index date: 
5. Date of data abstraction: 
6. Date of birth: 
7. Date of joining practice: 
(If not specifically stated, record date of 
first clinical consultation) 













9. Were any of the following conditions recorded in the clinical notes before 
the index date? 
(For cases only, if the occurrence of any of these conditions was recorded after the index date, 
include this information under question 18b.) 
Yes/No 
495 
D (a) Deep vein thrombosis 
Details, including dates: 
OJOJOJ 
(b) Superficial venous thrombosis 
Details, including dates: 
( c) Varicose veins 
Details, including dates: 
D 
Yes /No D 
OJOJOJ 
D 




(d) Pulmonary embolism 
Details, including dates: 
(e) Hypertension (during pregnancy) 
Details, including dates: 
(f) Hypertension (when not pregnant) 
Details, including dates: 
496 
Yes /No D 
[I] [IJ[IJ 
D 






(g) Myocardial infarction 
Details, including dates: 
(h) Angina 
Details, including dates: 
(i) Stroke 












(j) Transient ischaemic attack 
Details, including dates: 
(k) Other heart or blood vessel disease 
Details, including dates: 
(l) Diabetes mellitus 
Details, including dates: 
498 













(m) Blood disorders 
(Factor V Leiden, antithrombin deficiency, protein C or S deficiency, dysfibrinogenaemia, plasminogen 
deficiency, prothrombin G20210A, high factor Vill, increased platelets, homocysteinaemia, antiphospholipid 
syndrome/ anticardiolipin antibodies/ lupus anticoagulant.) 
D 
Details, including dates: 
(n) Cancer 
Details, including dates: 
( o) Immobility during previous year 
















(p) Injuries requiring medical attention during previous year 
Yes /No 
Details, including dates: 
( q) Operations during previous year 








D (r) Hysterectomy 












(t) Intellectual disability 
Details, including dates: 
Yes/No 















10. Were any pregnancies recorded in the clinical notes before the index 
date? 
(For cases only, if any information regarding pregnancies was recorded after the index date, 
include details under question 18b.) 
D 
If yes, 
(a) Record number of pregnancies: 
• Total number of pregnancies: 
• Miscarriages: 
• Terminations of pregnancy: 
• Ectopic pregnancies: 
• Live births: 
• Stillbirths: 
Yes /No 
(b) Any pregnancies in the year before the index date? 
Yes /No 
If yes, 












• If pregnancy ended before index date, 
o Date pregnancy ended: [D[D[D 
o Approximate gestation (in weeks )when pregnancy ended: 
• Was any surgery involved (termination of pregnancy, evacuation of retained 
products of conception, removal of ectopic pregnancy, other)? 
Yes /No 
Details, including dates: 
11. Was smoking status recorded in the clinical notes before the index date? 
(For cases only, if any information regarding smoking status was recorded after the index date, 
include details under question 18b.) 
Yes /No 
If yes, 







• Date this was recorded: [D[D[D 
• Any other details: 
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12. Menopausal status. 
(For cases only, if any information regarding menopausal status or hormone replacement therapy 
use was recorded after the index date, include details under question 18b.) 
(a) Any record (before the index date) of being post-menopausal? 
Yes/No 
If yes, 
• When was this recorded? 
D 
• Date of last period if known: [IJ[IJ[IJ 
(b) Any record (before the index date) ofperi-menopausal symptoms? 
Yes/No 
If yes, 
• When was this recorded? 







































13. Was the use of any of the following methods of contraception recorded in 
the clinical notes before the index date? 
(For cases only, if any information regarding contraceptive history was recorded after the index date, 
include details under question 18b.) 
Index date: _I _I_ 
Oral contraceptives 
Prior to the year 
of interest 
Yes/No 
( including non-contraceptive indications) 
Progestogen-only pill Yes/No 
DMPA ('Depo Provera') Yes /No 




Female sterilisation Yes/No 
Partner vasectomy Yes /No 
Natural family planning Yes /No 
Other Yes/No 
In the year 




Yes /No DD 
Yes/No DD 
Yes /No DD 
Yes/No DD 




(Record details of all methods used in the year before the index date, and oral contraceptive use prior to the 
year of interest, on the following pages.) 
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Details of all methods of contraception used in the year before the index date: 
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Details of any oral contraceptive use prior to the year of interest: 
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14. Was the use of any other medication recorded in the clinical notes in the 
year before the index date? 
(For cases only, if any information regarding medication use in this year was recorded after 
the index date, include details under question 18b.) 
Yes /No 




[D I I I I [D D 
[D I I I I [D D 
[D I I I I [D D 
[D I I I I [D D 
[D I 
I. ·1 
I I I [D D I' 
/ 
'Y [D I I I I [D D 
I 
[D I I I I [D D 
t ' 
' y [D I I I I [D D 
(" 
[D I I I I [D D 
[D I I I I [D D 
,.~ 
1, > [D I I I I [D D 
r ~ 
) [D I I I I [D D 
> 
[D I I I I [D D 
'~ 
[D I I I I [D D 
I [D I I I [D D ) '-~ 
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OJ I I I I OJ D 






15. Was any information regarding weight recorded in the clinical notes before 
the index date? 
(For cases only, if any information regarding weight was recorded after the index date, 
include details under question 18b.) 
D 
If yes, 
• Date weight recorded: 
• Weight: kilograms 
stone / pounds _/_ 







16. Was any information regarding height recorded in the clinical notes before the 
index date? 
(For cases only, if any information regarding height was recorded after the index date, 
include details under question 18b.) 
D Yes /No 
If yes, 
• Date height recorded: [IJ[IJ[IJ 
• Height: metres __ D[IJ 
feet/ inches _/_ D[IJ 








17. Was any family history of venous thromboembolism recorded in the 
clinical notes before the index date? 
If yes, 
• 
(For cases only, if any information regarding a family history of venous thromboembolism 
was recorded after the index date, include details under question 18b.) 
Yes /No 
Record details for each affected relative: 
D 
(Relationship to woman, deep vein thrombosis/ pulmonary embolism, fatal/ non-fatal, number 







18. For cases; 
(a) Details re clinical course and management of fatal episode (if any recorded): 











1. Study ID Number: 
2. Practice ID Number: 
) D f 3. Case or control? 
1. Case ,, 
0. Control 
', 





5. Index date: [IJ[IJ[IJ 
6. Date of data abstraction: [IJ[IJ[IJ 
I> 7. Date of birth: [IJ[IJ[IJ 
8. Date of joining practice: [IJ[IJ[IJ 
,\. 
_( 










(Use this cell if a 2nd ethnic identity was recorded) 








13. Date 1st episode of DVT diagnosed: DJDJDJ 
(If unknown, enter date that history of DVT 
1•1 recorded and enter '1' in date indicator box) 
14. Date indicator: D 











4. Not recorded 







17. Date 1st episode of SVT diagnosed: [IJ[IJ[IJ 
(If unknown, enter date that history of SVT 
1•1 recorded and enter']' in date indicator box) 
18. Date indicator: D 
(Complete only if date of diagnosis unknown) 




4. Not recorded 
20. Record of varicose veins before index date? 
1. Yes 
0. No 





22. Recorded history of treatment of varicose veins before index date? 
1. Yes 
0. No 






24. Date 1st episode of PE diagnosed: OJOJOJ 
(If unknown, enter date that history of PE 
1•1 recorded and enter '1' in date indicator box) 
25. Date indicator: 
(Complete only if date of diagnosis unknown) 




4. Not recorded 
27. Recorded diagnosis of hypertension during pregnancy before index date? 
(Defined as: elevated blood pressure treated by medication and I or 






28. Date 1st episode of hypertension during 
pregnancy diagnosed: 
OJOJOJ 
(If unknown, enter date that history of hypertension 
during pregnancy1•1 recorded and enter '1' in date indicator box) 
.! 
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29. Date indicator: 
(Complete only if date of diagnosis unknown) D 
30. Number of affected pregnancies before index date: [I] 
31. Recorded diagnosis of hypertension when not pregnant before index date? D 
(Defined as: elevated blood pressure treated by medication at any time before the index date) 
1. Yes 
0. No 
32. Date 1st commenced anti-hypertensive 
medication: 
[IJ[IJ[IJ 
(If unknown, enter date that history of anti-hypertensive 
treatment pt recorded and enter '1' in date indicator box) 
33. Date indicator: 
(Complete only if date that commenced treatment unknown) 





35. Date of 1st MI: [IJ[IJ[IJ 
(If unknown, enter date that history of MI 
pt recorded and enter '1' in date indicator box) 
36. Date indicator: D 
(Complete only if date of diagnosis unknown) 
; 
37. Number of recorded episodes of MI before index date: 
1. 1 
2. 2 
3. > 3 
4. Not recorded 






39. Date of 1st episode of angina: [D[D[D 
(If unknown, enter date that history of angina 
1'1 recorded and enter '1' in date indicator box) 
40. Date indicator: 
(Complete only if date of diagnosis unknown) 
D 
41. Recorded diagnosis of stroke before index date? D 
1. Yes 
0. No 
42. Date of 1st stroke: 
(If unknown, enter date that history of stroke 
1•1 recorded and enter '1' in date indicator box) 
43. Date indicator: 






44. Number of recorded strokes before index date: 
1. 1 
2. 2 
3. > 3 
4. Not recorded 






46. Date of 1st TIA: 
[D[D[D 
(If unknown, enter date that history of TIA 
/81 recorded and enter '1' in date indicator box) 
47. Date indicator: 
(Complete only if date of diagnosis unknown) 
48. Recorded diagnosis of other heart or blood vessel disease 
before index date? 
1. Yes 
0. No 




1. Known cardiac valvular abnormality and / or clinically significant murmur 
(e.g. requiring antibiotic prophylaxis) 
2. Murmur, not otherwise specified 
3. Arrhythmia 
4. Palpitations, not otherwise specified 
5. Peripheral vascular conditions, arterial 
6. Cardiac arrest, not otherwise specified 
7. Surgery for congenital heart condition 
8. Other arterial disease, excluding peripheral vascular disease 
9. Hyperlipidaemia, treated by medication 





I • f 
I 
1> 
50. Nature of heart or blood vessel disease: 
(Use this cell if a 2nd heart or blood vessel disease was recorded) 






52. Date diabetes mellitus 1st diagnosed: [IJ[IJ[IJ 
(If unknown, enter date that history of diabetes 
1'1 recorded and enter '1 ' in date indicator box) 
53. Date indicator: 
(Complete only if date of diagnosis unknown) 
54. Type of diabetes: 
1. Insulin-dependent 
2. Non- insulin-dependent 
3. Non- insulin-dependent, progressing to insulin-dependence 
4. Pregnancy-induced diabetes only 













55. Recorded diagnosis of blood disorders before index date? 
1. Yes 
0. No 
56. Type of blood disorder: 
1. Factor V Leiden 
2. Antithrombin deficiency 
3. Protein C deficiency 
4. Protein S deficiency 
5. Dysfibrinogenaemia 
6. Plasminogen deficiency 
7. Prothrombin G20210A 
8. Elevated factor VIII concentration 
9. Elevated platelet count (chronic) 





12. Antiphospholipid syndrome / anticardiolipin antibodies / lupus anticoagulant 
13. Polycythaemia (chronic) 
14. Polycythaemia (transient) 
15. Other 
57. Type of blood disorder: 
(Use this cell if a 2"d blood disorder was recorded) 
58. Type of blood disorder: 
(Use this cell if a 3rd blood disorder was recorded) 
59. Recorded diagnosis of cancer before the index date? 









60. Date cancer 1st diagnosed: 
(If unknown, enter date that history of cancer 
J'' recorded and enter 'I' in date indicator box) 
[IJ[IJ[IJ 
61. Date indicator: 
(Complete only if date of diagnosis unknown) 









63. Type of cancer: 
(Use this cell if a 2nd primary cancer was recorded) 
64. Type of cancer: 
(Use this cell if a 3rd primary cancer was recorded) 
65. Record of prolonged immobility during year before index date? 
(Defined as: confined to wheelchair, or documented confinement to bed or chair 
for at least a week) 
1. Yes 
0. No 





















67. Record of travel of at least 4 hours' duration during 2 months 
before index date? 
1. Yes 
0. No 




4. Not recorded 






6. More than one mode of transport used 
7. Not recorded 
70. Record of injuries reguiring medical attention during year 
before index date? 
(Include only: fractures of hip I pelvis I lower limb; severe soft tissue trauma 
lower limb; fractures or severe trauma trunk I head I neck I upper limb) 
1. Yes 
0. No 
71. Record of injuries reguiring medical attention during 










72. Record of operations during year before index date? 
(Include only: major general, urological, gynaecological, cardiothoracic, 
vascular, orthopaedic, or neurological surgery) 
1. Yes 
0. No 
73. Record of operations during 2 months before index date? 
1. Yes 
0. No 
74. Record of hysterectomy before index date? 







75. Date of hysterectomy: DJDJDJ 
(If unknown, enter date that history of hysterectomy 
rt recorded and enter '1' in date indicator box) 
76. Date indicator: 
(Complete only if date of hysterectomy unknown) 
77. Record of bilateral oophorectomy before index date? 





78. Date of oophorectomy: DJDJDJ 
(If unknown, enter date that history of oophorectomy 





' ,. I 
79. Date indicator: 
(Complete only if date of oophorectomy unknown) 
80. Record of intellectual disability before index date? 
1. Yes 
0. No 
81. Duration of disability: 
1. Since childhood 
0. Since event in adulthood 
82. Recorded diagnosis of psychiatric illness before index date? 
1. Yes 
0. No 
83. Details of psychiatric history: 
1. Diagnosis and treatment of a psychotic illness by a psychiatrist 
(as an inpatient) 








3. Diagnosis and treatment of a psychotic illness by a general practitioner only 
4. Diagnosis and treatment of another psychiatric illness by a psychiatrist (as an 
inpatient) 
5. Diagnosis and treatment of another psychiatric illness by a psychiatrist (as an 
outpatient) 
6. Diagnosis and treatment of another psychiatric illness by a general practitioner 
only 
84. Details of psychiatric history: D 
(Use this cell if a 2nd psychiatric illness was recorded) 
,, 
,_ 
85. Record of any other relevant history before index date? 
1. Yes 
0. No 
86. Details of other relevant conditions before index date: 
1. Inflammatory bowel disease 
2. Systemic lupus erythematosus 
3. Renal disease 
4. Other 
87. Details of other relevant conditions before index date: 
(Use this cell if a 2nd significant condition was recorded) 
88. Record of pregnancy before index date? 
(Leave blank if male) 
1. Yes 
0. No 
89. Total number of recorded pregnancies before index date: 
90. Number of recorded miscarriages before index date: 
91. Number of recorded terminations of pregnancy before index date: 
92. Number of recorded ectopic pregnancies before index date: 














94. Number of recorded stillbirths before index date: 
95. Number of pregnancies for which outcome was not recorded: 







97. If pregnant during year before index date, 
estimated date of last menstrual period: 
ITJITJITJ 
If date unknown, record 1/1/49 
98. If pregnant during year before index date, 
date that pregnancy ended: 
ITJITJITJ 
If date unknown but pregnancy known, 
or assumed (because of expected date of delivery), to have ended more than 
2 months before the index date, record 1/1150 
If notes clearly indicate that was pregnant at any time during the 2 months before the index date, 
and unless have a known date that pregnancy ended, record 1/1/51 
If no record of pregnancy status during 2 months before index date, but it is possible (because of 
expected date of delivery) that was pregnant during this time, record 1/1152 
99. Record of smoking status before index date? 
1. Yes 
0. No 










101. Date smoking status recorded: [IJ[IJ[IJ 
102. Record of being post-menopausal before index date? 
(Leave blank if male) 
1. Yes 
0. No 





104. Date of last menstrual period or surgery: [IJ[IJ[IJ 
(If unknown, enter date that post-menopausal 
status 1'1 recorded and enter '1' in date indicator box) 
105. Date indicator: 
(Complete only if date of last menstrual period or surgery unknown) 
106. If not known to be post-menopausal, record of peri-menopausal 
symptoms before index date? 
1. Yes 
0. No 
107. Record of hormone replacement therapy (HRT) before index date? 
(Defined as: use of systemically absorbed oestrogen with or without 







108 - 159. Details of HRT: 
(Each row represents an episode of continuous HRT ordered from the most, to the least, recent) 
(i) Regimen (ii) Date episode (iii) Date episode (iv) Current use? 
of use began of use ended 
D [I] [I] [I] [I] [I] [I] D 
., 
D [I] [I] [I] [I] [I] [I] D 
D [I] [I] [I] [I] [I] [I] D 
D [I] [I] [I] [I] [I] [I] D 
D [I] [I] [I] [I] [I] [I] D 
D [I] [I] [I] [I] [I] [I] D 
D [I] [I] [I] [I] [I] [I] D 
D [I] [I] [I] [I] [I] [I] D 
\ D [I] [I] [I] [I] [I] [I] D 
[· D [I] [I] [I] [I] [I] [I] D 
,. 
D [I] [I] [I] [I] [I] [I] D 
\ 
D [I] [I] [I] [I] [I] [I] D 
.. 
D [I] [I] [I] [I] [I] [I] D 
(i) Regimen: 
1. Oestrogen alone 




(ii) Date this episode of HRT began 
(Date of 1'1 prescription) 
(iii) Date this episode of HRT ended 
536 
(Calculate using date of final prescription plus number of months prescribed on that occasion; or 
record index date if was still using HRT on the index date) 
(iv) Current use? 













160 - 181. Recorded use of the following methods of contraception? 
(i) Before the year 
of interest 
Oral contraceptives (OC) 
(including for non-contraceptive indications) 
Progestogen-only pill 
Medroxyprogesterone acetate (DMPA) 
Morning after pill 









2. Not applicable, post-menopausal 













(ii) In the year 
















182 - 191. Details of contraception used in the year before index date 
(excluding OC use): 
538 
(Each row represents a contraceptive method ordered from the most, to the least, recently used) 






1. Progestogen-only pill, 28x Ethynodiol diacetate SOOµg (Femulen) 
2. Progestogen-only pill, 28x Levonorgestrel 30µg (Microlut, Microval) 
3. Progestogen-only pill, 28x Norethisterone 350µg (Noriday) 
4. Progestogen-only pill, not otherwise specified 
5. DMPA 




10. Female sterilisation 
11. Partner vasectomy 
12. Natural family planning 
13. Other 
(ii) Current use? 








192 - 268. Details of OC use (ever): 
(Each row represents an episode of continuous OC use ordered from the most, to the least, recent) 
(i) Preparation (iii) Date this episode (v) Date this episode (vii) Current use? 
of use began of use ended 
(ii) 1st extra (iv) 2nd extra (vi) Use in year 
data column data column before index date? 
DJ D DJDJDJ D DJDJDJ D D 
DJ D DJDJDJ D DJDJDJ D D 
DJ D DJDJDJ D DJDJDJ D D 
DJ D DJDJDJ D DJDJDJ D D 
DJ D DJDJDJ D DJDJDJ D D 
DJ D DJDJDJ D DJDJDJ D D 
DJ D DJDJDJ D DJDJDJ D D 
DJ D DJDJDJ D DJDJDJ D D 
DJ D DJDJDJ D DJDJDJ D D 
DJ D DJDJDJ D DJDJDJ D D 






1. 21x Desogestrel 150µg / Ethinyloestradiol 20µg tablets (MERCILON) 
2. 21x Desogestrel 150µg / Ethinyloestradiol 30µg tablets (MARVELON) 
3. 7x Desogestrel 25µg / Ethinyloestradiol 40µg tablets; 
15x Desogestrel 125µg / Ethinyloestradiol 30µg tablets (GRACIAL) 
4. 21x Gestodene 75µg / Ethinyloestradiol 30µg tablets (FEMODENE, MINULET) 
5. 21x Levonorgestrel lOOµg / Ethinyloestradiol 20µg tablets (LOETTE) 
6. 21x Levonorgestrel 150µg / Ethinyloestradiol 30µg tablets (MICROGYNON 30, 
NORDETTE, MONOFEME) 
7. 21x Levonorgestrel 125µg / Ethinyloestradiol 50µg tablets (MICROGYNON 50) 
8. MICROGYNON not otherwise specified 
9. 21x Levonorgestrel 250µg / Ethinyloestradiol 50µg tablets (NORDIOL, 
NEOGYNON) 
10. llx Levonorgestrel 50µg / Ethinyloestradiol 50µg tablets; 
lOx Levonorgestrel 125µg / Ethinyloestradiol 50µg tablets (BIPHASIL) 
11. 6x Levonorgestrel 50µg / Ethinyloestradiol 30µg tablets; 
5x Levonorgestrel 75µg / Ethinyloestradiol 40µg tablets 
lOx Levonorgestrel 125µg / Ethinyloestradiol 30µg tablets (TRIPHASIL, 
TRIQUILAR, TRIFEME) 
540 
12. 21x Norethisterone 500µg / Ethinyloestradiol 35µg tablets (NORIMIN, BREVINOR) 
13. 21x Norethisterone lOOOµg / Ethinyloestradiol 35µg tablets (BREVINOR-1) 
14. 21x Norethisterone acetate lOOOµg / Ethinyloestradiol 50µg tablets (ORLEST) 
15. 21x Norethisterone acetate 2500µg / Ethinyloestradiol 50µg tablets (NORLESTRIN 
28) 
16. 21x Norethisterone acetate 3000µg/ Ethinyloestradiol 50µg tablets (GYNOVLAR) 
17. 21x Norethisterone acetate 4000µg / Ethinyloestradiol 50µg tablets (ANOVULAR) 
18. 7x Norethisterone 500µg / Ethinyloestradiol 35µg tablets; 
9x Norethisterone lOOOµg / Ethinyloestradiol 35µg tablets; 
5x Norethisterone 500µg / Ethinyloestradiol 35µg tablets (SYNPHASIC) 
19. 21x Norethisterone lOOOµg / Mestranol 50µg tablets (NORINYL-1) 
20. 21x Norgestrel 500µg / Ethinyloestradiol 50µg tablets (OVRAL) 
21. 21x Ethynodiol diacetate 500µg / Ethinyloestradiol 50µg tablets (OVULEN 0.5/50) 
22. 21x Ethynodiol diacetate lOOOµg / Ethinyloestradiol 50µg tablets (OVULEN 1/50, 
EDULEN) 
23. OVULEN not otherwise specified 
24. 21x Lynoestrenol 750µg / Ethinyloestradiol 38µg tablets (RESTOV AR) 
25. 22x Lynoestrenol lOOOµg / Ethinyloestradiol 50µg tablets (OVOSTAT) 
26. 21x Lynoestrenol 2500µg / Mestranol 75µg tablets (L YNDIOL 2.5) 
27. LYNDIOL not otherwise specified 
28. 21x Norgestrel 500µg / Ethinyloestradiol 50µg tablets (EUGYNON) 
29. 21x Megestrol acetate lOOµg / Ethinyloestradiol lOOµg tablets (SERIAL C) 
30. 21x Megestrol acetate 4000µg / Ethinyloestradiol 50µg tablets (VOLIDAN) 
31. 21x Norethynodrel 5000µg / Mestranol 150µg tablets (ENA VID) 
32. 15x Chlormadinone acetate 2000µg / Mestranol 80µg tablets; 5x Chlormadinone 
acetate 2000µg / Mestranol 80µg tablets (SEQUENS) 
33. 21x Cyproterone acetate 2000µg / Ethinyloestradiol 35µg tablets (DIANE) 




(ii) 1st extra data column 
1. e.g. Nov 97 
2. e.g. 6 months 
(iii) Date this episode of OC use began 
(Date of 1'1 prescription) 
(iv) 2nd extra data column 
1. e.g. Nov 97 
2. e.g. pre-Dec 96 
(v) Date this episode of OC use ended 
(Calculate using date of final prescription plus number of months prescribed on that occasion; 
or record index date if still an OC user on the index date) 
(vi) Use in year before index date? 




(vii) Current user? 
















269. Any other medication prescribed in the year before the index date? D 
1. Yes 
0. No 
270 - 385. Details of other medication prescribed in the year before the index date: 
(i) Medication (ii) Indication for treatment (iii) Current use? 
Prefix Suffix 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
rn rn D 
542 
543 
DJ I I I I DJ D 
DJ I I I I DJ D 
DJ I I I I DJ D 
DJ I I I I DJ D 
DJ I I I I DJ D 
DJ I I I I DJ D 
,:r DJ I I I I DJ D 
DJ I I I I DJ D 
DJ I I I I DJ D 
I 
DJ I I I I DJ D 
DJ I I I I DJ D 
:,. 
;, DJ I I I I DJ D 
DJ I I I I DJ D 







(i) Medication code: 
(As per drug dictionary from Centre for Adverse Reactions Monitoring) 

































Ischaemic heart disease 
Oedema not otherwise specified 
Insulin dependent diabetes 
Non-insulin dependent diabetes 
Systemtic lupus erythematosus 
Inflammatory bowel disease 





Anxiety or insomnia 
Asthma 
Chest infection 
Upper respiratory tract infection 
Soft tissue infection lower limbs 
Infection other sites, including infection prophylaxis 
Infection, not otherwise specified 
Peri-menopausal symptoms, excluding abnormal vaginal bleeding 









(iii) Current user of this medication? 



















386. Any record of weight before index date? 
(Measured weight or comment about weight) 
1. Yes 
0. No 
387. Date of latest weight measurement 
before index date: 
(Or date of comment if not measured) 
388. Circumstances when weight recorded: 
1. Female, not pregnant 





3. Female, second or third trimester of pregnancy 
4. Female,$. 6 weeks post-partum 
5. Male 
389. Weight in kilograms: 
390. Weight in stones and pounds: 
391. Narrative comments about weight: 
(Record only if weight was not measured) 
1. Overweight 
2. Average weight 
3. Underweight 
392. Any record of height before index date? 















393. Date of latest height measurement 
before index date: 
[IJ[IJ[IJ 
( Or date of comment if not measured) 
394. Height in metres: 
395. Height in feet and inches: 
396. Narrative comments about height: 
(Record only if height was not measured) 
1. Above average height 
2. Average height 
3. Below average height 
397. Any recorded family history of venous thromboembolism 
before index date? 
1. Yes 
0. No 
398 - 401. Relationship to case: 





4. Aunt or uncle 
5. Grandparent 
6. Other 











APPENDIX C: CASE REPORTS AND CASE SERIES DESCRIBING 
VENOUS THROMBOEMBOLISM IN AIR TRAVELLERS 
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Table Case reports and case series describing venous thromboembolism following travel by air 
Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Homans 1954) 5 patients diagnosed with DVT 4 3 men, 1 woman. Aeroplane (2). Only stated for one During or immediately 
over a 13-year period, source (non-fatal) Car (2). case (14 hours). after travel (2), 2 hours 
not stated. Median age 53.5 years (range 19 (1), 4 days (1). 
-56) 
(Beighton and 25 consecutive patients who 1 49 year old "previously healthy" Aeroplane (1). Not stated, although On arrival. 
Richards 1968) were admitted directly to (fatal) woman developed DVT and was noted to be 
Hillingdon Hospital from subsequently died from cerebral Australian. 
Heathrow Airport, in the years embolism following the passage 
1963 to 1965, after suffering a of clot through a patent foramen 
cardiovascular event during or ovale. 
immediately after a flight. 
(Symington and 182 patients with PE who were 8 5 men, 3 women. Aeroplane (3), Median 9.5 hours Median 48 hours (range 
Stack 1977) admitted to hospitals in (non-fatal) all in (range 3 - 24). 2-96). 
Glasgow over a 3-year period. Median age 54 years (range 30 - economy 
84). class. 
6 cases had a history of "venous Car (3). 
disorders of the legs". Train (1). 
Train/ship (1). 
(Line and 1 patient with PE who was 1 29 year old man, very fit and Aeroplane (1). Was a pilot who Not stated. 
Whitaker 1979) admitted to a hospital in the UK. (non-fatal) active. always flew ::2'.. 3 
hours. 
(Thomas et al. 1 patient with PE who was 1 49 year old man, no risk factors. Aeroplane (1), 29 hours. On arrival. 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Marshall 1982) 1 patient with DVT who was 1 32 year old woman. Aeroplane (1). 8 hours. 24 hours. 
admitted to a hospital in (non-fatal) 
Munich. 
(Ledermann and 3 patients with PE who were 3 3 women. Aeroplane (3). All 3 flew from On arrival. 
Keshavarzian admitted directly to Hillingdon (1 fatal) Southern Hemisphere 
1983) Hospital from Heathrow Airport Median age 63 years (range 59 - (Australia, New 
during an undefined period. 66). Zealand, Zimbabwe). 
1 case had metastatic carcinoma 
of the breast, another was obese. 
None had a history of "venous 
disease". 
(Hart et al. 1985) 1 patient with PE who was 1 39 year old woman. Aeroplane (1). 27 hours. On arrival. 
admitted directly to Ashford (non-fatal) 
Hospital from Heathrow Symptoms of mild gastroenteritis 
Airport. immediately before and during 
flight. No other risk factors. 
(Holliday 1985) 1 patient with PE who was 1 44 year old man, mildly obese, Aeroplane (1). 15 hours. 2 weeks. 
admitted to hospital 19 days (non-fatal) "otherwise in good health". 
after flight. 
(Alberty-Ryoppy 1 patient with DVT who was 1 32 year old "previously healthy" Aeroplane (1). 12 hours. On arrival. 
et al. 1985) admitted Helsinki University (non-fatal) woman. 
General Hospital. 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Sarvesvaran 104 sudden deaths reported to 11 2 men, 9 women. Aeroplane 1 passenger died During flight. 
1986) the coroner, between February (all fatal) (11). during a 6 - 12 hour 
1979 and January 1982, which Ages not given. flight, 10 died during 
occurred in Heathrow Airport or 
8 cases reported to have no 
12 - 18 hour flights. 
on a flight terminating at the 
Airport ( 61 in-flight, 28 would-
significant medical history, details 
of risk factors of remaining cases 
be passengers, 15 staff or non- not discussed. 
travelling spectators). 11/61 
(18%) of in-flight deaths were 
due to PE, compared with 1/28 
(4%) of deaths among would-be 
passengers) 
(Cruickshank et 6 patients with PE, 2 of whom 6 5 men, 1 woman Aeroplane (6), 7 hours (1), 10 hours Median 1 day (range: 
al. 1988) were authors of the paper. The (non-fatal) at least 1 case (1), 24 hours (1). during flight and up to 
source of the other patients was Median age 49.5 years (range 31 (an author) 10 days after arrival). 
not described. -79). travelled in Flight duration not 
3 cases considered to have 
business class. reported for other 3 
cases: UK to Asia and 
predisposing conditions: acute multiple trips within 
nephritic syndrome and Asia over a 4-week 
dehydration (1), CHF (1) previous period (1), 
athletic injury 7 and 2 years Washington to 
earlier (1). London (1), UK to 
USA (1). 
(Finch et al. 2 patients with PE who were 2 66 year old man, overweight, Aeroplane (2). Thailand to UK. On arrival. 
1988) admitted directly to Ashford (both fatal) hypertensive, smoker. 
Hospital from Heathrow Airport China to UK. During flight. 
over a 3-week period. 84 year old woman, usually well. 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(O'Donnell 1988) 250 patients with VTE who 8 2 men, 6 women. Aeroplane (8). Flights to Western Not specifically stated -
were admitted to Freemantle (1 fatal) Australia from: admitted to hospital 
Hospital in Western Australia Mean age 61 years (range 38 - Europe (6), Africa after "recently" arriving 
over a 3-year period. 8 air 80). (1), Asia (1). in Australia. 
travellers. Another 5 had 
Risk factors (no of cases): undertaken "lengthy" 
(undefined) trips by road but the malignancy (1), previous DVT 
characteristics of these patients (1), obesity (1), smoker (3). 
were not described. Unclear whether 6 cases had risk 
factors or whether some cases had 
> 1 risk factor. 
(Biirki 1989) 2 patients (sisters) with DVT (1) 2 25 year old woman, overweight, Aeroplane (2). 11 hours (1). During flight (both). 
and PE (1). (1 fatal) OC, post-splenectomy 
thrombocytosis, strong family Switzerland to 
history of PE. Australia (1). 
31 year old woman, overweight, 
OC, splenectomy, family history 
as above. 
(Steinhauser and 3 USA Air Force pilots who 3 3 men aged 30, 32, and 36 years. Aeroplane (3). 5 hours (1), not stated At end of journey (1), 
Stewart 1989) were admitted to hospital with for others. not stated for others. 
DVT between 1984 and 1987. Risk factors (no of cases): 
previous post-operative 
mesenteric venous thrombosis (1), 
soft tissue knee injury (1). 
(Voorhoeve and 1 patient with DVT and 1 with 2 68 year old woman. Car (1). Italy to the At end of car journey. 
Bruyninckx PE, source not stated. (non-fatal) Netherlands by car 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Benoit 1992) 12 patients with DVT ± PE who 12 8 men, 4 women Aeroplane (9). Median 11.5 hours Median 2 hours ( on 
were admitted to hospital in (non-fatal) (range 3 - 40) arrival - 15 h) 
Geneva during an undefined Median age 47 years (range 23 - Aeroplane and 
period. 71). car (1). 
10/12 cases had 2". 1 pre-existing Car (1). 
risk factors for VTE 
Train (1). 
Risk factors (no of cases): 
previous VTE (5), family history 
of VTE (2), varicose veins (1), 
diarrhoea and dehydration (1), OC 
(1), CHF (1), > 1.8m tall (6). 
(Schmitt and 54 consecutive patients 14 No details provided. Aeroplane. No details provided. No details provided. 
Mihatsch 1992) diagnosed with isolated ( outcome not 
thrombosis of pop Ii teal vein at stated) Bus. 
the Cardiovascular Radiology 
(Numbers not Department of the University of 
Basel, Switzerland. provided). 
(Black 1993) 1 patient (the author) admitted 1 1 man, age and other Aeroplane (1). 1st episode: Trans- 1st episode: 10 days. 
to hospital with DVT following (non-fatal) characteristics not described. Atlantic flight from 
2nd episode: 1 week. a long-distance flight. Twenty USA to UK. 2nd 
years later he developed PE episode: "overnight 
after a flight. flight in cramped 
conditions" 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Sahiar and 1 patient admitted to hospital 1 61 year old man. Aeroplane (1), Domestic flight During flight. 
Mohler 1994) with DVT in left leg. (non-fatal) economy within USA 
Elective proximal tibial class. (Rochester to 
osteotomy of left knee six weeks Oklahoma City), 
earlier, plaster cast removed on duration not stated. 
day of flight. 
(Levy et al. 1995) 1 patient admitted to hospital 2 46 year old man, no risk factors. Aeroplane (2). 10 hours. 3 days. 
with PE and 1 admitted with (non-fatal) 
thrombosis of the femoral vein. 72 year old man, laryngeal 16 hours. "Several days". 
malignancy 20 years earlier 
(Paganin et al. 6 patients admitted to hospital 6 3 men, 3 women. Aeroplane (6), 12 hours. Median 42 hours (range: 
1996) with PE after flights from Paris (non-fatal) at least 5 in on arrival up to 4 days 
to Reunion Island over a 1-year 2 severe cases aged 58 and 59 economy after arrival). 
period. years, mean age of others was 62 class. 
years (SD 3.1). 
Only risk factor among cases was 
HRT (taken by 1 woman). 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Eklof et al. Retrospective review of records 44 24 men, 20 women. Aeroplane 5 - 17 hours, no other During flight (2), 
1996) of 254 patients with DVT ± PE, (non-fatal) (44). information given. < 1 week (37), 1 - 4 
who were admitted to Straub Mean age 63 years (range 32 - weeks (3), 5 - 6 weeks 
Hospital, Honolulu, between 86). (2). 
January 1988 and December 
37/44 (84.1 %) cases had~ 1 pre-1993. Not stated whether all 
patients were asked about travel, existing risk factors for VTB: 1 
but the records of 44 risk factor (32), 2 risk factors (5). 
documented air travel up to 6 Risk factors (no of cases): 
weeks before admission. previous DVT (15), malignancy 
or chronic illness (11), HRT or 
OC (7), minor to moderate lower 
limb injuries < 2 weeks earlier 
(5), recent surgery (2), femoral 
catheterisation < 3 weeks earlier 
(2). 
(Emonson 1997) 1 patient admitted to hospital 1 28 year old man, FVL mutation, Aeroplane (1). Not stated, was a 4 days. 
withDVT. (non-fatal) family history of DVT (sister and navigator with the 
both maternal grandparents). Royal Australian Air 
Force. 
(Nissen 1997) 1 patient with DVT and 4 with 5 1 woman, sex of others not stated. Aeroplane (4): Flights: 2.5 hours (1), 2 days - 4 weeks. 
PE who were admitted to a (non-fatal) business class 4.5 hours (1), 20 
German hospital. Median age 57 years (range 51 - (1), economy hours (1), Germany to 
60). class (1). South East Asia (1). 
Risk factors (no of cases): Car (1). Car: 8.5 hours (1). 
essential thrombocytosis (1), FVL 
mutation (2), malignancy (1). 
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Reference Cases No of cases who 
developed VTE 
following travel 
(Barker et al. President of the USA who 1 
1997) developed DVT on 3 occasions (non-fatal) 
after long-distance flights. 
(Ribier et al. 40 patients with DVT ± PE who 40 
1997) were admitted to hospital in (non-fatal) 
Martinique between 1989 and 
1995. 
(Mercer and Retrospective review of records 33 
Brown 1998) of 134 patients with DVT ± PE, (7 fatal) 
who were admitted to the 
Tripler Army Medical Center, 
Honolulu, over a 4-year period. 
Documented enquiry about air 
travel in the records of 66 
patients. 41/66 had flown~ 6 
months before onset of 
symptoms, but only those who 
had flown within 31 days of the 
onset of symptoms (33/44) were 
described further. 
..; 
'< ~ ,, 
';/_ '( 
Characteristics of cases who Mode of 
developed VTE following travel travel 
(no of cases) 
52 years when developed first Presidential 
DVT. aeroplane (1). 
11 men, 29 women. Aeroplane 
(40). 
Mean age 55.8 years (range 19 -
84). 
Risk factors (no of cases): 
previous VTE (12 cases, 6 were 
flight-related), chronic disease 
(4), malignancy (2), OC (7), 
recent surgery (9). 
27 men, 6 women. Aeroplane 
(33). 
Median age 48 years (range 19 -
80). 
21/33 (63.6%) cases had 2': 1 pre-
existing risk factors for VTE: 1 
risk factor (19), 2 risk factors (1), 
3 risk factors (1). 
Risk factors (no of cases): 
previous VTE (7), anti-cardiolipin 
antibody (2), malignancy (7), 
CHF (4), recent leg surgery (1), 
paraplegia (1), "oestrogen 
therapy" (1), not stated (1). 
..\ '' ' 
Duration of travel 
USA to Japan, to the 
Middle East, and to 
Russia. 
4 hours (2), 8 - 9 
hours (34), not stated 
(4). 
Minimum flight time 
was 4 hours. 
24 patients had flown 
to Honolulu from 
unspecified North 
American airports, 
8 from Asia, and 1 
from South America. 
Elapsed time from end 
of journey to onset of 
symptoms 
Not stated. 
On arrival (9), < 24 
hours (13), 1 - 3 days 
(2), 4 - 28 days (16). 
Time from start of flight 
to symptoms: median 4 
days (range: during 
flight - 31 days). 
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Reference 








Retrospective review of records 
of patients with DVT referred to 
the anticoagulation clinic St 
George's Hospital in London 
over a 3-year period. Identified 
20 patients who had 
spontaneously reported that they 
had flown at some time in the 
35 days before the onset of 
symptoms. 
70 patients with PE seen by the 
medical department at 
Aeroports De Paris between 
1984 and 1998 after arrival at 
Charles de Gaulle or Orly 
airports. The characteristics of 
64 patients who arrived between 
1990 and 19 98 were described. 
" 
y 
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Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE following travel travel of journey to onset of 
(no of cases) symptoms 
5 men, 15 women. Aeroplane Median 7 hours Median 2 days (range 0 
(20): business (range 1 - 23). - 35). 
Median age 40 years (22 - 66). class (2), 
15/20 (7 5 % ) cases had ~ 1 pre-
economy class 
(18). 
existing risk factors for VTE: 1 
risk factor (7), 2 risk factors (5), 3 
risk factors (3). 
Risk factors (no of cases): 
previous thrombosis (4), FVL 
mutation (5), protein S deficiency 
(1), OC use (5), HRT (2), 
puerperium (1), malignancy (1), 
injury to affected leg (2), 
pneumonia (1), family history of 
VTE (4). 
15 men, 49 women. Aeroplane Median 13 hours Before left airport. 
(64): first (range 3 - 23). 
Median age 59.5 years (range 26 class (3), 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Sinzinger et al. 19 patients referred to a 15 14 men, 1 woman. Aeroplane Median 9 hours Median 20 hours (range: 
1999) thrombosis centre in Austria (non-fatal) (15): first (range 5 - 22). during flight - 85 
over an 18-month period for Median age 50 years (range 33 - class (1), hours) 
diagnostic investigations, 75). economy class 
thrombophilia screening, and 
Risk factors (no of cases): 
(14). 
other coagulation tests. 15/19 
had objective evidence of VTE overweight (5), diarrhoea at time 
(all PE). of flight ( 4 ), fever and influenza 
symptoms (5). None had a 
15/19 travelled by air. history of VTE, a chronic disease, 
or abnormalities of the 
coagulation or prostaglandin 
systems. 
(Simon 1999) 77 patients with DVT, 39 with 77 41/77 (53.2%) cases had;:::: 1 pre- Aeroplane Mean 12 hours. Mean 3.1 days. 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Arfvidsson et al. 109 consecutive patients with 25 11 men, 14 women. Aeroplane Mean 9 hours (range Time from start of flight 
1999) DVT ± PE admitted to Straub (non-fatal) (25). 5-8). to symptoms: < 24 
Hospital, Honolulu, between Mean age 58 years (range 36 - hours (20, including 9 
July 1995 and October 1998. In 79). cases who developed 
contrast to the earlier case series 
23/25 (92%) cases had~ I pre-
symptoms during 
from this hospital, all the flight), I - 7 days (3), 
patients were asked about existing risk factors for VTE. 8 - 10 days (2). 
"recent" (undefined) air travel, Mean no of risk factors was 3. 
as well as other risk factors for Risk factors (no of cases): 
VTE, while they were still in previous VTE (7), HRT (6), OC 
hospital. (1), overweight or obese (19), 
malignancy (7), recent lower limb 
injury (4), recent surgery for 
malignancy (3), chronic heart 
disease (11), other chronic disease 
(8). 
(Parsi and 64 patients who developed SVT, 64 32 men, 32 women. Aeroplane Mean travel time by During flight ( 48), < I 
McGrath 2000; DVT, or PE~ 28 days after (non-fatal) (58): first air: 23.4 hours (range week (9), I - 4 weeks 
Parsi et al. 200 I) travel by air, car, train, or bus Median age 48 years. class (2), 3 - 55). (7). 
and were seen in the vascular 
Risk factors (no of cases): 
business class 
laboratory at St Vincent's (12), economy Mean travel time by 
Hospital, Sydney, between previous VTE (24), thrombophilia class (42), car: 23.2 hours (range 
1996 and 1999. (46), obesity (37), HRT or OC use cabin crew 11-44). 
(20), recent surgery or trauma (8), (2). 
infection (5), malignancy (3), 
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Cases No of cases who 
developed VTE 
following travel 
86 patients who developed DVT 86 
± PE :::; 28 days after air travel. (non-fatal) 
Series included 18 patients 
(interviewed face-to-face) who 
were part of an ongoing regional 
study of VTE by researchers at 
the Freeman Hospital in 
Newcastle on Tyne and 68 
people who responded to a 
notice in a national newspaper 
in March 1999 (initially 
completed a questionnaire and 
then were interviewed, 
presumably by telephone). 
543 consecutive patients with 39 
DVT ± PE admitted to (non-fatal) 
Wilhelminen Hospital in Vienna 




Characteristics of cases who 
developed VTE following travel 
44 men, 42 women. 
Mean age 59 years (range 20 -
83). 
62/86 (72 % ) cases had ~ 1 pre-
existing risk factors for VTE. 
Risk factors (no of cases): family 
history of VTE (17), HRT or OC 
(19), "~ 1 other of the VTE risk 
factors examined" (26). BMI of 
the cases was reported to be no 
different from general population. 
15 men, 24 women. 
Mean age 63.1 years (range not 
provided). 
Risk factors (no of cases): known 
malignancy (6), malignancy 




Mode of Duration of travel Elapsed time from end 
travel of journey to onset of 
(no of cases) symptoms 
Aeroplane "Up to 3 hours" (11). During flight or < 24 
(86): business hours ( 48), 24 - 96 
class (13), "3 - 6 hours" (12). hours (31), > 96 hours 
economy class (7). 
(73). "6 - 9 hours" (9). 
"9 - 12 hours" (17). 
5 patients had mild leg 
symptoms before the 
"12 - 15 hours" (12). flight which worsened 
during or after flight. 
"15 - 18 hours" (8). 
Symptoms following an 
"18 - 21 hours" (1). outbound flight in 29 
(18 undertook sequential 
"21 - 24 hours" (11). flights over several 
"> 24 hours" (5). 
days). 
7 5 had undertaken 
more than one flight. 
Aeroplane > 5 hours (39), no During, or directly after, 
(11). other details a flight (2). 
Car, bus, or 
provided. 
No information given 
train (28). about remaining cases. 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Cheung and Retrospective review of medical 14 3 men, 11 women. Aeroplane Median 15 hours During flight or within 2 
Duflou 2001) records and histological slides (fatal) (14): first or (range 2 - 23). hours of landing. 
of 14 of 15 passengers who died Median age 68.5 years (range 54 business class 
from PE on a flight that landed -76). (2), economy 
at Sydney International Airport 
Histological evidence of PE 
class (12). 
( 6) or within 2 hours of landing 
(8) over a 6-year period. which commenced before 
boarding plane found in 4 cases. 
In 10 cases, histological changes 
consistent with fresh thrombus 
formed during flight. 
(Johnston and 27 cases of VTE in pilots 11 Population of healthy workers, Aeroplane Not stated. 2 cases developed 
Evans 2001) between 1990 and 2000 in UK, (non-fatal) mean age 39 years. (16). symptoms "shortly 
identified from Civil Aviation after" flights as 
Authority Database. 16 cases passengers. 
followed trauma or surgery, 11 
no obvious risk factors other 
than flying. 
(Tan et al. 2002) Retrospective review of the 9 8 air travellers were all Aeroplane (8). Mean 10.3 hours Air passengers: all 
records of 42 consecutive ( unclear whether Caucasian, no other details (range 5 - 15), transferred directly from 
patients with PE who were any deaths) provided. Bus (1). included bus journey airport to hospital. 
admitted to Changi General of 8 hours. 
Hospital, near Changi 1 Chinese man who travelled by Bus passenger: not 
International Airport, Singapore bus had protein S deficiency and a stated. 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Kesteven and 1,250 consecutive patients with 47 21 men, 26 women. Aeroplane Median 6 hours Time from start of 
Robinson 2002) objectively confirmed DVT ± (not stated (28), all in (range 2.5 - 30). journey to symptoms: 
PE admitted to 5 hospitals whether any Mean age 60 years (range 29 - economy during journey (20), 
within the area covered by two deaths) 84). class. ~ 3 days (18), 4 - 7 days 
Health Authorities in the UK 
44/47 (94%) cases had~ 1 pre-
(4), 8 - 28 days (5). 
(Newcastle and North Tyneside, Car (11). 
and Northumberland) between existing risk factors for VTE. 
September 1998 and August Bus (6). Risk factors (no of cases): 
2000. Patients interviewed using varicose veins (23), ~ 1 "medical Train (2). 
a structured questionnaire risk factor" (25), family history of 
within 4 weeks of diagnosis. VTE (11), HRT or OC (7), BMI > 
30 kg/m2 (8). 9/18 cases who were 
tested had thrombophilia. 
(McQuillan et aL Retrospective review of the 58 30 men, 28 women. Aeroplane "< 4 hours" (7). Information available 
2003) records of an unstated number (not stated (48): PE (21), for 16 patients only: 
of consecutive patients with whether any Median age 49.8 years (range 17 proximal DVT "4- 8 hours" (17). median 2.8 days, (range 
objectively confirmed DVT, PE, deaths) -82). (17), 4 calf 0-28). 
or superficial thrombophlebitis DVT(4), SVT 
"8 - 12 hours" (10). 
who presented to a Perth No of acquired or genetic risk (6). "> 12 hours" (24). 
hospital or an affiliated private factors (no of cases): none (9), 1 
haematology clinic in Wes tern (19), 2 (21), ~ 3 (9). Car (7). 
Australia between July 1999 
Bus (3). and April 2001. 
(O'Connell et aL 1 patient admitted to 1 40 year old woman taking OC, Aeroplane (1). At least 24 hours (UK During flight. 
2005) Christchurch Hospital in New (non-fatal) BMI 29 kg/m2• to New Zealand). 
Zealand with massive PE. 
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Reference Cases No of cases who Characteristics of cases who Mode of Duration of travel Elapsed time from end 
developed VTE developed VTE following travel travel of journey to onset of 
following travel (no of cases) symptoms 
(Moghal and 1 child with DVT. 1 13 year old girl from the UK who Aeroplane (1). Trans-Atlantic flight 2 weeks after second 
Krishnan 2005) (non-fatal) undertook a return trans-Atlantic to and from UK. flight. 
trip, concurrent undiagnosed 
relapse of nephrotic syndrome. 
FVL mutation, maternal 
grandfather had a history of DVT. 
(Schreijer et al. 1 case of DVT. 1 33 year old woman who during a Aeroplane and 2 flights of 12 hours, Directly after return 
2005) (non-fatal) one month period undertook a bus (1). 2 bus trips of 6 and flight to the 
return trip from the Netherlands to 12 hours. Netherlands. 
Nepal. FVL mutation, took a 
diuretic to prevent altitude 
sickness. 
'Abbreviations used in the table BMI: body mass index, CHF: congestive heart failure, DVT: deep vein thrombosis, FVL: factor V Leiden, HRT: hormone replacement therapy, m: metres, OC: oral contraceptive, PE: pulmonary 
embolism, UK: United Kingdom, USA: United States of America, VTE: venous thromboembolism. 
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Consent Form 1: Next of kin who returned the contact details form 
Name(s) of case ______________ _ 
Name(s) of next of kin ____________ _ 
Relationship to case _____________ _ 
Address ------------------
Telephone number _____________ _ 
Hello, may I please speak to ( name of next of kin)? 
I am Lianne Parkin, a doctor from the Otago Medical School. Thank you very much for 
returning the form that I sent you. You said that this would be a good time to speak to you, is 
it still alright? (If yes, continue. If no, ask: when would you like me to ring back? Record 
date and time on page 2) As I said in the letter I sent you, we are carrying out a major study 
on the causes of pulmonary embolism. Our aim is to identify factors that could help in 
preventing deaths from this condition in the future. We are interviewing the relatives of 
people who have died from pulmonary embolism about their life and health before they 
became unwell. If you agree to take part in the study, all the information you give us will be 
recorded without names and will be kept strictly confidential. Also if you do not want to 
answer particular questions that is fine. Do you have any questions about the study that you 
wish to ask? Would you be willing to help by answering some questions about your 
(relative's) life and health for our study? 
Consent: Obtained / Refused 1 = obtained 2 = refused D 
Signed: ____________ _ Date: ________ _ 
565 
Subject no. .___.________________.I D 
If consent not given: Thank you very much for your time. Goodbye. 
If consent given: I'd like to make a time for ____ to call you back for the telephone 
interview. It will take about 20 minutes. When would be convenient? (record below) 
f 
Consent and interview booking contact: 
Dates phoned Time phoned Outcome (contacted/ not contacted, did/ did not consent) 
( continue on another sheet if necessary) 
Interview appointment date and time: ____________ _ 







Consent Form 2: Next of kin who did not return the contact details form 
Name(s) of case _____________ _ 
Name(s) of next of kin ___________ _ 
Relationship to case _____________ _ 
Address ------------------
Telephone number _____________ _ 
Hello, may I please speak to (name of next of kin)? 
I am Lianne Parkin, a doctor from the Otago Medical School. I am making follow up calls to 
people that I recently wrote to about our study of pulmonary embolism, and I am checking to 
see if you received my letter. Do you remember getting my letter? 
If no: Offer to resend the letter ( check that we have the correct address). If they don't want 
us to resend letter: I would like to be able to give you a little background information about 
our study before you make your final decision. Then go on from ** ( if, following discussion, 
they agree to take part in the study repeat the offer to send the letter so that they have a copy 
for their records) 
If yes: As I said in the letter I sent you, **we are carrying out a major study on the causes of 
pulmonary embolism. Our aim is to identify factors that could help in preventing deaths from 
this condition in the future. We are interviewing the relatives of people who have died from 
pulmonary embolism about their life and health before they became unwell. If you agree to 
take part in the study, all the information you give us will be recorded without names and will 
be kept strictly confidential. Also if you do not want to answer particular questions that is fine. 
Do you have any questions about the study that you wish to ask? Would you be willing to help 
by answering some questions about your (relative' s) life and health for our study? 
567 
Subject no. 
Consent: Obtained / Refused 1 = obtained 2 = refused D 
Signed: ____________ _ Date: -----------
')' 
If consent not given: Thank you very much for your time. Goodbye. 
If consent given: I'd like to make a time for ___ to call you back for the telephone 
interview. It will take about 20 minutes. When would be convenient? (record below) 
Consent and interview booking contact: 
Dates phoned Time phoned Outcome (contacted/ not contacted, did/ did not consent) 
( continue on another sheet if necessary) 
Interview appointment date and time: ____________ _ 




Consent Form 3: Controls who returned the contact details form 
Name(s) _______________ _ 
Address _________________ _ 
Telephone number _____________ _ 
Hello, may I please speak to (name of control)? 
I am Lianne Parkin, a doctor from the Otago Medical School. Thank you very much for 
returning the form that I sent you. You said that this would be a good time to speak to you, is 
it still alright? (If yes, continue. If no, ask: when would you like me to ring back? Record 
date and time on page 3) As I said in the letter I sent you, we are carrying out a major study 
on the causes of a serious condition that affects many New Zealanders every year. Our aim is 
to identify factors that could help in preventing deaths from this condition in the future. We 
are interviewing a large number of men and women all over New Zealand about their life and 
health. If you agree to take part in the study, all the information you give us will be recorded 
without your name and will be kept strictly confidential. Also if you do not want to answer 
particular questions that is fine. Do you have any questions about the study that you wish to 
ask? Would you be willing to help by answering some questions about your health for our 
study? 
Consent: Obtained / Refused 1 = obtained 2 = refused D 





If consent not given: Thank you very much for your time. Before you go please may I ask 
you two quick questions that we are asking every one who is not taking part? Of course this 
entirely up to you. 
Were you living in New Zealand on _!_I_ (index date)? 
(Prompt: if your home was in New Zealand but you were overseas on a holiday or a 
business trip on this date, you should answer yes to this question) 
1 =yes 2=no 3 = did not answer D 
Were you in New Zealand, or temporarily overseas on_/_/_ (date of death of case)? 
1 =in NZ 2 = overseas 3 = did not answer D 
Thank you again for your time. Goodbye. 
If consent given: In this study we want to interview people who were living in New Zealand 
on particular dates. Were you living in New Zealand on _!_I_ (index date)? 
(Prompt: if your home was in New Zealand but you were overseas on a holiday or a 
business trip on this date, you should answer yes to this question) 
1 =yes 2=no D 
If yes: I'd like to make a time for ____ to call you back for the telephone interview. It will 
take about 20 minutes. When would be convenient? (record on next page) 
If no: Thank you very much for agreeing to be part of this study, but as you weren't living in 




Consent and interview booking contact: 
Dates phoned Time phoned Outcome (contacted/ not contacted, did/ did not consent) 
., 
( continue on another sheet if necessary) 
Interview appointment date and time: ____________ _ 





Consent Form 4: Controls who did not return the contact details form 
Name(s) _______________ _ 
Address ------------------
Telephone number _____________ _ 
Hello, may I please speak to (name of control)? 
I am Lianne Parkin, a doctor from the Otago Medical School. I am making follow up calls to 
people that I recently wrote to about a study we are carrying out, and I am checking to see if 
you received my letter. Do you remember getting my letter? 
If no: Offer to resend the letter ( check that we have the correct address). If they don't want 
us to resend letter: I would like to be able to give you a little background information about 
our study before you make your final decision. Then go on from** (if, following discussion, 
they agree to take part in the study repeat the offer to send the letter so that they have a copy 
for their records) 
If yes: As I said in the letter I sent you, ** we are carrying out a major study on the causes of 
a serious health condition that affects many New Zealanders every year. Our aim is to 
identify factors that could help in preventing deaths from this condition in the future. We are 
interviewing a large number of men and women all over New Zealand about their life and 
health. If you agree to take part in the study, all the information you give us will be recorded 
without your name and will be kept strictly confidential. Also if you do not want to answer 
particular questions that is fine. Do you have any questions about the study that you wish to 




Consent: Obtained / Refused 1 = obtained 2 = refused D 
Date: [D[D[D --------------
Signed: ___________ _ D 
If consent not given: Thank you very much for your time. Before you go please may I ask 
you two quick questions that we are asking every one who is not taking part? Of course this 
entirely up to you. 
Were you living in New Zealand on_/_/_ (index date)? 
(Prompt: if your home was in New Zealand but you were overseas on a holiday or a 
business trip on this date, you should answer yes to this question) 
1 =yes 2=no 3 = did not answer D 
Were you in New Zealand, or temporarily overseas on_/_/_ (date of death of case)? 
1 =in NZ 2 = overseas 3 = did not answer D 
Thank you again for your time. Goodbye. 
If consent given: In this study we want to interview people who were living in New Zealand 
on particular dates. Were you living in New Zealand on _!_I_ (index date)? 
(Prompt: if your home was in New Zealand but you were overseas on a holiday or a 
business trip on this date, you should answer yes to this question) 





If yes: I'd like to make a time for _____ to call you back for the telephone interview. It 
will take about 20 minutes. When would be convenient? ( record below) 
If no: Thank you very much for agreeing to be part of this study, but as you weren't living in 
New Zealand on this date we can't include you in the study. Thank you very much for your 
time. Goodbye. 
Consent and interview booking contact: 
Dates phoned Time phoned Outcome (contacted/ not contacted, did/ did not consent) 
( continue on another sheet if necessary) 
Interview appointment date and time: ____________ _ 












APPENDIX E: INTERVIEWER-ADMINISTERED QUESTIONNAIRE 
1. On the following pages, the questionnaire sections are ordered according to the 
sequence in which they appeared on the computer screen during the telephone 
interview (that is, 1, 2, 3, 4a, 9a, 10, 5, 6, 7, and 8). The reason why the sections 
do not follow a strictly numerical sequence is that at the time the Abbey CATI 
software® was used, it was not possible to change the numbering of a section after 
it had been created. 
2. When the computerised version of the questionnaire was developed, a "loop" was 
incorporated so that it was possible to ask questions regarding up to 15 
international journeys by air and up to 15 domestic air journeys (within countries 
other than New Zealand). On the following pages, however, only one set of 
questions is shown for each type of journey . 
I>-
Fatal pulmonary embolism and long-distance air travel study 
Medical history Section 1 
QOOa Hello, may I please speak to <> <>? I am <> from the Otago Medical School. Thank you very much OOOa 
for agreeing to participate in our study of health problems. Is it still convenient to do the interview now? 
Before we begin, I'd like to emphasize that all the information you give me will be confidential and will 
be recorded without your name. You don't need to answer all the questions, and you may stop the 
interview at any time if you wish. I need to type your answers, so you might hear me typing during the 
interview. 
Do you have the calendar that we sent in front of you? 
IF YES: That's good. You'll also need a pen or pencil. Have you got one handy? 
(IF NO: ask them to go and get it. If they have lost it: fax them the calendar if possible, otherwise 
arrange to post another copy and reschedule the interview) 
During this interview I'm going to ask you questions about what <>your<><>your <>'S<> health was like 
before a particular date. That date is the <>. So before I ask you any more questions, I'd like you circle 
this date on your calendar. I'd also like you to circle two other dates. They are the <> and the <>. 
Response type: Statement 
Default next: 1 -OOb 
(Added 10/03/2003 04:43:27 PM by lparkin Modified 27/05/2003 08:55:58 PM by lianne parkin) 
QOOb <> To help you remember what your health was like before the<> it might be useful to think about 
where you were living on that date and how old you were. 
You could also think about particular events that happened around that time. For some people this 
might be a new job, a holiday, or the birth of a child. 
I'll give you a little bit of time to think about this now. You might find that it's helpful to write some 
things on the calendar. 
I don't need you to tell me about any of these things - it's just to help jog your memory about the time 
before the <>. Let me know when you're ready to carry on with the interview.<> 
I'd like to start the interview by asking a few SHORT questions about what <>your<> <>your <>'S<> 
health was like before the <>. 
For most of these questions a 'yes' or 'no' answer is all that I need. <-IIF(lreference.ucontrol and 
lower(reference.usamedate)<>"yes",[lt might be helpful to look at the calendar as you answer these 
questions, just to remind yourself that I'm ONLY asking about your <>'s health from the time <>S<>he 
was born up until the<>.],")-> 
<>I realise that you probably won't know every detail of your <>'s medical history. Please just answer 
these questions as best as you can.<> 
Response type: Statement 
Default next: 1 -01 
(Added 14/03/2003 02:32:41 PM by Jparkin Modified 28/05/2003 12:54:07 PM by lianne parkin) 
QOOb 
001 So, before the <>, <>were you <><>was your <><> EVER treated for any of the following conditions? 001 
Angina? 
Created with XFRX, www.eqeus.com, commercial use prohibited. 
Section 1 
' 1,-)--
Medical history Section 1 




Default next: 1 -02 
(Added 07/03/2003 01 :50:39 PM by lparkin Modified 14/05/2003 05:46:53 PM by lianne parkin) 
002 A heart attack? 




Default next: 1 -03 
{Added 14/05/2003 05:11 :48 PM by lianne parkin Modified / / 
Q03 A stroke? 




Default next: 1 -04 
: AM by) 
{Added 14/05/2003 05:12:12 PM by lianne parkin Modified / / : : AM by) 
Q02 
Q03 
Q04 High blood pressure <><>at a time when you WEREN'T PREGNANT<> ?<><><>at a time when she Q04 
WASN'T PREGNANT<>?<> 




Default next: 1 -05 
(Added 14/05/2003 05:12:44 PM by lianne parkin Modified / / 
Q05 Systemic lupus erythematosis or SLE? 
: AM by) 
{PROMPT IF NECESSARY: SLE is a chronic condition in which people often develop a rash over their 
cheekbones, as well as problems with their kidneys, spleen, lungs, heart, brain, and joints.) 




Default next: 1 -06 
006 
{Added 14/05/2003 05:13:26 PM by lianne parkin Modified 14/05/2003 05:47:06 PM by lianne parkin) 
Crohn's disease or ulcerative colitis? 
{PROMPT IF NECESSARY: People with these diseases have inflammation of the intestine and 
serious diarrhoea) 




Default next: 1 -07a 
(Added 14/05/2003 05:13:51 PM by lianne parkin Modified 16/05/2003 02:32:39 PM by lianne parkin) 
005 
Q06 
Q07a Now I just want to check that I've recorded your answers correctly. Q07a 
I have recorded that before the<>, <>you 
Section 1 
., 
Medical history Section 1 
WERE<><>your <> WAS<> treated for: 
<-iif(Qdata1 .q01=1,'Angina'+CHR(13),")-><-iif(Qdata1 .q02=1,'A heart 
attack'+CHR(13),'')-><-iif(Qdata1 .q03=1,'A stroke'+CHR(13),")-><·iil(Qdata1 .q04=1,'High blood 
pressure'+CHR(13),'')-><-iif(Qdata1 .q05=1, 'Systemic lupus 
erythematosis'+CHR(13),")-><-iif(Qdata1 .q06=1,''Crohn's disease or ulcerative colitis",'')·> 
Is that correct? (make corrections as necessary) 
Response type: Statement 
Default next: 1 -07b 
(Added 14/05/2003 05:15:10 PM by lianne parkin Modified 19/05/200311:21:50 AM by lianne parkin) 
Q07b And <>you WEREN'T <><>your <>WASN'T<> treated for: 
<-iif(Qdata1 .q01 =2,'Angina'+CHR(13),")-><-iif(Qdata1 .q02=2,'A heart 
attack'+CHR(13),")-><-iil(Qdata1 .q03=2,'A stroke'+CHR(13),'')-><-iif(Qdata1 .q04=2,'High blood 
pressure' +CHR(13), ")-><-iil(Qdata1 .q05=2, 'Systemic lupus 
erythematosis'+CHR(13),'')-><·iil(Qdata1 .q06=2,''Crohn's disease or ulcerative colitis",'')-> 
Is that correct? (make corrections as necessary) 
Response type: Statement 
Default next: 1 -07c 
(Added 14/05/2003 05:36:29 PM by lianne parkin Modified 16/05/2003 04:21 :50 PM by lianne parkin) 
Q07c And you DON'T KNOW whether <>you were<><>your <> was<> treated for: 
<-iif(Qdata1 .q01 =3,'Angina'+CHR(13),")-><-iif(Qdata1 .q02=3,'A heart 
attack'+CHR(13),'')-><-iif(Qdata 1.q03=3, 'A stroke'+CHR(13), ")-><-iif(Qdata1 .q04=3, 'High blood 
pressure'+CHR(13),")-><-iif(Qdata1 .q05=3,'Systemic lupus 
erythematosis'+CHR(13),'')-><-iif(Qdata1 .q06=3,"Crohn's disease or ulcerative colitis",")-> 
Is that correct? (correct answers as necessary) 
Response type: Statement 
Default next: 1 -08a 
(Added 14/05/2003 05:44:54 PM by lianne parkin Modified 16/05/2003 04:23:19 PM by lianne parkin) 
Q08a <>Were you<><>Was your<><> EVER treated for any other heart problems? 




Default next: 1 -09a 
Response logic: 
1 08b 
(Added 09/05/2003 04:12:28 PM by lianne parkin Modified 14/05/2003 04:25:04 PM by lianne parkin) 
Q08b What was the problem(s) <>you were<><><>S<>he was<> treated for? 
Response type: Single line text 
200 
Default next: 1 -08c 
Response logic: 
(Added 07/03/2003 04:13:51 PM by lparkin Modified 14/05/2003 04:25:59 PM by lianne parkin) 









Pre-logic: lower(gcusername)<>'lianne parkin' GOT0:1 08d 
Response type: Numeric 
999.9 
Default next: 1 -08d 
(Added 11/03/2003 05:17:53 PM by lparkin Modified 14/05/2003 04:59:40 PM by lianne parkin) 
Q08d Before the <> 
Response type: Statement 
Default next: 1 -09a 
(Added 20/03/2003 05:07:22 PM by lparkin Modified 14/05/2003 05:03:13 PM by lianne parkin) 
Q09a <>Were you<><>Was your<><> EVER treated for diabetes? 




Default next: 1 -10a 
Response logic: 
1 09b 
(Added 07/03/2003 04:18:51 PM by lparkin Modified 14/05/2003 04:56:49 PM by lianne parkin) 
Q09b What type of diabetes did <>YOU<><><>S<>he<> have? 
PROMPT IF NECESSARY: <>Were you<><>Was <>S<>he<> treated with insulin injections, with 
tablets, or with a particular diet? 
Response type: Single select from 
Insulin dependent 
Non-insulin dependent 
Gestational diabetes only 
Unknown 
Default next: 1 -09c 
(Added 07/03/2003 04:20:47 PM by lparkin Modified 14/05/2003 04:50:38 PM by lianne parkin) 
Q09c Before the <> 
Response type: Statement 
Default next: 1 -1 Oa 
(Added 20/03/2003 05:10:27 PM by lparkin Modified 14/05/2003 04:50:55 PM by lianne parkin) 
Q1 Oa <>Were you<><>Was your<><> EVER treated for kidney problems? 




Default next: 1 -11 a 
(Added 07/03/2003 04:34:16 PM by lparkin 
Response logic: 
110b 
Modified 14/05/2003 04:51 :13 PM by lianne parkin) 
Q10b What was the problem(s) <>you were<><><>S<>he was<> treated for? 
IF"KIDNEY INFECTION" STATED, ASK: 
<>Were you <><>Was <>S<>he <> treated with antibiotics? How many days <>were you <><>Was 
<>S<>he<> treated for? <>Were you <><>Was <>S<>he <> admitted to hospital? <>Were you 












Medical history Section 1 
IF "KIDNEY STONE" STATED, ASK: How was the stone diagnosed? Did <>YOU<><><>S<>he <> have 
an XRay or ultrasound? What treatment <>were you<><>was <>S<>he<> given? 
Response type: Single line text 
200 
Default next: 1 -10c 
(Added 07/03/2003 04:36:17 PM by lparkin Modified 19/05/2003 11 :29:39 AM by lianne parkin) 
010c What is (are) the ICD-9 code(s)?) 
Pre-logic: lower(gcusernam·e)<>'lianne parkin' GOT0:1 1 Od 
Response type: Numeric 
999.9 
Default next: 1 -10d 
(Added 11/03/2003 05:23:23 PM by lparkin Modified 14/05/2003 05:00:38 PM by lianne parkin) 
01 Od Before the <> 
Response type: Statement 
Default next: 1 -11 a 
(Added 20/03/2003 05:52:54 PM by lparkin Modified 14/05/2003 04:52:01 PM by lianne parkin) 
011 a <>Were you<> <>Was your <><> EVER treated for liver problems? 




Default next: 1 -12a 
Response logic: 
111b 
(Added 07/03/2003 04:37:30 PM by lparkin Modified 14/05/2003 04:52:19 PM by lianne parkin) 
011 b What was the problem(s) <>you were<><><>S<>he was<> treated for? 
Response type: Single line text 
200 
Default next: 1-11c 
(Added 07/03/2003 04:38:04 PM by lparkin Modified 14/05/2003 04:52:34 PM by lianne parkin) 
Q11 c What is (are) the ICD-9 code(s)? 
Pre-logic: lower(gcusername)<>'lianne parkin' GOT0:1 11d 
Response type: Numeric 
999.9 
Default next: 1 -11 d 
(Added 11/03/2003 05:26:49 PM by lparkin Modified 14/05/2003 05:01 :19 PM by lianne parkin) 
Q11 d Before the <> 
Response type: Statement 
Default next: 1 -12a 
(Added 20/03/2003 05:59:07 PM by lparkin Modified 14/05/2003 04:53:07 PM by lianne parkin) 
Q12a <>Were you<><>Was your<><> EVER 


















Default next: 1 -13a 
Response logic: 
112b 
(Added 07/03/2003 04:39:15 PM by lparkin Modified 14/05/2003 04:53:23 PM by lianne parkin) 
Q12b What type(s) of cancer did <>you <><><>S<>he<> have? 
NB. IF BONE, BRAIN, OR LIVER CANCER STATED, ASK: Where did the cancer start? 
IF SKIN CANCER STATED, ASK: Was it a melanoma skin cancer? 
IF CERVICAL CANCER STATED, ASK: What treatment <>Were you 
<><>Was <>She<><> given? 
Response type: Single line text 
200 
Default next: 1 -12c 
(Added 07/03/2003 04:39:42 PM by lparkin Modified 14/05/2003 08:30:29 PM by lianne parkin) 
Q12c When was the cancer first diagnosed? 
Response type: Single line text 
Default next: 1 -12d 
(Added 07/03/2003 04:40:04 PM by lparkin Modified 14/05/2003 04:53:52 PM by lianne parkin) 
Q12d What is (are) the ICD-9 code(s)? 
Pre-logic: lower{gcusername)<>'lianne parkin' GOT0:1 12e 
Response type: Numeric 
999.9 
Default next: 1 -12e 
(Added 11/03/2003 05:31 :02 PM by lparkin Modified 14/05/2003 05:01 :50 PM by lianne parkin) 
Qi 2e Before the <> 
Response type: Statement 
Default next: 1 -13a 
(Added 20/03/2003 06:02:59 PM by lparkin Modified 14/05/2003 04:54:20 PM by lianne parkin) 
013a Did <>you <><>your<><> EVER have varicose veins? 




Default next: 1 -14a 
Response logic: 
113b 
(Added 01/02/2003 12:00:00 AM by oblakey Modified 14/05/2003 04:54:39 PM by lianne parkin) 
Q13b <>Did you ever have treatment for your varicose veins?<><>Did your <> ever have treatment for 









Medical history Section 1 




Default next: 1 -13c 
(Added 01/02/2003 12:00:00 AM by cblakey Modified 14/05/2003 04:54:54 PM by lianne parkin} 
Q13c Before the<> 
Response type: Statement 
Default next: 1 -14a 
(Added 20/03/2003 06:06:50 PM by lparkin Modified 14/05/2003 04:57:41 PM by lianne parkin} 
Q13c 
Q14a Did <>YOU<><>your <><> EVER have a blood clot in the veins of <>your<><><>her<><>hiS<</Umale 014a 
»<> legs? 
PROMPT IF NECESSARY: Blood clots can occur in the veins on the SURFACE of the legs AND in 
the DEEP veins. The medical name for blood clots in the veins on the surface of the legs is superficial 
venous thrombosis or thrombophlebttis; and the medical name for blood clots in the deep veins of the 
legs or pelvis is deep vein thrombosis (or DVT for short). 




Default next: 1 -15a 
Response logic: 
114b 
(Added 07/03/2003 05:45:06 PM by lparkin Modified 14/05/2003 04:55:20 PM by lianne parkin} 
Q14b Was the blood clot in the veins on the SURFACE of your <><>'S<> leg, OR in the DEEP VEINS of 
<>your<><><>her<><>his«/Umale>><> leg? 
PROMPT IF NECESSARY: The medical names for blood clots in the veins on the surface of the legs 
are superficial venous thrombosis or thrombophlebitis; and the medical name for blood clots in the 
deep veins of the legs or pelvis is deep vein thrombosis, or DVT or short. 




Both, at different times 
Don't know 
Post-logic: Qdata1.q14b=1 or Qdata1.q14b=3 or Odata1.q14b=4 GOT0:1 14c 
Qdata1 .q14b=2 GOT0:1 14h 
Qdata1.q14b=5GOT0:114m 
Default next: 1 -15a 
{Added 07/03/2003 05:51 :04 PM by lparkin Modified 14/05/2003 05:05:27 PM by lianne parkin) 
014b 
Q14c I'd like to ask you some more questions about the clot in the veins on the SURFACE of your<., <>'S<> 014c 
leg. 
When was the {first episode if> 1) clot diagnosed? 
Response type: Single line text 
200 
Default next: 1-14d 
(Added 07/03/2003 05:53:45 PM by lparkin Modified 14/05/2003 04:56:05 PM by lianne parkin) 








Default next: 1 -141 
Response logic: 
1 14e 
(Added 07/03/2003 05:55:58 PM by lparkin Modified 14/05/2003 04:56:25 PM by lianne parkin) 
Q14e What treatment <>were you <><>was <>S<>he<> given? 
READ OUT IF NECESSARY AND SELECT AS MANY AS APPLY (scroll down): 
1. A drug to thin the blood that was given through an intravenous drip or injected under the skin 
(heparin or low molecular weight heparin) 
2. Pills to thin the blood such as warfarin or coumarin (usually given for at least 3 months) 
3. Aspirin or other pills (other than warfarin / coumarin) that help to thin the blood 
4. Anti-inflammatory pills 
5. Antibiotic pills 
6. Ointments 
7. Bed rest 
8. Other 
Response type: Multi choice from 
Heparin / LMWH 
Warfarin / coumarin 






Default next: 1 -141 
(Added 07/03/2003 06:01 :39 PM by lparkin Modified 14/05/2003 04:49:01 PM by lianne parkin) 
014f Did the (first episode if> 1) clot occur at any particular time, for example: 
<><>During pregnancy? 
After giving birth?<><> 
<><>During pregnancy? 
After giving birth?<><> 
After an operation? 
After an injury? 
During an illness? 




Default next: 1 -14h 
(Added 07/03/2003 06:03:09 PM by lparkin 
014g What were the circumstances? 
Response type: Multichoice from 





Default next: 1 -14h 
Response logic: 
114g 
Modified 14/05/2003 04:48:39 PM by lianne parkin) 





014h I'd like to ask you some more questions about the clot in the DEEP veins of your <><>'S<> leg. The 014h 
medical name for this condition is deep vein thrombosis. So, when was the (first episode if > 1) deep 





Medical history Section 1 
Pre-logic: Qdata1.q14b=1 GOT0:114r 
Response type: Single line text 
Default next: 1 -14i 
{Added 07/03/2003 06:05:59 PM by lparkin Modified 14/05/2003 05:06:09 PM by lianne parkin} 
014i <>Were you<><>Was your<><> given treatment for the (first episode if > 1} deep vein thrombosis? 014i 




Def au It next: 1 -14k 
Response logic: 
114j 
{Added 07/03/2003 06:10:29 PM by lparkin Modified 14/05/2003 04:47:35 PM by lianne parkin} 
014j What treatment <>Were you<><>was <>S<>he<> given? 
READ OUT IF NECESSARY AND SELECT AS MANY AS APPLY {scroll down}: 
1. A drug to thin the blood that was given through an intravenous drip or injected under the skin 
(heparin or low molecular weight heparin) 
2. Pills to thin the blood such as warfarin or coumarin 
3. Aspirin or other pills that help to thin the blood 
4. Anti-inflammatory pills 
5. Antibiotic pills 
6. Ointments 
7. Bed rest 
8. Other 
Response type: Multichoice from 
Heparin/ LMWH 
Warfarin / coumarin 






Default next: 1 -14k 
{Added 07/03/2003 06:11 :13 PM by lparkin Modified 14/05/2003 04:47:20 PM by lianne parkin} 
014k Did the (first episode if> 1) deep vein thrombosis occur al any particular time, for example: 
<><>During pregnancy? 
After giving birth?<><> 
<><>During pregnancy? 
After giving birth?<><> 
After an operation? 
After an injury? 
During an illness? 




Default next: 1 -14r 
Response logic: 
1 141 
(Added 07/03/2003 06:13:05 PM by lparkin Modified 14/05/2003 04:47:09 PM by lianne parkin) 
















Default next: 1 -14r 
(Added 07/03/2003 06:14:47 PM by lparkin Modified 14/05/2003 04:46:53 PM by lianne parkin) 
Section 1 
Q14m I'd like to ask you some more questions atiout the clot. When was it (first episode if > 1) diagnosed? Q14m 
Pre-logic: Qdata1.q14b<>5GOT0:115a 
Response type: Single line text 
Default next: 1 -14n 
(Added 11/03/2003 06:06:26 PM by lparkin Modified 14/05/2003 08:23 :42 PM tiy lianne parkin) 
Q14n <>Were you<><>Was your<><> given treatment for the (first episode if> 1) clot? 




Default next: 1 -14p 
Response logic: 
1140 
(Added 11/03/2003 06:08:04 PM by lparkin Modified 14/05/2003 04:46:28 PM by lianne parkin) 
Q14o What treatment <>were you<><>was <>S<>he<> given? 
READ OUT IF NECESSARY, AND SELECT AS MANY AS APPLY (scroll down): 
1. A drug to thin the blood that was given through an intravenous drip or injected under the skin 
(heparin or low molecular weight heparin) 
2. Pills to thin the blood such as warfarin or coumarin 
3. Aspirin or other pills that help to thin the blood 
4. Anti-inflammatory pills 
5. Antibiotic pills 
6. Ointments 
7. Bed rest 
a.Other 
Response type: Multichoice from 
Heparin/ LMWH 
Warfarin / coumarin 






Default next: 1 -14p 
Q14p 
(Added 11/03/2003 06:09:22 PM by lparkin Modified 14/05/2003 04:35:04 PM by lianne parkin) 
Did the (first episode if> 1) clot occur at any particular time, for example: 
<><>During preg[lancy? 
After giving birth?<><> 
<><>During pregnancy? 
After giving birth?<><> 
After an operation? 
After an injury? 

















Default next: 1 -14r 
Response logic: 
114q 
(Added 11/03/2003 06:11 :44 PM by lparkin Modified 14/05/2003 04:34:47 PM by lianne parkin) 
014q What were the circumstances? 
Response type: Multichoice from 





Default next: 1 -14r 
{Added 11/03/2003 06:15:24 PM by lparkin Modified 14/05/2003 04:34:29 PM by lianne parkin) 
014r Before the<> 
Response type: Statement 
Default next: 1 -15a 
(Added 20/03/2003 06:08:21 PM by lparkin Modified 14/05/2003 04:34:14 PM by lianne parkin) 





PROMPT IF REQUIRED This is a condition where blood clots, which have formed in the veins of the 
legs or pelvis, break off and travel up to the arteries of the lungs. 




Default next: 1 -16a 
Response logic: 
1 15b 
{Added 01/0212003 12:00:00 AM by cblakey Modified 14/05/2003 04:34:00 PM by lianne parkin) 
015b When was the (first episode if > 1) pulmonary embolism diagnosed? 
Response type: Single line text 
Default next: 1 -1 Sc 
(Added 01/02/2003 12:00:00 AM by cblakey Modified 14/05/2003 04:33:43 PM by lianne parkin) 
Q15b 
015c <>Were you<><>Was your<><> treated with medication to thin the blood (heparin, warfarin, coumarin)'Q1 Sc 




Default next: 1 -15d 
{Added 07/03/2003 06:20:54 PM by lparkin Modified 14/05/2003 04:29:03 PM by lianne parkin) 
015d Did the (first episode if> 1) pulmonary embolism occur at any particular time, for example: 
<><>During pregnancy? 
After giving birth?<><> 
<><>During pregnancy? 
After giving birth?<><> 
After an operation? 
After an injury? 






Medical history Section 1 




Default next: 1 -151 
(Added 07/03/2003 06:22:12 PM by lparkin 
Q1 Se What were the circumstances? 






Default next: 1 -151 
Response logic; 
115e 
Modified 14/05/2003 04:28:51 PM by lianne parkin) 
(Added 11/03/2003 06:25:21 PM by lparkin Modified 14/05/2003 04:28:34 PM by lianne parkin) 
Q1 Sf Before the<> 
Response type: Statement 
Default next: 1 -16a 
(Added 20/03/2003 06:11 :36 PM by lparkin Modified 14/05/2003 04:28:23 PM by lianne parkin) 
Q15e 
Q15f 
Q16a <>Were you EVER told that you had a blood disorder which increased the chances of Q16a 
developing deep vein thrombosis or pulmonary embolism?<><>Was your<> EVER told that <>S<>he 
had a blood disorder which increased the chances of developing deep vein thrombosis or pulmonary 
embolism?<> 
PROMPT IF REQUIRED Deep vein thrombosis is the condition where blood clots form in the deep 
veins of the legs or pelvis. And pulmonary embolism is the condition where these blood clots break off 
and travel up to the arteries of the lungs. 




Default next: 2 -00 
Response logic; 
116b 
(Added 01/02/2003 12:00:00 AM by cblakey Modified 27/05/2003 03:48:35 PM by lianne parkin) 
016b I am going to read out the names of some blood disorders. I would like you to tell me if <>you 
were<><>your <> was <>diagnosed with any of these disorders: 
(Read out name of each disorder. Select as many as apply, otherwise record unknown) 
Response type: Multichoice from 
Factor 5 Leiden 
Antithrombin deficiency 
Protein C deficiency 











Default next: 2 -00 





Reproductive history and hormonal exposure Section 2 
QOO Now I would like to ask a few questions about pregnancy and any female hormones <>YOLI<><>your 000 
<><> might have taken before the <> 
Pre-logic: (!Reference.ucontrol and Reference.umale) or (Reference.ucontrol and Reference.male) GOT0:3 
00 
Response type: Statement 
Default next: 2 -01 a 
(Added 12/03/2003 09:43:05 AM by lparkin Modified 08/05/2003 03:09:08 PM by lianne parkin) 
Q01 a <>Did you<><>Did your<><> give birth to any children before tl1e <>? 




Default next: 2 -02 
Response logic: 
2 01b 
(Added 10/03/2003 11 :47:02 AM by lparkin Modified 28/03/2003 04:20:51 PM by lparkin) 
001 b How many children did <>YOU<><>she<> have before 
this date? 
(record "-2" if don't know) 
Response type: Numeric 
99 
Default next: 2 -01c 
(Added 10/03/2003 11 :48:52 AM by lparkin Modified 31/03/2003 05:46:42 PM by lparkin) 
001a 
001b 
Q01 c Before the<> did <>YOU<><>your <><> ever have high blood pressure DURING PREGNANCY that 001 c 
required treatment with medication or with bed rest in hospital? 




Default next: 2 -02 
(Added 10/03/2003 11 :53:29 AM by lparkin Modified 28/03/2003 04:38:23 PM by lparkin) 
002 Before the <> did <>you<><>your <><> EVER use the oral contraceptive pill (the pill)? 




Default next: 2 -03 
003 
(Added 10/03/2003 11 :53:53 AM by lparkin Modified 31/03/2003 05:47:13 PM by lparkin) 
Before the<> did <>YOU<><>your <><> EVER take hormone replacement therapy or HRT? 
PROMPT IF NECESSARY: By hormone replacement therapy I mean the female hormone pills, skin 
patches, or implants that some women use around the time of the menopause or the change of life. 




Default next: 3 -00 







VTE risk factors in the three months before the index date Section 3 
000 Now I am going to ask you some questions about particular events during the three months before the 000 
<>. 
If you look at your calendar, you'll see that I'm talking about the period between the <> and the<>. 
So: 
Response type: Statement 
Default next: 3 -01a 
(Added 12/03/2003 09:43:52 AM by lparkin Modified 10/05/2003 04:59:35 PM by lianne parkin) 
001 a During those three months <>were you<><>was your<><> treated for a broken bone? 
(If limb fracture, record whether left or right limb) 




Default next: 3 -02a 
Response logic: 
3 01b 
(Added 10/03/2003 12:04:31 PM by lparkin Modified 13/05/2003 09:42:33 PM by lianne parkin) 
001 b Which bone(s) did <>YOU<><><>S<>he<> break? 
Response type: Single line text 
200 
Default next: 3 -01 c 
(Added 10/03/2003 12:06:45 PM by lparkin Modified 11/05/2003 06:33:00 PM by lianne parkin) 
001 c When did <>YOU<><><>S<>he<> break it? (record date I don't know) 
Response type: Single line text 
200 
Def au It next: 3 -01 d 
(Added 10/03/2003 12:07:58 PM by lparkin Modified 31/03/2003 05:48:30 PM by lparkin) 
001 d How was it treated? 
Response type: Single line text 
200 
Default next: 3 -01e 
(Added 10/03/2003 12:10:51 PM by lparkin Modified 13/04/2003 03:09:00 PM by lparkin) 
Q01 e That's the end of the questions about your <><>'S<> broken bone(s). 
Now I'm going to ask you some more questions about OTHER events in the three months between the 
<> and the<>. 
Response type: Statement 
Default next: 3 -02a 






Q02a During those three months <>were you<><>was your <><> admitted to hospital because of an injury? 002a 
Section 3 
·r 
VTE risk factors in the three months before the index date 




Default next 3 -03a 
Response logic: 
3 02b 
(Added 10/03/2003 12:12:37 PM by lparkin Modified 13/04/2003 03:16:38 PM by lparkin) 
Q02b What was the injury? 
(If injured limb, record whether left or right limb) 
Response type: Single line text 
200 
Dejault next: 3 -02c 
(Added 10/03/2003 12:13:02 PM by lparkin Modified 13/05/2003 09:42:45 PM by lianne parkin) 
Q02c When <>were you<><>was <>S<>he<> injured? 
(record date I don't know) 
Response type: Single line text 
200 
Default next: 3 -02d 
(Added 10/03/2003 12:14:13 PM by lparkin Modified 31/03/2003 05:49:04 PM by lparkin) 
002d What treatment(s) did <>YOU<><><>S<>he<> have? 
Response type: Single line text 
200 
Default next: 3 -02e 
(Added 10/03/2003 12:15:07 PM by lparkin Modified 14/03/2003 05:42:57 PM by lparkin) 
Q02e Which hospital(s) <>were you<><>Was <>S<>he<> admitted to? 
Response type: Single line text 
200 
Default next: 3 -021 
(Added 10/03/2003 01 :52:03 PM by lparkin Modified 14/03/2003 05:43:17 PM by lparkin) 
Q02f How many days <>were you<><>was <>S<>he<> in hospital? 
(record number of days/ don't know) 
Response type: Single line text 
200 
Default next: 3 -02g 
(Added 10/03/2003 12:17:36 PM by lparkin Modified 13/04/2003 03:16:04 PM by lparkin) 








Now I'm going to ask you some more questions about OTHER events in the three months between the 
<> and the<>. 
Response type: Statement 
Default next: 3 -03a 
(Added 13/04/2003 03:15:55 PM by lparkin Modified 12/05/2003 01 :23:1 O PM by lianne parkin) 
Q03a During those three months did <>YOU<><>your <><> have any operations? Q03a 
Section 3 
,.I 
VTE risk factors in the three months before the index date 




Default next: 3 -04a 
Response logic: 
3 03b 
(Added 10/03/2003 12:18:54 PM by lparkin Modified 13/04/2003 03:17:09 PM by lparkin) 
Q03b What was the operation(s)? 
(If limb surgery, record whether left or right limb) 
Response type: Single line text 
200 
Default next: 3 -03c 
(Added 10/03/2003 12:19:27 PM by lparkin Modified 13/05/2003 09:42:54 PM by lianne parkin) 
Q03c On what date(s) did <>YOU<><><>S<>he<> have the operation(s)? 
(record date/ don't know) 
Response type: Single line text 
200 
Def au It next: 3 -03d 
(Added 10/03/2003 12:21 :32 PM by lparkin Modified 31/03/2003 05:51 :06 PM by lparkin) 
003d In which hospital(s) did <>YOU<><><>S<>he<> have the operation(s)? 
Response type: Single line text 
200 
Default next: 3 -03e 
(Added 10/03/2003 12:22:52 PM by lparkin Modified 13/03/200310:09:18 AM by lparkin) 
Q03e How many days<> were you<><> was <>S<>he<> in hospital? 
(record number of days/ don't know) 
Response type: Single line text 
200 
Default next: 3 -031 
(Added 10/03/200312:24:40 PM by lparkin Modified 13/04/2003 03:18:29 PM by lparkin) 







Now I'm going to ask you some more questions about OTHER events in the three months between the 
<> and the<>. 
Response type: Statement 
Default next: 3 -04a 
(Added 13/04/2003 03:18:21 PM by lparkin Modified 12/05/2003 01 :23:32 PM by lianne parkin) 
Q04a During those three months <>were you<><>was your<><> admitted to hospital for any other reason? Q04a 




Default next: 3 -05a 
Response logic: 
3 04b 
(Added 10/03/2003 01 :55:29 PM by lparkin Modified 13/04/2003 03:17:23 PM by lparkin) 
Section 3 
> 
VTE risk factors in the three months before the index date 
004b What was the reason <>you were <><><>S<>he was<> admitted? 
Response type: Single line text 
200 
Default next: 3 -04c 
(Added 10/03/2003 02:01 :17 PM by lparkin Modified 13/03/2003 10:11 :26 AM by lparkin) 
Q04c Which hospital(s) <>Were you<><>was <>S<>he<> admitted to? 
Response type: Single line text 
200 
Default next: 3 -04d 
(Added 10/03/2003 02:02:50 PM by lparkin Modified 11/05/2003 03:27:44 PM by lianne parkin) 
Q04d On what date(s) <>were you<><>was <>S<>he<> admitted to hospital? 
(record date/ don't know) 
Response type: Single line text 
200 
Default next: 3 -04e 
{Added 10/03/2003 02:04:33 PM by lparkin Modified 31/03/2003 05:51 :49 PM by lparkin) 
Q04e How many days <>were you<><>was <>S<>he<> in hospital? 
(record number of days I don't know) 
Response type: Single line text 
200 
Default next: 3 -04f 
(Added 10/03/2003 02:05:25 PM by I parkin Modified 16/04/2003 11 :51 :44 AM by Jianne parkin) 







Now I'm going to ask you some more questions about OTHER events in the three months between the 
<> and the<>. 
Response type: Statement 
Default next: 3 -05a 
(Added 13/04/2003 03:20:02 PM by lparkin Modified 12/05/2003 01:23:45 PM by lianne parkin) 
Q05a During those three months did <>YOU<><>your <><> remain in bed or in a wheelchair for more than a 005a 
week? 




Default next: 3 -06a 
Response logic: 
3 05b 
(Added 10/03/2003 02:09:02 PM by lparkin Modified 13/04/2003 03:17:40 PM by lparkin) 
Q05b What was the reason for this? 
Response type: Single line text 
200 
Default next: 3 -06a 
(Added 10/03/2003 02:09:27 PM by lparkin Modified 20/03/2003 06:45:57 PM by lparkin) 
005b 
Q06a During those three months, that is between the <> and the <>, <>were yoU<><>was your<><> taking 006a 












VTE risk factors in the three months before the index date Section 3 




Default next: 3 -22a 
Response logic: 
3 06b 
{Added 10/03/2003 02:11 :25 PM by lparkin Modified 22/05/2003 10:24:40 AM by lianne parkin) 
Q06b IF MORE THAN ONE MEDICATION NAMED: I am going to ask you some questions about each Q06b 
medication. Lets take the first medication that <>you<><>your <><> took between the <> and the <>. 
Response type: Statement 
Default next: 3 -06c 
(Added 16/04/2003 05:29:46 PM by lianne parkin Modified 13/05/2003 12:09:18 PM by lianne parkin) 
Q06c What was the medication <>you were<><><>S<>he was<> taking? What was the name of the 
medicine? 
Response type: Single line text 
200 
Default next: 3 -06d Start of Loop 
(Added 13/03/2003 10:38:47 AM by lparkin Modified 11/05/2003 07:03:22 PM by lianne parkin) 
006c 
Q06d Why <>were you<><>Was <>S<>he<> taking this drug - what medical condition <>Were you<><>Was 006d 
your<><> being treated for? 




High blood pressure 
Systemic lupus erythematosis 
Crohn's disease or ulcerative colitis 





Superficial or deep vein thrombosis 
Pulmonary embolism 
Blood disorder which increased chances of clots 
Other 
Post-logic: bittest(Odata3.q06d, 1) and Qdata1 .q01 =2 GOT0:3 07a 
bittest(Qdata3.q06d, 1) and Qdata1 .q01 =3 GOT0:3 07c 
bittest(Qdata3.q06d,2) and Qdata1.q02=2 GOT0:3 08a 
bittest(Qdata3.q06d,2) and Qdata 1.q02=3 GOT0:3 08c 
bittest(Qdata3.q06d,3) and Odata1 .q03=2 GOT0:3 09a 
bittest(Odata3.q06d,3) and Odata1 .q03=3 GOT0:3 09c 
I Reference.ucontrol and Reference.um ale and bittest(Qdata3.q06d,4) and Qdata1 .q04=2 GOT0:3 
10a 
Reference.ucontrol and Reference.male and bittest(Qdata3.q06d,4) and Qdata1 .q04=2 GOT0:3 
10a 
IReference.ucontrol and Reference.ufemale and bittest(Qdata3.q06d,4) and Qdata1 .q04=2 and 
Qdata2.q01C<>1 GOT0:3 10a 
Reference.ucontrol and Reference.female and bittest(Qdata3.q06d,4) and Qdata1 .q04=2 and 
Qdata2.q01C<>1 GOT0:310a 
IReference.ucontrol and Reference.umale and bittest(Qdata3.q06d,4) and Qdata1.q04=3 GOT0:3 
10c 
Reference.ucontrol and Reference.male and bittest(Odata3.q06dA) and Qdata1 .q04=3 GOT0:3 
Section 3 
( 
VTE risk factors in the three months before the index date Section 3 
10c 
!Reference.ucontrol and Reference.ufemale and bittest(Qdata3.q06d,4) and Qdata1 .q04=3 and 
Qdata2.q01C<>1GOT0:310c 
Reference.ucontrol and Reference.female and bittest(Qdata3.q06d,4) and Qdata1.q04=3 and 
Qdata2.q01c<>1 GOT0:310c 
bittest(Qdata3.q06d,5) and Qdata1 .q05=2 GOT0:3 11a 
bittest(Qdata3.q06d,5) and Qdata1.q05=3 GOT0:3 11c 
bittest(Qdata3.q06d,6) and Qdata1.q06=2 GOT0:3 12a 
bittest(Qdata3.q06d,6) and Qdata1 .q06=3 GOT0:3 12c 
bittest(Qdata3.q06d,7) and Qdata1.q08a=2 GOT0:3 13a 
bittest(Qdata3.q06d,7) and Qdata1.q08a=3 GOT0:3 13c 
bittest(Qdata3.q06d,8) and Qdata1.q09a=2 GOT0:3 14a 
bittest( Qdata3.q06d,8) and Qdata1 .q09a=3 GOT0:3 14c 
bittest(Qdata3.q0Sd,9}and Qdata1 .q10a=2 GOT0:3 15a 
bittest( Qdata3.q06d,9) and Qdata1 .q10a=3 GOT0:3 15c 
bittest(Qdata3.q06d, 1 O) and Qdata1 .q11 a=2 GOT0:3 16a 
bittest( Qdata3.q06d,10) and Qdata1 .q11a=3 GOT0:3 16c 
bittest(Qdata3.q06d, 11) and Qdata1.q12a=2 GOT0:3 17a 
bittest( Qdata3.q06d,11) and Qdata1.q12a=3 GOT0:317c 
bittest(Qdata3.q06d,12) and Qdata1.q14a=2 GOT0:318a 
bittest( Qdata3.q06d, 12) and Qdata1 .q14a=3 GOT0:3 18c 
bittest(Qdata3.q06d, 13) and Qdata 1.q15a=2 GOT0:3 19a 
bittest( Qdata3.q06d, 13) and Qdata1.q15a=3 GOT0:3 19c 
bittest(Qdata3.q06d, 14) and Qdata1.q16a=2 GOT0:3 20a 
bittest( Qdata3.q06d,14) and Qdata1.q16a=3 GOT0:3 20c 
bittest(Qdata3.o06d,15l GOT0:3 06e 
Default next: 3 -06f 
(Added 10/03/2003 02:13:26 PM by lparkin Modified 14/05/2003 11 :19:08 PM by lianne parkin) 
Q06e (Record "other'' indication for drug) 
Response type: Single line text 
200 
Default next: 3 -06f 
006e 
,, (Added 15/05/2003 09:37:24 AM by lianne parkin Modified / / : AM by) 
.; 
Q06f What is the drug code prefix? 
Pre-logic: lower(gcusername)<>'lianne parkin' GOT0:3 21 
Response type: Numeric 
99 
Default next: 3 -06g 
(Added 11/03/2003 06:43:04 PM by lparkin Modified 15/05/2003 09:38:47 AM by lianne parkin) 
006g What is the drug code suffix? 
Pre-logic: lower(gcusername)<>'lianne parkin' GOT0:3 21 
Response type: Numeric 
999 
Default next: 3 -21 
(Added 11/03/2003 06:44:13 PM by lparkin Modified 15/05/2003 09:44:03 AM by lianne parkin) 
Q07a Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication to treat angina, BUT earlier 
you said that <>YOU WEREN'T <><><>S<>he WASN'T<> treated 
for angina before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 








VTE risk factors in the three months before the index date Section 3 
for angina at some time before the<>. 




Default next: 3 -21 
Response logic: 
3 07b 
(Added 19/03/2003 04:09:00 PM by lparkin Modified 14/05/2003 09:32:54 PM by lianne parkin) 
Q07b And <>were you<><>was <>S<>he<> given medication for angina during the three months 
between the <> and the <>? 




Default next: 3 -21 
Response logic: 
3 06f 
(Added 08/04/2003 03:17:27 PM by lparkin Modified 14/05/2003 09:33:06 PM by lianne parkin) 
Q07c Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication to treat angina, BUT earlier 
you said that you didn't know whether <>you were<><><>S<>he was<> treated for angina before the 
<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for angina at some time before the<>. 




Default next: 3 -21 
Response logic: 
3 07d 
(Added 01/04/2003 04:28:37 PM by lparkin Modified 14/05/2003 09:33:13 PM by lianne parkin) 
Q07b 
Q07c 
Q07d And <>were you<><>was <>S<>he<> given medication for angina during the three months between theQ07d 
<> and the <>? 




Default next: 3 -21 
Response logic: 
3 061 
(Added 08/04/2003 03:30:08 PM by lparkin Modified 14/05/2003 09:33:21 PM by lianne parkin) 
Q08a Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication because 
<>you'd<><><>S<>he'd<> had a heart attack, BUT earlier you said that <>you WEREN'T <><><>S<>he 






VTE risk factors in the three months before the index date Section 3 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for a heart attack at some time before the<>. 




Default next: 3 -21 
Response logic: 
3 08b 
(Added 24/03/2003 02:20:40 PM by lparkin Modified 14/05/2003 09:33:29 PM by lianne parkin} 
Q08b And <>were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -21 
Response logic: 
3 061 
(Added 08/04/2003 03:46:35 PM by lparkin Modified 14/05/2003 09:33:47 PM by lianne parkin} 
Q08c Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication because 
<>you'd<><><>S<>he'd<> had a heart attack, BUT earlier you said that you didn't know whether <>you 
were<><><>S<>he was<> treated for a heart attack before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for a heart attack at some time before the<>. 




Def au It next: 3 -21 
Response logic: 
3 08d 
(Added 01/04/2003 05:01 :30 PM by lparkin Modified 14/05/2003 09:33:56 PM by lianne parkin) 
Q08d And <>Were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -21 
Response logic: 
3 061 
(Added 08/04/2003 03:49:44 PM by lparkin Modified 14/05/2003 09:34:04 PM by lianne parkin) 
009a Now I'd like to double check something. 
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was<> given this medication because <>you'd<><><>S<>he'd<> had a stroke BUT earlier you said that 
<>you WEREN'T <><><>S<>he WASN'T<> treated for a stroke before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for a stroke at some time before the<>. 




Default next: 3 -21 
Response logic: 
3 09b 
(Added 24/03/2003 04:08:11 PM by lparkin Modified 14/05/2003 09:34:12 PM by lianne parkin) 
009b And <>Were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -21 
Response logic: 
3 061 
(Added 08/04/2003 04:18:23 PM by lparkin Modified 14/05/2003 09:34:20 PM by lianne parkin) 
Q09c Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication because 
<>you'd<><><>S<>he'd<> had a stroke, BUT earlier you said that you didn't know whether <>you 
were<><><>S<>he was<> treated for a stroke before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for a stroke at some time before the<>. 




Default next: 3 -21 
Response logic: 
3 09d 
(Added 01/04/2003 05:09:10 PM by lparkin Modified 14/05/2003 09:34:28 PM by lianne parkin) 
Q09b 
Q09c 
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Default next: 3 -21 
Response logic: 
3 061 
(Added 08/04/2003 04:20:29 PM by lparkin Modified 14/05/2003 09:34:37 PM by lianne parkin) 
01 Oa Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication to treat high blood pressure, 
BUT earlier you said that <>you WEREN'T <><><>S<>he WASN'T<> treated for high blood pressure 
before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><> Your<> WAS<> treated for high blood pressure at some time before the<>. 




Default next: 3 -21 
Response logic: 
310b 
(Added 24/03/2003 04:15:52 PM by lparkin Modified 14/05/2003 09:34:49 PM by lianne parkin) 
01 Ob And <>Were you<><>was 
<>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -21 
Response logic: 
3 061 
(Added 08/04/2003 04:22:43 PM by lparkin Modified 14/05/2003 09:34:57 PM by lianne parkin) 
01 Oc Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication to treat high blood pressure, 
BUT earlier you said that you didn't know whether <>you were<><><>S<>he was<> treated for 
highblood pressure before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<> You WERE<><> Your<> WAS<> treated for high blood pressure at some time before the <>. 




Default next: 3 -21 
(Added 08/04/2003 04:24:30 PM by lparkin 
Response logic: 
310d 
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010d And <>Were yoU<><>Was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 
Section 3 
010d 




Default next: 3 -21 
Response logic: 
3 06f 
(Added 08/04/2003 04:24:56 PM by lparkin Modified 14/05/2003 09:35:16 PM by lianne parkin) 
011 a Now I'd like to double check something. 011a 
You've just said that <>you were<><>your <> was<> given this medication to treat systemic lupus 
erythematosis, BUT earlier you said that <>you WEREN'T <><><>S<>he WASN'T<> treated for systemic 
lupus erythematosis before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for systemic lupus erythematosis at some time before the 
<>. 




Default next: 3 -21 
Response logic: 
311b 
(Added 24/03/2003 04:57:57 PM by lparkin Modified 14/05/2003 09:35:23 PM by lianne parkin) 
011 b And <>Were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -21 
Response logic: 
3 06f 
(Added 08/04/2003 04:28:33 PM by lparkin Modified 14/05/2003 09:35:31 PM by lianne parkin) 
011 c Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication to treat systemic lupus 
erythematosis, BUT earlier you said that you didn't know whether <>you were<><><>S<>he was<> 
treated for systemic lupus erythematosis before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
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Def au It next: 3 -21 
Response logic: 
311d 
(Added 02/04/2003 10:05:06 AM by lparkin Modified 14/05/2003 09:35:39 PM by lianne parkin) 
011 d And <>Were you<><>Was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -21 
Response logic: 
3 06f 
(Added 08/04/2003 04:30:20 PM by lparkin Modified 14/05/2003 09:35:46 PM by lianne parkin) 
012a Now I'd like to double check something. 
Q11d 
Q12a 
You've just said that <>you were<><>your <> was<> given this medication to treat Crohn's disease or 
ulcerative colitis, BUT earlier you said that <>you WEREN'T <><><>S<>he WASN'T<> treated for either 
of these conditions before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for Crohn's disease or ulcerative colitis at some time before 
the<>. 




Default next: 3 -21 
Response logic: 
312b 
(Added 24/03/2003 05:05:54 PM by lparkin Modified 14/05/2003 09:35:55 PM by lianne parkin) 
012b And <>were you<><>was <>S<>he<> given medication for this during the three months between the <>012b 
and the<>? 




Default next: 3 -21 
Response logic: 
3 061 
(Added 08/04/2003 04:34:33 PM by lparkin Modified 14/05/2003 09:36:03 PM by lianne parkin) 
012c Now I'd like to double check something. 
You've just said that <>you were<><>your <> 
was<> given this medication to treat Crohn's disease or ulcerative colitis, BUT earlier you 
said that you didn't know whether <>you 
were<><><>S<>he was<> treated for either 
of these conditions before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
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This is the sentence: 
Section 3 
<> You WERE<><>Your <> WAS<> treated for Crohn's disease or ulcerative colitis at some time before 
the<>. 




Default next: 3 -21 
Response logic: 
312d 
(Added 02/04/2003 10:35:55 AM by lparkin Modified 14/05/2003 09:36:12 PM by lianne parkin) 
012d And <>Were you<><>was <>S<>he<> given medication for this during the three months 
between 1he <> and the <>? 




Default next: 3 -21 
Response logic: 
3 061 
(Added 08/04/2003 04:36:37 PM by lparkin Modified 14/05/2003 09:36:19 PM by lianne parkin) 
013a Now I'd like to double check something. 
012d 
013a 
You've just said that <>you were<><>your <> was<> given this medication to treat a heart problem, BUT 
earlier you said that <>you WEREN'T <><><>S<>he WASN'T<> treated other heart problems before the 
<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for a heart problem at some time before the<>. 




Default next: 3 -21 
Response logic: 
313b 
(Added 24/03/2003 05:09:31 PM by lparkin Modified 14/05/2003 10:19:20 PM by lianne parkin) 
013b And <>were yoU<><>Was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -13e 
(Added 08/04/2003 04:47:02 PM by lparkin Modified 08/04/2003 05:53:36 PM by lparkin) 
013c Now I'd like to double check something. 
013b 
013c 
You've just said that <>you were<><>your <> was<> given this medication to treat a heart problem, BUT 
earlier you said that you didn't know whether <>you were<><><>S<>he was<> treated other heart 
problems before the <>. 
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tell me whether you think it is true or false. 
Section 3 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for a heart problem at some time before the<>. 




Default next: 3 -21 
(Added 02/04/2003 10:50:57 AM by lparkin 
Response logic: 
313d 
Modified 14/05/2003 10:19:34 PM by lianne parkin) 
Q13d And <>Were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -13e 
(Added 08/04/2003 04:47:43 PM by lparkin Modified 08/04/2003 05:53:55 PM by lparkin) 
Q13e I'd like to ask you a question about the heart problem and then we'll return to the questions about 
medications. So: 
What was the heart problem(s) <>you were<><>your <> was<> treated for? 
Response type: Single line text 
200 
Default next: 3 -13f 
(Added 02/04/2003 11 :18:26 AM by lparkin Modified 17/04/2003 12:09:44 PM by lianne parkin) 
Q13f What is (are) the ICD code(s)? 
Pre-logic: lower(gcusername)<>'lianne parkin' GOT0:3 13g 
Response type: Numeric 
999.9 
Default next: 3 -13g 
(Added 02/04/2003 11 :19:53 AM by lparkin Modified 14/05/2003 10:20:12 PM by lianne parkin) 
Q13g (Continue) 
Pre-logic: Qdata3.q13a=1 and Qdata3.q13b=1 GOT0:3 06f 
Qdata3.q13c=1 and Qdata3.q13d=1 GOT0:3 06f 
Qdata3.q13a=1 and Qdata3.q13b<>1GOT0:321 
Qdata3.q13c=1 and Qdata3.q13d<>1 GOT0:3 21 
Response type: Statement 
Default next: 3 -06f 
(Added 17/04/2003 12:13:34 PM by lianne parkin Modified 14/05/2003 10:22:28 PM by lianne parkin) 






You've just said that <>you were<><>your <> was<> given this medication to treat diabetes, BUT earlier 
you said that <>you WEREN'T <><><>S<>he WASN'T<> treated for diabetes before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
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<>You WERE<><>Your <> WAS<> treated 
for diabetes at some time before the<>. 




Default next: 3 -21 
Response logic: 
314b 
(Added 24/03/2003 05:14:22 PM by lparkin Modified 14/05/2003 09:37:03 PM by lianne parkin) 
014b And <>Were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -14e 
(Added 08/04/2003 04:50:54 PM by lparkin Modified 08/04/2003 05:54:20 PM by lparkin) 




You've just said that <>you were<><>your <> was<> given this medication to treat diabetes, BUT earlier 
you said that you didn't know whether <>you were<><><>S<>he was<> treated for diabetes before the 
<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<> You WERE<><> Your <> WAS<> treated for diabetes at some time before the <>, 




Default next: 3 -21 
Response logic: 
314d 
(Added 02/04/2003 11 :26:37 AM by lparkin Modified 14/05/2003 09:37:13 PM by lianne parkin) 
014d And <>were yoU<><>Was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -14e 
(Added 08/04/2003 04:52:34 PM by lparkin Modified 08/04/2003 05:54:31 PM by lparkin) 
Q14e I'd like to ask you a question about the diabetes and then we'll return to the questions about 
medications, So: 
What type of diabetes did <>YOU<><>your <><> have? 
PROMPT IF NECESSARY: <>Were you<><>Was <>S<>he<> treated with insulin injections, with 
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Response type: Single select from 
Insulin dependent 
Non-insulin dependent 
Gestational diabetes only 
Unknown 
Post-logic: Qdata3.q14a=1 and Qdata3.q14b=1GOT0:3061 
Qdata3.q14c=1 and Qdata3.q14d=1 GOT0:3 06! 
Qdata3.q14a=1 and Qdata3.q14b<>1GOT0:321 
Qdata3.q14c=1 and Qdata3.q14d<>1 GOT0:3 21 
Default next: 3 -06f 
{Added 02/04/2003 11 :34:27 AM by lparkin Modified 14/05/2003 10:23:50 PM by lianne parkin) 
01 Sa Now I'd like to double check something. 015a 
You've just said that <>you were<><>your <> was<> given this medication to treat a kidney problem, 
BUT earlier you said that <>you WEREN'T <><><>S<>he WASN'T<> treated for kidney problems before 
the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<> You WERE<><> Your<> WAS<> treated for a kidney problem at some time before the <>. 




Default next: 3 -21 
Response logic: 
3 15b 
{Added 24/03/2003 05:18:06 PM by lparkin Modified 14/05/2003 09:37:23 PM by lianne parkin) 
015b And <>were you<><>was <>S<>he<> given medication for this during the three months between the <>015b 
and the<>? 




Default next: 3 -15e 
{Added 08/04/2003 04:54:52 PM by lparkin Modified 08/04/2003 05:54:45 PM by lparkin) 
015c Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication to treat a kidney problem, 
BUT earlier you said that you didn't know whether <>you were<><><>S<>he 
was<> treated for kidney problems before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
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Def au It n,;lxt: 3 -21 
(Added 02/04/2003 11 :46:14 AM by lparkin 
Response logic: 
3 15d 
Modified 14/05/2003 09:37:32 PM by lianne parkin) 
015d And <>were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -15e 
(Added 08/04/2003 04:56:42 PM by lparkin Modified 08/04/2003 05:55:03 PM by lparkin) 
015d 
015e I'd like to ask you a question about the kidney problem(s) and then we'll return to the questions about 01 Se 
medications. So: 
What was the kidney problem(s) <>you were<><><>S<>he was<> treated for? 
Response type: Single line text 
200 
Default next: 3 -15f 
(Added 02/04/2003 01 :47:09 PM by lparkin Modified 08/04/2003 05:33:56 PM by lparkin} 
01 Sf What is (are} the ICD code(s}? 
Pre-logic: lower(gcusername)<>'lianne parkin' GOT0:3 15g 
Response type; Numeric 
999,9 
Default next: 3 -15g 
(Added 02/04/2003 01 :50:20 PM by lparkin Modified 11/05/2003 07:01 :13 PM by lianne parkin) 
015g (Continue) 
Pre-logic: Qdata3.q15a=1 and Qdata3.q15b=1 GOT0:3 061 
Qdata3.q15c=1 and Odata3.q15d=1 GOT0:3 061 
Qdata3.q15a=1 and Odata3.q15b<>1 GOT0:3 21 
Qdata3.q15c=1 and Odata3.q15d<>1 GOT0:3 21 
Response type: Statement 
Default next: 3 -061 
(Added 11/05/2003 01 :36:27 PM by lianne parkin Modified 14/05/2003 10:24:43 PM by lianne parkin) 




You've just said that <>you were<><>your <> was<> given this medication to treat a liver problem, BUT 
earlier you said that <>you WEREN'T <><><>S<>he WASN'T<> treated for liver problems before the<>, 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
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Default next: 3 -21 
Response logic: 
3 16b 
(Added 24/03/2003 05:20:38 PM by lparkin Modified 14/05/2003 09:37:42 PM by lianne parkin) 
Q16b And <>were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -16e 
(Added 08/04/2003 05:43:51 PM by lparkin Modified 08/04/2003 05:55:40 PM by lparkin) 




You've just said that <>you were<><>your <> was<> given this medication to treat a liver problem, BUT 
earlier you said that you didn't know whether <>you were<><><>S<>he was<> treated for liver problems 
before the <> . 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for a liver problem at some time before the<>. 




Default next: 3 -21 
Response logic: 
3 16d 
(Added 02/04/2003 01 :53:57 PM by lparkin Modified 14/05/2003 09:37:51 PM by lianne parkin) 
016d And <>were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -16e 
(Added 08/04/2003 05:47:56 PM by lparkin Modified 11/05/2003 01 :04:41 PM by lianne parkin) 
016e I'd like to ask you a question about the liver problem(s) and then we'll return to the questions about 
medications. So: 
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Response type: Single line text 
200 
Default next: 3 -161 
(Added 02/04/2003 01 :55:17 PM by lparkin Modified 08/04/2003 05:48:08 PM by lparkin) 
016f What is (are) the ICD code(s)? 
Pre-logic: lower(gcusername)<>'lianne parkin' GOT0:3 16g 
Response type: Numeric 
999.9 
Default next: 3 -16g 
(Added 02/04/2003 01 :56:23 PM by lparkin Modified 11/05/2003 01 :40:06 PM by lianne parkin} 
016g (Continue} 
Pre-logic: Qdata3.q16a=1 and Qdata3.q16b=1 GOT0:3 061 
Qdata3.q16c=1 and Qdata3.q16d=1GOT0:3061 
Qdata3.q16a=1 and Qdata3.q16b<>1GOT0:321 
Qdata3.q16c=1 and Qdata3.q16d<>1GOT0:321 
Response type: Statement 
Post-logic: Qdata3.q16a=1 and Qdata3.q16b=1GOT0:3061 
Qdata3.q16c=1 and Qdata3.q16d=1 GOT0:3 061 
Qdata3.q16a=1 and Qdata3.q16b<>1GOT0:323 
Qdata3.q16c=1 and Qdata3.q16d<>1GOT0:323 
Default next: 3 -06f 
(Added 17/04/2003 12:23:07 PM by lianne parkin Modified 14/05/2003 10:25:24 PM by lianne parkin) 
017a Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication to treat cancer, BUT earlier 
you said that <>you WEREN'T <><><>S<>he WASN'T<> treated for cancer before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<> You WERE<><>Your <> WAS<> treated for cancer at some time before the<>. 




Default next: 3 -21 
Response logic: 
317b 
(Added 24/03/2003 05:23:02 PM by lparkin Modified 14/05/2003 09:38:01 PM by lianne parkin} 
Q17b And <>Were yoLI<><>Was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -17e 
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Default next: 3 -17e 
(Added 08/04/2003 05:57:20 PM by lparkin Modified / / : : AM by) 
Q17c Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication to treat cancer, BUT earlier 
you said that you didn't know whether <>you were<><><>S<>he was<> treated for cancer before the 
<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for cancer at some time before the<>. 




Default next: 3 -21 
Response logic: 
3 17d 
(Added 02/04/2003 02:01 :44 PM by lparkin Modified 14/05/2003 09:38:14 PM by lianne parkin) 
017d And <>were you<><>was 
<>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -17e 
(Added 08/04/2003 05:59:10 PM by lparkin Modified / / : : AM by ) 
017c 
017d 
017e I'd like to ask you a few short questions about the cancer and then we'll return to the questions about 017e 
medications. So: 
What type(s) of cancer did <>you <><><>S<>he<> have? 
NB. IF BONE, BRAIN, OR LIVER CANCER STATED, ASK: Where did the cancer start? 
IF SKIN CANCER STATED, ASK: Was it a melanoma skin cancer? 
Response type: Single line text 
200 
Default next: 3 -171 
(Added 02/04/2003 02:04:26 PM by lparkin Modified 11/05/2003 01 :48:06 PM by lianne parkin) 
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Response type: Single line text 
200 
Default next: 3 -17g 
(Added 02/04/2003 02:05:10 PM by lparkin Modified 10/05/2003 03:57:53 PM by lianne parkin) 
017g What is (are) the ICD code{s)? 
Pre-logic: lower(gcusername)<>'lianne parkin' GOT0:3 17h 
Response type: Numeric 
999.9 
Default next: 3 -1711 
(Added 02/04/2003 02:05:26 PM by lparkin Modified 11/05/2003 01 :44:24 PM by lianne parkin) 
017h Now I'm going to continue with the questions about medications. 
Response type: Statement 
Post-logic: Qdata3.q17a=1 and Qdata3.q17b=1GOT0:3061 
Qdata3.q17c=1 and Qdata3.q17d=1GOT0:3061 
Qdata3.q17a=1 and Qdata3.q17b<>1GOT0:321 
Qdata3.q17c=1 and Qdata3.q17d<>1GOT0:321 
Def au It next: 3 -061 
(Added 02/04/2003 02:06:51 PM by lparkin Modified 14/05/2003 10:26:26 PM by lianne parkin) 
018a Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication to treat a blood clot in the 
veins of the leg, BUT earlier you said that <>you WEREN'T <><><>S<>he WASN'T<> treated for blood 
clots before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for a blood clot in the veins of the leg at some time before 
the<>. 




Default next: 3 -21 
Response logic: 
318b 
(Added 24/03/2003 05:27:01 PM by lparkin Modified 14/05/2003 09:38:25 PM by lianne parkin) 




Default next: 3 -21 
Response logic: 
318b 
(Added 09/04/2003 01:39:38 PM by lparkin Modified 14/05/2003 09:38:33 PM by lianne parkin) 
01 Sb And <>were you<><>Was <>S<>he<> given medication for this during the three months 
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Default next: 3 -18e 
(Added 08/04/2003 06:03:54 PM by lparkin Modified / / : AM by) 
01 Be Now I'd like to double check something. 
You've just said that <>you were<><>your <> was<> given this medication to treat a blood clot in the 
legs, BUT earlier you said that you didn't know whether <>you were<><><>S<>he was<> treated for 
blood clots before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><> Your<> WAS<> treated for a blood clot in the legs at some time before the<>. 




Default next: 3 -21 
Response logic: 
3 18d 
(Added 02/04/2003 02:11 :05 PM by lparkin Modified 14/05/2003 09:38:48 PM by lianne parkin) 
01 Bd And <>were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -18e 
{Added 08/04/2003 06:24:1 O PM by lparkin Modified I I : : AM by ) 
01 Be I'd like to ask you a few short questions about the blood clot and then we'll return to the questions 
about medications. So: 
Was the blood clot in the veins on the SURFACE of your <><>'S<> leg, OR in the DEEP VEINS of 
<>your<><><>her<><>hiS<<iUmale>><> leg? 
PROMPT IF NECESSARY: The medical names for blood clots in the veins on the surface of the legs 
are superficial venous thrombosis or thrombophlebitis; and the medical name for blood clots in the 
deep veins of the legs or pelvis is deep vein thrombosis, or DVT or short. 




Both, at different times 
Don't know 
Post-logic: Qdata3.q18e=1 or Qdata3.q18e=3 or Qdata3.q18e=4 GOT0:3 181 
Qdata3.q18e=2 GOT0:3 18k 
Qdata3.q18e=5 GOT0:3 18q 
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(Added 02/04/2003 02:13:48 PM by Jparkin Modified 14/05/2003 09:39:03 PM by lianne parkin) 
018f I'd like to ask you some more questions about the clot in the veins on the SURFACE of your 
<><>'S<> leg. 
When was the (first episode if> 1) clot diagnosed? 
Response type: Single line text 
200 
Default next: 3 -18g 
(Added 02/04/2003 02:19:09 PM by lparkin Modified 11/05/2003 02:12:21 PM by Jianne parkin) 
018g <>Were you<><>Was your<><> treated for the (first episode if> 1) clot? 




Default next: 3 -18i 
Response logic: 
3 18h 
(Added 02/04/2003 02:20:38 PM by Jparkin Modified 08/04/2003 06:05:54 PM by lparkin) 
018h What treatment <>were you<><> was <>S<>he<> given? 
READ OUT IF NECESSARY AND SELECT AS MANY AS APPLY (scroll down): 
1. A drug to thin the blood that was given through an intravenous drip or injected under the skin 
(heparin or low molecular weight heparin) 
2. Pills to thin the blood such as warfarin or coumarin (usually given for at least 3 months) 
3. Aspirin or other pills (other than warfarin / coumarin) that help to thin the blood 
4. Anti-inflammatory pills 
5. Antibiotic pills 
6. Ointments 
7. Bed rest 
8. Other 
Response type: Multichoice from 
Heparin/ LMWH 
Warfarin / coumarin 






Default next: 3 -1 Si 
(Added 02/04/2003 02:53:26 PM by Jparkin Modified 11/05/2003 02:14:47 PM by Jianne parkin) 
018i Did the (first episode if> 1) clot occur at any particular time, for example: 
<><>During pregnancy? 
After giving birth?<><> 
<><>During pregnancy? 
After giving birth?<><> 
After an operation? 
After an injury? 
During an illness? 




Default next: 3 -18k 
Response logic: 
318j 
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018j What were the circumstances? 






Default next: 3 -18k 
(Added 02/04/2003 02:57:00 PM by lparkin Modified 08/04/2003 06:08:37 PM by lparkin) 
01 Bk I'd like to ask you some more questions about the clot in the DEEP veins of your <><>'S<> leg. 
Pre-logic: Qdata3.q18e=1 GOT0:3 18v 
Response type: Statement 
Default next: 3 -181 




0181 When was the (first episode if> 1) clot in the DEEP veins of your legs diagnosed? The medical name 0181 
for this condition is deep vein thrombosis. 
Pre-logic: Qdata3.q18c=1 GOT0:3 18t 
Response type: Single line text 
Default next: 3 -18m 
(Added 02/04/2003 02:59:17 PM by lparkin Modified 08/04/2003 06:09:49 PM by lparkin) 
01 Sm <>Were you<><>Was your<><> given treatment for the deep vein thrombosis? 




Def au It next: 3 -180 
Response logic: 
3 18n 
(Added 02/04/2003 03:03:00 PM by lparkin Modified 08/04/2003 06:10:27 PM by lparkin) 
01 Sn What treatment <>Were you<><>was <>S<>he <> given? 
READ OUT IF NECESSARY AND SELECT AS MANY AS APPLY (scroll down): 
1. A drug to thin the blood that was given through an intravenous drip or injected under the skin 
(heparin or low molecular weight heparin) 
2. Pills to thin the blood such as warfarin or coumarin (usually given for at least 3 months) 
3. Aspirin or other pills (other than warfarin / coumarin) that help to thin the blood 
4. Anti-inflammatory pills 
5. Antibiotic pills 
6. Ointments 
7. Bed rest 
8. Other 
Response type: Multichoice from 
Heparin/ LMWH 
Warfarin / coumarin 






Default next: 3 -180 
(Added 02/04/2003 03:04:17 PM by lparkin Modified 11/05/2003 02:15:02 PM by lianne parkin) 
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<><>During pregnancy? 
After giving birth?<><> 
<><>During pregnancy? 
After giving birth?<><> 
After an operation? 
After an injury? 
During an illness? 




Default next: 3 -18v 
Response logic: 
318p 
(Added 02/04/2003 03:06:24 PM by lparkin Modified 11/05/2003 02:19:45 PM by lianne parkin) 
01 Sp What were the circumstances? 






Default next: 3 -18v 
(Added 02/04/2003 03:06:31 PM by lparkin Modified 08/04/2003 06:21 :07 PM by lparkin) 
Q18q When was the clot (first episode if> 1) diagnosed? 
Response type: Single line text 
200 
Default next: 3 -18r 
(Added 02/04/2003 03:07:22 PM by lparkin Modified 13/05/2003 09:58:52 PM by lianne parkin) 
018r <>Were you<><>Was your<><> given treatment for the (first episode if> 1) clot? 




Default next: 3 -18t 
Response logic: 
318s 
(Added 02/04/2003 03:14:35 PM by lparkin Modified 08/04/2003 06:13:22 PM by lparkin) 
018s What treatment <>were you<><>was <>S<>he<> given? 
READ OUT IF NECESSARY AND SELECT AS MANY AS APPLY (scroll down): 
1. A drug to thin the blood that was given through an intravenous drip or injected under the skin 
(heparin or low molecular weight heparin) 
2. Pills to thin the blood such as warfarin or coumarin (usually given for at least 3 months) 
3. Aspirin or other pills (other than warfarin / coumarin) that help to thin the blood 
4. Anti-inflammatory pills 
5. Antibiotic pills 
6. Ointments 
7. Bed rest 
8. Other 
Response type: Single select from 
Heparin / LMWH 
Warfarin / coumarin 
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Other 
Default next: 3 -18t 
(Added 02/04/2003 03:16:01 PM by lparkin Modified 11/05/2003 02:15:14 PM by lianne parkin) 
Q18t Did the (first episode if> 1)) clot occur at any particular time, for example: 
<><>During pregnancy? 
After giving birth?<><> 
<><>During pregnancy? 
After giving birth?<><> 
After an operation? 
After an injury? 
During an illness? 




Default next: 3 -18v 
Response logic: 
3 18u 
(Added 02/04/2003 03:17:14 PM by lparkin Modified 11/05/2003 02:19:59 PM by lianne parkin) 
Q1 au What were the circumstances? 






Default next: 3 -18v 
(Added 02/04/2003 03:18:16 PM by lparkin Modified 08/04/2003 06:20:41 PM by lparkin) 
Q18v Now I'm going to continue with the questions about medications. 
Response type: Statement 
Post-logic: Qdata3.q18a=1 and Qdata3.q18b=1 GOT0:3 061 
Qdata3.q18c=1 and Qdata3.q18d=1GOT0:3061 
Qdata3.q18a=1 and Qdata3.q18b<>1GOT0:321 
Qdata3.q18c=1 and Qdata3.q18d<>1GOT0:321 
Default next: 3 -061 
(Added 02/04/2003 03:19:12 PM by lparkin Modified 14/05/2003 10:27:19 PM by lianne parkin) 






You've just said that <>you were<><>your <> was<> given this medication to treat pulmonary embolism, 
BUT earlier you said that <>you WEREN'T <><><>S<>he WASN'T<> treated for pulmonary embolism 
before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for pulmonary embolism at some time before the<>. 




Default next: 3 -21 
Response logic: 
319b 
(Added 24/03/2003 05:30:46 PM by lparkin Modified 14/05/2003 09:39:24 PM by lianne parkin) 
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<>S<>he<> given medication for this during the three months between the <> and the<>? 




Default next: 3 -19e 
(Added 09104/2003 01:43:41 PM by lparkin Modified / / : : AM by) 
019c Now I'd like to double check something. 
Section 3 
019c 
You've just said that <>you were<><>your <>. was<> given this medication to treat pulmonary embolism, 
BUT earlier you said that you didn't know whether <>you were<><><>S<>he was<> treated for 
pulmonary embolism before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for pulmonary embolism at some time before the<>. 




Default next: 3 -21 
Response logic: 
319d 
(Added 02/04/2003 03:34:06 PM by lparkin Modified 14/05/2003 09:39:35 PM by lianne parkin) 
019d And <>Were yOU<><>Was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -19e 
(Added 09/04/2003 01 :45:42 PM by lparkin Modified / / : : AM by ) 
019e I'd like to ask you a few short questions about the pulmonary embolism and then we'll return to the 
questions about medications. So: 
When was the (first episode if> 1) pulmonary embolism diagnosed? 
Response type: Single line text 
200 
Default next: 3 -191 
(Added 02/04/2003 03:34:18 PM by lparkin Modified 09/04/2003 01 :46:12 PM by lparkin) 
019d 
019e 
Q19f <>Were you<><>Was your<><> treated with medication to thin the blood (heparin, warfarin, coumarin)'019f 




Default next: 3 -19g 
(Added 02/04/2003 04:08:05 PM by lparkin Modified 09/04/2003 01 :48:11 PM by lparkin) 
Section 3 
I 
VTE risk factors in the three months before the index date 
019g Did the (first episode if> 1) pulmonary embolism occur at any particular time, for example: 
<><>During pregnancy? 
After giving birth?<><> 
<><>During pregnancy? 
After giving birth?<><> 
After an operation? 
After an injury? 
DurinQ an illness? 




Default next: 3 -19i 
Response logic: 
319h 
(Added 02/04/2003 04:09:12 PM by lparkin Modified 11/05/2003 02:21 :45 PM by lianne parkin) 
019h What were the circumstances? 






Default next 3 -19i 
(Added 02/04/2003 04:38:57 PM by lparkin Modified 09/04/2003 01 :48:25 PM by lparkin) 
019i Now I'm going to continue with the questions about medications. 
Response type: Statement 
Post-logic: Qdata3.q19a=1 and Qdata3.q19b=1 GOT0:3 061 
Qdata3.q19c=1 and Odata3.q19d=1 GOT0:3 06f 
Qdata3.q19a=1 and Qdata3.q19b<>1GOT0:321 
Qdata3.q19c=1 and Qdata3.q19d<>1GOT0:321 
Default next: 3 -061 
(Added 03/04/2003 10:00:25 AM by lparkin Modified 14/05/2003 10:27:50 PM by lianne parkin) 






You've just said that <>you were<><>your <> was<> given this medication to treat a blood disorder 
which increased the chances of developing a deep vein thrombosis or pulmonary embolism, BUT earlier 
you said that <>you WEREN'T <><><>S<>he WASN'T<> treated such a condition before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd Hke you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for a blood disorder which increased the chances of 
developing a deep vein thrombosis or pulmonary embolism at some time before the<>. 




Default next: 3 -21 
Response logic: 
3 20b 
(Added 24/03/2003 05:34:12 PM by lparkin Modified 14/05/2003 09:39:46 PM by lianne parkin) 
020b And <>were yoU<><>Was <>S<>he<> given medication for this during the three months 
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Default next: 3 -20e 
(Added 09/04/2003 03:30:24 PM by lparkin Modified 09/04/2003 03:32:16 PM by lparkin) 
020c Now I'd like to double check something. 020c 
You've just said that <>you were<><>your <> was<> given this medication to treat a blood disorder 
which increased the chances of developing a deep vein thrombosis or pulmonary embolism, BUT earlier 
you said that you didn't know whether <>you were<><><>S<>he was<> treated for such a condition 
before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. 
This is the sentence: 
<>You WERE<><>Your <> WAS<> treated for a blood disorder which increased the chances of 
developing a deep vein thrombosis or pulmonary embolism at some time before the <>. 




Default next: 3 -21 
Response logic: 
3 20d 
(Added 03/04/2003 10:02:21 AM by lparkin Modified 14/05/2003 09:39:55 PM by lianne parkin) 
020d And <>were you<><>was <>S<>he<> given medication for this during the three months 
between the <> and the <>? 




Default next: 3 -20e 
(Added 09/04/2003 03:32:45 PM by lparkin Modified / / : : AM by) 
Q20e I'd like to ask you a question about the blood disorder and then we'll return to the questions about 
medications. So: 
I am going to read out the names of some disorders. I would like you to tell me if <>you were<><>your 
<> was <>diagnosed with any of these disorders: . 
Record name(s) of disorder(s) if known, otherwise record unknown 
Response type: Multichoice from 
Factor V Leiden 
Antithrombin deficiency 
Protein C deficiency 
Protein S deficiency 
Dysfibrinogenaemia 
Plasminogen deficiency 
Prothrombin 2021 OA 











VTE risk factors in the three months before the index date 
Post-logic: Qdata3.q20a=1 and Qdata3.q20b=1 GOT0:3 06f 
Qdata3.q20c=1 and Qdata3.q20d=1GOT0:3061 
Qdata3.q20a=1 and Qdata3.q20b<>1 GOT0:3 21 
Qdata3.q20c=1 and Qdata3.q20d<>1GOT0:321 
Default next: 3 -061 
(Added 03/04/2003 10:05:32 AM by lparkin Modified 14/05/2003 10:28:26 PM by lianne parkin) 
Section 3 
021 <>Were you<><>Was your<><> taking any other medications durinQ the three months between the <>021 
and the<>? 




Default next: 3 -22a End of Loop 
Response logic: 
3 06c 
(Added 11/03/2003 06:47:35 PM by lparkin Modified 15/05/2003 09:44:54 AM by lianne parkin) 
022a During those three months, that is between the<> and the<>, <>did you<><>did your<><> smoke at 022a 
least one cigarette a day? 




Default next: 3 -22b 
Response logic: 
3 23 
(Added 10/03/2003 02:18:34 PM by lparkin Modified 14/05/2003 09:17:03 PM by lianne parkin) 
0?2b Before the<>, <>did you<><>did <>S<>he<> EVER smoke at least one cigarette a day? 




Default next: 3 -23 
(Added 20/03/2003 11 :52:29 AM by lparkin Modified 14/05/2003 09:17:17 PM by lianne parkin) 
022b 
023 Now I would like to ask you a few questions about pregnancy and female hormones that <>YOU<><>youQ23 
<><> might have taken in the three months between the <> and the<>. We are interviewing people of 
different ages, ~o some of these questions may appear strange for someone of your <><>'s <> age. 
Pre-logic: (Reference.ucontrol and Reference.male) or (1 Reference.ucontrol and Reference.umale) 
GOT0:4a00 
Response type: Statement 
Default next: 3 -24a 
(Added 10/03/2003 02:26:21 PM by lparkin Modified 14/05/2003 09:17:31 PM by Jianne parkin) 
024a <>Were you<><>Was your<><> pregnant at any time between the<> and the<>? 024a 
Pre-logic: (Reference.ucontrol and Reference.male) or(! Reference.ucontrol and Reference.umaJe) GOT0:4 
00 




Default next: 3 -25a 
Response logic: 
3 24b 
(Added 10/03/2003 02:29:14 PM by lparkin Modified 14/05/2003 09:17:48 PM by lianne parkin) 
<>Were you<><>Was she<> still pregnant on the 
Section 3 
">-
VTE risk factors in the three months before the index date 
Q24b 
<>7 




Default next: 3 -24c 
Response logic: 
325a 
(Added 28/03/2003 09:46:38 AM by lparkin Modified 14/05/2003 09:18:17 PM by lianne parkin) 
Q24c On what date did <>your<><>her<> pregnancy end? 
(record date/ don't know) 
Response type: Single line text 
200 
Default next: 3 -24d 




024d How many weeks pregnant <>were you<><>Was she<> when the pregancy ended? (record number of 024d 
weeks, or -2 if don't know) 
PROMPT IF NECESSARY: A normal full term pregnancy is about 40 weeks 
Response type: Numeric 
99.9 
Default next: 3 -24e 
(Added 10/03/2003 02:33:19 PM by lparkin Modified 14/05/2003 09:19:13 PM by lianne parkin) 
Q24e <>Were you<><>Was your <><> admitted to hospital at that time? 




Default next: 3 -25a 
Response logic: 
3241 
(Added 10/03/2003 02:36:51 PM by lparkin Modified 14/05/2003 09:19:29 PM by lianne parkin) 
Q24f What hospital <>were you<><>was she<> admitted to? 
(record name of hospital / don't know) 
Response type: Single line text 
200 
Default next: 3 -25a 
(Added 03/04/2003 04:44:23 PM by lparkin Modified 14/05/2003 09:19:42 PM by lianne parkin) 
Q24e 
Q24f 
Q25a Did <>YOU<><>your <><> take the oral contraceptive pill (the pill) at any time between the<> and the Q25a 
<>? 





Post-logic: Qdata2.q02=1 and Qdata3.q25a=1 GOT0:3 25f 
Qdata2.q02=2 and Qdata3.q25a=1 GOT0:3 25b 
Qdata2.q02=2 and Qdata3.q25a=3 GOT0:3 25c 
Qdata2.q02=3 and Qdata3.q25a=1GOT0:325d 
Default next: 3 -26a 
(Added 10/03/2003 02:38:26 PM by lparkin Modified 15/05/2003 05:00:28 PM by lianne parkin) 
Q25b Now I'd like to double check something. 
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DID take the oral contraceptive pill in the three months between the<> and the<>, BUT earlier you said 
that <>you<><>your <> <> HAD NEVER taken the pill before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. This is the sentence: 
<> You<><> Your<><> DID take the oral contraceptive pill at some time before the<>. 




Default next: 3 -26a 
Response logic: 
3 25e 
(Added 25/03/2003 04:40:38 PM by lparkin Modified 14/05/2003 09:23:55 PM by lianne parkin) 
025c Now I'd like to double check something. 025c 
You've just said that you DON'T KNOW whether <>YOU <><>your<><> took the oral contraceptive pill in 
the three months between the<> and the<>, BUT earlier you said that <>YOU<><>she<> HAD NEVER 
taken the pill before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. This is the sentence: 
<>You<><>Your <><> DID take the oral contraceptive pill at some time before the<>. 




Default next: 3 -26a 
Response logic: 
3 25e 
(Added 28/03/2003 02:14:08 PM by lparkin Modified 15/05/2003 05:01 :28 PM by lianne parkin) 
Q25d Now I'd like to double check something. 
You've just said that <>you <><>your<><> DID take the oral contraceptive pill in the three months 
between the <> and the <>, BUT earlier you said that you DIDN'T KNOW whether <>YOU<><>your <> 
<> had ever taken the pill before the <>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. This is the sentence: 
<> You<><>Your <><> DID take the oral contraceptive pill at some time before the<>. 




Default next: 3 -26a 
Response logic: 
3 25e 
(Added 25/03/2003 04:19:14 PM by lparkin Modified 15/05/2003 05:01 :50 PM by lianne parkin) 
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Default next: 3 -26a 
Response logic: 
3 25f 
(Added 16/04/2003 12:01 :25 PM by lianne parkin Modified 14/0512003 09:25:01 PM by lianne parkin) 
Q25f Do you remember the name of <>your<><>her<> pill? (record name of pill I don't know) Q25f 
Response type: Single line text 
200 
Default next: 3 -25g 
(Added 10/0312003 02:39:59 PM by lparkin Modified 1410512003 09:25:25 PM by lianne parkin) 
025g What is the drug code prefix? 
Pre-logic: lower(gcusername)<>'lianne parkin' GOT0:3 26a 
Response type: Numeric 
99 
Default next: 3 -25h 
(Added 14/0512003 09:14:41 PM by lianne parkin Modified 15/05/2003 04:45:34 PM by lianne parkin) 
025g 
025h What is the drug code suffix? 025h 
Response type: Numeric 
999 
Default next: 3 -26a 
(Added 14/05/2003 09:15:08 PM by lianne parkin Modified 14/05/2003 09:26:13 PM by lianne parkin) 
Q26a Did <>YOU<><>your <><> take hormone replacement therapy at any time between the<> and the<>? Q26a 
PROMPT IF NECESSARY: By hormone replacement therapy I mean the female hormone pills, skin 
patches, or implants that some women use around the time of the menopause or the change of life. 





Post-logic: Qdata2.q03=1 and Qdata3.q26a=1 GOT0:3 261 
Qdata2.q03=2 and Qdata3.q26a=1 GOT0:3 26b 
Qdata2.q03=2 and Qdata3.q26a=3 GOT0:3 26c 
Qdata2.q03=3 and Qdata3.q26a=1 GOT0:3 26d 
Default next: 4a-OO 
(Added 10/03/2003 02:38:26 PM by lparkin Modified 15/05/2003 05:03:32 PM by lianne parkin) 
026b Now I'd like to double check something. 
You've just said that <>YOU<><>your <><> DID take hormone replacement therapy in the three months 
between the<> and the<>, BUT earlier you said that <>YOU<><>your <><>HAD NEVER taken 
hormone replacement therapy before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. This is the sentence: 






VTE risk factors in the three months before the index date Section 3 




Default next: 4a-OO 
(Added 31/03/2003 11 :39:00 AM by lparkin 
Q26c Now I'd like to double check something. 
Response logic: 
3 26e 
Modified 14/05/2003 09:30:02 PM by lianne parkin) 
You've just said that you DON'T KNOW whether <>you <><>your<><> took hormone replacement 
therapy in the three months between the <> and the <>, BUT earlier you said that <>YOU<><>She<> 
HAD NEVER taken hormone replacement therapy before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. This is the sentence: 
<>YOU<><>Your <><> DID take hormone replacement therapy at some time before the<>. 




Default next: 4a-OO 
Response logic: 
3 26e 
(Added 31/03/2003 11 :41 :14 AM by lparkin Modified 14/05/2003 09:30:25 PM by lianne parkin) 
Q26d Now I'd like to double check something. 
You've just said that <>you <><>your<><> DID take hormone replacement therapy in the three months 
between the<> and the<>, BUT earlier you said that you DIDN'T KNOW whether <>YOU<><>your <> 
<> had ever taken hormone replacement therapy before the<>. 
I know that it's difficult to remember so far back, but I'm going to read out a sentence and I'd like you to 
tell me whether you think it is true or false. This is the sentence: 
<> YOU<><> Your<><> DID take hormone replacement therapy at some time before the<>. 




Default next: 4a-OO 
Response logic: 
3 26e 
(Added 06/04/2003 03:58:30 PM by lparkin Modified 14/05/2003 09:30:51 PM by lianne parkin) 
026c 
Q26d 
Q26e And did <>YOU<><>She<> take hormone replacement therapy in the three months between the <> and Q26e 
the<>? 




Default next: 4a-OO 
Response logic: 
3 261 
(Added 16/04/2003 04:54:47 PM by lianne parkin Modified 15/05/2003 04:48:55 PM by lianne parkin) 
Q26f What is the drug code prefix? Q26f 
Section 3 
, ... , 
> 
1:. 
VTE risk factors in the three months before the index date Section 3 
Pre-logic: lower(gcusername)<>'lianne parkin' GOT0:4a00 
Response type: Numeric 
99 
Default next: 3 -26g 
(Added 15/05/2003 04:47:45 PM by lianne parkin Modified 15/05/2003 05:02:46 PM by lianne parkin) 
026g What is the drug code suffix? 
Response type: Numeric 
999 
Default next: 4a-OO 
026g 




First international flight during the four weeks before the index date Section 4a 
000 Now I am going to ask you some questions· about your <><>'S<> activities in the four weeks before the 000 
<>. 
If you look at your calendar you'll see that I'm referring to the weeks between the <> and the<>. 
So: 
Response type: Statement 
Def au It next: 4a-01 
001 
(Added 14/03/2003 09:37:35 AM by lparkin Modified 17/04/2003 11 :46:50 AM by lianne parkin) 
Did <>YOU<><>your <><>goon any international flights during those four weeks? 
You may need to look at passports and other records before you can answer this question. Or you 
may need to talk to relatives or friends. I am happy to wait while you do this, or we can arrange a time 
for me to phone you back. 
PROMPT IF NECESSARY: By international flights I mean flights out of New Zealand, flights into New 
Zealand from another country, and flights between countries other than New Zealand. 






Default next: 9a-00a 
(Added 13/03/2003 05:02:02 PM by lparkin Modified 16/04/2003 10:45:08 AM by lianne parkin) 
001 
002 IF MORE THAN ONE INTERNATIONAL FLIGHT DURING FOUR WEEK PERIOD: I am going to ask 002 
you some questions about each flight. Lets take the first INTERNATIONAL flight that <>YOU<><>your 
<><> had between the <> and the <>. 
From which INTERNATIONAL airport did your<> <>'S<> flight depart? 
(record name I don't know) 
Response type: Single line text 
200 
Default next: 4a-03 
003 
(Added 13/03/2003 05:08:15 PM by lparkin Modified 11/05/2003 07:09:07 PM by lianne parkin) 
On what date did <>YOU<><>your <><> depart from this internat'lonal airport? 
(record dd/mm/yy [local time] / don't know) 
Response type: Single line text 
200 
Default next: 4a-04 
Q04 
(Added 11/03/2003 09:43:02 AM by lparkin Modified 11/05/2003 03:25:39 PM by lianne parkin) 
At which airport did your<> <>'S<> international flight arrive? 
(record name of final destination/ don't know) 








First international flight during the four weeks before the index date 
Response type: Single line text 
200 
Default next: 4a-05 
005 
(Added 24/03/2003 10:32:21 AM by lparkin Modified 11/05/2003 07:06:37 PM by lianne parkin) 
On what date did <>YOU<><>your <><> arrive at this airport? 
(record dd/mm/yy [local time] / don't know) 
Response type: Single line text 
200 
Default next: 4a-06 
(Added 11/03/2003 09:45:51 AM by lparkin Modiiied 11/04/2003 05:15:17 PM by lparkin) 
Section 4a 
005 
006 Did the aeroplane land anywhere between ___ (international airport where began journey) and 006 
___ (final destination)? 




Default next: 4a-07 
Response logic: 
4a12 
(Added 11/03/2003 10:13:55 AM by lparkin Modified 13/04/2003 05:10:50 PM by lparkin) 
007 How long was the flight between ___ (international a·1rport from which departed) and __ _ 
(final destination)? 
(record hours, or minutes, or "-2" if don't know) 
Response type: Text entry with input mask 
xx.xhrs(xxm) 
Post-logic: alltrim(QData4a.q07)="-2" GOT0:4a08 
Default next: 4a-09 
(Added 13/04/2003 05:09:11 PM by lparkin Modified 20/05/2003 11 :19:34 AM by lianne parkin) 
007 
008 Do you think it would have been less than 4 hours, between 4 to 8 hours, between 9 to 12 hours, or 008 
more than 12 hours? 
Response type: Single select from 
Less than 4 hours 
4 - 8 hours 
9-12 hours 
More than 12 hours 
Don't know 
Default next: 4a-09 
(Added 11/03/2003 10:41 :36 AM by lparkin Modified 13/04/2003 05:13:26 PM by lparkin) 
009 Which class <>Were you<><>was your<><> travelling in? 009 
PROMPT IF NECESSARY: Was it first class, business class, economy class, or some other class? 






Default next: 4a-1 O 
(Added 11/03/2003 10:06:47 AM by lparkin Modified 13/04/2003 05:13:39 PM by lparkin) 





First international flight during the four weeks before the index date 




Default next: 4a-11 
{Added 11/03/2003 10:09:54 AM by lparkin Modified 15/04/2003 10:30:04 AM by lparkin) 
011 Did <>YOU<><>your <><> take any sleeping pills immediately before, or during, the flight? 




Default next: 4a-26 
012 
(Added 11/03/2003 09:48:41 AM by lparkin Modified 15/04/2003 10:37:04 AM by lparkin) 
Where did the aeroplane land? 
(record name of airport/ don't know) 
Response type: Single line text 
200 
Default next: 4a-13 Start of Loop 
(Added 11/03/2003 10:21 :31 AM by lparkin Modified 13/04/2003 06:16:10 PM by lparkin) 
013 How long was the flight between ___ (airport from which departed on this leg of journey) and 
___ (airport at which arrived on this leg of journey)? 
(record hours, or minutes, or "-2" if don't know) 
Response type: Text entry with input mask 
xx.xhrs(xxm) 
Post-logic: alltrim(QData4a.q13) ="-2" GOT0:4a14 
Default next: 4a-15 





Q14 Do you think it would have been less than 4 hours, between 4 to 8 hours, between 9 to 12 hours, or 014 
more than 12 hours? 
Response type: Single select from 
Less than 4 hours 
4-8 hours 
9-12hours 
More than 12 hours 
Don't know 
Default next: 4a-15 
015 
(Added 13/04/2003 05:22:46 PM by lparkin Modified 13/04/2003 05:23:12 PM by lparkin) 
Which class <>were you<><>was your<><> travelling in on this leg of 
<>your <><><>her <><>hiS<<IUmale>><> journey? 
Q15 
PROMPT IF NECESSARY: Was it first class, business class, economy class, or some other class? 






Default next: 4a-16 






First international flight during the four weeks before the index date Section 4a 
016 Did <>YOU<><>your <><> have a seat on the aisle on this leg of <>your<><><>her<><>his«/Umale 016 
»<> journey? 




Default next: 4a-17 
017 
(Added 13/04/2003 05:17:09 PM by lparkin Modified 15/04/2003 01:47:18 PM by lparkin) 
Did <>YOU<><>your<><> take any sleeping pills immediately before, or during, this leg of 
<>your<><><>her<><>hiS<<iUmale>><> journey? 




Default next: 4a-18 
(Added 13/04/2003 05:17:51 PM by lparkin Modified 15/04/2003 10:06:50 AM by lparkin) 
017 
018 How long did <>YOU<><>your <><> spend at the ____ airport (airport at which landed at end of 018 
this leg of journey)? 
(record hours, or minutes, or "-2" if don't know) 
Response type: Text entry with input mask 
xx.xhrs(xxm) 
Post-logic: alltrim(QData4a.q18) ="-2" GOT0:4a19 
Default next: 4a-20 
019 
(Added 11/03/2003 10:22:44 AM by lparkin Modified 20/05/2003 11 :20:46 AM by lianne parkin) 
Do you think it would have been less than 2 hours, between 2 - 4 hours, between 5 to 8 hours, 
between 9 to 12 hours, or more than 12 hours? 
Response type: Single select from 
Less than 2 hours 
2- 4 hours 
5 - 8 hours 
9- 12 hours 
More than 12 hours 
Don't know 
Default next: 4a-20 
(Added 11/03/200310:37:42 AM by lparkin Modified 14/04/2003 08:58:13 PM by lparkin) 
019 
020 Did <>your<><>your<>'S<> aeroplane land anywhere else before it reached ____ airport (final 020 
destination)? 




Default next: 4a-21 End of Loop 
Response logic: 
4a12 
(Added 11/04/2003 05:31 :15 PM by lparkin Modified 13/04/2003 06:41 :24 PM by lparkin) 
021 How long was the flight between ___ (airport from which departed on this leg of journey) and 
___ (final destination)? 






First international flight during the four weeks before the index date 
Response type: Text entry with input mask 
xx.xhrs(xxm) 
Post-logic: alltrim(QData4a.q21 )="-2" GOT0:4a22 
Default next: 4a-23 
(Added 13/04/2003 06:12:22 PM by lparkin Modified 20/05/2003 11 :21 :13 AM by lianne parkin) 
Section 4a 
Q22 Do you think it would have been less than 4 hours, between 4 to 8 hours, between 9 to 12 hours, or Q22 
more than 12 hours? 
Response type: Single select from 
Less than 4 hours 
4 - 8 hours 
9 -12 hours 
More than 12 hours 
Don't know 
Default next: 4a-23 
Q23 
(Added 13/04/2003 06:12:48 PM by lparkin Modified 13/04/2003 06:13:14 PM by lparkin) 
Which class <>were you<><>was your <><> travelling in on this leg of 
<>your<><><>her<><>his<</Umale>><> journey? 
Q23 
PROMPT IF NECESSARY: Was it first class, business class, economy class, or some other class? 






Default next: 4a-24 
(Added 13/04/2003 06:13:54 PM by lparkin Modified 15/04/2003 10:07:10 AM by lparkin) 
Q24 Did <>YOU<><>your <><> have a seat onthe aisle on this leg ok>your<><><>her<><>his«/Umale»<:024 
journey? 




Default next: 4a-25 
Q25 
(Added 13/04/2003 06:14:48 PM by lparkin Modified 15/04/2003 10:07:19 AM by lparkin) 
Did <>YOU<><>your<><> take any sleepingpills immediately before, or during, this leg of 
<>your<><><>her<><>his<<IUmale>><> journey? 




Default next: 4a-26 
Q26 
(Added 13/04/2003 06:15:27 PM by lparkin Modified 15/04/200310:07:31 AM by lparkin) 
Did <>YOU<><>your <><>goon any domestic flights within New Zealand, or another country, 








First international flight during the four weeks before the index date 




Default next: 4a-29 
Response logic: 
4a27 
(Added 14/03/2003 10:10:28 AM by lparkin Modified 13/04/2003 06:41 :38 PM by lparkin) 
027 From which airport(s) did the domestic flight(s) depart? 
(record name(s) of airport(s) / don't know) 
Response type: Single line text 
200 
Default next: 4a-28 
(Added 11/03/2003 11 :27:01 AM by lparkin Modified 13/04/2003 06:10:45 PM by lparkin) 
028 On what date(s) did <>YOU<><>your <><> depart from this airport(s)? 
(record dd/mm/yy [local time]/ don't know) 
Response type: Single line text 
200 
Default next: 4a-29 
(Added 11/03/2003 11 :29:20 AM by lparkin Modified 13/04/2003 06:10:23 PM by lparkin) 
029 Did <>YOU<><>your <><>goon any domestic flights within New Zealand, or another country, 
DIRECTLY AFTER the international flight? 




Default next: 4a-32 
Response logic: 
4a30 
(Added 11/03/2003 11 :21 :36 AM by lparkin Modified 13/04/2003 06:08:53 PM by lparkin) 
030 At which airport(s) did the domestic flight(s} arrive? 
(record name(s} of airport(s} / don't know) 
Response type: Single line text 
200 
Default next: 4a-31 
031 
(Added 13/04/2003 05:32:13 PM by lparkin Modified 13/04/2003 06:08:20 PM by lparkin) 
On what date(s) did <>YOU<><>your <><> arrive at this airport(s}? 
(record dd/mm/yy [local lime]/ don't know} 
Response type: Single line text 
200 
Default next: 4a-32 







032 Did <>YOU<><>your <><> go on any other international flights during the four weeks between the <> aniQ32 
the<>? 




Post-logic: QData4a.q32=1 GOT0:4b01 
Default next: 9a-00a 








First domestic flight within another country in the four weeks before 
the index date 
Section 9a 
QOOa Now I would like to ask you some questions about any domestic flights that <>YOU<><>your <><> QOOa 
might have taken WITHIN a country OTHER THAN New Zealand in the four weeks between the <> and 
the<>. 
Pre-logic: Qdata4a.q01 = 1 GOT0:9aOOb 
Response type: Statement 
Default next: 9a-01 
(Added 13/03/2003 03:42:16 PM by lparkin Modified 11/05/2003 07:22:25 PM by lianne parkin) 
OOOb Now I would like to ask you some questions about any domestic flights that <>YOU<><>your <><> OOOb 
might have taken WITHIN a country OTHER THAN New Zealand in the four weeks between the<> and 
the<>. 
I would like to know about all your <><>'S<> domestic flights within another country, not just the ones 
that <>you<><><>S<><>h6<> <> might have been on directly before, or after, an international flight. 
Response type: Statement 
Default next: 9a-01 
(Added 13/03/2003 03:51 :10 PM by lparkin Modified 11/05/2003 06:37:41 PM by lianne parkin) 
001 Did <>YOU<><>your <><> go on any domestic flights WITHIN a country OTHER THAN New Zealand 001 
between the <> and the <>? 






Default next: 10-00 
002 
(Added 13/03/2003 03:44:43 PM by lparkin Modified 11/05/2003 04:05:25 PM by lianne parkin) 
From which airport did <>your<><>your <.>'S<> flight depart? 
(record name of airport/ don't know) 
IF MORE THAN ONE FLIGHT DURING FOUR WEEK PERIOD: I am going to ask you some 
questions about each flight. 
Lets take the first flight that <>YOLI<><>your <><> had between the <> and the<>. 
Response type: Single line text 
200 
Default next: 9a-03 
Q03 
(Added 13/03/2003 03:59:40 PM by lparkin Modified 15/04/2003 04:56:39 PM by lianne parkin) 
On what date did <>YOU<><>your <><> depart from this airport? 
(record dd/mm/yy [local time]/ don't know) 
Response type: Single line text 
200 
Default next: 9a-04 
004 
(Added 13/03/2003 04:00:56 PM by lparkin Modified 15/04/2003 10:44:00 AM by lparkin) 
At which airport did <>your<><>your <>'S<> flight arrive? 









First domestic flight within another country in the four weeks before 
the 
Response type: Single line text 
200 
Default next: 9a-05 
(Added 13/03/2003 04:21 :55 PM by lparkin Modified 15/04/2003 10:12:24 AM by lparkin) 
005 On what date did <>YOU<><>your <><> arrive at this airport? 
(record dd/mm/yy [local time] I don't know) 
Response type: Single line text 
200 
Default next: 9a-06 
(Added 13/03/2003 04:23:33 PM by lparkin Modified 14/04/2003 08:11 :14 PM by lparkin) 
006 Did the aeroplane land anywhere between ___ (airport where began journey) and 
----'(final destination)? 




Default next: 9a-07 
Response logic: 
9a12 
(Added 13/03/2003 04:29:48 PM by lparkin Modified 14/04/2003 08:11 :58 PM by lparkin) 
007 How long was the flight between ___ (airport where began journey) and (final 
destination)? 
(record hours, or minutes, or "-2" if don't know) 
Response type: Text entry with input mask 
xx.xhrs(xxm) 
Post-logic: al1trim(0Data9a.q07)="-2" GOT0:9a08 
Default next: 9a-09 
008 
(Added 13/03/2003 05:28:14 PM by lparkin Modified 20/05/2003 12:05:05 PM by lianne parkin) 
Do you think it would have been less than 2 hours, between 2 - 4 hours, between 5 to 8 hours, 
between 9 to 12 hours, or more than 12 hours? 
Response type: Single select from 
Less than 2 hours 
2 - 4 hours 
5 - 8 hours 
9-12hours 
More than 12 hours 
Don't know 
Default next: 9a-09 
(Added 13/03/2003 05:30:38 PM by lparkin Modified 14/04/2003 08:59:42 PM by lparkin) 







PROMPT IF NECESSARY: Was it first class, business class, economy class, or some other class? 






Default next: 9a-10 














First domestic flight within another country in the four weeks before 
the 
010 Did <>YOU<><>your <><> have a seat on the aisle? 




Default next: 9a-11 
(Added 13/03/2003 04:27:11 PM by lparkin Modified 14/04/2003 08:15:58 PM by lparkin) 
011 Did <>YOU<><>your <><> take any sleeping pills immediately before, or during, the flight? 




Default next: 9a-26 
012 
(Added 13/03/2003 04:24:42 PM by lparkin Modified 14/04/2003 08:50:26 PM by lparkin) 
Where did the aeroplane land? 
(record name of airport/ don't know) 
Response type: Single line text 
200 
Default next: 9a-13 Start of Loop 
(Added 13/03/2003 04:30:29 PM by lparkin Modified 14/04/2003 08:16:27 PM by lparkin) 
013 How long was the flight between ___ (airport from which departed on this leg of journey) and 
___ (airport at which arrived on this leg of journey)? 
(record hours, or minutes, or "-2" if don't know) 
Response type: Text entry with input mask 
xx.xhrs(xxm) 
Post-logic: alltrim(QData9a.q13)="-2" GOT0:9a14 
Default next: 9a-15 
014 
(Added 14/04/2003 08:18:22 PM by lparkin Modified 20/05/2003 12:05:30 PM by lianne parkin) 
Do you think it would have been less than 2 hours, between 2 - 4 hours, between 5 to 8 hours, 
between 9 to 12 hours, or more than 12 hours? 
Response type: Single select from 
Less than 2 hours 
2- 4 hours 
5 - 8 hours 
9 -12 hours 
More than 12 hours 
Don't know 
Default next: 9a-15 
015 
(Added 14/04/2003 08:19:14 PM by lparkin Modified 14/04/2003 08:59:26 PM by lparkin) 









PROMPT IF NECESSARY: Was it first class, business class, economy class, or some other class? 
Section 9a 
,-.-
First domestic flight within another country in the four weeks before 
the 






Default next: 9a-16 
(Added 14/04/2003 08:24:53 PM by lparkin Modified 15/04/200310:16:40 AM by lparkin) 
Section 9a 
016 Did <>YOU<><>your <><> have a seat on the aisle on this leg ok>your<><><>her<><>his«/Umale>> 016 
<> journey? 




Default next: 9a-17 
(Added 14/04/2003 08:25:58 PM by lparkin Modified 15/04/2003 10:16:49 AM by lparkin) 
017 Did <>YOU<><>your <><> take any sleeping pills immediately before, or during, the flight on this leg of 017 
<>your<><><>her<><>his<<iUmale>><> journey? 




Def au It next: 9a-1 B 
(Added 14/04/2003 08:27:17 PM by lparkin Modified 15/04/2003 10:16:58 AM by lparkin) 
018 How long did <>YOU<><>your <><> spend at the ____ airport (airport at which landed at end of 018 
this leg of journey)? 
(record hours, or minutes, or "-2" if don't know) 
Response type: Text entry with input mask 
xx.xhrs(xxm) 
Post-logic: alltrim(QData9a.q1B)~"-2" GOT0:9a19· 
Default next: 9a-20 
019 
(Added 13/03/2003 04:31 :59 PM by lparkin Modified 20/05/2003 12:05:51 PM by lianne parkin) 
Do you think it would have been less than 2 hours, between 2 - 4 hours, between 5 to B hours, 
between 9 to 12 hours, or more than 12 hours? 
Response type: Single select from 
Less than 2 hours 
2 - 4 hours 
5-8 hours 
9 -12 hours 
More than 12 hours 
Don't know 
Default next: 9a-20 
(Added 13/03/2003 04:32:19 PM by lparkin Modified 14/04/2003 08:59:11 PM by lparkin) 
019 









First domestic flight within another country in the four weeks before 
the 




Default next: 9a-21 End of Loop 
Response logic: 
9a12 
(Added 14/04/2003 08:38:55 PM by lparkin Modified 15/04/2003 10:44:35 AM by lparkin) 
021 How long was the flight between ___ (airport from which departed on this leg of journey) and 
___ (final destination)? 
(record hours, or minutes, or "-2" if don't know) 
Response type: Text entry with input mask 
xx.xhrs(xxm) 
Post-logic: al1trim(0Data9a.q21)="-2" GOT0:9a22 
Default next: 9a-23 
022 
(Added 14/04/2003 08:39:40 PM by lparkin Modified 20/05/2003 12:06:11 PM by lianne parkin) 
Do you think it would have been less than 2 hours, between 2 - 4 hours, between 5 to 8 hours, 
between 9 to 12 hours, or more than 12 hours? 
Response type: Single select from 
Less than 2 hours 
2- 4 hours· 
5 - 8 hours 
9 -12 hours 
More than 12 hours 
Don't know 
Deiault next: 9a-23 
023 
(Added 14/04/2003 08:40:46 PM by lparkin Modified 14/04/2003 08:58:59 PM by lparkin) 






PROMPT IF NECESSARY: Was it first class, business class, economy class, or some other class? 






Default next: 9a-24 
(Added 14/04/2003 08:42:09 PM by lparkin Modified 15/04/2003 10:17:33 AM by lparkin) 
Q24 Did <>YOU<><>your <><> have a seat onthe aisle on this leg ok>your<><><>her<><>his«/Umale»<Q24 
journey? 




Default next: 9a-25 
(Added 14/04/2003 08:43:18 PM by lparkin Modified 15/04/200310:17:43 AM by lparkin) 




First domestic flight within another country in the four weeks before 
the 
»<> journey? 




Default next: 9a-26 
(Added 14/04/2003 08:43:47 PM by lparkin Modified 15/04/2003 10:17:57 AM by lparkin) 
Section 9a 
026 Did <>YOLI<><>your <><>goon any other flights WITHIN a country OTHER THAN New Zealand duringQ26 
the four weeks between the <> and the <>? 




Post-logic: Odata9a.q26=1 GOT0:9b01 
Default next: 10-00 
Response logic: 






Other travel in the four weeks before the index date Section 10 
QOO Now I would like to ask you some questions about any other travel that <>your<><> might have done irQOO 
the four weeks between the <> and the<>. 
I realise that it may be difficult to remember, just do the best you can. 
Pre-logic: Reference.ucontrol GOT0:5 00 
Response type: Statement 
Default next: 10-01 
(Added 13/03/2003 03:42:16 PM by lparkin Modified 11/05/2003 07:39:22 PM by lianne parkin) 
Q01 Did <>your<><> go on any long journeys (by car, bus, train, or some other form of transport) that took Q01 
at least four hours in the four weeks between the <> and the <>? (record details, including dates, mode 
of transport, and duration of journey[s]) 
Response type: Edit box (open ended) Response logic: 
Default next: 5 -00 








Height and weight 
000 I now have a few questions about <>your<><>your 
<>'S<> height and weight in the past. 
Section 5 
000 
I realise that it can be difficult to give exact answers to these sorts of questions. Just do the best that 
you can. 
Response type: Statement 
Default next: 5 -01a 
(Added 11/03/2003 02:09:58 PM by lparkin Modified 16/04/2003 09:00:17 PM by lianne parkin) 
001 a How tall do you think <>you were<><>your <> 
was<> on the <>? 
(record height (feet and inches or metres]/ or "-2" if don't know) 
PROMPT IF NECESSARY: You can answer in feet and inches, or in metres and centimetres 
(Further prompt for next of kin): It might be helpful to think about how tall you are, and then how tall 
<> was in relation to you. 
Response type: Text entry with input mask 
#.##m#(#ft##") 
Post-logic: alltrim(Qdata5.q01a) ="-2" GOT0:5 01 b 
Def au It next: 5 -02a 
(Added 11/03/2003 01 :43:05 PM by lparkin Modified 27/05/2003 03:54:14 PM by lianne parkin) 
001 b <>Were you<><>Was 
<>S<>he<> of average height, above average height, or below 
average height? 





Default next: 5 -01c 
(Added 11/03/2003 01 :49:32 PM by lparkin Modified 20/03/2003 12:04:20 PM by lparkin) 
001 c (Record any other comments about height) 
Response type: Single line text 
200 
Default next: 5 -02a 
(Added I I : AM by Modified / / 
002a What do you think <>YOU<><>your <><> 
would have weighed when <>you 
were<><><>S<>he was<> 20 years old? 
: AM by) 





Pre-logic: (Reference.ucontrol and Reference.age<=20) or (!Reference.ucontrol and Reference.uage<=20) 
GOT0:5 03a 
Response type: Text entry with input mask 
###.#kg#(##st###pds) 
Post-logic: alltrim(Qdata5.q02a) ="-2" GOT0:5 02b 
Default next: 5 -03a 
(Added 11/03/2003 01 :51 :08 PM by lparkin Modified 20/05/2003 12:32:06 PM by lianne parkin) 
Q02b Do you think 
<>your<><><>her<><>his«/Umale 







Height and weight 
Response type: Single select from 
Average 
More than average 
Less than average 
Don't know 
Default next: 5 -02c 
(Added 11/03/2003 01 :59:30 PM by lparkin Modified 15/05/2003 03:47:11 PM by lianne parkin) 
Q02c (Record any other comments about weight) 
Response type: Single line text 
200 
Default next: 5 -03a 
(Added I I : AM by Modified I I 
003a What do you think <>YOU<><>your <><> 
would have weighed on the<>? 
: AM by) 
(record weight [stones and pounds or kilograms]/ or "-2" if don't know) 
Response type: Text entry with input mask 
###.#kg#(##st###pds) 
Post-logic: alltrim(Qdata5.q03a) ="-2" GOT0:5 03b 
Default next: 5 -04a 
{Added 11/03/2003 02:01 :43 PM by lparkin Modified 20/05/2003 12:32:27 PM by lianne parkin) 
Q03b Do you think 
<>your<><><>her<><>his<<IUmale 
»<> weight would have been about average, more than average, or less than average? 
Response type: Single select from 
Average 
More than average 
Less than average 
Don't know 
Default next: 5 -03c 
(Added 11/03/2003 02:03:1 O PM by lparkin Modified 16/04/2003 10:50:26 AM by lianne parkin) 
Q03c (Record any other comments about weight) 
Response type: Single line text 
200 
Default next: 5 -04a 
(Added 16/04/2003 10:50:35 AM by lianne parkin Modified / / 
Q04a I have one last question about weight and height. For <>your<> 
<><>her<><>hiS<><> height, 
<>were you<><>was your<><> about the 
right weight, overweight, or underweight on the<>? 





Default next: 5 -04b 
: AM by} 
(Added 11/03/2003 02:07:25 PM bylparkin Modified 16/04/200310:44:05 AM by lianne parkin) 













Height and weight 
Response type: Single line text 
200 
Default next: 6 -00 









Family history Section 6 
000 Now I would like to ask you a few questions about the medical history of <>your<><>your <>'S<> familyOOO 
before the <>. 
I realise that you won't necessarily know a lot about the medical history of <>your<><>your <>'S<> 
family. Just answer the questions as best as you can. 
So, before the<>: 
Response type: Statement 
Default next: 6 -01 a 
(Added 19/03/2003 10:18:20 AM by lparkin Modified 16/04/2003 09:01 :00 PM by lianne parkin) 
001a As tar as you know, was anyone in <>your<><>your <>'S<> immediate, or extended, family (and by 001 a 
extended family I mean grandparents, aunts, cousins, nieces etc) ever treated for deep vein thrombosis? 
PROMPT IF NECESSARY: This is a condition where blood clots have formed in the deep veins of the 
legs or pelvis 




Default next: 6 -02a 
Response logic: 
6 01b 
(Added 11/03/2003 02:15:30 PM by lparkin Modified 19/03/2003 10:20:23 AM by lparkin) 
001 b What relationship was this person/ were these people to <>YOU<><> to your<><>? 
(NB. (i) Record only biological relatives 
(ii) For aunts, uncles, cousins, grandparents, and great-grandparents, record whether maternal, 
paternal, or unknown 
(iii) Record the number of relatives who had a DVT. For example: 3 maternal aunts) 
IF AN UNCLE OR AUNT IS IDENTIFIED, ASK: Is this a direct relative, or are they related to 
<>YOU<><>your <><> through marriage? 
ALSO ASK: Did <>yOU<><>your <><> have any other relatives who were treated for deep vein 
thrombosis? 
Response type: Single line text 
200 
Default next: 6 -02a 
(Added 11/03/2003 02:22:58 PM by lparkin Modified 11/05/2003 07:~2:19 PM by lianne parkin) 
001b 
002a As far as you know, was anyone in <>your<><>your <>'S<> immediate, or extended, family ever treatedQ02a 
for pulmonary embolism? 
PROMPT IF NECESSARY: This is the condition where blood clots in the legs or pelvis break off and 
travel up to the arteries of the lungs. 




Default next: 7 -00 
Response logic: 
602b 
(Added 11/03/2003 02:27:37 PM by lparkin Modified 19/03/2003 10:36:27 AM by lparkin) 
002b What relationship was this person/ were these people to <>YOU<><>to your<><>? 








(ii) For aunts, uncles, cousins, grandparents, and great-grandparents, record whether maternal, 
paternal, or unknown 
Section 6 
(iii) Record the number of relatives who had pulmonary embolism. For example: 3 maternal aunts) 
IF AN UNCLE OR AUNT IS IDENTIFIED, ASK: Is this a direct relative, or are tl1ey related to 
<>YOU<><>your <><> through marriage? 
ALSO ASK: Did <>yOU<><>your <><> have any other relatives who were treated for deep vein 
throm basis? 
Response type: Single line text 
200 
Default next: 7 -00 











General demographic data 
000 Finally I would like to ask you some general questions about <>yourself<><>your <><>. 
The reason for asking these questions is that people's health can sometimes be affected by their 
personal circumstances. 
The first questions are about education. 
Response type: Statement 
Default next: 7 -01 
(Added 11/03/2003 06:57:59 PM by lparkin Modified 27/05/2003 08:55:33 PM by lianne parkin) 
Section 7 
QOO 
001 How many years did <>YOU<><>your <><> spend at secondary school (high school, technical school) 001 
before<>? 
(record country and number of years, or don't know) 
PROMPT IF NECESSARY: The maximum time that people usually spend at secondary school in New 
Zealand is 5 years. 
Response type: Single line text 
200 
Default next: 7 -02a 
(Added 11/03/2003 02:37:34 PM by lparkin Modified 19/05/2003 11 :23:02 AM by lianne parkin) 
Q02a Before the<> did <>YOU<><>your <><> get any qualifications after <>YOU<><><>S<>he<> had left 
school? 
(PROMPT IF NECESSARY By qualifications I mean degrees, diplomas, certificates, and the 
completion of apprenticeships) 




Still studying for qualification 
Post-logic: Qdata7.q02a=1 or Qdata7.q02a=4 GOT0:7 02b 
Default next: 7 -03a 
Response logic: 
(Added 11/03/2003 02:38:10 PM by lparkin Modified 22/05/2003 10:23:27 AM by lianne parkin) 
Q02b What was <>your<><><>her<><>his«/Umale»<> highest qualification? 
Response type: Single line text 
200 
Default next: 7 -03a 
(Added 11/03/2003 02:44:26 PM by lparkin Modified 20/03/2003 12:11 :18 PM by lparkin) 
Q02c Classify the highest qualification 
Pre-logic: lower(gcusername)<>"lianne parkin" GOT0:7 03a 
Response type: Numeric 
99 
Default next: 7 -03a 
(Added 11/03/2003 02:47:01 PM by lparkin Modified 11/05/2003 02:29:00 PM by lianne parkin) 







General demographic data 




Spontaneously reported was retired 
Default next: 7 -03c 
(Added 11/03/2003 02:48:29 PM by lparkin 
Q03b What was that job? 
Response logic: 
7 03b 
Modified 16/04/2003 09:03:23 PM by lianne parkin) 
IF NAME OR TYPE OF WORKPLACE STATED, ASK: What sort of work did 
<>YOU<><>YOUr <><> do there? 
Response type: Single line text 
200 
Default next: 7 -03d 
(Added 11/03/2003 02:51 :23 PM by lparkin Modified 19/03/2003 01 :25:29 PM by lparkin) 
Q03c What was the last job<>YOLI<><><>S<>he<> did before the <>? 
IF NAME OR TYPE OF WORKPLACE STATED, ASK: What sort of work did 
<>YOU<><>YOUr <><> do there? 
Response type: Single line text 
200 
Default next: 7 -03d 
(Added 11/03/2003 03:16:14 PM by lparkin Modified 13/05/2003 09:26:58 PM by lianne parkin) 
003d What is the NZSEI code for that type of work? 
Pre-logic: lower(gcusername)<>"lianne parkin" GOTO:? 04a 
Response type: Numeric 
999 
Default next: 7 -04a 
(Added 11/03/2003 03:21 :57 PM by lparkin Modified 11/05/2003 07:13:38 PM by lianne parkin) 
Q04a Did <>YOLI<><>your <><> live with <>a spouse or partner<><>you I a spouse or partner<> 
on the<>? 




Default next: 7 -05a 
Response logic: 
704b 
(Added 11/03/2003 03:24:37 PM by lparkin Modified 27/05/2003 03:33:11 PM by lianne parkin) 
Q04b Did <>your spouse or partner<><>YOLI<> have a job on that date? 




Spontaneously reported was retired 
Default next: 7 -04d 
(Added 11/03/2003 03:27:14 PM by lparkin 
Q04c What was that job? 
Response logic: 
7 04c 















General demographic data 
IF NAME OR TYPE OF WORKPLACE STATED, ASK: What sort of work did <>your 
spouse or partner<><>YOU<> do there? 
Response type: Single line text 
200 
Default next: 7 -04e 
{Added 11/03/2003 03:27:47 PM by lparkin Modified 11/05/2003 03:19:49 PM by lianne parkin) 
Q04d What was the last job <>your spouse or partner<><>YOU<> did before the<>? 
IF NAME OR TYPE OF WORKPLACE STATED, ASK: What sort ol work did<>your spouse 
or partner<><>YOU<> do there? 
Response type: Single line text 
200 
Default next: 7 -04e 
(Added 11/03/2003 03:31 :31 PM by lparkin Modified 11/05/2003 03:19:55 PM by lianne parkin) 
Q04e What is the NZSEI code for that type of work? 
Pre-logic: lower{gcusername)<>"lianne parkin" GOTO:? 05a 
Re:lponse type: Numeric 
999 
Default next: 7 -05a 




QOSa Now I'd like to ask you a question about ethnicity. Which ethnic group <>do you<><>did your<><> 005a 
belong to? 
(read out if necessary and select as many as apply) 
Response type: Multi choice from Response logic: 
New Zealand European 
New Zealand Maori 
Samoan 





Other European (specify on next page) 
Other non-European (specify on next page 
Post-logic: bittest(Qdata7.q05a,9) or bittest(Qdata7.q05a, 10) GOTO:? 05b 
Default next: 7 -05c 
(Added 11/03/2003 03:35:00 PM by lparkin Modified 16/05/2003 02:01 :20 PM by lianne parkin) 
QOSb (If classified as "Other European" or "Other", specify ethnicity) 
Response type: Single line text 
200 
Default next: 7 -05c 
(Added 11/05/2003 02:42:06 PM by lianne parkin Modified / I : : AM by) 
QOSc One of the risk factors for the condition we are studying is more common among people who have 
SOME ancestors who were European. So I would like to ask you a question about the ethnicity of 
your<> <>'S<> ancestors. 
Were either of your<> <>'S<> parents, or any of <>your<><><>her<><>his<<IUmale>><> 







General demographic data 
Pre-logic: bittest(Qdata7.q05a, 1) or bittest(Odata7.q05a,9) GOT0:8 00 




Default next: 8 -00 
Response logic: 
7 05d 
(Added 11/03/2003 03:40:18 PM by lparkin Modified 28/05/2003 12:33:52 PM by cblakey) 
QOSd What relationship were they to <>YOU<><>your 
<><>? 
(For grandparents and great-grandparents, record whether maternal or paternal) 
Response type: Single line text 
200 
Default next: 8 -00 











000 We have almost come to the end of the interview. 
Response type: Statement 
Default next: 8 -01 
(Added 11/03/2003 04:22:11 PM by lparkin Modified / / : : AM by) 
Section 8 
000 
001 I just want to confirm where you were on a particular date. Were you in New Zealand or temporarily 001 
overseas (for example on a holiday or a work-related trip) on the<>? 
Pre-logic: !Reference.ucontrol GOT0:8 04 
Response type: Single select from 
In New Zeland 
Overseas 
Don't know 
Default next: 8 -02 
002 
(Added 11/03/2003 04:07:57 PM by lparkin Modified 11/05/2003 02:31 :04 PM by lianne parkin) 
I also want to confirm wrtere you were on another date. Were you in New Zealand or temporarily 
overseas on the <>? 
Pre-logic: Reference.uindexdate=Reference.udod GOT0:8 03 
Response type: Single select from 
In New Zealand 
Overseas 
Don't know 
Default next: 8 -03 
(Added 11/03/2003 04:10:04 PM by lparkin Modified 24/03/2003 10:44:55 AM by lparkin) 
002 
003 Would you be willing to give your consent for us to confirm the dates of any hospital admissions you 003 
have had? We can do this without looking at your medical records. 
(PROMPT IF NECESSARY: Public and private hospitals use a confidential computer system to record 
the dates that people were admitted to hospital) 
Response type: Password 
Default next: 8 -04 
(Added 11/03/2003 04:13:23 PM by lparkin Modified 13/05/2003 09:50:45 PM by lianne parkin) 
004 If we needed to obtain further information for our research, may we write to you again? 004 
Response type: Password 
Default next: 8 -05 
(Added 11/03/2003 04:15:33 PM by lparkin Modified 12/05/2003 01 :24:58 PM by lianne parkin) 
005 Would you like to be sent a summary of the results of this study when it is completed? 
Response type: Single select from 
Yes 
No 
Default next: 8 -06 
(Added 11/03/2003 04:16:06 PM by lparkin Modified / / : : AM by) 
006 Is there anything you wish to ask me, or any comments you would like to make? 
Response type: Edit box (open ended) 
Default next: 8 -07 
(Added 11/03/2003 04:16:47 PM by lparkin Modified 16/04/2003 09:07:09 PM by lianne parkin) 















The end Section 8 
Response type: Statement 
Default next: 8 -10 
008 
(Added 11/03/2003 04:17:23 PM by lparkin Modified 15/04/2003 05:00:13 PM by lianne parkin) 
Record information about other international flights (if more than 15) 
(Record departure and destination airports, dates of departure and arrival, whether plane landed 
anywhere, time spent at airport, duration of flight(s), class of travel, aisle seat, use of sleeping pills, and 
whether any domestic flights before or after international flight) 
Response type: Edit box (open ended) 
Default next: 9a-00a 
(Added 15/04/2003 04:58:46 PM by lianne parkin Modified 13/05/2003 09:47:58 PM by lianne parkin) 
008 
009 Record information about domestic flights within a country other than New Zealand (if more than 15) 009 
(Record departure and destination airports, dates of departure and arrival, whether plane landed 
anywhere, time spent at airport, duration of flight(s), class of travel, aisle seat, and use of sleeping 
Response type: Edit box (open ended) 
Default next: 5 -00 
(Added 15/04/2003 05:01 :11 PM by lianne parkin Modified 13/05/2003 09:48:24 PM by lianne parkin) 
01 O (Interviewer comments) 
Response type: Edit box (open ended) 
Default next: 8 -11 
(Added 11/03/2003 04:20:01 PM by lparkin Modified 12/05/2003 01 :25:39 PM by lianne parkin) 
Q11 (Name and signature of interviewer) 
Response type: Password 
Default next: 99-9999 



















I Research letters I 
Oral contraceptives and fatal pulmonary embolism 
Lianne Parkin, David C G Skegg, Meg Wilson, G Peter Herbison, Charlotte Paul 
See CommentatY page 2088 
In a national case-<:ontrol study of fatal pulmonary embolism in 
New Zealand women of childbearing age, we estimated that 
current users of combined oral contraceptives had a relative 
risk of 9·6 (95% Cl 3·1-29·1). From national distribution data, 
the absolute risk of death from pulmonary embolism in current 
users was estimated to be 10·5 per million woman-years. 
Since nearly all studies showing associations between oral 
contraception and venous thromboembolism (VTE) have 
involved non-fatal events, the possibility of referral or 
diagnostic bias has been suggested.' Such bias is unlikely in a 
study of fatal cases, since most young women who die 
unexpectedly are referred for necropsy. We studied fatal 
pulmonary embolism among all New Zealand women aged 
15-49 years. Cases were identified from deaths between 
January, 1990, and August, 1998, certified with the 
underlying cause as codes 415·1, 451, or 453, from the 
International Classification of Diseases, ninth revision. We 
obtained clinical details and the names of family physicians 
from coroners' and police reports and hospital records; if 
necessary, we also wrote to the next of kin to ask for the 
name of the family physician. Of 43 women identified, four 
had insufficient evidence for the diagnosis of pulmonary 
embolism, and three did not normally live in New Zealand. 
For the 36 eligible women, we asked the family physicians 
if an investigator (LP) could examine the records of the case 
and four controls. Every family physician agreed, but for 
seven cases the records had been lost. For the remainder of 
cases, the diagnosis had been confirmed by necropsy in 26, 
by ventilation-perfusion scans and pulmonary angiography 
in two, or by two independent physicians using standard 
criteria in one. 2 The median age was 32 years. We used the 
date of onset of the fatal episode as an index date. 
For each case we selected four controls from the same 
family physician's group practice who had the same year of 
birth as the case (except five controls who were each born in 
an adjacent year). The controls were selected randomly from 
an age-sex register in 27 practices ( computerised in all 
except one), and in the other two practices by random 
selection of medical records. We excluded potential controls 
if they were not normally resident in New Zealand, or did 
nOt belong to the practice, on the index date. The cases and 
controls had been with the same practices for an average of 
8·2 years and 8·0 years, respectively. We obtained 
information about medical and contraceptive histories from 
the group practice and any family-planning-clinic records, by 
the same approach for cases and controls. 








Current use of oral contraceptives was defined as 
prescribed use at any time during the 3 months before the 
index date. We excluded women who had reached the 
menopause (one case, five controls) or who had a history of 
VTE (two further cases). 17 (65%) of26 cases and 25 (23%) 
of 111 controls were current users of combined oral 
contraceptives (table). We calculated odds ratios and 95% 
CI for vrE, by use of unconditional logistic regression. We 
did not use matched analysis since unstable estimates were 
obtained because of sparse data. 
If we took non-users of any combined oral contraceptive 
as the reference group, the odds ratio (adjusted for age, 
weight, and family physician's practice) for all current users 
was 9·6 (95% CI 3·1-29·1). If we omitted controls with 
excluded cases, the adjusted odds ratio increased slightly to 
10·2. Two cases had other potential causes of vrE (long-
term immobility or major surgery); neither was using oral 
contraceptives. When such cases and controls were 
excluded, the odds ratio increased to 11 ·7 (3·5-38·5). 
The women who died while using oral contraceptives had 
a median age of 29. Only three cases were first-time users of 
any combined oral contraceptive (with durations of use 3 
months, 18 months, and 40 months, respectively). Third-
generation oral contraceptives, containing desogestrel (seven 
deaths) or gestodene (five), were the most commonly used 
by the cases. Two cases were using a contraceptive pill that 
contains cyproterone acetate and ethinyloestradiol, and the 
odds ratio for such women was 17·6 (2·7-113). A study by 
WHO also found a high odds ratio of 14·9 (3·7-59·4) for this 
product.2 
Only six (35%) deaths among cases using oral 
contraceptives had been reported to the Centre for Adverse 
Reactions Monitoring (CARM). CARM had been notified 
of a further death from pulmonary embolism ( confirmed by 
necropsy) in a woman taking a contraceptive containing 
desogestrel, which had been miscoded in national mortality 
data. Contraceptive-supply data provided by the Ministry of 
Health showed that there were up to I 717 153 woman-
years of use of combined oral contraceptives in New Zealand 
during the period of the study, during which 18 users died. 
Thus, the absolute risk of death from idiopathic pulmonary 
embolism in women taking combined oral contraceptives 
was estimated to be 10·5 (6·2-16·6) per million woman-
years. This estimate is probably conservative, since family-
physician records could not be found for several cases and 
we ignored deaths for which pulmonary embolism was not 
Adjusted odds 
ratio (95% Cl)* 
1·0 
certified as the underlying cause. 
Levonorgestrel 3 
Desogestrel or gestodene 12 
Cyproterone acetate 2 













This death rate was higher than 
expected because the annual incidence 
of VTE in oral-contraceptive users has 
been estimated at one or two per 10 000 
women, with a case fatality rate of only 
1-2%.' The high mortality in New 
Zealand may partly reflect the extensive 
use of third-generation oral contra-
*Adjusted for age (by individual year), weight (four categories, including missing values), and clustered on practice. 
tone control using combined oral contraceptive containing norethisterone. 
Current use of combined oral contraceptives 
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risk ofVTE than older contraceptives.3 Another case-control 
study of oral contraceptives and fatal pulmonary embolism, 
which involved deaths in England and Wales between 1986 
and 1988,' would have included few if any women using 
these preparations. A death rate of 14 per million woman-
years (based on six deaths) can be derived from a later cohort 
srudy. 5 Deaths from pulmonary embolism are rare among 
users of oral contraceptives, but the absolute risks should not 
be thought of as "infinitesimal, of no clinical importance and 
definitely of no public health significance".' 
This study was funded by the New Zealand .Ministry of Health. We thank 
family physicians and the Family Planning Association for their assistance, 
and David Coulter and Janelle Ashton for information from CARM. 
Spitzer WO. The aftermath of a pill scare: regression to reassurance, 
Hum Reprod Update 1999; S: 736-45. 
2 WHO Collaborative Study. Venous thromboembolic disease and 
combined oral contraceptives: results of international multicentre 
case-control study. Lancet 1995; 346: 1575-88. 
Walker AM. Newer oral contraceptives and the risk of venous 
thromboembolism. Contracepzion 1998; 57: 169-81. 
4 Thorogood M, MannJ, Murphy M, Vessey M. Risk factors for fatal 
venous thromboembolism in young women: a case-control study. Inz J 
Epidemiol 1992; 21: 48-52. 
Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of 
idiopathic cardiovascular death and nonfatal venous 
thromboembolism in women using oral contraceptives with differing 
progestagen components, Lancet 1995; 346: 1589-93. 
Department of Preventive and Social Medicine, University of 
Otago, PO Box 913, Dunedin, New Zealand (L Parkin MB, 
Prof D C G Skegg FRSNZ, M Wilson MHeaisc, G P Herbison MSc, 
C Paul PhD) 
Correspondence to: Prof David Skegg 
Pharmacological implications of 
lengthened in-utero exposure to 
nevi rapine 
G P Taylor, E G H Lyall, D Back, C Ward, G Tudor-Williams 
Given as a single dose to the mother during labour, nevirapine 
can protect the neonate from HIV-1 infection for up to 7 days. 
However, after maternal nevirapine therapy during pregnancy, 
neonatal plasma concentrations of nevirapine decline more 
rapidly, suggesting in-utero liver enzyme induction. 
Mother-to-child transmission of HIV-I can be reduced to 
less than 2% by avoidance of breastfeeding, elective 
caesarean section, and perinatal zidovudine. 1 Also) when 
given as a single oral dose to the mother once labour has 
been established, nevirapine rapidly crosses the placenta and 
has a lengthened half-life in the neonate such that 
therapeutic plasma concentrations can be sustained for 
7 days with only one additional oral dose given to the 
neonate after 48-72 h.' With this intervention, early 
peripartum transmission of HIV-I can be reduced by 50% 
compared with zidovudine taken during the same period.3 
Current guidelines recommend that triple antiretroviral 
therapy rather than zidovudine monotherapy should be 
started during the second and third trimesters of pregnancy 
for women with symptomatic HIV-I infection, high viral 
load, or low CD4-lymphocyte counts.' A regimen of 
nevirapine with two nucleoside analogue reverse-
transcriptase inhibitors (NRTis) is frequently prescribed 
because of its simplicity, tolerability, and efficacy. However, 
with the exception of zidovudine, didanosine, and, during 
the last 2 weeks of gestation, lamivudine, antiretroviral 
therapy pharmacokinetics during pregnancy have not been 
2134 
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Maternal blood Cord blood 24 h 48 h 
at delivery 
Neonatal blood 
Mean plasma nevirapine concentrations in mothers at delivery 
in umbilical-cord blood, and in neonates at 24-48 h 
Bars indicate SDs. 
reported. We measured steady-state nevirapine plasma 
concentrations in women prescribed nevirapine (plus two 
NRTis) during the second and third trimesters of 
pregnancy, and in their babies. 
18 pregnant women (15 African, two white, and one 
Asian) were treated with nevirapine-containing regimens 
according to national guidelines. 4 For antiretroviral-naive 
mothers the combination of nevirapine, zidovudine, and 
larnivudine was commonly the first-line therapy. The 
therapy of mothers who conceived at the time of treatment 
was only changed in the case of viral failure or side-effects. 
For mothers previously exposed to antiretroviral therapy or 
for whom therapy had failed, new regimens were chosen 
after testing for genotypic resistance. The women were 
advised of the potential risks and benefits of therapy, and 
gave informed consent for therapeutic drug monitoring and 
for nevirapine concentration to be measured using the same 
blood sample taken for diagnostic HIV-1 DNA PCR. 
Nevirapine 200 mg daily was prescribed for the first 2 weeks, 
and thereafter 200 mg twice daily, with the regular doses 
taken on the day of delivery. Three mothers took their initial 
dose of nevirapine during labour or shortly before elective 
caesarean section. Whole blood was centrifuged after 
venesection and plasma stored at -20°C until analysis for 
nevirapine concentration by high-performance liquid 
chromatography. 
Plasma nevirapine concentrations are shown in the figure. 
In the three mothers who started nevirapine on the day of 
delivery, mean neonatal nevirapine plasma concentrations at 
24 h (1·39 mg/L) were 81 % of maternal concentrations 
(1 ·71 mg/L), and 107% of cord concentrations (1 ·29 mg/L). 
In the 15 mothers who were treated during pregnancy, the 
mean maternal plasma concentrations at the end of the first 
4 weeks of therapy (4·62 mg/L) and at delivery (4·45 mg/L), 
were more than 400 times the reported median inhibitory 
concentration ofnevirapine for wild-type HIV-1. 5 The mean 
concentration in cord blood (3·41 mg/L) was 76% of 
maternal nevirapine concentration at delivery (p=0·03, 
paired t test). 24 h after delivery the mean neonatal 
concentration (2·71 mg/L) was 60% of the maternal 
concentration at delivery (p=O·Ol). Because this suggested 
more rapid clearance of nevirapine than expected, 
venesection of one infant was deferred until 48 h after 
delivery. In this neonate the plasma nevirapine concentration 
(0·2 mg/L) was only 5% of the concentration in cord blood 
and 3% of the concentration in maternal blood. 
Steady-state plasma nevirapine concentrations during the 
second and third trimesters of pregnancy were similar to 
published data for non-pregnant adults,' which suggests that 
the dose of nevirapine does not require adjustment in 






PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2003; 12: 647-652 
Published online 22 April 2003 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/pds.841 
ORIGINAL REPORT 
Psychotropic drugs and fatal pulmonary embolism. 
Lianne Parkin MB, DPH, David C. G. Skegg MB, DPhil*, G. Peter Herbison MSc and 
Charlotte Paul MB, PhD 
Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand 
SUMMARY 
Purpose To examine the association between the use of psychotropic drugs and fatal pulmonary embolism. 
Methods We conducted a national case-control study of fatal pulmonary embolism. Cases were 75 New Zealand men and 
women aged 15-59 years who died between I January 1990 and 31 December 1998, where the underlying cause of death 
was certified as codes 415.1, 451 or 453 of the International Classification of Diseases (9th Revision). Four controls, 
matched for sex and age, were selected from the general practice to which each case had belonged. Information was 
abstracted from the records of general practitioners, family planning clinics and psychiatric services. Odds ratios and 
95% confidence intervals (95% CI) were estimated using conditional logistic regression. The key analyses were restricted 
to cases (n = 62) and controls (n = 243) without major risk factors for venous thromboembolism. 
Results Compared to non-use, the adjusted odds ratio for current use of antipsychotic drugs was 13.3 (95% CI: 2.3-76.3). 
Low potency antipsychotics appeared to carry the highest risk (odds ratio: 20.8 [95% CI: 1.7-259.0)). The main drug 
involved was thioridazine. The odds ratio for current use of antidepressants was also increased, at 4.9 (95% CI: 1.1-22.5). 
Conclusions Our results for conventional antipsychotics are consistent with previous studies of non-fatal venous throm-
boembolism. The finding for antidepressants needs to be replicated in other studies. Copyright © 2003 John Wiley & Sons, 
Ltd. 
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INTRODUCTION 
In the year 2000, Zomberg and Jick reported that cur-
rent users of antipsychotic drugs have an increased 
risk of non-fatal idiopathic venous thromboembo-
lism.1 Their study, based on the United Kingdom Gen-
eral Practice Research Database (GPRD), estimated 
the relative risk at 7.1 (95% CI: 2.3-21.9) for all anti-
psychotics and at 24.1 (95% CI: 3.3-172.7) for low 
potency preparations. Re-analysis of a case-control 
study of deep vein thrombosis provided support for 
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the hypothesis that antipsychotic drugs may be a risk 
factor for this condition.2 
The only study to examine formally the risk of fatal 
venous thromboembolic events in users of anti psycho-
tics was confined to an atypical preparation (cloza-
pine).3 We expanded a national case-control study of 
fatal pulmonary embolism4 to explore any associa-
tions with antipsychotics or other psychotropic drugs. 
The deaths occurred between 1990 and 1998, when 
conventional antipsychotic drugs accounted for the 
majority of prescriptions. 
METHODS 
We identified all New Zealand men and women aged 
15-59 years who died between 1 January 1990 and 31 
December 1998, where the underlying cause was 
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certified as codes 415.1, 451 or 453 of the Interna-
tional Classification of Diseases (9th revision). Clini-
cal information and names of general practitioners 
were obtained from coroners' and police records, 
death certificates and hospital records; when neces-
sary, we also wrote to next of kin to ask for the name 
of the general practitioner. Of the 122 potential cases 
identified, 8 did not normally live in New Zealand, 9 
had insufficient evidence for a diagnosis of pulmonary 
embolism and for 13, the pulmonary embolism was 
not the underlying cause of death (5 had advanced 
cancer, 7 had post-operative pulmonary emboli and 
1 had portal vein thrombosis). The general practi-
tioners of 2 of the 92 eligible cases could not be iden-
tified. For the others, general practitioners were asked 
if one of us (Lianne Parkin) could visit their practice 
and examine the records of the case and 4 controls. No 
doctor refused, but for 15 patients, the medical records 
had been lost. For the remaining 75, the diagnosis of 
pulmonary embolism was confirmed by necropsy in 
69, by ventilation-perfusion scans or angiography in 
3 and by two specialist clinicians (using standard cri-
teria5 and blinded to exposure status) in 3. The date of 
onset of the fatal episode was taken as an index date. 
For each case, 4 controls, matched for sex and year 
of birth (except for 14 controls who were born in adja-
cent years to the cases), were selected from the group 
medical practice to which the case had belonged on 
the index date. The controls were selected randomly 
from an age-sex register in 71 practices (computerised 
in all except 1 ), from patient registration slips in 1 
practice and by random selection of medical records 
in 3 practices. Potential controls were excluded if they 
were not normally residing in New Zealand or did not 
belong to the practice on the index date. Information 
about medical histories and drug exposures before the 
index date was abstracted from the records of general 
practitioners, psychiatric services and family planning 
clinics, using an identical approach for cases and con-
trols. The date on which each patient had joined their 
general practice was recorded and because the records 
of many patients included information from practices 
to which they had previously belonged, the date of the 
earliest information was also noted. 
Users of psychotropic drugs were defined as those 
who had been prescribed medication for at least 1 
month. Current use was defined as prescribed use at 
any time during the 3 months before the index date . 
Psychotropic drugs were divided into three groups: 
antipsychotics, antidepressants and other psycho-
tropics (a group including benzodiazepines and 
other anxiolytics, lithium carbonate, carbamazepine, 
sodium valproate and zopiclone). Antipsychotic 
Copyright © 2003 John Wiley & Sons, Ltd. 
agents were classified according to potency, that is, 
the dose of the drug required to achieve a therapeutic 
effect.6-9 In matched analyses, using conditional 
logistic regression (STATA v7.0), we estimated rela-
tive risks by calculating odds ratios and 95% confi-
dence intervals. We adjusted for weight (four 
categories, including missing values, for both sexes) 
and combined oral contraceptive use and hormone 
replacement therapy within 3 months of the index 
date. Because conditional logistic regression can give 
misleading estimates with small numbers, we checked 
the analyses with unconditional logistic regression, 
adjusting for the matching factors. The association 
between psychotropic drug use and fatal pulmonary 
embolism was examined for all subjects, although 
the key analyses were restricted to those without 
major risk factors for venous thromboembolism. The 
latter group is regarded as the most informative for 
studying adverse effects of medicines. Ethical 
approval for the study was granted by each of the 
regional ethics committees. 
RESULTS 
Of the 75 cases, 51 were female (median age 43.0 
years) and 24 were male (median age 49.5 years). 
The mean times that cases and controls had been 
members of their practices were 9.9 years (standard 
error [SE]= 1.0) and 8.7 (SE= 0.6) years, respec-
tively. The difference was not statistically significant 
(p = 0.2). The mean number of years of recorded 
medical information was 13.5 (SE= 1.2) for cases 
and 12.2 (SE= 0.6) for controls. Again the difference 
was not statistically significant (p = 0.2). 
Ten cases and 2 controls had a past history of 
venous thromboembolism. A further 3 cases had a 
severe injury or prolonged immobility in the 2 months 
before the index date; while 3 controls were pregnant 
and 1 had major surgery during the same period. All 
of these people were classified as having major risk 
factors for venous thromboembolism. The following 
presentation of results will focus on people without 
major risk factors, although the tables also include 
results for all subjects. 
Of the 62 cases without major risk factors, 43 were 
female (median age 42.0 years) and 19 were male 
(median age 47.0 years). Eight cases and 2 controls 
were current users of antipsychotics (Table 1). Thior-
idazine, a low potency antipsychotic·, was used by 6 
cases and 1 control. High potency antipsychotics were 
used by 2 cases (haloperidol) and by 1 control (pro-
chlorperazine ). There were no users of atypical 
agents. All users, except for the control who was 
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* Adjusted for weight (four categories, including missing values, for both sexes), combined oral contraceptive use and hormone replacement 
therapy during the 3 months before the index date. 
INon-users of antipsychotics (never and past-users combined) are the reference group. 
INo history of venous thromboembolism or of prolonged immobility, severe injury, major surgery or pregnancy during the 2 months before 
the index date. 
prescribed prochlorperazine for labyrinthitis 6 weeks 
before the index date, had received antipsychotic 
medication either continuously or intermittently over 
many years. Four cases and 1 control had a diagnosis 
of schizophrenia noted in their records, while another 
case had a possible diagnosis of schizophrenia 
recorded. Of the remaining cases, 1 had a bipolar 
affective disorder, 1 had an intellectual disability 
and was prescribed thioridazine for behavioural con-
trol and 1 was taking thioridazine to treat insomnia. 
No user had an acute psychotic episode in the 3 
months before the index date; 1 man was admitted 
to hospital following an overdose. 
Taking non-users (never and past-users combined) 
as the reference group, the odds ratio (adjusted for 
weight, combined oral contraceptive use and hormone 
replacement therapy) for current use of antipsychotics 
was 13.3 (95% CI: 2.3-76.3). Low potency antipsy-
chotics carried the highest risk, with an adjusted odds 
ratio of 20.8 (95% CI: 1.7-259.0). The increased risk 
of pulmonary embolism in users of any antipsychotic 
persisted when women who were current users of 
combined oral contraceptives or hormone replace-
ment therapy were excluded from the analysis, with 
an odds ratio (adjusted for weight) of 8.3 (95% CI: 
1.3-53.5). Although the odds ratio for past use of anti-
Table 2. Current use of antidepressants 
psychotics, compared with never use, was elevated, 
this was not statistically significant (adjusted odds 
ratio 5.3 [95% CI: 0.6-45.8)). The adjusted odds ratio 
for use of antipsychotic medication within 1 month of 
the index date was 11.2 (95% CI: 1.9-65.4). An 
unmatched analysis (adjusted for age, sex, weight, 
combined oral contraceptive use, hormone replace-
ment therapy and clustered on practice) gave similar 
results to the matched analysis, with an odds ratio 
for antipsychotic use within 3 months of the index 
date of 14.1 (95%CI: 3.3-61.1). 
When current users of antipsychotics were 
excluded, 6 cases and 7 controls without major risk 
factors for venous thromboembolism were current 
users of antidepressants (Table 2). Tricyclic antide-
pressants were used by 4 cases and 5 controls. One 
of these cases and 1 further case were taking a selec-
tive serotonin reuptake inhibitor; the other case was 
taking a monoamine oxidase inhibitor. Of the remain-
ing controls, 1 was using a selective serotonin re-
uptake inhibitor, while the other was taking a monoa-
mine oxidase inhibitor. None of the users had been 
admitted to hospital for depression during the 3 
months before the index date, although 2 cases were 
diagnosed with acute depression and were prescribed 
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* Adjusted for weight (four categories, including missing values, for both sexes), combined oral contraceptive use and hormone replacement 
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index date. Only 1 user, a control, was taking a tricyc-
lic for a reason other than depression (migraine pro-
phylaxis). Of the remaining users, 1 case first 
commenced treatment 9 months before the index date, 
while all the others had been taking antidepressants 
intermittently or continuously for years. With non-
users as the reference group, the odds ratio (adjusted 
for weight, combined oral contraceptive use and hor-
mone replacement therapy) for current use of antide-
pressants was 4.9 (95% CI: 1.1-22.5). The adjusted 
odds ratios for current and past use of antidepressants, 
compared to never use, were 6.3 (95% CI: 1.3-30.8) 
and 2.9 (95% CI: 0.7-11.5) respectively. An analysis 
including current users of antipsychotics, but adjust-
ing for such use, also found an increased risk in cur-
rent users of antidepressants (odds ratio 5.5 [95% CI: 
1.3-23.8]). 
There was no increased risk for current or past use 
of other psychotropic drugs as a group. When we 
excluded users of antipsychotics or antidepressants, 
the adjusted odds ratio for current use was 1.4 
(95% CI: 0.3-7.7). Adjusting for antipsychotic and 
antidepressant use produced an identical point esti-
mate (odds ratio 1.4 [95%CI: 0.3-5.8]). 
DISCUSSION 
This case-control study found that current users of 
antipsychotic drugs had an increased risk of fatal pul-
monary embolism, when compared with non-users. 
Low potency antipsychotics carried the highest risk, 
with thioridazine being the main drug involved. The 
odds ratio for current use of antidepressants was also 
increased. The odds ratios for past use of antipsycho-
tics and antidepressants were not significantly in-
creased. 
The study was population-based and it was possible 
to identify all cases of idiopathic fatal pulmonary 
embolism that occurred in New Zealand during the 
study period. Diagnostic bias was unlikely because 
most people who die unexpectedly in New Zealand 
are referred for necropsy. Information about drugs pre-
scribed and medical history was derived from medical 
records and hence was not subject to recall bias. Con-
trols were selected from the same general practices as 
cases and there was no significant difference in the 
mean time that cases and controls had been members 
of their practices or in the number of years of recorded 
medical information. The date of onset of the fatal epi-
sode (rather than the date of death) was taken as the 
index date, so the prescription of antipsychotic or anti-
depressant drugs for unrecognised early symptoms of 
venous thromboembolism is an unlikely explanation 
Copyright © 2003 John Wiley & Sons, Ltd. 
for our results. Moreover, most of the cases had been 
taking their medication for at least a year. 
Confounding by sex, age, weight, concomitant drug 
use or underlying medical conditions is unlikely: con-
trols were matched to cases for sex and year of birth; 
we adjusted for weight, use of combined oral contra-
ceptives and hormone replacement therapy; and we 
excluded individuals with major risk factors from 
the key analyses. It was not possible to adjust for body 
mass index because the height of many patients was 
unrecorded, but it is unlikely that adjusting for weight 
instead of body mass index made a substantial differ-
ence to our results. 
The number of cases was inevitably restricted by 
the size of the New Zealand population. This limi-
ted our capacity to examine a number of features-
especially any association with classes of drugs other 
than antipsychotics and antidepressants. The general 
practice records of 15 cases could not be located, 
which might have biased our results. However, this 
was mostly due to practice-related reasons (such as 
doctors moving premises, retiring or dying) and it 
did not appear to be related to particular characteristics 
of cases. 
Our finding of an increased risk of fatal pulmonary 
embolism in current users of conventional antipsycho-
tics is consistent with previous studies of non-fatal 
venous thromboembolism. 1•2 Like Zomberg and 
Jick, 1 we found that users of!ow potency formulations 
carried the highest risk. The re-analysis of the Leiden 
Thrombophilia Study in the Netherlands found that 4 
of the 474 cases with deep vein thrombosis and none 
of the matched controls, were current users of antipsy-
chotics. 2 The findings of a Canadian cohort study 
were less consistent. 10 Using linked data from health 
care administrative records, Ray et al. compared the 
risk of venous thromboembolism in users of antipsy-
chotic drugs and users of thyroid replacement hor-
mone. An increased risk was found for users of 
butyrophenone antipsychotics only (adjusted relative 
risk 1.43 [95% CI: 1.18-1.74]). However, the study 
was confined to patients of age 65 years and more 
and diagnostic bias could not be ruled out since users 
of antipsychotics were older, were more likely to be 
living in long-term care facilities and may have been 
more cognitively impaired than the comparison group. 
Information about antipsychotic use and fatal 
venous thromboembolism is limited. Thomassen 
et al. reviewed necropsy reports at the Leiden Univer-
sity Medical Centre in the Netherlands.2 Ten of the 27 
deaths from idiopathic pulmonary embolism occurred 
in psychiatric patients, 5 of whom were known users 
of antipsychotic drugs. In a case-control study of fatal 
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cardiovascular disease in women of childbearing age 
in England and Wales, Thorogood et al. unexpectedly 
found an increased risk of myocardial infarction in 
users of psychotropic drugs, particularly tricyclic anti-
depressants and benzodiazepines. 11 An almost three-
fold increased risk of pulmonary embolism in current 
users of psychotropics was also observed, although 
no estimates were reported for individual drug groups. 
Walker et al. linked data from a national registry 
of clozapine users with death registrations in the 
United States.3 Among those aged 10-54 years, the 
standardised mortality rate for pulmonary embolism 
in current users was five times that of past users (rela-
tive risk 5.2). This may be a conservative estimate 
since patients who were classified as past users of 
clozapine could have been taking other antipsy-
chotics . 
Antipsychotic drugs have also been implicated in 
sudden cardiac death 12 and it is possible that deaths 
from pulmonary embolism could be misclassified as 
due to myocardial infarction or arrhythmia when 
necropsies are not performed. For example, in a recent 
case-control study, thioridazine was identified as a risk 
factor for sudden unexplained death among psychia-
tric inpatients (adjusted odds ratio 5.3 [95% CI: 1.7-
16.21).13 Drug-induced arrhythmia was thought to be 
the most likely cause. Since a necropsy was per-
formed in only 36% of the cases, the possibility that 
some of the remaining patients died from pulmonary 
embolism cannot be ruled out. Interestingly when the 
analysis was confined to patients who had undergone a 
necropsy, a significant association between thiorida-
zine and sudden unexplained death was not found 
(adjusted odds ratio 2.9 [95% CI: 0.7-11.7]). 
The previous evidence of an increased risk of non-
fatal venous thromboembolism in antipsychotic users 
tends to argue against differential survival as an alter-
native explanation for our results. Moreover, the 
absence of a significantly increased risk for past use 
in our study is consistent with the hypothesis .that 
the drugs, rather than any underlying characteristics 
of the people who used them, were responsible for 
the increased risk among current users. Nevertheless, 
the estimate for past use was elevated, with a wide 
confidence interval, so the possibility that people 
who are considered to need these drugs carry some 
increased risk cannot be ruled out. Earlier studies that 
found significantly elevated risks for current users of 
conventional1 and atypical3 antipsychotics, took past 
users as the reference group. This provided some con-
trol for the underlying condition, but it did not permit 
the evaluation of a possible increased background risk 
in users of antipsychotic drugs. 
Copyright © 2003 John Wiley & Sons, Ltd. 
There is no clear explanation for the increased risk 
of venous thrombosis in users of antipsychotics. Sev-
eral hypotheses have been proposed, including 
enhanced aggregation of platelets, 1 anticardiolipin 
antibodies, 1 exacerbation of venous stasis during 
sedation, 1 increased adrenaline secretion in the acute 
psychotic phase2 and hyperhomocysteinaemia. 10 
The observed association between current use of 
antidepressants and fatal pulmonary embolism was 
not expected, although it should be noted that tricyclic 
drugs closely resemble the phenothiazines chemi-
cally.14 There have been isolated reports of venous 
thromboembolic events in users of antidepressants 
who were also immobilised15 or concurrently using 
antipsychotics. 16 Zomberg and Jick found an odds ratio 
of 1.7 (95% CI: 0.8-3.7) for current use of antidepres-
sants.1 This result was based on only 3 exposed cases 
and 20 exposed controls, so it was not incompatible 
with our observation. In the re-analysis of the Leiden 
Thrombophilia Study, 9 cases and 4 controls were cur-
rent users of antidepressants, giving an odds ratio for 
current use of 2.3 (95% CI: 0.6-10.2).2 The adjusted 
relative risk for current use of antidepressants in the 
Canadian cohort study was 1.04 (95% CI: 0.94-1J5). 10 
If the association between antidepressant drugs and 
fatal pulmonary embolism is real, it needs to be estab-
lished whether antidepressant drugs increase the risk 
of venous thromboembolism or whether the people 
with depression are more likely to die from the condi-
tion. Antidepressants are widely used and further stu-
dies are required to clarify the association between 
these drugs and venous thromboembolism. 
KEY POINTS 
• Compared to non-use, current use of conven-
tional antipsychotics was associated with an 
increased risk of fatal pulmonary embolism 
(adjusted odds ratio 13.3 [95% CI: 2.3-76.3]). 
• Low potency antipsychotics carried the highest 
risk (adjusted odds ratio 20.8 [95% CI: 1.7-
259.0]). 
• The odds ratio for current use of antidepressants 
was also increased (adjusted odds ratio 4.9 
[95% CI: 1.1-22.5]). 
• Current use of other psychotropic drugs was not 
associated with an increased risk. 
• The findings for antipsychotics were consistent 
with previous studies, but the association 
between use of antidepressants and fatal pul-
monary embolism was not expected and needs 
to be replicated. 
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Air travel and fatal pulmonary embolism 
Lianne Parkin, Melanie L. Bell, G. Peter Herbison, Charlotte Paul, David C. G. Skegg . 
Department of Preventive and Social Medicine, University of Otago, New Zealand 
Summary 
Although long-distance air travel is commonly regarded as a risk 
factor for venous thromboembolism, the risk of clinically im-
portant events has not been well defined.We estimated the ab-
solute risk of dying from pulmonary embolism following long-
distance air travel in a national population-based descriptive 
study of 121 men and women who were aged 15-59 years (the 
age range in which the majority of international arrivals are 
found) and whose underlying cause of death was certified as 
codes 415.1, 451, or 453 of the International Classification of 
Diseases (ninth revision). Eleven cases had undertaken long-
distance air travel in the four weeks before the onset of the fatal 
episode. The estimated risks of fatal pulmonary embolism fol-
lowing a fiight of at least three hours' duration were 0.5 (95% Cl 
0.2-1.2) and 0.6 (95% Cl 0.2-1.4) per million arrivals for over-
Keywords 
Clinical / epidemiological studies, pulmonary embolism 
Introduction 
It is commonly believed that there is a link between air travel and 
venous thromboembolism (VTE) (!), but the risk has not been 
clearly defined (2). The relative risk of fatal events has not been 
examined and the only study to estimate pulmonary embolism 
mortality in air travellers linked Western Australian immigration 
and hospital admission data (3), thus excluding people who died 
in the community. We therefore conducted a national population-
based study to estimate both the relative and absolute risks of 
fatal pulmonary embolism following Jong-distance air travel. 
There were two components to the research: a descriptive study 
of men and women who died from pulmonary embolism in New 
Zealand between 1990 and 2000, and a case-control study. The 
principal aims were to examine any association between Jong-
distance air travel and the risk of dying from pulmonary embol-
ism, and to estimate the absolute risk of death from pulmonary 
embolism in air travellers aged 15-59 years. A secondary objec-
tive was to compare the mortality rate from pulmonary embol-
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Dr Lianne Parkin 
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University of Otago 
P.O. Box 913. Dunedin 
New Zealand 
Tel.: + 64 3 4798425, Fax: + 64 3 4797298 
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seas visitors and New Zealand residents, respectively. For air 
travel of more than eight hours' duration, the risk in New Zeal-
and residents was 1.3 (95% Cl 0.4-3.0) per million arrivals. We 
also conducted a case-control study based on those cases who 
were normally resident in New Zealand and registered on the 
electoral roll (n=99). For each case, four controls matched for 
sex, age, and electorate, were randomly selected from the elec-
toral roll. In the key analysis (based on 88 cases and 334 con-
trols), the adjusted odds ratio for travellers who had flown for 
more than eight hours was 7.9 (95% Cl 1.1-55.1) compared 
with those who did not undertake a long-distance flight. Long-
distance air travellers have a higher risk of dying from pulmonary 
embolism than non-travellers, but the absolute risk in people 
aged 15-59 years appears to be very small. 
Thromb Haemost 2006; 95: 807-14 
ism in a population in which almost all people had recently 
undertaken Jong-distance air travel (overseas visitors to New 
Zealand) with the rate in a population where few would recently 
have travelled (the resident population of New Zealand). 
The relative geographic isolation ofNew Zealand makes it an 
ideal country in which to undertake such research. With the ex-
ception of flights from neighbouring Pacific Islands and the east 
coast of Australia (3-4 hour flights), and from other parts of Aus-
tralia (5-8 hour flights), passengers arriving in New Zealand 
have all undertaken journeys with flight times of more than eight 
hours, and in many cases more than 24 hours. 
Descriptive study 
Materials and methods 
Selection of cases 
The New Zealand Health Information Service (NZHIS) identi-
fied all New Zealand residents and overseas visitors aged 15-59 
years who died in New Zealand between I January 1990 and 31 
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December 2000, for whom the underlying cause of death was 
coded to one of the following rubrics of the ninth revision of the 
International Classification of Diseases (ICD): 415.1 (pulmon-
ary embolism and infarction), 451 (phlebitis and thrombophlebi-
tis), or 453 (other venous embolism and thrombosis). People for 
whom the underlying cause was coded as rubrics 451 or 453 were 
Potential cases identified by NZHIS 
(n=149) 
12 insufficient evidence for a diagnosis of pulmonary 
embolism 
16 pulmonary embolism occurred, but not the underlying 
cause of death: 
- 9 post-surgery 
- 6 advanced cancer 
- 1 portal vein thrombosis 
121 eligible for inclusion, diagnosis confirmed by: 
- 113 necropsy 
- 4 pulmonary angiography or ventilation-perfusion 
scans 
- 4 by 2 internists using standard criteria and blinded 
to exposure status 
Participation of next of kin of eligible cases 
(n=121) 
8 overseas visitors: 
- 1 no response from any next of kin 
- 2 not traced 
- 5 interviewed 
113 New Zealand residents: 
- 8 did not wish lo participate 
- 2 initially consented, subsequently not contactable 
- 4 no response from any next of kin 
• 1 no known next of kin 
- 98 interviewed 
Figure I: Descriptive study: participation of next of kin. 
included in the study only ifthere was clear evidence that distal 
venous thrombosis had been complicated by pulmonary embol-
ism. The research was confined to people aged 15-59 years be-
cause the majority (77%) of people who arrived in New Zealand 
on international flights during the study period were within this 
age range ( data provided by Statistics New Zealand). 
We sought clinical information and names of the next of kin 
from death certificates and from coroners', police, hospital, gen-
eral practice, mental health, and family planning records. The 
clinical information obtained included the circmnstances of the 
fatal episode, reported symptoms, the results of any physical 
examination and diagnostic tests, necropsy findings, as well as 
details about medical history and medication use. The date of 
onset of the fatal episode was taken as an index date. Of 149 po-
tential cases identified, 121 were eligible for inclusion in the 
study (Fig. 1). The diagnosis of pulmonary embolism was con-
firmed by necropsy in 113 and by ventilation-perfusion scans or 
puhnonary angiography in four. Of the remaining four cases, two 
had venograms that demonstrated venous thrombosis. Two 
specialists in internal medicine, using standard criteria ( 4) and 
blinded to exposure status, determined that these four cases also 
had sufficient evidence for a diagnosis of pulmonary embolism. 
Definition of long-distance air travel 
In both the descriptive and case-control studies, we defined long-
distance air travel as a flight of at least three consecutive hours. 
This allowed comparisons with the studies that had been pub-
lished at the time the study was initiated (5-7). Furthermore, 
since domestic air travel within New Zealand involves flight 
times of less than three hours while international flights to and 
from New Zealand involve journeys of at least three hours' du-
ration, such a definition simply required study participants to re-
call any international travel during the relevant period. Such 
travel could often be verified by reference to passports and other 
personal records. For similar reasons, any domestic flights with-
in countries other than New Zealand that had involved flight 
times of more than three hours would probably be identified. 
Estimation of absolute risks 
For each person who died from pulmonary embolism, we sought 
information about long-distance air travel in the four weeks be-
fore the date of onset from medical and death records and from 
next of kin ( discussed below). The 4-week period was chosen to 
allow comparisons with previous studies ( 5-8). 
The numbers of New Zealand residents and overseas visitors 
arriving in New Zealand on international flights, by sex and 
5-year age groups, in the years 1990 to 2000 were provided by 
Statistics New Zealand. These data were derived from analyses 
of the arrival cards which all travellers arriving in New Zealand 
are required to complete. Because travellers are asked to record 
only the airport from which their last flight departed, these data 
provided insufficient information about the total duration of air 
travel undertaken by arriving passengers. Therefore, we used in-
formation from the control seiies in the case-control study (see 
below) to estimate the number of arrivals by New Zealand resi-
dents following air travel of more than eight hours during the same 
period. The proportion of controls who had undertaken a journey 
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before the index date was multiplied by 13 (to estimate the propor-
tion over one year) and the product multiplied by the annual esti-
mates of the New Zealand population aged 15-59 years to calcu-
late the number of arrivals by New Zealand residents on flights of 
more than eight hours in the years 1990 to 2000. To assess the 
validity of this approach, we also estimated the number of arrivals 
on flights of any duration and compared this figure with the arriv-
als data provided by Statistics New Zealand. 
Comparison of mortality rates in overseas visitors and 
New Zealand residents 
The numbers of deaths from all causes in New Zealand residents 
and overseas visitors by sex and 5-year age groups for the years 
1990-1998 were obtained from NZHIS. Data for 1999 and 2000 
-were not available for all-cause deaths because the country of 
usual residence was not coded in these years. Existing records 
were used to determine whether people who died from pulmon-
ary embolism in 1999 and 2000 had been resident in New Zeal-
and or overseas. 
Statistics New Zealand provided the number ofNew Zealand 
residents within each sex and 5-year age group (based on quin-
quennial census counts and adjusted for net migration and 
deaths) for each year of the study period. Corresponding data for 
overseas visitors were derived by linear interpolation between 
census counts. Because seasonal trends were evident in the 
monthly overseas visitor arrival data, the census counts and esti-
mated population in non-census years were seasonally adjusted. 
Sex and age-specific population data for New Zealand residents 
and for overseas visitors were added together to calculate the 
person-years of observation in residents and visitors for the 
ielevant periods. In the years 1990 and 2000, the total resident 
population of New Zealand was 3,379,250 and 3,832,930, re-
spectively. 
We used direct and indirect methods of sex and age standard-
isation to compare mortality rates for pulmonaiy embolism and 
all causes in the overseas visitor population with the rates in the 
New Zealand resident population (9). The Poisson distribution 
was used to compute 95% confidence intervals (95% CI) for ad-
justed rate ratios, standardised mortality ratios, and absolute risks. 
Results 
Deaths from pulmonary embolism 
Of the 121 deaths, 113 occurred in people who were usually resi-
dent in New Zealand on the index date and eight were in overseas 
visitors. Eighty were female (median age 43. I years) and 41 were 
male (median age 49.0 years). Eleven people (9.1 % of deaths) 
had undertaken long-distance air travel in the four weeks before 
the index date. These comprised five residents and six overseas 
visitors. 
The characteristics of the people who died after long-
distance air travel are shown in Table I. 
One person had undertaken three long-distance journeys dur-
ing the relevant period, and two others had flown on two separate 
occasions. The remaining cases flew only once in the four weeks 
before the index date, although two undertook further air travel 
after the onset of symptoms. Nine (five residents and four visi-
tors) of the 11 air travellers had undertaken journeys with total 
flight times of more than eight hours. Seven travelled in economy 
class, one had undertaken two flights in economy class and one 
in business class, and for three cases the class of travel was not 
determined. None were reported to have taken hypnotic drugs 
immediately before or during air travel. For nine people, symp-
toms ofVTE developed within eight days of air travel. Only two 
of the air travellers were admitted to and died in hospital, two 
others died on arrival at hospital emergency departments, and 
seven died in the community. 
Table I: Characteristics of cases who undertook long-distance air travel in the four weeks before the onset of their fatal episode . 
Case• Sex Age {years) History ofVTE BMlt Other risk factors forVTE i Family history ofVTE 
(kg/m1) 
female 47 No 34.9 Norethisterone No 
Medroxyprogesterone acetate Tranexamic acid 
Female 51 DVTinpregnancy ,,rather obese" History of varicose veins l unde,3 cousins 
(,.average") 
Female 58 No 21.6 History of varicose veins No 
Hormone replacement therapy 
Male 36 No 31.2 Nil No 
Male 49 No 34.3 Paraptegia33 years No 
Female 42 No ,.well-built" Nil No 
(26.1) 
female 47 No 43.6 Nil No 
Female 54 Unknown Unknown Unknown Unknown 
Female 57 Unknown 30.4 Nil reported to airport medics Unknown 
10 Male 32 lnjury-relatedDVT ,,well-nourished'' Nil I aunt 
(28.9) 
II Male 39 No 24.2 Nil No 
* Cases 1-5 were usually resident in New Zealand on the index date. cases 6-11 were overseas visitors. Information about cases 8 and 9 was obtained from coroners' and hospital records only, as next of kin 
were not traced. t Pathologists' comments and BMI calculated from weight and height at necropsy. Next of kin comments and BMI calculated from reported weight and height are shown in parentheses. t In-
formation was sought abo~ major risk factors forVTE in the three months before the index date 0ncluding surgery, major injury, prolonged immobility, pregnancy, hospit.al admissions for other reasons, her• 
mone replacement therapy. and the use of oral contraceptives, psychotropic drugs, and other medications), varicose veins, known thrombophilia, systemic lupus erythematosis, inflammatory bowel disease, 
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Table 2: Absolute risks of dying from pulmonary embolism following long-distance air travel. 
Exposure 
Overseas visitors, air travel ~3 hours 
New Zealand residents, air travel ~3 hours 
New Zealand residents, air travel ~3 hours 
New Zealand residents. air travel >8 hours 
Number of deaths among intematlonal 
arrivals aged I S-59 years, 1990-2000 
Number of international arrivals aged 





Absolute risk per million international 





*The absolute risks were obtained by dividing the number of deaths from pulmonary embolism among arrivals aged I 5-59 years on international flights between 1990 and 2000 by the number of passengers of 
the S'ilme age who arrived during the same period. tNumber of arrivals provided by Statistics New Zealand. fEstimated number of arrivals based on data from the case-control srudy. 
Table 3: Mortality from pulmonary embolism and from all 
causes in the overseas visitor and New Zealand resident popu .. 
lations. 
Cause of death Mortality rate in Mortality rate in New Adjusted rate 
overseas visitor Zealand resident ratio (95% Cl) 
population* (per population (per 
million person-years) million person-years) 
Pulmonary embolism 19.70 4.56 4.32 (J.94 - 4.72) 
A!lcauses 1465.8] 202142 0.72 (0.71-0.73) 
*Standardised to the sex and age distribution of the New Zealand resident population. 
Absolute risks 
The risks of developing fatal pulmonary embolism in the four 
weeks following long-distance air travel are shown in Table 2. 
Using Statistics New Zealand arrival data as the denominator, 
the risks following a flight of at least three hours' duration were 
0.5 (95% CI 0.2-1.2) and 0.6 (95% Cl 0.2-1.4) per million arriv-
als for visitors and residents, respectively. 
Using arrival estimates based on exposure data from controls 
in the case-control study as the denominator, the risk in residents 
following air travel of more than eight hours' duration was 1.3 
(95% Cl 0.4-3.0) per million arrivals. 
Pulmonary embolism and all-cause mortality rates 
The mortality rate from pulmonary embolism in overseas visi-
tors was higher than the rate in the New Zealand resident popu-
lation (Table 3 ); the sex and age-adjusted mortality rate ratio was 
4.3 (95% CI 3.9-4. 7) and the standardised mortality ratio (SMR) 
was 3.8 (95% CI 1.6-7.4). This is consistent with an increased 
risk of pulmonary embolism in air travellers, since almost all 
overseas visitors arrive by air and most remain in New Zealand 
for less than 30 days (10), while only a small proportion of the 
resident population undertakes international air travel during a 
4-week period. The results are particularly striking, given that 
there appears to be a "healthy traveller" effect: the adjusted mor-
tality rate ratio and SMR for deaths from all causes in overseas 
visitors were 0.72 (95% CI 0.71-0.73) and 0.71 (95% Cl 
0.64-0.76), respectively. 
Case-control study 
Materials and methods 
Selection of cases 
The case-control study was based on a subset of the 121 cases 
identified in the descriptive study. We excluded the eight over-
seas visitors as it was not possible to identify and contact 
members of an appropriate comparison group. For the same rea-
son, 14 residents who were not registered on the New Zealand 
electoral roll on the index date were also excluded. Thus 99 cases 
were considered eligible for inclusion in the case-control study. 
Selection of controls 
For each eligible case, four controls matched by individual year 
of age, sex, and electorate were selected randomly from the 
electoral roll. People who were not usually resident in New Zeal-
and / or not registered in the appropriate electorate on the index 
date were excluded, as were those not born within one year of 
their case. Those who did not meet the eligibility criteria could 
not be traced, or did not consent to be interviewed were replaced. 
Potential controls who did not wish to participate were asked 
if they were willing to answer three questions to establish eligi-
bility. 
Contacting participants 
A Jetter was sent to potential controls and the next of kin of eli-
gible cases, inviting them to take part in the study, and to return 
a form with contact details. Subsequently, oral consent was 
sought for a telephone interview. In situations where next of kin 
had died, could not be traced, or did not respond to three letters of 
invitation, other relatives were contacted. 
The interview 
Computer-assisted telephone interviews of next of kin and con-
trols were all undertaken by a registered nurse or one ofus (LP), 
using a standardised questionnaire. To assist recall about events 
before the index date, participants were sent a life-events calen-
dar w1tl1 the invitation letter and this was referred to during the 
interview. Participants were asked to check passports or other re-
cords before they answered questions about air travel in the four 
weeks before the index date. For long-distance air travellers, we 
enquired about the class of travel, whether the passenger had sat 
in an aisle seat, and the use of hypnotics. Permission was ob-
tained from controls to check the dates of any hospital admis-
sions before the index date. This information was already avail-
able for cases. 
Body mass index (BMI) was calculated from the reported 
weight and height on the index date, and was classified as under-
weight (< 20 kg/m2), normal weight (20 to < 25 kg/m2), over-
weight (25 to< 30 kg/m2), and obese (:2: 30 kg/m2). Three controls 
and the next of kin of26 cases were unable to provide an estimate 
of weight or height on the index date. For these people, the BMI 
810 
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category was assigned using narrative comments about weight in 
relation to height. The New Zealand Socio-Economic Index 
1996 (I !)was used to classify socio-economic status. For people 
living with a partner or parents, the highest score in the house-
hold was taken. 
The case-control study was based solely on data obtained 
during telephone interviews and the confirmation ofhospital ad-
mission dates. No infonnation about cases derived from other 
sources was used for comparisons between cases and controls. 
Statistical methods 
Conditional logistic regression was used to perform matched 
analyses using SAS (version 8). The exposures of any long-
distance flight and flight times of greater than eight hours were 
modelled separately. The key analyses were restricted to persons 
who did not have advanced cancer, were not pregnant, and had 
not undergone major surgery (since the selection of cases ex-
cluded patients with these conditions). Unadjusted and adjusted 
odds ratios are reported, with confounders chosen using back-
wards selection and confinned in univariate analyses. 
Results 
The participation of next of kin and controls is shown in Figure 
2. One case was reported by relatives to have undergone surgery 
following major injury in the three months before the index date. 
Although this was not confirmed by hospital or necropsy re-
cords, we excluded this person from the case-control study since 
we did not have full access to the hospital records of the controls 
who reported surgery. Twenty-two controls were excluded from 
the key analyses: three had a history of cancer ( excluding loca-
lised malignant melanoma), a further two had undergone major 
surgery in the three months before the index date, 13 were preg-
nant, and four were matched to the excluded case. 
The characteristics of cases and controls are shown in Table 
4. There were almost twice as many female cases as male, and the 
female cases were younger. Cases were more likely than controls 
to be obese, to have a past history ofVTE, and to belong to the lo-
west socio-economic group. Cases were also more likely to have 
been admitted to hospital, have been immobilised, and have used 
oral contraceptives and antipsychotics in the three months before 
the index date. During this period, cases and controls had similar 
rates of smoking and use of hormone replacement therapy and 
aspirin. One case and no controls were reported to be taking an 
anticoagulant (warfatin). Similar proportions of cases and con-
trols had a history of varicose veins and a family history ofVTE. 
The ethnicity of subjects did not differ appreciably between the 
case and control groups. 
Five cases and nine controls had undertaken at least one long-
distance flight in the four weeks before the index date (Table 5). 
All of the cases and four of the controls had undertaken journeys 
with total flight times of more than eight hours. There were no 
additional cases or controls who had undertaken domestic flights 
within a country other than New Zealand during the relevant 
period. The median ages of the cases and controls who flew long-
distance were 49.0 years and 52.5 years, respectively. 
Taking those who had not flown as the reference group, the 
odds ratio (adjusted for a past history ofVTE, for the BM! cat-
egory, and for prolonged immobility, a hospital admission owing 
to a medical condition, combined oral contraceptive, or antipsy-
chotic use in the three months before the index date) for a flight 
ofat least three hours' duration was 1.8 (95% CI 0.5-7.1). For 
flight times of more than eight hours, the adjusted odds ratio was 
7. 9 (9 5% CI 1.1- 55. I). Socio-economic status did not confound 
the association. We obtained a similar point estin1ate when we 
excluded people with a past history ofVTE, or of major injury or 
prolonged immobility in the three months before the index date. 
The odds ratio ( adjusted for the BM! category, and for any hos-
pital admission owing to a medical condition, combined oral 
contraceptive, or antipsychotic use in the three months before the 
index date) for all air travel of more than eight hours was then 7. I 
(95% CI 0.8-64.1). Excluding controls who were not in New 
Zealand on the date of death of their case (n =2) had minimal im-
pact on the results. 
Discussion 
In the case-control study, people who had undertaken air travel of 
more than eight hours' duration were estimated to have an 8-fold 
increased risk of fatal pulmonary embolism compared with people 
who had not undertaken such a journey. This is consistent with the 
findings of the descriptive study from which, allowing for a "heal-
thy traveller" effect, a 6-fold increase in risk can be estimated. In 
Table 4: Characteristics of cases and controls. 
Characteristic Cases Controls 
(,=88) (a=JJ4)' 
Sex (no[%]) 
Male JO (34.1) 120 (J5.9) 
Female 58(65.9), 214 (64.1) 
Age (years, median) 
All 45.5 47.1 
Male 50,8 50.4 
Female 42.6 43.0 
BMI (no 1%]1 
<20 7(8.0) 26 (7.8) 
20-24 Jl(J5.2) 153 (45.8) 
25-29 21 (23.9) 104 (JI.I) 
?:30 28(31.8) 51(15.J) 
Did not answer question 1(1.1) 0 
Reported history (no [%]) 
Venous thromboembolism 16(18.2) 9(17) 
Varicose veins 23(26.1) '80 (24.0) 
Risk factors in l months before index date (no [%]) 
Major fracture J (0.9) 
Major injury 1(1.1) I (O.J) 
Hospital admission for other reasons 9 (10.2) 4(1.2) 
Prolonged immobility 8(9.1) J(0.9) 
Medication use in 3 months before mdex date 
Antipsychotic (no[% total]) 6(6.8) 3(0.9) 
Combined oral contraceptives (no[% female]} 22(37.9) 41 (19.2) 
Hormone replacement therapy (no[% female]) 4 (6.9) 17(7.9) 
*Eighteen controls are excluded: three had a history of cancer. two had surgery, and 13 were preg-
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B overseas visitors 
Potential cases 
(n=121) 
14 New Zealand residents not registered on electoral roll 
99 eligible for interview, diagnosis confirmed by: 
92 necropsy 
3 pulmonary angiography or ventilation-perfusion scans 
4 by 2 physicians using standard criteria and blinded to 
exposure status 
Participation of next of kin 
99 eligible for interview: 
8 did not wish to participate 
1 initially consented, subsequently not contactable 
1 no response from any next of kin 
89 interviewed 
89 interviewed: 
1 reported by next of kin to have undergone surgery 
88 included in key analyses 
Figure 2: Case-control study: participation of next of kin and controls. 
812 
Potential controls selected from electoral roll 
(n=4B2) 
21 not eligible for interview: 
5 wrong sex 
12 wrong age (3 died after index date) 
4 not living in New Zealand on index date 
55 eligibility status unknown: 
15 died after index date 
14 no response to three letters 
23 not traced 
3 did not answer eligibility questions 
386 eligible for interview 
Participation of controls 
386 eligible for interview: 
28 did not wish to participate 
1 too ill to be interviewed 




- 3 advanced cancer 
13 pregnant 
4 controls of excluded case 
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absolute terms, however, the risk of dying from pulmonary embol-
ism after long-distance air travel appears to be very low. In this 
population-based research we were able to include all deaths that 
occurred in New Zealand during the study period for which pul-
monary embolism was considered the underlying cause. In al-
most all cases the diagnosis of massive pulmonary embolism 
was confirmed by necropsy or other objective investigations. It is 
unlikely that we missed any relevant deaths because legal 
requirements to identify the cause of death ( 12) mean that almost 
all people aged 15-59 years who die unexpectedly in New Zeal-
and are referred for necropsy, generally at the request of a coron-
er. Any air travellers who died en-route to New Zealand would 
also have been identified, except in situations where the aircraft 
did not proceed as intended. Because we studied fatal events, and 
because we included cases that occurred before widespread 
media publicity about a possible link between long-distance 
flights and VTE, referral bias is also unlikely to have influenced 
our results. 
The response rates of next of kin in the descriptive and case-
control studies were high (85.1 % and 89 .9%, respectively). The 
response rate of potential controls lay between 80. 7% and 
92.2%, since it is unlikely that everyone for whom eligibility 
status was not determined would have been eligible. lt is also 
possible that potential controls who died after the index date, or 
could not be traced or contacted, were less likely to have under-
taken long-distance air travel because of illness or because they 
belonged to a lower socio-economic group. Thus, any selection 
bias would tend to weaken the association between air travel and 
pulmonary embolism. It appears, however, that the control group 
gave a reliable estimate of exposure in the population that gave 
rise to the cases, since the estimated number of arrivals based on 
the proportion of exposed controls was very similar to the 
number of arrivals identified in official migration data. 
The use of a standardised questionnaire minimised any po-
tential for interviewer bias. Next of kin and controls were not in-
formed of the study hypothesis, nor were the controls told about 
the condition being studied until their interview was completed . 
The use of passports and other records to confirm travel details 
helped to ensure that accurate information about air travel as far 
back as 1990 was obtained. All long-distance flights reported by 
next of kin in the descriptive study were confirmed by medical 
and death records. 
Confounding by sex, age, proximity to an international air-
port, BM!, concomitant drug use, or an underlying medical con-
dition is an unlikely explanation for our findings in the case-
control study. Controls were matched to cases by sex, age, and 
electorate; we adjusted for a past history ofVTE, BM! category, 
and for hospital admissions, prolonged immobility, oral contra-
ceptive use and antipsychotic use in the three months before the 
index date; and we excluded individuals with a history of cancer, 
surgery or pregnancy in the three months before the index date. 
Temporal changes in travel patterns are also an unlikely expla-
nation because controls were asked about air travel during the 
same calendar period as their cases. 
There are several limitations to our research. Because fatal 
pulmonary embolism is a rare condition, there were only 121 
deaths over an I I-year period among people aged 15-59 years in 
which pulmonary embolism was considered the underlying 
Table 5: Odds ratios of fatal pulmonary embolism in the four 
weeks following long-distance air travel. 
Flight details Cases Controls Unadjusted OR Adjusted OR* 
(95%CI) (95%CI) 
No long-distance flight BJ 325 1.0 1.0 
Airtrave1~3 hours 2.2 (0.7 - 6.8) 1.8 (0.5- 7.1) 
No long-distance flight BJ 325 1.0 1.0 
Air travel > 8 hoursf 6.0 (1.4- 25.4) 7.9 (1.1-55.1) 
*Adjusted for past history ofVTE, BM[ (four categories), and for prolonged immobility (confined to 
bed or a wheelchair for more than a week), an admission owing to a medical condition, combined 
oral contraceptive, and antipsychotic use in the three months before the index date. 
tFlve controls who undertook air travel of eight hours or less exduded from analysis. 
cause. Of these, 98 were identified as being eligible for inclusion 
in the case-control study and the next of kin of 88 were inter-
viewed. This limited the_ precision of our estimates of relative 
risk, as demonstrated by the wide 95% confidence intervals. 
While use of proxy respondents for cases could have introduced 
some bias, we were able to verify dates ofhospital admissions for 
both cases and controls, and we tested the reliability of in-
formation provided by next of kin by comparing it with in-
formation from other sources. 
Because of the way in which mortality data were recorded 
during the study period, we were unable to identify all people for 
whom pulmonary embolism was the mechanism, although not 
the underlying cause, of death. Hence we could not estimate 
flight-related mortality rates in groups with predisposing condi-
tions, in whom the risk of fatal pulmonary embolism following a 
long-distance flight is likely to be greater. Nevertheless, we did 
not study an entirely idiopathic group, since people with a per-
sonal history ofVTE, a recent hospital admission, major injury, 
prolonged immobilisation or obesity, as well as users of oral 
contraceptives, hormone replacement therapy and antipsy-
chotics, were included. 
Our finding of an increased risk of fatal pulmonary embol-
ism following Jong-distance air travel is consistent with the find-
ings of some (3, 5, 7, 8, 13-18), but not all (6, 19), epidemiologi-
cal studies of travel and non-fatal VTE. We found a similar mag-
nitude of risk to that reported in two recent studies (3, 13). In a 
population-based case-control study in the Netherlands, air 
travel was associated with a 6-fold increased risk of non-fatal 
VTB (odds ratio 5.8 [95% CI 2.0-16.6]) (13). The Western Aus-
tralian record-linkage study used a case-crossover approach to 
estimate the risk of being admitted to hospital with VTB follow-
ing an international flight relative to the baseline risk (3). The 
relative risks of VTE in the first and second weeks after flying 
were 5.61 (95% CI 3.94-7.97) and 2.63 (95% CI 1.55-4.45), re-
spectively. The risk was not elevated after a 14-day period. All of 
the flight-related cases in our case-control study developed 
symptoms ofVTE within eight days of a journey of more than 
eight hours' duration. 
There is evidence to suggest that flight-related VTB is most 
likely to occur in passengers with other risk factors(!, 7, 13, 14, 
17). It was not possible to determine whether the cases and con-
trols had prothrombotic mutations, and we were unable to exam-
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air travel in other subgroups, such as oral contraceptive users, 
since the number of cases was inevitably restricted by the size of 
the New Zealand population. Recent studies have found interac-
tions between air travel, thrombophilia, and oral contraceptives. 
Air travellers with a prothrombotic mutation were reported to 
have a 13- to 16-fold increased risk ofnon-fatal VTE when com-
pared with non-travellers without a mutation (13, 14), while cur-
rent users of oral contraceptives who flew were reported to be 14 
times more likely to develop non-fatal VTE than non-users who 
did not fly (14). 
response relationship between the duration of travel and 1isk of 
VTE reported in previous studies (16, 18). 
Our estimates of absolute risk following a flight of at least 
three hours are consistent with the estimate of0.5 deaths per mil-
lion arrivals reported in the Western Australian study (3 ), though 
the study groups were not strictly comparable. People who died 
in the community were excluded from that study, while our study 
suggests that most travel-related deaths occur outside hospital. 
Their inclusion of cases older than 59 years probably accounts 
for the similar estimate of risk. 
Assuming a case fatality rate of2% (1 ), our estimates of pul-
monary embolism mortality are higher than would be expected 
from studies of non-fatal cases referred to hospitals near airports 
( 16, 18, 20), presumably because we were able to include all 
deaths that occurred in New Zealand in the days following long-
distance air travel. In contrast, our estimates are much lower than 
would be expected from studies of asymptomatic VTE (15, 
21-26) and from a study in which 1% of volunteers were re-
ported to have developed symptomatic non-fatal VTE after a 
flight of at least 10 hours (27). The clinical relevance of asymp-
tomatic VTE is unclear, and the latter study included subjects up 
to the age of 70 years and may have included a non-represen-
tative group of air travellers. Our findings confirm the dose-
In conclusion, while we confirmed that long-distance air 
travellers have a greater risk of dying from pulmonary embolism 
than non-travellers, we were reassured to find that fatal events 
were rare. Risks of the order of one in a million are much lower 
than recent publicity about the "economy class syndrome" has 
implied. 
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